Inclusion NCT03923946 0 9 O
Criteria NCT03923946 10 18 O
: NCT03923946 19 20 O

- NCT03923946 24 25 O
Eligible NCT03923946 27 35 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03923946 36 39 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03923946 40 43 O
early NCT03923946 44 49 B-Modifier
supported NCT03923946 50 59 I-Modifier
discharge NCT03923946 60 69 B-Encounter
pathway NCT03923946 70 77 O
this NCT03923946 78 82 O
includes NCT03923946 83 91 O
: NCT03923946 92 93 O

- NCT03923946 102 103 O
Confirmed NCT03923946 105 114 O
diagnosis NCT03923946 115 124 O
of NCT03923946 125 127 O
a NCT03923946 128 129 O
new NCT03923946 130 133 B-Eq-Comparison
stroke NCT03923946 134 140 B-Condition
. NCT03923946 141 142 O

- NCT03923946 151 152 O
Over NCT03923946 154 158 B-Eq-Comparison
18 NCT03923946 159 161 I-Eq-Comparison
Years NCT03923946 162 167 I-Eq-Comparison
old NCT03923946 168 171 B-Age
. NCT03923946 172 173 O

- NCT03923946 182 183 O
Able NCT03923946 185 189 O
to NCT03923946 190 192 O
consent NCT03923946 193 200 O
to NCT03923946 201 203 O
being NCT03923946 204 209 O
in NCT03923946 210 212 O
the NCT03923946 213 216 O
study NCT03923946 217 222 B-Study
. NCT03923946 223 224 O

- NCT03923946 233 234 O
The NCT03923946 236 239 O
patient NCT03923946 240 247 B-Family-Member___Family-Member-Type:patient
and NCT03923946 248 251 B-And
their NCT03923946 252 257 O
family NCT03923946 258 264 B-Family-Member
/ NCT03923946 265 266 O
carer NCT03923946 267 272 O
agree NCT03923946 273 278 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03923946 279 281 I-Assertion___Assertion-Type-Value:hypothetical
rehabilitation NCT03923946 282 296 B-Procedure
process NCT03923946 297 304 O
continuing NCT03923946 305 315 O
at NCT03923946 316 318 O
home NCT03923946 319 323 O
. NCT03923946 324 325 O

- NCT03923946 334 335 O
The NCT03923946 337 340 O
home NCT03923946 341 345 O
environment NCT03923946 346 357 O
is NCT03923946 358 360 O
conducive NCT03923946 361 370 O
to NCT03923946 371 373 O
the NCT03923946 374 377 O
community NCT03923946 378 387 O
- NCT03923946 388 389 O
based NCT03923946 390 395 O
rehabilitation NCT03923946 396 410 O
. NCT03923946 411 412 O

- NCT03923946 421 422 O
Achievable NCT03923946 424 434 O
rehabilitation NCT03923946 435 449 B-Procedure
goals NCT03923946 450 455 O
can NCT03923946 456 459 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03923946 460 462 I-Assertion___Assertion-Type-Value:hypothetical
identified NCT03923946 463 473 O
. NCT03923946 474 475 O

- NCT03923946 484 485 O
Document NCT03923946 487 495 O
acknowledgement NCT03923946 496 511 O
that NCT03923946 512 516 O
the NCT03923946 517 520 O
patient NCT03923946 521 528 O
is NCT03923946 529 531 O
sufficiently NCT03923946 532 544 O
well NCT03923946 545 549 O
enough NCT03923946 550 556 O
from NCT03923946 557 561 O
a NCT03923946 562 563 O
medical NCT03923946 564 571 O
perspective NCT03923946 572 583 O
to NCT03923946 584 586 O
be NCT03923946 587 589 O
managed NCT03923946 590 597 O
in NCT03923946 598 600 O
the NCT03923946 601 604 O
community NCT03923946 605 614 O
. NCT03923946 615 616 O

- NCT03923946 625 626 O
The NCT03923946 628 631 O
patient NCT03923946 632 639 O
's NCT03923946 639 641 O
language NCT03923946 642 650 O
and NCT03923946 651 654 O
/ NCT03923946 655 656 O
or NCT03923946 657 659 O
cognitive NCT03923946 660 669 O
skills NCT03923946 670 676 O
are NCT03923946 677 680 O
at NCT03923946 681 683 O
a NCT03923946 684 685 O
level NCT03923946 686 691 O
for NCT03923946 692 695 O
them NCT03923946 696 700 O
to NCT03923946 701 703 O
manage NCT03923946 704 710 O
on NCT03923946 711 713 O
their NCT03923946 714 719 O
own NCT03923946 720 723 O
for NCT03923946 724 727 O
periods NCT03923946 728 735 O
as NCT03923946 736 738 O
is NCT03923946 739 741 O
necessary NCT03923946 742 751 O
. NCT03923946 752 753 O

In NCT03923946 755 757 O
addition NCT03923946 758 766 O
to NCT03923946 767 769 O
ESSD NCT03923946 770 774 B-Condition
criteria NCT03923946 775 783 O
participants NCT03923946 784 796 O
must NCT03923946 797 801 O
; NCT03923946 801 802 O

- NCT03923946 805 806 O
Have NCT03923946 808 812 O
a NCT03923946 813 814 O
good NCT03923946 815 819 O
grasp NCT03923946 820 825 O
of NCT03923946 826 828 O
the NCT03923946 829 832 O
English NCT03923946 833 840 O
language NCT03923946 841 849 O

- NCT03923946 852 853 O
Have NCT03923946 855 859 O
been NCT03923946 860 864 B-Eq-Comparison
discharged NCT03923946 865 875 B-Encounter
from NCT03923946 876 880 O
the NCT03923946 881 884 O
ESSD NCT03923946 885 889 B-Condition
pathway NCT03923946 890 897 O

Exclusion NCT03923946 898 907 O
Criteria NCT03923946 908 916 O
: NCT03923946 917 918 O

- NCT03923946 922 923 O
Participants NCT03923946 925 937 O
will NCT03923946 938 942 O
be NCT03923946 943 945 O
excluded NCT03923946 946 954 O
if NCT03923946 955 957 O
they NCT03923946 958 962 O
: NCT03923946 963 964 O

- NCT03923946 973 974 O
Have NCT03923946 976 980 O
any NCT03923946 981 984 O
communication NCT03923946 985 998 B-Condition
difficulties NCT03923946 999 1011 I-Condition
that NCT03923946 1012 1016 O
would NCT03923946 1017 1022 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03923946 1023 1030 B-Negation
them NCT03923946 1031 1035 O
from NCT03923946 1036 1040 O
engaging NCT03923946 1041 1049 O
in NCT03923946 1050 1052 O
the NCT03923946 1053 1056 O
intervention NCT03923946 1057 1069 B-Procedure
( NCT03923946 1070 1071 O
including NCT03923946 1072 1081 O
hearing NCT03923946 1082 1089 B-Condition
impairments NCT03923946 1090 1101 I-Condition
, NCT03923946 1102 1103 O
visual NCT03923946 1104 1110 B-Condition
impairments NCT03923946 1111 1122 I-Condition
, NCT03923946 1123 1124 O
inability NCT03923946 1125 1134 B-Negation
to NCT03923946 1135 1137 O
understand NCT03923946 1138 1148 O
English NCT03923946 1149 1156 O
) NCT03923946 1157 1158 O
. NCT03923946 1159 1160 O
These NCT03923946 1162 1167 O
will NCT03923946 1168 1172 O
be NCT03923946 1173 1175 O
assessed NCT03923946 1176 1184 O
at NCT03923946 1185 1187 O
researcher NCT03923946 1188 1198 O
's NCT03923946 1198 1200 O
discretion NCT03923946 1201 1211 O
during NCT03923946 1212 1218 O
baseline NCT03923946 1219 1227 O
assessments NCT03923946 1228 1239 O
. NCT03923946 1240 1241 O

- NCT03923946 1250 1251 O
Had NCT03923946 1253 1256 O
a NCT03923946 1257 1258 O
diagnosis NCT03923946 1259 1268 O
of NCT03923946 1269 1271 O
dementia NCT03923946 1272 1280 B-Condition
prior NCT03923946 1281 1286 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03923946 1287 1289 O
the NCT03923946 1290 1293 O
stroke NCT03923946 1294 1300 B-Condition
. NCT03923946 1301 1302 O

- NCT03923946 1311 1312 O
Are NCT03923946 1314 1317 O
deemed NCT03923946 1318 1324 O
to NCT03923946 1325 1327 O
lack NCT03923946 1328 1332 O
capacity NCT03923946 1333 1341 O
to NCT03923946 1342 1344 O
give NCT03923946 1345 1349 O
informed NCT03923946 1350 1358 O
consent NCT03923946 1359 1366 O
. NCT03923946 1366 1367 O
This NCT03923946 1369 1373 O
will NCT03923946 1374 1378 O
be NCT03923946 1379 1381 O
judged NCT03923946 1382 1388 O
via NCT03923946 1389 1392 O
a NCT03923946 1393 1394 O
qualified NCT03923946 1395 1404 O
clinician NCT03923946 1405 1414 O
. NCT03923946 1415 1416 O

- NCT03923946 1425 1426 O
Have NCT03923946 1428 1432 O
had NCT03923946 1433 1436 O
previous NCT03923946 1437 1445 B-Eq-Comparison
experience NCT03923946 1446 1456 O
of NCT03923946 1457 1459 O
CFT NCT03923946 1460 1463 B-Procedure

- NCT03923946 1471 1472 O
Were NCT03923946 1474 1478 B-Eq-Comparison
receiving NCT03923946 1479 1488 I-Eq-Comparison
medical NCT03923946 1489 1496 B-Modifier
or NCT03923946 1497 1499 B-Or
psychological NCT03923946 1500 1513 B-Modifier
treatment NCT03923946 1514 1523 B-Procedure
for NCT03923946 1524 1527 O
a NCT03923946 1528 1529 O
mental NCT03923946 1530 1536 B-Condition
illness NCT03923946 1537 1544 I-Condition
at NCT03923946 1545 1547 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03923946 1548 1551 O
time NCT03923946 1552 1556 O
of NCT03923946 1557 1559 O
their NCT03923946 1560 1565 O
stroke NCT03923946 1566 1572 B-Condition
. NCT03923946 1572 1573 O

Inclusion NCT03923985 0 9 O
Criteria NCT03923985 10 18 O
: NCT03923985 19 20 O

- NCT03923985 24 25 O
Healthy NCT03923985 27 34 B-Condition
women NCT03923985 35 40 O
between NCT03923985 41 48 B-Eq-Comparison
18 NCT03923985 49 51 I-Eq-Comparison
and NCT03923985 52 55 I-Eq-Comparison
45 NCT03923985 56 58 I-Eq-Comparison
years NCT03923985 59 64 I-Eq-Comparison
old NCT03923985 65 68 B-Age

- NCT03923985 71 72 O
Women NCT03923985 74 79 O
without NCT03923985 80 87 B-Negation
current NCT03923985 88 95 B-Eq-Comparison
symptoms NCT03923985 96 104 B-Assertion___Assertion-Type-Value:possible
of NCT03923985 105 107 O
vaginal NCT03923985 108 115 B-Condition
infection NCT03923985 116 125 I-Condition

- NCT03923985 128 129 O
Negative NCT03923985 131 139 O
bacteriological NCT03923985 140 155 B-Modifier
and NCT03923985 156 159 B-And
clinical NCT03923985 160 168 B-Modifier
examination NCT03923985 169 180 B-Procedure

Exclusion NCT03923985 181 190 O
Criteria NCT03923985 191 199 O
: NCT03923985 200 201 O

- NCT03923985 205 206 O
Women NCT03923985 208 213 O
with NCT03923985 214 218 B-And
vaginal NCT03923985 219 226 B-Condition
infection NCT03923985 227 236 I-Condition

- NCT03923985 239 240 O
Women NCT03923985 242 247 O
with NCT03923985 248 252 B-And
undiagnosed NCT03923985 253 264 O
vaginal NCT03923985 265 272 B-Condition
bleeding NCT03923985 273 281 I-Condition

- NCT03923985 284 285 O
Patients NCT03923985 287 295 O
with NCT03923985 296 300 O
endometrial NCT03923985 301 312 B-Condition
hyperplasia NCT03923985 313 324 I-Condition

- NCT03923985 327 328 O
Suspicion NCT03923985 330 339 B-Assertion___Assertion-Type-Value:possible
of NCT03923985 340 342 O
neoplasia NCT03923985 343 352 B-Condition
or NCT03923985 353 355 B-Or
active NCT03923985 356 362 B-Eq-Comparison
neoplasia NCT03923985 363 372 B-Condition

- NCT03923985 375 376 O
Women NCT03923985 378 383 O
with NCT03923985 384 388 B-And
intolerance NCT03923985 389 400 B-Condition
, NCT03923985 401 402 O
allergy NCT03923985 403 410 B-Allergy
or NCT03923985 411 413 B-Or
hypersensitivity NCT03923985 414 430 B-Condition
to NCT03923985 431 433 O
the NCT03923985 434 437 O
components NCT03923985 438 448 O
of NCT03923985 449 451 O
the NCT03923985 452 455 O
probiotic NCT03923985 456 465 B-Drug

- NCT03923985 468 469 O
Women NCT03923985 471 476 O
with NCT03923985 477 481 B-And
immunosuppressive NCT03923985 482 499 B-Condition
disorders NCT03923985 500 509 I-Condition
or NCT03923985 510 512 B-Or
with NCT03923985 513 517 O
HIV NCT03923985 518 521 B-Condition

- NCT03923985 524 525 O
Women NCT03923985 527 532 O
who NCT03923985 533 536 B-And
are NCT03923985 537 540 O
currently NCT03923985 541 550 B-Eq-Comparison
using NCT03923985 551 556 I-Eq-Comparison
probiotics NCT03923985 557 567 B-Drug
by NCT03923985 568 570 O
any NCT03923985 571 574 O
route NCT03923985 575 580 O
of NCT03923985 581 583 O
administration NCT03923985 584 598 O

- NCT03923985 601 602 O
Women NCT03923985 604 609 O
who NCT03923985 610 613 B-And
are NCT03923985 614 617 O
using NCT03923985 618 623 B-Eq-Comparison
some NCT03923985 624 628 O
treatment NCT03923985 629 638 B-Procedure
for NCT03923985 639 642 O
vaginal NCT03923985 643 650 B-Modifier
sepsis NCT03923985 651 657 B-Condition

- NCT03923985 660 661 O
Chronic NCT03923985 663 670 B-Modifier
decompensated NCT03923985 671 684 B-Modifier
noncommunicable NCT03923985 685 700 B-Condition
diseases NCT03923985 701 709 I-Condition
( NCT03923985 710 711 O
diabetes NCT03923985 712 720 B-Condition
mellitus NCT03923985 721 729 I-Condition
, NCT03923985 730 731 O
heart NCT03923985 732 737 B-Condition
disease NCT03923985 738 745 I-Condition
. NCT03923985 746 747 O
. NCT03923985 748 749 O
. NCT03923985 750 751 O
) NCT03923985 752 753 O

- NCT03923985 757 758 O
Pregnant NCT03923985 760 768 B-Condition
women NCT03923985 769 774 O
or NCT03923985 775 777 B-Or
those NCT03923985 778 783 O
with NCT03923985 784 788 O
precocious NCT03923985 789 799 B-Condition
menopause NCT03923985 800 809 I-Condition

Inclusion NCT03926143 0 9 O
Criteria NCT03926143 10 18 O
: NCT03926143 19 20 O

- NCT03926143 24 25 O
Participants NCT03926143 27 39 O
ongoing NCT03926143 40 47 O
in NCT03926143 48 50 O
an NCT03926143 51 53 O
applicable NCT03926143 54 64 O
Bayer NCT03926143 65 70 O
- NCT03926143 71 72 O
sponsored NCT03926143 73 82 O
anetumab NCT03926143 83 91 B-Drug
ravtansine NCT03926143 92 102 I-Drug
parent NCT03926143 103 109 O
study NCT03926143 110 115 B-Study
at NCT03926143 116 118 O
the NCT03926143 119 122 O
time NCT03926143 123 127 O
of NCT03926143 128 130 O
its NCT03926143 131 134 O
planned NCT03926143 135 142 O
study NCT03926143 143 148 O
closure NCT03926143 149 156 O
. NCT03926143 157 158 O

- NCT03926143 162 163 O
For NCT03926143 165 168 O
on NCT03926143 169 171 B-Eq-Comparison
- NCT03926143 172 173 O
treatment NCT03926143 174 183 B-Procedure
participants NCT03926143 184 196 O
: NCT03926143 197 198 O
participant NCT03926143 199 210 O
is NCT03926143 211 213 O
eligible NCT03926143 214 222 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926143 223 225 O
receive NCT03926143 226 233 O
the NCT03926143 234 237 O
next NCT03926143 238 242 O
dose NCT03926143 243 247 O
of NCT03926143 248 250 O
study NCT03926143 251 256 B-Study
intervention NCT03926143 257 269 B-Drug
per NCT03926143 270 273 O
the NCT03926143 274 277 O
parent NCT03926143 278 284 O
study NCT03926143 285 290 O
protocol NCT03926143 291 299 O
. NCT03926143 300 301 O

Exclusion NCT03926143 303 312 O
Criteria NCT03926143 313 321 O
: NCT03926143 322 323 O

- NCT03926143 327 328 O
For NCT03926143 330 333 O
on NCT03926143 334 336 B-Eq-Comparison
- NCT03926143 337 338 O
treatment NCT03926143 339 348 B-Procedure
participants NCT03926143 349 361 O
: NCT03926143 362 363 O
a NCT03926143 364 365 O
positive NCT03926143 366 374 O
serum NCT03926143 375 380 B-Observation
pregnancy NCT03926143 381 390 I-Observation
test NCT03926143 391 395 I-Observation
. NCT03926143 396 397 O

- NCT03926143 401 402 O
For NCT03926143 404 407 O
on NCT03926143 408 410 B-Eq-Comparison
- NCT03926143 411 412 O
treatment NCT03926143 413 422 B-Procedure
participants NCT03926143 423 435 O
: NCT03926143 436 437 O
use NCT03926143 438 441 O
of NCT03926143 442 444 O
one NCT03926143 445 448 B-Eq-Comparison
or NCT03926143 449 451 I-Eq-Comparison
more NCT03926143 452 456 I-Eq-Comparison
of NCT03926143 457 459 O
the NCT03926143 460 463 O
prohibited NCT03926143 464 474 O
medications NCT03926143 475 486 B-Drug
listed NCT03926143 487 493 O
in NCT03926143 494 496 O
the NCT03926143 497 500 O
respective NCT03926143 501 511 O
parent NCT03926143 512 518 O
study NCT03926143 519 524 O
protocol NCT03926143 525 533 O
. NCT03926143 534 535 O

- NCT03926143 539 540 O
Participants NCT03926143 542 554 O
who NCT03926143 555 558 O
are NCT03926143 559 562 O
receiving NCT03926143 563 572 B-Eq-Comparison
standard NCT03926143 573 581 O
- NCT03926143 582 583 O
of NCT03926143 584 586 O
- NCT03926143 587 588 O
care NCT03926143 589 593 O
agent NCT03926143 594 599 B-Drug
( NCT03926143 600 601 I-Drug
s NCT03926143 602 603 I-Drug
) NCT03926143 604 605 I-Drug
but NCT03926143 606 609 B-And
not NCT03926143 610 613 B-Negation
anetumab NCT03926143 614 622 B-Drug
ravtansine NCT03926143 623 633 I-Drug
in NCT03926143 634 636 O
the NCT03926143 637 640 O
parent NCT03926143 641 647 O
study NCT03926143 648 653 O
, NCT03926143 654 655 O
and NCT03926143 656 659 B-And
are NCT03926143 660 663 O
able NCT03926143 664 668 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926143 669 671 I-Assertion___Assertion-Type-Value:hypothetical
receive NCT03926143 672 679 O
standard NCT03926143 680 688 O
- NCT03926143 689 690 O
of NCT03926143 691 693 O
- NCT03926143 694 695 O
care NCT03926143 696 700 O
agent NCT03926143 701 706 B-Drug
outside NCT03926143 707 714 B-Other
of NCT03926143 715 717 O
the NCT03926143 718 721 O
clinical NCT03926143 722 730 O
study NCT03926143 731 736 B-Study
. NCT03926143 736 737 O

Inclusion NCT03926962 0 9 O
Criteria NCT03926962 10 18 O
: NCT03926962 19 20 O

- NCT03926962 24 25 O
BMI NCT03926962 27 30 B-Observation
: NCT03926962 31 32 O
18 NCT03926962 33 35 B-Eq-Comparison
- NCT03926962 36 37 I-Eq-Comparison
30 NCT03926962 38 40 I-Eq-Comparison
kg NCT03926962 41 43 I-Eq-Comparison
/ NCT03926962 44 45 I-Eq-Comparison
m2 NCT03926962 46 48 I-Eq-Comparison
( NCT03926962 49 50 O
Body NCT03926962 51 55 B-Observation
Mass NCT03926962 56 60 I-Observation
Index NCT03926962 61 66 I-Observation
[ NCT03926962 67 68 O
BMI NCT03926962 69 72 B-Observation
] NCT03926962 73 74 O
[ NCT03926962 75 76 O
kg NCT03926962 77 79 O
/ NCT03926962 80 81 O
m2 NCT03926962 82 84 O
] NCT03926962 85 86 O
= NCT03926962 87 88 O
Body NCT03926962 89 93 O
weight NCT03926962 94 100 O
[ NCT03926962 101 102 O
kg NCT03926962 103 105 O
] NCT03926962 106 107 O
Height2 NCT03926962 108 115 O
[ NCT03926962 116 117 O
m2 NCT03926962 118 120 O
] NCT03926962 121 122 O
) NCT03926962 124 125 O

- NCT03926962 129 130 O
Ability NCT03926962 132 139 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03926962 140 143 B-And
willingness NCT03926962 144 155 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926962 156 158 I-Assertion___Assertion-Type-Value:hypothetical
abstain NCT03926962 159 166 B-Negation
from NCT03926962 167 171 O
alcohol NCT03926962 172 179 B-Drug
, NCT03926962 180 181 O
methylxanthine NCT03926962 182 196 B-Drug
- NCT03926962 197 198 O
containing NCT03926962 199 209 O
beverages NCT03926962 210 219 O
or NCT03926962 220 222 O
food NCT03926962 223 227 O
( NCT03926962 228 229 O
coffee NCT03926962 230 236 O
, NCT03926962 237 238 O
tea NCT03926962 239 242 O
, NCT03926962 243 244 O
cola NCT03926962 245 249 O
, NCT03926962 250 251 O
chocolate NCT03926962 252 261 O
, NCT03926962 262 263 O
" NCT03926962 264 265 O
powerdrinks NCT03926962 265 276 O
" NCT03926962 276 277 O
) NCT03926962 278 279 O
, NCT03926962 281 282 O
grapefruit NCT03926962 283 293 O
( NCT03926962 294 295 O
juice NCT03926962 296 301 O
) NCT03926962 302 303 O
from NCT03926962 304 308 O
48 NCT03926962 309 311 B-Eq-Comparison
h NCT03926962 312 313 I-Eq-Comparison
prior NCT03926962 314 319 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926962 320 322 I-Temporal-Connection___Temporal-Connection-Type-Value:before
entry NCT03926962 323 328 B-Study
in NCT03926962 329 331 O
the NCT03926962 332 335 O
clinical NCT03926962 336 344 O
research NCT03926962 345 353 O
center NCT03926962 354 360 O
until NCT03926962 361 366 B-Temporal-Connection___Temporal-Connection-Type-Value:before
discharge NCT03926962 367 376 B-Encounter

- NCT03926962 379 380 O
Medical NCT03926962 382 389 O
history NCT03926962 390 397 B-Eq-Comparison
without NCT03926962 398 405 B-Negation
major NCT03926962 406 411 B-Modifier
pathology NCT03926962 412 421 B-Condition

Exclusion NCT03926962 422 431 O
Criteria NCT03926962 432 440 O
: NCT03926962 441 442 O

- NCT03926962 446 447 O
Evidence NCT03926962 449 457 O
of NCT03926962 458 460 O
clinically NCT03926962 461 471 O
relevant NCT03926962 472 480 B-Modifier
pathology NCT03926962 481 490 B-Condition

- NCT03926962 493 494 O
Mental NCT03926962 496 502 B-Condition
handicap NCT03926962 503 511 I-Condition

- NCT03926962 514 515 O
History NCT03926962 517 524 B-Eq-Comparison
of NCT03926962 525 527 O
relevant NCT03926962 528 536 O
drug NCT03926962 537 541 O
and NCT03926962 542 545 B-Or
/ NCT03926962 546 547 I-Or
or NCT03926962 548 550 I-Or
food NCT03926962 551 555 O
allergies NCT03926962 556 565 B-Allergy

- NCT03926962 568 569 O
Regular NCT03926962 571 578 O
/ NCT03926962 579 580 O
routine NCT03926962 581 588 B-Eq-Comparison
treatment NCT03926962 589 598 B-Procedure
with NCT03926962 599 603 O
non NCT03926962 604 607 B-Negation
- NCT03926962 608 609 O
topical NCT03926962 610 617 B-Drug
medications NCT03926962 618 629 I-Drug
within NCT03926962 630 636 B-Eq-Comparison
30 NCT03926962 637 639 I-Eq-Comparison
days NCT03926962 640 644 I-Eq-Comparison
prior NCT03926962 645 650 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926962 651 653 I-Temporal-Connection___Temporal-Connection-Type-Value:before
entry NCT03926962 654 659 B-Study
into NCT03926962 660 664 O
the NCT03926962 665 668 O
clinical NCT03926962 669 677 O
research NCT03926962 678 686 O
center NCT03926962 687 693 O

- NCT03926962 696 697 O
Smoking NCT03926962 699 706 B-Condition
within NCT03926962 707 713 B-Eq-Comparison
60 NCT03926962 714 716 I-Eq-Comparison
days NCT03926962 717 721 I-Eq-Comparison
prior NCT03926962 722 727 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926962 728 730 I-Temporal-Connection___Temporal-Connection-Type-Value:before
drug NCT03926962 731 735 B-Procedure
administration NCT03926962 736 750 I-Procedure
and NCT03926962 751 754 B-And
through NCT03926962 755 762 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03926962 763 766 O
follow NCT03926962 767 773 B-Encounter
- NCT03926962 774 775 I-Encounter
up NCT03926962 776 778 I-Encounter
visit NCT03926962 779 784 I-Encounter

- NCT03926962 787 788 O
History NCT03926962 790 797 B-Eq-Comparison
of NCT03926962 798 800 O
alcohol NCT03926962 801 808 B-Condition
abuse NCT03926962 809 814 I-Condition
or NCT03926962 815 817 B-Or
drug NCT03926962 818 822 B-Condition
addiction NCT03926962 823 832 I-Condition
( NCT03926962 833 834 O
including NCT03926962 835 844 O
soft NCT03926962 845 849 B-Condition
drugs NCT03926962 850 855 I-Condition
like NCT03926962 856 860 O
cannabis NCT03926962 861 869 B-Condition
products NCT03926962 870 878 O
) NCT03926962 879 880 O

Inclusion NCT03922906 0 9 O
Criteria NCT03922906 10 18 O
: NCT03922906 19 20 O

1 NCT03922906 24 25 I-Eq-Comparison
. NCT03922906 25 26 O
Subjects NCT03922906 28 36 O
with NCT03922906 37 41 O
history NCT03922906 42 49 B-Eq-Comparison
of NCT03922906 50 52 O
inadequate NCT03922906 53 63 B-Condition
bowel NCT03922906 64 69 I-Condition
preparation NCT03922906 70 81 I-Condition
. NCT03922906 82 83 O

2 NCT03922906 87 88 O
. NCT03922906 88 89 O
Subjects NCT03922906 91 99 O
in NCT03922906 100 102 O
the NCT03922906 103 106 O
age NCT03922906 107 110 B-Age
range NCT03922906 111 116 O
of NCT03922906 117 119 O
22 NCT03922906 120 122 B-Eq-Comparison
- NCT03922906 123 124 I-Eq-Comparison
75 NCT03922906 125 127 I-Eq-Comparison
years NCT03922906 128 133 I-Eq-Comparison
inclusive NCT03922906 134 143 O

3 NCT03922906 146 147 O
. NCT03922906 147 148 O
Subjects NCT03922906 150 158 O
with NCT03922906 159 163 O
BodyMass NCT03922906 164 172 B-Observation
Index NCT03922906 173 178 I-Observation
( NCT03922906 179 180 O
BMI NCT03922906 181 184 B-Observation
) NCT03922906 185 186 O
within NCT03922906 187 193 O
the NCT03922906 194 197 O
range NCT03922906 198 203 O
of NCT03922906 204 206 O
18.5 NCT03922906 207 211 B-Eq-Comparison
- NCT03922906 212 213 I-Eq-Comparison
35 NCT03922906 214 216 I-Eq-Comparison
inclusive NCT03922906 217 226 O

4 NCT03922906 229 230 O
. NCT03922906 230 231 O
Subject NCT03922906 233 240 O
has NCT03922906 241 244 O
signed NCT03922906 245 251 O
the NCT03922906 252 255 O
informed NCT03922906 256 264 O
consent NCT03922906 265 272 O

Exclusion NCT03922906 273 282 O
Criteria NCT03922906 283 291 O
: NCT03922906 292 293 O

1 NCT03922906 297 298 O
. NCT03922906 298 299 O
Patients NCT03922906 301 309 O
with NCT03922906 310 314 O
active NCT03922906 315 321 B-Eq-Comparison
Inflammatory NCT03922906 322 334 B-Condition
Bowel NCT03922906 335 340 I-Condition
Disease NCT03922906 341 348 I-Condition

2 NCT03922906 351 352 O
. NCT03922906 352 353 O
Patients NCT03922906 355 363 O
with NCT03922906 364 368 O
previous NCT03922906 369 377 B-Eq-Comparison
history NCT03922906 378 385 I-Eq-Comparison
of NCT03922906 386 388 O
acute NCT03922906 389 394 O
diverticulitis NCT03922906 395 409 B-Condition
disease NCT03922906 410 417 I-Condition
or NCT03922906 418 420 B-Or
with NCT03922906 421 425 O
prior NCT03922906 426 431 B-Eq-Comparison
incomplete NCT03922906 432 442 B-Modifier
colonoscopy NCT03922906 443 454 B-Procedure
due NCT03922906 455 458 O
to NCT03922906 459 461 O
diverticular NCT03922906 462 474 B-Condition
disease NCT03922906 475 482 I-Condition

3 NCT03922906 485 486 O
. NCT03922906 486 487 O
Patients NCT03922906 489 497 O
with NCT03922906 498 502 O
known NCT03922906 503 508 O
bowel NCT03922906 509 514 B-Condition
obstruction NCT03922906 515 526 I-Condition
/ NCT03922906 527 528 B-Or
strictures NCT03922906 529 539 B-Condition

4 NCT03922906 542 543 O
. NCT03922906 543 544 O
History NCT03922906 546 553 B-Eq-Comparison
of NCT03922906 554 556 I-Eq-Comparison
prior NCT03922906 557 562 I-Eq-Comparison
surgery NCT03922906 563 570 B-Procedure
to NCT03922906 571 573 O
colon NCT03922906 574 579 B-Modifier
and NCT03922906 580 583 B-Or
/ NCT03922906 584 585 I-Or
or NCT03922906 586 588 I-Or
rectum NCT03922906 589 595 B-Modifier

5 NCT03922906 598 599 O
. NCT03922906 599 600 O
ASA NCT03922906 602 605 B-Condition
≥ NCT03922906 606 607 B-Eq-Comparison
III NCT03922906 608 611 I-Eq-Comparison

6 NCT03922906 614 615 O
. NCT03922906 615 616 O
Renal NCT03922906 618 623 B-Condition
insufficiency NCT03922906 624 637 I-Condition
( NCT03922906 638 639 O
Creatinine NCT03922906 640 650 B-Observation
≥ NCT03922906 651 652 B-Eq-Comparison
1.5 NCT03922906 653 656 I-Eq-Comparison
mg NCT03922906 657 659 I-Eq-Comparison
/ NCT03922906 660 661 I-Eq-Comparison
dL NCT03922906 662 664 I-Eq-Comparison
) NCT03922906 665 666 O
( NCT03922906 667 668 O
based NCT03922906 669 674 O
on NCT03922906 675 677 O
medical NCT03922906 678 685 O
history NCT03922906 686 693 O
) NCT03922906 694 695 O

7 NCT03922906 699 700 O
. NCT03922906 700 701 O
Abnormal NCT03922906 703 711 O
Liver NCT03922906 712 717 B-Condition
enzymes NCT03922906 718 725 I-Condition
( NCT03922906 726 727 O
ALT NCT03922906 728 731 B-Observation
/ NCT03922906 732 733 B-Or
AST NCT03922906 734 737 B-Observation
≥ NCT03922906 738 739 B-Eq-Comparison
2 NCT03922906 740 741 I-Eq-Comparison
times NCT03922906 742 747 I-Eq-Comparison
upper NCT03922906 748 753 I-Eq-Comparison
limits NCT03922906 754 760 I-Eq-Comparison
of NCT03922906 761 763 I-Eq-Comparison
normal NCT03922906 764 770 I-Eq-Comparison
) NCT03922906 771 772 O
( NCT03922906 773 774 O
based NCT03922906 775 780 O
on NCT03922906 781 783 O
medical NCT03922906 784 791 O
history NCT03922906 792 799 O
) NCT03922906 800 801 O

8 NCT03922906 805 806 O
. NCT03922906 806 807 O
Patients NCT03922906 809 817 O
taking NCT03922906 818 824 B-Eq-Comparison
anticoagulants NCT03922906 825 839 B-Drug
drugs NCT03922906 840 845 I-Drug
( NCT03922906 846 847 O
excluding NCT03922906 848 857 B-Exception
aspirin NCT03922906 858 865 B-Drug
) NCT03922906 866 867 O
or NCT03922906 868 870 B-Or
dual NCT03922906 871 875 B-Modifier
antiplatelet NCT03922906 876 888 B-Procedure
therapy NCT03922906 889 896 I-Procedure

9 NCT03922906 899 900 O
. NCT03922906 900 901 O
Patients NCT03922906 903 911 O
with NCT03922906 912 916 O
known NCT03922906 917 922 O
coagulation NCT03922906 923 934 B-Condition
disorder NCT03922906 935 943 I-Condition
( NCT03922906 944 945 O
INR NCT03922906 946 949 B-Observation
> NCT03922906 950 951 B-Eq-Comparison
1.5 NCT03922906 952 955 O
) NCT03922906 956 957 O
. NCT03922906 959 960 O

10 NCT03922906 963 965 O
. NCT03922906 965 966 O
Patients NCT03922906 968 976 O
at NCT03922906 977 979 O
risk NCT03922906 980 984 B-Risk
of NCT03922906 985 987 O
hypokalemia NCT03922906 988 999 B-Condition
or NCT03922906 1000 1002 B-Or
hyponatremia NCT03922906 1003 1015 B-Condition

11 NCT03922906 1017 1019 O
. NCT03922906 1019 1020 O
Patients NCT03922906 1022 1030 O
with NCT03922906 1031 1035 O
congestive NCT03922906 1036 1046 B-Condition
cardiac NCT03922906 1047 1054 I-Condition
failure NCT03922906 1055 1062 I-Condition

12 NCT03922906 1064 1066 O
. NCT03922906 1066 1067 O
Pregnancy NCT03922906 1069 1078 B-Condition
( NCT03922906 1079 1080 O
as NCT03922906 1081 1083 O
stated NCT03922906 1084 1090 O
by NCT03922906 1091 1093 O
patient NCT03922906 1094 1101 O
) NCT03922906 1102 1103 O
or NCT03922906 1104 1106 B-Or
breast NCT03922906 1107 1113 B-Condition
feeding NCT03922906 1114 1121 I-Condition

13 NCT03922906 1123 1125 O
. NCT03922906 1125 1126 O
Patients NCT03922906 1128 1136 O
with NCT03922906 1137 1141 O
altered NCT03922906 1142 1149 B-Condition
mental NCT03922906 1150 1156 I-Condition
status NCT03922906 1157 1163 I-Condition
/ NCT03922906 1164 1165 O
inability NCT03922906 1166 1175 O
to NCT03922906 1176 1178 O
provide NCT03922906 1179 1186 O
informed NCT03922906 1187 1195 O
consent NCT03922906 1196 1203 O

14 NCT03922906 1205 1207 O
. NCT03922906 1207 1208 O
Patients NCT03922906 1210 1218 O
who NCT03922906 1219 1222 O
have NCT03922906 1223 1227 O
participated NCT03922906 1228 1240 O
in NCT03922906 1241 1243 O
another NCT03922906 1244 1251 B-Other
interventional NCT03922906 1252 1266 O
clinical NCT03922906 1267 1275 O
study NCT03922906 1276 1281 B-Study
in NCT03922906 1282 1284 O
the NCT03922906 1285 1288 O
last NCT03922906 1289 1293 B-Eq-Comparison
2 NCT03922906 1294 1295 I-Eq-Comparison
months NCT03922906 1296 1302 I-Eq-Comparison

Inclusion NCT03925714 0 9 O
Criteria NCT03925714 10 18 O
: NCT03925714 19 20 O

- NCT03925714 24 25 O
Prediabetic NCT03925714 27 38 B-Condition
subjects NCT03925714 39 47 O
. NCT03925714 48 49 O

Exclusion NCT03925714 51 60 O
Criteria NCT03925714 61 69 O
: NCT03925714 70 71 O

- NCT03925714 75 76 O
Confirmed NCT03925714 78 87 O
diabetes NCT03925714 88 96 B-Condition
. NCT03925714 97 98 O

- NCT03925714 102 103 O
Hepatic NCT03925714 105 112 B-Modifier
or NCT03925714 113 115 B-Or
renal NCT03925714 116 121 B-Modifier
impairment NCT03925714 122 132 B-Condition
. NCT03925714 132 133 O

Inclusion NCT03926221 0 9 O
Criteria NCT03926221 10 18 O
: NCT03926221 19 20 O

1 NCT03926221 24 25 O
. NCT03926221 25 26 O
Age NCT03926221 28 31 B-Age
between NCT03926221 32 39 B-Eq-Comparison
10 NCT03926221 40 42 I-Eq-Comparison
and NCT03926221 43 46 I-Eq-Comparison
18 NCT03926221 47 49 I-Eq-Comparison
and NCT03926221 50 53 O
living NCT03926221 54 60 O
with NCT03926221 61 65 O
a NCT03926221 66 67 O
parent NCT03926221 68 74 B-Family-Member___Family-Member-Type:parent
or NCT03926221 75 77 O
guardian NCT03926221 78 86 O

2 NCT03926221 89 90 O
. NCT03926221 90 91 O
Lowest NCT03926221 93 99 O
quartile NCT03926221 100 108 O
of NCT03926221 109 111 O
the NCT03926221 112 115 O
widely NCT03926221 116 122 O
used NCT03926221 123 127 O
and NCT03926221 128 131 O
well NCT03926221 132 136 O
- NCT03926221 137 138 O
validated NCT03926221 139 148 O
Children NCT03926221 149 157 B-Observation
's NCT03926221 157 159 I-Observation
Morningness NCT03926221 160 171 I-Observation
- NCT03926221 172 173 I-Observation
Eveningness NCT03926221 174 185 I-Observation
Preferences NCT03926221 186 197 I-Observation
Scale NCT03926221 198 203 I-Observation
( NCT03926221 204 205 O
CMEP NCT03926221 206 210 B-Observation
; NCT03926221 210 211 O
27 NCT03926221 212 214 B-Eq-Comparison
or NCT03926221 215 217 I-Eq-Comparison
lower NCT03926221 218 223 I-Eq-Comparison
) NCT03926221 224 225 O
and NCT03926221 226 229 O

3 NCT03926221 232 233 O
. NCT03926221 233 234 O
Youth NCT03926221 236 241 O
self NCT03926221 242 246 O
- NCT03926221 247 248 O
reported NCT03926221 249 257 O
weekday NCT03926221 258 265 O
sleep NCT03926221 266 271 B-Observation
onset NCT03926221 272 277 I-Observation
time NCT03926221 278 282 I-Observation
for NCT03926221 283 286 O
the NCT03926221 287 290 O
past NCT03926221 291 295 B-Eq-Comparison
month NCT03926221 296 301 I-Eq-Comparison
later NCT03926221 302 307 B-Eq-Comparison
than NCT03926221 308 312 I-Eq-Comparison
10 NCT03926221 313 315 I-Eq-Comparison
: NCT03926221 316 317 I-Eq-Comparison
40 NCT03926221 318 320 I-Eq-Comparison
pm NCT03926221 321 323 I-Eq-Comparison
for NCT03926221 324 327 O
10 NCT03926221 328 330 B-Eq-Comparison
- NCT03926221 331 332 I-Eq-Comparison
to NCT03926221 333 335 I-Eq-Comparison
13 NCT03926221 336 338 I-Eq-Comparison
- NCT03926221 339 340 I-Eq-Comparison
year NCT03926221 341 345 I-Eq-Comparison
- NCT03926221 346 347 O
olds NCT03926221 348 352 B-Age
; NCT03926221 352 353 O
11 NCT03926221 354 356 B-Eq-Comparison
: NCT03926221 357 358 I-Eq-Comparison
00 NCT03926221 359 361 I-Eq-Comparison
pm NCT03926221 362 364 I-Eq-Comparison
for NCT03926221 365 368 O
14 NCT03926221 369 371 B-Eq-Comparison
- NCT03926221 372 373 I-Eq-Comparison
16 NCT03926221 374 376 I-Eq-Comparison
year NCT03926221 377 381 I-Eq-Comparison
olds NCT03926221 382 386 B-Age
, NCT03926221 387 388 O
and NCT03926221 389 392 B-Or
later NCT03926221 393 398 B-Eq-Comparison
than NCT03926221 399 403 I-Eq-Comparison
11 NCT03926221 404 406 I-Eq-Comparison
: NCT03926221 407 408 I-Eq-Comparison
20 NCT03926221 409 411 I-Eq-Comparison
for NCT03926221 412 415 O
17 NCT03926221 416 418 B-Eq-Comparison
- NCT03926221 419 420 I-Eq-Comparison
18 NCT03926221 421 423 I-Eq-Comparison
year NCT03926221 424 428 I-Eq-Comparison
olds NCT03926221 429 433 B-Age
at NCT03926221 434 436 B-Eq-Comparison
least NCT03926221 437 442 I-Eq-Comparison
3 NCT03926221 443 444 I-Eq-Comparison
nights NCT03926221 445 451 I-Eq-Comparison
per NCT03926221 452 455 I-Eq-Comparison
week NCT03926221 456 460 I-Eq-Comparison
; NCT03926221 460 461 O

4 NCT03926221 464 465 O
. NCT03926221 465 466 O
English NCT03926221 468 475 O
language NCT03926221 476 484 O
fluency NCT03926221 485 492 O
; NCT03926221 492 493 O

5 NCT03926221 496 497 O
. NCT03926221 497 498 O
able NCT03926221 500 504 O
and NCT03926221 505 508 O
willing NCT03926221 509 516 O
to NCT03926221 517 519 O
give NCT03926221 520 524 O
informed NCT03926221 525 533 O
assent NCT03926221 534 540 O
; NCT03926221 540 541 O

6 NCT03926221 544 545 O
. NCT03926221 545 546 O
at NCT03926221 548 550 B-Eq-Comparison
least NCT03926221 551 556 I-Eq-Comparison
one NCT03926221 557 560 I-Eq-Comparison
parent NCT03926221 561 567 B-Family-Member___Family-Member-Type:parent
/ NCT03926221 568 569 O
primary NCT03926221 570 577 O
caregiver NCT03926221 578 587 O
who NCT03926221 588 591 O
lives NCT03926221 592 597 O
in NCT03926221 598 600 O
the NCT03926221 601 604 O
same NCT03926221 605 609 O
household NCT03926221 610 619 O
as NCT03926221 620 622 O
the NCT03926221 623 626 O
teen NCT03926221 627 631 O
for NCT03926221 632 635 O
at NCT03926221 636 638 B-Eq-Comparison
least NCT03926221 639 644 I-Eq-Comparison
50 NCT03926221 645 647 I-Eq-Comparison
% NCT03926221 648 649 I-Eq-Comparison
of NCT03926221 650 652 I-Eq-Comparison
the NCT03926221 653 656 I-Eq-Comparison
week NCT03926221 657 661 I-Eq-Comparison
must NCT03926221 662 666 O
participate NCT03926221 667 678 O
in NCT03926221 679 681 O
all NCT03926221 682 685 O
study NCT03926221 686 691 O
sessions NCT03926221 692 700 O
. NCT03926221 701 702 O

Exclusion NCT03926221 704 713 O
Criteria NCT03926221 714 722 O
: NCT03926221 723 724 O

1 NCT03926221 728 729 O
. NCT03926221 729 730 O
An NCT03926221 732 734 O
active NCT03926221 735 741 B-Eq-Comparison
, NCT03926221 742 743 O
progressive NCT03926221 744 755 B-Modifier
physical NCT03926221 756 764 B-Condition
illness NCT03926221 765 772 I-Condition
directly NCT03926221 773 781 O
related NCT03926221 782 789 O
to NCT03926221 790 792 O
the NCT03926221 793 796 O
onset NCT03926221 797 802 B-Eq-Comparison
and NCT03926221 803 806 O
course NCT03926221 807 813 O
of NCT03926221 814 816 O
the NCT03926221 817 820 O
sleep NCT03926221 821 826 B-Condition
disturbance NCT03926221 827 838 I-Condition
; NCT03926221 838 839 O

2 NCT03926221 842 843 O
. NCT03926221 843 844 O
evidence NCT03926221 846 854 O
of NCT03926221 855 857 O
sleep NCT03926221 858 863 B-Condition
apnea NCT03926221 864 869 I-Condition
, NCT03926221 870 871 O
restless NCT03926221 872 880 B-Condition
legs NCT03926221 881 885 I-Condition
or NCT03926221 886 888 B-Or
periodic NCT03926221 889 897 B-Modifier
limb NCT03926221 898 902 B-Condition
movements NCT03926221 903 912 I-Condition
; NCT03926221 912 913 O

3 NCT03926221 916 917 O
. NCT03926221 917 918 O
significantly NCT03926221 920 933 O
impairing NCT03926221 934 943 O
pervasive NCT03926221 944 953 B-Modifier
developmental NCT03926221 954 967 B-Condition
disorder NCT03926221 968 976 I-Condition
; NCT03926221 976 977 O

4 NCT03926221 980 981 O
. NCT03926221 981 982 O
history NCT03926221 984 991 B-Eq-Comparison
of NCT03926221 992 994 O
substance NCT03926221 995 1004 B-Condition
dependence NCT03926221 1005 1015 I-Condition
in NCT03926221 1016 1018 O
the NCT03926221 1019 1022 O
past NCT03926221 1023 1027 B-Eq-Comparison
six NCT03926221 1028 1031 I-Eq-Comparison
months NCT03926221 1032 1038 I-Eq-Comparison
; NCT03926221 1038 1039 O

5 NCT03926221 1042 1043 O
. NCT03926221 1043 1044 O
suicide NCT03926221 1046 1053 B-Condition
risk NCT03926221 1054 1058 B-Risk
; NCT03926221 1058 1059 O
bipolar NCT03926221 1060 1067 B-Condition
disorder NCT03926221 1068 1076 I-Condition
or NCT03926221 1077 1079 B-Or
schizophrenia NCT03926221 1080 1093 B-Condition
or NCT03926221 1094 1096 O
another NCT03926221 1097 1104 B-Other
current NCT03926221 1105 1112 B-Eq-Comparison
Axis NCT03926221 1113 1117 B-Eq-Comparison
I NCT03926221 1118 1119 I-Eq-Comparison
disorder NCT03926221 1120 1128 B-Condition
if NCT03926221 1129 1131 O
there NCT03926221 1132 1137 O
is NCT03926221 1138 1140 O
a NCT03926221 1141 1142 O
significant NCT03926221 1143 1154 O
risk NCT03926221 1155 1159 B-Risk
of NCT03926221 1160 1162 O
harm NCT03926221 1163 1167 B-Condition
and NCT03926221 1168 1171 B-Or
/ NCT03926221 1172 1173 I-Or
or NCT03926221 1174 1176 I-Or
decompensation NCT03926221 1177 1191 B-Condition
if NCT03926221 1192 1194 O
treatment NCT03926221 1195 1204 B-Procedure
of NCT03926221 1205 1207 O
that NCT03926221 1208 1212 B-Condition|Coreference
comorbid NCT03926221 1213 1221 I-Condition|Coreference
condition NCT03926221 1222 1231 I-Condition|Coreference
is NCT03926221 1232 1234 O
delayed NCT03926221 1235 1242 O
as NCT03926221 1243 1245 O
a NCT03926221 1246 1247 O
function NCT03926221 1248 1256 O
of NCT03926221 1257 1259 O
participating NCT03926221 1260 1273 O
in NCT03926221 1274 1276 O
any NCT03926221 1277 1280 O
stage NCT03926221 1281 1286 O
of NCT03926221 1287 1289 O
this NCT03926221 1290 1294 O
study NCT03926221 1295 1300 B-Study
; NCT03926221 1300 1301 O

6 NCT03926221 1304 1305 O
. NCT03926221 1305 1306 O
Participants NCT03926221 1308 1320 O
will NCT03926221 1321 1325 O
not NCT03926221 1326 1329 B-Negation
be NCT03926221 1330 1332 O
excluded NCT03926221 1333 1341 B-Negation
if NCT03926221 1342 1344 O
medications NCT03926221 1345 1356 B-Drug
are NCT03926221 1357 1360 O
stable NCT03926221 1361 1367 O
( NCT03926221 1368 1369 O
> NCT03926221 1371 1372 B-Eq-Comparison
4 NCT03926221 1373 1374 I-Eq-Comparison
weeks NCT03926221 1375 1380 I-Eq-Comparison
) NCT03926221 1381 1382 O
. NCT03926221 1383 1384 O

Inclusion NCT03924999 0 9 O
Criteria NCT03924999 10 18 O
: NCT03924999 19 20 O

- NCT03924999 24 25 O
Subject NCT03924999 27 34 O
diagnosed NCT03924999 35 44 O
with NCT03924999 45 49 O
lipedema NCT03924999 50 58 B-Condition
according NCT03924999 59 68 O
to NCT03924999 69 71 O
the NCT03924999 72 75 O
criteria NCT03924999 76 84 O
of NCT03924999 85 87 O
revised NCT03924999 88 95 O
Wold NCT03924999 96 100 O
. NCT03924999 101 102 O

- NCT03924999 106 107 O
Subject NCT03924999 109 116 O
did NCT03924999 117 120 O
not NCT03924999 121 124 B-Negation
participate NCT03924999 125 136 O
in NCT03924999 137 139 O
any NCT03924999 140 143 O
exercise NCT03924999 144 152 B-Procedure
program NCT03924999 153 160 I-Procedure
within NCT03924999 161 167 B-Eq-Comparison
the NCT03924999 168 171 I-Eq-Comparison
last NCT03924999 172 176 I-Eq-Comparison
three NCT03924999 177 182 I-Eq-Comparison
months NCT03924999 183 189 I-Eq-Comparison
. NCT03924999 190 191 O

- NCT03924999 195 196 O
No NCT03924999 198 200 B-Negation
pregnancy NCT03924999 201 210 B-Condition
/ NCT03924999 211 212 B-Or
breastfeeding NCT03924999 213 226 B-Condition

Exclusion NCT03924999 227 236 O
Criteria NCT03924999 237 245 O
: NCT03924999 246 247 O

- NCT03924999 251 252 O
History NCT03924999 254 261 B-Eq-Comparison
of NCT03924999 262 264 O
acute NCT03924999 265 270 O
infection NCT03924999 271 280 B-Condition
, NCT03924999 281 282 O
cancer NCT03924999 283 289 B-Condition
, NCT03924999 290 291 O
inflammatory NCT03924999 292 304 B-Modifier
rheumatic NCT03924999 305 314 I-Modifier
/ NCT03924999 315 316 B-Or
connective NCT03924999 317 327 B-Modifier
tissue NCT03924999 328 334 I-Modifier
diseases NCT03924999 335 343 B-Condition

- NCT03924999 346 347 O
History NCT03924999 349 356 B-Eq-Comparison
of NCT03924999 357 359 O
cardiovascular NCT03924999 360 374 B-Modifier
or NCT03924999 375 377 B-Or
musculoskeletal NCT03924999 378 393 B-Modifier
problems NCT03924999 394 402 B-Condition
that NCT03924999 403 407 O
may NCT03924999 408 411 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03924999 412 419 B-Negation
them NCT03924999 420 424 O
from NCT03924999 425 429 O
participating NCT03924999 430 443 O
in NCT03924999 444 446 O
the NCT03924999 447 450 O
exercise NCT03924999 451 459 B-Procedure
program NCT03924999 460 467 I-Procedure

Inclusion NCT03926156 0 9 O
Criteria NCT03926156 10 18 O
: NCT03926156 19 20 O

1 NCT03926156 24 25 O
. NCT03926156 25 26 O
Provision NCT03926156 28 37 O
of NCT03926156 38 40 O
signed NCT03926156 41 47 O
and NCT03926156 48 51 O
dated NCT03926156 52 57 O
informed NCT03926156 58 66 O
consent NCT03926156 67 74 O
form NCT03926156 75 79 O

2 NCT03926156 82 83 O
. NCT03926156 83 84 O
Stated NCT03926156 86 92 O
willingness NCT03926156 93 104 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926156 105 107 O
comply NCT03926156 108 114 O
with NCT03926156 115 119 O
all NCT03926156 120 123 O
study NCT03926156 124 129 B-Study
procedures NCT03926156 130 140 B-Procedure
and NCT03926156 141 144 O
availability NCT03926156 145 157 O
for NCT03926156 158 161 O
the NCT03926156 162 165 O
duration NCT03926156 166 174 O
of NCT03926156 175 177 O
the NCT03926156 178 181 O
study NCT03926156 182 187 O

3 NCT03926156 190 191 O
. NCT03926156 191 192 O
Men NCT03926156 194 197 O
and NCT03926156 198 201 B-Or
women NCT03926156 202 207 O
≥ NCT03926156 208 209 B-Eq-Comparison
18 NCT03926156 210 212 I-Eq-Comparison
year NCT03926156 213 217 I-Eq-Comparison
- NCT03926156 218 219 I-Eq-Comparison
old NCT03926156 220 223 I-Age|Eq-Comparison

4 NCT03926156 226 227 O
. NCT03926156 227 228 O
Diagnosed NCT03926156 230 239 O
with NCT03926156 240 244 O
moderate NCT03926156 245 253 B-Eq-Comparison
to NCT03926156 254 256 I-Eq-Comparison
severe NCT03926156 257 263 I-Eq-Comparison
mitral NCT03926156 264 270 B-Condition
stenosis NCT03926156 271 279 I-Condition
who NCT03926156 280 283 B-And
have NCT03926156 284 288 O
a NCT03926156 289 290 O
history NCT03926156 291 298 B-Eq-Comparison
of NCT03926156 299 301 O
AF NCT03926156 302 304 B-Condition
of NCT03926156 305 307 O
any NCT03926156 308 311 O
duration NCT03926156 312 320 O
documented NCT03926156 321 331 O
by NCT03926156 332 334 O
any NCT03926156 335 338 O
electrical NCT03926156 339 349 B-Procedure
tracing NCT03926156 350 357 I-Procedure
within NCT03926156 358 364 O
the NCT03926156 365 368 O
prior NCT03926156 369 374 B-Eq-Comparison
12 NCT03926156 375 377 I-Eq-Comparison
months NCT03926156 378 384 I-Eq-Comparison
and NCT03926156 385 388 B-And
for NCT03926156 389 392 O
which NCT03926156 393 398 O
anticoagulation NCT03926156 399 414 B-Procedure
is NCT03926156 415 417 O
indicated NCT03926156 418 427 B-Indication
and NCT03926156 428 431 O
planned NCT03926156 432 439 B-Eq-Comparison
for NCT03926156 440 443 I-Eq-Comparison
the NCT03926156 444 447 O
duration NCT03926156 448 456 B-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03926156 457 459 O
the NCT03926156 460 463 O
study NCT03926156 464 469 B-Study
. NCT03926156 470 471 O

5 NCT03926156 475 476 O
. NCT03926156 476 477 O
Ability NCT03926156 479 486 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926156 487 489 I-Assertion___Assertion-Type-Value:hypothetical
take NCT03926156 490 494 O
oral NCT03926156 495 499 B-Procedure
medication NCT03926156 500 510 I-Procedure
and NCT03926156 511 514 B-And
be NCT03926156 515 517 O
willing NCT03926156 518 525 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926156 526 528 I-Assertion___Assertion-Type-Value:hypothetical
adhere NCT03926156 529 535 O
to NCT03926156 536 538 O
the NCT03926156 539 542 O
rivaroxaban NCT03926156 543 554 B-Drug
regimen NCT03926156 555 562 O

Exclusion NCT03926156 563 572 O
Criteria NCT03926156 573 581 O
: NCT03926156 582 583 O

1 NCT03926156 587 588 O
. NCT03926156 588 589 O
Left NCT03926156 591 595 B-Modifier
atrial NCT03926156 596 602 I-Modifier
clot NCT03926156 603 607 B-Condition

2 NCT03926156 610 611 O
. NCT03926156 611 612 O
Severe NCT03926156 614 620 O
renal NCT03926156 621 626 B-Condition
dysfunction NCT03926156 627 638 I-Condition
( NCT03926156 639 640 O
creatinine NCT03926156 641 651 B-Observation
clearance NCT03926156 652 661 I-Observation
[ NCT03926156 662 663 O
CrCl NCT03926156 664 668 B-Observation
] NCT03926156 669 670 O
< NCT03926156 671 672 B-Eq-Comparison
15 NCT03926156 673 675 I-Eq-Comparison
mL NCT03926156 676 678 I-Eq-Comparison
/ NCT03926156 679 680 I-Eq-Comparison
min NCT03926156 681 684 I-Eq-Comparison
) NCT03926156 685 686 O
, NCT03926156 688 689 O
subjects NCT03926156 690 698 O
with NCT03926156 699 703 O

3 NCT03926156 706 707 O
. NCT03926156 707 708 O
A NCT03926156 710 711 O
condition NCT03926156 712 721 B-Condition
associated NCT03926156 722 732 O
with NCT03926156 733 737 O
a NCT03926156 738 739 O
high NCT03926156 740 744 O
risk NCT03926156 745 749 B-Risk
of NCT03926156 750 752 O
bleeding NCT03926156 753 761 B-Condition

4 NCT03926156 764 765 O
. NCT03926156 765 766 O
Allergic NCT03926156 768 776 B-Allergy
to NCT03926156 777 779 O
rivaroxabn NCT03926156 780 790 B-Drug
/ NCT03926156 791 792 B-Or
warfarin NCT03926156 793 801 B-Drug

Inclusion NCT03920527 0 9 O
Criteria NCT03920527 10 18 O
: NCT03920527 19 20 O
includes NCT03920527 21 29 O
presence NCT03920527 30 38 O
of NCT03920527 39 41 O
all NCT03920527 42 45 O
the NCT03920527 46 49 O
following NCT03920527 50 59 O
: NCT03920527 60 61 O

- NCT03920527 65 66 O
one NCT03920527 68 71 B-Eq-Comparison
or NCT03920527 72 74 I-Eq-Comparison
more NCT03920527 75 79 I-Eq-Comparison
clinical NCT03920527 80 88 B-Condition
symptoms NCT03920527 89 97 I-Condition
( NCT03920527 98 99 O
persistent NCT03920527 100 110 B-Modifier
cough NCT03920527 111 116 B-Condition
, NCT03920527 117 118 O
recurrent NCT03920527 119 128 B-Modifier
hemoptysis NCT03920527 129 139 B-Condition
, NCT03920527 140 141 O
weight NCT03920527 142 148 B-Condition
loss NCT03920527 149 153 I-Condition
, NCT03920527 154 155 O
malaise NCT03920527 156 163 B-Condition
, NCT03920527 164 165 O
fever NCT03920527 166 171 B-Condition
and NCT03920527 172 175 B-Or
dyspnea NCT03920527 176 183 B-Condition
) NCT03920527 184 185 O
for NCT03920527 186 189 O
≥ NCT03920527 190 191 B-Eq-Comparison
3 NCT03920527 192 193 I-Eq-Comparison
months NCT03920527 194 200 I-Eq-Comparison

- NCT03920527 203 204 O
slowly NCT03920527 206 212 B-Modifier
progressive NCT03920527 213 224 I-Modifier
or NCT03920527 225 227 B-Or
persistent NCT03920527 228 238 B-Modifier
radiological NCT03920527 239 251 B-Procedure
findings NCT03920527 252 260 B-Condition
( NCT03920527 261 262 O
one NCT03920527 263 266 B-Eq-Comparison
or NCT03920527 267 269 I-Eq-Comparison
more NCT03920527 270 274 I-Eq-Comparison
cavities NCT03920527 275 283 B-Condition
and NCT03920527 284 287 B-Or
surrounding NCT03920527 288 299 B-Modifier
fibrosis NCT03920527 300 308 B-Condition
, NCT03920527 309 310 O
infiltrates NCT03920527 311 322 B-Condition
, NCT03920527 323 324 O
consolidation NCT03920527 325 338 B-Condition
, NCT03920527 339 340 O
with NCT03920527 341 345 O
or NCT03920527 346 348 O
without NCT03920527 349 356 O
fungal NCT03920527 357 363 B-Condition
ball NCT03920527 364 368 I-Condition
or NCT03920527 369 371 B-Or
progressive NCT03920527 372 383 B-Modifier
pleural NCT03920527 384 391 B-Condition
thickening NCT03920527 392 402 I-Condition
) NCT03920527 403 404 O
on NCT03920527 405 407 O
computed NCT03920527 408 416 B-Procedure
tomography NCT03920527 417 427 I-Procedure
( NCT03920527 428 429 O
CT NCT03920527 430 432 B-Procedure
) NCT03920527 433 434 O
of NCT03920527 435 437 O
the NCT03920527 438 441 O
thorax NCT03920527 442 448 B-Modifier

- NCT03920527 451 452 O
immunological NCT03920527 454 467 B-Modifier
( NCT03920527 468 469 O
A. NCT03920527 470 472 B-Organism
fumigatus NCT03920527 473 482 I-Organism
- NCT03920527 483 484 O
specific NCT03920527 485 493 O
IgG NCT03920527 494 497 B-Observation
> NCT03920527 498 499 B-Eq-Comparison
27 NCT03920527 500 502 I-Eq-Comparison
mgA NCT03920527 503 506 I-Eq-Comparison
/ NCT03920527 507 508 I-Eq-Comparison
L NCT03920527 509 510 I-Eq-Comparison
or NCT03920527 511 513 B-Or
positive NCT03920527 514 522 O
Aspergillus NCT03920527 523 534 B-Organism
precipitins NCT03920527 535 546 I-Organism
) NCT03920527 547 548 O
or NCT03920527 549 551 O
microbiological NCT03920527 552 567 B-Observation
evidence NCT03920527 568 576 O
of NCT03920527 577 579 O
Aspergillus NCT03920527 580 591 B-Modifier
infection NCT03920527 592 601 B-Condition
( NCT03920527 602 603 O
growth NCT03920527 604 610 O
of NCT03920527 611 613 O
Aspergillus NCT03920527 614 625 B-Organism
in NCT03920527 626 628 O
respiratory NCT03920527 629 640 B-Observation
secretions NCT03920527 641 651 I-Observation
or NCT03920527 652 654 B-Or
serum NCT03920527 655 660 B-Observation
galactomannan NCT03920527 661 674 I-Observation
index NCT03920527 675 680 I-Observation
> NCT03920527 681 682 B-Eq-Comparison
0.5 NCT03920527 683 686 I-Eq-Comparison
or NCT03920527 687 689 B-Or
BALF NCT03920527 690 694 B-Observation
galactomannan NCT03920527 695 708 I-Observation
index NCT03920527 709 714 I-Observation
> NCT03920527 715 716 B-Eq-Comparison
1 NCT03920527 717 718 I-Eq-Comparison
) NCT03920527 719 720 O
and NCT03920527 721 724 B-And
, NCT03920527 725 726 O

- NCT03920527 730 731 O
exclusion NCT03920527 733 742 B-Negation
of NCT03920527 743 745 O
other NCT03920527 746 751 B-Other
pulmonary NCT03920527 752 761 B-Modifier
disorders NCT03920527 762 771 B-Condition
with NCT03920527 772 776 O
similar NCT03920527 777 784 O
presentation NCT03920527 785 797 O
. NCT03920527 798 799 O

Exclusion NCT03920527 801 810 O
Criteria NCT03920527 811 819 O
: NCT03920527 820 821 O

- NCT03920527 825 826 O
failure NCT03920527 828 835 O
to NCT03920527 836 838 O
provide NCT03920527 839 846 O
informed NCT03920527 847 855 O
consent NCT03920527 856 863 O

- NCT03920527 866 867 O
patients NCT03920527 869 877 O
on NCT03920527 878 880 B-Eq-Comparison
immunosuppressive NCT03920527 881 898 B-Drug
drugs NCT03920527 899 904 I-Drug
, NCT03920527 905 906 O
intake NCT03920527 907 913 O
of NCT03920527 914 916 O
prednisolone NCT03920527 917 929 B-Drug
( NCT03920527 930 931 O
or NCT03920527 932 934 O
equivalent NCT03920527 935 945 O
) NCT03920527 946 947 O
> NCT03920527 948 949 B-Eq-Comparison
10 NCT03920527 950 952 I-Eq-Comparison
mg NCT03920527 953 955 I-Eq-Comparison
for NCT03920527 956 959 O
at NCT03920527 960 962 B-Eq-Comparison
least NCT03920527 963 968 I-Eq-Comparison
3 NCT03920527 969 970 I-Eq-Comparison
weeks NCT03920527 971 976 I-Eq-Comparison
or NCT03920527 977 979 B-Or
a NCT03920527 980 981 O
diagnosis NCT03920527 982 991 O
of NCT03920527 992 994 O
human NCT03920527 995 1000 B-Condition
immunodeficiency NCT03920527 1001 1017 I-Condition
virus NCT03920527 1018 1023 I-Condition
syndrome NCT03920527 1024 1032 I-Condition

- NCT03920527 1035 1036 O
intake NCT03920527 1038 1044 O
antifungal NCT03920527 1045 1055 B-Drug
azoles NCT03920527 1056 1062 I-Drug
for NCT03920527 1063 1066 O
> NCT03920527 1067 1068 B-Eq-Comparison
3 NCT03920527 1069 1070 I-Eq-Comparison
weeks NCT03920527 1071 1076 I-Eq-Comparison
in NCT03920527 1077 1079 O
the NCT03920527 1080 1083 O
preceding NCT03920527 1084 1093 B-Eq-Comparison
six NCT03920527 1094 1097 I-Eq-Comparison
months NCT03920527 1098 1104 I-Eq-Comparison

- NCT03920527 1107 1108 O
subjects NCT03920527 1110 1118 O
with NCT03920527 1119 1123 O
active NCT03920527 1124 1130 B-Eq-Comparison
pulmonary NCT03920527 1131 1140 B-Modifier
infection NCT03920527 1141 1150 B-Condition
due NCT03920527 1151 1154 O
to NCT03920527 1155 1157 O
mycobacterium NCT03920527 1158 1171 B-Organism
tuberculosis NCT03920527 1172 1184 I-Organism
or NCT03920527 1185 1187 B-Or
mycobacteria NCT03920527 1188 1200 B-Organism
other NCT03920527 1201 1206 B-Exception
than NCT03920527 1207 1211 I-Exception
tuberculosis NCT03920527 1212 1224 B-Condition
( NCT03920527 1225 1226 O
MOTT NCT03920527 1227 1231 B-Condition
) NCT03920527 1232 1233 O

- NCT03920527 1237 1238 O
subjects NCT03920527 1240 1248 O
with NCT03920527 1249 1253 O
others NCT03920527 1254 1260 B-Other
forms NCT03920527 1261 1266 O
of NCT03920527 1267 1269 O
pulmonary NCT03920527 1270 1279 B-Modifier
aspergillosis NCT03920527 1280 1293 B-Condition
( NCT03920527 1294 1295 O
allergic NCT03920527 1296 1304 B-Modifier
bronchopulmonary NCT03920527 1305 1321 I-Modifier
aspergillosis NCT03920527 1322 1335 B-Condition
, NCT03920527 1336 1337 O
chronic NCT03920527 1338 1345 B-Modifier
necrotizing NCT03920527 1346 1357 I-Modifier
aspergillosis NCT03920527 1358 1371 B-Condition
and NCT03920527 1372 1375 B-Or
angio NCT03920527 1376 1381 B-Modifier
- NCT03920527 1382 1383 I-Modifier
invasive NCT03920527 1384 1392 I-Modifier
aspergillosis NCT03920527 1393 1406 B-Condition
) NCT03920527 1407 1408 O

- NCT03920527 1412 1413 O
pregnancy NCT03920527 1415 1424 B-Condition

Inclusion NCT03920241 0 9 O
Criteria NCT03920241 10 18 O
: NCT03920241 19 20 O

- NCT03920241 24 25 O
18 NCT03920241 27 29 B-Eq-Comparison
years NCT03920241 30 35 I-Eq-Comparison
of NCT03920241 36 38 I-Eq-Comparison
age NCT03920241 39 42 I-Eq-Comparison
or NCT03920241 43 45 I-Eq-Comparison
more NCT03920241 46 50 I-Eq-Comparison

- NCT03920241 53 54 O
Fluency NCT03920241 56 63 O
in NCT03920241 64 66 O
oral NCT03920241 67 71 O
and NCT03920241 72 75 O
written NCT03920241 76 83 O
Spanish NCT03920241 84 91 O

Exclusion NCT03920241 92 101 O
Criteria NCT03920241 102 110 O
: NCT03920241 111 112 O

- NCT03920241 116 117 O
Having NCT03920241 119 125 O
any NCT03920241 126 129 O
current NCT03920241 130 137 B-Eq-Comparison
of NCT03920241 138 140 O
serious NCT03920241 141 148 O
psychological NCT03920241 149 162 B-Condition
disorder NCT03920241 163 171 I-Condition
or NCT03920241 172 174 B-Or
substance NCT03920241 175 184 B-Condition
abuse NCT03920241 185 190 B-Modifier
/ NCT03920241 191 192 B-Or
dependence NCT03920241 193 203 B-Modifier
. NCT03920241 204 205 O

- NCT03920241 209 210 O
Being NCT03920241 212 217 O
currently NCT03920241 218 227 B-Eq-Comparison
enrolled NCT03920241 228 236 O
in NCT03920241 237 239 O
another NCT03920241 240 247 O
standardized NCT03920241 248 260 O
meditation NCT03920241 261 271 B-Procedure
program NCT03920241 272 279 I-Procedure

Inclusion NCT03927274 0 9 O
Criteria NCT03927274 10 18 O
: NCT03927274 19 20 O

- NCT03927274 24 25 O
Histologically NCT03927274 27 41 B-Procedure
confirmed NCT03927274 42 51 O
diagnosis NCT03927274 52 61 O
of NCT03927274 62 64 O
supratentorial NCT03927274 65 79 B-Modifier
WHO NCT03927274 80 83 O
Grade NCT03927274 84 89 B-Eq-Comparison
III NCT03927274 90 93 I-Eq-Comparison
or NCT03927274 94 96 I-Eq-Comparison
IV NCT03927274 97 99 I-Eq-Comparison
Glioma NCT03927274 100 106 B-Condition
( NCT03927274 107 108 O
High NCT03927274 109 113 B-Modifier
Grade NCT03927274 114 119 I-Modifier
Glioma NCT03927274 120 126 B-Condition
) NCT03927274 127 128 O
that NCT03927274 129 133 O
has NCT03927274 134 137 B-And
undergone NCT03927274 138 147 B-Eq-Comparison
surgical NCT03927274 148 156 B-Procedure
biopsy NCT03927274 157 163 I-Procedure
or NCT03927274 164 166 B-Or
resection NCT03927274 167 176 B-Procedure
followed NCT03927274 177 185 B-Temporal-Connection___Temporal-Connection-Type-Value:before
by NCT03927274 186 188 I-Temporal-Connection___Temporal-Connection-Type-Value:before
adjuvant NCT03927274 189 197 B-Procedure
chemoradiotherapy NCT03927274 198 215 I-Procedure
, NCT03927274 216 217 O
that NCT03927274 218 222 O
has NCT03927274 223 226 B-And
evidence NCT03927274 227 235 O
of NCT03927274 236 238 O
recurrence NCT03927274 239 249 B-Coreference
or NCT03927274 250 252 B-Or
progression NCT03927274 253 264 B-Coreference
based NCT03927274 265 270 O
on NCT03927274 271 273 O
imaging NCT03927274 274 281 B-Procedure
studies NCT03927274 282 289 O
and NCT03927274 290 293 B-And
a NCT03927274 294 295 O
stereotactic NCT03927274 296 308 B-Modifier
biopsy NCT03927274 309 315 B-Procedure
is NCT03927274 316 318 O
indicated NCT03927274 319 328 B-Indication
for NCT03927274 329 332 O
confirmation NCT03927274 333 345 O
of NCT03927274 346 348 O
recurrence NCT03927274 349 359 B-Coreference
/ NCT03927274 360 361 B-Or
progression NCT03927274 362 373 B-Coreference
. NCT03927274 374 375 O

- NCT03927274 379 380 O
18 NCT03927274 382 384 B-Eq-Comparison
years NCT03927274 385 390 I-Eq-Comparison
of NCT03927274 391 393 I-Eq-Comparison
age NCT03927274 394 397 I-Eq-Comparison
or NCT03927274 398 400 I-Eq-Comparison
older NCT03927274 401 406 I-Eq-Comparison

- NCT03927274 409 410 O
Karnofsky NCT03927274 412 421 B-Observation
Performance NCT03927274 422 433 I-Observation
Status NCT03927274 434 440 I-Observation
70 NCT03927274 441 443 B-Eq-Comparison
- NCT03927274 444 445 I-Eq-Comparison
100 NCT03927274 446 449 O
; NCT03927274 450 451 O

- NCT03927274 454 455 O
MRI NCT03927274 457 460 B-Procedure
demonstration NCT03927274 461 474 O
of NCT03927274 475 477 O
a NCT03927274 478 479 O
stereotactically NCT03927274 480 496 B-Modifier
accessible NCT03927274 497 507 I-Modifier
enhancing NCT03927274 508 517 I-Modifier
or NCT03927274 518 520 B-Or
predominantly NCT03927274 521 534 B-Modifier
non NCT03927274 535 538 I-Modifier
- NCT03927274 539 540 I-Modifier
enhancing NCT03927274 541 550 I-Modifier
mass NCT03927274 551 555 B-Condition
that NCT03927274 556 560 B-And
does NCT03927274 561 565 O
not NCT03927274 566 569 B-Negation
require NCT03927274 570 577 B-Assertion___Assertion-Type-Value:hypothetical
resection NCT03927274 578 587 B-Procedure
to NCT03927274 588 590 O
relieve NCT03927274 591 598 O
clinically NCT03927274 599 609 O
significant NCT03927274 610 621 O
mass NCT03927274 622 626 B-Condition
effect NCT03927274 627 633 I-Condition
; NCT03927274 633 634 O

- NCT03927274 637 638 O
Participant NCT03927274 640 651 O
understands NCT03927274 652 663 O
the NCT03927274 664 667 O
procedures NCT03927274 668 678 O
and NCT03927274 679 682 O
agrees NCT03927274 683 689 O
to NCT03927274 690 692 O
comply NCT03927274 693 699 O
with NCT03927274 700 704 O
the NCT03927274 705 708 O
study NCT03927274 709 714 O
requirements NCT03927274 715 727 O
by NCT03927274 728 730 O
providing NCT03927274 731 740 O
written NCT03927274 741 748 O
informed NCT03927274 749 757 O
consent NCT03927274 758 765 O

- NCT03927274 768 769 O
Adequate NCT03927274 771 779 O
organ NCT03927274 780 785 B-Condition
function NCT03927274 786 794 I-Condition
as NCT03927274 795 797 O
indicated NCT03927274 798 807 O
in NCT03927274 808 810 O
protocol NCT03927274 811 819 O

Exclusion NCT03927274 820 829 O
Criteria NCT03927274 830 838 O
: NCT03927274 839 840 O

- NCT03927274 844 845 O
Participant NCT03927274 847 858 O
is NCT03927274 859 861 O
mentally NCT03927274 862 870 B-Modifier
or NCT03927274 871 873 B-Or
legally NCT03927274 874 881 B-Modifier
incapacitated NCT03927274 882 895 B-Condition
at NCT03927274 896 898 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03927274 899 902 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03927274 903 907 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03927274 908 910 O
the NCT03927274 911 914 O
study NCT03927274 915 920 B-Study
; NCT03927274 920 921 O

- NCT03927274 924 925 O
Known NCT03927274 927 932 O
HIV NCT03927274 933 936 B-Condition
( NCT03927274 937 938 O
+ NCT03927274 940 941 O
) NCT03927274 943 944 O
or NCT03927274 945 947 B-Or
has NCT03927274 948 951 O
been NCT03927274 952 956 O
diagnosed NCT03927274 957 966 O
with NCT03927274 967 971 O
AIDS NCT03927274 972 976 B-Condition

- NCT03927274 979 980 O
Participation NCT03927274 982 995 O
in NCT03927274 996 998 O
another NCT03927274 999 1006 B-Other
investigational NCT03927274 1007 1022 O
drug NCT03927274 1023 1027 B-Drug
study NCT03927274 1028 1033 B-Study
in NCT03927274 1034 1036 O
the NCT03927274 1037 1040 O
prior NCT03927274 1041 1046 B-Eq-Comparison
4 NCT03927274 1047 1048 I-Eq-Comparison
weeks NCT03927274 1049 1054 I-Eq-Comparison

- NCT03927274 1057 1058 O
Positive NCT03927274 1060 1068 O
pregnancy NCT03927274 1069 1078 B-Observation
test NCT03927274 1079 1083 I-Observation
in NCT03927274 1084 1086 O
a NCT03927274 1087 1088 O
female NCT03927274 1089 1095 O

- NCT03927274 1098 1099 O
Patient NCT03927274 1101 1108 O
, NCT03927274 1109 1110 O
in NCT03927274 1111 1113 O
the NCT03927274 1114 1117 O
opinion NCT03927274 1118 1125 O
of NCT03927274 1126 1128 O
the NCT03927274 1129 1132 O
investigator NCT03927274 1133 1145 O
, NCT03927274 1146 1147 O
is NCT03927274 1148 1150 O
likely NCT03927274 1151 1157 O
to NCT03927274 1158 1160 O
be NCT03927274 1161 1163 O
poorly NCT03927274 1164 1170 O
compliant NCT03927274 1171 1180 O
. NCT03927274 1181 1182 O

- NCT03927274 1186 1187 O
Diffuse NCT03927274 1189 1196 B-Condition
subependymal NCT03927274 1197 1209 I-Condition
or NCT03927274 1210 1212 B-Or
Cerebral NCT03927274 1213 1221 B-Modifier
Spinal NCT03927274 1222 1228 I-Modifier
Fluid NCT03927274 1229 1234 I-Modifier
( NCT03927274 1235 1236 O
CSF NCT03927274 1237 1240 B-Condition
) NCT03927274 1241 1242 O
disease NCT03927274 1243 1250 B-Condition

- NCT03927274 1253 1254 O
Tumors NCT03927274 1256 1262 B-Condition
involving NCT03927274 1263 1272 O
the NCT03927274 1273 1276 O
cerebellum NCT03927274 1277 1287 B-Modifier

- NCT03927274 1290 1291 O
Tumor NCT03927274 1293 1298 B-Condition
enhancement NCT03927274 1299 1310 B-Modifier
involving NCT03927274 1311 1320 I-Modifier
both NCT03927274 1321 1325 I-Modifier
hemispheres NCT03927274 1326 1337 I-Modifier

- NCT03927274 1340 1341 O
Active NCT03927274 1343 1349 B-Eq-Comparison
infection NCT03927274 1350 1359 B-Condition
requiring NCT03927274 1360 1369 B-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03927274 1370 1379 B-Procedure

- NCT03927274 1382 1383 O
Unexplained NCT03927274 1385 1396 B-Modifier
febrile NCT03927274 1397 1404 B-Condition
illness NCT03927274 1405 1412 I-Condition

- NCT03927274 1415 1416 O
Radiation NCT03927274 1418 1427 B-Procedure
or NCT03927274 1428 1430 B-Or
chemotherapy NCT03927274 1431 1443 B-Procedure
within NCT03927274 1444 1450 B-Eq-Comparison
4 NCT03927274 1451 1452 I-Eq-Comparison
weeks NCT03927274 1453 1458 I-Eq-Comparison
of NCT03927274 1459 1461 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03927274 1462 1472 B-Study

- NCT03927274 1475 1476 O
Systemic NCT03927274 1478 1486 B-Modifier
diseases NCT03927274 1487 1495 B-Condition
associated NCT03927274 1496 1506 O
with NCT03927274 1507 1511 O
unacceptable NCT03927274 1512 1524 O
anesthesia NCT03927274 1525 1535 B-Procedure
or NCT03927274 1536 1538 B-Or
operative NCT03927274 1539 1548 B-Procedure
risk NCT03927274 1549 1553 B-Risk

- NCT03927274 1556 1557 O
Inability NCT03927274 1559 1568 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03927274 1569 1571 O
undergo NCT03927274 1572 1579 O
magnetic NCT03927274 1580 1588 B-Procedure
resonance NCT03927274 1589 1598 I-Procedure
imaging NCT03927274 1599 1606 I-Procedure
( NCT03927274 1607 1608 O
MRI NCT03927274 1609 1612 B-Procedure
) NCT03927274 1613 1614 O

Inclusion NCT03921177 0 9 O
Criteria NCT03921177 10 18 O
: NCT03921177 19 20 O

- NCT03921177 24 25 O
Resident NCT03921177 27 35 O
of NCT03921177 36 38 O
566 NCT03921177 39 42 O
rural NCT03921177 43 48 O
sectors NCT03921177 49 56 O
( NCT03921177 57 58 O
clusters NCT03921177 59 67 O
) NCT03921177 68 69 O
in NCT03921177 70 72 O
Gaibandha NCT03921177 73 82 O
district NCT03921177 83 91 O

- NCT03921177 94 95 O
Recently NCT03921177 97 105 B-Eq-Comparison
- NCT03921177 106 107 O
married NCT03921177 108 115 B-Condition
woman NCT03921177 116 121 O

- NCT03921177 124 125 O
Nulligravid NCT03921177 127 138 B-Condition

Exclusion NCT03921177 139 148 O
Criteria NCT03921177 149 157 O
: NCT03921177 158 159 O

- NCT03921177 163 164 O
Women NCT03921177 166 171 O
with NCT03921177 172 176 B-And
a NCT03921177 177 178 O
history NCT03921177 179 186 B-Eq-Comparison
of NCT03921177 187 189 I-Eq-Comparison
previous NCT03921177 190 198 I-Eq-Comparison
pregnancy NCT03921177 199 208 B-Condition

- NCT03921177 211 212 O
Women NCT03921177 214 219 O
who NCT03921177 220 223 O
refuse NCT03921177 224 230 O
consent NCT03921177 231 238 O
for NCT03921177 239 242 O
participation NCT03921177 243 256 O

Inclusion NCT03925311 0 9 O
Criteria NCT03925311 10 18 O
: NCT03925311 19 20 O

Age NCT03925311 22 25 B-Age
20 NCT03925311 26 28 B-Eq-Comparison
- NCT03925311 29 30 I-Eq-Comparison
40 NCT03925311 31 33 I-Eq-Comparison
years NCT03925311 34 39 I-Eq-Comparison
. NCT03925311 40 41 O

Exclusion NCT03925311 43 52 O
Criteria NCT03925311 53 61 O
: NCT03925311 62 63 O

- NCT03925311 67 68 O
Uncorrected NCT03925311 70 81 B-Modifier
uterine NCT03925311 82 89 I-Modifier
anomalies NCT03925311 90 99 B-Condition
, NCT03925311 100 101 O
such NCT03925311 102 106 O
as NCT03925311 107 109 O
septate NCT03925311 110 117 B-Modifier
or NCT03925311 118 120 B-Or
bicornuate NCT03925311 121 131 B-Modifier
uterus NCT03925311 132 138 B-Condition
, NCT03925311 139 140 O
fibroids NCT03925311 141 149 B-Condition
( NCT03925311 150 151 O
submucous NCT03925311 152 161 B-Modifier
/ NCT03925311 162 163 B-Or
intramural NCT03925311 164 174 B-Modifier
) NCT03925311 175 176 O
. NCT03925311 178 179 O

- NCT03925311 183 184 O
Intrauterine NCT03925311 186 198 B-Condition
adhesions NCT03925311 199 208 I-Condition
. NCT03925311 209 210 O

- NCT03925311 214 215 O
Adenomyosis NCT03925311 217 228 B-Condition
. NCT03925311 228 229 O

Key NCT03926195 0 3 O
Inclusion NCT03926195 4 13 O
Criteria NCT03926195 14 22 O
: NCT03926195 23 24 O

- NCT03926195 28 29 O
Male NCT03926195 31 35 O
participants NCT03926195 36 48 O
who NCT03926195 49 52 B-And
are NCT03926195 53 56 O
between NCT03926195 57 64 B-Eq-Comparison
the NCT03926195 65 68 I-Eq-Comparison
ages NCT03926195 69 73 I-Age|Eq-Comparison
of NCT03926195 74 76 I-Eq-Comparison
21 NCT03926195 77 79 I-Eq-Comparison
and NCT03926195 80 83 I-Eq-Comparison
65 NCT03926195 84 86 I-Eq-Comparison
years NCT03926195 87 92 I-Eq-Comparison
( NCT03926195 93 94 O
inclusive NCT03926195 95 104 O
) NCT03926195 105 106 O
on NCT03926195 107 109 O
the NCT03926195 110 113 O
day NCT03926195 114 117 O
of NCT03926195 118 120 O
signing NCT03926195 121 128 O
informed NCT03926195 129 137 O
consent NCT03926195 138 145 O

- NCT03926195 148 149 O
Diagnosis NCT03926195 151 160 O
of NCT03926195 161 163 O
active NCT03926195 164 170 B-Eq-Comparison
rheumatoid NCT03926195 171 181 B-Condition
arthritis NCT03926195 182 191 I-Condition
, NCT03926195 192 193 O
psoriatic NCT03926195 194 203 B-Condition
arthritis NCT03926195 204 213 I-Condition
, NCT03926195 214 215 O
ankylosing NCT03926195 216 226 B-Condition
spondylitis NCT03926195 227 238 I-Condition
or NCT03926195 239 241 B-Or
, NCT03926195 242 243 O
non NCT03926195 244 247 B-Modifier
- NCT03926195 248 249 I-Modifier
radiographic NCT03926195 250 262 I-Modifier
axial NCT03926195 263 268 B-Condition
spondyloarthritis NCT03926195 269 286 I-Condition
for NCT03926195 287 290 O
at NCT03926195 291 293 B-Eq-Comparison
least NCT03926195 294 299 I-Eq-Comparison
12 NCT03926195 300 302 I-Eq-Comparison
weeks NCT03926195 303 308 I-Eq-Comparison
prior NCT03926195 309 314 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926195 315 317 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03926195 318 327 B-Study
, NCT03926195 328 329 O
meeting NCT03926195 330 337 O
the NCT03926195 338 341 O
corresponding NCT03926195 342 355 O
specific NCT03926195 356 364 O
disease NCT03926195 365 372 O
classification NCT03926195 373 387 O
criteria NCT03926195 388 396 O
as NCT03926195 397 399 O
specified NCT03926195 400 409 O
in NCT03926195 410 412 O
the NCT03926195 413 416 O
protocol NCT03926195 417 425 O

Key NCT03926195 426 429 O
Exclusion NCT03926195 430 439 O
Criteria NCT03926195 440 448 O
: NCT03926195 449 450 O

- NCT03926195 454 455 O
Previously NCT03926195 457 467 B-Eq-Comparison
documented NCT03926195 468 478 O
problems NCT03926195 479 487 B-Condition
with NCT03926195 488 492 I-Condition
male NCT03926195 493 497 I-Condition
reproductive NCT03926195 498 510 I-Condition
health NCT03926195 511 517 I-Condition

- NCT03926195 520 521 O
Prior NCT03926195 523 528 B-Eq-Comparison
diagnosis NCT03926195 529 538 O
of NCT03926195 539 541 O
male NCT03926195 542 546 B-Condition
infertility NCT03926195 547 558 I-Condition

- NCT03926195 561 562 O
Use NCT03926195 564 567 B-Eq-Comparison
of NCT03926195 568 570 O
any NCT03926195 571 574 O
prohibited NCT03926195 575 585 B-Modifier
concomitant NCT03926195 586 597 I-Modifier
medication NCT03926195 598 608 B-Drug
as NCT03926195 609 611 O
outlined NCT03926195 612 620 O
by NCT03926195 621 623 O
protocol NCT03926195 624 632 O

Note NCT03926195 633 637 O
: NCT03926195 638 639 O
Other NCT03926195 640 645 O
protocol NCT03926195 646 654 O
- NCT03926195 655 656 O
defined NCT03926195 657 664 O
Inclusion NCT03926195 665 674 O
/ NCT03926195 675 676 O
Exclusion NCT03926195 677 686 O
criteria NCT03926195 687 695 O
may NCT03926195 696 699 O
apply NCT03926195 700 705 O
. NCT03926195 705 706 O

Inclusion NCT03928379 0 9 O
Criteria NCT03928379 10 18 O
: NCT03928379 19 20 O

- NCT03928379 24 25 O
Have NCT03928379 27 31 O
Type NCT03928379 32 36 B-Condition
II NCT03928379 37 39 I-Condition
diabetes NCT03928379 40 48 I-Condition

- NCT03928379 51 52 O
Body NCT03928379 54 58 B-Observation
mass NCT03928379 59 63 I-Observation
index NCT03928379 64 69 I-Observation
( NCT03928379 70 71 O
BMI NCT03928379 72 75 B-Observation
) NCT03928379 76 77 O
of NCT03928379 78 80 O
25 NCT03928379 81 83 B-Eq-Comparison
- NCT03928379 84 85 I-Eq-Comparison
40 NCT03928379 86 88 I-Eq-Comparison
kilograms NCT03928379 89 98 I-Eq-Comparison
per NCT03928379 99 102 I-Eq-Comparison
square NCT03928379 103 109 I-Eq-Comparison
meter NCT03928379 110 115 I-Eq-Comparison
( NCT03928379 116 117 O
kg NCT03928379 118 120 O
/ NCT03928379 121 122 O
m² NCT03928379 123 125 O
) NCT03928379 126 127 O
, NCT03928379 129 130 O
inclusive NCT03928379 131 140 O

- NCT03928379 143 144 O
Have NCT03928379 146 150 O
a NCT03928379 151 152 O
body NCT03928379 153 157 B-Observation
weight NCT03928379 158 164 I-Observation
of NCT03928379 165 167 O
< NCT03928379 168 169 B-Eq-Comparison
150 NCT03928379 170 173 I-Eq-Comparison
kilograms NCT03928379 174 183 I-Eq-Comparison
( NCT03928379 184 185 O
kg NCT03928379 186 188 O
) NCT03928379 189 190 O

- NCT03928379 194 195 O
Have NCT03928379 197 201 O
clinical NCT03928379 202 210 O
lab NCT03928379 211 214 B-Observation
test NCT03928379 215 219 I-Observation
results NCT03928379 220 227 O
within NCT03928379 228 234 B-Eq-Comparison
normal NCT03928379 235 241 I-Eq-Comparison
reference NCT03928379 242 251 I-Eq-Comparison
range NCT03928379 252 257 I-Eq-Comparison
for NCT03928379 258 261 O
the NCT03928379 262 265 O
population NCT03928379 266 276 O
or NCT03928379 277 279 O
investigator NCT03928379 280 292 O
site NCT03928379 293 297 O
, NCT03928379 298 299 O
or NCT03928379 300 302 O
results NCT03928379 303 310 O
with NCT03928379 311 315 O
acceptable NCT03928379 316 326 O
deviations NCT03928379 327 337 O
that NCT03928379 338 342 O
are NCT03928379 343 346 O
judged NCT03928379 347 353 O
to NCT03928379 354 356 O
be NCT03928379 357 359 O
not NCT03928379 360 363 O
clinically NCT03928379 364 374 O
significant NCT03928379 375 386 O
by NCT03928379 387 389 O
the NCT03928379 390 393 O
investigator NCT03928379 394 406 O
; NCT03928379 406 407 O
however NCT03928379 408 415 O
, NCT03928379 416 417 O
should NCT03928379 418 424 O
have NCT03928379 425 429 O
serum NCT03928379 430 435 B-Observation
magnesium NCT03928379 436 445 I-Observation
and NCT03928379 446 449 B-And
potassium NCT03928379 450 459 B-Observation
levels NCT03928379 460 466 I-Observation
, NCT03928379 467 468 O
along NCT03928379 469 474 B-And
with NCT03928379 475 479 I-And
lactate NCT03928379 480 487 B-Observation
dehydrogenase NCT03928379 488 501 I-Observation
, NCT03928379 502 503 O
CK NCT03928379 504 506 B-Observation
values NCT03928379 507 513 O
within NCT03928379 514 520 B-Eq-Comparison
the NCT03928379 521 524 I-Eq-Comparison
normal NCT03928379 525 531 I-Eq-Comparison
range NCT03928379 532 537 I-Eq-Comparison
at NCT03928379 538 540 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03928379 541 550 B-Study
and NCT03928379 551 554 B-And
Day NCT03928379 555 558 B-Study
- NCT03928379 559 560 O
2 NCT03928379 561 562 O
. NCT03928379 562 563 O

Exclusion NCT03928379 565 574 O
Criteria NCT03928379 575 583 O
: NCT03928379 584 585 O

- NCT03928379 589 590 O
Have NCT03928379 592 596 O
Type NCT03928379 597 601 B-Condition
1 NCT03928379 602 603 I-Condition
diabetes NCT03928379 604 612 I-Condition
or NCT03928379 613 615 B-Or
latent NCT03928379 616 622 B-Modifier
autoimmune NCT03928379 623 633 I-Modifier
diabetes NCT03928379 634 642 B-Condition
in NCT03928379 643 645 B-Modifier
adults NCT03928379 646 652 I-Modifier

- NCT03928379 655 656 O
Have NCT03928379 658 662 O
uncontrolled NCT03928379 663 675 B-Modifier
diabetes NCT03928379 676 684 B-Condition
defined NCT03928379 685 692 O
as NCT03928379 693 695 O
an NCT03928379 696 698 O
episode NCT03928379 699 706 O
of NCT03928379 707 709 O
ketoacidosis NCT03928379 710 722 B-Condition
or NCT03928379 723 725 B-Or
hyperosmolar NCT03928379 726 738 B-Condition
state NCT03928379 739 744 I-Condition
requiring NCT03928379 745 754 O
hospitalization NCT03928379 755 770 B-Encounter
for NCT03928379 771 774 O
6 NCT03928379 775 776 B-Eq-Comparison
months NCT03928379 777 783 I-Eq-Comparison
prior NCT03928379 784 789 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03928379 790 792 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03928379 793 802 B-Study

- NCT03928379 805 806 O
Have NCT03928379 808 812 O
had NCT03928379 813 816 O
an NCT03928379 817 819 O
episode NCT03928379 820 827 O
of NCT03928379 828 830 O
severe NCT03928379 831 837 O
hypoglycemia NCT03928379 838 850 B-Condition
, NCT03928379 851 852 O
defined NCT03928379 853 860 O
by NCT03928379 861 863 O
the NCT03928379 864 867 O
occurrence NCT03928379 868 878 O
of NCT03928379 879 881 O
neuroglycopenic NCT03928379 882 897 B-Condition
symptoms NCT03928379 898 906 B-Assertion___Assertion-Type-Value:possible
requiring NCT03928379 907 916 O
the NCT03928379 917 920 O
assistance NCT03928379 921 931 B-Observation
of NCT03928379 932 934 I-Observation
another NCT03928379 935 942 I-Observation
person NCT03928379 943 949 I-Observation
for NCT03928379 950 953 O
recovery NCT03928379 954 962 O
, NCT03928379 963 964 O
within NCT03928379 965 971 B-Eq-Comparison
6 NCT03928379 972 973 I-Eq-Comparison
months NCT03928379 974 980 I-Eq-Comparison
prior NCT03928379 981 986 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03928379 987 989 O
Visit NCT03928379 990 995 B-Study
1 NCT03928379 996 997 O

- NCT03928379 1001 1002 O
Have NCT03928379 1004 1008 O
an NCT03928379 1009 1011 O
abnormal NCT03928379 1012 1020 O
12 NCT03928379 1021 1023 B-Procedure
- NCT03928379 1024 1025 I-Procedure
lead NCT03928379 1026 1030 I-Procedure
electrocardiogram NCT03928379 1031 1048 I-Procedure
( NCT03928379 1049 1050 O
ECG NCT03928379 1051 1054 B-Procedure
) NCT03928379 1055 1056 O
at NCT03928379 1057 1059 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03928379 1060 1069 B-Study
and NCT03928379 1070 1073 B-Or
/ NCT03928379 1074 1075 I-Or
or NCT03928379 1076 1078 I-Or
Day NCT03928379 1079 1082 B-Study
- NCT03928379 1083 1084 O
2 NCT03928379 1085 1086 O
that NCT03928379 1087 1091 O
, NCT03928379 1092 1093 O
in NCT03928379 1094 1096 O
the NCT03928379 1097 1100 O
opinion NCT03928379 1101 1108 O
of NCT03928379 1109 1111 O
the NCT03928379 1112 1115 O
investigator NCT03928379 1116 1128 O
, NCT03928379 1129 1130 O
increases NCT03928379 1131 1140 O
the NCT03928379 1141 1144 O
risks NCT03928379 1145 1150 B-Risk
associated NCT03928379 1151 1161 O
with NCT03928379 1162 1166 O
participating NCT03928379 1167 1180 O
in NCT03928379 1181 1183 O
the NCT03928379 1184 1187 O
study NCT03928379 1188 1193 B-Study
or NCT03928379 1194 1196 O
may NCT03928379 1197 1200 O
confound NCT03928379 1201 1209 O
ECG NCT03928379 1210 1213 O
data NCT03928379 1214 1218 O
analysis NCT03928379 1219 1227 O

- NCT03928379 1230 1231 O
Have NCT03928379 1233 1237 O
poorly NCT03928379 1238 1244 B-Modifier
controlled NCT03928379 1245 1255 I-Modifier
hypertension NCT03928379 1256 1268 B-Condition
at NCT03928379 1269 1271 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03928379 1272 1281 B-Study
; NCT03928379 1281 1282 O
or NCT03928379 1283 1285 B-Or
a NCT03928379 1286 1287 O
change NCT03928379 1288 1294 O
in NCT03928379 1295 1297 O
antihypertensive NCT03928379 1298 1314 B-Drug
medication NCT03928379 1315 1325 I-Drug
within NCT03928379 1326 1332 B-Eq-Comparison
30 NCT03928379 1333 1335 I-Eq-Comparison
days NCT03928379 1336 1340 I-Eq-Comparison
of NCT03928379 1341 1343 B-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03928379 1344 1353 B-Study

- NCT03928379 1356 1357 O
Have NCT03928379 1359 1363 O
an NCT03928379 1364 1366 O
estimated NCT03928379 1367 1376 B-Observation
glomerular NCT03928379 1377 1387 I-Observation
filtration NCT03928379 1388 1398 I-Observation
rate NCT03928379 1399 1403 I-Observation
< NCT03928379 1404 1405 B-Eq-Comparison
45 NCT03928379 1406 1408 I-Eq-Comparison
milliliters NCT03928379 1409 1420 I-Eq-Comparison
per NCT03928379 1421 1424 I-Eq-Comparison
minute NCT03928379 1425 1431 I-Eq-Comparison
per NCT03928379 1432 1435 I-Eq-Comparison
1.73 NCT03928379 1436 1440 I-Eq-Comparison
meters NCT03928379 1441 1447 I-Eq-Comparison
squared NCT03928379 1448 1455 I-Eq-Comparison
of NCT03928379 1456 1458 O
body NCT03928379 1459 1463 O
surface NCT03928379 1464 1471 O
area NCT03928379 1472 1476 O
( NCT03928379 1477 1478 O
mL NCT03928379 1479 1481 O
/ NCT03928379 1482 1483 O
min NCT03928379 1484 1487 O
/ NCT03928379 1488 1489 O
1.73 NCT03928379 1490 1494 O
m² NCT03928379 1495 1497 O
) NCT03928379 1498 1499 O

Inclusion NCT03925649 0 9 O
Criteria NCT03925649 10 18 O
: NCT03925649 19 20 O

- NCT03925649 24 25 O
Cognitively NCT03925649 27 38 O
intact NCT03925649 39 45 O
, NCT03925649 46 47 O
capable NCT03925649 48 55 O
of NCT03925649 56 58 O
giving NCT03925649 59 65 O
informed NCT03925649 66 74 O
consent NCT03925649 75 82 O

- NCT03925649 85 86 O
Clinical NCT03925649 88 96 O
diagnosis NCT03925649 97 106 O
of NCT03925649 107 109 O
a NCT03925649 110 111 O
non NCT03925649 112 115 B-Modifier
- NCT03925649 116 117 I-Modifier
penetrating NCT03925649 118 129 I-Modifier
traumatic NCT03925649 130 139 I-Modifier
SCI NCT03925649 140 143 B-Condition

- NCT03925649 146 147 O
Asia NCT03925649 149 153 B-Condition
Impairment NCT03925649 154 164 I-Condition
Scale NCT03925649 165 170 I-Condition
grade NCT03925649 171 176 B-Eq-Comparison
of NCT03925649 177 179 I-Eq-Comparison
A NCT03925649 180 181 I-Eq-Comparison
, NCT03925649 182 183 I-Eq-Comparison
B NCT03925649 184 185 I-Eq-Comparison
, NCT03925649 186 187 I-Eq-Comparison
or NCT03925649 188 190 I-Eq-Comparison
C NCT03925649 191 192 I-Eq-Comparison

Exclusion NCT03925649 193 202 O
Criteria NCT03925649 203 211 O
: NCT03925649 212 213 O

1 NCT03925649 217 218 O
. NCT03925649 218 219 O
Prior NCT03925649 221 226 B-Eq-Comparison
history NCT03925649 227 234 O
of NCT03925649 235 237 O
: NCT03925649 238 239 O

- NCT03925649 248 249 O
Brain NCT03925649 251 256 B-Modifier
injury NCT03925649 257 263 B-Condition

- NCT03925649 271 272 O
Recent NCT03925649 274 280 B-Eq-Comparison
or NCT03925649 281 283 B-Or
ongoing NCT03925649 284 291 B-Eq-Comparison
infection NCT03925649 292 301 B-Condition

- NCT03925649 309 310 O
Clinically NCT03925649 312 322 O
significant NCT03925649 323 334 O
cardiovascular NCT03925649 335 349 B-Modifier
, NCT03925649 350 351 O
lung NCT03925649 352 356 B-Modifier
, NCT03925649 357 358 O
renal NCT03925649 359 364 B-Modifier
, NCT03925649 365 366 O
hepatic NCT03925649 367 374 B-Modifier
or NCT03925649 375 377 B-Or
endocrine NCT03925649 378 387 B-Modifier
disease NCT03925649 388 395 B-Condition
, NCT03925649 396 397 O

- NCT03925649 406 407 O
Neurodegenerative NCT03925649 409 426 B-Condition
disorders NCT03925649 427 436 I-Condition

- NCT03925649 444 445 O
Cancer NCT03925649 447 453 B-Condition

- NCT03925649 461 462 O
Immunosuppression NCT03925649 464 481 B-Condition
as NCT03925649 482 484 O
defined NCT03925649 485 492 O
by NCT03925649 493 495 O
WBC NCT03925649 496 499 B-Observation
< NCT03925649 500 501 B-Eq-Comparison
3 NCT03925649 502 503 I-Eq-Comparison
, NCT03925649 504 505 I-Eq-Comparison
000 NCT03925649 506 509 I-Eq-Comparison
cells NCT03925649 510 515 I-Eq-Comparison
/ NCT03925649 516 517 I-Eq-Comparison
ml NCT03925649 518 520 I-Eq-Comparison
at NCT03925649 521 523 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03925649 524 532 B-Study
screening NCT03925649 533 542 O
, NCT03925649 543 544 O

- NCT03925649 553 554 O
HIV NCT03925649 556 559 B-Condition
+ NCT03925649 560 561 O

- NCT03925649 570 571 O
Chemical NCT03925649 573 581 B-Modifier
or NCT03925649 582 584 B-Or
ETOH NCT03925649 585 589 B-Modifier
dependency NCT03925649 590 600 B-Condition

2 NCT03925649 603 604 O
. NCT03925649 604 605 O
Having NCT03925649 607 613 O
a NCT03925649 614 615 O
contraindication NCT03925649 616 632 B-Contraindication
to NCT03925649 633 635 O
MRI NCT03925649 636 639 B-Procedure
scans NCT03925649 640 645 O

3 NCT03925649 648 649 O
. NCT03925649 649 650 O
Other NCT03925649 652 657 O
acute NCT03925649 658 663 O
or NCT03925649 664 666 B-Or
chronic NCT03925649 667 674 B-Modifier
medical NCT03925649 675 682 B-Condition
conditions NCT03925649 683 693 I-Condition
that NCT03925649 694 698 O
, NCT03925649 699 700 O
in NCT03925649 701 703 O
the NCT03925649 704 707 O
opinion NCT03925649 708 715 O
of NCT03925649 716 718 O
the NCT03925649 719 722 O
investigator NCT03925649 723 735 O
, NCT03925649 736 737 O
may NCT03925649 738 741 B-Assertion___Assertion-Type-Value:hypothetical
increase NCT03925649 742 750 O
the NCT03925649 751 754 O
risks NCT03925649 755 760 B-Risk
associated NCT03925649 761 771 O
with NCT03925649 772 776 O
study NCT03925649 777 782 B-Study
participation NCT03925649 783 796 O
or NCT03925649 797 799 B-Or
HB NCT03925649 800 802 B-Drug
- NCT03925649 803 804 I-Drug
adMSC NCT03925649 805 810 I-Drug
administration NCT03925649 811 825 O

4 NCT03925649 828 829 O
. NCT03925649 829 830 O
Participation NCT03925649 832 845 O
in NCT03925649 846 848 O
other NCT03925649 849 854 B-Other
interventional NCT03925649 855 869 O
research NCT03925649 870 878 O
studies NCT03925649 879 886 B-Study

5 NCT03925649 889 890 O
. NCT03925649 890 891 O
Unwillingness NCT03925649 893 906 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03925649 907 909 O
return NCT03925649 910 916 O
for NCT03925649 917 920 O
follow NCT03925649 921 927 B-Encounter
- NCT03925649 928 929 I-Encounter
up NCT03925649 930 932 I-Encounter
visits NCT03925649 933 939 I-Encounter

Inclusion NCT03922126 0 9 O
Criteria NCT03922126 10 18 O
: NCT03922126 19 20 O

- NCT03922126 24 25 O
male NCT03922126 27 31 O
sex NCT03922126 32 35 O
( NCT03922126 36 37 O
at NCT03922126 38 40 B-Temporal-Connection___Temporal-Connection-Type-Value:during
birth NCT03922126 41 46 B-Birth
) NCT03922126 47 48 O

- NCT03922126 52 53 O
adult NCT03922126 55 60 O
aged NCT03922126 61 65 B-Age
18 NCT03922126 66 68 B-Eq-Comparison
and NCT03922126 69 72 I-Eq-Comparison
older NCT03922126 73 78 I-Eq-Comparison

- NCT03922126 81 82 O
immigrant NCT03922126 84 93 B-Observation
( NCT03922126 94 95 O
not NCT03922126 96 99 B-Negation
born NCT03922126 100 104 B-Birth
in NCT03922126 105 107 O
continental NCT03922126 108 119 O
U. NCT03922126 120 122 O
S. NCT03922126 123 125 O
) NCT03922126 126 127 O

- NCT03922126 131 132 O
Latino NCT03922126 134 140 O
( NCT03922126 141 142 O
identifies NCT03922126 143 153 O
as NCT03922126 154 156 O
either NCT03922126 157 163 O
Latinx NCT03922126 164 170 O
or NCT03922126 171 173 B-Or
Hispanic NCT03922126 174 182 O

- NCT03922126 185 186 O
reports NCT03922126 188 195 O
sex NCT03922126 196 199 B-Observation
with NCT03922126 200 204 O
men NCT03922126 205 208 O
in NCT03922126 209 211 O
past NCT03922126 212 216 B-Eq-Comparison
12 NCT03922126 217 219 O
months NCT03922126 220 226 O

- NCT03922126 229 230 O
reports NCT03922126 232 239 O
not NCT03922126 240 243 B-Negation
knowing NCT03922126 244 251 B-Assertion___Assertion-Type-Value:hypothetical
their NCT03922126 252 257 O
HIV NCT03922126 258 261 B-Condition
status NCT03922126 262 268 O
or NCT03922126 269 271 B-Or
being NCT03922126 272 277 O
HIV NCT03922126 278 281 B-Condition
negative NCT03922126 282 290 O

Exclusion NCT03922126 291 300 O
Criteria NCT03922126 301 309 O
: NCT03922126 310 311 O

- NCT03922126 315 316 O
Does NCT03922126 318 322 O
not NCT03922126 323 326 B-Negation
identify NCT03922126 327 335 O
as NCT03922126 336 338 O
Latino NCT03922126 339 345 O
/ NCT03922126 346 347 B-Or
Hispanic NCT03922126 348 356 O

- NCT03922126 359 360 O
Born NCT03922126 362 366 B-Birth
in NCT03922126 367 369 O
the NCT03922126 370 373 O
continental NCT03922126 374 385 O
U. NCT03922126 386 388 O
S NCT03922126 389 390 O
. NCT03922126 391 392 O

- NCT03922126 396 397 O
Female NCT03922126 399 405 O
sex NCT03922126 406 409 O
( NCT03922126 410 411 O
at NCT03922126 412 414 O
birth NCT03922126 415 420 O
) NCT03922126 421 422 O

- NCT03922126 426 427 O
Does NCT03922126 429 433 O
not NCT03922126 434 437 B-Negation
report NCT03922126 438 444 O
sex NCT03922126 445 448 B-Condition
with NCT03922126 449 453 I-Condition
men NCT03922126 454 457 I-Condition
in NCT03922126 458 460 O
the NCT03922126 461 464 O
last NCT03922126 465 469 B-Eq-Comparison
12 NCT03922126 470 472 I-Eq-Comparison
months NCT03922126 473 479 I-Eq-Comparison

- NCT03922126 482 483 O
Reports NCT03922126 485 492 O
being NCT03922126 493 498 O
HIV NCT03922126 499 502 B-Condition
positive NCT03922126 503 511 O

- NCT03922126 514 515 O
Younger NCT03922126 517 524 B-Eq-Comparison
than NCT03922126 525 529 I-Eq-Comparison
18 NCT03922126 530 532 I-Eq-Comparison
years NCT03922126 533 538 I-Eq-Comparison
old NCT03922126 539 542 B-Age

Inclusion NCT03924557 0 9 O
Criteria NCT03924557 10 18 O
: NCT03924557 19 20 O

- NCT03924557 24 25 O
Must NCT03924557 27 31 O
have NCT03924557 32 36 O
a NCT03924557 37 38 O
clinical NCT03924557 39 47 O
diagnosis NCT03924557 48 57 O
of NCT03924557 58 60 O
solid NCT03924557 61 66 B-Modifier
tumor NCT03924557 67 72 I-Modifier
cancer NCT03924557 73 79 B-Condition
and NCT03924557 80 83 O
be NCT03924557 84 86 O
seeking NCT03924557 87 94 B-Assertion___Assertion-Type-Value:intention
treatment NCT03924557 95 104 B-Procedure
and NCT03924557 105 108 B-And
supportive NCT03924557 109 119 B-Procedure
care NCT03924557 120 124 I-Procedure
at NCT03924557 125 127 O
the NCT03924557 128 131 O
UF NCT03924557 132 134 O
Health NCT03924557 135 141 O
Cancer NCT03924557 142 148 O
Center NCT03924557 149 155 O
( NCT03924557 156 157 O
Medical NCT03924557 158 165 O
Plaza NCT03924557 166 171 O
) NCT03924557 172 173 O

- NCT03924557 177 178 O
Patients NCT03924557 180 188 O
must NCT03924557 189 193 O
plan NCT03924557 194 198 B-Eq-Comparison
to NCT03924557 199 201 O
receive NCT03924557 202 209 O
chemotherapy NCT03924557 210 222 B-Procedure
known NCT03924557 223 228 O
to NCT03924557 229 231 O
be NCT03924557 232 234 O
associated NCT03924557 235 245 O
with NCT03924557 246 250 O
the NCT03924557 251 254 O
need NCT03924557 255 259 O
for NCT03924557 260 263 O
supportive NCT03924557 264 274 O
care NCT03924557 275 279 O
within NCT03924557 280 286 B-Eq-Comparison
30 NCT03924557 287 289 I-Eq-Comparison
days NCT03924557 290 294 I-Eq-Comparison
of NCT03924557 295 297 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03924557 298 308 B-Study

- NCT03924557 311 312 O
Life NCT03924557 314 318 B-Observation
expectancy NCT03924557 319 329 I-Observation
must NCT03924557 330 334 O
be NCT03924557 335 337 O
greater NCT03924557 338 345 B-Eq-Comparison
than NCT03924557 346 350 I-Eq-Comparison
6 NCT03924557 351 352 I-Eq-Comparison
months NCT03924557 353 359 I-Eq-Comparison

- NCT03924557 362 363 O
Must NCT03924557 365 369 O
have NCT03924557 370 374 O
Eastern NCT03924557 375 382 B-Observation
Cooperative NCT03924557 383 394 I-Observation
Oncology NCT03924557 395 403 I-Observation
Group NCT03924557 404 409 I-Observation
( NCT03924557 410 411 O
ECOG NCT03924557 412 416 B-Observation
) NCT03924557 417 418 O
performance NCT03924557 419 430 O
status NCT03924557 431 437 O
of NCT03924557 438 440 O
0 NCT03924557 441 442 B-Eq-Comparison
- NCT03924557 443 444 I-Eq-Comparison
2 NCT03924557 445 446 O

- NCT03924557 450 451 O
Written NCT03924557 453 460 O
informed NCT03924557 461 469 O
consent NCT03924557 470 477 O
obtained NCT03924557 478 486 O
from NCT03924557 487 491 O
the NCT03924557 492 495 O
patient NCT03924557 496 503 O

- NCT03924557 506 507 O
The NCT03924557 509 512 O
ability NCT03924557 513 520 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03924557 521 524 O
the NCT03924557 525 528 O
patient NCT03924557 529 536 O
to NCT03924557 537 539 O
comply NCT03924557 540 546 O
with NCT03924557 547 551 O
all NCT03924557 552 555 O
the NCT03924557 556 559 O
study NCT03924557 560 565 B-Study
- NCT03924557 566 567 O
related NCT03924557 568 575 O
procedures NCT03924557 576 586 B-Procedure
. NCT03924557 587 588 O

Exclusion NCT03924557 590 599 O
Criteria NCT03924557 600 608 O
: NCT03924557 609 610 O

- NCT03924557 614 615 O
Patients NCT03924557 617 625 O
unwilling NCT03924557 626 635 O
or NCT03924557 636 638 O
unable NCT03924557 639 645 O
to NCT03924557 646 648 O
provide NCT03924557 649 656 O
voluntary NCT03924557 657 666 O
informed NCT03924557 667 675 O
consent NCT03924557 676 683 O

- NCT03924557 686 687 O
Patients NCT03924557 689 697 O
who NCT03924557 698 701 O
are NCT03924557 702 705 O
unwilling NCT03924557 706 715 O
or NCT03924557 716 718 O
unable NCT03924557 719 725 O
to NCT03924557 726 728 O
comply NCT03924557 729 735 O
with NCT03924557 736 740 O
protocol NCT03924557 741 749 O
requirement NCT03924557 750 761 O
and NCT03924557 762 765 O
/ NCT03924557 766 767 O
or NCT03924557 768 770 O
follow NCT03924557 771 777 O
- NCT03924557 778 779 O
up NCT03924557 780 782 O
procedures NCT03924557 783 793 O

- NCT03924557 796 797 O
Patients NCT03924557 799 807 O
planned NCT03924557 808 815 B-Eq-Comparison
to NCT03924557 816 818 I-Eq-Comparison
undergo NCT03924557 819 826 I-Eq-Comparison
cancer NCT03924557 827 833 B-Condition
therapy NCT03924557 834 841 B-Procedure
other NCT03924557 842 847 B-Exception
than NCT03924557 848 852 I-Exception
chemotherapy NCT03924557 853 865 B-Procedure
( NCT03924557 866 867 O
i. NCT03924557 868 870 O
e. NCT03924557 871 873 O
, NCT03924557 874 875 O
radiation NCT03924557 876 885 B-Procedure
, NCT03924557 886 887 O
surgery NCT03924557 888 895 B-Procedure
or NCT03924557 896 898 B-Or
hormonal NCT03924557 899 907 B-Procedure
treatment NCT03924557 908 917 I-Procedure
alone NCT03924557 918 923 O
) NCT03924557 924 925 O

- NCT03924557 929 930 O
Prisoners NCT03924557 932 941 B-Observation
or NCT03924557 942 944 B-Or
patients NCT03924557 945 953 O
who NCT03924557 954 957 O
are NCT03924557 958 961 O
involuntarily NCT03924557 962 975 B-Observation
incarcerated NCT03924557 976 988 I-Observation
. NCT03924557 988 989 O
Patients NCT03924557 991 999 O
who NCT03924557 1000 1003 O
are NCT03924557 1004 1007 O
compulsorily NCT03924557 1008 1020 O
detained NCT03924557 1021 1029 O
for NCT03924557 1030 1033 O
treatment NCT03924557 1034 1043 B-Procedure
of NCT03924557 1044 1046 O
either NCT03924557 1047 1053 O
a NCT03924557 1054 1055 O
psychiatric NCT03924557 1056 1067 B-Modifier
or NCT03924557 1068 1070 B-Or
physical NCT03924557 1071 1079 B-Modifier
illness NCT03924557 1080 1087 B-Condition
. NCT03924557 1087 1088 O

Inclusion NCT03927937 0 9 O
Criteria NCT03927937 10 18 O
: NCT03927937 19 20 O

- NCT03927937 24 25 O
Tooth NCT03927937 27 32 O
with NCT03927937 33 37 O
imposible NCT03927937 38 47 O
prognosis NCT03927937 48 57 O

- NCT03927937 60 61 O
Plaque NCT03927937 63 69 B-Observation
index NCT03927937 70 75 I-Observation
score NCT03927937 76 81 I-Observation
less NCT03927937 82 86 B-Eq-Comparison
than NCT03927937 87 91 I-Eq-Comparison
30 NCT03927937 92 94 I-Eq-Comparison
% NCT03927937 95 96 I-Eq-Comparison

- NCT03927937 100 101 O
No NCT03927937 103 105 B-Negation
relevant NCT03927937 106 114 O
systemic NCT03927937 115 123 B-Modifier
disease NCT03927937 124 131 B-Condition

- NCT03927937 134 135 O
Smokers NCT03927937 137 144 B-Observation
( NCT03927937 145 146 O
Less NCT03927937 147 151 B-Eq-Comparison
than NCT03927937 152 156 I-Eq-Comparison
20 NCT03927937 157 159 I-Eq-Comparison
cigars NCT03927937 160 166 I-Eq-Comparison
/ NCT03927937 167 168 I-Eq-Comparison
day NCT03927937 169 172 I-Eq-Comparison
) NCT03927937 173 174 O

Exclusion NCT03927937 176 185 O
Criteria NCT03927937 186 194 O
: NCT03927937 195 196 O

- NCT03927937 200 201 O
Pregnancy NCT03927937 203 212 B-Condition
- NCT03927937 213 214 B-Or
Lactation NCT03927937 215 224 B-Condition

- NCT03927937 227 228 O
Relevant NCT03927937 230 238 O
systemic NCT03927937 239 247 B-Modifier
disease NCT03927937 248 255 B-Condition

Inclusion NCT03929926 0 9 O
Criteria NCT03929926 10 18 O
: NCT03929926 19 20 O

- NCT03929926 24 25 O
Had NCT03929926 27 30 O
a NCT03929926 31 32 O
recent NCT03929926 33 39 B-Eq-Comparison
office NCT03929926 40 46 B-Encounter
visit NCT03929926 47 52 I-Encounter
with NCT03929926 53 57 O
a NCT03929926 58 59 O
primary NCT03929926 60 67 B-Provider
care NCT03929926 68 72 I-Provider
physician NCT03929926 73 82 I-Provider
in NCT03929926 83 85 O
one NCT03929926 86 89 O
of NCT03929926 90 92 O
the NCT03929926 93 96 O
study NCT03929926 97 102 O
practices NCT03929926 103 112 O
. NCT03929926 113 114 O

- NCT03929926 118 119 O
History NCT03929926 121 128 B-Eq-Comparison
of NCT03929926 129 131 O
smoking NCT03929926 132 139 B-Condition
( NCT03929926 140 141 O
current NCT03929926 142 149 B-Eq-Comparison
or NCT03929926 150 152 B-Or
former NCT03929926 153 159 B-Eq-Comparison
) NCT03929926 160 161 O
in NCT03929926 162 164 O
the NCT03929926 165 168 O
electronic NCT03929926 169 179 O
health NCT03929926 180 186 O
record NCT03929926 187 193 O
( NCT03929926 194 195 O
EHR NCT03929926 196 199 O
) NCT03929926 200 201 O
. NCT03929926 203 204 O

Exclusion NCT03929926 206 215 O
Criteria NCT03929926 216 224 O
: NCT03929926 225 226 O

- NCT03929926 230 231 O
LDCT NCT03929926 233 237 B-Procedure
performed NCT03929926 238 247 O
in NCT03929926 248 250 O
the NCT03929926 251 254 O
12 NCT03929926 255 257 B-Eq-Comparison
months NCT03929926 258 264 I-Eq-Comparison
prior NCT03929926 265 270 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03929926 271 273 I-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03929926 274 279 B-Study
initiation NCT03929926 280 290 O
according NCT03929926 291 300 O
to NCT03929926 301 303 O
EHR NCT03929926 304 307 O
. NCT03929926 308 309 O

- NCT03929926 313 314 O
Diagnosis NCT03929926 316 325 O
of NCT03929926 326 328 O
lung NCT03929926 329 333 B-Modifier
cancer NCT03929926 334 340 B-Condition
indicated NCT03929926 341 350 O
in NCT03929926 351 353 O
problem NCT03929926 354 361 O
list NCT03929926 362 366 O
in NCT03929926 367 369 O
the NCT03929926 370 373 O
EHR NCT03929926 374 377 O
. NCT03929926 377 378 O

Inclusion NCT03928392 0 9 O
Criteria NCT03928392 10 18 O
: NCT03928392 19 20 O

- NCT03928392 24 25 O
18 NCT03928392 27 29 B-Eq-Comparison
to NCT03928392 30 32 I-Eq-Comparison
95 NCT03928392 33 35 I-Eq-Comparison
years NCT03928392 36 41 I-Eq-Comparison
of NCT03928392 42 44 O
age NCT03928392 45 48 B-Age

- NCT03928392 51 52 O
Participation NCT03928392 54 67 O
in NCT03928392 68 70 O
WAVES NCT03928392 71 76 O
Project NCT03928392 77 84 O
for NCT03928392 85 88 O
at NCT03928392 89 91 B-Eq-Comparison
least NCT03928392 92 97 I-Eq-Comparison
3 NCT03928392 98 99 I-Eq-Comparison
months NCT03928392 100 106 I-Eq-Comparison

- NCT03928392 109 110 O
Completion NCT03928392 112 122 O
of NCT03928392 123 125 O
3 NCT03928392 126 127 B-Eq-Comparison
open NCT03928392 128 132 B-Observation
water NCT03928392 133 138 I-Observation
dives NCT03928392 139 144 I-Observation

- NCT03928392 147 148 O
Proficient NCT03928392 150 160 O
in NCT03928392 161 163 O
written NCT03928392 164 171 O
and NCT03928392 172 175 O
verbal NCT03928392 176 182 O
English NCT03928392 183 190 O

Exclusion NCT03928392 191 200 O
Criteria NCT03928392 201 209 O
: NCT03928392 210 211 O

- NCT03928392 215 216 O
Younger NCT03928392 218 225 B-Eq-Comparison
than NCT03928392 226 230 I-Eq-Comparison
18 NCT03928392 231 233 I-Eq-Comparison
years NCT03928392 234 239 I-Eq-Comparison
of NCT03928392 240 242 O
age NCT03928392 243 246 B-Age
or NCT03928392 247 249 B-Or
older NCT03928392 250 255 B-Eq-Comparison
than NCT03928392 256 260 I-Eq-Comparison
95 NCT03928392 261 263 I-Eq-Comparison
years NCT03928392 264 269 I-Eq-Comparison
of NCT03928392 270 272 O
age NCT03928392 273 276 B-Age

- NCT03928392 279 280 O
Not NCT03928392 282 285 B-Negation
a NCT03928392 286 287 O
member NCT03928392 288 294 O
of NCT03928392 295 297 O
WAVES NCT03928392 298 303 O
Project NCT03928392 304 311 O
within NCT03928392 312 318 B-Eq-Comparison
3 NCT03928392 319 320 I-Eq-Comparison
months NCT03928392 321 327 I-Eq-Comparison
of NCT03928392 328 330 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03928392 331 336 B-Study
recruitment NCT03928392 337 348 O

- NCT03928392 351 352 O
Has NCT03928392 354 357 O
not NCT03928392 358 361 B-Negation
completed NCT03928392 362 371 O
3 NCT03928392 372 373 B-Eq-Comparison
open NCT03928392 374 378 B-Observation
water NCT03928392 379 384 I-Observation
dives NCT03928392 385 390 I-Observation

- NCT03928392 393 394 O
Not NCT03928392 396 399 B-Negation
proficient NCT03928392 400 410 O
in NCT03928392 411 413 O
written NCT03928392 414 421 O
and NCT03928392 422 425 O
verbal NCT03928392 426 432 O
English NCT03928392 433 440 O

Inclusion NCT03922867 0 9 O
Criteria NCT03922867 10 18 O
: NCT03922867 19 20 O

- NCT03922867 24 25 O
Meets NCT03922867 27 32 O
diagnostic NCT03922867 33 43 O
criteria NCT03922867 44 52 O
for NCT03922867 53 56 O
fibromyalgia NCT03922867 57 69 B-Condition

- NCT03922867 72 73 O
Has NCT03922867 75 78 O
insomnia NCT03922867 79 87 B-Condition

- NCT03922867 90 91 O
Have NCT03922867 93 97 O
internet NCT03922867 98 106 O
access NCT03922867 107 113 O
and NCT03922867 114 117 O
a NCT03922867 118 119 O
device NCT03922867 120 126 O
that NCT03922867 127 131 O
can NCT03922867 132 135 O
access NCT03922867 136 142 O
the NCT03922867 143 146 O
web NCT03922867 147 150 O
- NCT03922867 151 152 O
based NCT03922867 153 158 O
program NCT03922867 159 166 O
. NCT03922867 167 168 O

Exclusion NCT03922867 170 179 O
Criteria NCT03922867 180 188 O
: NCT03922867 189 190 O

- NCT03922867 194 195 O
Active NCT03922867 197 203 B-Eq-Comparison
sleep NCT03922867 204 209 B-Condition
disorder NCT03922867 210 218 I-Condition
which NCT03922867 219 224 O
is NCT03922867 225 227 O
not NCT03922867 228 231 B-Negation
treated NCT03922867 232 239 B-Procedure
( NCT03922867 240 241 O
obstructive NCT03922867 242 253 B-Condition
sleep NCT03922867 254 259 I-Condition
apnea NCT03922867 260 265 I-Condition
, NCT03922867 266 267 O
obesity NCT03922867 268 275 B-Condition
hypoventilation NCT03922867 276 291 I-Condition
syndrome NCT03922867 292 300 I-Condition
) NCT03922867 301 302 O

- NCT03922867 306 307 O
Active NCT03922867 309 315 B-Eq-Comparison
psychiatric NCT03922867 316 327 B-Condition
disorder NCT03922867 328 336 I-Condition
( NCT03922867 337 338 O
Bipolar NCT03922867 339 346 B-Condition
affective NCT03922867 347 356 I-Condition
disorder NCT03922867 357 365 I-Condition
, NCT03922867 366 367 O
anxiety NCT03922867 368 375 B-Condition
, NCT03922867 376 377 O
depression NCT03922867 378 388 B-Condition
, NCT03922867 389 390 O
schizophrenia NCT03922867 391 404 B-Condition
) NCT03922867 405 406 O
which NCT03922867 407 412 O
is NCT03922867 413 415 O
not NCT03922867 416 419 O
optimally NCT03922867 420 429 O
managed NCT03922867 430 437 O
. NCT03922867 438 439 O

- NCT03922867 443 444 O
Chronic NCT03922867 446 453 B-Modifier
fatigue NCT03922867 454 461 B-Condition
syndrome NCT03922867 462 470 I-Condition

- NCT03922867 473 474 O
Morbid NCT03922867 476 482 B-Condition
obesity NCT03922867 483 490 I-Condition

Inclusion NCT03920891 0 9 O
Criteria NCT03920891 10 18 O
: NCT03920891 19 20 O

- NCT03920891 24 25 O
1 NCT03920891 27 28 O
. NCT03920891 28 29 O
Patient NCT03920891 31 38 O
with NCT03920891 39 43 O
hemodynamic NCT03920891 44 55 B-Modifier
corrected NCT03920891 56 65 I-Modifier
valvular NCT03920891 66 74 I-Modifier
atrial NCT03920891 75 81 B-Condition
fibrillation NCT03920891 82 94 I-Condition
who NCT03920891 95 98 B-And
is NCT03920891 99 101 O
scheduled NCT03920891 102 111 B-Eq-Comparison
for NCT03920891 112 115 O
ablation NCT03920891 116 124 B-Procedure
procedure NCT03920891 125 134 I-Procedure
and NCT03920891 135 138 B-And
≥ NCT03920891 139 140 B-Eq-Comparison
20 NCT03920891 141 143 I-Eq-Comparison
and NCT03920891 144 147 B-And
≤ NCT03920891 148 149 B-Eq-Comparison
80 NCT03920891 150 152 I-Eq-Comparison
years NCT03920891 153 158 I-Eq-Comparison
of NCT03920891 159 161 O
age NCT03920891 162 165 B-Age

- NCT03920891 168 169 O
2 NCT03920891 171 172 O
. NCT03920891 172 173 O
Left NCT03920891 175 179 B-Observation
atrium NCT03920891 180 186 I-Observation
size NCT03920891 187 191 I-Observation
< NCT03920891 192 193 B-Eq-Comparison
50 NCT03920891 194 196 I-Eq-Comparison
mm NCT03920891 197 199 I-Eq-Comparison

- NCT03920891 202 203 O
3 NCT03920891 205 206 O
. NCT03920891 206 207 O
paroxysmal NCT03920891 209 219 B-Modifier
atrial NCT03920891 220 226 B-Condition
fibrillation NCT03920891 227 239 I-Condition
that NCT03920891 240 244 O
is NCT03920891 245 247 O
recurrence NCT03920891 248 258 O
during NCT03920891 259 265 B-Temporal-Connection___Temporal-Connection-Type-Value:during
antiarrhythmic NCT03920891 266 280 B-Drug
drug NCT03920891 281 285 I-Drug
treatment NCT03920891 286 295 B-Procedure
or NCT03920891 296 298 B-Or
is NCT03920891 299 301 O
not NCT03920891 302 305 B-Negation
able NCT03920891 306 310 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03920891 311 313 I-Assertion___Assertion-Type-Value:hypothetical
use NCT03920891 314 317 O
an NCT03920891 318 320 O
antiarrhythmic NCT03920891 321 335 B-Drug
drug NCT03920891 336 340 I-Drug
. NCT03920891 341 342 O

- NCT03920891 346 347 O
4 NCT03920891 349 350 O
. NCT03920891 350 351 O
Patient NCT03920891 353 360 O
who NCT03920891 361 364 O
is NCT03920891 365 367 O
indicated NCT03920891 368 377 B-Indication
for NCT03920891 378 381 O
anticoagulation NCT03920891 382 397 B-Procedure
therapy NCT03920891 398 405 I-Procedure
( NCT03920891 406 407 O
for NCT03920891 408 411 O
prevention NCT03920891 412 422 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03920891 423 425 I-Assertion___Assertion-Type-Value:hypothetical
cerebral NCT03920891 426 434 B-Condition
infarction NCT03920891 435 445 I-Condition
) NCT03920891 446 447 O

Exclusion NCT03920891 449 458 O
Criteria NCT03920891 459 467 O
: NCT03920891 468 469 O

- NCT03920891 473 474 O
1 NCT03920891 476 477 O
. NCT03920891 477 478 O
Patients NCT03920891 480 488 O
with NCT03920891 489 493 O
permanent NCT03920891 494 503 B-Modifier
atrial NCT03920891 504 510 B-Condition
fibrillation NCT03920891 511 523 I-Condition

- NCT03920891 526 527 O
2 NCT03920891 529 530 O
. NCT03920891 530 531 O
Atrial NCT03920891 533 539 B-Condition
fibrillation NCT03920891 540 552 I-Condition
associated NCT03920891 553 563 O
with NCT03920891 564 568 O
severe NCT03920891 569 575 O
cardiac NCT03920891 576 583 B-Condition
malformation NCT03920891 584 596 I-Condition
or NCT03920891 597 599 B-Or
a NCT03920891 600 601 O
structural NCT03920891 602 612 B-Modifier
heart NCT03920891 613 618 B-Condition
disease NCT03920891 619 626 I-Condition
that NCT03920891 627 631 O
is NCT03920891 632 634 O
hemodynamically NCT03920891 635 650 B-Modifier
affected NCT03920891 651 659 O

- NCT03920891 662 663 O
3 NCT03920891 665 666 O
. NCT03920891 666 667 O
Patients NCT03920891 669 677 O
with NCT03920891 678 682 O
severe NCT03920891 683 689 O
renal NCT03920891 690 695 B-Modifier
impairment NCT03920891 696 706 B-Condition
or NCT03920891 707 709 B-Or
CT NCT03920891 710 712 B-Procedure
imaging NCT03920891 713 720 I-Procedure
difficulty NCT03920891 721 731 B-Assertion___Assertion-Type-Value:hypothetical|Negation
using NCT03920891 732 737 O
contrast NCT03920891 738 746 B-Procedure
media NCT03920891 747 752 I-Procedure

- NCT03920891 755 756 O
4 NCT03920891 758 759 O
. NCT03920891 759 760 O
Patients NCT03920891 762 770 O
with NCT03920891 771 775 O
a NCT03920891 776 777 O
past NCT03920891 778 782 B-Eq-Comparison
history NCT03920891 783 790 I-Eq-Comparison
of NCT03920891 791 793 O
radiofrequency NCT03920891 794 808 B-Procedure
ablation NCT03920891 809 817 I-Procedure
for NCT03920891 818 821 O
atrial NCT03920891 822 828 B-Condition
fibrillation NCT03920891 829 841 I-Condition
or NCT03920891 842 844 B-Or
other NCT03920891 845 850 B-Other
cardiac NCT03920891 851 858 B-Modifier
surgery NCT03920891 859 866 B-Procedure

- NCT03920891 869 870 O
5 NCT03920891 872 873 O
. NCT03920891 873 874 O
Patients NCT03920891 876 884 O
with NCT03920891 885 889 O
active NCT03920891 890 896 B-Eq-Comparison
internal NCT03920891 897 905 B-Modifier
bleeding NCT03920891 906 914 B-Condition

- NCT03920891 917 918 O
6 NCT03920891 920 921 O
. NCT03920891 921 922 O
Patients NCT03920891 924 932 O
with NCT03920891 933 937 O
contraindications NCT03920891 938 955 B-Contraindication
for NCT03920891 956 959 O
anticoagulation NCT03920891 960 975 B-Procedure
therapy NCT03920891 976 983 I-Procedure
( NCT03920891 984 985 O
for NCT03920891 986 989 O
prevention NCT03920891 990 1000 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03920891 1001 1003 I-Assertion___Assertion-Type-Value:hypothetical
cerebral NCT03920891 1004 1012 B-Condition
infarction NCT03920891 1013 1023 I-Condition
) NCT03920891 1024 1025 O
and NCT03920891 1026 1029 B-Or
antiarrhythmic NCT03920891 1030 1044 B-Drug
drugs NCT03920891 1045 1050 I-Drug

- NCT03920891 1053 1054 O
7 NCT03920891 1056 1057 O
. NCT03920891 1057 1058 O
Patients NCT03920891 1060 1068 O
with NCT03920891 1069 1073 O
non NCT03920891 1074 1077 B-Modifier
- NCT03920891 1078 1079 I-Modifier
valvular NCT03920891 1080 1088 I-Modifier
atrial NCT03920891 1089 1095 B-Condition
fibrillation NCT03920891 1096 1108 I-Condition

- NCT03920891 1111 1112 O
8 NCT03920891 1114 1115 O
. NCT03920891 1115 1116 O
Patients NCT03920891 1118 1126 O
with NCT03920891 1127 1131 O
a NCT03920891 1132 1133 O
severe NCT03920891 1134 1140 O
comorbid NCT03920891 1141 1149 B-Condition
disease NCT03920891 1150 1157 I-Condition

- NCT03920891 1160 1161 O
9 NCT03920891 1163 1164 O
. NCT03920891 1164 1165 O
Expected NCT03920891 1167 1175 B-Observation
survival NCT03920891 1176 1184 I-Observation
< NCT03920891 1185 1186 B-Eq-Comparison
1 NCT03920891 1187 1188 I-Eq-Comparison
year NCT03920891 1189 1193 I-Eq-Comparison

- NCT03920891 1196 1197 O
10 NCT03920891 1199 1201 O
. NCT03920891 1201 1202 O
Drug NCT03920891 1204 1208 B-Condition
addicts NCT03920891 1209 1216 I-Condition
or NCT03920891 1217 1219 B-Or
alcoholics NCT03920891 1220 1230 B-Condition

- NCT03920891 1233 1234 O
11 NCT03920891 1236 1238 O
. NCT03920891 1238 1239 O
Patients NCT03920891 1241 1249 O
who NCT03920891 1250 1253 O
can NCT03920891 1254 1257 O
not NCT03920891 1257 1260 O
read NCT03920891 1261 1265 O
the NCT03920891 1266 1269 O
consent NCT03920891 1270 1277 O
form NCT03920891 1278 1282 O
( NCT03920891 1283 1284 O
illiterates NCT03920891 1285 1296 B-Condition
, NCT03920891 1297 1298 O
foreigners NCT03920891 1299 1309 O
, NCT03920891 1310 1311 O
etc NCT03920891 1312 1315 O
. NCT03920891 1315 1316 O
) NCT03920891 1317 1318 O

- NCT03920891 1322 1323 O
12 NCT03920891 1325 1327 O
. NCT03920891 1327 1328 O
Other NCT03920891 1330 1335 O
patients NCT03920891 1336 1344 O
who NCT03920891 1345 1348 O
are NCT03920891 1349 1352 O
judged NCT03920891 1353 1359 O
by NCT03920891 1360 1362 O
the NCT03920891 1363 1366 O
principal NCT03920891 1367 1376 O
or NCT03920891 1377 1379 O
sub NCT03920891 1380 1383 O
- NCT03920891 1384 1385 O
investigator NCT03920891 1386 1398 O
to NCT03920891 1399 1401 O
be NCT03920891 1402 1404 O
ineligible NCT03920891 1405 1415 O
for NCT03920891 1416 1419 O
participation NCT03920891 1420 1433 O
in NCT03920891 1434 1436 O
this NCT03920891 1437 1441 O
clinical NCT03920891 1442 1450 O
study NCT03920891 1451 1456 O

Inclusion NCT03924349 0 9 O
Criteria NCT03924349 10 18 O
: NCT03924349 19 20 O

- NCT03924349 24 25 O
Cases NCT03924349 27 32 O
which NCT03924349 33 38 O
are NCT03924349 39 42 O
deemed NCT03924349 43 49 O
necessary NCT03924349 50 59 O
to NCT03924349 60 62 O
mark NCT03924349 63 67 O
the NCT03924349 68 71 O
location NCT03924349 72 80 O
of NCT03924349 81 83 O
the NCT03924349 84 87 O
colon NCT03924349 88 93 B-Modifier
lesion NCT03924349 94 100 B-Condition
before NCT03924349 101 107 B-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03924349 108 115 B-Procedure

Exclusion NCT03924349 116 125 O
Criteria NCT03924349 126 134 O
: NCT03924349 135 136 O

- NCT03924349 140 141 O
Pre NCT03924349 143 146 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03924349 147 156 B-Procedure
colonoscopy NCT03924349 157 168 B-Procedure
is NCT03924349 169 171 O
not NCT03924349 172 175 B-Negation
possible NCT03924349 176 184 B-Assertion___Assertion-Type-Value:hypothetical
due NCT03924349 185 188 O
to NCT03924349 189 191 O
intestinal NCT03924349 192 202 B-Condition
obstruction NCT03924349 203 214 I-Condition

- NCT03924349 217 218 O
If NCT03924349 220 222 O
the NCT03924349 223 226 O
lesion NCT03924349 227 233 B-Condition
is NCT03924349 234 236 O
located NCT03924349 237 244 O
in NCT03924349 245 247 O
the NCT03924349 248 251 O
rectal NCT03924349 252 258 B-Modifier
area NCT03924349 259 263 I-Modifier
and NCT03924349 264 267 B-And
the NCT03924349 268 271 O
lesion NCT03924349 272 278 B-Condition
can NCT03924349 279 282 O
be NCT03924349 283 285 O
confirmed NCT03924349 286 295 O
by NCT03924349 296 298 O
digital NCT03924349 299 306 B-Modifier
rectal NCT03924349 307 313 B-Procedure
exam NCT03924349 314 318 I-Procedure

- NCT03924349 321 322 O
disagreement NCT03924349 324 336 O
with NCT03924349 337 341 O
the NCT03924349 342 345 O
study NCT03924349 346 351 B-Study

Inclusion NCT03923426 0 9 O
Criteria NCT03923426 10 18 O
: NCT03923426 19 20 O

1 NCT03923426 24 25 O
. NCT03923426 25 26 O
Hospitalized NCT03923426 28 40 B-Encounter
patient NCT03923426 41 48 O
≥ NCT03923426 49 50 B-Eq-Comparison
18 NCT03923426 51 53 I-Eq-Comparison
years NCT03923426 54 59 I-Eq-Comparison
old NCT03923426 60 63 B-Age
or NCT03923426 64 66 B-Or
considered NCT03923426 67 77 O
an NCT03923426 78 80 O
adult NCT03923426 81 86 O
in NCT03923426 87 89 O
accordance NCT03923426 90 100 O
with NCT03923426 101 105 O
the NCT03923426 106 109 O
age NCT03923426 110 113 O
of NCT03923426 114 116 O
majority NCT03923426 117 125 O
in NCT03923426 126 128 O
the NCT03923426 129 132 O
participant NCT03923426 133 144 O
's NCT03923426 144 146 O
country NCT03923426 147 154 O
of NCT03923426 155 157 O
residence NCT03923426 158 167 O
at NCT03923426 168 170 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03923426 171 174 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03923426 175 179 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03923426 180 182 O
treatment NCT03923426 183 192 B-Procedure
with NCT03923426 193 197 O
ceftazidime NCT03923426 198 209 B-Drug
- NCT03923426 210 211 I-Drug
avibactam NCT03923426 212 221 I-Drug
. NCT03923426 222 223 O

2 NCT03923426 227 228 O
. NCT03923426 228 229 O
Patient NCT03923426 231 238 O
received NCT03923426 239 247 B-Eq-Comparison
≥ NCT03923426 248 249 B-Eq-Comparison
1 NCT03923426 250 251 I-Eq-Comparison
dose NCT03923426 252 256 O
of NCT03923426 257 259 O
ceftazidime NCT03923426 260 271 B-Drug
- NCT03923426 272 273 I-Drug
avibactam NCT03923426 274 283 I-Drug
in NCT03923426 284 286 O
routine NCT03923426 287 294 O
practice NCT03923426 295 303 O
at NCT03923426 304 306 O
participating NCT03923426 307 320 O
site NCT03923426 321 325 O
since NCT03923426 326 331 B-Eq-Comparison
01 NCT03923426 332 334 I-Eq-Comparison
January NCT03923426 335 342 I-Eq-Comparison
, NCT03923426 343 344 I-Eq-Comparison
2018 NCT03923426 345 349 I-Eq-Comparison
onwards NCT03923426 350 357 O
or NCT03923426 358 360 B-Or
since NCT03923426 361 366 O
the NCT03923426 367 370 O
date NCT03923426 371 375 O
of NCT03923426 376 378 O
launch NCT03923426 379 385 O
in NCT03923426 386 388 O
the NCT03923426 389 392 O
country NCT03923426 393 400 O
if NCT03923426 401 403 O
it NCT03923426 404 406 O
is NCT03923426 407 409 O
after NCT03923426 410 415 B-Temporal-Connection___Temporal-Connection-Type-Value:after
01 NCT03923426 416 418 B-Eq-Comparison
January NCT03923426 419 426 I-Eq-Comparison
, NCT03923426 427 428 I-Eq-Comparison
2018 NCT03923426 429 433 I-Eq-Comparison
. NCT03923426 433 434 O

3 NCT03923426 438 439 O
. NCT03923426 439 440 O
Patient NCT03923426 442 449 O
underwent NCT03923426 450 459 B-Eq-Comparison
microbiologic NCT03923426 460 473 B-Observation
sampling NCT03923426 474 482 I-Observation
≤ NCT03923426 483 484 B-Eq-Comparison
5 NCT03923426 485 486 I-Eq-Comparison
days NCT03923426 487 491 I-Eq-Comparison
before NCT03923426 492 498 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03923426 499 502 O
initiation NCT03923426 503 513 B-Eq-Comparison
of NCT03923426 514 516 O
ceftazidime NCT03923426 517 528 B-Drug
- NCT03923426 529 530 I-Drug
avibactam NCT03923426 531 540 I-Drug
( NCT03923426 541 542 O
irrespective NCT03923426 543 555 O
of NCT03923426 556 558 O
results NCT03923426 559 566 O
and NCT03923426 567 570 O
actual NCT03923426 571 577 O
bacteriological NCT03923426 578 593 O
identification NCT03923426 594 608 O
) NCT03923426 609 610 O
. NCT03923426 612 613 O

4 NCT03923426 617 618 O
. NCT03923426 618 619 O
Patient NCT03923426 621 628 O
has NCT03923426 629 632 O
all NCT03923426 633 636 O
required NCT03923426 637 645 O
essential NCT03923426 646 655 O
data NCT03923426 656 660 O
elements NCT03923426 661 669 O
which NCT03923426 670 675 O
include NCT03923426 676 683 O
: NCT03923426 684 685 O

1 NCT03923426 694 695 O
. NCT03923426 695 696 O
Start NCT03923426 698 703 O
and NCT03923426 704 707 O
stop NCT03923426 708 712 O
dates NCT03923426 713 718 O
of NCT03923426 719 721 O
ceftazidime NCT03923426 722 733 B-Drug
- NCT03923426 734 735 I-Drug
avibactam NCT03923426 736 745 I-Drug
, NCT03923426 746 747 O

2 NCT03923426 756 757 O
. NCT03923426 757 758 O
Start NCT03923426 760 765 O
and NCT03923426 766 769 O
stop NCT03923426 770 774 O
dates NCT03923426 775 780 O
of NCT03923426 781 783 O
prior NCT03923426 784 789 B-Eq-Comparison
antibiotic NCT03923426 790 800 B-Procedure
therapy NCT03923426 801 808 I-Procedure
used NCT03923426 809 813 O
for NCT03923426 814 817 O
the NCT03923426 818 821 O
index NCT03923426 822 827 O
infection NCT03923426 828 837 B-Condition
, NCT03923426 838 839 O

3 NCT03923426 848 849 O
. NCT03923426 849 850 O
Type NCT03923426 852 856 O
of NCT03923426 857 859 O
combined NCT03923426 860 868 O
antibiotic NCT03923426 869 879 B-Procedure
therapy NCT03923426 880 887 I-Procedure
( NCT03923426 888 889 O
if NCT03923426 890 892 O
applicable NCT03923426 893 903 O
) NCT03923426 904 905 O
and NCT03923426 906 909 B-And
start NCT03923426 910 915 O
and NCT03923426 916 919 O
stop NCT03923426 920 924 O
dates NCT03923426 925 930 O
of NCT03923426 931 933 O
any NCT03923426 934 937 O
antibiotic NCT03923426 938 948 B-Drug
combined NCT03923426 949 957 B-And
with NCT03923426 958 962 I-And
ceftazidime NCT03923426 963 974 B-Drug
- NCT03923426 975 976 I-Drug
avibactam NCT03923426 977 986 I-Drug
. NCT03923426 987 988 O

5 NCT03923426 992 993 O
. NCT03923426 993 994 O
Evidence NCT03923426 996 1004 O
of NCT03923426 1005 1007 O
a NCT03923426 1008 1009 O
personally NCT03923426 1010 1020 O
signed NCT03923426 1021 1027 O
and NCT03923426 1028 1031 O
dated NCT03923426 1032 1037 O
informed NCT03923426 1038 1046 O
consent NCT03923426 1047 1054 O
document NCT03923426 1055 1063 O
indicating NCT03923426 1064 1074 O
that NCT03923426 1075 1079 O
the NCT03923426 1080 1083 O
patient NCT03923426 1084 1091 O
( NCT03923426 1092 1093 O
or NCT03923426 1094 1096 O
a NCT03923426 1097 1098 O
legally NCT03923426 1099 1106 O
acceptable NCT03923426 1107 1117 O
representative NCT03923426 1118 1132 O
) NCT03923426 1133 1134 O
has NCT03923426 1135 1138 O
been NCT03923426 1139 1143 O
informed NCT03923426 1144 1152 O
of NCT03923426 1153 1155 O
all NCT03923426 1156 1159 O
pertinent NCT03923426 1160 1169 O
aspects NCT03923426 1170 1177 O
of NCT03923426 1178 1180 O
the NCT03923426 1181 1184 O
study NCT03923426 1185 1190 O
where NCT03923426 1191 1196 O
required NCT03923426 1197 1205 O
by NCT03923426 1206 1208 O
local NCT03923426 1209 1214 O
regulations NCT03923426 1215 1226 O
. NCT03923426 1227 1228 O

Exclusion NCT03923426 1230 1239 O
Criteria NCT03923426 1240 1248 O
: NCT03923426 1249 1250 O

Patients NCT03923426 1252 1260 O
must NCT03923426 1261 1265 O
not NCT03923426 1266 1269 O
meet NCT03923426 1270 1274 O
any NCT03923426 1275 1278 O
of NCT03923426 1279 1281 O
the NCT03923426 1282 1285 O
following NCT03923426 1286 1295 O
exclusion NCT03923426 1296 1305 O
criteria NCT03923426 1306 1314 O
to NCT03923426 1315 1317 O
be NCT03923426 1318 1320 O
eligible NCT03923426 1321 1329 O
: NCT03923426 1330 1331 O

1 NCT03923426 1335 1336 O
. NCT03923426 1336 1337 O
The NCT03923426 1339 1342 O
patient NCT03923426 1343 1350 O
is NCT03923426 1351 1353 O
enrolled NCT03923426 1354 1362 O
in NCT03923426 1363 1365 O
any NCT03923426 1366 1369 B-Other
clinical NCT03923426 1370 1378 B-Study
trial NCT03923426 1379 1384 I-Study
of NCT03923426 1385 1387 O
an NCT03923426 1388 1390 O
investigational NCT03923426 1391 1406 B-Drug
product NCT03923426 1407 1414 I-Drug
. NCT03923426 1414 1415 O
Patients NCT03923426 1417 1425 O
who NCT03923426 1426 1429 O
are NCT03923426 1430 1433 O
enrolled NCT03923426 1434 1442 O
in NCT03923426 1443 1445 O
non NCT03923426 1446 1449 O
- NCT03923426 1450 1451 O
interventional NCT03923426 1452 1466 O
studies NCT03923426 1467 1474 O
( NCT03923426 1475 1476 O
NISs NCT03923426 1477 1481 O
) NCT03923426 1482 1483 O
( NCT03923426 1484 1485 O
e. NCT03923426 1486 1488 O
g. NCT03923426 1489 1491 O
registries NCT03923426 1493 1503 O
) NCT03923426 1504 1505 O
are NCT03923426 1506 1509 O
eligible NCT03923426 1510 1518 O
for NCT03923426 1519 1522 O
inclusion NCT03923426 1523 1532 O
. NCT03923426 1533 1534 O

2 NCT03923426 1538 1539 O
. NCT03923426 1539 1540 O
The NCT03923426 1542 1545 O
patient NCT03923426 1546 1553 O
has NCT03923426 1554 1557 O
received NCT03923426 1558 1566 B-Eq-Comparison
ceftazidime NCT03923426 1567 1578 B-Drug
- NCT03923426 1579 1580 I-Drug
avibactam NCT03923426 1581 1590 I-Drug
in NCT03923426 1591 1593 B-Temporal-Connection___Temporal-Connection-Type-Value:during
a NCT03923426 1594 1595 O
compassionate NCT03923426 1596 1609 B-Procedure
care NCT03923426 1610 1614 I-Procedure
program NCT03923426 1615 1622 I-Procedure
setting NCT03923426 1623 1630 O
. NCT03923426 1631 1632 O

3 NCT03923426 1636 1637 O
. NCT03923426 1637 1638 O
The NCT03923426 1640 1643 O
patient NCT03923426 1644 1651 O
was NCT03923426 1652 1655 O
exposed NCT03923426 1656 1663 B-Eq-Comparison
to NCT03923426 1664 1666 O
ceftazidime NCT03923426 1667 1678 B-Drug
- NCT03923426 1679 1680 I-Drug
avibactam NCT03923426 1681 1690 I-Drug
before NCT03923426 1691 1697 B-Temporal-Connection___Temporal-Connection-Type-Value:before
use NCT03923426 1698 1701 O
for NCT03923426 1702 1705 O
the NCT03923426 1706 1709 O
index NCT03923426 1710 1715 O
infection NCT03923426 1716 1725 B-Condition
. NCT03923426 1725 1726 O

Inclusion NCT03929679 0 9 O
Criteria NCT03929679 10 18 O
: NCT03929679 19 20 O

- NCT03929679 24 25 O
Signed NCT03929679 27 33 O
informed NCT03929679 34 42 O
consent NCT03929679 43 50 O
obtained NCT03929679 51 59 O
before NCT03929679 60 66 O
any NCT03929679 67 70 O
study NCT03929679 71 76 O
- NCT03929679 77 78 O
related NCT03929679 79 86 O
activities NCT03929679 87 97 O
( NCT03929679 98 99 O
study NCT03929679 100 105 O
- NCT03929679 106 107 O
related NCT03929679 108 115 O
activities NCT03929679 116 126 O
are NCT03929679 127 130 O
any NCT03929679 131 134 O
procedures NCT03929679 135 145 O
related NCT03929679 146 153 O
to NCT03929679 154 156 O
recording NCT03929679 157 166 O
of NCT03929679 167 169 O
data NCT03929679 170 174 O
according NCT03929679 175 184 O
to NCT03929679 185 187 O
protocol NCT03929679 188 196 O
) NCT03929679 197 198 O

- NCT03929679 202 203 O
The NCT03929679 205 208 O
decision NCT03929679 209 217 O
to NCT03929679 218 220 O
initiate NCT03929679 221 229 O
treatment NCT03929679 230 239 O
with NCT03929679 240 244 O
commercially NCT03929679 245 257 O
available NCT03929679 258 267 O
semaglutide NCT03929679 268 279 O
has NCT03929679 280 283 O
been NCT03929679 284 288 O
made NCT03929679 289 293 O
by NCT03929679 294 296 O
the NCT03929679 297 300 O
patient NCT03929679 301 308 O
/ NCT03929679 309 310 O
Legally NCT03929679 311 318 O
Acceptable NCT03929679 319 329 O
Representative NCT03929679 330 344 O
and NCT03929679 345 348 O
the NCT03929679 349 352 O
treating NCT03929679 353 361 O
physician NCT03929679 362 371 O
before NCT03929679 372 378 O
and NCT03929679 379 382 O
independently NCT03929679 383 396 O
from NCT03929679 397 401 O
the NCT03929679 402 405 O
decision NCT03929679 406 414 O
to NCT03929679 415 417 O
include NCT03929679 418 425 O
the NCT03929679 426 429 O
patient NCT03929679 430 437 O
in NCT03929679 438 440 O
this NCT03929679 441 445 O
study NCT03929679 446 451 O

- NCT03929679 454 455 O
Male NCT03929679 457 461 O
or NCT03929679 462 464 B-Or
female NCT03929679 465 471 O
, NCT03929679 472 473 O
age NCT03929679 474 477 B-Age
greater NCT03929679 478 485 B-Eq-Comparison
than NCT03929679 486 490 I-Eq-Comparison
or NCT03929679 491 493 I-Eq-Comparison
equal NCT03929679 494 499 I-Eq-Comparison
to NCT03929679 500 502 I-Eq-Comparison
18 NCT03929679 503 505 I-Eq-Comparison
years NCT03929679 506 511 I-Eq-Comparison
at NCT03929679 512 514 O
the NCT03929679 515 518 O
time NCT03929679 519 523 O
of NCT03929679 524 526 O
signing NCT03929679 527 534 O
informed NCT03929679 535 543 O
consent NCT03929679 544 551 O

- NCT03929679 554 555 O
Diagnosed NCT03929679 557 566 O
with NCT03929679 567 571 O
type NCT03929679 572 576 B-Condition
2 NCT03929679 577 578 I-Condition
diabetes NCT03929679 579 587 I-Condition
at NCT03929679 588 590 B-Eq-Comparison
least NCT03929679 591 596 I-Eq-Comparison
12 NCT03929679 597 599 I-Eq-Comparison
weeks NCT03929679 600 605 I-Eq-Comparison
prior NCT03929679 606 611 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03929679 612 614 I-Temporal-Connection___Temporal-Connection-Type-Value:before
inclusion NCT03929679 615 624 B-Study

- NCT03929679 627 628 O
Available NCT03929679 630 639 O
and NCT03929679 640 643 O
documented NCT03929679 644 654 O
haemoglobin NCT03929679 655 666 B-Observation
A1c NCT03929679 667 670 I-Observation
( NCT03929679 671 672 O
HbA1c NCT03929679 673 678 B-Observation
) NCT03929679 679 680 O
value NCT03929679 681 686 O
less NCT03929679 687 691 B-Eq-Comparison
than NCT03929679 692 696 I-Eq-Comparison
or NCT03929679 697 699 I-Eq-Comparison
equal NCT03929679 700 705 I-Eq-Comparison
to NCT03929679 706 708 I-Eq-Comparison
12 NCT03929679 709 711 I-Eq-Comparison
weeks NCT03929679 712 717 I-Eq-Comparison
prior NCT03929679 718 723 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03929679 724 726 I-Temporal-Connection___Temporal-Connection-Type-Value:before
initiation NCT03929679 727 737 B-Eq-Comparison
of NCT03929679 738 740 O
semaglutide NCT03929679 741 752 B-Drug
treatment NCT03929679 753 762 B-Procedure

Exclusion NCT03929679 763 772 O
Criteria NCT03929679 773 781 O
: NCT03929679 782 783 O

- NCT03929679 787 788 O
Previous NCT03929679 790 798 B-Eq-Comparison
participation NCT03929679 799 812 O
in NCT03929679 813 815 O
this NCT03929679 816 820 O
study NCT03929679 821 826 B-Study
. NCT03929679 826 827 O
Participation NCT03929679 829 842 O
is NCT03929679 843 845 O
defined NCT03929679 846 853 O
as NCT03929679 854 856 O
having NCT03929679 857 863 O
given NCT03929679 864 869 O
informed NCT03929679 870 878 O
consent NCT03929679 879 886 O
in NCT03929679 887 889 O
this NCT03929679 890 894 O
study NCT03929679 895 900 O

- NCT03929679 903 904 O
Mental NCT03929679 906 912 B-Condition
incapacity NCT03929679 913 923 I-Condition
, NCT03929679 924 925 O
unwillingness NCT03929679 926 939 O
or NCT03929679 940 942 B-Or
language NCT03929679 943 951 B-Condition
barriers NCT03929679 952 960 I-Condition
precluding NCT03929679 961 971 O
adequate NCT03929679 972 980 O
understanding NCT03929679 981 994 O
or NCT03929679 995 997 O
cooperation NCT03929679 998 1009 O

- NCT03929679 1012 1013 O
Treatment NCT03929679 1015 1024 B-Procedure
with NCT03929679 1025 1029 O
any NCT03929679 1030 1033 O
investigational NCT03929679 1034 1049 B-Study
drug NCT03929679 1050 1054 B-Drug
within NCT03929679 1055 1061 B-Eq-Comparison
90 NCT03929679 1062 1064 I-Eq-Comparison
days NCT03929679 1065 1069 I-Eq-Comparison
prior NCT03929679 1070 1075 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03929679 1076 1078 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrolment NCT03929679 1079 1088 O
into NCT03929679 1089 1093 O
the NCT03929679 1094 1097 O
study NCT03929679 1098 1103 B-Study

- NCT03929679 1106 1107 O
Hypersensitivity NCT03929679 1109 1125 B-Condition
to NCT03929679 1126 1128 O
semaglutide NCT03929679 1129 1140 B-Drug
or NCT03929679 1141 1143 O
to NCT03929679 1144 1146 O
any NCT03929679 1147 1150 O
of NCT03929679 1151 1153 O
the NCT03929679 1154 1157 O
excipients NCT03929679 1158 1168 O

Inclusion NCT03924375 0 9 O
Criteria NCT03924375 10 18 O
: NCT03924375 19 20 O

- NCT03924375 24 25 O
Gastroscopy NCT03924375 27 38 B-Procedure
can NCT03924375 39 42 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03924375 43 45 I-Assertion___Assertion-Type-Value:hypothetical
performed NCT03924375 46 55 O

- NCT03924375 58 59 O
Serologic NCT03924375 61 70 B-Observation
markers NCT03924375 71 78 I-Observation
including NCT03924375 79 88 O
serum NCT03924375 89 94 B-Observation
pepsinogen NCT03924375 95 105 I-Observation
can NCT03924375 106 109 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03924375 110 112 I-Assertion___Assertion-Type-Value:hypothetical
measured NCT03924375 113 121 O

Exclusion NCT03924375 122 131 O
Criteria NCT03924375 132 140 O
: NCT03924375 141 142 O

- NCT03924375 146 147 O
Age NCT03924375 149 152 B-Age
< NCT03924375 153 154 B-Eq-Comparison
20 NCT03924375 155 157 I-Eq-Comparison
or NCT03924375 158 160 B-Or
> NCT03924375 161 162 B-Eq-Comparison
70 NCT03924375 163 165 I-Eq-Comparison
years NCT03924375 166 171 I-Eq-Comparison

- NCT03924375 174 175 O
Anemia NCT03924375 177 183 B-Condition
( NCT03924375 184 185 O
serum NCT03924375 186 191 B-Observation
hemoglobin NCT03924375 192 202 I-Observation
level NCT03924375 203 208 I-Observation
< NCT03924375 209 210 B-Eq-Comparison
10 NCT03924375 211 213 I-Eq-Comparison
g NCT03924375 214 215 I-Eq-Comparison
/ NCT03924375 216 217 I-Eq-Comparison
dL NCT03924375 218 220 I-Eq-Comparison
) NCT03924375 221 222 O

- NCT03924375 226 227 O
Severe NCT03924375 229 235 O
systemic NCT03924375 236 244 B-Modifier
disease NCT03924375 245 252 B-Condition

- NCT03924375 255 256 O
Advanced NCT03924375 258 266 O
chronic NCT03924375 267 274 B-Modifier
liver NCT03924375 275 280 B-Condition
disease NCT03924375 281 288 I-Condition

- NCT03924375 291 292 O
Use NCT03924375 294 297 B-Eq-Comparison
of NCT03924375 298 300 O
certain NCT03924375 301 308 O
medications NCT03924375 309 320 B-Drug
, NCT03924375 321 322 O
including NCT03924375 323 332 O
proton NCT03924375 333 339 B-Drug
pump NCT03924375 340 344 I-Drug
inhibitors NCT03924375 345 355 I-Drug
, NCT03924375 356 357 O
H2 NCT03924375 358 360 B-Drug
- NCT03924375 361 362 I-Drug
receptor NCT03924375 363 371 I-Drug
antagonists NCT03924375 372 383 I-Drug
, NCT03924375 384 385 O
or NCT03924375 386 388 B-Or
antibiotics NCT03924375 389 400 B-Drug

- NCT03924375 403 404 O
History NCT03924375 406 413 B-Eq-Comparison
of NCT03924375 414 416 O
H. NCT03924375 417 419 B-Organism
pylori NCT03924375 421 427 I-Organism
eradication NCT03924375 428 439 B-Condition

- NCT03924375 442 443 O
History NCT03924375 445 452 B-Eq-Comparison
of NCT03924375 453 455 O
gastric NCT03924375 456 463 B-Procedure
surgery NCT03924375 464 471 I-Procedure

- NCT03924375 474 475 O
Recent NCT03924375 477 483 O
history NCT03924375 484 491 B-Eq-Comparison
of NCT03924375 492 494 O
upper NCT03924375 495 500 B-Modifier
gastrointestinal NCT03924375 501 517 I-Modifier
bleeding NCT03924375 518 526 B-Condition

Inclusion NCT03921580 0 9 O
Criteria NCT03921580 10 18 O
: NCT03921580 19 20 O

- NCT03921580 24 25 O
Men NCT03921580 27 30 O
and NCT03921580 31 34 B-Or
women NCT03921580 35 40 O
from NCT03921580 41 45 O
18 NCT03921580 46 48 B-Eq-Comparison
to NCT03921580 49 51 I-Eq-Comparison
65 NCT03921580 52 54 I-Eq-Comparison
years NCT03921580 55 60 I-Eq-Comparison
old NCT03921580 61 64 B-Age
. NCT03921580 65 66 O

- NCT03921580 70 71 O
Body NCT03921580 73 77 B-Observation
Mass NCT03921580 78 82 I-Observation
Index NCT03921580 83 88 I-Observation
( NCT03921580 89 90 O
BMI NCT03921580 91 94 B-Observation
) NCT03921580 95 96 O
≥ NCT03921580 97 98 B-Eq-Comparison
25 NCT03921580 99 101 I-Eq-Comparison
and NCT03921580 102 105 B-And
< NCT03921580 106 107 B-Eq-Comparison
30 NCT03921580 108 110 I-Eq-Comparison
kg NCT03921580 111 113 I-Eq-Comparison
/ NCT03921580 114 115 I-Eq-Comparison
m2 NCT03921580 116 118 I-Eq-Comparison
. NCT03921580 118 119 O

- NCT03921580 123 124 O
Adequate NCT03921580 126 134 O
cultural NCT03921580 135 143 O
level NCT03921580 144 149 O
and NCT03921580 150 153 O
understanding NCT03921580 154 167 O
for NCT03921580 168 171 O
the NCT03921580 172 175 O
clinical NCT03921580 176 184 O
trial NCT03921580 185 190 O
. NCT03921580 191 192 O

- NCT03921580 196 197 O
Signed NCT03921580 199 205 O
informed NCT03921580 206 214 O
consent NCT03921580 215 222 O

Exclusion NCT03921580 223 232 O
Criteria NCT03921580 233 241 O
: NCT03921580 242 243 O

- NCT03921580 247 248 O
Subjects NCT03921580 250 258 O
with NCT03921580 259 263 O
BMI NCT03921580 264 267 B-Observation
≥ NCT03921580 268 269 B-Eq-Comparison
30 NCT03921580 270 272 I-Eq-Comparison
or NCT03921580 273 275 B-Or
< NCT03921580 276 277 B-Eq-Comparison
25 NCT03921580 278 280 I-Eq-Comparison
kg NCT03921580 281 283 I-Eq-Comparison
/ NCT03921580 284 285 I-Eq-Comparison
m2 NCT03921580 286 288 I-Eq-Comparison

- NCT03921580 291 292 O
Subjects NCT03921580 294 302 O
diagnosed NCT03921580 303 312 O
with NCT03921580 313 317 O
Diabetes NCT03921580 318 326 B-Condition
Mellitus NCT03921580 327 335 I-Condition
. NCT03921580 336 337 O

- NCT03921580 341 342 O
Subjects NCT03921580 344 352 O
with NCT03921580 353 357 O
dyslipidemia NCT03921580 358 370 B-Condition
on NCT03921580 371 373 B-Eq-Comparison
pharmacological NCT03921580 374 389 B-Procedure
treatment NCT03921580 390 399 I-Procedure

- NCT03921580 402 403 O
Subjects NCT03921580 405 413 O
with NCT03921580 414 418 O
hypertension NCT03921580 419 431 B-Condition
on NCT03921580 432 434 B-Eq-Comparison
pharmacological NCT03921580 435 450 B-Procedure
treatment NCT03921580 451 460 I-Procedure

- NCT03921580 463 464 O
Subjects NCT03921580 466 474 O
with NCT03921580 475 479 O
established NCT03921580 480 491 O
diagnosis NCT03921580 492 501 O
of NCT03921580 502 504 O
eating NCT03921580 505 511 B-Condition
disorder NCT03921580 512 520 I-Condition

- NCT03921580 523 524 O
Smokers NCT03921580 526 533 O
or NCT03921580 534 536 O
those NCT03921580 537 542 O
subjects NCT03921580 543 551 O
with NCT03921580 552 556 O
high NCT03921580 557 561 O
alcohol NCT03921580 562 569 B-Observation
consumption NCT03921580 570 581 I-Observation
( NCT03921580 582 583 O
> NCT03921580 585 586 B-Eq-Comparison
2 NCT03921580 587 588 I-Eq-Comparison
- NCT03921580 589 590 I-Eq-Comparison
3 NCT03921580 591 592 I-Eq-Comparison
servings NCT03921580 593 601 I-Eq-Comparison
/ NCT03921580 602 603 I-Eq-Comparison
day NCT03921580 604 607 I-Eq-Comparison
in NCT03921580 608 610 O
men NCT03921580 611 614 O
and NCT03921580 615 618 B-Or
> NCT03921580 619 620 B-Eq-Comparison
1 NCT03921580 621 622 I-Eq-Comparison
serving NCT03921580 623 630 I-Eq-Comparison
/ NCT03921580 631 632 I-Eq-Comparison
day NCT03921580 633 636 I-Eq-Comparison
in NCT03921580 637 639 O
women NCT03921580 640 645 O
( NCT03921580 646 647 O
1 NCT03921580 648 649 O
serving NCT03921580 650 657 O
= NCT03921580 658 659 O
1 NCT03921580 660 661 O
glass NCT03921580 662 667 O
of NCT03921580 668 670 O
wine NCT03921580 671 675 O
or NCT03921580 676 678 O
1 NCT03921580 679 680 O
bottle NCT03921580 681 687 O
of NCT03921580 688 690 O
beer NCT03921580 691 695 O
) NCT03921580 696 697 O

- NCT03921580 701 702 O
Subjects NCT03921580 704 712 O
under NCT03921580 713 718 O
pharmacological NCT03921580 719 734 B-Procedure
treatment NCT03921580 735 744 I-Procedure
( NCT03921580 745 746 O
except NCT03921580 747 753 B-Exception
oral NCT03921580 754 758 B-Drug
contraceptives NCT03921580 759 773 I-Drug
) NCT03921580 774 775 O

- NCT03921580 779 780 O
Subjects NCT03921580 782 790 O
with NCT03921580 791 795 O
large NCT03921580 796 801 O
weight NCT03921580 802 808 B-Observation
fluctuations NCT03921580 809 821 O
of NCT03921580 822 824 O
more NCT03921580 825 829 B-Eq-Comparison
than NCT03921580 830 834 I-Eq-Comparison
4 NCT03921580 835 836 I-Eq-Comparison
kg NCT03921580 837 839 I-Eq-Comparison
or NCT03921580 840 842 B-Or
who NCT03921580 843 846 O
have NCT03921580 847 851 O
undergone NCT03921580 852 861 B-Eq-Comparison
in NCT03921580 862 864 O
six NCT03921580 865 868 B-Eq-Comparison
months NCT03921580 869 875 I-Eq-Comparison
a NCT03921580 876 877 O
weight NCT03921580 878 884 B-Procedure
loss NCT03921580 885 889 I-Procedure
diet NCT03921580 890 894 I-Procedure

- NCT03921580 897 898 O
Subjects NCT03921580 900 908 O
with NCT03921580 909 913 O
sensory NCT03921580 914 921 O
problems NCT03921580 922 930 O

- NCT03921580 933 934 O
Subjects NCT03921580 936 944 O
with NCT03921580 945 949 O
gastrointestinal NCT03921580 950 966 B-Condition
diseases NCT03921580 967 975 I-Condition
that NCT03921580 976 980 O
affect NCT03921580 981 987 O
the NCT03921580 988 991 O
digestion NCT03921580 992 1001 B-Condition
or NCT03921580 1002 1004 B-Or
absorption NCT03921580 1005 1015 B-Condition
of NCT03921580 1016 1018 I-Condition
nutrients NCT03921580 1019 1028 I-Condition

- NCT03921580 1031 1032 O
Pregnant NCT03921580 1034 1042 B-Condition
or NCT03921580 1043 1045 B-Or
breastfeeding NCT03921580 1046 1059 B-Condition
women NCT03921580 1060 1065 O

- NCT03921580 1068 1069 O
Women NCT03921580 1071 1076 O
with NCT03921580 1077 1081 B-And
menstrual NCT03921580 1082 1091 B-Condition
irregularities NCT03921580 1092 1106 I-Condition
( NCT03921580 1107 1108 O
absence NCT03921580 1109 1116 B-Condition
of NCT03921580 1117 1119 I-Condition
menstrual NCT03921580 1120 1129 I-Condition
cycle NCT03921580 1130 1135 I-Condition
at NCT03921580 1136 1138 B-Eq-Comparison
least NCT03921580 1139 1144 I-Eq-Comparison
2 NCT03921580 1145 1146 I-Eq-Comparison
months NCT03921580 1147 1153 I-Eq-Comparison
) NCT03921580 1154 1155 O

- NCT03921580 1159 1160 O
Subjects NCT03921580 1162 1170 O
with NCT03921580 1171 1175 O
intense NCT03921580 1176 1183 O
physical NCT03921580 1184 1192 B-Observation
activity NCT03921580 1193 1201 I-Observation
. NCT03921580 1202 1203 O

- NCT03921580 1207 1208 O
Subjects NCT03921580 1210 1218 O
with NCT03921580 1219 1223 O
food NCT03921580 1224 1228 O
allergies NCT03921580 1229 1238 B-Allergy
to NCT03921580 1239 1241 O
meals NCT03921580 1242 1247 O
included NCT03921580 1248 1256 O
in NCT03921580 1257 1259 O
breakfast NCT03921580 1260 1269 O
, NCT03921580 1270 1271 O
study NCT03921580 1272 1277 B-Study
product NCT03921580 1278 1285 B-Drug
or NCT03921580 1286 1288 O
lunch NCT03921580 1289 1294 O
or NCT03921580 1295 1297 O
that NCT03921580 1298 1302 O
reject NCT03921580 1303 1309 O
their NCT03921580 1310 1315 O
consumption NCT03921580 1316 1327 O

- NCT03921580 1330 1331 O
Subjects NCT03921580 1333 1341 O
with NCT03921580 1342 1346 O
a NCT03921580 1347 1348 O
diagnosis NCT03921580 1349 1358 O
of NCT03921580 1359 1361 O
celiac NCT03921580 1362 1368 B-Condition
disease NCT03921580 1369 1376 I-Condition
or NCT03921580 1377 1379 B-Or
a NCT03921580 1380 1381 O
gluten NCT03921580 1382 1388 B-Condition
intolerance NCT03921580 1389 1400 I-Condition

Inclusion NCT03929692 0 9 O
Criteria NCT03929692 10 18 O
: NCT03929692 19 20 O

- NCT03929692 24 25 O
Intervention NCT03929692 27 39 O
group NCT03929692 40 45 O
: NCT03929692 46 47 O
Participants NCT03929692 48 60 O
must NCT03929692 61 65 O
be NCT03929692 66 68 O
in NCT03929692 69 71 O
10 NCT03929692 72 74 O
th NCT03929692 75 77 O
school NCT03929692 78 84 O
grade NCT03929692 85 90 O
or NCT03929692 91 93 O
aged NCT03929692 94 98 B-Age
15 NCT03929692 99 101 B-Eq-Comparison
to NCT03929692 102 104 I-Eq-Comparison
16 NCT03929692 105 107 I-Eq-Comparison
years NCT03929692 108 113 I-Eq-Comparison
when NCT03929692 114 118 O
recruited NCT03929692 119 128 O
in NCT03929692 129 131 O
training NCT03929692 132 140 O
companies NCT03929692 141 150 O
. NCT03929692 151 152 O

- NCT03929692 156 157 O
Control NCT03929692 159 166 O
Group NCT03929692 167 172 O
: NCT03929692 173 174 O
Participants NCT03929692 175 187 O
must NCT03929692 188 192 O
be NCT03929692 193 195 O
in NCT03929692 196 198 O
12 NCT03929692 199 201 O
th NCT03929692 202 204 O
school NCT03929692 205 211 O
grade NCT03929692 212 217 O
or NCT03929692 218 220 O
aged NCT03929692 221 225 B-Age
17 NCT03929692 226 228 B-Eq-Comparison
to NCT03929692 229 231 I-Eq-Comparison
18 NCT03929692 232 234 I-Eq-Comparison
years NCT03929692 235 240 I-Eq-Comparison
when NCT03929692 241 245 O
recruited NCT03929692 246 255 O
in NCT03929692 256 258 O
training NCT03929692 259 267 O
companies NCT03929692 268 277 O
. NCT03929692 278 279 O

Exclusion NCT03929692 281 290 O
Criteria NCT03929692 291 299 O
: NCT03929692 300 301 O

- NCT03929692 304 305 O
none NCT03929692 306 310 O

Inclusion NCT03927456 0 9 O
Criteria NCT03927456 10 18 O
: NCT03927456 19 20 O

1 NCT03927456 24 25 O
. NCT03927456 25 26 O
Has NCT03927456 28 31 O
the NCT03927456 32 35 O
pathologically NCT03927456 36 50 O
- NCT03927456 51 52 O
confirmed NCT03927456 53 62 O
diagnosis NCT03927456 63 72 O
of NCT03927456 73 75 O
locally NCT03927456 76 83 B-Modifier
recurrent NCT03927456 84 93 I-Modifier
or NCT03927456 94 96 B-Or
metastatic NCT03927456 97 107 B-Modifier
, NCT03927456 108 109 O
hormone NCT03927456 110 117 B-Modifier
- NCT03927456 118 119 I-Modifier
receptor NCT03927456 120 128 I-Modifier
positive NCT03927456 129 137 I-Modifier
, NCT03927456 138 139 O
HER2 NCT03927456 140 144 B-Modifier
negative NCT03927456 145 153 I-Modifier
Breast NCT03927456 154 160 I-Modifier
Cancer NCT03927456 161 167 B-Condition
. NCT03927456 168 169 O

2 NCT03927456 173 174 O
. NCT03927456 174 175 O
Age NCT03927456 177 180 B-Age
: NCT03927456 181 182 O
18 NCT03927456 183 185 B-Eq-Comparison
- NCT03927456 186 187 I-Eq-Comparison
75 NCT03927456 188 190 I-Eq-Comparison
years NCT03927456 191 196 I-Eq-Comparison
old NCT03927456 197 200 O
, NCT03927456 201 202 O
postmenopausal NCT03927456 203 217 B-Condition
women NCT03927456 218 223 O
or NCT03927456 224 226 B-Or
prepostmenopausal NCT03927456 227 244 B-Condition
women NCT03927456 245 250 O

3 NCT03927456 253 254 O
. NCT03927456 254 255 O
Received NCT03927456 257 265 B-Eq-Comparison
prior NCT03927456 266 271 I-Eq-Comparison
endocrine NCT03927456 272 281 B-Procedure
therapy NCT03927456 282 289 I-Procedure

4 NCT03927456 292 293 O
. NCT03927456 293 294 O
One NCT03927456 296 299 B-Eq-Comparison
previous NCT03927456 300 308 B-Eq-Comparison
line NCT03927456 309 313 O
of NCT03927456 314 316 O
chemotherapy NCT03927456 317 329 B-Procedure
for NCT03927456 330 333 O
advanced NCT03927456 334 342 B-Modifier
/ NCT03927456 343 344 B-Or
metastatic NCT03927456 345 355 B-Modifier
disease NCT03927456 356 363 B-Condition
is NCT03927456 364 366 O
allowed NCT03927456 367 374 O
in NCT03927456 375 377 B-And
addition NCT03927456 378 386 I-And
to NCT03927456 387 389 O
endocrine NCT03927456 390 399 B-Procedure
therapy NCT03927456 400 407 I-Procedure
. NCT03927456 408 409 O

5 NCT03927456 413 414 O
. NCT03927456 414 415 O
Eastern NCT03927456 417 424 B-Condition
Cooperative NCT03927456 425 436 I-Condition
Oncology NCT03927456 437 445 I-Condition
Group NCT03927456 446 451 I-Condition
[ NCT03927456 452 453 O
ECOG NCT03927456 454 458 B-Condition
] NCT03927456 459 460 O
0 NCT03927456 461 462 B-Eq-Comparison
- NCT03927456 463 464 I-Eq-Comparison
1 NCT03927456 465 466 O

Exclusion NCT03927456 468 477 O
Criteria NCT03927456 478 486 O
: NCT03927456 487 488 O

1 NCT03927456 492 493 O
. NCT03927456 493 494 O
Patients NCT03927456 496 504 O
who NCT03927456 505 508 O
received NCT03927456 509 517 B-Eq-Comparison
prior NCT03927456 518 523 I-Eq-Comparison
treatment NCT03927456 524 533 B-Procedure
with NCT03927456 534 538 O
any NCT03927456 539 542 O
CDK4 NCT03927456 543 547 B-Drug
/ NCT03927456 548 549 I-Drug
6 NCT03927456 550 551 I-Drug
inhibitor NCT03927456 552 561 I-Drug
, NCT03927456 562 563 O
everolimus NCT03927456 564 574 B-Drug
or NCT03927456 575 577 B-Or
fulvestant NCT03927456 578 588 B-Drug
. NCT03927456 589 590 O

2 NCT03927456 594 595 O
. NCT03927456 595 596 O
Clinically NCT03927456 598 608 O
significant NCT03927456 609 620 O
cardiovascular NCT03927456 621 635 B-Modifier
and NCT03927456 636 639 B-Or
cerebrovascular NCT03927456 640 655 B-Modifier
diseases NCT03927456 656 664 B-Condition
, NCT03927456 665 666 O
including NCT03927456 667 676 O
but NCT03927456 677 680 O
not NCT03927456 681 684 O
limited NCT03927456 685 692 O
to NCT03927456 693 695 O
severe NCT03927456 696 702 O
acute NCT03927456 703 708 B-Condition
myocardial NCT03927456 709 719 I-Condition
infarction NCT03927456 720 730 I-Condition
within NCT03927456 731 737 B-Eq-Comparison
6 NCT03927456 738 739 I-Eq-Comparison
months NCT03927456 740 746 I-Eq-Comparison
before NCT03927456 747 753 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03927456 754 764 B-Study
, NCT03927456 765 766 O
unstable NCT03927456 767 775 B-Modifier
or NCT03927456 776 778 B-Or
severe NCT03927456 779 785 O
angina NCT03927456 786 792 B-Condition
, NCT03927456 793 794 O
Congestive NCT03927456 795 805 B-Condition
heart NCT03927456 806 811 I-Condition
failure NCT03927456 812 819 I-Condition
( NCT03927456 820 821 O
New NCT03927456 822 825 B-Condition
York NCT03927456 826 830 I-Condition
heart NCT03927456 831 836 I-Condition
association NCT03927456 837 848 I-Condition
( NCT03927456 849 850 O
NYHA NCT03927456 851 855 B-Condition
) NCT03927456 856 857 O
class NCT03927456 858 863 B-Eq-Comparison
> NCT03927456 864 865 I-Eq-Comparison
2 NCT03927456 866 867 I-Eq-Comparison
) NCT03927456 868 869 O
, NCT03927456 871 872 O
or NCT03927456 873 875 B-Or
ventricular NCT03927456 876 887 B-Condition
arrhythmia NCT03927456 888 898 I-Condition
which NCT03927456 899 904 O
need NCT03927456 905 909 B-Assertion___Assertion-Type-Value:hypothetical
medical NCT03927456 910 917 O
intervention NCT03927456 918 930 B-Procedure
. NCT03927456 930 931 O

Inclusion NCT03920488 0 9 O
Criteria NCT03920488 10 18 O
: NCT03920488 19 20 O

1 NCT03920488 24 25 O
. NCT03920488 25 26 O
age NCT03920488 28 31 B-Age
between NCT03920488 32 39 B-Eq-Comparison
18 NCT03920488 40 42 I-Eq-Comparison
and NCT03920488 43 46 I-Eq-Comparison
60 NCT03920488 47 49 I-Eq-Comparison
years NCT03920488 50 55 I-Eq-Comparison

2 NCT03920488 58 59 O
. NCT03920488 59 60 O
has NCT03920488 62 65 O
signed NCT03920488 66 72 O
informed NCT03920488 73 81 O
consent NCT03920488 82 89 O

3 NCT03920488 92 93 O
. NCT03920488 93 94 O
histologically NCT03920488 96 110 B-Procedure
confirmed NCT03920488 111 120 O
triple NCT03920488 121 127 B-Modifier
negative NCT03920488 128 136 O
breast NCT03920488 137 143 B-Modifier
cancer NCT03920488 144 150 B-Condition
( NCT03920488 151 152 O
ER NCT03920488 153 155 B-Observation
( NCT03920488 156 157 O
Estrogen NCT03920488 158 166 B-Observation
Receptors NCT03920488 167 176 I-Observation
) NCT03920488 177 178 O
< NCT03920488 179 180 B-Eq-Comparison
1 NCT03920488 181 182 I-Eq-Comparison
% NCT03920488 183 184 I-Eq-Comparison
, NCT03920488 186 187 O
PgR NCT03920488 188 191 B-Observation
( NCT03920488 192 193 O
Progesterone NCT03920488 194 206 B-Observation
Receptors NCT03920488 207 216 I-Observation
) NCT03920488 217 218 O
< NCT03920488 219 220 B-Eq-Comparison
1 NCT03920488 221 222 I-Eq-Comparison
% NCT03920488 223 224 I-Eq-Comparison
, NCT03920488 226 227 O
HER2 NCT03920488 228 232 B-Condition
/ NCT03920488 233 234 B-Or
neu NCT03920488 235 238 B-Condition
negative NCT03920488 239 247 O
( NCT03920488 248 249 O
IHC NCT03920488 250 253 B-Observation
0 NCT03920488 254 255 B-Eq-Comparison
, NCT03920488 256 257 I-Eq-Comparison
1 NCT03920488 258 259 I-Eq-Comparison
+ NCT03920488 260 261 I-Eq-Comparison
or NCT03920488 262 264 I-Eq-Comparison
2 NCT03920488 265 266 I-Eq-Comparison
+ NCT03920488 267 268 I-Eq-Comparison
FISH NCT03920488 269 273 B-Condition
negative NCT03920488 274 282 O
) NCT03920488 283 284 O
. NCT03920488 286 287 O

4 NCT03920488 291 292 O
. NCT03920488 292 293 O
Stage NCT03920488 295 300 B-Eq-Comparison
I NCT03920488 301 302 I-Eq-Comparison
- NCT03920488 303 304 I-Eq-Comparison
III NCT03920488 305 308 I-Eq-Comparison

5 NCT03920488 311 312 O
. NCT03920488 312 313 O
Able NCT03920488 315 319 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03920488 320 322 I-Assertion___Assertion-Type-Value:hypothetical
undergo NCT03920488 323 330 O
surgery NCT03920488 331 338 B-Procedure
( NCT03920488 339 340 O
primary NCT03920488 341 348 B-Modifier
or NCT03920488 349 351 B-Or
post NCT03920488 352 356 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03920488 357 358 O
neoadjuvant NCT03920488 359 370 B-Procedure
) NCT03920488 371 372 O

6 NCT03920488 376 377 O
. NCT03920488 377 378 O
Availability NCT03920488 380 392 O
of NCT03920488 393 395 O
surgical NCT03920488 396 404 B-Modifier
/ NCT03920488 405 406 B-Or
bioptic NCT03920488 407 414 B-Modifier
material NCT03920488 415 423 B-Observation
within NCT03920488 424 430 B-Eq-Comparison
6 NCT03920488 431 432 I-Eq-Comparison
months NCT03920488 433 439 I-Eq-Comparison
from NCT03920488 440 444 B-Temporal-Connection___Temporal-Connection-Type-Value:after
enrolment NCT03920488 445 454 B-Study

Exclusion NCT03920488 455 464 O
Criteria NCT03920488 465 473 O
: NCT03920488 474 475 O

- NCT03920488 479 480 O
unable NCT03920488 482 488 B-Assertion___Assertion-Type-Value:hypothetical|Negation
or NCT03920488 489 491 B-Or
unwilling NCT03920488 492 501 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03920488 502 504 O
receive NCT03920488 505 512 O
genetic NCT03920488 513 520 B-Procedure
counselling NCT03920488 521 532 I-Procedure

Inclusion NCT03923803 0 9 O
Criteria NCT03923803 10 18 O
: NCT03923803 19 20 O

- NCT03923803 23 24 O
Patients NCT03923803 25 33 O
admitted NCT03923803 34 42 B-Encounter
to NCT03923803 43 45 O
the NCT03923803 46 49 O
hospital NCT03923803 50 58 O

Exclusion NCT03923803 59 68 O
Criteria NCT03923803 69 77 O
: NCT03923803 78 79 O

- NCT03923803 83 84 O
patients NCT03923803 86 94 O
with NCT03923803 95 99 O
malignancies NCT03923803 100 112 B-Condition

- NCT03923803 115 116 O
patients NCT03923803 118 126 O
with NCT03923803 127 131 O
other NCT03923803 132 137 B-Other
systemic NCT03923803 138 146 B-Modifier
infection NCT03923803 147 156 B-Condition

- NCT03928639 1 2 O
INCLUSION NCT03928639 4 13 O
CRITERIA NCT03928639 14 22 O
: NCT03928639 23 24 O

- NCT03928639 28 29 O
Adults NCT03928639 31 37 O
age NCT03928639 38 41 B-Age
greater NCT03928639 42 49 B-Eq-Comparison
than NCT03928639 50 54 I-Eq-Comparison
or NCT03928639 55 57 I-Eq-Comparison
equal NCT03928639 58 63 I-Eq-Comparison
to NCT03928639 64 66 I-Eq-Comparison
18 NCT03928639 67 69 I-Eq-Comparison
years NCT03928639 70 75 I-Eq-Comparison
. NCT03928639 76 77 O

- NCT03928639 81 82 O
Receiving NCT03928639 84 93 B-Eq-Comparison
care NCT03928639 94 98 B-Procedure
from NCT03928639 99 103 O
the NCT03928639 104 107 O
structural NCT03928639 108 118 O
heart NCT03928639 119 124 O
and NCT03928639 125 128 O
valve NCT03928639 129 134 O
program NCT03928639 135 142 O
at NCT03928639 143 145 O
the NCT03928639 146 149 O
participating NCT03928639 150 163 O
NHLBI NCT03928639 164 169 O
structural NCT03928639 170 180 O
heart NCT03928639 181 186 O
disease NCT03928639 187 194 O
network NCT03928639 195 202 O
site NCT03928639 203 207 O
. NCT03928639 208 209 O

- NCT03928639 213 214 O
Consent NCT03928639 216 223 O
to NCT03928639 224 226 O
participate NCT03928639 227 238 O
in NCT03928639 239 241 O
the NCT03928639 242 245 O
protocol NCT03928639 246 254 O
, NCT03928639 255 256 O
directly NCT03928639 257 265 O
, NCT03928639 266 267 O
or NCT03928639 268 270 O
through NCT03928639 271 278 O
legally NCT03928639 279 286 O
authorized NCT03928639 287 297 O
representatives NCT03928639 298 313 O
( NCT03928639 314 315 O
LAR NCT03928639 316 319 O
) NCT03928639 320 321 O
. NCT03928639 323 324 O

EXCLUSION NCT03928639 326 335 O
CRITERIA NCT03928639 336 344 O
: NCT03928639 345 346 O

- NCT03928639 349 350 O
Does NCT03928639 351 355 O
not NCT03928639 356 359 O
consent NCT03928639 360 367 O
to NCT03928639 368 370 O
participate NCT03928639 371 382 O
in NCT03928639 383 385 O
this NCT03928639 386 390 O
protocol NCT03928639 391 399 O
. NCT03928639 399 400 O

Inclusion NCT03927287 0 9 O
Criteria NCT03927287 10 18 O
: NCT03927287 19 20 O

For NCT03927287 22 25 O
the NCT03927287 26 29 O
two NCT03927287 30 33 O
retrospective NCT03927287 34 47 O
cohorts NCT03927287 48 55 O
: NCT03927287 56 57 O

1 NCT03927287 61 62 O
. NCT03927287 62 63 O
All NCT03927287 65 68 O
patients NCT03927287 69 77 O
that NCT03927287 78 82 O
older NCT03927287 83 88 I-Eq-Comparison
than NCT03927287 89 93 I-Eq-Comparison
18 NCT03927287 94 96 I-Eq-Comparison
treated NCT03927287 97 104 B-Procedure
for NCT03927287 105 108 O
localized NCT03927287 109 118 B-Modifier
adenocarcinoma NCT03927287 119 133 B-Condition
of NCT03927287 134 136 O
the NCT03927287 137 140 O
prostate NCT03927287 141 149 B-Modifier
between NCT03927287 150 157 B-Eq-Comparison
2000 NCT03927287 158 162 I-Eq-Comparison
and NCT03927287 163 166 I-Eq-Comparison
2017 NCT03927287 167 171 I-Eq-Comparison
with NCT03927287 172 176 O
either NCT03927287 177 183 O
radical NCT03927287 184 191 B-Procedure
prostatectomy NCT03927287 192 205 I-Procedure
or NCT03927287 206 208 B-Or
radiotherapy NCT03927287 209 221 B-Procedure

2 NCT03927287 224 225 O
. NCT03927287 225 226 O
All NCT03927287 228 231 O
treated NCT03927287 232 239 O
patients NCT03927287 240 248 O
had NCT03927287 249 252 O
a NCT03927287 253 254 O
rising NCT03927287 255 261 O
post NCT03927287 262 266 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03927287 267 268 O
treatment NCT03927287 269 278 B-Procedure
PSA NCT03927287 279 282 B-Observation
, NCT03927287 283 284 O
with NCT03927287 285 289 B-And
at NCT03927287 290 292 B-Eq-Comparison
least NCT03927287 293 298 I-Eq-Comparison
one NCT03927287 299 302 I-Eq-Comparison
post NCT03927287 303 307 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03927287 308 309 O
treatment NCT03927287 310 319 B-Procedure
free NCT03927287 320 324 O
PSA NCT03927287 325 328 B-Observation
blood NCT03927287 329 334 I-Observation
test NCT03927287 335 339 I-Observation
. NCT03927287 340 341 O

For NCT03927287 343 346 O
the NCT03927287 347 350 O
biobank NCT03927287 351 358 O
validation NCT03927287 359 369 O
cohort NCT03927287 370 376 O
: NCT03927287 377 378 O

1 NCT03927287 380 381 O
. NCT03927287 381 382 O
All NCT03927287 384 387 O
patients NCT03927287 388 396 O
treated NCT03927287 397 404 O
with NCT03927287 405 409 O
radical NCT03927287 410 417 B-Procedure
prostatectomy NCT03927287 418 431 I-Procedure
for NCT03927287 432 435 O
localized NCT03927287 436 445 B-Modifier
prostate NCT03927287 446 454 I-Modifier
cancer NCT03927287 455 461 B-Condition
between NCT03927287 462 469 B-Eq-Comparison
2000 NCT03927287 470 474 I-Eq-Comparison
and NCT03927287 475 478 I-Eq-Comparison
2017 NCT03927287 479 483 I-Eq-Comparison
who NCT03927287 484 487 B-And
had NCT03927287 488 491 O
biobank NCT03927287 492 499 B-Observation
samples NCT03927287 500 507 I-Observation
taken NCT03927287 508 513 B-Eq-Comparison
when NCT03927287 514 518 B-Temporal-Connection___Temporal-Connection-Type-Value:during
developing NCT03927287 519 529 O
biochemical NCT03927287 530 541 B-Condition
recurrence NCT03927287 542 552 I-Condition
. NCT03927287 553 554 O

Exclusion NCT03927287 556 565 O
Criteria NCT03927287 566 574 O
: NCT03927287 575 576 O

1 NCT03927287 580 581 O
. NCT03927287 581 582 O
Patients NCT03927287 584 592 O
that NCT03927287 593 597 O
were NCT03927287 598 602 O
younger NCT03927287 603 610 I-Eq-Comparison
than NCT03927287 611 615 I-Eq-Comparison
18 NCT03927287 616 618 I-Eq-Comparison
, NCT03927287 619 620 O

2 NCT03927287 625 626 O
. NCT03927287 626 627 O
Patients NCT03927287 629 637 O
with NCT03927287 638 642 O
prostate NCT03927287 643 651 B-Modifier
cancer NCT03927287 652 658 B-Condition
other NCT03927287 659 664 B-Exception
than NCT03927287 665 669 I-Exception
adenocarcinoma NCT03927287 670 684 B-Condition
, NCT03927287 685 686 O
such NCT03927287 687 691 O
as NCT03927287 692 694 O
small NCT03927287 695 700 B-Modifier
cell NCT03927287 701 705 I-Modifier
and NCT03927287 706 709 B-Or
neuroendocrine NCT03927287 710 724 B-Modifier
cancer NCT03927287 725 731 B-Condition

3 NCT03927287 734 735 O
. NCT03927287 735 736 O
Patients NCT03927287 738 746 O
with NCT03927287 747 751 O
prostate NCT03927287 752 760 B-Modifier
adenocarcinoma NCT03927287 761 775 B-Condition
that NCT03927287 776 780 B-And
did NCT03927287 781 784 O
not NCT03927287 785 788 B-Negation
develop NCT03927287 789 796 O
biochemical NCT03927287 797 808 B-Condition
recurrence NCT03927287 809 819 I-Condition
. NCT03927287 820 821 O

4 NCT03927287 825 826 O
. NCT03927287 826 827 O
In NCT03927287 829 831 O
the NCT03927287 832 835 O
retrospective NCT03927287 836 849 O
cohorts NCT03927287 850 857 O
- NCT03927287 858 859 O
patients NCT03927287 860 868 O
that NCT03927287 869 873 O
did NCT03927287 874 877 O
not NCT03927287 878 881 B-Negation
have NCT03927287 882 886 O
at NCT03927287 887 889 B-Eq-Comparison
least NCT03927287 890 895 I-Eq-Comparison
one NCT03927287 896 899 I-Eq-Comparison
post NCT03927287 900 904 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03927287 905 906 O
treatment NCT03927287 907 916 B-Procedure
free NCT03927287 917 921 O
PSA NCT03927287 922 925 B-Observation
blood NCT03927287 926 931 I-Observation
test NCT03927287 932 936 I-Observation
. NCT03927287 936 937 O

Inclusion NCT03921190 0 9 O
Criteria NCT03921190 10 18 O
: NCT03921190 19 20 O

- NCT03921190 24 25 O
Adult NCT03921190 27 32 O
patients NCT03921190 33 41 O
( NCT03921190 42 43 O
16 NCT03921190 44 46 B-Eq-Comparison
years NCT03921190 47 52 I-Eq-Comparison
old NCT03921190 53 56 I-Eq-Comparison
and NCT03921190 57 60 I-Eq-Comparison
older NCT03921190 61 66 I-Eq-Comparison
) NCT03921190 67 68 O

- NCT03921190 72 73 O
Healthy NCT03921190 75 82 B-Condition
( NCT03921190 83 84 O
American NCT03921190 85 93 B-Condition
Society NCT03921190 94 101 I-Condition
of NCT03921190 102 104 I-Condition
Anaesthesiologists NCT03921190 105 123 I-Condition
( NCT03921190 124 125 O
ASA NCT03921190 126 129 B-Condition
) NCT03921190 130 131 O
category NCT03921190 132 140 B-Eq-Comparison
I NCT03921190 141 142 I-Eq-Comparison
or NCT03921190 143 145 I-Eq-Comparison
II NCT03921190 146 148 I-Eq-Comparison
) NCT03921190 149 150 O

- NCT03921190 154 155 O
A NCT03921190 157 158 O
maxillary NCT03921190 159 168 B-Modifier
posterior NCT03921190 169 178 I-Modifier
tooth NCT03921190 179 184 I-Modifier
( NCT03921190 185 186 O
excluding NCT03921190 187 196 B-Exception
third NCT03921190 197 202 B-Modifier
molars NCT03921190 203 209 I-Modifier
) NCT03921190 210 211 O
referred NCT03921190 212 220 O
for NCT03921190 221 224 O
root NCT03921190 225 229 B-Procedure
canal NCT03921190 230 235 I-Procedure
treatment NCT03921190 236 245 I-Procedure
and NCT03921190 246 249 B-And
diagnosed NCT03921190 250 259 O
with NCT03921190 260 264 O
irreversible NCT03921190 265 277 B-Condition
pulpitis NCT03921190 278 286 I-Condition
and NCT03921190 287 290 B-And
normal NCT03921190 291 297 O
apical NCT03921190 298 304 B-Condition
tissues NCT03921190 305 312 I-Condition

Exclusion NCT03921190 313 322 O
Criteria NCT03921190 323 331 O
: NCT03921190 332 333 O

- NCT03921190 337 338 O
Psychological NCT03921190 340 353 B-Condition
disorders NCT03921190 354 363 I-Condition

- NCT03921190 366 367 O
Intraoral NCT03921190 369 378 B-Modifier
soft NCT03921190 379 383 B-Condition
tissue NCT03921190 384 390 I-Condition
abnormalities NCT03921190 391 404 I-Condition

- NCT03921190 407 408 O
necrotic NCT03921190 410 418 B-Condition
pulp NCT03921190 419 423 I-Condition
with NCT03921190 424 428 O
/ NCT03921190 429 430 O
without NCT03921190 431 438 O
apical NCT03921190 439 445 B-Condition
pathology NCT03921190 446 455 I-Condition

- NCT03921190 458 459 O
tenderness NCT03921190 461 471 B-Condition
to NCT03921190 472 474 O
palpation NCT03921190 475 484 B-Procedure
and NCT03921190 485 488 B-Or
/ NCT03921190 489 490 I-Or
or NCT03921190 491 493 I-Or
percussion NCT03921190 494 504 B-Procedure

- NCT03921190 507 508 O
The NCT03921190 510 513 O
use NCT03921190 514 517 O
of NCT03921190 518 520 O
analgesics NCT03921190 521 531 B-Drug
in NCT03921190 532 534 O
the NCT03921190 535 538 O
preceding NCT03921190 539 548 B-Eq-Comparison
12 NCT03921190 549 551 I-Eq-Comparison
hours NCT03921190 552 557 I-Eq-Comparison
before NCT03921190 558 564 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03921190 565 568 O
appointment NCT03921190 569 580 B-Encounter
. NCT03921190 580 581 O

Inclusion NCT03921437 0 9 O
conditions NCT03921437 10 20 O
: NCT03921437 21 22 O

1 NCT03921437 26 27 O
. NCT03921437 27 28 O
The NCT03921437 30 33 O
fifth NCT03921437 34 39 B-Eq-Comparison
stage NCT03921437 40 45 I-Eq-Comparison
of NCT03921437 46 48 O
chronic NCT03921437 49 56 B-Modifier
renal NCT03921437 57 62 B-Condition
failure NCT03921437 63 70 I-Condition
diagnosed NCT03921437 71 80 O
by NCT03921437 81 83 O
a NCT03921437 84 85 O
physician NCT03921437 86 95 O
. NCT03921437 96 97 O

2 NCT03921437 101 102 O
. NCT03921437 102 103 O
The NCT03921437 105 108 O
physician NCT03921437 109 118 O
advises NCT03921437 119 126 O
and NCT03921437 127 130 O
informs NCT03921437 131 138 O
the NCT03921437 139 142 O
patient NCT03921437 143 150 O
who NCT03921437 151 154 O
has NCT03921437 155 158 O
to NCT03921437 159 161 O
undergo NCT03921437 162 169 B-Eq-Comparison
renal NCT03921437 170 175 B-Procedure
replacement NCT03921437 176 187 I-Procedure
therapy NCT03921437 188 195 I-Procedure
but NCT03921437 196 199 B-And
has NCT03921437 200 203 O
not NCT03921437 204 207 B-Negation
yet NCT03921437 208 211 O
decided NCT03921437 212 219 O
what NCT03921437 220 224 O
treatment NCT03921437 225 234 B-Procedure
to NCT03921437 235 237 O
take NCT03921437 238 242 O
. NCT03921437 243 244 O

3 NCT03921437 248 249 O
. NCT03921437 249 250 O
Being NCT03921437 252 257 O
able NCT03921437 258 262 O
to NCT03921437 263 265 O
communicate NCT03921437 266 277 O
in NCT03921437 278 280 O
Mandarin NCT03921437 281 289 O
and NCT03921437 290 293 B-And
Taiwan NCT03921437 294 300 O
. NCT03921437 301 302 O

4 NCT03921437 306 307 O
. NCT03921437 307 308 O
Ages NCT03921437 310 314 B-Age
over NCT03921437 315 319 O
20 NCT03921437 320 322 B-Eq-Comparison
years NCT03921437 323 328 I-Eq-Comparison
old NCT03921437 329 332 O
. NCT03921437 333 334 O

Exclusion NCT03921437 336 345 O
conditions NCT03921437 346 356 O
: NCT03921437 357 358 O

1 NCT03921437 362 363 O
. NCT03921437 363 364 O
Cognitive NCT03921437 366 375 B-Condition
impairment NCT03921437 376 386 I-Condition
: NCT03921437 387 388 O
The NCT03921437 389 392 O
MMSE NCT03921437 393 397 B-Observation
of NCT03921437 398 400 O
the NCT03921437 401 404 O
above NCT03921437 405 410 O
- NCT03921437 411 412 O
mentioned NCT03921437 413 422 O
educators NCT03921437 423 432 O
was NCT03921437 433 436 O
26 NCT03921437 437 439 B-Eq-Comparison
points NCT03921437 440 446 I-Eq-Comparison
, NCT03921437 447 448 O
and NCT03921437 449 452 B-And
the NCT03921437 453 456 O
national NCT03921437 457 465 B-Observation
minimum NCT03921437 466 473 I-Observation
was NCT03921437 474 477 O
< NCT03921437 478 479 B-Eq-Comparison
21 NCT03921437 480 482 I-Eq-Comparison
points NCT03921437 483 489 I-Eq-Comparison
, NCT03921437 490 491 O
those NCT03921437 492 497 O
who NCT03921437 498 501 O
are NCT03921437 502 505 O
not NCT03921437 506 509 B-Negation
educated NCT03921437 510 518 B-Condition
are NCT03921437 519 522 O
< NCT03921437 523 524 B-Eq-Comparison
16 NCT03921437 525 527 I-Eq-Comparison
points NCT03921437 528 534 I-Eq-Comparison
, NCT03921437 535 536 O
and NCT03921437 537 540 O
the NCT03921437 541 544 O
case NCT03921437 545 549 O
is NCT03921437 550 552 O
excluded NCT03921437 553 561 O
. NCT03921437 562 563 O

2 NCT03921437 567 568 O
. NCT03921437 568 569 O
Patients NCT03921437 571 579 O
who NCT03921437 580 583 O
have NCT03921437 584 588 O
received NCT03921437 589 597 B-Eq-Comparison
non NCT03921437 598 601 B-Negation
- NCT03921437 602 603 O
emergency NCT03921437 604 613 B-Modifier
dialysis NCT03921437 614 622 B-Procedure
treatment NCT03921437 623 632 I-Procedure
. NCT03921437 633 634 O

3 NCT03921437 638 639 O
. NCT03921437 639 640 O
Patients NCT03921437 642 650 O
with NCT03921437 651 655 O
severe NCT03921437 656 662 O
cardiopulmonary NCT03921437 663 678 B-Modifier
dysfunction NCT03921437 679 690 B-Condition
, NCT03921437 691 692 O
severe NCT03921437 693 699 O
shock NCT03921437 700 705 B-Condition
, NCT03921437 706 707 O
low NCT03921437 708 711 B-Condition
blood NCT03921437 712 717 I-Condition
pressure NCT03921437 718 726 I-Condition
, NCT03921437 727 728 O
and NCT03921437 729 732 O
large NCT03921437 733 738 O
bleeding NCT03921437 739 747 B-Condition
are NCT03921437 748 751 O
not NCT03921437 752 755 O
controlled NCT03921437 756 766 O
. NCT03921437 767 768 O

4 NCT03921437 772 773 O
. NCT03921437 773 774 O
Patients NCT03921437 776 784 O
with NCT03921437 785 789 O
chronic NCT03921437 790 797 B-Modifier
active NCT03921437 798 804 B-Eq-Comparison
hepatitis NCT03921437 805 814 B-Condition
, NCT03921437 815 816 O
cirrhosis NCT03921437 817 826 B-Condition
or NCT03921437 827 829 B-Or
liver NCT03921437 830 835 B-Condition
failure NCT03921437 836 843 I-Condition
. NCT03921437 844 845 O

5 NCT03921437 849 850 O
. NCT03921437 850 851 O
A NCT03921437 853 854 O
history NCT03921437 855 862 B-Eq-Comparison
of NCT03921437 863 865 O
cancer NCT03921437 866 872 B-Condition
that NCT03921437 873 877 O
may NCT03921437 878 881 O
be NCT03921437 882 884 O
transferred NCT03921437 885 896 O
. NCT03921437 897 898 O

6 NCT03921437 902 903 O
. NCT03921437 903 904 O
Severe NCT03921437 906 912 O
bleeding NCT03921437 913 921 B-Condition
tendency NCT03921437 922 930 O
. NCT03921437 931 932 O

7 NCT03921437 936 937 O
. NCT03921437 937 938 O
Loss NCT03921437 940 944 O
of NCT03921437 945 947 O
peritoneal NCT03921437 948 958 B-Condition
function NCT03921437 959 967 I-Condition
or NCT03921437 968 970 B-Or
extensive NCT03921437 971 980 O
peritoneal NCT03921437 981 991 B-Condition
adhesion NCT03921437 992 1000 I-Condition
, NCT03921437 1001 1002 O
unable NCT03921437 1003 1009 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03921437 1010 1012 O
use NCT03921437 1013 1016 O
peritoneal NCT03921437 1017 1027 B-Procedure
dialysis NCT03921437 1028 1036 I-Procedure
. NCT03921437 1037 1038 O

8 NCT03921437 1042 1043 O
. NCT03921437 1043 1044 O
Unable NCT03921437 1046 1052 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03921437 1053 1055 O
correct NCT03921437 1056 1063 B-Procedure
physiological NCT03921437 1064 1077 B-Condition
defects NCT03921437 1078 1085 I-Condition
, NCT03921437 1086 1087 O
may NCT03921437 1088 1091 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03921437 1092 1101 O
with NCT03921437 1102 1106 O
peritoneal NCT03921437 1107 1117 B-Procedure
dialysis NCT03921437 1118 1126 I-Procedure
, NCT03921437 1127 1128 O
or NCT03921437 1129 1131 B-Or
increase NCT03921437 1132 1140 O
the NCT03921437 1141 1144 O
chance NCT03921437 1145 1151 B-Risk
of NCT03921437 1152 1154 I-Risk
infection NCT03921437 1155 1164 B-Condition
, NCT03921437 1165 1166 O
such NCT03921437 1167 1171 O
as NCT03921437 1172 1174 O
umbilical NCT03921437 1175 1184 B-Condition
hernia NCT03921437 1185 1191 I-Condition
. NCT03921437 1192 1193 O

9 NCT03921437 1197 1198 O
. NCT03921437 1198 1199 O
The NCT03921437 1201 1204 O
patient NCT03921437 1205 1212 O
is NCT03921437 1213 1215 O
unable NCT03921437 1216 1222 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03921437 1223 1225 O
operate NCT03921437 1226 1233 O
the NCT03921437 1234 1237 O
fluid NCT03921437 1238 1243 B-Procedure
change NCT03921437 1244 1250 I-Procedure
, NCT03921437 1251 1252 O
hand NCT03921437 1253 1257 O
shake NCT03921437 1258 1263 O
, NCT03921437 1264 1265 O
and NCT03921437 1266 1269 O
no NCT03921437 1270 1272 B-Negation
family NCT03921437 1273 1279 B-Family-Member
members NCT03921437 1280 1287 I-Family-Member
can NCT03921437 1288 1291 O
assist NCT03921437 1292 1298 O
. NCT03921437 1299 1300 O

10 NCT03921437 1303 1305 O
. NCT03921437 1305 1306 O
Patients NCT03921437 1308 1316 O
who NCT03921437 1317 1320 O
are NCT03921437 1321 1324 O
blind NCT03921437 1325 1330 B-Condition
, NCT03921437 1331 1332 O
have NCT03921437 1333 1337 O
poor NCT03921437 1338 1342 B-Condition
eyesight NCT03921437 1343 1351 I-Condition
, NCT03921437 1352 1353 O
and NCT03921437 1354 1357 B-Or
have NCT03921437 1358 1362 O
difficulty NCT03921437 1363 1373 B-Condition
operating NCT03921437 1374 1383 I-Condition
. NCT03921437 1383 1384 O

Inclusion NCT03929731 0 9 O
Criteria NCT03929731 10 18 O
: NCT03929731 19 20 O

- NCT03929731 24 25 O
Participants NCT03929731 27 39 O
will NCT03929731 40 44 O
have NCT03929731 45 49 O
completed NCT03929731 50 59 O
the NCT03929731 60 63 O
previous NCT03929731 64 72 B-Eq-Comparison
PCV NCT03929731 73 76 B-Procedure
RCTs NCT03929731 77 81 O
: NCT03929731 82 83 O
EVEREST NCT03929731 84 91 O
II NCT03929731 92 94 O
, NCT03929731 95 96 O
PLANET NCT03929731 97 103 O
and NCT03929731 104 107 O
PCV NCT03929731 108 111 B-Procedure
T&amp;E NCT03929731 112 119 O
studies NCT03929731 120 127 O

- NCT03929731 130 131 O
Are NCT03929731 133 136 O
able NCT03929731 137 141 O
to NCT03929731 142 144 O
give NCT03929731 145 149 O
consent NCT03929731 150 157 O
for NCT03929731 158 161 O
this NCT03929731 162 166 O
follow NCT03929731 167 173 O
up NCT03929731 174 176 O
study NCT03929731 177 182 O

Exclusion NCT03929731 183 192 O
Criteria NCT03929731 193 201 O
: NCT03929731 202 203 O

- NCT03929731 207 208 O
No NCT03929731 210 212 O
exclusion NCT03929731 213 222 O
criteria NCT03929731 223 231 O
unless NCT03929731 232 238 O
they NCT03929731 239 243 O
do NCT03929731 244 246 O
not NCT03929731 247 250 O
meet NCT03929731 251 255 O
the NCT03929731 256 259 O
inclusion NCT03929731 260 269 O
criteria NCT03929731 270 278 O

Inclusion NCT03920098 0 9 O
Criteria NCT03920098 10 18 O
: NCT03920098 19 20 O

- NCT03920098 24 25 O
Primipara NCT03920098 27 36 B-Condition
( NCT03920098 37 38 O
no NCT03920098 39 41 B-Negation
previous NCT03920098 42 50 B-Eq-Comparison
pregnancies NCT03920098 51 62 B-Condition
) NCT03920098 63 64 O

- NCT03920098 68 69 O
18 NCT03920098 71 73 B-Eq-Comparison
to NCT03920098 74 76 I-Eq-Comparison
25 NCT03920098 77 79 I-Eq-Comparison
years NCT03920098 80 85 I-Eq-Comparison
of NCT03920098 86 88 O
age NCT03920098 89 92 B-Age

- NCT03920098 95 96 O
Gestation NCT03920098 98 107 B-Observation
< NCT03920098 108 109 B-Eq-Comparison
15 NCT03920098 110 112 I-Eq-Comparison
weeks NCT03920098 113 118 I-Eq-Comparison
at NCT03920098 119 121 B-Temporal-Connection___Temporal-Connection-Type-Value:during
first NCT03920098 122 127 B-Eq-Comparison
prenatal NCT03920098 128 136 B-Condition
visit NCT03920098 137 142 B-Encounter

- NCT03920098 145 146 O
No NCT03920098 148 150 B-Negation
intention NCT03920098 151 160 B-Assertion___Assertion-Type-Value:intention
to NCT03920098 161 163 O
move NCT03920098 164 168 B-Observation
outside NCT03920098 169 176 O
the NCT03920098 177 180 O
city NCT03920098 181 185 O
of NCT03920098 186 188 O
Santiago NCT03920098 189 197 O
in NCT03920098 198 200 O
the NCT03920098 201 204 O
next NCT03920098 205 209 B-Eq-Comparison
to NCT03920098 210 212 I-Eq-Comparison
years NCT03920098 213 218 I-Eq-Comparison

Exclusion NCT03920098 219 228 O
Criteria NCT03920098 229 237 O
: NCT03920098 238 239 O

- NCT03920098 243 244 O
Multipara NCT03920098 246 255 B-Condition

- NCT03920098 258 259 O
Pre NCT03920098 261 264 B-Eq-Comparison
- NCT03920098 265 266 I-Eq-Comparison
existing NCT03920098 267 275 I-Eq-Comparison
cancer NCT03920098 276 282 B-Condition
( NCT03920098 283 284 O
except NCT03920098 285 291 B-Exception
non NCT03920098 292 295 B-Modifier
- NCT03920098 296 297 I-Modifier
melanoma NCT03920098 298 306 I-Modifier
skin NCT03920098 307 311 B-Modifier
cancer NCT03920098 312 318 B-Condition
) NCT03920098 319 320 O

- NCT03920098 324 325 O
Family NCT03920098 327 333 B-Family-Member
history NCT03920098 334 341 I-Family-Member
of NCT03920098 342 344 O
breast NCT03920098 345 351 B-Modifier
cancer NCT03920098 352 358 B-Condition
( NCT03920098 359 360 O
one NCT03920098 361 364 B-Eq-Comparison
first NCT03920098 365 370 B-Modifier
- NCT03920098 371 372 I-Modifier
degree NCT03920098 373 379 I-Modifier
female NCT03920098 380 386 B-Family-Member
relative NCT03920098 387 395 I-Family-Member
diagnosed NCT03920098 396 405 O
with NCT03920098 406 410 O
breast NCT03920098 411 417 B-Modifier
cancer NCT03920098 418 424 B-Condition
) NCT03920098 425 426 O

- NCT03920098 430 431 O
High NCT03920098 433 437 B-Modifier
- NCT03920098 438 439 I-Modifier
risk NCT03920098 440 444 I-Modifier
pregnancy NCT03920098 445 454 B-Condition
according NCT03920098 455 464 O
to NCT03920098 465 467 O
national NCT03920098 468 476 O
guidelines NCT03920098 477 487 O

- NCT03920098 490 491 O
During NCT03920098 493 499 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03920098 500 503 O
follow NCT03920098 504 510 B-Encounter
- NCT03920098 511 512 I-Encounter
up NCT03920098 513 515 I-Encounter
, NCT03920098 516 517 O
pregnant NCT03920098 518 526 B-Condition
women NCT03920098 527 532 O
under NCT03920098 533 538 O
any NCT03920098 539 542 O
treatment NCT03920098 543 552 B-Procedure
that NCT03920098 553 557 O
may NCT03920098 558 561 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03920098 562 568 O
the NCT03920098 569 572 O
levels NCT03920098 573 579 O
of NCT03920098 580 582 O
metabolic NCT03920098 583 592 B-Observation
markers NCT03920098 593 600 I-Observation
will NCT03920098 601 605 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03920098 606 608 I-Assertion___Assertion-Type-Value:hypothetical
excluded NCT03920098 609 617 B-Negation
from NCT03920098 618 622 O
the NCT03920098 623 626 O
analysis NCT03920098 627 635 B-Study

- NCT03920098 638 639 O
Pregnant NCT03920098 641 649 B-Condition
women NCT03920098 650 655 O
with NCT03920098 656 660 B-And
pre NCT03920098 661 664 B-Condition
- NCT03920098 665 666 I-Condition
eclampsia NCT03920098 667 676 I-Condition
or NCT03920098 677 679 B-Or
with NCT03920098 680 684 O
preterm NCT03920098 685 692 B-Condition
birth NCT03920098 693 698 I-Condition
( NCT03920098 699 700 O
less NCT03920098 701 705 B-Eq-Comparison
than NCT03920098 706 710 I-Eq-Comparison
37 NCT03920098 711 713 I-Eq-Comparison
weeks NCT03920098 714 719 I-Eq-Comparison
of NCT03920098 720 722 O
gestational NCT03920098 723 734 B-Observation
age NCT03920098 735 738 I-Observation
) NCT03920098 739 740 O
will NCT03920098 741 745 O
be NCT03920098 746 748 O
also NCT03920098 749 753 O
excluded NCT03920098 754 762 B-Negation

Inclusion NCT03926403 0 9 O
Criteria NCT03926403 10 18 O
: NCT03926403 19 20 O

- NCT03926403 24 25 O
Patient NCT03926403 27 34 O
treated NCT03926403 35 42 B-Eq-Comparison
under NCT03926403 43 48 O
local NCT03926403 49 54 B-Procedure
anaesthesia NCT03926403 55 66 I-Procedure
in NCT03926403 67 69 O
the NCT03926403 70 73 O
Maxillo NCT03926403 74 81 O
Facial NCT03926403 82 88 O
Surgery NCT03926403 89 96 O
department NCT03926403 97 107 O
with NCT03926403 108 112 O
ultra NCT03926403 113 118 B-Procedure
- NCT03926403 119 120 I-Procedure
short NCT03926403 121 126 I-Procedure
circuit NCT03926403 127 134 I-Procedure

- NCT03926403 137 138 O
Patient NCT03926403 140 147 O
undergoing NCT03926403 148 158 B-Eq-Comparison
face NCT03926403 159 163 B-Modifier
surgery NCT03926403 164 171 B-Procedure

- NCT03926403 174 175 O
Patient NCT03926403 177 184 O
who NCT03926403 185 188 O
has NCT03926403 189 192 O
received NCT03926403 193 201 B-Eq-Comparison
appropriate NCT03926403 202 213 O
information NCT03926403 214 225 O
and NCT03926403 226 229 O
has NCT03926403 230 233 O
provided NCT03926403 234 242 O
informed NCT03926403 243 251 O
consent NCT03926403 252 259 O

- NCT03926403 262 263 O
Adult NCT03926403 265 270 O
patient NCT03926403 271 278 O
≥ NCT03926403 279 280 B-Eq-Comparison
18 NCT03926403 281 283 I-Eq-Comparison
years NCT03926403 284 289 I-Eq-Comparison
old NCT03926403 290 293 B-Age

- NCT03926403 296 297 O
Patient NCT03926403 299 306 O
with NCT03926403 307 311 O
a NCT03926403 312 313 O
score NCT03926403 314 319 O
of NCT03926403 320 322 O
≥ NCT03926403 323 324 B-Eq-Comparison
46 NCT03926403 325 327 I-Eq-Comparison
on NCT03926403 328 330 O
the NCT03926403 331 334 O
initial NCT03926403 335 342 B-Eq-Comparison
anxiety NCT03926403 343 350 B-Observation
self NCT03926403 351 355 I-Observation
- NCT03926403 356 357 I-Observation
assessment NCT03926403 358 368 I-Observation
questionnaire NCT03926403 369 382 I-Observation

Exclusion NCT03926403 383 392 O
Criteria NCT03926403 393 401 O
: NCT03926403 402 403 O

- NCT03926403 407 408 O
Patient NCT03926403 410 417 O
under NCT03926403 418 423 O
general NCT03926403 424 431 B-Procedure
anaesthesia NCT03926403 432 443 I-Procedure

- NCT03926403 446 447 O
Patients NCT03926403 449 457 O
treated NCT03926403 458 465 B-Eq-Comparison
in NCT03926403 466 468 O
conventional NCT03926403 469 481 O
inpatient NCT03926403 482 491 B-Encounter
care NCT03926403 492 496 I-Encounter
or NCT03926403 497 499 B-Or
in NCT03926403 500 502 O
the NCT03926403 503 506 O
traditional NCT03926403 507 518 O
ambulatory NCT03926403 519 529 B-Encounter
circuit NCT03926403 530 537 I-Encounter

- NCT03926403 540 541 O
Patient NCT03926403 543 550 O
under NCT03926403 551 556 B-Observation
guardianship NCT03926403 557 569 I-Observation
or NCT03926403 570 572 B-Or
trusteeship NCT03926403 573 584 B-Observation

- NCT03926403 587 588 O
Minor NCT03926403 590 595 O
patient NCT03926403 596 603 O
< NCT03926403 604 605 B-Eq-Comparison
18 NCT03926403 606 608 I-Eq-Comparison
years NCT03926403 609 614 I-Eq-Comparison
of NCT03926403 615 617 O
age NCT03926403 618 621 B-Age

- NCT03926403 624 625 O
Patient NCT03926403 627 634 O
who NCT03926403 635 638 O
has NCT03926403 639 642 O
not NCT03926403 643 646 O
provided NCT03926403 647 655 O
informed NCT03926403 656 664 O
consent NCT03926403 665 672 O
or NCT03926403 673 675 O
who NCT03926403 676 679 O
can NCT03926403 680 683 O
not NCT03926403 683 686 O
submit NCT03926403 687 693 O
to NCT03926403 694 696 O
the NCT03926403 697 700 O
study NCT03926403 701 706 O
protocol NCT03926403 707 715 O

- NCT03926403 718 719 O
Patient NCT03926403 721 728 O
suffering NCT03926403 729 738 O
from NCT03926403 739 743 O
cognitive NCT03926403 744 753 B-Condition
disorders NCT03926403 754 763 I-Condition
( NCT03926403 764 765 O
ex NCT03926403 766 768 O
: NCT03926403 769 770 O
Alzheimer NCT03926403 771 780 B-Condition
's NCT03926403 780 782 I-Condition
disease NCT03926403 783 790 I-Condition
) NCT03926403 791 792 O

- NCT03926403 796 797 O
Patients NCT03926403 799 807 O
who NCT03926403 808 811 O
are NCT03926403 812 815 O
deaf NCT03926403 816 820 B-Condition
or NCT03926403 821 823 B-Or
hearing NCT03926403 824 831 B-Condition
- NCT03926403 832 833 I-Condition
impaired NCT03926403 834 842 I-Condition

Inclusion NCT03922659 0 9 O
Criteria NCT03922659 10 18 O
: NCT03922659 19 20 O

- NCT03922659 24 25 O
Diagnosis NCT03922659 27 36 O
as NCT03922659 37 39 O
heroin NCT03922659 40 46 B-Condition
dependence NCT03922659 47 57 I-Condition
according NCT03922659 58 67 O
to NCT03922659 68 70 O
DSM NCT03922659 71 74 O
- NCT03922659 75 76 O
IV NCT03922659 77 79 O
criteria NCT03922659 80 88 O

- NCT03922659 91 92 O
No NCT03922659 94 96 O
definite NCT03922659 97 105 O
history NCT03922659 106 113 B-Eq-Comparison
of NCT03922659 114 116 O
neurological NCT03922659 117 129 B-Condition
diseases NCT03922659 130 138 I-Condition
and NCT03922659 139 142 B-Or
psychological NCT03922659 143 156 B-Condition
problems NCT03922659 157 165 I-Condition

- NCT03922659 168 169 O
Volunteer NCT03922659 171 180 O
to NCT03922659 181 183 O
participate NCT03922659 184 195 O
the NCT03922659 196 199 O
study NCT03922659 200 205 O
, NCT03922659 206 207 O
cooperate NCT03922659 208 217 O
to NCT03922659 218 220 O
be NCT03922659 221 223 O
followed NCT03922659 224 232 O
up NCT03922659 233 235 O

Exclusion NCT03922659 236 245 O
Criteria NCT03922659 246 254 O
: NCT03922659 255 256 O

- NCT03922659 260 261 O
Acute NCT03922659 263 268 O
withdrawal NCT03922659 269 279 B-Condition
state NCT03922659 280 285 I-Condition
and NCT03922659 286 289 O
CIWA NCT03922659 290 294 B-Observation
score NCT03922659 295 300 O
> NCT03922659 301 302 B-Eq-Comparison
9 NCT03922659 303 304 I-Eq-Comparison

- NCT03922659 308 309 O
With NCT03922659 311 315 O
other NCT03922659 316 321 B-Other
neurological NCT03922659 322 334 B-Condition
diseases NCT03922659 335 343 I-Condition
and NCT03922659 344 347 B-Or
psychological NCT03922659 348 361 B-Condition
problems NCT03922659 362 370 I-Condition

- NCT03922659 373 374 O
With NCT03922659 376 380 O
ever NCT03922659 381 385 B-Eq-Comparison
brain NCT03922659 386 391 B-Modifier
trauma NCT03922659 392 398 B-Condition
and NCT03922659 399 402 B-Or
damage NCT03922659 403 409 B-Condition

- NCT03922659 412 413 O
With NCT03922659 415 419 O
other NCT03922659 420 425 B-Other
psychological NCT03922659 426 439 B-Drug
medications NCT03922659 440 451 I-Drug
or NCT03922659 452 454 B-Or
other NCT03922659 455 460 B-Other
substance NCT03922659 461 470 B-Condition
dependence NCT03922659 471 481 I-Condition

- NCT03922659 484 485 O
With NCT03922659 487 491 O
other NCT03922659 492 497 B-Other
contraindications NCT03922659 498 515 B-Contraindication
to NCT03922659 516 518 O
have NCT03922659 519 523 O
transcranial NCT03922659 524 536 B-Procedure
magnetic NCT03922659 537 545 I-Procedure
stimulation NCT03922659 546 557 I-Procedure

Inclusion NCT03929718 0 9 O
Criteria NCT03929718 10 18 O
: NCT03929718 19 20 O

- NCT03929718 24 25 O
diagnosis NCT03929718 27 36 O
of NCT03929718 37 39 O
typical NCT03929718 40 47 B-Modifier
AFL NCT03929718 48 51 B-Condition
confirmed NCT03929718 52 61 O
by NCT03929718 62 64 O
12 NCT03929718 65 67 B-Procedure
- NCT03929718 68 69 I-Procedure
lead NCT03929718 70 74 I-Procedure
ECG NCT03929718 75 78 I-Procedure

- NCT03929718 81 82 O
no NCT03929718 84 86 B-Negation
documented NCT03929718 87 97 O
AF NCT03929718 98 100 B-Condition
on NCT03929718 101 103 O
ECG NCT03929718 104 107 B-Procedure
, NCT03929718 108 109 O
ambulatory NCT03929718 110 120 B-Procedure
monitor NCT03929718 121 128 I-Procedure
, NCT03929718 129 130 O
pacemaker NCT03929718 131 140 B-Procedure
or NCT03929718 141 143 B-Or
ICD NCT03929718 144 147 B-Procedure
at NCT03929718 148 150 O
any NCT03929718 151 154 B-Eq-Comparison
time NCT03929718 155 159 I-Eq-Comparison

- NCT03929718 162 163 O
scheduled NCT03929718 165 174 B-Eq-Comparison
to NCT03929718 175 177 O
undergo NCT03929718 178 185 O
catheter NCT03929718 186 194 B-Procedure
ablation NCT03929718 195 203 I-Procedure
of NCT03929718 204 206 O
the NCT03929718 207 210 O
CTI NCT03929718 211 214 B-Modifier
for NCT03929718 215 218 O
treatment NCT03929718 219 228 B-Procedure
of NCT03929718 229 231 O
AFL NCT03929718 232 235 B-Condition

- NCT03929718 238 239 O
history NCT03929718 241 248 B-Eq-Comparison
of NCT03929718 249 251 O
hypertension NCT03929718 252 264 B-Condition
( NCT03929718 265 266 O
HTN NCT03929718 267 270 B-Condition
) NCT03929718 271 272 O
or NCT03929718 273 275 B-Or
heart NCT03929718 276 281 B-Condition
failure NCT03929718 282 289 I-Condition
( NCT03929718 290 291 O
HF NCT03929718 292 294 B-Condition
) NCT03929718 295 296 O
( NCT03929718 297 298 O
reduced NCT03929718 299 306 B-Modifier
or NCT03929718 307 309 B-Or
preserved NCT03929718 310 319 B-Modifier
systolic NCT03929718 320 328 B-Condition
function NCT03929718 329 337 I-Condition
) NCT03929718 338 339 O

Exclusion NCT03929718 341 350 O
Criteria NCT03929718 351 359 O
: NCT03929718 360 361 O

- NCT03929718 365 366 O
history NCT03929718 368 375 B-Eq-Comparison
of NCT03929718 376 378 O
known NCT03929718 379 384 O
AF NCT03929718 385 387 B-Condition
episodes NCT03929718 388 396 O

- NCT03929718 399 400 O
previous NCT03929718 402 410 B-Eq-Comparison
CTI NCT03929718 411 414 B-Modifier
or NCT03929718 415 417 B-Or
PVI NCT03929718 418 421 B-Modifier
ablation NCT03929718 422 430 B-Procedure
procedure NCT03929718 431 440 I-Procedure

- NCT03929718 443 444 O
other NCT03929718 446 451 B-Other
SVT NCT03929718 452 455 B-Condition
mechanisms NCT03929718 456 466 I-Condition
demonstrated NCT03929718 467 479 O
( NCT03929718 480 481 O
AVNRT NCT03929718 482 487 B-Condition
, NCT03929718 488 489 O
AVRT NCT03929718 490 494 B-Condition
or NCT03929718 495 497 B-Or
accessory NCT03929718 498 507 B-Condition
pathways NCT03929718 508 516 I-Condition
) NCT03929718 517 518 O

- NCT03929718 522 523 O
amiodarone NCT03929718 525 535 B-Drug
usage NCT03929718 536 541 O
within NCT03929718 542 548 B-Eq-Comparison
the NCT03929718 549 552 I-Eq-Comparison
past NCT03929718 553 557 I-Eq-Comparison
3 NCT03929718 558 559 I-Eq-Comparison
months NCT03929718 560 566 I-Eq-Comparison
, NCT03929718 567 568 O

- NCT03929718 572 573 O
unwillingness NCT03929718 575 588 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03929718 589 591 O
participate NCT03929718 592 603 O
or NCT03929718 604 606 O
undergo NCT03929718 607 614 O
insertable NCT03929718 615 625 B-Procedure
monitor NCT03929718 626 633 I-Procedure
implantation NCT03929718 634 646 I-Procedure

- NCT03929718 649 650 O
hyperkalemia NCT03929718 652 664 B-Condition
( NCT03929718 665 666 O
potassium NCT03929718 667 676 B-Observation
> NCT03929718 677 678 B-Eq-Comparison
5.0 NCT03929718 679 682 I-Eq-Comparison
mEq NCT03929718 683 686 I-Eq-Comparison
/ NCT03929718 687 688 I-Eq-Comparison
L NCT03929718 689 690 I-Eq-Comparison
) NCT03929718 691 692 O

- NCT03929718 696 697 O
severe NCT03929718 699 705 O
renal NCT03929718 706 711 B-Condition
disease NCT03929718 712 719 I-Condition
( NCT03929718 720 721 O
Cr NCT03929718 722 724 B-Observation
> NCT03929718 725 726 B-Eq-Comparison
2.5 NCT03929718 727 730 I-Eq-Comparison
mg NCT03929718 731 733 I-Eq-Comparison
/ NCT03929718 734 735 I-Eq-Comparison
dL NCT03929718 736 738 I-Eq-Comparison
[ NCT03929718 739 740 O
men NCT03929718 741 744 O
] NCT03929718 745 746 O
, NCT03929718 748 749 O
> NCT03929718 750 751 B-Eq-Comparison
2.0 NCT03929718 752 755 I-Eq-Comparison
mg NCT03929718 756 758 I-Eq-Comparison
/ NCT03929718 759 760 I-Eq-Comparison
dL NCT03929718 761 763 I-Eq-Comparison
[ NCT03929718 764 765 O
women NCT03929718 766 771 O
, NCT03929718 772 773 O
GFR NCT03929718 774 777 B-Observation
< NCT03929718 778 779 B-Eq-Comparison
30 NCT03929718 780 782 I-Eq-Comparison
mL NCT03929718 783 785 I-Eq-Comparison
/ NCT03929718 786 787 I-Eq-Comparison
min NCT03929718 788 791 I-Eq-Comparison
/ NCT03929718 792 793 I-Eq-Comparison
1.73 NCT03929718 794 798 I-Eq-Comparison
m2 NCT03929718 799 801 I-Eq-Comparison
) NCT03929718 802 803 O

- NCT03929718 807 808 O
life NCT03929718 810 814 B-Observation
expectancy NCT03929718 815 825 I-Observation
< NCT03929718 826 827 B-Eq-Comparison
18 NCT03929718 828 830 I-Eq-Comparison
months NCT03929718 831 837 I-Eq-Comparison

- NCT03929718 840 841 O
prior NCT03929718 843 848 B-Eq-Comparison
intolerance NCT03929718 849 860 B-Condition
to NCT03929718 861 863 O
treatment NCT03929718 864 873 B-Procedure
with NCT03929718 874 878 O
an NCT03929718 879 881 O
aldosterone NCT03929718 882 893 B-Drug
antagonist NCT03929718 894 904 I-Drug

- NCT03929718 907 908 O
current NCT03929718 910 917 B-Eq-Comparison
treatment NCT03929718 918 927 B-Procedure
with NCT03929718 928 932 O
an NCT03929718 933 935 O
aldosterone NCT03929718 936 947 B-Drug
antagonist NCT03929718 948 958 I-Drug

- NCT03929718 961 962 O
need NCT03929718 964 968 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03929718 969 972 I-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03929718 973 982 B-Procedure
with NCT03929718 983 987 O
a NCT03929718 988 989 O
class NCT03929718 990 995 B-Eq-Comparison
I NCT03929718 996 997 I-Eq-Comparison
or NCT03929718 998 1000 I-Eq-Comparison
III NCT03929718 1001 1004 I-Eq-Comparison
AAD NCT03929718 1005 1008 B-Drug
for NCT03929718 1009 1012 O
another NCT03929718 1013 1020 B-Other
indication NCT03929718 1021 1031 B-Indication

- NCT03929718 1034 1035 O
operative NCT03929718 1037 1046 B-Modifier
AFL NCT03929718 1047 1050 B-Condition
( NCT03929718 1051 1052 O
occurring NCT03929718 1053 1062 O
within NCT03929718 1063 1069 B-Eq-Comparison
30 NCT03929718 1070 1072 I-Eq-Comparison
days NCT03929718 1073 1077 I-Eq-Comparison
of NCT03929718 1078 1080 B-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03929718 1081 1088 B-Procedure
) NCT03929718 1089 1090 O
that NCT03929718 1091 1095 O
is NCT03929718 1096 1098 O
expected NCT03929718 1099 1107 O
to NCT03929718 1108 1110 O
resolve NCT03929718 1111 1118 O

- NCT03929718 1121 1122 O
presence NCT03929718 1124 1132 O
of NCT03929718 1133 1135 O
a NCT03929718 1136 1137 O
cardiac NCT03929718 1138 1145 B-Procedure
rhythm NCT03929718 1146 1152 I-Procedure
device NCT03929718 1153 1159 I-Procedure
( NCT03929718 1160 1161 O
pacemaker NCT03929718 1162 1171 B-Procedure
or NCT03929718 1172 1174 B-Or
ICD NCT03929718 1175 1178 B-Procedure
) NCT03929718 1179 1180 O
capable NCT03929718 1181 1188 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03929718 1189 1191 O
AF NCT03929718 1192 1194 B-Procedure
monitoring NCT03929718 1195 1205 I-Procedure

- NCT03929718 1208 1209 O
currently NCT03929718 1211 1220 O
pregnant NCT03929718 1221 1229 B-Condition
or NCT03929718 1230 1232 B-Or
nursing NCT03929718 1233 1240 B-Condition
a NCT03929718 1241 1242 I-Condition
child NCT03929718 1243 1248 I-Condition

- NCT03929718 1251 1252 O
unwilling NCT03929718 1254 1263 B-Assertion___Assertion-Type-Value:hypothetical|Negation
not NCT03929718 1264 1267 B-Negation
to NCT03929718 1268 1270 O
become NCT03929718 1271 1277 O
pregnant NCT03929718 1278 1286 B-Condition
and NCT03929718 1287 1290 B-And
to NCT03929718 1291 1293 O
use NCT03929718 1294 1297 O
birth NCT03929718 1298 1303 B-Procedure
control NCT03929718 1304 1311 I-Procedure
while NCT03929718 1312 1317 B-Temporal-Connection___Temporal-Connection-Type-Value:during
taking NCT03929718 1318 1324 B-Eq-Comparison
spironolactone NCT03929718 1325 1339 B-Drug

Inclusion NCT03926832 0 9 O
Criteria NCT03926832 10 18 O
: NCT03926832 19 20 O

- NCT03926832 24 25 O
Subjects NCT03926832 27 35 O
with NCT03926832 36 40 O
a NCT03926832 41 42 O
definite NCT03926832 43 51 O
diagnosis NCT03926832 52 61 O
of NCT03926832 62 64 O
sarcoidosis NCT03926832 65 76 B-Condition
according NCT03926832 77 86 O
to NCT03926832 87 89 O
international NCT03926832 90 103 O
ATS NCT03926832 104 107 O
and NCT03926832 108 111 O
WASOG NCT03926832 112 117 O
guideline NCT03926832 118 127 O

Exclusion NCT03926832 128 137 O
Criteria NCT03926832 138 146 O
: NCT03926832 147 148 O

- NCT03926832 152 153 O
Ongoing NCT03926832 155 162 B-Eq-Comparison
CPAP NCT03926832 163 167 B-Procedure
treatment NCT03926832 168 177 I-Procedure

- NCT03926832 180 181 O
Psychiatric NCT03926832 183 194 B-Condition
disorders NCT03926832 195 204 I-Condition

Inclusion NCT03923023 0 9 O
Criteria NCT03923023 10 18 O
: NCT03923023 19 20 O

- NCT03923023 24 25 O
Pregnant NCT03923023 27 35 B-Condition
women NCT03923023 36 41 O
who NCT03923023 42 45 B-And
seek NCT03923023 46 50 B-Assertion___Assertion-Type-Value:intention
Antenatal NCT03923023 51 60 B-Provider
care NCT03923023 61 65 I-Provider
services NCT03923023 66 74 I-Provider
and NCT03923023 75 78 B-And
plan NCT03923023 79 83 B-Assertion___Assertion-Type-Value:intention
to NCT03923023 84 86 I-Assertion___Assertion-Type-Value:intention
deliver NCT03923023 87 94 B-Procedure
in NCT03923023 95 97 O
the NCT03923023 98 101 O
selected NCT03923023 102 110 O
health NCT03923023 111 117 O
facilities NCT03923023 118 128 O

- NCT03923023 131 132 O
Women NCT03923023 134 139 O
who NCT03923023 140 143 O
reside NCT03923023 144 150 O
within NCT03923023 151 157 O
the NCT03923023 158 161 O
larger NCT03923023 162 168 O
catchment NCT03923023 169 178 O
area NCT03923023 179 183 O
of NCT03923023 184 186 O
the NCT03923023 187 190 O
selected NCT03923023 191 199 O
3 NCT03923023 200 201 B-Eq-Comparison
health NCT03923023 202 208 O
facilities NCT03923023 209 219 O

Exclusion NCT03923023 220 229 O
Criteria NCT03923023 230 238 O
: NCT03923023 239 240 O

- NCT03923023 244 245 O
Women NCT03923023 247 252 O
who NCT03923023 253 256 O
reside NCT03923023 257 263 O
outside NCT03923023 264 271 B-Other
the NCT03923023 272 275 O
larger NCT03923023 276 282 O
catchment NCT03923023 283 292 O
area NCT03923023 293 297 O
of NCT03923023 298 300 O
the NCT03923023 301 304 O
health NCT03923023 305 311 O
facilities NCT03923023 312 322 O

- NCT03923023 325 326 O
Women NCT03923023 328 333 O
who NCT03923023 334 337 B-And
have NCT03923023 338 342 O
not NCT03923023 343 346 B-Negation
sought NCT03923023 347 353 B-Assertion___Assertion-Type-Value:intention
antenatal NCT03923023 354 363 B-Provider
care NCT03923023 364 368 I-Provider
services NCT03923023 369 377 I-Provider
in NCT03923023 378 380 O
the NCT03923023 381 384 O
3 NCT03923023 385 386 B-Eq-Comparison
health NCT03923023 387 393 O
facilities NCT03923023 394 404 O
and NCT03923023 405 408 O
have NCT03923023 409 413 O
come NCT03923023 414 418 O
to NCT03923023 419 421 O
only NCT03923023 422 426 O
deliver NCT03923023 427 434 O
there NCT03923023 435 440 O

Inclusion NCT03923751 0 9 O
Criteria NCT03923751 10 18 O
: NCT03923751 19 20 O

- NCT03923751 24 25 O
All NCT03923751 27 30 O
Polish NCT03923751 31 37 O
hospitals NCT03923751 38 47 O
practising NCT03923751 48 58 O
anesthesiology NCT03923751 59 73 O
and NCT03923751 74 77 O
intensive NCT03923751 78 87 O
care NCT03923751 88 92 O
in NCT03923751 93 95 O
the NCT03923751 96 99 O
national NCT03923751 100 108 O
register NCT03923751 109 117 O
of NCT03923751 118 120 O
medical NCT03923751 121 128 O
practices NCT03923751 129 138 O
( NCT03923751 139 140 O
www NCT03923751 141 144 O
. NCT03923751 144 145 O
rpwdl NCT03923751 146 151 O
. NCT03923751 151 152 O
csioz NCT03923751 153 158 O
. NCT03923751 158 159 O
gov NCT03923751 160 163 O
. NCT03923751 163 164 O
pl NCT03923751 165 167 O
) NCT03923751 168 169 O

Exclusion NCT03923751 171 180 O
Criteria NCT03923751 181 189 O
: NCT03923751 190 191 O

- NCT03923751 195 196 O
Hospitals NCT03923751 198 207 O
and NCT03923751 208 211 O
medical NCT03923751 212 219 O
practices NCT03923751 220 229 O
not NCT03923751 230 233 O
practising NCT03923751 234 244 O
anesthesiology NCT03923751 245 259 O
or NCT03923751 260 262 O
intensive NCT03923751 263 272 O
care NCT03923751 273 277 O

Inclusion NCT03923816 0 9 O
Criteria NCT03923816 10 18 O
: NCT03923816 19 20 O

- NCT03923816 24 25 O
patients NCT03923816 27 35 O
> NCT03923816 36 37 B-Eq-Comparison
18 NCT03923816 38 40 I-Eq-Comparison
years NCT03923816 41 46 I-Eq-Comparison
old NCT03923816 47 50 B-Age
, NCT03923816 51 52 O
undergoing NCT03923816 53 63 B-Eq-Comparison
elective NCT03923816 64 72 O
hepatobiliary NCT03923816 73 86 B-Procedure
surgery NCT03923816 87 94 I-Procedure
under NCT03923816 95 100 O
general NCT03923816 101 108 B-Procedure
anesthesia NCT03923816 109 119 I-Procedure
and NCT03923816 120 123 B-And
American NCT03923816 124 132 B-Condition
Society NCT03923816 133 140 I-Condition
of NCT03923816 141 143 I-Condition
Anesthesiologists NCT03923816 144 161 I-Condition
grade NCT03923816 162 167 B-Eq-Comparison
II NCT03923816 168 170 I-Eq-Comparison
. NCT03923816 171 172 O

Exclusion NCT03923816 174 183 O
Criteria NCT03923816 184 192 O
: NCT03923816 193 194 O

- NCT03923816 198 199 O
1 NCT03923816 201 202 O
- NCT03923816 203 204 O
patient NCT03923816 205 212 O
refusal NCT03923816 213 220 O
. NCT03923816 220 221 O
2 NCT03923816 223 224 O
- NCT03923816 225 226 O
psychiatric NCT03923816 227 238 B-Condition
disorders NCT03923816 239 248 I-Condition
. NCT03923816 248 249 O
3 NCT03923816 251 252 O
- NCT03923816 253 254 O
pregnancy NCT03923816 255 264 B-Condition
and NCT03923816 265 268 B-And
lactation NCT03923816 269 278 B-Condition
. NCT03923816 278 279 O
4 NCT03923816 281 282 O
- NCT03923816 283 284 O
preexisting NCT03923816 285 296 B-Eq-Comparison
neurological NCT03923816 297 309 B-Condition
dysfunction NCT03923816 310 321 I-Condition
( NCT03923816 322 323 O
history NCT03923816 324 331 B-Eq-Comparison
of NCT03923816 332 334 O
cerebrovascular NCT03923816 335 350 B-Condition
stroke NCT03923816 351 357 I-Condition
CVS NCT03923816 358 361 B-Condition
) NCT03923816 362 363 O
5 NCT03923816 364 365 O
- NCT03923816 366 367 O
metastatic NCT03923816 368 378 B-Modifier
cancer NCT03923816 379 385 B-Condition
. NCT03923816 386 387 O

6 NCT03923816 394 395 O
- NCT03923816 396 397 O
Inflammatory NCT03923816 398 410 B-Condition
bowel NCT03923816 411 416 I-Condition
disease NCT03923816 417 424 I-Condition
. NCT03923816 424 425 O
7 NCT03923816 427 428 O
- NCT03923816 429 430 O
Diabetes NCT03923816 431 439 B-Condition
mellitus NCT03923816 440 448 I-Condition
. NCT03923816 448 449 O
8 NCT03923816 451 452 O
- NCT03923816 453 454 O
Renal NCT03923816 455 460 B-Condition
insufficiency NCT03923816 461 474 I-Condition
( NCT03923816 475 476 O
serum NCT03923816 477 482 B-Observation
creatinine NCT03923816 483 493 I-Observation
level NCT03923816 494 499 I-Observation
more NCT03923816 500 504 B-Eq-Comparison
than NCT03923816 505 509 I-Eq-Comparison
180 NCT03923816 510 513 I-Eq-Comparison
μmol NCT03923816 514 518 I-Eq-Comparison
/ NCT03923816 519 520 I-Eq-Comparison
l NCT03923816 521 522 I-Eq-Comparison
) NCT03923816 523 524 O
. NCT03923816 525 526 O
9 NCT03923816 528 529 O
- NCT03923816 530 531 O
unexpected NCT03923816 532 542 B-Assertion___Assertion-Type-Value:hypothetical
intraoperative NCT03923816 543 557 B-Condition
findings NCT03923816 558 566 I-Condition
( NCT03923816 567 568 O
inoperable NCT03923816 569 579 O
) NCT03923816 580 581 O
. NCT03923816 582 583 O
10 NCT03923816 585 587 O
- NCT03923816 588 589 O
accidental NCT03923816 590 600 B-Modifier
massive NCT03923816 601 608 I-Modifier
intraoperative NCT03923816 609 623 B-Condition
hemorrhage NCT03923816 624 634 I-Condition
. NCT03923816 634 635 O

Inclusion NCT03926013 0 9 O
Criteria NCT03926013 10 18 O
: NCT03926013 19 20 O

- NCT03926013 24 25 O
Histology NCT03926013 27 36 O
: NCT03926013 37 38 O
Part NCT03926013 39 43 O
1 NCT03926013 44 45 I-Eq-Comparison
: NCT03926013 46 47 O
Metastatic NCT03926013 48 58 B-Modifier
castration NCT03926013 59 69 I-Modifier
- NCT03926013 70 71 I-Modifier
resistant NCT03926013 72 81 I-Modifier
prostate NCT03926013 82 90 I-Modifier
cancer NCT03926013 91 97 B-Condition
( NCT03926013 98 99 I-Eq-Comparison
mCRPC NCT03926013 100 105 B-Condition
) NCT03926013 106 107 I-Eq-Comparison
with NCT03926013 108 112 B-And
histologic NCT03926013 113 123 B-Procedure
confirmation NCT03926013 124 136 O
of NCT03926013 137 139 O
adenocarcinoma NCT03926013 140 154 B-Condition
. NCT03926013 154 155 O
Adenocarcinoma NCT03926013 157 171 B-Condition
with NCT03926013 172 176 O
small NCT03926013 177 182 B-Modifier
- NCT03926013 183 184 I-Modifier
cell NCT03926013 185 189 I-Modifier
or NCT03926013 190 192 B-Eq-Comparison|Or
neuroendocrine NCT03926013 193 207 B-Modifier
features NCT03926013 208 216 O
is NCT03926013 217 219 O
allowed NCT03926013 220 227 O
. NCT03926013 227 228 O
mCRPC NCT03926013 230 235 B-Condition
is NCT03926013 236 238 O
defined NCT03926013 239 246 O
by NCT03926013 247 249 O
prostate NCT03926013 250 258 O
Cancer NCT03926013 259 265 O
Working NCT03926013 266 273 O
Group NCT03926013 274 279 O
( NCT03926013 280 281 O
PCWG NCT03926013 282 286 O
) NCT03926013 287 288 O
3 NCT03926013 289 290 O
criteria NCT03926013 291 299 O
. NCT03926013 299 300 O
Part NCT03926013 302 306 O
2 NCT03926013 307 308 O
: NCT03926013 309 310 O
mCRPC NCT03926013 311 316 B-Condition
as NCT03926013 317 319 O
defined NCT03926013 320 327 O
above NCT03926013 328 333 O
or NCT03926013 334 336 B-Or
pathologically NCT03926013 337 351 B-Procedure
confirmed NCT03926013 352 361 O
metastatic NCT03926013 362 372 B-Modifier
renal NCT03926013 373 378 I-Modifier
cell NCT03926013 379 383 I-Modifier
carcinoma NCT03926013 384 393 B-Condition
( NCT03926013 394 395 O
RCC NCT03926013 396 399 B-Condition
) NCT03926013 400 401 O
as NCT03926013 402 404 O
defined NCT03926013 405 412 O
by NCT03926013 413 415 O
world NCT03926013 416 421 O
health NCT03926013 422 428 O
organization NCT03926013 429 441 O
( NCT03926013 442 443 O
WHO NCT03926013 444 447 O
) NCT03926013 448 449 O

2016 NCT03926013 456 460 O
Classifications NCT03926013 461 476 O

- NCT03926013 479 480 O
Measurable NCT03926013 482 492 B-Modifier
or NCT03926013 493 495 B-Or
evaluable NCT03926013 496 505 B-Modifier
disease NCT03926013 506 513 B-Condition
: NCT03926013 514 515 O
Part NCT03926013 516 520 O
1 NCT03926013 521 522 O
: NCT03926013 523 524 O
Either NCT03926013 525 531 O
measurable NCT03926013 532 542 B-Modifier
or NCT03926013 543 545 B-Or
evaluable NCT03926013 546 555 B-Modifier
disease NCT03926013 556 563 B-Condition
for NCT03926013 564 567 O
prostate NCT03926013 568 576 B-Modifier
cancer NCT03926013 577 583 B-Condition
. NCT03926013 583 584 O
Part NCT03926013 586 590 O
2 NCT03926013 591 592 O
: NCT03926013 593 594 O
At NCT03926013 595 597 B-Eq-Comparison
least NCT03926013 598 603 I-Eq-Comparison
one NCT03926013 604 607 I-Eq-Comparison
measurable NCT03926013 608 618 O
lesion NCT03926013 619 625 B-Condition
as NCT03926013 626 628 O
per NCT03926013 629 632 O
RECIST NCT03926013 633 639 O
v1.1 NCT03926013 640 644 O
. NCT03926013 644 645 O

- NCT03926013 649 650 O
Evidence NCT03926013 652 660 O
of NCT03926013 661 663 O
disease NCT03926013 664 671 B-Condition
progression NCT03926013 672 683 I-Condition
on NCT03926013 684 686 O
prior NCT03926013 687 692 B-Eq-Comparison
therapy NCT03926013 693 700 B-Procedure
that NCT03926013 701 705 O
requires NCT03926013 706 714 B-Assertion___Assertion-Type-Value:hypothetical
a NCT03926013 715 716 O
new NCT03926013 717 720 O
line NCT03926013 721 725 O
of NCT03926013 726 728 O
treatment NCT03926013 729 738 B-Procedure

- NCT03926013 741 742 O
Participants NCT03926013 744 756 O
with NCT03926013 757 761 O
accessible NCT03926013 762 772 O
lesions NCT03926013 773 780 B-Condition
enrolled NCT03926013 781 789 O
in NCT03926013 790 792 O
selected NCT03926013 793 801 O
pharmacokinetic NCT03926013 802 817 O
( NCT03926013 818 819 O
PK NCT03926013 820 822 O
) NCT03926013 823 824 O
/ NCT03926013 826 827 O
pharmacodynamics NCT03926013 828 844 O
( NCT03926013 845 846 O
PD NCT03926013 847 849 O
) NCT03926013 850 851 O
cohorts NCT03926013 852 859 O
and NCT03926013 860 863 O
in NCT03926013 864 866 O
Part NCT03926013 867 871 O
2 NCT03926013 872 873 O
must NCT03926013 874 878 O
agree NCT03926013 879 884 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926013 885 887 I-Assertion___Assertion-Type-Value:hypothetical|Eq-Comparison
undergo NCT03926013 888 895 O
the NCT03926013 896 899 O
mandatory NCT03926013 900 909 O
fresh NCT03926013 910 915 B-Modifier
tumor NCT03926013 916 921 I-Modifier
biopsies NCT03926013 922 930 B-Procedure
, NCT03926013 931 932 O
unless NCT03926013 933 939 B-Exception
collection NCT03926013 940 950 O
of NCT03926013 951 953 O
the NCT03926013 954 957 O
biopsy NCT03926013 958 964 B-Procedure
presents NCT03926013 965 973 O
a NCT03926013 974 975 O
safety NCT03926013 976 982 O
risk NCT03926013 983 987 B-Risk

Exclusion NCT03926013 988 997 O
Criteria NCT03926013 998 1006 O
: NCT03926013 1007 1008 O

- NCT03926013 1012 1013 O
At NCT03926013 1015 1017 B-Eq-Comparison
least NCT03926013 1018 1023 I-Eq-Comparison
2 NCT03926013 1024 1025 I-Eq-Comparison
weeks NCT03926013 1026 1031 I-Eq-Comparison
between NCT03926013 1032 1039 B-Temporal-Connection___Temporal-Connection-Type-Value:after
prior NCT03926013 1040 1045 B-Eq-Comparison
anticancer NCT03926013 1046 1056 B-Procedure
treatment NCT03926013 1057 1066 I-Procedure
( NCT03926013 1067 1068 O
including NCT03926013 1069 1078 O
radiotherapy NCT03926013 1079 1091 B-Procedure
) NCT03926013 1092 1093 O
discontinuation NCT03926013 1094 1109 O
and NCT03926013 1110 1113 O
the NCT03926013 1114 1117 O
first NCT03926013 1118 1123 B-Eq-Comparison
dose NCT03926013 1124 1128 O
of NCT03926013 1129 1131 O
study NCT03926013 1132 1137 B-Study
drug NCT03926013 1138 1142 B-Drug
, NCT03926013 1143 1144 O
and NCT03926013 1145 1148 O
toxicities NCT03926013 1149 1159 B-Observation
have NCT03926013 1160 1164 O
returned NCT03926013 1165 1173 O
to NCT03926013 1174 1176 O
Grade NCT03926013 1177 1182 B-Eq-Comparison
less NCT03926013 1183 1187 I-Eq-Comparison
than NCT03926013 1188 1192 I-Eq-Comparison
or NCT03926013 1193 1195 O
equal NCT03926013 1196 1201 I-Eq-Comparison
to NCT03926013 1202 1204 O
( NCT03926013 1205 1206 O
< NCT03926013 1208 1209 B-Eq-Comparison
= NCT03926013 1211 1212 I-Eq-Comparison
) NCT03926013 1214 1215 O
1 NCT03926013 1216 1217 O
or NCT03926013 1218 1220 B-Or
baseline NCT03926013 1221 1229 B-Study

- NCT03926013 1232 1233 O
Prior NCT03926013 1235 1240 B-Eq-Comparison
treatment NCT03926013 1241 1250 B-Procedure
with NCT03926013 1251 1255 O
prostate NCT03926013 1256 1264 B-Drug
- NCT03926013 1265 1266 I-Drug
specific NCT03926013 1267 1275 I-Drug
membrane NCT03926013 1276 1284 I-Drug
antigen NCT03926013 1285 1292 I-Drug
( NCT03926013 1293 1294 O
PSMA NCT03926013 1295 1299 B-Drug
) NCT03926013 1300 1301 O
- NCT03926013 1303 1304 O
targeted NCT03926013 1305 1313 O
therapy NCT03926013 1314 1321 O
except NCT03926013 1322 1328 B-Exception
for NCT03926013 1329 1332 O
PSMA NCT03926013 1333 1337 B-Immunization
- NCT03926013 1338 1339 I-Immunization
targeted NCT03926013 1340 1348 I-Immunization
vaccine NCT03926013 1349 1356 I-Immunization
is NCT03926013 1357 1359 O
permitted NCT03926013 1360 1369 O

- NCT03926013 1372 1373 O
Solid NCT03926013 1375 1380 B-Modifier
organ NCT03926013 1381 1386 I-Modifier
or NCT03926013 1387 1389 B-Or
bone NCT03926013 1390 1394 B-Modifier
marrow NCT03926013 1395 1401 I-Modifier
transplantation NCT03926013 1402 1417 B-Procedure

- NCT03926013 1420 1421 O
Seizure NCT03926013 1423 1430 B-Condition
or NCT03926013 1431 1433 B-Or
known NCT03926013 1434 1439 O
condition NCT03926013 1440 1449 B-Condition
that NCT03926013 1450 1454 O
may NCT03926013 1455 1458 B-Assertion___Assertion-Type-Value:hypothetical
predispose NCT03926013 1459 1469 O
to NCT03926013 1470 1472 O
seizure NCT03926013 1473 1480 B-Condition
or NCT03926013 1481 1483 B-Or
intracranial NCT03926013 1484 1496 B-Condition
masses NCT03926013 1497 1503 I-Condition

- NCT03926013 1506 1507 O
Other NCT03926013 1509 1514 B-Other
active NCT03926013 1515 1521 B-Eq-Comparison
malignancy NCT03926013 1522 1532 B-Condition
requiring NCT03926013 1533 1542 B-Assertion___Assertion-Type-Value:hypothetical
systemic NCT03926013 1543 1551 B-Modifier
treatment NCT03926013 1552 1561 B-Procedure
< NCT03926013 1562 1563 O
= NCT03926013 1565 1566 O
12 NCT03926013 1567 1569 I-Eq-Comparison
months NCT03926013 1570 1576 I-Eq-Comparison
prior NCT03926013 1577 1582 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926013 1583 1585 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03926013 1586 1596 B-Study

Inclusion NCT03920462 0 9 O
Criteria NCT03920462 10 18 O
: NCT03920462 19 20 O

- NCT03920462 24 25 O
Capacity NCT03920462 27 35 O
to NCT03920462 36 38 O
ride NCT03920462 39 43 O
a NCT03920462 44 45 O
bike NCT03920462 46 50 O

- NCT03920462 53 54 O
Volunteer NCT03920462 56 65 O
without NCT03920462 66 73 B-Negation
a NCT03920462 74 75 O
contraindication NCT03920462 76 92 B-Contraindication
to NCT03920462 93 95 O
moderate NCT03920462 96 104 O
physical NCT03920462 105 113 B-Observation
activity NCT03920462 114 122 I-Observation
or NCT03920462 123 125 B-Or
cycling NCT03920462 126 133 B-Observation
( NCT03920462 134 135 O
acute NCT03920462 136 141 O
coronary NCT03920462 142 150 B-Condition
artery NCT03920462 151 157 I-Condition
disease NCT03920462 158 165 I-Condition
less NCT03920462 166 170 B-Eq-Comparison
than NCT03920462 171 175 I-Eq-Comparison
2 NCT03920462 176 177 I-Eq-Comparison
years NCT03920462 178 183 I-Eq-Comparison
old NCT03920462 184 187 O
, NCT03920462 188 189 O
musculoskeletal NCT03920462 190 205 B-Modifier
problem NCT03920462 206 213 B-Condition
of NCT03920462 214 216 O
the NCT03920462 217 220 O
spine NCT03920462 221 226 B-Modifier
or NCT03920462 227 229 B-Or
lower NCT03920462 230 235 B-Modifier
limbs NCT03920462 236 241 I-Modifier
incompatible NCT03920462 242 254 B-Negation
with NCT03920462 255 259 O
cycling NCT03920462 260 267 B-Observation
) NCT03920462 268 269 O
. NCT03920462 271 272 O

- NCT03920462 276 277 O
weight NCT03920462 279 285 B-Observation
< NCT03920462 286 287 B-Eq-Comparison
125 NCT03920462 288 291 I-Eq-Comparison
kg NCT03920462 292 294 I-Eq-Comparison

- NCT03920462 297 298 O
volunteer NCT03920462 300 309 O
available NCT03920462 310 319 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03920462 320 323 I-Assertion___Assertion-Type-Value:hypothetical
an NCT03920462 324 326 O
intervention NCT03920462 327 339 B-Procedure
of NCT03920462 340 342 O
2 NCT03920462 343 344 B-Eq-Comparison
- NCT03920462 345 346 I-Eq-Comparison
3 NCT03920462 347 348 I-Eq-Comparison
hours NCT03920462 349 354 I-Eq-Comparison
twice NCT03920462 355 360 I-Eq-Comparison
a NCT03920462 361 362 I-Eq-Comparison
week NCT03920462 363 367 I-Eq-Comparison
during NCT03920462 368 374 B-Temporal-Connection___Temporal-Connection-Type-Value:during
1 NCT03920462 375 376 B-Eq-Comparison
month NCT03920462 377 382 I-Eq-Comparison
. NCT03920462 383 384 O

Exclusion NCT03920462 386 395 O
Criteria NCT03920462 396 404 O
: NCT03920462 405 406 O

- NCT03920462 410 411 O
Person NCT03920462 413 419 O
deprived NCT03920462 420 428 B-Observation
of NCT03920462 429 431 I-Observation
liberty NCT03920462 432 439 I-Observation
or NCT03920462 440 442 B-Or
legal NCT03920462 443 448 B-Observation
protection NCT03920462 449 459 I-Observation
measure NCT03920462 460 467 O

Inclusion NCT03928002 0 9 O
Criteria NCT03928002 10 18 O
: NCT03928002 19 20 O

- NCT03928002 24 25 O
Patient NCT03928002 27 34 O
≥ NCT03928002 35 36 B-Eq-Comparison
7 NCT03928002 37 38 I-Eq-Comparison
years NCT03928002 39 44 I-Eq-Comparison
old NCT03928002 45 48 B-Age

- NCT03928002 51 52 O
Patient NCT03928002 54 61 O
affiliated NCT03928002 62 72 O
to NCT03928002 73 75 O
a NCT03928002 76 77 O
social NCT03928002 78 84 O
security NCT03928002 85 93 O
system NCT03928002 94 100 O

- NCT03928002 103 104 O
Giving NCT03928002 106 112 O
their NCT03928002 113 118 O
informed NCT03928002 119 127 O
consent NCT03928002 128 135 O
for NCT03928002 136 139 O
the NCT03928002 140 143 O
study NCT03928002 144 149 O
( NCT03928002 150 151 O
adults NCT03928002 152 158 O
, NCT03928002 159 160 O
parents NCT03928002 161 168 O
of NCT03928002 169 171 O
minors NCT03928002 172 178 O
) NCT03928002 179 180 O

- NCT03928002 184 185 O
Patients NCT03928002 187 195 O
with NCT03928002 196 200 O
PAH NCT03928002 201 204 B-Condition
associated NCT03928002 205 215 O
with NCT03928002 216 220 O
congenital NCT03928002 221 231 B-Condition
heart NCT03928002 232 237 I-Condition
disease NCT03928002 238 245 I-Condition
requiring NCT03928002 246 255 B-Assertion___Assertion-Type-Value:hypothetical
cardiac NCT03928002 256 263 B-Procedure
catheterization NCT03928002 264 279 I-Procedure
and NCT03928002 280 283 B-And
2 NCT03928002 284 285 B-Modifier
D NCT03928002 286 287 I-Modifier
MRI NCT03928002 288 291 B-Procedure
for NCT03928002 292 295 O
the NCT03928002 296 299 O
diagnosis NCT03928002 300 309 O
or NCT03928002 310 312 O
follow NCT03928002 313 319 O
- NCT03928002 320 321 O
up NCT03928002 322 324 O
of NCT03928002 325 327 O
PAH NCT03928002 328 331 B-Condition
associated NCT03928002 332 342 O
with NCT03928002 343 347 O
congenital NCT03928002 348 358 B-Condition
heart NCT03928002 359 364 I-Condition
disease NCT03928002 365 372 I-Condition

Exclusion NCT03928002 373 382 O
Criteria NCT03928002 383 391 O
: NCT03928002 392 393 O

- NCT03928002 397 398 O
➢ NCT03928002 400 401 O
Patient NCT03928002 402 409 O
< NCT03928002 410 411 B-Eq-Comparison
7 NCT03928002 412 413 I-Eq-Comparison
years NCT03928002 414 419 I-Eq-Comparison
old NCT03928002 420 423 B-Age

- NCT03928002 431 432 O
Pregnant NCT03928002 434 442 B-Condition
woman NCT03928002 443 448 O

- NCT03928002 456 457 O
Contraindications NCT03928002 459 476 B-Contraindication
to NCT03928002 477 479 O
MRI NCT03928002 480 483 B-Procedure
( NCT03928002 484 485 O
claustrophobia NCT03928002 486 500 B-Condition
, NCT03928002 501 502 O
intraocular NCT03928002 503 514 B-Modifier
metal NCT03928002 515 520 B-Condition
foreign NCT03928002 521 528 I-Condition
bodies NCT03928002 529 535 I-Condition
, NCT03928002 536 537 O
pacemaker NCT03928002 538 547 B-Procedure
, NCT03928002 548 549 O
neurostimulator NCT03928002 550 565 B-Procedure
, NCT03928002 566 567 O
cochlear NCT03928002 568 576 B-Procedure
implants NCT03928002 577 585 I-Procedure
, NCT03928002 586 587 O
old NCT03928002 588 591 B-Modifier
heart NCT03928002 592 597 B-Procedure
valves NCT03928002 598 604 I-Procedure
) NCT03928002 605 606 O

- NCT03928002 615 616 O
Contraindication NCT03928002 618 634 B-Contraindication
to NCT03928002 635 637 O
gadolinium NCT03928002 638 648 B-Drug
injection NCT03928002 649 658 B-Procedure
( NCT03928002 659 660 O
allergy NCT03928002 661 668 B-Allergy
, NCT03928002 669 670 O
renal NCT03928002 671 676 B-Condition
failure NCT03928002 677 684 I-Condition
with NCT03928002 685 689 B-And
DFG NCT03928002 690 693 B-Observation
< NCT03928002 694 695 B-Eq-Comparison
30 NCT03928002 696 698 I-Eq-Comparison
ml NCT03928002 699 701 I-Eq-Comparison
/ NCT03928002 702 703 I-Eq-Comparison
min NCT03928002 704 707 I-Eq-Comparison
/ NCT03928002 708 709 I-Eq-Comparison
1.73 NCT03928002 710 714 I-Eq-Comparison
m² NCT03928002 715 717 I-Eq-Comparison
) NCT03928002 718 719 O

- NCT03928002 728 729 O
Hemodynamically NCT03928002 731 746 O
unstable NCT03928002 747 755 O
patients NCT03928002 756 764 O

- NCT03928002 772 773 O
Refusal NCT03928002 775 782 O
to NCT03928002 783 785 O
participate NCT03928002 786 797 O

Inclusion NCT03927872 0 9 O
criteria NCT03927872 10 18 O
: NCT03927872 19 20 O

- NCT03927872 24 25 O
CES NCT03927872 27 30 B-Condition
and NCT03927872 31 34 B-Or
non NCT03927872 35 38 B-Negation
- NCT03927872 39 40 O
CES NCT03927872 41 44 B-Condition
diagnosis NCT03927872 45 54 O
was NCT03927872 55 58 O
according NCT03927872 59 68 O
to NCT03927872 69 71 O
Trial NCT03927872 72 77 O
of NCT03927872 78 80 O
Org NCT03927872 81 84 O
10172 NCT03927872 85 90 O
in NCT03927872 91 93 O
Acute NCT03927872 94 99 B-Procedure
Stroke NCT03927872 100 106 I-Procedure
Treatment NCT03927872 107 116 I-Procedure
﴾ NCT03927872 117 118 O
TOAST NCT03927872 119 124 B-Procedure
﴿ NCT03927872 125 126 O
classification NCT03927872 127 141 O
criteria NCT03927872 142 150 O
. NCT03927872 151 152 O

- NCT03927872 156 157 O
non NCT03927872 159 162 B-Negation
- NCT03927872 163 164 O
CES NCT03927872 165 168 B-Condition
were NCT03927872 169 173 O
selected NCT03927872 174 182 O
to NCT03927872 183 185 O
match NCT03927872 186 191 O
patients NCT03927872 192 200 O
with NCT03927872 201 205 O
CES NCT03927872 206 209 B-Condition
regarding NCT03927872 210 219 O
age NCT03927872 220 223 O
and NCT03927872 224 227 O
vascular NCT03927872 228 236 O
risk NCT03927872 237 241 O
factors NCT03927872 242 249 O
as NCT03927872 250 252 O
a NCT03927872 253 254 O
control NCT03927872 255 262 O
group NCT03927872 263 268 O
. NCT03927872 269 270 O

- NCT03927872 274 275 O
Patients NCT03927872 277 285 O
with NCT03927872 286 290 O
National NCT03927872 291 299 B-Condition
Institutes NCT03927872 300 310 I-Condition
of NCT03927872 311 313 I-Condition
Health NCT03927872 314 320 I-Condition
Stroke NCT03927872 321 327 I-Condition
Scale NCT03927872 328 333 I-Condition
﴾ NCT03927872 334 335 O
NIHSS NCT03927872 336 341 B-Condition
﴿ NCT03927872 342 343 O
score NCT03927872 344 349 O
more NCT03927872 350 354 B-Eq-Comparison
than NCT03927872 355 359 I-Eq-Comparison
5 NCT03927872 360 361 I-Eq-Comparison
. NCT03927872 361 362 O

- NCT03927872 366 367 O
Adult NCT03927872 369 374 O
patients NCT03927872 375 383 O
with NCT03927872 384 388 B-And
their NCT03927872 389 394 O
ages NCT03927872 395 399 B-Age
more NCT03927872 400 404 B-Eq-Comparison
than NCT03927872 405 409 I-Eq-Comparison
18 NCT03927872 410 412 I-Eq-Comparison
year NCT03927872 413 417 I-Eq-Comparison
. NCT03927872 418 419 O

Exclusion NCT03927872 421 430 O
criteria NCT03927872 431 439 O
: NCT03927872 440 441 O

- NCT03927872 445 446 O
Lacunar NCT03927872 448 455 B-Modifier
stroke NCT03927872 456 462 B-Condition
and NCT03927872 463 466 O
transient NCT03927872 467 476 B-Condition
ischemic NCT03927872 477 485 I-Condition
attacks NCT03927872 486 493 I-Condition
( NCT03927872 494 495 O
TIAs NCT03927872 496 500 B-Condition
) NCT03927872 501 502 O

- NCT03927872 506 507 O
Haemorrhagic NCT03927872 509 521 B-Modifier
stroke NCT03927872 522 528 B-Condition
. NCT03927872 529 530 O

- NCT03927872 534 535 O
Neurological NCT03927872 537 549 B-Condition
causes NCT03927872 550 556 I-Condition
of NCT03927872 557 559 O
acute NCT03927872 560 565 O
focal NCT03927872 566 571 B-Modifier
cerebral NCT03927872 572 580 B-Condition
dysfunction NCT03927872 581 592 I-Condition
such NCT03927872 593 597 O
as NCT03927872 598 600 O
cerebral NCT03927872 601 609 B-Condition
venous NCT03927872 610 616 I-Condition
sinus NCT03927872 617 622 I-Condition
thrombosis NCT03927872 623 633 I-Condition
, NCT03927872 634 635 O
head NCT03927872 636 640 B-Modifier
trauma NCT03927872 641 647 B-Condition
, NCT03927872 648 649 O
infection NCT03927872 650 659 B-Condition
, NCT03927872 660 661 O
and NCT03927872 662 665 B-Or
auto NCT03927872 666 670 B-Condition
immune NCT03927872 671 677 I-Condition
disorders NCT03927872 678 687 I-Condition

- NCT03927872 690 691 O
Heart NCT03927872 693 698 B-Condition
failure NCT03927872 699 706 I-Condition

- NCT03927872 709 710 O
Liver NCT03927872 712 717 B-Condition
failure NCT03927872 718 725 I-Condition

- NCT03927872 728 729 O
Chronic NCT03927872 731 738 B-Condition
renal NCT03927872 739 744 I-Condition
disease NCT03927872 745 752 I-Condition
. NCT03927872 752 753 O

Inclusion NCT03929900 0 9 O
Criteria NCT03929900 10 18 O
: NCT03929900 19 20 O

- NCT03929900 24 25 O
Age NCT03929900 27 30 B-Age
45 NCT03929900 31 33 B-Eq-Comparison
- NCT03929900 34 35 I-Eq-Comparison
79 NCT03929900 36 38 I-Eq-Comparison
years NCT03929900 39 44 I-Eq-Comparison

- NCT03929900 47 48 O
Estimated NCT03929900 50 59 B-Observation
glomerular NCT03929900 60 70 I-Observation
filtration NCT03929900 71 81 I-Observation
rate NCT03929900 82 86 I-Observation
20 NCT03929900 87 89 B-Eq-Comparison
- NCT03929900 90 91 I-Eq-Comparison
60 NCT03929900 92 94 I-Eq-Comparison
mL NCT03929900 95 97 I-Eq-Comparison
/ NCT03929900 98 99 I-Eq-Comparison
min NCT03929900 100 103 I-Eq-Comparison
/ NCT03929900 104 105 I-Eq-Comparison
1.73 NCT03929900 106 110 I-Eq-Comparison
m2 NCT03929900 111 113 I-Eq-Comparison
based NCT03929900 114 119 O
on NCT03929900 120 122 O
CKD NCT03929900 123 126 O
- NCT03929900 127 128 O
EPI NCT03929900 129 132 O
( NCT03929900 133 134 O
Cr NCT03929900 135 137 O
) NCT03929900 138 139 O
equation NCT03929900 140 148 O

- NCT03929900 151 152 O
Non NCT03929900 154 157 B-Condition
- NCT03929900 158 159 I-Condition
dialysis NCT03929900 160 168 I-Condition
dependent NCT03929900 169 178 I-Condition
( NCT03929900 179 180 O
NDD NCT03929900 181 184 B-Condition
) NCT03929900 185 186 O

Exclusion NCT03929900 188 197 O
Criteria NCT03929900 198 206 O
: NCT03929900 207 208 O

- NCT03929900 212 213 O
Autosomal NCT03929900 215 224 B-Condition
dominant NCT03929900 225 233 I-Condition
polycystic NCT03929900 234 244 I-Condition
kidney NCT03929900 245 251 I-Condition
disease NCT03929900 252 259 I-Condition

- NCT03929900 262 263 O
Unable NCT03929900 265 271 O
or NCT03929900 272 274 O
unwilling NCT03929900 275 284 O
to NCT03929900 285 287 O
give NCT03929900 288 292 O
consent NCT03929900 293 300 O

- NCT03929900 303 304 O
Previously NCT03929900 306 316 B-Eq-Comparison
received NCT03929900 317 325 I-Eq-Comparison
chronic NCT03929900 326 333 B-Modifier
dialysis NCT03929900 334 342 B-Procedure

- NCT03929900 345 346 O
Previous NCT03929900 348 356 B-Eq-Comparison
any NCT03929900 357 360 O
organ NCT03929900 361 366 B-Procedure
transplant NCT03929900 367 377 I-Procedure

- NCT03929900 380 381 O
Patients NCT03929900 383 391 O
who NCT03929900 392 395 O
diagnosed NCT03929900 396 405 O
heart NCT03929900 406 411 B-Condition
failure NCT03929900 412 419 I-Condition
with NCT03929900 420 424 B-And
NYHA NCT03929900 425 429 B-Condition
class NCT03929900 430 435 B-Eq-Comparison
3 NCT03929900 436 437 I-Eq-Comparison
or NCT03929900 438 440 I-Eq-Comparison
4 NCT03929900 441 442 I-Eq-Comparison

- NCT03929900 446 447 O
Known NCT03929900 449 454 O
liver NCT03929900 455 460 B-Condition
cirrhosis NCT03929900 461 470 I-Condition
( NCT03929900 471 472 O
Child NCT03929900 473 478 B-Condition
- NCT03929900 479 480 I-Condition
pugh NCT03929900 481 485 I-Condition
class NCT03929900 486 491 B-Eq-Comparison
2 NCT03929900 492 493 I-Eq-Comparison
or NCT03929900 494 496 I-Eq-Comparison
3 NCT03929900 497 498 I-Eq-Comparison
) NCT03929900 499 500 O

- NCT03929900 504 505 O
Pregnant NCT03929900 507 515 B-Condition
women NCT03929900 516 521 O

- NCT03929900 524 525 O
Single NCT03929900 527 533 B-Condition
kidney NCT03929900 534 540 I-Condition
due NCT03929900 541 544 O
to NCT03929900 545 547 O
trauma NCT03929900 548 554 B-Condition
or NCT03929900 555 557 B-Or
donation NCT03929900 558 566 B-Condition

- NCT03929900 569 570 O
Patients NCT03929900 572 580 O
who NCT03929900 581 584 O
received NCT03929900 585 593 B-Eq-Comparison
immunosuppressive NCT03929900 594 611 B-Drug
agent NCT03929900 612 617 I-Drug
within NCT03929900 618 624 B-Eq-Comparison
the NCT03929900 625 628 I-Eq-Comparison
past NCT03929900 629 633 I-Eq-Comparison
1 NCT03929900 634 635 I-Eq-Comparison
year NCT03929900 636 640 I-Eq-Comparison

- NCT03929900 643 644 O
Patients NCT03929900 646 654 O
who NCT03929900 655 658 O
diagnosed NCT03929900 659 668 O
with NCT03929900 669 673 O
glomerulonephritis NCT03929900 674 692 B-Condition
through NCT03929900 693 700 O
kidney NCT03929900 701 707 B-Modifier
biopsy NCT03929900 708 714 B-Procedure

Inclusion NCT03928834 0 9 O
Criteria NCT03928834 10 18 O
: NCT03928834 19 20 O

1 NCT03928834 24 25 O
. NCT03928834 25 26 O
HIV NCT03928834 28 31 B-Condition
- NCT03928834 32 33 O
positive NCT03928834 34 42 O
adolescents NCT03928834 43 54 O
aged NCT03928834 55 59 B-Age
10 NCT03928834 60 62 B-Eq-Comparison
- NCT03928834 63 64 I-Eq-Comparison
19 NCT03928834 65 67 I-Eq-Comparison
years NCT03928834 68 73 I-Eq-Comparison
who NCT03928834 74 77 O
know NCT03928834 78 82 O
their NCT03928834 83 88 O
status NCT03928834 89 95 O

2 NCT03928834 98 99 O
. NCT03928834 99 100 O
On NCT03928834 102 104 B-Eq-Comparison
ART NCT03928834 105 108 B-Procedure
for NCT03928834 109 112 O
at NCT03928834 113 115 B-Eq-Comparison
least NCT03928834 116 121 I-Eq-Comparison
6 NCT03928834 122 123 I-Eq-Comparison
months NCT03928834 124 130 I-Eq-Comparison
as NCT03928834 131 133 O
per NCT03928834 134 137 O
clinic NCT03928834 138 144 O
records NCT03928834 145 152 O
: NCT03928834 153 154 O
the NCT03928834 155 158 O
patient NCT03928834 159 166 O
will NCT03928834 167 171 O
have NCT03928834 172 176 O
attended NCT03928834 177 185 B-Encounter
the NCT03928834 186 189 O
clinic NCT03928834 190 196 O
as NCT03928834 197 199 O
shown NCT03928834 200 205 O
in NCT03928834 206 208 O
clinic NCT03928834 209 215 O
records NCT03928834 216 223 O
at NCT03928834 224 226 B-Eq-Comparison
least NCT03928834 227 232 I-Eq-Comparison
once NCT03928834 233 237 I-Eq-Comparison
since NCT03928834 238 243 B-Temporal-Connection___Temporal-Connection-Type-Value:after
initiation NCT03928834 244 254 B-Eq-Comparison
AND NCT03928834 255 258 B-And
will NCT03928834 259 263 O
have NCT03928834 264 268 O
re NCT03928834 269 271 O
- NCT03928834 272 273 O
filled NCT03928834 274 280 O
their NCT03928834 281 286 O
ART NCT03928834 287 290 B-Procedure
at NCT03928834 291 293 B-Eq-Comparison
least NCT03928834 294 299 I-Eq-Comparison
once NCT03928834 300 304 I-Eq-Comparison
since NCT03928834 305 310 O
initiation NCT03928834 311 321 O
as NCT03928834 322 324 O
shown NCT03928834 325 330 O
in NCT03928834 331 333 O
clinic NCT03928834 334 340 O
records NCT03928834 341 348 O
. NCT03928834 348 349 O
. NCT03928834 350 351 O

3 NCT03928834 355 356 O
. NCT03928834 356 357 O
Planning NCT03928834 359 367 B-Assertion___Assertion-Type-Value:intention
to NCT03928834 368 370 O
stay NCT03928834 371 375 O
in NCT03928834 376 378 O
care NCT03928834 379 383 B-Encounter
at NCT03928834 384 386 O
that NCT03928834 387 391 O
facility NCT03928834 392 400 O
for NCT03928834 401 404 O
at NCT03928834 405 407 B-Eq-Comparison
least NCT03928834 408 413 I-Eq-Comparison
12 NCT03928834 414 416 I-Eq-Comparison
months NCT03928834 417 423 I-Eq-Comparison

Exclusion NCT03928834 424 433 O
Criteria NCT03928834 434 442 O
: NCT03928834 443 444 O

1 NCT03928834 448 449 O
. NCT03928834 449 450 O
Participant NCT03928834 452 463 O
and NCT03928834 464 467 O
/ NCT03928834 468 469 O
or NCT03928834 470 472 O
caregiver NCT03928834 473 482 O
unable NCT03928834 483 489 O
to NCT03928834 490 492 O
give NCT03928834 493 497 O
consent NCT03928834 498 505 O
and NCT03928834 506 509 O
assent NCT03928834 510 516 O

2 NCT03928834 519 520 O
. NCT03928834 520 521 O
Those NCT03928834 523 528 O
participants NCT03928834 529 541 O
who NCT03928834 542 545 O
the NCT03928834 546 549 O
healthcare NCT03928834 550 560 O
worker NCT03928834 561 567 O
considers NCT03928834 568 577 O
to NCT03928834 578 580 O
be NCT03928834 581 583 O
too NCT03928834 584 587 O
ill NCT03928834 588 591 O
to NCT03928834 592 594 O
participate NCT03928834 595 606 O

For NCT03920267 0 3 O
more NCT03920267 4 8 O
information NCT03920267 9 20 O
regarding NCT03920267 21 30 O
Bristol NCT03920267 31 38 O
- NCT03920267 39 40 O
Myers NCT03920267 41 46 O
Squibb NCT03920267 47 53 O
Clinical NCT03920267 54 62 O
Trial NCT03920267 63 68 O
participation NCT03920267 69 82 O
, NCT03920267 83 84 O
please NCT03920267 85 91 O

visit NCT03920267 92 97 O
www NCT03920267 98 101 O
. NCT03920267 101 102 O
BMSStudyConnect NCT03920267 103 118 O
. NCT03920267 118 119 O
com NCT03920267 120 123 O

Inclusion NCT03920267 124 133 O
Criteria NCT03920267 134 142 O
: NCT03920267 143 144 O

- NCT03920267 148 149 O
Completion NCT03920267 151 161 O
of NCT03920267 162 164 O
SLE NCT03920267 165 168 O
Study NCT03920267 169 174 O
( NCT03920267 175 176 O
NCT03252587 NCT03920267 177 188 O
) NCT03920267 189 190 O
through NCT03920267 191 198 O
the NCT03920267 199 202 O
protocol NCT03920267 203 211 O
- NCT03920267 212 213 O
required NCT03920267 214 222 O
treatment NCT03920267 223 232 O
period NCT03920267 233 239 O
, NCT03920267 240 241 O
and NCT03920267 242 245 O
currently NCT03920267 246 255 B-Eq-Comparison
receiving NCT03920267 256 265 I-Eq-Comparison
blinded NCT03920267 266 273 O
study NCT03920267 274 279 B-Study
drug NCT03920267 280 284 B-Drug

- NCT03920267 287 288 O
Women NCT03920267 290 295 O
of NCT03920267 296 298 B-And
childbearing NCT03920267 299 311 B-Condition
potential NCT03920267 312 321 I-Condition
( NCT03920267 322 323 O
WOCBP NCT03920267 324 329 B-Condition
) NCT03920267 330 331 O
must NCT03920267 332 336 O
have NCT03920267 337 341 O
a NCT03920267 342 343 O
negative NCT03920267 344 352 O
urine NCT03920267 353 358 B-Observation
pregnancy NCT03920267 359 368 I-Observation
test NCT03920267 369 373 I-Observation
and NCT03920267 374 377 B-And
must NCT03920267 378 382 O
agree NCT03920267 383 388 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03920267 389 391 I-Assertion___Assertion-Type-Value:hypothetical
use NCT03920267 392 395 O
correctly NCT03920267 396 405 O
a NCT03920267 406 407 O
highly NCT03920267 408 414 O
effective NCT03920267 415 424 O
method NCT03920267 425 431 O
( NCT03920267 432 433 O
s NCT03920267 434 435 O
) NCT03920267 436 437 O
of NCT03920267 438 440 O
contraception NCT03920267 441 454 B-Procedure
for NCT03920267 455 458 O
the NCT03920267 459 462 O
duration NCT03920267 463 471 B-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03920267 472 474 O
treatment NCT03920267 475 484 B-Procedure
with NCT03920267 485 489 O
study NCT03920267 490 495 B-Study
drug NCT03920267 496 500 B-Drug

Exclusion NCT03920267 501 510 O
Criteria NCT03920267 511 519 O
: NCT03920267 520 521 O

- NCT03920267 525 526 O
Any NCT03920267 528 531 O
disease NCT03920267 532 539 B-Condition
or NCT03920267 540 542 B-Or
medical NCT03920267 543 550 B-Condition
condition NCT03920267 551 560 I-Condition
that NCT03920267 561 565 O
, NCT03920267 566 567 O
in NCT03920267 568 570 O
the NCT03920267 571 574 O
opinion NCT03920267 575 582 O
of NCT03920267 583 585 O
the NCT03920267 586 589 O
investigator NCT03920267 590 602 O
, NCT03920267 603 604 O
would NCT03920267 605 610 B-Assertion___Assertion-Type-Value:hypothetical
make NCT03920267 611 615 O
the NCT03920267 616 619 O
subject NCT03920267 620 627 O
unsuitable NCT03920267 628 638 B-Negation
for NCT03920267 639 642 O
this NCT03920267 643 647 O
study NCT03920267 648 653 B-Study
, NCT03920267 654 655 O
would NCT03920267 656 661 O
interfere NCT03920267 662 671 O
with NCT03920267 672 676 O
the NCT03920267 677 680 O
interpretation NCT03920267 681 695 O
of NCT03920267 696 698 O
subject NCT03920267 699 706 O
safety NCT03920267 707 713 O
or NCT03920267 714 716 O
study NCT03920267 717 722 O
results NCT03920267 723 730 O
, NCT03920267 731 732 O
or NCT03920267 733 735 O
considered NCT03920267 736 746 O
unsuitable NCT03920267 747 757 O
by NCT03920267 758 760 O
the NCT03920267 761 764 O
investigator NCT03920267 765 777 O
for NCT03920267 778 781 O
any NCT03920267 782 785 O
other NCT03920267 786 791 O
reason NCT03920267 792 798 O

- NCT03920267 801 802 O
Evidence NCT03920267 804 812 O
of NCT03920267 813 815 O
active NCT03920267 816 822 B-Eq-Comparison
tuberculosis NCT03920267 823 835 B-Condition
( NCT03920267 836 837 O
TB NCT03920267 838 840 B-Condition
) NCT03920267 841 842 O

Other NCT03920267 844 849 O
protocol NCT03920267 850 858 O
defined NCT03920267 859 866 O
inclusion NCT03920267 867 876 O
/ NCT03920267 877 878 O
exclusion NCT03920267 879 888 O
criteria NCT03920267 889 897 O
could NCT03920267 898 903 O
apply NCT03920267 904 909 O

Inclusion NCT03927534 0 9 O
Criteria NCT03927534 10 18 O
: NCT03927534 19 20 O

- NCT03927534 24 25 O
Age NCT03927534 27 30 B-Age
between NCT03927534 31 38 B-Eq-Comparison
45 NCT03927534 39 41 I-Eq-Comparison
- NCT03927534 42 43 I-Eq-Comparison
75 NCT03927534 44 46 I-Eq-Comparison
years NCT03927534 47 52 I-Eq-Comparison

- NCT03927534 55 56 O
Have NCT03927534 58 62 O
overweight NCT03927534 63 73 B-Condition
or NCT03927534 74 76 B-Or
obesity NCT03927534 77 84 B-Condition
condition NCT03927534 85 94 O
based NCT03927534 95 100 O
in NCT03927534 101 103 O
BMI NCT03927534 104 107 B-Observation
( NCT03927534 108 109 O
Body NCT03927534 110 114 B-Observation
Mass NCT03927534 115 119 I-Observation
Index NCT03927534 120 125 I-Observation
) NCT03927534 126 127 O
. NCT03927534 128 129 O
Individuals NCT03927534 131 142 O
with NCT03927534 143 147 O
BMI NCT03927534 148 151 B-Observation
of NCT03927534 152 154 O
25 NCT03927534 155 157 B-Eq-Comparison
or NCT03927534 158 160 I-Eq-Comparison
more NCT03927534 161 165 I-Eq-Comparison
. NCT03927534 166 167 O

- NCT03927534 171 172 O
Have NCT03927534 174 178 O
two NCT03927534 179 182 B-Eq-Comparison
of NCT03927534 183 185 B-Criteria-Count
these NCT03927534 186 191 I-Criteria-Count
three NCT03927534 192 197 B-Eq-Comparison
risk NCT03927534 198 202 B-Risk
: NCT03927534 203 204 O
sedentary NCT03927534 205 214 B-Condition
lifestyle NCT03927534 215 224 I-Condition
, NCT03927534 225 226 O
poor NCT03927534 227 231 B-Condition
diet NCT03927534 232 236 I-Condition
and NCT03927534 237 240 B-Or
binge NCT03927534 241 246 B-Condition
episodes NCT03927534 247 255 I-Condition
. NCT03927534 256 257 O

- NCT03927534 261 262 O
Ability NCT03927534 264 271 O
to NCT03927534 272 274 O
understand NCT03927534 275 285 O
oral NCT03927534 286 290 O
and NCT03927534 291 294 O
written NCT03927534 295 302 O
Spanish NCT03927534 303 310 O
. NCT03927534 311 312 O

- NCT03927534 316 317 O
Willingness NCT03927534 319 330 O
to NCT03927534 331 333 O
participate NCT03927534 334 345 O
in NCT03927534 346 348 O
the NCT03927534 349 352 O
study NCT03927534 353 358 O
and NCT03927534 359 362 O
signing NCT03927534 363 370 O
informed NCT03927534 371 379 O
consent NCT03927534 380 387 O
. NCT03927534 388 389 O

Exclusion NCT03927534 391 400 O
Criteria NCT03927534 401 409 O
: NCT03927534 410 411 O

- NCT03927534 415 416 O
Any NCT03927534 418 421 O
diagnosis NCT03927534 422 431 O
of NCT03927534 432 434 O
a NCT03927534 435 436 O
disease NCT03927534 437 444 B-Condition
that NCT03927534 445 449 O
may NCT03927534 450 453 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03927534 454 460 O
the NCT03927534 461 464 O
central NCT03927534 465 472 B-Condition
nervous NCT03927534 473 480 I-Condition
system NCT03927534 481 487 I-Condition
( NCT03927534 488 489 O
brain NCT03927534 490 495 B-Modifier
condition NCT03927534 496 505 B-Condition
, NCT03927534 506 507 O
traumatic NCT03927534 508 517 B-Condition
brain NCT03927534 518 523 I-Condition
injury NCT03927534 524 530 I-Condition
, NCT03927534 531 532 O
dementia NCT03927534 533 541 B-Condition
, NCT03927534 542 543 O
etc NCT03927534 544 547 O
) NCT03927534 548 549 O
. NCT03927534 551 552 O

- NCT03927534 556 557 O
Other NCT03927534 559 564 O
psychiatric NCT03927534 565 576 B-Condition
diagnoses NCT03927534 577 586 I-Condition
or NCT03927534 587 589 B-Or
acute NCT03927534 590 595 O
psychiatric NCT03927534 596 607 B-Condition
illness NCT03927534 608 615 I-Condition
( NCT03927534 616 617 O
substance NCT03927534 618 627 B-Condition
dependence NCT03927534 628 638 B-Modifier
or NCT03927534 639 641 B-Or
abuse NCT03927534 642 647 B-Modifier
, NCT03927534 648 649 O
history NCT03927534 650 657 B-Eq-Comparison
of NCT03927534 658 660 O
schizophrenia NCT03927534 661 674 B-Condition
or NCT03927534 675 677 O
other NCT03927534 678 683 B-Other
psychotic NCT03927534 684 693 B-Condition
disorders NCT03927534 694 703 I-Condition
, NCT03927534 704 705 O
etc NCT03927534 706 709 O
. NCT03927534 709 710 O
) NCT03927534 711 712 O
, NCT03927534 714 715 O
except NCT03927534 716 722 B-Exception
for NCT03927534 723 726 I-Exception
anxiety NCT03927534 727 734 B-Condition
disorder NCT03927534 735 743 I-Condition
or NCT03927534 744 746 B-Or
personality NCT03927534 747 758 B-Condition
disorders NCT03927534 759 768 I-Condition
. NCT03927534 769 770 O

- NCT03927534 774 775 O
Presence NCT03927534 777 785 O
of NCT03927534 786 788 O
delusional NCT03927534 789 799 B-Condition
ideas NCT03927534 800 805 I-Condition
or NCT03927534 806 808 B-Or
hallucinations NCT03927534 809 823 B-Condition
whether NCT03927534 824 831 O
consistent NCT03927534 832 842 O
or NCT03927534 843 845 O
not NCT03927534 846 849 O
with NCT03927534 850 854 O
mood NCT03927534 855 859 O
. NCT03927534 860 861 O

- NCT03927534 865 866 O
Suicide NCT03927534 868 875 B-Condition
risk NCT03927534 876 880 B-Risk
. NCT03927534 880 881 O

Inclusion NCT03928613 0 9 O
Criteria NCT03928613 10 18 O
: NCT03928613 19 20 O

- NCT03928613 24 25 O
Aged NCT03928613 27 31 B-Age
above NCT03928613 32 37 B-Eq-Comparison
60 NCT03928613 38 40 I-Eq-Comparison

- NCT03928613 44 45 O
Confirmed NCT03928613 47 56 O
literacy NCT03928613 57 65 B-Condition
o NCT03928613 66 67 O
Diagnosed NCT03928613 68 77 O
with NCT03928613 78 82 O
mild NCT03928613 83 87 O
cognitive NCT03928613 88 97 B-Condition
impairment NCT03928613 98 108 I-Condition
by NCT03928613 109 111 O
International NCT03928613 112 125 O
Working NCT03928613 126 133 O
Group NCT03928613 134 139 O
on NCT03928613 140 142 O
Mild NCT03928613 143 147 O
Cognitive NCT03928613 148 157 O
Impairment NCT03928613 158 168 O
and NCT03928613 169 172 B-And
Clinical NCT03928613 173 181 B-Observation
Dementia NCT03928613 182 190 I-Observation
Rating NCT03928613 191 197 I-Observation
( NCT03928613 198 199 O
CDR NCT03928613 200 203 B-Observation
) NCT03928613 204 205 O
of NCT03928613 206 208 O
0 NCT03928613 209 210 B-Eq-Comparison
or NCT03928613 211 213 I-Eq-Comparison
0.5 NCT03928613 214 217 I-Eq-Comparison
. NCT03928613 217 218 O

Exclusion NCT03928613 220 229 O
Criteria NCT03928613 230 238 O
: NCT03928613 239 240 O

- NCT03928613 244 245 O
Evidence NCT03928613 247 255 O
of NCT03928613 256 258 O
delirium NCT03928613 259 267 B-Condition
, NCT03928613 268 269 O
confusion NCT03928613 270 279 B-Condition

- NCT03928613 282 283 O
Any NCT03928613 285 288 O
neurological NCT03928613 289 301 B-Condition
conditions NCT03928613 302 312 I-Condition
causing NCT03928613 313 320 O
cognitive NCT03928613 321 330 B-Condition
decline NCT03928613 331 338 I-Condition
such NCT03928613 339 343 O
as NCT03928613 344 346 O
Parkinson NCT03928613 347 356 B-Condition
's NCT03928613 356 358 I-Condition
disease NCT03928613 359 366 I-Condition
, NCT03928613 367 368 O
brain NCT03928613 369 374 B-Modifier
hemorrhage NCT03928613 375 385 B-Condition
, NCT03928613 386 387 O
brain NCT03928613 388 393 B-Modifier
tumor NCT03928613 394 399 B-Condition
, NCT03928613 400 401 O
normal NCT03928613 402 408 B-Condition
pressure NCT03928613 409 417 I-Condition
hydrocephalus NCT03928613 418 431 I-Condition

- NCT03928613 434 435 O
Evidence NCT03928613 437 445 O
of NCT03928613 446 448 O
severe NCT03928613 449 455 O
cerebrovascular NCT03928613 456 471 B-Condition
pathology NCT03928613 472 481 I-Condition

- NCT03928613 484 485 O
Presence NCT03928613 487 495 O
of NCT03928613 496 498 O
depressive NCT03928613 499 509 B-Condition
symptoms NCT03928613 510 518 B-Assertion___Assertion-Type-Value:possible
that NCT03928613 519 523 O
could NCT03928613 524 529 B-Assertion___Assertion-Type-Value:hypothetical
influence NCT03928613 530 539 O
cognitive NCT03928613 540 549 B-Condition
function NCT03928613 550 558 I-Condition

- NCT03928613 561 562 O
Presence NCT03928613 564 572 O
of NCT03928613 573 575 O
medical NCT03928613 576 583 B-Condition
comorbidities NCT03928613 584 597 I-Condition
that NCT03928613 598 602 O
could NCT03928613 603 608 B-Assertion___Assertion-Type-Value:hypothetical
result NCT03928613 609 615 O
in NCT03928613 616 618 O
any NCT03928613 619 622 O
difficulties NCT03928613 623 635 B-Negation
in NCT03928613 636 638 O
study NCT03928613 639 644 B-Study
participation NCT03928613 645 658 O

Inclusion NCT03925337 0 9 O
Criteria NCT03925337 10 18 O
: NCT03925337 19 20 O

- NCT03925337 24 25 O
Patients NCT03925337 27 35 O
age NCT03925337 36 39 B-Age
: NCT03925337 40 41 O
≥ NCT03925337 42 43 B-Eq-Comparison
22 NCT03925337 44 46 I-Eq-Comparison
years NCT03925337 47 52 I-Eq-Comparison

- NCT03925337 55 56 O
Patients NCT03925337 58 66 O
presenting NCT03925337 67 77 B-Eq-Comparison
for NCT03925337 78 81 O
routine NCT03925337 82 89 B-Modifier
colonoscopy NCT03925337 90 101 B-Procedure
for NCT03925337 102 105 O
screening NCT03925337 106 115 B-Procedure
and NCT03925337 116 119 B-Or
/ NCT03925337 120 121 I-Or
or NCT03925337 122 124 I-Or
surveillance NCT03925337 125 137 B-Procedure
purposes NCT03925337 138 146 O
. NCT03925337 147 148 O

- NCT03925337 152 153 O
Willingness NCT03925337 155 166 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03925337 167 169 O
undergo NCT03925337 170 177 O
two NCT03925337 178 181 B-Eq-Comparison
withdrawals NCT03925337 182 193 B-Condition
with NCT03925337 194 198 O
and NCT03925337 199 202 O
without NCT03925337 203 210 O
the NCT03925337 211 214 O
use NCT03925337 215 218 O
of NCT03925337 219 221 O
computer NCT03925337 222 230 O
- NCT03925337 231 232 O
aided NCT03925337 233 238 O
software NCT03925337 239 247 O
while NCT03925337 248 253 B-Temporal-Connection___Temporal-Connection-Type-Value:during
undergoing NCT03925337 254 264 O
conventional NCT03925337 265 277 B-Modifier
colonoscopy NCT03925337 278 289 B-Procedure
with NCT03925337 290 294 O
sedation NCT03925337 295 303 B-Procedure

- NCT03925337 306 307 O
Ability NCT03925337 309 316 O
to NCT03925337 317 319 O
provide NCT03925337 320 327 O
written NCT03925337 328 335 O
, NCT03925337 336 337 O
informed NCT03925337 338 346 O
consent NCT03925337 347 354 O
and NCT03925337 355 358 O
understand NCT03925337 359 369 O
the NCT03925337 370 373 O
responsibilities NCT03925337 374 390 O
of NCT03925337 391 393 O
trial NCT03925337 394 399 O
participation NCT03925337 400 413 O

Exclusion NCT03925337 414 423 O
Criteria NCT03925337 424 432 O
: NCT03925337 433 434 O

- NCT03925337 438 439 O
Minors NCT03925337 441 447 O
aged NCT03925337 448 452 B-Age
< NCT03925337 453 454 B-Eq-Comparison
22 NCT03925337 455 457 I-Eq-Comparison
years NCT03925337 458 463 I-Eq-Comparison
. NCT03925337 464 465 O

- NCT03925337 469 470 O
People NCT03925337 472 478 O
with NCT03925337 479 483 O
diminished NCT03925337 484 494 B-Condition
cognitive NCT03925337 495 504 I-Condition
capacity NCT03925337 505 513 I-Condition

- NCT03925337 516 517 O
Patients NCT03925337 519 527 O
undergoing NCT03925337 528 538 B-Eq-Comparison
diagnostic NCT03925337 539 549 B-Modifier
colonoscopy NCT03925337 550 561 B-Procedure
( NCT03925337 562 563 O
e. NCT03925337 564 566 O
g. NCT03925337 567 569 O
as NCT03925337 571 573 O
an NCT03925337 574 576 O
evaluation NCT03925337 577 587 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03925337 588 591 I-Assertion___Assertion-Type-Value:hypothetical
active NCT03925337 592 598 B-Eq-Comparison
gastrointestinal NCT03925337 599 615 B-Modifier
bleed NCT03925337 616 621 B-Condition
, NCT03925337 622 623 O
referring NCT03925337 624 633 O
collectively NCT03925337 634 646 O
to NCT03925337 647 649 O
the NCT03925337 650 653 O
stomach NCT03925337 654 661 B-Modifier
and NCT03925337 662 665 B-Or
the NCT03925337 666 669 O
small NCT03925337 670 675 B-Modifier
and NCT03925337 676 679 B-Or
large NCT03925337 680 685 B-Modifier
intestine NCT03925337 686 695 I-Modifier
) NCT03925337 696 697 O
. NCT03925337 699 700 O

- NCT03925337 704 705 O
Patients NCT03925337 707 715 O
with NCT03925337 716 720 O
incomplete NCT03925337 721 731 B-Modifier
colonoscopies NCT03925337 732 745 B-Procedure
( NCT03925337 746 747 O
those NCT03925337 748 753 O
where NCT03925337 754 759 O
endoscopists NCT03925337 760 772 O
did NCT03925337 773 776 O
not NCT03925337 777 780 B-Negation
successfully NCT03925337 781 793 O
intubate NCT03925337 794 802 B-Procedure
the NCT03925337 803 806 O
cecum NCT03925337 807 812 B-Modifier
due NCT03925337 813 816 O
to NCT03925337 817 819 O
technical NCT03925337 820 829 O
difficulties NCT03925337 830 842 O
or NCT03925337 843 845 B-Or
poor NCT03925337 846 850 B-Modifier
bowel NCT03925337 851 856 B-Procedure
preparation NCT03925337 857 868 I-Procedure
) NCT03925337 869 870 O

- NCT03925337 874 875 O
Patients NCT03925337 877 885 O
that NCT03925337 886 890 O
have NCT03925337 891 895 O
standard NCT03925337 896 904 O
contraindications NCT03925337 905 922 B-Contraindication
to NCT03925337 923 925 O
colonoscopy NCT03925337 926 937 B-Procedure
in NCT03925337 938 940 O
general NCT03925337 941 948 O
( NCT03925337 949 950 O
e. NCT03925337 951 953 O
g. NCT03925337 954 956 O
documented NCT03925337 958 968 O
acute NCT03925337 969 974 O
diverticulitis NCT03925337 975 989 B-Condition
, NCT03925337 990 991 O
fulminant NCT03925337 992 1001 B-Condition
colitis NCT03925337 1002 1009 I-Condition
and NCT03925337 1010 1013 O
known NCT03925337 1014 1019 O
or NCT03925337 1020 1022 O
suspected NCT03925337 1023 1032 B-Assertion___Assertion-Type-Value:possible
perforation NCT03925337 1033 1044 B-Condition
) NCT03925337 1045 1046 O
. NCT03925337 1048 1049 O

- NCT03925337 1053 1054 O
Patients NCT03925337 1056 1064 O
with NCT03925337 1065 1069 O
inflammatory NCT03925337 1070 1082 B-Condition
bowel NCT03925337 1083 1088 I-Condition
disease NCT03925337 1089 1096 I-Condition

- NCT03925337 1099 1100 O
Patients NCT03925337 1102 1110 O
with NCT03925337 1111 1115 O
any NCT03925337 1116 1119 O
polypoid NCT03925337 1120 1128 B-Modifier
/ NCT03925337 1129 1130 B-Or
ulcerated NCT03925337 1131 1140 B-Modifier
lesion NCT03925337 1141 1147 B-Observation
> NCT03925337 1148 1149 B-Eq-Comparison
2 NCT03925337 1150 1151 I-Eq-Comparison
cm NCT03925337 1152 1154 I-Eq-Comparison
concerning NCT03925337 1155 1165 O
for NCT03925337 1166 1169 O
invasive NCT03925337 1170 1178 B-Modifier
cancer NCT03925337 1179 1185 B-Condition
on NCT03925337 1186 1188 O
endoscopy NCT03925337 1189 1198 B-Procedure

- NCT03925337 1201 1202 O
Patients NCT03925337 1204 1212 O
referred NCT03925337 1213 1221 B-Encounter
for NCT03925337 1222 1225 O
endoscopic NCT03925337 1226 1236 B-Procedure
mucosal NCT03925337 1237 1244 I-Procedure
resection NCT03925337 1245 1254 I-Procedure
( NCT03925337 1255 1256 O
EMR NCT03925337 1257 1260 B-Procedure
) NCT03925337 1261 1262 O
, NCT03925337 1264 1265 O
which NCT03925337 1266 1271 O
is NCT03925337 1272 1274 O
a NCT03925337 1275 1276 O
procedure NCT03925337 1277 1286 O
to NCT03925337 1287 1289 O
remove NCT03925337 1290 1296 O
early NCT03925337 1297 1302 O
- NCT03925337 1303 1304 O
stage NCT03925337 1305 1310 O
cancer NCT03925337 1311 1317 O
and NCT03925337 1318 1321 O
precancerous NCT03925337 1322 1334 O
growths NCT03925337 1335 1342 O
from NCT03925337 1343 1347 O
the NCT03925337 1348 1351 O
lining NCT03925337 1352 1358 O
of NCT03925337 1359 1361 O
the NCT03925337 1362 1365 O
digestive NCT03925337 1366 1375 O
tract NCT03925337 1376 1381 O
. NCT03925337 1381 1382 O

Inclusion NCT03924362 0 9 O
Criteria NCT03924362 10 18 O
: NCT03924362 19 20 O

All NCT03924362 22 25 O
subjects NCT03924362 26 34 O
with NCT03924362 35 39 O
a NCT03924362 40 41 O
clinical NCT03924362 42 50 O
diagnosis NCT03924362 51 60 O
of NCT03924362 61 63 O
struvite NCT03924362 64 72 B-Condition
calculi NCT03924362 73 80 I-Condition
will NCT03924362 81 85 O
potentially NCT03924362 86 97 O
be NCT03924362 98 100 O
included NCT03924362 101 109 O
. NCT03924362 110 111 O

Specific NCT03924362 113 121 O
inclusion NCT03924362 122 131 O
criteria NCT03924362 132 140 O
include NCT03924362 141 148 O
the NCT03924362 149 152 O
following NCT03924362 153 162 O
: NCT03924362 163 164 O

1 NCT03924362 168 169 O
. NCT03924362 169 170 O
Age NCT03924362 172 175 B-Age
> NCT03924362 176 177 B-Eq-Comparison
18 NCT03924362 178 180 I-Eq-Comparison
years NCT03924362 181 186 I-Eq-Comparison

2 NCT03924362 189 190 O
. NCT03924362 190 191 O
Any NCT03924362 193 196 O
patient NCT03924362 197 204 O
with NCT03924362 205 209 O
bilateral NCT03924362 210 219 B-Condition
stone NCT03924362 220 225 I-Condition
burden NCT03924362 226 232 I-Condition
eligible NCT03924362 233 241 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03924362 242 245 B-And
appropriate NCT03924362 246 257 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03924362 258 261 O
PCNL NCT03924362 262 266 B-Procedure
procedure NCT03924362 267 276 I-Procedure

3 NCT03924362 279 280 O
. NCT03924362 280 281 O
Medically NCT03924362 283 292 O
fit NCT03924362 293 296 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03924362 297 300 I-Assertion___Assertion-Type-Value:hypothetical
definitive NCT03924362 301 311 O
surgical NCT03924362 312 320 B-Procedure
management NCT03924362 321 331 I-Procedure
of NCT03924362 332 334 O
stone NCT03924362 335 340 B-Condition
. NCT03924362 341 342 O

Exclusion NCT03924362 344 353 O
Criteria NCT03924362 354 362 O
: NCT03924362 363 364 O

Patients NCT03924362 366 374 O
with NCT03924362 375 379 O
any NCT03924362 380 383 O
of NCT03924362 384 386 O
the NCT03924362 387 390 O
following NCT03924362 391 400 O
characteristics NCT03924362 401 416 O
will NCT03924362 417 421 O
not NCT03924362 422 425 B-Negation
be NCT03924362 426 428 O
eligible NCT03924362 429 437 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03924362 438 441 O
the NCT03924362 442 445 O
present NCT03924362 446 453 O

study NCT03924362 454 459 B-Study
: NCT03924362 460 461 O

1 NCT03924362 465 466 O
. NCT03924362 466 467 O
Those NCT03924362 469 474 O
with NCT03924362 475 479 O
medical NCT03924362 480 487 B-Condition
comorbidities NCT03924362 488 501 I-Condition
preventing NCT03924362 502 512 B-Assertion___Assertion-Type-Value:hypothetical|Negation
them NCT03924362 513 517 O
from NCT03924362 518 522 O
safely NCT03924362 523 529 O
undergoing NCT03924362 530 540 O
definitive NCT03924362 541 551 O
surgical NCT03924362 552 560 B-Procedure
therapy NCT03924362 561 568 I-Procedure
. NCT03924362 569 570 O

2 NCT03924362 574 575 O
. NCT03924362 575 576 O
Patients NCT03924362 578 586 O
who NCT03924362 587 590 O
are NCT03924362 591 594 O
unable NCT03924362 595 601 O
to NCT03924362 602 604 O
provide NCT03924362 605 612 O
informed NCT03924362 613 621 O
consent NCT03924362 622 629 O
. NCT03924362 630 631 O

3 NCT03924362 635 636 O
. NCT03924362 636 637 O
Patients NCT03924362 639 647 O
who NCT03924362 648 651 O
are NCT03924362 652 655 O
planned NCT03924362 656 663 B-Eq-Comparison
for NCT03924362 664 667 O
alternative NCT03924362 668 679 B-Other
procedures NCT03924362 680 690 B-Procedure
( NCT03924362 691 692 O
ureteroscopy NCT03924362 693 705 B-Procedure
, NCT03924362 706 707 O
extracorporeal NCT03924362 708 722 B-Procedure
shock NCT03924362 723 728 I-Procedure
wave NCT03924362 729 733 I-Procedure
lithotripsy NCT03924362 734 745 I-Procedure
) NCT03924362 746 747 O

4 NCT03924362 751 752 O
. NCT03924362 752 753 O
Anyone NCT03924362 755 761 O
who NCT03924362 762 765 O
is NCT03924362 766 768 O
unable NCT03924362 769 775 O
to NCT03924362 776 778 O
give NCT03924362 779 783 O
their NCT03924362 784 789 O
informed NCT03924362 790 798 O
consent NCT03924362 799 806 O

5 NCT03924362 809 810 O
. NCT03924362 810 811 O
Anyone NCT03924362 813 819 O
under NCT03924362 820 825 B-Eq-Comparison
the NCT03924362 826 829 I-Eq-Comparison
age NCT03924362 830 833 I-Eq-Comparison
of NCT03924362 834 836 I-Eq-Comparison
19 NCT03924362 837 839 I-Eq-Comparison

6 NCT03924362 843 844 O
. NCT03924362 844 845 O
Anyone NCT03924362 847 853 O
who NCT03924362 854 857 O
, NCT03924362 858 859 O
in NCT03924362 860 862 O
the NCT03924362 863 866 O
opinion NCT03924362 867 874 O
of NCT03924362 875 877 O
the NCT03924362 878 881 O
PI NCT03924362 882 884 O
, NCT03924362 885 886 O
is NCT03924362 887 889 O
unfit NCT03924362 890 895 O
or NCT03924362 896 898 O
unsuitable NCT03924362 899 909 O
to NCT03924362 910 912 O
participate NCT03924362 913 924 O
in NCT03924362 925 927 O
the NCT03924362 928 931 O
study NCT03924362 932 937 B-Study

Inclusion NCT03926039 0 9 O
Criteria NCT03926039 10 18 O
: NCT03926039 19 20 O

1 NCT03926039 24 25 O
. NCT03926039 25 26 O
Primary NCT03926039 28 35 B-Modifier
liver NCT03926039 36 41 I-Modifier
cancer NCT03926039 42 48 B-Condition
patients NCT03926039 49 57 O
( NCT03926039 58 59 O
ICD NCT03926039 60 63 O
10 NCT03926039 64 66 O
is NCT03926039 67 69 O
C22.0 NCT03926039 70 75 O
) NCT03926039 76 77 O
and NCT03926039 78 81 B-And
Barcelona NCT03926039 82 91 B-Condition
stage NCT03926039 92 97 I-Condition
( NCT03926039 98 99 O
BCLC NCT03926039 100 104 B-Condition
stage NCT03926039 105 110 I-Condition
) NCT03926039 111 112 O
0 NCT03926039 113 114 B-Eq-Comparison
- NCT03926039 115 116 I-Eq-Comparison
A NCT03926039 117 118 I-Eq-Comparison
. NCT03926039 119 120 O

2 NCT03926039 124 125 O
. NCT03926039 125 126 O
At NCT03926039 128 130 B-Eq-Comparison
least NCT03926039 131 136 I-Eq-Comparison
20 NCT03926039 137 139 I-Eq-Comparison
years NCT03926039 140 145 I-Eq-Comparison
of NCT03926039 146 148 O
age NCT03926039 149 152 B-Age
. NCT03926039 153 154 O

3 NCT03926039 158 159 O
. NCT03926039 159 160 O
No NCT03926039 162 164 B-Negation
mental NCT03926039 165 171 B-Condition
illness NCT03926039 172 179 I-Condition
. NCT03926039 180 181 O

4 NCT03926039 185 186 O
. NCT03926039 186 187 O
Patients NCT03926039 189 197 O
who NCT03926039 198 201 O
can NCT03926039 202 205 O
communicate NCT03926039 206 217 O
in NCT03926039 218 220 O
Mandarin NCT03926039 221 229 O
or NCT03926039 230 232 B-Or
Taiwanese NCT03926039 233 242 O
. NCT03926039 243 244 O

Exclusion NCT03926039 246 255 O
Criteria NCT03926039 256 264 O
: NCT03926039 265 266 O

1 NCT03926039 270 271 O
. NCT03926039 271 272 O
Do NCT03926039 274 276 O
n't NCT03926039 276 279 O
know NCT03926039 280 284 O
himself NCT03926039 285 292 O
condition NCT03926039 293 302 B-Condition
. NCT03926039 303 304 O

2 NCT03926039 308 309 O
. NCT03926039 309 310 O
Unconscious NCT03926039 312 323 B-Condition
patients NCT03926039 324 332 O
. NCT03926039 333 334 O

3 NCT03926039 338 339 O
. NCT03926039 339 340 O
Patients NCT03926039 342 350 O
with NCT03926039 351 355 O
liver NCT03926039 356 361 B-Modifier
cancer NCT03926039 362 368 B-Procedure
resection NCT03926039 369 378 I-Procedure
or NCT03926039 379 381 B-Or
partial NCT03926039 382 389 B-Modifier
liver NCT03926039 390 395 I-Modifier
resection NCT03926039 396 405 B-Procedure
were NCT03926039 406 410 O
performed NCT03926039 411 420 B-Eq-Comparison
within NCT03926039 421 427 B-Eq-Comparison
3 NCT03926039 428 429 I-Eq-Comparison
months NCT03926039 430 436 I-Eq-Comparison
. NCT03926039 437 438 O


Inclusion NCT03927469 0 9 O
Criteria NCT03927469 10 18 O
: NCT03927469 19 20 O

- NCT03927469 24 25 O
Being NCT03927469 27 32 O
hospitalized NCT03927469 33 45 B-Encounter
in NCT03927469 46 48 O
the NCT03927469 49 52 O
hospital NCT03927469 53 61 O
between NCT03927469 62 69 B-Eq-Comparison
January NCT03927469 70 77 I-Eq-Comparison
2015 NCT03927469 78 82 I-Eq-Comparison
and NCT03927469 83 86 I-Eq-Comparison
July NCT03927469 87 91 I-Eq-Comparison
2018 NCT03927469 92 96 I-Eq-Comparison
, NCT03927469 97 98 O
according NCT03927469 99 108 O
to NCT03927469 109 111 O
ICD NCT03927469 112 115 O
10 NCT03927469 116 118 O
code NCT03927469 119 123 O
; NCT03927469 123 124 O
hemiplegia NCT03927469 125 135 B-Condition
( NCT03927469 136 137 O
G81 NCT03927469 138 141 O
) NCT03927469 142 143 O
, NCT03927469 145 146 O
flaccid NCT03927469 147 154 B-Condition
hemiplegia NCT03927469 155 165 I-Condition
( NCT03927469 166 167 O
G81.0 NCT03927469 168 173 O
) NCT03927469 174 175 O
, NCT03927469 177 178 O
hemiplegia NCT03927469 179 189 B-Condition
, NCT03927469 190 191 I-Condition
unspecified NCT03927469 192 203 I-Condition
( NCT03927469 204 205 O
G81.9 NCT03927469 206 211 O
) NCT03927469 212 213 O
, NCT03927469 215 216 O
Spastic NCT03927469 217 224 B-Condition
hemiplegia NCT03927469 225 235 I-Condition
( NCT03927469 236 237 O
G81.1 NCT03927469 238 243 O
) NCT03927469 244 245 O

- NCT03927469 249 250 O
Being NCT03927469 252 257 O
ischemic NCT03927469 258 266 B-Modifier
or NCT03927469 267 269 B-Or
hemorrhagic NCT03927469 270 281 B-Modifier
stroke NCT03927469 282 288 B-Condition

Exclusion NCT03927469 289 298 O
Criteria NCT03927469 299 307 O
: NCT03927469 308 309 O

- NCT03927469 313 314 O
Being NCT03927469 316 321 O
hemiplegic NCT03927469 322 332 B-Condition
due NCT03927469 333 336 O
to NCT03927469 337 339 O
trauma NCT03927469 340 346 B-Condition
, NCT03927469 347 348 O
cancer NCT03927469 349 355 B-Condition
and NCT03927469 356 359 B-Or
intracranial NCT03927469 360 372 B-Procedure
operation NCT03927469 373 382 I-Procedure

Inclusion NCT03920306 0 9 O
Criteria NCT03920306 10 18 O
: NCT03920306 19 20 O

- NCT03920306 24 25 O
Eligible NCT03920306 27 35 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03920306 36 39 I-Assertion___Assertion-Type-Value:hypothetical
gastrostomy NCT03920306 40 51 B-Procedure
tube NCT03920306 52 56 I-Procedure
removal NCT03920306 57 64 I-Procedure

Exclusion NCT03920306 65 74 O
Criteria NCT03920306 75 83 O
: NCT03920306 84 85 O

- NCT03920306 89 90 O
Recurrent NCT03920306 92 101 O
gastrocutaneous NCT03920306 102 117 B-Condition
fistula NCT03920306 118 125 I-Condition

- NCT03920306 128 129 O
Non NCT03920306 131 134 O
- NCT03920306 135 136 O
consenting NCT03920306 137 147 O

- NCT03920306 150 151 O
Unable NCT03920306 153 159 O
to NCT03920306 160 162 O
comply NCT03920306 163 169 O
with NCT03920306 170 174 O
follow NCT03920306 175 181 O
up NCT03920306 182 184 O
assessments NCT03920306 185 196 O

- NCT03920306 199 200 O
Known NCT03920306 202 207 O
allergic NCT03920306 208 216 B-Allergy
reaction NCT03920306 217 225 O
to NCT03920306 226 228 O
study NCT03920306 229 234 B-Study
products NCT03920306 235 243 B-Drug

Inclusion NCT03928028 0 9 O
Criteria NCT03928028 10 18 O
: NCT03928028 19 20 O
Adolescents NCT03928028 21 32 O

1 NCT03928028 35 36 O
. NCT03928028 36 37 O
Age NCT03928028 39 42 B-Age
12 NCT03928028 43 45 B-Eq-Comparison
- NCT03928028 46 47 I-Eq-Comparison
18 NCT03928028 48 50 O

2 NCT03928028 54 55 O
. NCT03928028 55 56 O
Currently NCT03928028 58 67 B-Eq-Comparison
meets NCT03928028 68 73 O
Diagnostic NCT03928028 74 84 O
and NCT03928028 85 88 O
Statistical NCT03928028 89 100 O
Manual NCT03928028 101 107 O
- NCT03928028 108 109 O
5 NCT03928028 110 111 O
criteria NCT03928028 112 120 O
for NCT03928028 121 124 O
Anorexia NCT03928028 125 133 B-Condition
Nervosa NCT03928028 134 141 I-Condition

3 NCT03928028 144 145 O
. NCT03928028 145 146 O
Medically NCT03928028 148 157 O
stable NCT03928028 158 164 B-Condition
for NCT03928028 165 168 B-Assertion___Assertion-Type-Value:hypothetical
outpatient NCT03928028 169 179 B-Encounter
treatment NCT03928028 180 189 B-Procedure

4 NCT03928028 192 193 O
. NCT03928028 193 194 O
Fluent NCT03928028 196 202 O
in NCT03928028 203 205 O
English NCT03928028 206 213 O

5 NCT03928028 216 217 O
. NCT03928028 217 218 O
No NCT03928028 220 222 B-Negation
co NCT03928028 223 225 B-Condition
- NCT03928028 226 227 I-Condition
morbid NCT03928028 228 234 I-Condition
condition NCT03928028 235 244 I-Condition
that NCT03928028 245 249 O
would NCT03928028 250 255 O
exclude NCT03928028 256 263 O
participation NCT03928028 264 277 O

6 NCT03928028 280 281 O
. NCT03928028 281 282 O
Medical NCT03928028 284 291 O
clearance NCT03928028 292 301 O
from NCT03928028 302 306 O
primary NCT03928028 307 314 O
care NCT03928028 315 319 O
physician NCT03928028 320 329 O
and NCT03928028 330 333 O
permission NCT03928028 334 344 O
to NCT03928028 345 347 O
speak NCT03928028 348 353 O
to NCT03928028 354 356 O
Primary NCT03928028 357 364 O
Care NCT03928028 365 369 O
Physician NCT03928028 370 379 O
about NCT03928028 380 385 O
clinical NCT03928028 386 394 O
issues NCT03928028 395 401 O

7 NCT03928028 404 405 O
. NCT03928028 405 406 O
Biological NCT03928028 408 418 O
parent NCT03928028 419 425 B-Family-Member___Family-Member-Type:parent
or NCT03928028 426 428 O
primary NCT03928028 429 436 O
caregiver NCT03928028 437 446 O
willing NCT03928028 447 454 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03928028 455 457 I-Assertion___Assertion-Type-Value:hypothetical
engage NCT03928028 458 464 O
in NCT03928028 465 467 O
treatment NCT03928028 468 477 B-Procedure
and NCT03928028 478 481 O
who NCT03928028 482 485 O
live NCT03928028 486 490 O
with NCT03928028 491 495 O
the NCT03928028 496 499 O
adolescent NCT03928028 500 510 O

Inclusion NCT03928028 511 520 O
Criteria NCT03928028 521 529 O
: NCT03928028 530 531 O
Parents NCT03928028 532 539 B-Family-Member___Family-Member-Type:parent

1 NCT03928028 542 543 O
. NCT03928028 543 544 O
Age NCT03928028 546 549 B-Age
> NCT03928028 550 551 B-Eq-Comparison
18 NCT03928028 552 554 I-Eq-Comparison

2 NCT03928028 558 559 O
. NCT03928028 559 560 O
Child NCT03928028 562 567 O
with NCT03928028 568 572 B-And
a NCT03928028 573 574 O
diagnoses NCT03928028 575 584 O
of NCT03928028 585 587 O
AN NCT03928028 588 590 B-Condition

3 NCT03928028 593 594 O
. NCT03928028 594 595 O
Both NCT03928028 597 601 O
parents NCT03928028 602 609 O
willing NCT03928028 610 617 O
to NCT03928028 618 620 O
participate NCT03928028 621 632 O

4 NCT03928028 635 636 O
. NCT03928028 636 637 O
Fluent NCT03928028 639 645 O
in NCT03928028 646 648 O
English NCT03928028 649 656 O

5 NCT03928028 659 660 O
. NCT03928028 660 661 O
No NCT03928028 663 665 B-Negation
co NCT03928028 666 668 B-Condition
- NCT03928028 669 670 I-Condition
morbid NCT03928028 671 677 I-Condition
condition NCT03928028 678 687 I-Condition
that NCT03928028 688 692 O
would NCT03928028 693 698 O
exclude NCT03928028 699 706 O
participation NCT03928028 707 720 O

Exclusion NCT03928028 721 730 O
Criteria NCT03928028 731 739 O
: NCT03928028 740 741 O
Adolescent NCT03928028 742 752 O

1 NCT03928028 755 756 O
. NCT03928028 756 757 O
Adolescent NCT03928028 759 769 O
outside NCT03928028 770 777 B-Negation
age NCT03928028 778 781 B-Age
range NCT03928028 782 787 B-Eq-Comparison

2 NCT03928028 790 791 O
. NCT03928028 791 792 O
Adolescent NCT03928028 794 804 O
adopted NCT03928028 805 812 B-Condition

3 NCT03928028 815 816 O
. NCT03928028 816 817 O
Pregnant NCT03928028 819 827 B-Condition
adolescent NCT03928028 828 838 O

4 NCT03928028 841 842 O
. NCT03928028 842 843 O
Presence NCT03928028 845 853 O
of NCT03928028 854 856 O
: NCT03928028 857 858 O
pervasive NCT03928028 859 868 O
developmental NCT03928028 869 882 B-Condition
disability NCT03928028 883 893 I-Condition
, NCT03928028 894 895 O
psychosis NCT03928028 896 905 B-Condition
, NCT03928028 906 907 O
bipolar NCT03928028 908 915 B-Condition
disorder NCT03928028 916 924 I-Condition
, NCT03928028 925 926 O
substance NCT03928028 927 936 B-Condition
abuse NCT03928028 937 942 I-Condition
, NCT03928028 943 944 O
autism NCT03928028 945 951 B-Condition
spectrum NCT03928028 952 960 I-Condition
disorder NCT03928028 961 969 I-Condition
, NCT03928028 970 971 O
or NCT03928028 972 974 B-Or
intellectual NCT03928028 975 987 B-Condition
disability NCT03928028 988 998 I-Condition

5 NCT03928028 1001 1002 O
. NCT03928028 1002 1003 O
Presence NCT03928028 1005 1013 O
of NCT03928028 1014 1016 O
: NCT03928028 1017 1018 O
a NCT03928028 1019 1020 O
brain NCT03928028 1021 1026 B-Modifier
disorder NCT03928028 1027 1035 B-Condition
or NCT03928028 1036 1038 B-Or
injury NCT03928028 1039 1045 B-Condition
( NCT03928028 1046 1047 O
such NCT03928028 1048 1052 O
as NCT03928028 1053 1055 O
TBI NCT03928028 1056 1059 B-Condition
) NCT03928028 1060 1061 O
that NCT03928028 1062 1066 O
could NCT03928028 1067 1072 B-Assertion___Assertion-Type-Value:hypothetical
impact NCT03928028 1073 1079 O
the NCT03928028 1080 1083 O
ability NCT03928028 1084 1091 O
to NCT03928028 1092 1094 O
engage NCT03928028 1095 1101 O
in NCT03928028 1102 1104 O
treatment NCT03928028 1105 1114 B-Procedure

6 NCT03928028 1117 1118 O
. NCT03928028 1118 1119 O
Use NCT03928028 1121 1124 B-Eq-Comparison
of NCT03928028 1125 1127 O
anti NCT03928028 1128 1132 B-Drug
- NCT03928028 1133 1134 I-Drug
psychotic NCT03928028 1135 1144 I-Drug
medication NCT03928028 1145 1155 I-Drug

7 NCT03928028 1158 1159 O
. NCT03928028 1159 1160 O
Concurrent NCT03928028 1162 1172 B-Eq-Comparison
psychosocial NCT03928028 1173 1185 B-Procedure
therapy NCT03928028 1186 1193 I-Procedure

Exclusion NCT03928028 1194 1203 O
Criteria NCT03928028 1204 1212 O
: NCT03928028 1213 1214 O
Parents NCT03928028 1215 1222 B-Family-Member___Family-Member-Type:parent

1 NCT03928028 1225 1226 O
. NCT03928028 1226 1227 O
Presence NCT03928028 1229 1237 O
of NCT03928028 1238 1240 O
: NCT03928028 1241 1242 O
pervasive NCT03928028 1243 1252 O
developmental NCT03928028 1253 1266 B-Condition
disability NCT03928028 1267 1277 I-Condition
, NCT03928028 1278 1279 O
psychosis NCT03928028 1280 1289 B-Condition
, NCT03928028 1290 1291 O
bipolar NCT03928028 1292 1299 B-Condition
disorder NCT03928028 1300 1308 I-Condition
, NCT03928028 1309 1310 O
substance NCT03928028 1311 1320 B-Condition
abuse NCT03928028 1321 1326 I-Condition
, NCT03928028 1327 1328 O
autism NCT03928028 1329 1335 B-Condition
spectrum NCT03928028 1336 1344 I-Condition
disorder NCT03928028 1345 1353 I-Condition
, NCT03928028 1354 1355 O
or NCT03928028 1356 1358 B-Or
intellectual NCT03928028 1359 1371 B-Condition
disability NCT03928028 1372 1382 I-Condition
. NCT03928028 1383 1384 O

2 NCT03928028 1388 1389 O
. NCT03928028 1389 1390 O
Presence NCT03928028 1392 1400 O
of NCT03928028 1401 1403 O
: NCT03928028 1404 1405 O
a NCT03928028 1406 1407 O
brain NCT03928028 1408 1413 B-Modifier
disorder NCT03928028 1414 1422 B-Condition
or NCT03928028 1423 1425 B-Or
injury NCT03928028 1426 1432 B-Condition
( NCT03928028 1433 1434 O
such NCT03928028 1435 1439 O
as NCT03928028 1440 1442 O
TBI NCT03928028 1443 1446 B-Condition
) NCT03928028 1447 1448 O
that NCT03928028 1449 1453 O
could NCT03928028 1454 1459 B-Assertion___Assertion-Type-Value:hypothetical
impact NCT03928028 1460 1466 O
the NCT03928028 1467 1470 O
ability NCT03928028 1471 1478 O
to NCT03928028 1479 1481 O
engage NCT03928028 1482 1488 O
in NCT03928028 1489 1491 O
treatment NCT03928028 1492 1501 B-Procedure

3 NCT03928028 1504 1505 O
. NCT03928028 1505 1506 O
Use NCT03928028 1508 1511 B-Eq-Comparison
of NCT03928028 1512 1514 O
anti NCT03928028 1515 1519 B-Drug
- NCT03928028 1520 1521 I-Drug
psychotic NCT03928028 1522 1531 I-Drug
medication NCT03928028 1532 1542 I-Drug

Inclusion NCT03927482 0 9 O
Criteria NCT03927482 10 18 O
: NCT03927482 19 20 O

- NCT03927482 24 25 O
Currently NCT03927482 27 36 B-Eq-Comparison
enrolled NCT03927482 37 45 O
community NCT03927482 46 55 O
college NCT03927482 56 63 O
student NCT03927482 64 71 O

- NCT03927482 74 75 O
At NCT03927482 77 79 B-Eq-Comparison
least NCT03927482 80 85 I-Eq-Comparison
2 NCT03927482 86 87 I-Eq-Comparison
heavy NCT03927482 88 93 B-Condition
drinking NCT03927482 94 102 I-Condition
episodes NCT03927482 103 111 O
in NCT03927482 112 114 O
past NCT03927482 115 119 B-Eq-Comparison
2 NCT03927482 120 121 I-Eq-Comparison
weeks NCT03927482 122 127 I-Eq-Comparison
at NCT03927482 128 130 B-Temporal-Connection___Temporal-Connection-Type-Value:during
recruitment NCT03927482 131 142 B-Study

- NCT03927482 145 146 O
Own NCT03927482 148 151 O
smart NCT03927482 152 157 O
phone NCT03927482 158 163 O

Exclusion NCT03927482 164 173 O
Criteria NCT03927482 174 182 O
: NCT03927482 183 184 O

- NCT03927482 188 189 O
Alcohol NCT03927482 191 198 B-Condition
abuse NCT03927482 199 204 I-Condition
disorder NCT03927482 205 213 I-Condition
or NCT03927482 214 216 B-Or
currently NCT03927482 217 226 B-Eq-Comparison
in NCT03927482 227 229 O
treatment NCT03927482 230 239 B-Procedure
for NCT03927482 240 243 O
alcohol NCT03927482 244 251 B-Condition
- NCT03927482 252 253 I-Condition
related NCT03927482 254 261 I-Condition
problems NCT03927482 262 270 I-Condition

Inclusion NCT03920514 0 9 O
Criteria NCT03920514 10 18 O
: NCT03920514 19 20 O

- NCT03920514 24 25 O
Mild NCT03920514 27 31 O
male NCT03920514 32 36 B-Condition
infertility NCT03920514 37 48 I-Condition
or NCT03920514 49 51 B-Or
unexplained NCT03920514 52 63 B-Modifier
infertility NCT03920514 64 75 B-Condition

Exclusion NCT03920514 76 85 O
Criteria NCT03920514 86 94 O
: NCT03920514 95 96 O

- NCT03920514 100 101 O
Adanced NCT03920514 103 110 O
male NCT03920514 111 115 B-Modifier
factor NCT03920514 116 122 I-Modifier
endometriosis NCT03920514 123 136 B-Condition
uterine NCT03920514 137 144 B-Condition
abnormality NCT03920514 145 156 I-Condition
sever NCT03920514 157 162 O
semen NCT03920514 163 168 B-Condition
parameters NCT03920514 169 179 I-Condition
i NCT03920514 180 181 O
impairment NCT03920514 182 192 O
according NCT03920514 193 202 O
to NCT03920514 203 205 O
WHO NCT03920514 206 209 O
2010 NCT03920514 210 214 O
non NCT03920514 215 218 B-Condition
ovulatory NCT03920514 219 228 I-Condition
cycles NCT03920514 229 235 I-Condition
bilatral NCT03920514 236 244 B-Modifier
tubal NCT03920514 245 250 B-Condition
block NCT03920514 251 256 I-Condition

Inclusion NCT03923790 0 9 O
Criteria NCT03923790 10 18 O
: NCT03923790 19 20 O

- NCT03923790 24 25 O
Ischemic NCT03923790 27 35 B-Modifier
and NCT03923790 36 39 B-Or
hemorrhagic NCT03923790 40 51 B-Modifier
stroke NCT03923790 52 58 B-Condition
patients NCT03923790 59 67 O

- NCT03923790 70 71 O
Presence NCT03923790 73 81 O
of NCT03923790 82 84 O
at NCT03923790 85 87 B-Eq-Comparison
least NCT03923790 88 93 I-Eq-Comparison
one NCT03923790 94 97 I-Eq-Comparison
of NCT03923790 98 100 O
the NCT03923790 101 104 B-Criteria-Count
following NCT03923790 105 114 I-Criteria-Count
high NCT03923790 115 119 O
risk NCT03923790 120 124 B-Risk
criteria NCT03923790 125 133 O
: NCT03923790 134 135 O
uninsured NCT03923790 136 145 B-Negation
, NCT03923790 146 147 O
Medicaid NCT03923790 148 156 O
payer NCT03923790 157 162 O
status NCT03923790 163 169 O
, NCT03923790 170 171 O
small NCT03923790 172 177 B-Modifier
vessel NCT03923790 178 184 I-Modifier
ischemic NCT03923790 185 193 B-Condition
stroke NCT03923790 194 200 I-Condition
, NCT03923790 201 202 O
hypertensive NCT03923790 203 215 B-Modifier
ICH NCT03923790 216 219 B-Condition
) NCT03923790 220 221 O

- NCT03923790 225 226 O
Age NCT03923790 228 231 B-Age
≥ NCT03923790 232 233 B-Eq-Comparison
18 NCT03923790 234 236 I-Eq-Comparison
; NCT03923790 237 238 O
presence NCT03923790 239 247 O
of NCT03923790 248 250 O
hypertension NCT03923790 251 263 B-Condition
( NCT03923790 264 265 O
by NCT03923790 266 268 O
clinical NCT03923790 269 277 B-Observation
history NCT03923790 278 285 I-Observation
or NCT03923790 286 288 B-Or
hospital NCT03923790 289 297 O
BP NCT03923790 298 300 B-Observation
≥ NCT03923790 301 302 B-Eq-Comparison
140 NCT03923790 303 306 I-Eq-Comparison
/ NCT03923790 307 308 O
90 NCT03923790 309 311 O
on NCT03923790 312 314 O
two NCT03923790 315 318 B-Eq-Comparison
occasions NCT03923790 319 328 O
) NCT03923790 329 330 O

- NCT03923790 334 335 O
Plan NCT03923790 337 341 B-Eq-Comparison
to NCT03923790 342 344 O
discharge NCT03923790 345 354 B-Encounter
home NCT03923790 355 359 O
after NCT03923790 360 365 B-Temporal-Connection___Temporal-Connection-Type-Value:after
stroke NCT03923790 366 372 B-Condition

- NCT03923790 375 376 O
Ability NCT03923790 378 385 O
to NCT03923790 386 388 O
provide NCT03923790 389 396 O
consent NCT03923790 397 404 O
( NCT03923790 405 406 O
patient NCT03923790 407 414 O
or NCT03923790 415 417 O
caregiver NCT03923790 418 427 O
) NCT03923790 428 429 O

- NCT03923790 433 434 O
Ability NCT03923790 436 443 O
to NCT03923790 444 446 O
communicate NCT03923790 447 458 O
in NCT03923790 459 461 O
English NCT03923790 462 469 O

Exclusion NCT03923790 470 479 O
Criteria NCT03923790 480 488 O
: NCT03923790 489 490 O

- NCT03923790 494 495 O
modified NCT03923790 497 505 B-Observation
Rankin NCT03923790 506 512 I-Observation
scale NCT03923790 513 518 I-Observation
> NCT03923790 519 520 B-Eq-Comparison
4 NCT03923790 521 522 I-Eq-Comparison
at NCT03923790 523 525 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03923790 526 529 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03923790 530 534 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03923790 535 537 O
enrollment NCT03923790 538 548 B-Study
( NCT03923790 549 550 O
severe NCT03923790 551 557 O
disability NCT03923790 558 568 B-Condition
) NCT03923790 569 570 O

- NCT03923790 574 575 O
life NCT03923790 577 581 B-Observation
expectancy NCT03923790 582 592 I-Observation
< NCT03923790 593 594 B-Eq-Comparison
1 NCT03923790 595 596 I-Eq-Comparison
year NCT03923790 597 601 I-Eq-Comparison
or NCT03923790 602 604 B-Or
terminal NCT03923790 605 613 B-Condition
illness NCT03923790 614 621 I-Condition
, NCT03923790 622 623 O

- NCT03923790 627 628 O
eGFR NCT03923790 630 634 B-Observation
< NCT03923790 635 636 B-Eq-Comparison
30 NCT03923790 637 639 I-Eq-Comparison
at NCT03923790 640 642 B-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03923790 643 647 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03923790 648 650 I-Temporal-Connection___Temporal-Connection-Type-Value:during
discharge NCT03923790 651 660 B-Encounter

- NCT03923790 663 664 O
pregnancy NCT03923790 666 675 B-Condition

- NCT03923790 678 679 O
symptomatic NCT03923790 681 692 B-Condition
flow NCT03923790 693 697 I-Condition
limiting NCT03923790 698 706 O
carotid NCT03923790 707 714 B-Condition
stenosis NCT03923790 715 723 I-Condition
without NCT03923790 724 731 B-Negation
plan NCT03923790 732 736 B-Assertion___Assertion-Type-Value:intention
for NCT03923790 737 740 O
intervention NCT03923790 741 753 B-Procedure

- NCT03923790 756 757 O
urine NCT03923790 759 764 B-Observation
toxicology NCT03923790 765 775 I-Observation
positive NCT03923790 776 784 O
for NCT03923790 785 788 O
cocaine NCT03923790 789 796 B-Drug
or NCT03923790 797 799 B-Or
methamphetamine NCT03923790 800 815 B-Drug
or NCT03923790 816 818 B-Or
recent NCT03923790 819 825 B-Eq-Comparison
use NCT03923790 826 829 B-Coreference

- NCT03923790 832 833 O
long NCT03923790 835 839 B-Modifier
- NCT03923790 840 841 I-Modifier
term NCT03923790 842 846 I-Modifier
BP NCT03923790 847 849 B-Observation
goal NCT03923790 850 854 B-Assertion___Assertion-Type-Value:hypothetical
≥ NCT03923790 855 856 B-Eq-Comparison
130 NCT03923790 857 860 I-Eq-Comparison
/ NCT03923790 861 862 I-Eq-Comparison
80 NCT03923790 863 865 I-Eq-Comparison
mmHg NCT03923790 866 870 I-Eq-Comparison
according NCT03923790 871 880 O
to NCT03923790 881 883 O
clinical NCT03923790 884 892 O
team NCT03923790 893 897 O

Inclusion NCT03929068 0 9 O
Criteria NCT03929068 10 18 O
: NCT03929068 19 20 O

- NCT03929068 24 25 O
Diagnosis NCT03929068 27 36 O
of NCT03929068 37 39 O
ALS NCT03929068 40 43 B-Condition
or NCT03929068 44 46 B-Or
PLS NCT03929068 47 50 B-Condition

- NCT03929068 53 54 O
Age NCT03929068 56 59 B-Age
greater NCT03929068 60 67 B-Eq-Comparison
than NCT03929068 68 72 I-Eq-Comparison
18 NCT03929068 73 75 I-Eq-Comparison
years NCT03929068 76 81 I-Eq-Comparison

- NCT03929068 84 85 O
Clinically NCT03929068 87 97 O
significant NCT03929068 98 109 O
spasticity NCT03929068 110 120 B-Condition
. NCT03929068 121 122 O

Exclusion NCT03929068 124 133 O
Criteria NCT03929068 134 142 O
: NCT03929068 143 144 O

- NCT03929068 148 149 O
Individuals NCT03929068 151 162 O
currently NCT03929068 163 172 B-Eq-Comparison
taking NCT03929068 173 179 I-Eq-Comparison
carbidopa NCT03929068 180 189 B-Drug
- NCT03929068 190 191 I-Drug
levodopa NCT03929068 192 200 I-Drug
or NCT03929068 201 203 B-Or
with NCT03929068 204 208 O
known NCT03929068 209 214 O
hypersensitivity NCT03929068 215 231 B-Condition
of NCT03929068 232 234 O
any NCT03929068 235 238 O
component NCT03929068 239 248 O
of NCT03929068 249 251 O
carbidopa NCT03929068 252 261 B-Drug
- NCT03929068 262 263 I-Drug
levodopa NCT03929068 264 272 I-Drug

- NCT03929068 275 276 O
Narrow NCT03929068 278 284 B-Condition
- NCT03929068 285 286 I-Condition
angle NCT03929068 287 292 I-Condition
glaucoma NCT03929068 293 301 I-Condition

- NCT03929068 304 305 O
Current NCT03929068 307 314 B-Eq-Comparison
use NCT03929068 315 318 I-Eq-Comparison
of NCT03929068 319 321 O
a NCT03929068 322 323 O
non NCT03929068 324 327 B-Drug
- NCT03929068 328 329 I-Drug
selective NCT03929068 330 339 I-Drug
monoamine NCT03929068 340 349 I-Drug
oxidase NCT03929068 350 357 I-Drug
inhibitor NCT03929068 358 367 I-Drug
( NCT03929068 368 369 O
MAOI NCT03929068 370 374 B-Drug
) NCT03929068 375 376 O

- NCT03929068 380 381 O
History NCT03929068 383 390 B-Eq-Comparison
of NCT03929068 391 393 O
malignant NCT03929068 394 403 B-Condition
melanoma NCT03929068 404 412 I-Condition
or NCT03929068 413 415 B-Or
suspicious NCT03929068 416 426 O
skin NCT03929068 427 431 B-Condition
lesions NCT03929068 432 439 I-Condition

- NCT03929068 442 443 O
History NCT03929068 445 452 B-Eq-Comparison
of NCT03929068 453 455 O
depression NCT03929068 456 466 B-Condition
, NCT03929068 467 468 O
suicidal NCT03929068 469 477 B-Condition
ideation NCT03929068 478 486 I-Condition
, NCT03929068 487 488 O
or NCT03929068 489 491 B-Or
psychosis NCT03929068 492 501 B-Condition

- NCT03929068 504 505 O
History NCT03929068 507 514 B-Eq-Comparison
of NCT03929068 515 517 O
myocardial NCT03929068 518 528 B-Condition
infarction NCT03929068 529 539 I-Condition
, NCT03929068 540 541 O
ventricular NCT03929068 542 553 B-Condition
arrhythmia NCT03929068 554 564 I-Condition
, NCT03929068 565 566 O
or NCT03929068 567 569 B-Or
severe NCT03929068 570 576 O
cardiopulmonary NCT03929068 577 592 B-Condition
disease NCT03929068 593 600 I-Condition

- NCT03929068 603 604 O
Uncontrolled NCT03929068 606 618 B-Modifier
hypertension NCT03929068 619 631 B-Condition

- NCT03929068 634 635 O
Asthma NCT03929068 637 643 B-Condition

- NCT03929068 646 647 O
Renal NCT03929068 649 654 B-Condition
disease NCT03929068 655 662 I-Condition

- NCT03929068 665 666 O
Hepatic NCT03929068 668 675 B-Condition
disease NCT03929068 676 683 I-Condition

- NCT03929068 686 687 O
Endocrine NCT03929068 689 698 B-Condition
disease NCT03929068 699 706 I-Condition

- NCT03929068 709 710 O
History NCT03929068 712 719 B-Eq-Comparison
of NCT03929068 720 722 O
peptic NCT03929068 723 729 B-Condition
ulcer NCT03929068 730 735 I-Condition

- NCT03929068 738 739 O
Pregnant NCT03929068 741 749 O
and NCT03929068 750 753 O
/ NCT03929068 754 755 O
or NCT03929068 756 758 O
breastfeeding NCT03929068 759 772 O

- NCT03929068 775 776 O
Current NCT03929068 778 785 B-Eq-Comparison
participation NCT03929068 786 799 O
in NCT03929068 800 802 O
another NCT03929068 803 810 B-Other
interventional NCT03929068 811 825 O
study NCT03929068 826 831 B-Study

Inclusion NCT03926429 0 9 O
Criteria NCT03926429 10 18 O
: NCT03926429 19 20 O

- NCT03926429 24 25 O
reactive NCT03926429 27 35 B-Condition
arthritis NCT03926429 36 45 I-Condition
diagnosed NCT03926429 46 55 O
in NCT03926429 56 58 O
one NCT03926429 59 62 O
of NCT03926429 63 65 O
the NCT03926429 66 69 O
two NCT03926429 70 73 O
rheumatology NCT03926429 74 86 O
departments NCT03926429 87 98 O
from NCT03926429 99 103 O
Centre NCT03926429 104 110 O
Hospitalier NCT03926429 111 122 O
Lyon NCT03926429 123 127 O
Sud NCT03926429 128 131 O
or NCT03926429 132 134 B-Or
Besançon NCT03926429 135 143 O

Exclusion NCT03926429 144 153 O
Criteria NCT03926429 154 162 O
: NCT03926429 163 164 O

- NCT03926429 168 169 O
presence NCT03926429 171 179 O
of NCT03926429 180 182 O
other NCT03926429 183 188 B-Other
known NCT03926429 189 194 O
causes NCT03926429 195 201 B-Condition
of NCT03926429 202 204 O
arthritis NCT03926429 205 214 B-Condition
, NCT03926429 215 216 O
such NCT03926429 217 221 O
as NCT03926429 222 224 O
other NCT03926429 225 230 B-Other
defined NCT03926429 231 238 O
spondyloarthritides NCT03926429 239 258 B-Condition
, NCT03926429 259 260 O
septic NCT03926429 261 267 B-Modifier
arthritis NCT03926429 268 277 B-Condition
, NCT03926429 278 279 O
Lyme NCT03926429 280 284 B-Condition
disease NCT03926429 285 292 I-Condition
, NCT03926429 293 294 O
microcrystalline NCT03926429 295 311 B-Modifier
arthritis NCT03926429 312 321 B-Condition
or NCT03926429 322 324 B-Or
rheumatoid NCT03926429 325 335 B-Modifier
arthritis NCT03926429 336 345 B-Condition

Inclusion NCT03927079 0 9 O
Criteria NCT03927079 10 18 O
: NCT03927079 19 20 O

- NCT03927079 24 25 O
patients NCT03927079 27 35 O
who NCT03927079 36 39 O
undergo NCT03927079 40 47 O
a NCT03927079 48 49 O
flexible NCT03927079 50 58 O
bronchoscopic NCT03927079 59 72 B-Procedure
lavage NCT03927079 73 79 I-Procedure
and NCT03927079 80 83 B-And
with NCT03927079 84 88 O
a NCT03927079 89 90 O
beta NCT03927079 91 95 B-Drug
lactamines NCT03927079 96 106 I-Drug
treatment NCT03927079 107 116 B-Procedure
as NCT03927079 117 119 O
cephalosporin NCT03927079 120 133 B-Drug
of NCT03927079 134 136 O
3 NCT03927079 137 138 B-Modifier
rd NCT03927079 139 141 I-Modifier
generation NCT03927079 142 152 I-Modifier
( NCT03927079 153 154 O
CEFTRIAXONE NCT03927079 155 166 B-Drug
/ NCT03927079 167 168 B-Or
CEFOTAXIME NCT03927079 169 179 B-Drug
, NCT03927079 180 181 O
CEFTAZIDIME NCT03927079 182 193 B-Drug
) NCT03927079 194 195 O
, NCT03927079 197 198 O
of NCT03927079 199 201 O
4 NCT03927079 202 203 B-Modifier
th NCT03927079 204 206 I-Modifier
generation NCT03927079 207 217 I-Modifier
( NCT03927079 218 219 O
CEFEPIM NCT03927079 220 227 B-Drug
) NCT03927079 228 229 O
, NCT03927079 231 232 O
or NCT03927079 233 235 B-Or
AMOXICILLIN NCT03927079 236 247 B-Drug
- NCT03927079 248 249 I-Drug
CLAVULANIC NCT03927079 250 260 I-Drug
ACID NCT03927079 261 265 I-Drug
, NCT03927079 266 267 O
or NCT03927079 268 270 B-Or
PIPERACILLIN NCT03927079 271 283 B-Drug
- NCT03927079 284 285 I-Drug
TAZOBACTAM NCT03927079 286 296 I-Drug

- NCT03927079 299 300 O
patient NCT03927079 302 309 O
major NCT03927079 310 315 O

- NCT03927079 318 319 O
informed NCT03927079 321 329 O
and NCT03927079 330 333 O
signed NCT03927079 334 340 O
consent NCT03927079 341 348 O
form NCT03927079 349 353 O

Exclusion NCT03927079 354 363 O
Criteria NCT03927079 364 372 O
: NCT03927079 373 374 O

- NCT03927079 378 379 O
patient NCT03927079 381 388 O
under NCT03927079 389 394 B-Eq-Comparison
chronic NCT03927079 395 402 B-Modifier
dialysis NCT03927079 403 411 B-Procedure

- NCT03927079 414 415 O
patient NCT03927079 417 424 O
placed NCT03927079 425 431 O
under NCT03927079 432 437 O
judicial NCT03927079 438 446 B-Observation
protection NCT03927079 447 457 I-Observation

Inclusion NCT03922698 0 9 O
Criteria NCT03922698 10 18 O
: NCT03922698 19 20 O

- NCT03922698 24 25 O
age NCT03922698 27 30 B-Age
≥ NCT03922698 31 32 B-Eq-Comparison
45 NCT03922698 33 35 I-Eq-Comparison
and NCT03922698 36 39 B-And
≤ NCT03922698 40 41 B-Eq-Comparison
90 NCT03922698 42 44 I-Eq-Comparison
years NCT03922698 45 50 I-Eq-Comparison
; NCT03922698 50 51 O

- NCT03922698 54 55 O
patients NCT03922698 57 65 O
with NCT03922698 66 70 O
severe NCT03922698 71 77 O
( NCT03922698 78 79 O
70 NCT03922698 80 82 B-Eq-Comparison
- NCT03922698 83 84 I-Eq-Comparison
99 NCT03922698 85 87 I-Eq-Comparison
% NCT03922698 88 89 I-Eq-Comparison
) NCT03922698 91 92 O
carotid NCT03922698 93 100 B-Observation
stenosis NCT03922698 101 109 I-Observation
, NCT03922698 110 111 O
diagnosed NCT03922698 112 121 O
with NCT03922698 122 126 O
color NCT03922698 127 132 B-Procedure
doppler NCT03922698 133 140 I-Procedure
echography NCT03922698 141 151 I-Procedure
or NCT03922698 152 154 B-Or
angio NCT03922698 155 160 B-Modifier
- NCT03922698 161 162 O
MRI NCT03922698 163 166 B-Procedure
or NCT03922698 167 169 B-Or
angiography NCT03922698 170 181 B-Procedure
; NCT03922698 181 182 O

- NCT03922698 185 186 O
written NCT03922698 188 195 O
informed NCT03922698 196 204 O
consent NCT03922698 205 212 O
. NCT03922698 213 214 O

Exclusion NCT03922698 216 225 O
Criteria NCT03922698 226 234 O
: NCT03922698 235 236 O

- NCT03922698 240 241 O
carotid NCT03922698 243 250 B-Observation
stenosis NCT03922698 251 259 I-Observation
< NCT03922698 260 261 B-Eq-Comparison
70 NCT03922698 262 264 I-Eq-Comparison
% NCT03922698 265 266 I-Eq-Comparison
at NCT03922698 267 269 O
carotid NCT03922698 270 277 B-Modifier
bifurcation NCT03922698 278 289 I-Modifier
or NCT03922698 290 292 B-Or
diagnosed NCT03922698 293 302 O
with NCT03922698 303 307 O
color NCT03922698 308 313 B-Procedure
doppler NCT03922698 314 321 I-Procedure
echography NCT03922698 322 332 I-Procedure
or NCT03922698 333 335 B-Or
angio NCT03922698 336 341 B-Modifier
- NCT03922698 342 343 O
MRI NCT03922698 344 347 B-Procedure
or NCT03922698 348 350 B-Or
angiography NCT03922698 351 362 B-Procedure
; NCT03922698 362 363 O

- NCT03922698 366 367 O
severe NCT03922698 369 375 O
neoplasia NCT03922698 376 385 B-Condition
; NCT03922698 385 386 O

- NCT03922698 389 390 O
participation NCT03922698 392 405 O
to NCT03922698 406 408 O
other NCT03922698 409 414 B-Other
clinical NCT03922698 415 423 B-Study
trial NCT03922698 424 429 I-Study
, NCT03922698 430 431 O
ongoing NCT03922698 432 439 B-Eq-Comparison
or NCT03922698 440 442 B-Or
terminated NCT03922698 443 453 O
less NCT03922698 454 458 B-Eq-Comparison
than NCT03922698 459 463 I-Eq-Comparison
one NCT03922698 464 467 I-Eq-Comparison
month NCT03922698 468 473 I-Eq-Comparison
before NCT03922698 474 480 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrolment NCT03922698 481 490 O
in NCT03922698 491 493 O
this NCT03922698 494 498 O
study NCT03922698 499 504 B-Study
. NCT03922698 504 505 O

Inclusion NCT03927092 0 9 O
Criteria NCT03927092 10 18 O
: NCT03927092 19 20 O

- NCT03927092 24 25 O
Diagnosed NCT03927092 27 36 O
as NCT03927092 37 39 O
having NCT03927092 40 46 O
Multiple NCT03927092 47 55 B-Condition
Sclerosis NCT03927092 56 65 I-Condition

- NCT03927092 68 69 O
Attends NCT03927092 71 78 O
the NCT03927092 79 82 O
annual NCT03927092 83 89 O
patient NCT03927092 90 97 O
education NCT03927092 98 107 O
seminar NCT03927092 108 115 O
at NCT03927092 116 118 O
the NCT03927092 119 122 O
investigators NCT03927092 123 136 O
' NCT03927092 136 137 O
university NCT03927092 138 148 O
hospital NCT03927092 149 157 O

- NCT03927092 160 161 O
Older NCT03927092 163 168 B-Eq-Comparison
than NCT03927092 169 173 I-Eq-Comparison
18 NCT03927092 174 176 I-Eq-Comparison
years NCT03927092 177 182 I-Eq-Comparison
of NCT03927092 183 185 O
age NCT03927092 186 189 B-Age

- NCT03927092 192 193 O
Can NCT03927092 195 198 O
read NCT03927092 199 203 O
and NCT03927092 204 207 O
write NCT03927092 208 213 O

Exclusion NCT03927092 214 223 O
Criteria NCT03927092 224 232 O
: NCT03927092 233 234 O

- NCT03927092 238 239 O
Does NCT03927092 241 245 O
not NCT03927092 246 249 B-Negation
accept NCT03927092 250 256 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03927092 257 259 O
answer NCT03927092 260 266 O
the NCT03927092 267 270 O
questionnaire NCT03927092 271 284 B-Observation

- NCT03927092 287 288 O
Unable NCT03927092 290 296 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03927092 297 299 O
answer NCT03927092 300 306 O
the NCT03927092 307 310 O
questions NCT03927092 311 320 B-Procedure
due NCT03927092 321 324 O
to NCT03927092 325 327 O
a NCT03927092 328 329 O
cognitive NCT03927092 330 339 B-Condition
impairment NCT03927092 340 350 I-Condition

Inclusion NCT03920930 0 9 O
Criteria NCT03920930 10 18 O
: NCT03920930 19 20 O

• NCT03920930 22 23 O
patients NCT03920930 24 32 O
undergoing NCT03920930 33 43 B-Eq-Comparison
elective NCT03920930 44 52 O
, NCT03920930 53 54 O
primary NCT03920930 55 62 B-Modifier
knee NCT03920930 63 67 B-Procedure
joint NCT03920930 68 73 I-Procedure
replacement NCT03920930 74 85 I-Procedure
in NCT03920930 86 88 O
combined NCT03920930 89 97 O
general NCT03920930 98 105 B-Procedure
anaesthesia NCT03920930 106 117 I-Procedure

Exclusion NCT03920930 118 127 O
Criteria NCT03920930 128 136 O
: NCT03920930 137 138 O

- NCT03920930 142 143 O
heart NCT03920930 145 150 B-Condition
insufficiency NCT03920930 151 164 I-Condition
NYHA NCT03920930 165 169 B-Condition
> NCT03920930 170 171 B-Eq-Comparison
2 NCT03920930 172 173 I-Eq-Comparison

- NCT03920930 177 178 O
liver NCT03920930 180 185 B-Condition
insufficiency NCT03920930 186 199 I-Condition
> NCT03920930 200 201 O
CHILD NCT03920930 202 207 O
B NCT03920930 208 209 O

- NCT03920930 212 213 O
evidence NCT03920930 215 223 O
of NCT03920930 224 226 O
diabetic NCT03920930 227 235 B-Condition
polyneuropathy NCT03920930 236 250 I-Condition

- NCT03920930 253 254 O
severe NCT03920930 256 262 O
adipositas NCT03920930 263 273 B-Condition
BMI NCT03920930 274 277 B-Observation
> NCT03920930 278 279 B-Eq-Comparison
40 NCT03920930 280 282 I-Eq-Comparison

- NCT03920930 286 287 O
patients NCT03920930 289 297 O
< NCT03920930 298 299 B-Eq-Comparison
18 NCT03920930 300 302 I-Eq-Comparison
years NCT03920930 303 308 I-Age|Eq-Comparison

- NCT03920930 311 312 O
pregnancy NCT03920930 314 323 B-Condition

- NCT03920930 326 327 O
in NCT03920930 329 331 O
case NCT03920930 332 336 O
of NCT03920930 337 339 O
police NCT03920930 340 346 B-Observation
custody NCT03920930 347 354 I-Observation

- NCT03920930 357 358 O
participation NCT03920930 360 373 O
in NCT03920930 374 376 O
a NCT03920930 377 378 O
paralleled NCT03920930 379 389 B-Other
interventional NCT03920930 390 404 O
RCT NCT03920930 405 408 B-Study
in NCT03920930 409 411 O
a NCT03920930 412 413 O
time NCT03920930 414 418 O
frame NCT03920930 419 424 O
of NCT03920930 425 427 O
30 NCT03920930 428 430 B-Eq-Comparison
days NCT03920930 431 435 I-Eq-Comparison

- NCT03920930 438 439 O
chronic NCT03920930 441 448 B-Modifier
opioid NCT03920930 449 455 B-Procedure
therapy NCT03920930 456 463 I-Procedure
> NCT03920930 464 465 B-Eq-Comparison
3 NCT03920930 466 467 I-Eq-Comparison
months NCT03920930 468 474 I-Eq-Comparison
before NCT03920930 475 481 B-Temporal-Connection___Temporal-Connection-Type-Value:before
scheduled NCT03920930 482 491 B-Eq-Comparison
surgery NCT03920930 492 499 B-Procedure

- NCT03920930 502 503 O
allergy NCT03920930 505 512 B-Allergy
against NCT03920930 513 520 O
medication NCT03920930 521 531 B-Drug
required NCT03920930 532 540 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03920930 541 544 I-Assertion___Assertion-Type-Value:hypothetical
surgery NCT03920930 545 552 B-Procedure
or NCT03920930 553 555 B-Or
anaesthesia NCT03920930 556 567 B-Procedure


Inclusion NCT03922841 0 9 O
Criteria NCT03922841 10 18 O
: NCT03922841 19 20 O

- NCT03922841 24 25 O
The NCT03922841 27 30 O
subject NCT03922841 31 38 O
must NCT03922841 39 43 O
meet NCT03922841 44 48 O
all NCT03922841 49 52 O
of NCT03922841 53 55 O
the NCT03922841 56 59 O
following NCT03922841 60 69 O
inclusion NCT03922841 70 79 O
criteria NCT03922841 80 88 O
to NCT03922841 89 91 O
participate NCT03922841 92 103 O
in NCT03922841 104 106 O
this NCT03922841 107 111 O
study NCT03922841 112 117 O
. NCT03922841 118 119 O

1 NCT03922841 128 129 O
. NCT03922841 129 130 O
Evidence NCT03922841 132 140 O
of NCT03922841 141 143 O
pleural NCT03922841 144 151 B-Condition
disease NCT03922841 152 159 I-Condition
on NCT03922841 160 162 O
chest NCT03922841 163 168 B-Procedure
radiograph NCT03922841 169 179 I-Procedure
or NCT03922841 180 182 B-Or
bedside NCT03922841 183 190 B-Procedure
ultrasound NCT03922841 191 201 I-Procedure
or NCT03922841 202 204 B-Or
Computed NCT03922841 205 213 B-Procedure
Tomography NCT03922841 214 224 I-Procedure
regardless NCT03922841 225 235 O
of NCT03922841 236 238 O
underlying NCT03922841 239 249 O
aetiology NCT03922841 250 259 O

2 NCT03922841 267 268 O
. NCT03922841 268 269 O
No NCT03922841 271 273 B-Negation
age NCT03922841 274 277 B-Age
or NCT03922841 278 280 B-Or
gender NCT03922841 281 287 O
restrictions NCT03922841 288 300 O

3 NCT03922841 308 309 O
. NCT03922841 309 310 O
Ability NCT03922841 312 319 O
to NCT03922841 320 322 O
provide NCT03922841 323 330 O
informed NCT03922841 331 339 O
consent NCT03922841 340 347 O

Exclusion NCT03922841 348 357 O
Criteria NCT03922841 358 366 O
: NCT03922841 367 368 O

- NCT03922841 372 373 O
Subjects NCT03922841 375 383 O
who NCT03922841 384 387 O
no NCT03922841 388 390 B-Negation
radiographic NCT03922841 391 403 B-Procedure
evidence NCT03922841 404 412 O
of NCT03922841 413 415 O
pleural NCT03922841 416 423 B-Condition
disease NCT03922841 424 431 I-Condition
or NCT03922841 432 434 O
who NCT03922841 435 438 O
are NCT03922841 439 442 O
unwilling NCT03922841 443 452 O
/ NCT03922841 453 454 O
unable NCT03922841 455 461 O
to NCT03922841 462 464 O
provide NCT03922841 465 472 O
informed NCT03922841 473 481 O
consent NCT03922841 482 489 O

Inclusion NCT03922672 0 9 O
Criteria NCT03922672 10 18 O
: NCT03922672 19 20 O

- NCT03922672 24 25 O
Caregiver NCT03922672 27 36 O
: NCT03922672 37 38 O

- NCT03922672 47 48 O
Are NCT03922672 50 53 O
currently NCT03922672 54 63 B-Eq-Comparison
a NCT03922672 64 65 O
primary NCT03922672 66 73 B-Observation
caregiver NCT03922672 74 83 I-Observation
to NCT03922672 84 86 O
an NCT03922672 87 89 O
adult NCT03922672 90 95 O
with NCT03922672 96 100 B-And
PD NCT03922672 101 103 B-Condition

- NCT03922672 111 112 O
Are NCT03922672 114 117 O
between NCT03922672 118 125 O
the NCT03922672 126 129 O
age NCT03922672 130 133 B-Age
of NCT03922672 134 136 O
40 NCT03922672 137 139 B-Eq-Comparison
- NCT03922672 140 141 I-Eq-Comparison
80 NCT03922672 142 144 I-Eq-Comparison
years NCT03922672 145 150 I-Eq-Comparison

- NCT03922672 158 159 O
Have NCT03922672 161 165 O
less NCT03922672 166 170 B-Eq-Comparison
than NCT03922672 171 175 I-Eq-Comparison
5 NCT03922672 176 177 I-Eq-Comparison
years NCT03922672 178 183 I-Eq-Comparison
of NCT03922672 184 186 O
music NCT03922672 187 192 B-Observation
training NCT03922672 193 201 I-Observation

- NCT03922672 209 210 O
Speak NCT03922672 212 217 O
and NCT03922672 218 221 O
read NCT03922672 222 226 O
English NCT03922672 227 234 O
fluently NCT03922672 235 243 O

Adult NCT03922672 244 249 O
with NCT03922672 250 254 B-And
PD NCT03922672 255 257 B-Condition
: NCT03922672 258 259 O

- NCT03922672 263 264 O
Stage NCT03922672 266 271 B-Eq-Comparison
1 NCT03922672 272 273 I-Eq-Comparison
- NCT03922672 274 275 I-Eq-Comparison
3 NCT03922672 276 277 I-Eq-Comparison
Parkinson NCT03922672 278 287 B-Condition
's NCT03922672 287 289 I-Condition
disease NCT03922672 290 297 I-Condition

- NCT03922672 300 301 O
Are NCT03922672 303 306 O
between NCT03922672 307 314 O
the NCT03922672 315 318 O
age NCT03922672 319 322 B-Age
of NCT03922672 323 325 O
40 NCT03922672 326 328 B-Eq-Comparison
- NCT03922672 329 330 I-Eq-Comparison
80 NCT03922672 331 333 O

- NCT03922672 337 338 O
Have NCT03922672 340 344 O
less NCT03922672 345 349 B-Eq-Comparison
than NCT03922672 350 354 I-Eq-Comparison
5 NCT03922672 355 356 I-Eq-Comparison
years NCT03922672 357 362 I-Eq-Comparison
of NCT03922672 363 365 O
music NCT03922672 366 371 B-Observation
training NCT03922672 372 380 I-Observation

- NCT03922672 383 384 O
Speak NCT03922672 386 391 O
and NCT03922672 392 395 O
read NCT03922672 396 400 O
English NCT03922672 401 408 O
fluently NCT03922672 409 417 O

Exclusion NCT03922672 418 427 O
Criteria NCT03922672 428 436 O
: NCT03922672 437 438 O

- NCT03922672 442 443 O
Does NCT03922672 445 449 O
n't NCT03922672 449 452 O
meet NCT03922672 453 457 O
all NCT03922672 458 461 O
the NCT03922672 462 465 O
inclusion NCT03922672 466 475 O
criteria NCT03922672 476 484 O

Inclusion NCT03929055 0 9 O
Criteria NCT03929055 10 18 O
: NCT03929055 19 20 O

- NCT03929055 24 25 O
patient NCT03929055 27 34 O
with NCT03929055 35 39 O
acute NCT03929055 40 45 B-Condition
respiratory NCT03929055 46 57 I-Condition
failure NCT03929055 58 65 I-Condition
, NCT03929055 66 67 O
not NCT03929055 68 71 B-Negation
intubated NCT03929055 72 81 B-Procedure
, NCT03929055 82 83 O
who NCT03929055 84 87 B-And
require NCT03929055 88 95 B-Assertion___Assertion-Type-Value:hypothetical
non NCT03929055 96 99 B-Modifier
invasive NCT03929055 100 108 I-Modifier
mechanical NCT03929055 109 119 B-Procedure
ventilation NCT03929055 120 131 I-Procedure

Exclusion NCT03929055 132 141 O
Criteria NCT03929055 142 150 O
: NCT03929055 151 152 O

- NCT03929055 156 157 O
patients NCT03929055 159 167 O
in NCT03929055 168 170 O
which NCT03929055 171 176 O
it NCT03929055 177 179 O
is NCT03929055 180 182 O
not NCT03929055 183 186 B-Negation
possible NCT03929055 187 195 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929055 196 198 O
place NCT03929055 199 204 O
the NCT03929055 205 208 O
esophageal NCT03929055 209 219 B-Modifier
catheter NCT03929055 220 228 B-Procedure
or NCT03929055 229 231 B-Or
it NCT03929055 232 234 O
is NCT03929055 235 237 O
not NCT03929055 238 241 B-Negation
possible NCT03929055 242 250 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929055 251 253 O
detect NCT03929055 254 260 O
the NCT03929055 261 264 O
diaphragm NCT03929055 265 274 B-Condition
by NCT03929055 275 277 O
ultrasound NCT03929055 278 288 B-Procedure
or NCT03929055 289 291 B-Or
it NCT03929055 292 294 O
is NCT03929055 295 297 O
not NCT03929055 298 301 B-Negation
possible NCT03929055 302 310 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929055 311 313 O
apply NCT03929055 314 319 O
the NCT03929055 320 323 O
nasal NCT03929055 324 329 B-Procedure
cannula NCT03929055 330 337 I-Procedure
device NCT03929055 338 344 I-Procedure

Inclusion NCT03928405 0 9 O
Criteria NCT03928405 10 18 O
: NCT03928405 19 20 O

- NCT03928405 24 25 O
Having NCT03928405 27 33 O
mild NCT03928405 34 38 O
or NCT03928405 39 41 B-Or
moderate NCT03928405 42 50 O
severity NCT03928405 51 59 O
of NCT03928405 60 62 O
AD NCT03928405 63 65 B-Condition

- NCT03928405 68 69 O
Lack NCT03928405 71 75 B-Negation
of NCT03928405 76 78 O
communication NCT03928405 79 92 B-Condition
difficulties NCT03928405 93 105 B-Modifier
or NCT03928405 106 108 B-Or
problems NCT03928405 109 117 B-Modifier

- NCT03928405 120 121 O
Volunteering NCT03928405 123 135 O
to NCT03928405 136 138 O
participate NCT03928405 139 150 O
in NCT03928405 151 153 O
the NCT03928405 154 157 O
study NCT03928405 158 163 B-Study

- NCT03928405 166 167 O
Cerebrovascular NCT03928405 169 184 B-Condition
event NCT03928405 185 190 I-Condition
, NCT03928405 191 192 O

- NCT03928405 196 197 O
Having NCT03928405 199 205 O
disturbing NCT03928405 206 216 O
the NCT03928405 217 220 O
balance NCT03928405 221 228 B-Condition
and NCT03928405 229 232 B-Or
coordination NCT03928405 233 245 B-Condition
of NCT03928405 246 248 O
neurological NCT03928405 249 261 B-Condition
disease NCT03928405 262 269 I-Condition
such NCT03928405 270 274 O
as NCT03928405 275 277 O
Parkinson NCT03928405 278 287 B-Condition
, NCT03928405 288 289 O
MS NCT03928405 290 292 B-Condition
, NCT03928405 293 294 O

- NCT03928405 298 299 O
Mini NCT03928405 301 305 B-Observation
Mental NCT03928405 306 312 I-Observation
Test NCT03928405 313 317 I-Observation
Score NCT03928405 318 323 I-Observation
, NCT03928405 324 325 O
18 NCT03928405 326 328 B-Eq-Comparison
to NCT03928405 329 331 I-Eq-Comparison
24 NCT03928405 332 334 I-Eq-Comparison
points NCT03928405 335 341 O
from NCT03928405 342 346 O
being NCT03928405 347 352 O
scored NCT03928405 353 359 O

- NCT03928405 362 363 O
being NCT03928405 365 370 O
65 NCT03928405 371 373 B-Eq-Comparison
- NCT03928405 374 375 I-Eq-Comparison
80 NCT03928405 376 378 O
aged NCT03928405 379 383 B-Age
. NCT03928405 384 385 O

Exclusion NCT03928405 387 396 O
Criteria NCT03928405 397 405 O
: NCT03928405 406 407 O

- NCT03928405 411 412 O
Patients NCT03928405 414 422 O
diagnosed NCT03928405 423 432 O
with NCT03928405 433 437 O
dementia NCT03928405 438 446 B-Condition
( NCT03928405 447 448 O
infection NCT03928405 449 458 B-Condition
, NCT03928405 459 460 O
vascular NCT03928405 461 469 B-Condition
, NCT03928405 470 471 O
hematological NCT03928405 472 485 B-Condition
diseases NCT03928405 486 494 I-Condition
) NCT03928405 495 496 O
, NCT03928405 498 499 O
patients NCT03928405 500 508 O
who NCT03928405 509 512 O
could NCT03928405 513 518 O
not NCT03928405 519 522 B-Negation
be NCT03928405 523 525 O
contacted NCT03928405 526 535 B-Observation
during NCT03928405 536 542 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928405 543 546 O
follow NCT03928405 547 553 B-Study
- NCT03928405 554 555 I-Study
up NCT03928405 556 558 I-Study
period NCT03928405 559 565 I-Study
or NCT03928405 566 568 B-Or
who NCT03928405 569 572 O
did NCT03928405 573 576 O
not NCT03928405 577 580 B-Negation
come NCT03928405 581 585 O
to NCT03928405 586 588 O
control NCT03928405 589 596 B-Modifier
, NCT03928405 597 598 O
cardiac NCT03928405 599 606 B-Modifier
and NCT03928405 607 610 B-Or
cerebrovascular NCT03928405 611 626 B-Modifier
event NCT03928405 627 632 B-Condition
, NCT03928405 633 634 O

- NCT03928405 638 639 O
Endocrine NCT03928405 641 650 B-Condition
disorder NCT03928405 651 659 I-Condition
, NCT03928405 660 661 O
fluid NCT03928405 662 667 B-Condition
- NCT03928405 668 669 I-Condition
electrolyte NCT03928405 670 681 I-Condition
imbalance NCT03928405 682 691 I-Condition
and NCT03928405 692 695 B-Or
infection NCT03928405 696 705 B-Condition

- NCT03928405 708 709 O
Patients NCT03928405 711 719 O
with NCT03928405 720 724 O
malignancy NCT03928405 725 735 B-Condition
and NCT03928405 736 739 B-Or
malignancy NCT03928405 740 750 B-Condition
, NCT03928405 751 752 O
chemotherapy NCT03928405 753 765 B-Procedure
and NCT03928405 766 769 B-Or
radiotherapy NCT03928405 770 782 B-Procedure
, NCT03928405 783 784 O

- NCT03928405 788 789 O
Patients NCT03928405 791 799 O
with NCT03928405 800 804 O
delirium NCT03928405 805 813 B-Condition
or NCT03928405 814 816 B-Or
depression NCT03928405 817 827 B-Condition

- NCT03928405 830 831 O
Those NCT03928405 833 838 O
with NCT03928405 839 843 O
protective NCT03928405 844 854 B-Condition
sensation NCT03928405 855 864 I-Condition
loss NCT03928405 865 869 I-Condition
( NCT03928405 870 871 O
those NCT03928405 872 877 O
with NCT03928405 878 882 O
Semmes NCT03928405 883 889 B-Observation
- NCT03928405 890 891 I-Observation
Weinstein NCT03928405 892 901 I-Observation
Monofilament NCT03928405 902 914 I-Observation
Thickness NCT03928405 915 924 I-Observation
4.56 NCT03928405 925 929 B-Eq-Comparison
and NCT03928405 930 933 I-Eq-Comparison
above NCT03928405 934 939 I-Eq-Comparison
) NCT03928405 940 941 O

- NCT03928405 945 946 O
patients NCT03928405 948 956 O
with NCT03928405 957 961 O
lower NCT03928405 962 967 B-Modifier
or NCT03928405 968 970 B-Or
upper NCT03928405 971 976 B-Modifier
extremity NCT03928405 977 986 I-Modifier
amputations NCT03928405 987 998 B-Procedure
at NCT03928405 999 1001 O
any NCT03928405 1002 1005 O
level NCT03928405 1006 1011 O

Inclusion NCT03921970 0 9 O
Criteria NCT03921970 10 18 O
: NCT03921970 19 20 O

- NCT03921970 24 25 O
American NCT03921970 27 35 B-Condition
Society NCT03921970 36 43 I-Condition
of NCT03921970 44 46 I-Condition
Anesthesiologists NCT03921970 47 64 I-Condition
( NCT03921970 65 66 O
ASA NCT03921970 67 70 B-Condition
) NCT03921970 71 72 O
classification NCT03921970 73 87 B-Eq-Comparison
I NCT03921970 88 89 I-Eq-Comparison
- NCT03921970 90 91 I-Eq-Comparison
II NCT03921970 92 94 I-Eq-Comparison

- NCT03921970 97 98 O
Scheduled NCT03921970 100 109 B-Eq-Comparison
for NCT03921970 110 113 O
laparoscopic NCT03921970 114 126 B-Procedure
sleeve NCT03921970 127 133 I-Procedure
gastrectomy NCT03921970 134 145 I-Procedure
under NCT03921970 146 151 O
general NCT03921970 152 159 B-Procedure
anesthesia NCT03921970 160 170 I-Procedure

Exclusion NCT03921970 171 180 O
Criteria NCT03921970 181 189 O
: NCT03921970 190 191 O

- NCT03921970 195 196 O
Bleeding NCT03921970 198 206 B-Condition
diathesis NCT03921970 207 216 I-Condition

- NCT03921970 219 220 O
Receiving NCT03921970 222 231 B-Eq-Comparison
anticoagulant NCT03921970 232 245 B-Drug
treatment NCT03921970 246 255 B-Procedure

- NCT03921970 258 259 O
Known NCT03921970 261 266 O
local NCT03921970 267 272 O
anesthetics NCT03921970 273 284 O
and NCT03921970 285 288 B-Or
opioid NCT03921970 289 295 B-Drug
allergy NCT03921970 296 303 B-Allergy

- NCT03921970 306 307 O
Infection NCT03921970 309 318 B-Condition
of NCT03921970 319 321 O
the NCT03921970 322 325 O
skin NCT03921970 326 330 B-Modifier
at NCT03921970 331 333 I-Modifier
the NCT03921970 334 337 I-Modifier
site NCT03921970 338 342 I-Modifier
of NCT03921970 343 345 I-Modifier
the NCT03921970 346 349 I-Modifier
needle NCT03921970 350 356 I-Modifier
puncture NCT03921970 357 365 I-Modifier

- NCT03921970 368 369 O
Pregnancy NCT03921970 371 380 B-Condition
or NCT03921970 381 383 B-Or
lactation NCT03921970 384 393 B-Condition

- NCT03921970 396 397 O
Patients NCT03921970 399 407 O
who NCT03921970 408 411 O
do NCT03921970 412 414 O
not NCT03921970 415 418 B-Negation
accept NCT03921970 419 425 B-Assertion___Assertion-Type-Value:hypothetical
the NCT03921970 426 429 O
procedure NCT03921970 430 439 B-Procedure

Inclusion NCT03923829 0 9 O
Criteria NCT03923829 10 18 O
: NCT03923829 19 20 O

- NCT03923829 24 25 O
Controlled NCT03923829 27 37 B-Modifier
Type NCT03923829 38 42 I-Modifier
- NCT03923829 43 44 I-Modifier
2 NCT03923829 45 46 I-Modifier
diabetes NCT03923829 47 55 B-Condition
mellitus NCT03923829 56 64 I-Condition

- NCT03923829 67 68 O
Stage NCT03923829 70 75 B-Eq-Comparison
- NCT03923829 76 77 I-Eq-Comparison
II NCT03923829 78 80 I-Eq-Comparison
& NCT03923829 81 82 I-Eq-Comparison
III NCT03923829 82 85 I-Eq-Comparison
periodontitis NCT03923829 86 99 B-Condition

- NCT03923829 102 103 O
At NCT03923829 105 107 B-Eq-Comparison
least NCT03923829 108 113 I-Eq-Comparison
2 NCT03923829 114 115 I-Eq-Comparison
sites NCT03923829 116 121 I-Eq-Comparison
with NCT03923829 122 126 O
clinical NCT03923829 127 135 O
attachment NCT03923829 136 146 B-Observation
loss NCT03923829 147 151 I-Observation
3 NCT03923829 152 153 B-Eq-Comparison
or NCT03923829 154 156 I-Eq-Comparison
4 NCT03923829 157 158 I-Eq-Comparison
mm NCT03923829 159 161 I-Eq-Comparison
to NCT03923829 162 164 I-Eq-Comparison
≥ NCT03923829 165 166 I-Eq-Comparison
5 NCT03923829 167 168 I-Eq-Comparison
mm NCT03923829 169 171 I-Eq-Comparison
and NCT03923829 172 175 B-And
radiographic NCT03923829 176 188 B-Procedure
bone NCT03923829 189 193 B-Observation
loss NCT03923829 194 198 I-Observation
15 NCT03923829 199 201 B-Eq-Comparison
% NCT03923829 202 203 I-Eq-Comparison
Extending NCT03923829 204 213 B-Modifier
to NCT03923829 214 216 I-Modifier
mid NCT03923829 217 220 I-Modifier
- NCT03923829 221 222 I-Modifier
third NCT03923829 223 228 I-Modifier
of NCT03923829 229 231 I-Modifier
root NCT03923829 232 236 I-Modifier
and NCT03923829 237 240 I-Modifier
beyond NCT03923829 241 247 I-Modifier
. NCT03923829 248 249 O

- NCT03923829 253 254 O
Probing NCT03923829 256 263 B-Observation
depth NCT03923829 264 269 I-Observation
from NCT03923829 270 274 O
≤ NCT03923829 275 276 B-Eq-Comparison
5 NCT03923829 277 278 I-Eq-Comparison
mm NCT03923829 279 281 I-Eq-Comparison
to NCT03923829 282 284 I-Eq-Comparison
≥ NCT03923829 285 286 I-Eq-Comparison
6 NCT03923829 287 288 I-Eq-Comparison
mm NCT03923829 289 291 I-Eq-Comparison

Exclusion NCT03923829 292 301 O
Criteria NCT03923829 302 310 O
: NCT03923829 311 312 O

- NCT03923829 316 317 O
Any NCT03923829 319 322 O
periodontal NCT03923829 323 334 B-Procedure
or NCT03923829 335 337 B-Or
Antibiotic NCT03923829 338 348 B-Drug
treatment NCT03923829 349 358 B-Procedure
during NCT03923829 359 365 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03923829 366 369 O
last NCT03923829 370 374 B-Eq-Comparison
six NCT03923829 375 378 I-Eq-Comparison
months NCT03923829 379 385 I-Eq-Comparison
. NCT03923829 386 387 O

- NCT03923829 391 392 O
Receiving NCT03923829 394 403 B-Eq-Comparison
trace NCT03923829 404 409 B-Drug
element NCT03923829 410 417 I-Drug
supplements NCT03923829 418 429 I-Drug
in NCT03923829 430 432 O
the NCT03923829 433 436 O
previous NCT03923829 437 445 B-Eq-Comparison
three NCT03923829 446 451 I-Eq-Comparison
months NCT03923829 452 458 I-Eq-Comparison

- NCT03923829 461 462 O
Pregnant NCT03923829 464 472 B-Condition
or NCT03923829 473 475 B-Or
lactating NCT03923829 476 485 B-Condition
females NCT03923829 486 493 O

- NCT03923829 496 497 O
Gastric NCT03923829 499 506 B-Modifier
or NCT03923829 507 509 B-Or
diuretic NCT03923829 510 518 B-Modifier
treatment NCT03923829 519 528 B-Procedure

- NCT03923829 531 532 O
Acute NCT03923829 534 539 O
renal NCT03923829 540 545 B-Condition
failure NCT03923829 546 553 I-Condition

- NCT03923829 556 557 O
smoking NCT03923829 559 566 B-Condition

Inclusion NCT03920475 0 9 O
Criteria NCT03920475 10 18 O
: NCT03920475 19 20 O

- NCT03920475 24 25 O
Patients NCT03920475 27 35 O
with NCT03920475 36 40 O
uni NCT03920475 41 44 B-Modifier
- NCT03920475 45 46 O
or NCT03920475 47 49 B-Or
bipolar NCT03920475 50 57 B-Modifier
depression NCT03920475 58 68 B-Condition
, NCT03920475 69 70 O
diagnosed NCT03920475 71 80 O
according NCT03920475 81 90 O
to NCT03920475 91 93 O
the NCT03920475 94 97 O
criteria NCT03920475 98 106 O
of NCT03920475 107 109 O
the NCT03920475 110 113 O
DSM NCT03920475 114 117 O
- NCT03920475 118 119 O
IV NCT03920475 120 122 O
via NCT03920475 123 126 O
MINI NCT03920475 127 131 O
6.0 NCT03920475 132 135 O
diagnostic NCT03920475 136 146 O
tool NCT03920475 147 151 O
. NCT03920475 152 153 O

- NCT03920475 157 158 O
At NCT03920475 160 162 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03920475 163 166 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03920475 167 171 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03920475 172 174 O
inclusion NCT03920475 175 184 O
in NCT03920475 185 187 O
the NCT03920475 188 191 O
study NCT03920475 192 197 B-Study
, NCT03920475 198 199 O
the NCT03920475 200 203 O
symptoms NCT03920475 204 212 O
must NCT03920475 213 217 O
meet NCT03920475 218 222 O
at NCT03920475 223 225 O
least NCT03920475 226 231 O
the NCT03920475 232 235 O
requirements NCT03920475 236 248 O
of NCT03920475 249 251 O
a NCT03920475 252 253 O
moderately NCT03920475 254 264 O
severe NCT03920475 265 271 O
depression NCT03920475 272 282 B-Condition
, NCT03920475 283 284 O
defined NCT03920475 285 292 O
by NCT03920475 293 295 O
a NCT03920475 296 297 O
minimum NCT03920475 298 305 O
score NCT03920475 306 311 O
of NCT03920475 312 314 O
≥ NCT03920475 315 316 B-Eq-Comparison
22 NCT03920475 317 319 I-Eq-Comparison
on NCT03920475 320 322 O
the NCT03920475 323 326 O
Montgomery NCT03920475 327 337 B-Observation
- NCT03920475 338 339 I-Observation
Åsberg NCT03920475 340 346 I-Observation
Depression NCT03920475 347 357 I-Observation
Scale NCT03920475 358 363 I-Observation
. NCT03920475 364 365 O

Exclusion NCT03920475 367 376 O
Criteria NCT03920475 377 385 O
: NCT03920475 386 387 O

- NCT03920475 391 392 O
Patients NCT03920475 394 402 O
with NCT03920475 403 407 O
severe NCT03920475 408 414 O
somatic NCT03920475 415 422 B-Modifier
, NCT03920475 423 424 O
rheumatic NCT03920475 425 434 B-Modifier
, NCT03920475 435 436 O
endocrine NCT03920475 437 446 B-Modifier
or NCT03920475 447 449 B-Or
neurological NCT03920475 450 462 B-Modifier
comorbidities NCT03920475 463 476 B-Condition
. NCT03920475 476 477 O
This NCT03920475 479 483 O
includes NCT03920475 484 492 O
in NCT03920475 493 495 O
particular NCT03920475 496 506 O
neurological NCT03920475 507 519 B-Condition
disorders NCT03920475 520 529 I-Condition
associated NCT03920475 530 540 O
with NCT03920475 541 545 O
cognitive NCT03920475 546 555 B-Condition
disorder NCT03920475 556 564 I-Condition
, NCT03920475 565 566 O
severe NCT03920475 567 573 O
liver NCT03920475 574 579 B-Modifier
, NCT03920475 580 581 O
kidney NCT03920475 582 588 B-Modifier
and NCT03920475 589 592 B-Or
cardiac NCT03920475 593 600 B-Modifier
diseases NCT03920475 601 609 B-Condition
. NCT03920475 610 611 O

- NCT03920475 615 616 O
Patients NCT03920475 618 626 O
, NCT03920475 627 628 O
who NCT03920475 629 632 O
are NCT03920475 633 636 O
being NCT03920475 637 642 B-Eq-Comparison
treated NCT03920475 643 650 I-Eq-Comparison
permanently NCT03920475 651 662 O
with NCT03920475 663 667 O
anti NCT03920475 668 672 B-Drug
- NCT03920475 673 674 I-Drug
inflammatory NCT03920475 675 687 I-Drug
or NCT03920475 688 690 B-Or
immunosuppressive NCT03920475 691 708 B-Drug
drugs NCT03920475 709 714 I-Drug
( NCT03920475 715 716 O
e. NCT03920475 717 719 O
g. NCT03920475 720 722 O
corticosteroids NCT03920475 724 739 B-Drug
or NCT03920475 740 742 O
alpha NCT03920475 743 748 B-Modifier
/ NCT03920475 749 750 B-Or
beta NCT03920475 751 755 B-Modifier
- NCT03920475 756 757 O
a NCT03920475 758 759 B-Drug
( NCT03920475 760 761 I-Drug
nta NCT03920475 762 765 I-Drug
) NCT03920475 766 767 I-Drug
gonists NCT03920475 768 775 I-Drug
, NCT03920475 776 777 O
immuno NCT03920475 778 784 B-Drug
suppressant NCT03920475 785 796 I-Drug
drugs NCT03920475 797 802 I-Drug
) NCT03920475 803 804 O
. NCT03920475 806 807 O

- NCT03920475 811 812 O
Patients NCT03920475 814 822 O
with NCT03920475 823 827 O
severe NCT03920475 828 834 O
psychiatric NCT03920475 835 846 B-Condition
disorders NCT03920475 847 856 I-Condition
( NCT03920475 857 858 O
Axis NCT03920475 859 863 B-Eq-Comparison
I NCT03920475 864 865 I-Eq-Comparison
) NCT03920475 866 867 O
such NCT03920475 868 872 O
as NCT03920475 873 875 O
schizophrenia NCT03920475 876 889 B-Condition
, NCT03920475 890 891 O
dementia NCT03920475 892 900 B-Condition
, NCT03920475 901 902 O
ADHD NCT03920475 903 907 B-Condition
, NCT03920475 908 909 O
obsessive NCT03920475 910 919 B-Condition
- NCT03920475 920 921 I-Condition
compulsive NCT03920475 922 932 I-Condition
disorder NCT03920475 933 941 I-Condition
, NCT03920475 942 943 O
current NCT03920475 944 951 B-Eq-Comparison
alcohol NCT03920475 952 959 B-Modifier
, NCT03920475 960 961 O
drugs NCT03920475 962 967 B-Modifier
or NCT03920475 968 970 B-Or
drug NCT03920475 971 975 B-Modifier
addiction NCT03920475 976 985 B-Condition
. NCT03920475 986 987 O

- NCT03920475 991 992 O
Patients NCT03920475 994 1002 O
who NCT03920475 1003 1006 O
have NCT03920475 1007 1011 O
already NCT03920475 1012 1019 B-Eq-Comparison
been NCT03920475 1020 1024 O
treated NCT03920475 1025 1032 B-Procedure
unsuccessfully NCT03920475 1033 1047 O
with NCT03920475 1048 1052 O
sertraline NCT03920475 1053 1063 B-Drug
and NCT03920475 1064 1067 B-Or
all NCT03920475 1068 1071 O
alternate NCT03920475 1072 1081 B-Drug
medications NCT03920475 1082 1093 I-Drug
allowed NCT03920475 1094 1101 O
in NCT03920475 1102 1104 O
the NCT03920475 1105 1108 O
study NCT03920475 1109 1114 B-Study
. NCT03920475 1115 1116 O

- NCT03920475 1120 1121 O
Pregnant NCT03920475 1123 1131 B-Condition
or NCT03920475 1132 1134 B-Or
lactating NCT03920475 1135 1144 B-Condition
( NCT03920475 1145 1146 O
breast NCT03920475 1147 1153 B-Condition
feeding NCT03920475 1154 1161 I-Condition
) NCT03920475 1162 1163 O
women NCT03920475 1164 1169 O
. NCT03920475 1169 1170 O

Inclusion NCT03925519 0 9 O
Criteria NCT03925519 10 18 O
: NCT03925519 19 20 O

- NCT03925519 24 25 O
patients NCT03925519 27 35 O
with NCT03925519 36 40 O
type NCT03925519 41 45 B-Condition
2 NCT03925519 46 47 I-Condition
diabetes NCT03925519 48 56 I-Condition
for NCT03925519 57 60 O
more NCT03925519 61 65 B-Eq-Comparison
than NCT03925519 66 70 I-Eq-Comparison
5 NCT03925519 71 72 I-Eq-Comparison
years NCT03925519 73 78 I-Eq-Comparison
. NCT03925519 79 80 O

- NCT03925519 84 85 O
Patients NCT03925519 87 95 O
who NCT03925519 96 99 O
were NCT03925519 100 104 O
diagnosed NCT03925519 105 114 O
according NCT03925519 115 124 O
to NCT03925519 125 127 O
the NCT03925519 128 131 O
criteria NCT03925519 132 140 O
of NCT03925519 141 143 O
the NCT03925519 144 147 O
American NCT03925519 148 156 O
diabetes NCT03925519 157 165 O
association NCT03925519 166 177 O
. NCT03925519 178 179 O

- NCT03925519 183 184 O
Not NCT03925519 186 189 B-Negation
receiving NCT03925519 190 199 B-Eq-Comparison
any NCT03925519 200 203 O
drugs NCT03925519 204 209 B-Drug
affecting NCT03925519 210 219 O
the NCT03925519 220 223 O
data NCT03925519 224 228 O
obtained NCT03925519 229 237 O

- NCT03925519 240 241 O
had NCT03925519 243 246 O
Normal NCT03925519 247 253 O
daily NCT03925519 254 259 B-Eq-Comparison
diets NCT03925519 260 265 B-Observation

- NCT03925519 268 269 O
Not NCT03925519 271 274 B-Negation
participating NCT03925519 275 288 O
in NCT03925519 289 291 O
any NCT03925519 292 295 O
other NCT03925519 296 301 B-Other
exercise NCT03925519 302 310 B-Procedure
programs NCT03925519 311 319 I-Procedure

- NCT03925519 322 323 O
Without NCT03925519 325 332 B-Negation
any NCT03925519 333 336 O
musculoskeletal NCT03925519 337 352 B-Condition
disorders NCT03925519 353 362 I-Condition
affecting NCT03925519 363 372 O
an NCT03925519 373 375 O
exercise NCT03925519 376 384 B-Procedure
program NCT03925519 385 392 I-Procedure

Exclusion NCT03925519 393 402 O
Criteria NCT03925519 403 411 O
: NCT03925519 412 413 O

- NCT03925519 417 418 O
Exclusion NCT03925519 420 429 O
criteria NCT03925519 430 438 O
included NCT03925519 439 447 O
anemia NCT03925519 448 454 B-Condition
, NCT03925519 455 456 O
overt NCT03925519 457 462 O
complications NCT03925519 463 476 B-Condition
of NCT03925519 477 479 O
diabetes NCT03925519 480 488 B-Condition
like NCT03925519 489 493 O
nephropathy NCT03925519 494 505 B-Condition
, NCT03925519 506 507 O
neuropathy NCT03925519 508 518 B-Condition
, NCT03925519 519 520 O
retinopathy NCT03925519 521 532 B-Condition
, NCT03925519 533 534 O
obvious NCT03925519 535 542 O
ischemic NCT03925519 543 551 B-Condition
heart NCT03925519 552 557 I-Condition
disease NCT03925519 558 565 I-Condition
( NCT03925519 566 567 O
angina NCT03925519 568 574 B-Condition
, NCT03925519 575 576 O
myocardial NCT03925519 577 587 B-Condition
infarction NCT03925519 588 598 I-Condition
, NCT03925519 599 600 O
and NCT03925519 601 604 O
lead NCT03925519 605 609 B-Procedure
electrocardiogram NCT03925519 610 627 I-Procedure
abnormalities NCT03925519 628 641 O
) NCT03925519 642 643 O
, NCT03925519 645 646 O
HCV NCT03925519 647 650 B-Condition
, NCT03925519 651 652 O
HBV NCT03925519 653 656 B-Condition
, NCT03925519 657 658 O
chronic NCT03925519 659 666 B-Modifier
liver NCT03925519 667 672 I-Modifier
and NCT03925519 673 676 B-Or
kidney NCT03925519 677 683 B-Modifier
diseases NCT03925519 684 692 B-Condition
, NCT03925519 693 694 O
hypothyroidism NCT03925519 695 709 B-Condition
, NCT03925519 710 711 O
and NCT03925519 712 715 B-Or
drugs NCT03925519 716 721 B-Drug
( NCT03925519 722 723 O
diuretics NCT03925519 724 733 B-Drug
; NCT03925519 733 734 O
oral NCT03925519 735 739 B-Drug
contraceptives NCT03925519 740 754 I-Drug
) NCT03925519 755 756 O
. NCT03925519 757 758 O

Inclusion NCT03927326 0 9 O
Criteria NCT03927326 10 18 O
: NCT03927326 19 20 O

- NCT03927326 24 25 O
Patients NCT03927326 27 35 O
scheduled NCT03927326 36 45 B-Eq-Comparison
for NCT03927326 46 49 O
elective NCT03927326 50 58 O
laparoscopic NCT03927326 59 71 B-Procedure
colorectal NCT03927326 72 82 I-Procedure
surgery NCT03927326 83 90 I-Procedure
at NCT03927326 91 93 O
UWMC NCT03927326 94 98 O
requiring NCT03927326 99 108 B-Assertion___Assertion-Type-Value:hypothetical
inpatient NCT03927326 109 118 B-Encounter
stay NCT03927326 119 123 I-Encounter

Exclusion NCT03927326 124 133 O
Criteria NCT03927326 134 142 O
: NCT03927326 143 144 O

- NCT03927326 148 149 O
Patients NCT03927326 151 159 O
on NCT03927326 160 162 B-Eq-Comparison
chronic NCT03927326 163 170 B-Modifier
pain NCT03927326 171 175 B-Condition
mediations NCT03927326 176 186 B-Drug
equaling NCT03927326 187 195 B-Eq-Comparison
or NCT03927326 196 198 I-Eq-Comparison
exceeding NCT03927326 199 208 I-Eq-Comparison
> NCT03927326 209 210 I-Eq-Comparison
25 NCT03927326 211 213 I-Eq-Comparison
morphine NCT03927326 214 222 I-Eq-Comparison
daily NCT03927326 223 228 I-Eq-Comparison
equivalents NCT03927326 229 240 I-Eq-Comparison

- NCT03927326 243 244 O
Patients NCT03927326 246 254 O
allergic NCT03927326 255 263 B-Allergy
to NCT03927326 264 266 O
bupivacaine NCT03927326 267 278 B-Drug

- NCT03927326 281 282 O
Patients NCT03927326 284 292 O
with NCT03927326 293 297 O
ASA NCT03927326 298 301 B-Condition
status NCT03927326 302 308 O
IV NCT03927326 309 311 B-Eq-Comparison
, NCT03927326 312 313 I-Eq-Comparison
V NCT03927326 314 315 I-Eq-Comparison
, NCT03927326 316 317 I-Eq-Comparison
or NCT03927326 318 320 I-Eq-Comparison
VI NCT03927326 321 323 I-Eq-Comparison

- NCT03927326 326 327 O
Patients NCT03927326 329 337 O
unable NCT03927326 338 344 O
to NCT03927326 345 347 O
consent NCT03927326 348 355 O

- NCT03927326 358 359 O
Patients NCT03927326 361 369 O
that NCT03927326 370 374 O
are NCT03927326 375 378 O
pregnant NCT03927326 379 387 B-Condition

- NCT03927326 390 391 O
Patients NCT03927326 393 401 O
that NCT03927326 402 406 O
are NCT03927326 407 410 O
incarcerated NCT03927326 411 423 B-Observation

- NCT03927326 426 427 O
Patients NCT03927326 429 437 O
receiving NCT03927326 438 447 B-Eq-Comparison
procedures NCT03927326 448 458 B-Procedure
in NCT03927326 459 461 B-Exception
addition NCT03927326 462 470 I-Exception
to NCT03927326 471 473 I-Exception
laparoscopic NCT03927326 474 486 B-Procedure
colorectal NCT03927326 487 497 I-Procedure
procedure NCT03927326 498 507 I-Procedure

- NCT03927326 510 511 O
Patients NCT03927326 513 521 O
on NCT03927326 522 524 B-Eq-Comparison
systemic NCT03927326 525 533 B-Modifier
anticoagulation NCT03927326 534 549 B-Procedure
precluding NCT03927326 550 560 B-Negation
them NCT03927326 561 565 O
from NCT03927326 566 570 O
regional NCT03927326 571 579 B-Procedure
blocks NCT03927326 580 586 I-Procedure

Inclusion NCT03928015 0 9 O
Criteria NCT03928015 10 18 O
: NCT03928015 19 20 O

1 NCT03928015 24 25 O
. NCT03928015 25 26 O
Male NCT03928015 28 32 O
or NCT03928015 33 35 B-Or
female NCT03928015 36 42 O
, NCT03928015 43 44 O
18 NCT03928015 45 47 B-Eq-Comparison
years NCT03928015 48 53 I-Eq-Comparison
to NCT03928015 54 56 I-Eq-Comparison
65 NCT03928015 57 59 I-Eq-Comparison
years NCT03928015 60 65 I-Eq-Comparison
old NCT03928015 66 69 B-Age
( NCT03928015 70 71 O
inclusive NCT03928015 72 81 O
) NCT03928015 82 83 O

2 NCT03928015 87 88 O
. NCT03928015 88 89 O
Index NCT03928015 91 96 O
admission NCT03928015 97 106 B-Encounter
for NCT03928015 107 110 O
traumatic NCT03928015 111 120 B-Condition
injury NCT03928015 121 127 I-Condition

3 NCT03928015 130 131 O
. NCT03928015 131 132 O
High NCT03928015 134 138 O
initial NCT03928015 139 146 B-Eq-Comparison
morphine NCT03928015 147 155 B-Drug
equivalent NCT03928015 156 166 O
use NCT03928015 167 170 O
≥ NCT03928015 171 172 B-Eq-Comparison
90 NCT03928015 173 175 I-Eq-Comparison
mg NCT03928015 176 178 I-Eq-Comparison
in NCT03928015 179 181 O
the NCT03928015 182 185 O
first NCT03928015 186 191 B-Eq-Comparison
24 NCT03928015 192 194 I-Eq-Comparison
hours NCT03928015 195 200 I-Eq-Comparison
from NCT03928015 201 205 B-Temporal-Connection___Temporal-Connection-Type-Value:after
admission NCT03928015 206 215 B-Encounter

4 NCT03928015 218 219 O
. NCT03928015 219 220 O
Baseline NCT03928015 222 230 O
pain NCT03928015 231 235 B-Condition
assessed NCT03928015 236 244 O
at NCT03928015 245 247 O
screening NCT03928015 248 257 B-Procedure
of NCT03928015 258 260 O
≥ NCT03928015 261 262 B-Eq-Comparison
5 NCT03928015 263 264 I-Eq-Comparison
on NCT03928015 265 267 O
the NCT03928015 268 271 O
pain NCT03928015 272 276 B-Observation
numeric NCT03928015 277 284 I-Observation
rating NCT03928015 285 291 I-Observation
score NCT03928015 292 297 I-Observation
( NCT03928015 298 299 O
NRS NCT03928015 300 303 B-Observation
) NCT03928015 304 305 O

5 NCT03928015 309 310 O
. NCT03928015 310 311 O
Willing NCT03928015 313 320 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03928015 321 323 I-Assertion___Assertion-Type-Value:hypothetical
divulge NCT03928015 324 331 O
habitual NCT03928015 332 340 O
marijuana NCT03928015 341 350 B-Condition
usage NCT03928015 351 356 O
( NCT03928015 357 358 O
yes NCT03928015 359 362 O
or NCT03928015 363 365 O
no NCT03928015 366 368 O
. NCT03928015 368 369 O
Yes NCT03928015 371 374 O
, NCT03928015 375 376 O
habitual NCT03928015 377 385 O
/ NCT03928015 386 387 O
chronic NCT03928015 388 395 O
usage NCT03928015 396 401 O
; NCT03928015 401 402 O
no NCT03928015 403 405 O
, NCT03928015 406 407 O
recreational NCT03928015 408 420 O
, NCT03928015 421 422 O
former NCT03928015 423 429 O
, NCT03928015 430 431 O
or NCT03928015 432 434 O
never NCT03928015 435 440 O
usage NCT03928015 441 446 O
) NCT03928015 447 448 O

Exclusion NCT03928015 454 463 O
Criteria NCT03928015 464 472 O
: NCT03928015 473 474 O

1 NCT03928015 478 479 O
. NCT03928015 479 480 O
Patients NCT03928015 482 490 O
on NCT03928015 491 493 B-Eq-Comparison
a NCT03928015 494 495 O
pain NCT03928015 496 500 B-Procedure
management NCT03928015 501 511 I-Procedure
agreement NCT03928015 512 521 O

2 NCT03928015 524 525 O
. NCT03928015 525 526 O
Patients NCT03928015 528 536 O
who NCT03928015 537 540 O
are NCT03928015 541 544 O
nil NCT03928015 545 548 B-Procedure
per NCT03928015 549 552 I-Procedure
os NCT03928015 553 555 I-Procedure
( NCT03928015 556 557 O
NPO NCT03928015 558 561 B-Procedure
) NCT03928015 562 563 O
at NCT03928015 564 566 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928015 567 570 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03928015 571 575 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03928015 576 578 O
randomization NCT03928015 579 592 B-Study
or NCT03928015 593 595 B-Or
are NCT03928015 596 599 O
expected NCT03928015 600 608 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03928015 609 611 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03928015 612 614 O
NPO NCT03928015 615 618 B-Procedure
within NCT03928015 619 625 B-Eq-Comparison
the NCT03928015 626 629 I-Eq-Comparison
next NCT03928015 630 634 I-Eq-Comparison
48 NCT03928015 635 637 I-Eq-Comparison
hours NCT03928015 638 643 I-Eq-Comparison

3 NCT03928015 646 647 O
. NCT03928015 647 648 O
Patients NCT03928015 650 658 O
who NCT03928015 659 662 O
have NCT03928015 663 667 O
received NCT03928015 668 676 B-Eq-Comparison
or NCT03928015 677 679 B-Or
are NCT03928015 680 683 O
expected NCT03928015 684 692 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03928015 693 695 I-Assertion___Assertion-Type-Value:hypothetical
receive NCT03928015 696 703 O
neuraxial NCT03928015 704 713 B-Modifier
/ NCT03928015 714 715 B-Or
locoregional NCT03928015 716 728 B-Modifier
blocks NCT03928015 729 735 B-Drug
for NCT03928015 736 739 O
pain NCT03928015 740 744 B-Condition
within NCT03928015 745 751 B-Eq-Comparison
the NCT03928015 752 755 I-Eq-Comparison
next NCT03928015 756 760 I-Eq-Comparison
48 NCT03928015 761 763 I-Eq-Comparison
hours NCT03928015 764 769 I-Eq-Comparison

4 NCT03928015 772 773 O
. NCT03928015 773 774 O
Known NCT03928015 776 781 O
allergy NCT03928015 782 789 B-Allergy
or NCT03928015 790 792 B-Or
previous NCT03928015 793 801 B-Eq-Comparison
hypersensitivity NCT03928015 802 818 B-Condition
reaction NCT03928015 819 827 O
to NCT03928015 828 830 O
dronabinol NCT03928015 831 841 B-Drug
or NCT03928015 842 844 B-Or
sesame NCT03928015 845 851 B-Drug
oil NCT03928015 852 855 I-Drug

5 NCT03928015 858 859 O
. NCT03928015 859 860 O
Patients NCT03928015 862 870 O
prescribed NCT03928015 871 881 B-Eq-Comparison
dronabinol NCT03928015 882 892 B-Drug
between NCT03928015 893 900 B-Temporal-Connection___Temporal-Connection-Type-Value:after
arrival NCT03928015 901 908 B-Encounter
and NCT03928015 909 912 O
prior NCT03928015 913 918 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03928015 919 921 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03928015 922 931 B-Study
/ NCT03928015 932 933 B-Or
randomization NCT03928015 934 947 B-Study

6 NCT03928015 950 951 O
. NCT03928015 951 952 O
Pregnancy NCT03928015 954 963 B-Condition
or NCT03928015 964 966 B-Or
breast NCT03928015 967 973 B-Condition
feeding NCT03928015 974 981 I-Condition

7 NCT03928015 984 985 O
. NCT03928015 985 986 O
Incarceration NCT03928015 988 1001 B-Observation


Inclusion NCT03920449 0 9 O
Criteria NCT03920449 10 18 O
: NCT03920449 19 20 O

- NCT03920449 24 25 O
Chronic NCT03920449 27 34 B-Modifier
anal NCT03920449 35 39 B-Condition
fissure NCT03920449 40 47 I-Condition
lasting NCT03920449 48 55 O
more NCT03920449 56 60 B-Eq-Comparison
than NCT03920449 61 65 I-Eq-Comparison
6 NCT03920449 66 67 I-Eq-Comparison
weeks NCT03920449 68 73 I-Eq-Comparison

Exclusion NCT03920449 74 83 O
Criteria NCT03920449 84 92 O
: NCT03920449 93 94 O

- NCT03920449 98 99 O
Pregnant NCT03920449 101 109 B-Condition

- NCT03920449 112 113 O
cardiovascular NCT03920449 115 129 B-Condition
disease NCT03920449 130 137 I-Condition
or NCT03920449 138 140 B-Or
heart NCT03920449 141 146 B-Condition
failure NCT03920449 147 154 I-Condition

- NCT03920449 157 158 O
on NCT03920449 160 162 B-Eq-Comparison
antihypertensive NCT03920449 163 179 B-Drug
medications NCT03920449 180 191 I-Drug

- NCT03920449 194 195 O
recurrent NCT03920449 197 206 O
anal NCT03920449 207 211 B-Condition
fissure NCT03920449 212 219 I-Condition
after NCT03920449 220 225 B-Temporal-Connection___Temporal-Connection-Type-Value:after
previous NCT03920449 226 234 B-Eq-Comparison
sphincterotomy NCT03920449 235 249 B-Procedure

- NCT03920449 252 253 O
prior NCT03920449 255 260 B-Eq-Comparison
history NCT03920449 261 268 I-Eq-Comparison
of NCT03920449 269 271 O
anal NCT03920449 272 276 B-Modifier
surgery NCT03920449 277 284 B-Procedure

- NCT03920449 287 288 O
other NCT03920449 290 295 B-Other
benign NCT03920449 296 302 B-Modifier
anorectal NCT03920449 303 312 B-Condition
diseases NCT03920449 313 321 I-Condition

- NCT03920449 324 325 O
with NCT03920449 327 331 O
inflammatory NCT03920449 332 344 B-Condition
bowel NCT03920449 345 350 I-Condition
diseases NCT03920449 351 359 I-Condition

Inclusion NCT03923140 0 9 O
Criteria NCT03923140 10 18 O
: NCT03923140 19 20 O

- NCT03923140 24 25 O
All NCT03923140 27 30 O
patients NCT03923140 31 39 O
must NCT03923140 40 44 O
meet NCT03923140 45 49 O
the NCT03923140 50 53 O
following NCT03923140 54 63 O
diagnostic NCT03923140 64 74 O
criteria NCT03923140 75 83 O
of NCT03923140 84 86 O
CAPS NCT03923140 87 91 B-Condition
and NCT03923140 92 95 B-And
have NCT03923140 96 100 O
pathogenic NCT03923140 101 111 B-Condition
mutation NCT03923140 112 120 I-Condition
( NCT03923140 121 122 I-Condition
s NCT03923140 123 124 I-Condition
) NCT03923140 125 126 I-Condition
in NCT03923140 127 129 O
NLRP3 NCT03923140 130 135 B-Modifier
gene NCT03923140 136 140 I-Modifier
. NCT03923140 141 142 O

1 NCT03923140 151 152 O
. NCT03923140 152 153 O
Raised NCT03923140 155 161 B-Condition
inflammatory NCT03923140 162 174 I-Condition
markers NCT03923140 175 182 I-Condition
( NCT03923140 183 184 O
CRP NCT03923140 185 188 B-Condition
/ NCT03923140 189 190 B-Or
SAA NCT03923140 191 194 B-Condition
) NCT03923140 195 196 O
( NCT03923140 197 198 O
mandatory NCT03923140 199 208 O
criteria NCT03923140 209 217 O
) NCT03923140 218 219 O

2 NCT03923140 228 229 O
. NCT03923140 229 230 O
≥ NCT03923140 232 233 B-Eq-Comparison
2 NCT03923140 234 235 I-Eq-Comparison
of NCT03923140 236 238 O
6 NCT03923140 239 240 O
CAPS NCT03923140 241 245 B-Condition
typical NCT03923140 246 253 O
signs NCT03923140 254 259 O
/ NCT03923140 260 261 O
symptoms NCT03923140 262 270 B-Assertion___Assertion-Type-Value:possible
: NCT03923140 271 272 O

1 NCT03923140 286 287 O
. NCT03923140 287 288 O
Urticaria NCT03923140 290 299 B-Condition
- NCT03923140 300 301 I-Condition
like NCT03923140 302 306 I-Condition
rash NCT03923140 307 311 I-Condition
; NCT03923140 311 312 O

2 NCT03923140 325 326 O
. NCT03923140 326 327 O
Cold NCT03923140 329 333 B-Condition
/ NCT03923140 334 335 B-Or
stress NCT03923140 336 342 B-Condition
triggered NCT03923140 343 352 O
episodes NCT03923140 353 361 O
; NCT03923140 361 362 O

3 NCT03923140 375 376 O
. NCT03923140 376 377 O
Sensorineural NCT03923140 379 392 B-Condition
hearing NCT03923140 393 400 I-Condition
loss NCT03923140 401 405 I-Condition
; NCT03923140 405 406 O

4 NCT03923140 419 420 O
. NCT03923140 420 421 O
Musculoskeletal NCT03923140 423 438 B-Condition
symptoms NCT03923140 439 447 B-Assertion___Assertion-Type-Value:possible
( NCT03923140 448 449 O
arthralgia NCT03923140 450 460 B-Condition
/ NCT03923140 461 462 B-Or
arthritis NCT03923140 463 472 B-Condition
/ NCT03923140 473 474 B-Or
myalgia NCT03923140 475 482 B-Condition
) NCT03923140 483 484 O
; NCT03923140 485 486 O

5 NCT03923140 499 500 O
. NCT03923140 500 501 O
Chronic NCT03923140 503 510 B-Modifier
aseptic NCT03923140 511 518 B-Condition
meningitis NCT03923140 519 529 I-Condition
; NCT03923140 529 530 O

6 NCT03923140 543 544 O
. NCT03923140 544 545 O
Skeletal NCT03923140 547 555 B-Modifier
abnormalities NCT03923140 556 569 B-Condition
( NCT03923140 570 571 O
epiphyseal NCT03923140 572 582 B-Condition
overgrowth NCT03923140 583 593 I-Condition
/ NCT03923140 594 595 B-Or
frontal NCT03923140 596 603 B-Condition
bossing NCT03923140 604 611 I-Condition
) NCT03923140 612 613 O
. NCT03923140 615 616 O

Exclusion NCT03923140 618 627 O
Criteria NCT03923140 628 636 O
: NCT03923140 637 638 O

- NCT03923140 642 643 O
Patients NCT03923140 645 653 O
will NCT03923140 654 658 O
not NCT03923140 659 662 O
be NCT03923140 663 665 O
included NCT03923140 666 674 O
if NCT03923140 675 677 O
meets NCT03923140 678 683 O
any NCT03923140 684 687 O
of NCT03923140 688 690 O
the NCT03923140 691 694 O
following NCT03923140 695 704 O
criteria NCT03923140 705 713 O
: NCT03923140 714 715 O

1 NCT03923140 724 725 O
. NCT03923140 725 726 O
Being NCT03923140 728 733 B-Eq-Comparison
treated NCT03923140 734 741 B-Procedure
with NCT03923140 742 746 O
IL NCT03923140 747 749 B-Drug
- NCT03923140 750 751 I-Drug
1 NCT03923140 752 753 I-Drug
inhibitor NCT03923140 754 763 I-Drug
, NCT03923140 764 765 O
other NCT03923140 766 771 B-Other
biological NCT03923140 772 782 B-Drug
agents NCT03923140 783 789 I-Drug
and NCT03923140 790 793 B-Or
immunosuppressants NCT03923140 794 812 B-Drug

2 NCT03923140 820 821 O
. NCT03923140 821 822 O
Pregnant NCT03923140 824 832 B-Condition
and NCT03923140 833 836 B-Or
lactating NCT03923140 837 846 B-Condition
women NCT03923140 847 852 O

3 NCT03923140 860 861 O
. NCT03923140 861 862 O
Serious NCT03923140 864 871 O
organ NCT03923140 872 877 B-Condition
function NCT03923140 878 886 I-Condition
failure NCT03923140 887 894 I-Condition
, NCT03923140 895 896 O
expected NCT03923140 897 905 B-Observation
life NCT03923140 906 910 I-Observation
time NCT03923140 911 915 I-Observation
less NCT03923140 916 920 B-Eq-Comparison
than NCT03923140 921 925 I-Eq-Comparison
6 NCT03923140 926 927 I-Eq-Comparison
months NCT03923140 928 934 I-Eq-Comparison

Inclusion NCT03929848 0 9 O
Criteria NCT03929848 10 18 O
: NCT03929848 19 20 O

- NCT03929848 24 25 O
patients NCT03929848 27 35 O
who NCT03929848 36 39 O
is NCT03929848 40 42 O
scheduled NCT03929848 43 52 B-Eq-Comparison
for NCT03929848 53 56 O
laryngomicrosurgery NCT03929848 57 76 B-Procedure
due NCT03929848 77 80 O
to NCT03929848 81 83 O
simple NCT03929848 84 90 B-Modifier
vocal NCT03929848 91 96 I-Modifier
cord NCT03929848 97 101 I-Modifier
cyst NCT03929848 102 106 B-Condition
or NCT03929848 107 109 B-Or
nodule NCT03929848 110 116 B-Condition

Exclusion NCT03929848 117 126 O
Criteria NCT03929848 127 135 O
: NCT03929848 136 137 O

- NCT03929848 141 142 O
Who NCT03929848 144 147 O
does NCT03929848 148 152 B-Negation
n't NCT03929848 152 155 I-Negation
agree NCT03929848 156 161 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929848 162 164 I-Assertion___Assertion-Type-Value:hypothetical
enroll NCT03929848 165 171 B-Study

- NCT03929848 174 175 O
do NCT03929848 177 179 O
not NCT03929848 180 183 B-Negation
use NCT03929848 184 187 O
a NCT03929848 188 189 O
reinforced NCT03929848 190 200 B-Procedure
tracheal NCT03929848 201 209 I-Procedure
tube NCT03929848 210 214 I-Procedure
of NCT03929848 215 217 O
internal NCT03929848 218 226 B-Observation
diameter NCT03929848 227 235 I-Observation
of NCT03929848 236 238 O
5.5 NCT03929848 239 242 B-Eq-Comparison
mm NCT03929848 243 245 I-Eq-Comparison
for NCT03929848 246 249 O
male NCT03929848 250 254 O
patient NCT03929848 255 262 O

- NCT03929848 265 266 O
do NCT03929848 268 270 O
not NCT03929848 271 274 B-Negation
use NCT03929848 275 278 O
a NCT03929848 279 280 O
reinforced NCT03929848 281 291 B-Procedure
tracheal NCT03929848 292 300 I-Procedure
tube NCT03929848 301 305 I-Procedure
of NCT03929848 306 308 O
internal NCT03929848 309 317 B-Observation
diameter NCT03929848 318 326 I-Observation
of NCT03929848 327 329 O
5.0 NCT03929848 330 333 B-Eq-Comparison
mm NCT03929848 334 336 I-Eq-Comparison
for NCT03929848 337 340 O
female NCT03929848 341 347 O
patient NCT03929848 348 355 O

Inclusion NCT03920878 0 9 O
Criteria NCT03920878 10 18 O
: NCT03920878 19 20 O

- NCT03920878 24 25 O
Adults NCT03920878 27 33 O
over NCT03920878 34 38 B-Eq-Comparison
age NCT03920878 39 42 I-Eq-Comparison
18 NCT03920878 43 45 I-Eq-Comparison
with NCT03920878 46 50 B-And
diabetes NCT03920878 51 59 B-Condition
mellitus NCT03920878 60 68 I-Condition
, NCT03920878 69 70 O
diabetic NCT03920878 71 79 B-Condition
macular NCT03920878 80 87 I-Condition
edema NCT03920878 88 93 I-Condition
and NCT03920878 94 97 B-And
visually NCT03920878 98 106 O
significant NCT03920878 107 118 O
cataracts NCT03920878 119 128 B-Condition
planning NCT03920878 129 137 B-Eq-Comparison
to NCT03920878 138 140 O
undergo NCT03920878 141 148 O
cataract NCT03920878 149 157 B-Procedure
surgery NCT03920878 158 165 I-Procedure

Exclusion NCT03920878 166 175 O
Criteria NCT03920878 176 184 O
: NCT03920878 185 186 O

- NCT03920878 190 191 O
Patients NCT03920878 193 201 O
who NCT03920878 202 205 O
have NCT03920878 206 210 O
undergone NCT03920878 211 220 B-Eq-Comparison
panretinal NCT03920878 221 231 B-Procedure
photocoagulation NCT03920878 232 248 I-Procedure
( NCT03920878 249 250 O
PRP NCT03920878 251 254 B-Procedure
) NCT03920878 255 256 O
in NCT03920878 257 259 O
prior NCT03920878 260 265 B-Eq-Comparison
4 NCT03920878 266 267 I-Eq-Comparison
months NCT03920878 268 274 I-Eq-Comparison
or NCT03920878 275 277 B-Or
an NCT03920878 278 280 O
ocular NCT03920878 281 287 B-Condition
condition NCT03920878 288 297 I-Condition
( NCT03920878 298 299 O
other NCT03920878 300 305 B-Exception
than NCT03920878 306 310 I-Exception
cataract NCT03920878 311 319 B-Condition
and NCT03920878 320 323 B-Or
DME NCT03920878 324 327 B-Condition
) NCT03920878 328 329 O
that NCT03920878 330 334 O
might NCT03920878 335 340 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03920878 341 347 O
visual NCT03920878 348 354 B-Condition
acuity NCT03920878 355 361 I-Condition
during NCT03920878 362 368 B-Temporal-Connection___Temporal-Connection-Type-Value:during
course NCT03920878 369 375 O
of NCT03920878 376 378 O
study NCT03920878 379 384 B-Study
. NCT03920878 385 386 O

- NCT03920878 390 391 O
Patients NCT03920878 393 401 O
with NCT03920878 402 406 O
history NCT03920878 407 414 B-Eq-Comparison
of NCT03920878 415 417 O
vitrectomy NCT03920878 418 428 B-Condition
. NCT03920878 429 430 O

- NCT03920878 434 435 O
Patients NCT03920878 437 445 O
with NCT03920878 446 450 O
neovascular NCT03920878 451 462 B-Condition
glaucoma NCT03920878 463 471 I-Condition
. NCT03920878 471 472 O

Inclusion NCT03929874 0 9 O
Criteria NCT03929874 10 18 O
: NCT03929874 19 20 O

- NCT03929874 24 25 O
Patients NCT03929874 27 35 O
under NCT03929874 36 41 B-Eq-Comparison
40 NCT03929874 42 44 I-Eq-Comparison
or NCT03929874 45 47 B-Or
over NCT03929874 48 52 B-Eq-Comparison
60 NCT03929874 53 55 I-Eq-Comparison
years NCT03929874 56 61 I-Eq-Comparison
of NCT03929874 62 64 O
age NCT03929874 65 68 B-Age
who NCT03929874 69 72 B-And
require NCT03929874 73 80 B-Assertion___Assertion-Type-Value:hypothetical
spinal NCT03929874 81 87 B-Procedure
anesthesia NCT03929874 88 98 I-Procedure
for NCT03929874 99 102 O
orthopedic NCT03929874 103 113 B-Procedure
surgery NCT03929874 114 121 I-Procedure
, NCT03929874 122 123 O

- NCT03929874 127 128 O
with NCT03929874 130 134 O
ASA NCT03929874 135 138 B-Condition
physical NCT03929874 139 147 O
status NCT03929874 148 154 O
classification NCT03929874 155 169 O
system NCT03929874 170 176 O
I NCT03929874 177 178 B-Eq-Comparison
, NCT03929874 179 180 I-Eq-Comparison
II NCT03929874 181 183 I-Eq-Comparison
, NCT03929874 184 185 I-Eq-Comparison
III NCT03929874 186 189 I-Eq-Comparison

Exclusion NCT03929874 190 199 O
Criteria NCT03929874 200 208 O
: NCT03929874 209 210 O

- NCT03929874 214 215 O
Patients NCT03929874 217 225 O
with NCT03929874 226 230 O
contraindication NCT03929874 231 247 B-Contraindication
to NCT03929874 248 250 O
spinal NCT03929874 251 257 B-Procedure
anesthesia NCT03929874 258 268 I-Procedure
( NCT03929874 269 270 O
coagulopathy NCT03929874 271 283 B-Condition
, NCT03929874 284 285 O
local NCT03929874 286 291 B-Modifier
infection NCT03929874 292 301 B-Condition
, NCT03929874 302 303 O
allergy NCT03929874 304 311 B-Allergy
to NCT03929874 312 314 O
local NCT03929874 315 320 B-Procedure
anesthetic NCT03929874 321 331 I-Procedure
) NCT03929874 332 333 O

- NCT03929874 337 338 O
Patients NCT03929874 340 348 O
with NCT03929874 349 353 O
communication NCT03929874 354 367 B-Condition
difficulties NCT03929874 368 380 I-Condition

- NCT03929874 383 384 O
Patient NCT03929874 386 393 O
who NCT03929874 394 397 O
can NCT03929874 398 401 O
not NCT03929874 402 405 B-Negation
take NCT03929874 406 410 O
a NCT03929874 411 412 O
sitting NCT03929874 413 420 B-Modifier
or NCT03929874 421 423 B-Or
lateral NCT03929874 424 431 B-Modifier
decubitus NCT03929874 432 441 I-Modifier
position NCT03929874 442 450 B-Condition
( NCT03929874 451 452 O
fracture NCT03929874 453 461 B-Condition
) NCT03929874 462 463 O

- NCT03929874 467 468 O
Patients NCT03929874 470 478 O
with NCT03929874 479 483 O
a NCT03929874 484 485 O
history NCT03929874 486 493 B-Eq-Comparison
of NCT03929874 494 496 O
spinal NCT03929874 497 503 B-Procedure
surgery NCT03929874 504 511 I-Procedure

- NCT03929874 514 515 O
Patient NCT03929874 517 524 O
with NCT03929874 525 529 O
anatomical NCT03929874 530 540 B-Condition
abnormality NCT03929874 541 552 I-Condition
of NCT03929874 553 555 O
the NCT03929874 556 559 O
spine NCT03929874 560 565 B-Modifier

Inclusion NCT03927859 0 9 O
Criteria NCT03927859 10 18 O
: NCT03927859 19 20 O

Only NCT03927859 22 26 O
patients NCT03927859 27 35 O
diagnosed NCT03927859 36 45 O
with NCT03927859 46 50 O
Type NCT03927859 51 55 B-Modifier
I NCT03927859 56 57 I-Modifier
or NCT03927859 58 60 B-Or
Type NCT03927859 61 65 B-Modifier
II NCT03927859 66 68 I-Modifier
Diabetes NCT03927859 69 77 B-Condition
with NCT03927859 78 82 B-And
no NCT03927859 83 85 B-Negation
evidence NCT03927859 86 94 O
in NCT03927859 95 97 O
their NCT03927859 98 103 O
medical NCT03927859 104 111 O
records NCT03927859 112 119 O
of NCT03927859 120 122 O
a NCT03927859 123 124 O
screening NCT03927859 125 134 B-Procedure
within NCT03927859 135 141 B-Eq-Comparison
the NCT03927859 142 145 I-Eq-Comparison
last NCT03927859 146 150 I-Eq-Comparison
2 NCT03927859 151 152 I-Eq-Comparison
years NCT03927859 153 158 I-Eq-Comparison
will NCT03927859 159 163 O
be NCT03927859 164 166 O
included NCT03927859 167 175 O
in NCT03927859 176 178 O
the NCT03927859 179 182 O
study NCT03927859 183 188 B-Study
and NCT03927859 189 192 O
only NCT03927859 193 197 O
individuals NCT03927859 198 209 O
18 NCT03927859 210 212 B-Eq-Comparison
years NCT03927859 213 218 I-Eq-Comparison
of NCT03927859 219 221 I-Eq-Comparison
age NCT03927859 222 225 I-Eq-Comparison
or NCT03927859 226 228 I-Eq-Comparison
older NCT03927859 229 234 I-Eq-Comparison
will NCT03927859 235 239 O
be NCT03927859 240 242 O
included NCT03927859 243 251 O
. NCT03927859 252 253 O

Exclusion NCT03927859 255 264 O
Criteria NCT03927859 265 273 O
: NCT03927859 274 275 O

Patients NCT03927859 277 285 O
screened NCT03927859 286 294 B-Procedure
within NCT03927859 295 301 B-Eq-Comparison
the NCT03927859 302 305 I-Eq-Comparison
last NCT03927859 306 310 I-Eq-Comparison
year NCT03927859 311 315 I-Eq-Comparison
. NCT03927859 315 316 O
In NCT03927859 318 320 O
addition NCT03927859 321 329 O
, NCT03927859 330 331 O
individuals NCT03927859 332 343 O
who NCT03927859 344 347 O
can NCT03927859 348 351 B-Negation
not NCT03927859 351 354 I-Negation
speak NCT03927859 355 360 O
English NCT03927859 361 368 O
will NCT03927859 369 373 O
be NCT03927859 374 376 O
excluded NCT03927859 377 385 B-Negation
from NCT03927859 386 390 O
the NCT03927859 391 394 O
study NCT03927859 395 400 B-Study
to NCT03927859 401 403 O
minimize NCT03927859 404 412 O
additional NCT03927859 413 423 O
workload NCT03927859 424 432 O
placed NCT03927859 433 439 O
on NCT03927859 440 442 O
administrative NCT03927859 443 457 O
staff NCT03927859 458 463 O
. NCT03927859 464 465 O


Inclusion NCT03929653 0 9 O
Criteria NCT03929653 10 18 O
: NCT03929653 19 20 O

1 NCT03929653 24 25 O
. NCT03929653 25 26 O
Is NCT03929653 28 30 O
equal NCT03929653 31 36 B-Eq-Comparison
to NCT03929653 37 39 I-Eq-Comparison
or NCT03929653 40 42 I-Eq-Comparison
greater NCT03929653 43 50 I-Eq-Comparison
than NCT03929653 51 55 I-Eq-Comparison
18 NCT03929653 56 58 I-Eq-Comparison
years NCT03929653 59 64 I-Eq-Comparison
of NCT03929653 65 67 O
age NCT03929653 68 71 B-Age
. NCT03929653 72 73 O

2 NCT03929653 77 78 O
. NCT03929653 78 79 O
Histologic NCT03929653 81 91 B-Procedure
or NCT03929653 92 94 B-Or
cytologic NCT03929653 95 104 B-Procedure
confirmation NCT03929653 105 117 O
of NCT03929653 118 120 O
advanced NCT03929653 121 129 B-Modifier
refractory NCT03929653 130 140 I-Modifier
solid NCT03929653 141 146 B-Condition
tumors NCT03929653 147 153 I-Condition
with NCT03929653 154 158 O
no NCT03929653 159 161 B-Negation
standard NCT03929653 162 170 O
treatment NCT03929653 171 180 B-Procedure
options NCT03929653 181 188 B-Assertion___Assertion-Type-Value:hypothetical
, NCT03929653 189 190 O
including NCT03929653 191 200 O
some NCT03929653 201 205 O
patients NCT03929653 206 214 O
with NCT03929653 215 219 O
advanced NCT03929653 220 228 B-Coreference
disease NCT03929653 229 236 I-Coreference
in NCT03929653 237 239 O
reduced NCT03929653 240 247 B-Condition
general NCT03929653 248 255 I-Condition
condition NCT03929653 256 265 I-Condition
( NCT03929653 266 267 O
Eastern NCT03929653 268 275 B-Condition
Cooperative NCT03929653 276 287 I-Condition
Oncology NCT03929653 288 296 I-Condition
Group NCT03929653 297 302 I-Condition
( NCT03929653 303 304 O
ECOG NCT03929653 305 309 B-Condition
) NCT03929653 310 311 O
3 NCT03929653 312 313 B-Eq-Comparison
and NCT03929653 314 317 I-Eq-Comparison
4 NCT03929653 318 319 I-Eq-Comparison
) NCT03929653 320 321 O
. NCT03929653 323 324 O

3 NCT03929653 328 329 O
. NCT03929653 329 330 O
Patients NCT03929653 332 340 O
with NCT03929653 341 345 O
measurable NCT03929653 346 356 B-Modifier
or NCT03929653 357 359 B-Or
evaluable NCT03929653 360 369 B-Modifier
disease NCT03929653 370 377 B-Condition
per NCT03929653 378 381 O
Response NCT03929653 382 390 O
Evaluation NCT03929653 391 401 O
Criteria NCT03929653 402 410 O
In NCT03929653 411 413 O
Solid NCT03929653 414 419 O
Tumors NCT03929653 420 426 O
( NCT03929653 427 428 O
RECIST NCT03929653 429 435 O
) NCT03929653 436 437 O
version NCT03929653 438 445 O
1.1 NCT03929653 446 449 O
. NCT03929653 449 450 O

4 NCT03929653 454 455 O
. NCT03929653 455 456 O
Patients NCT03929653 458 466 O
must NCT03929653 467 471 O
be NCT03929653 472 474 O
able NCT03929653 475 479 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929653 480 482 I-Assertion___Assertion-Type-Value:hypothetical
provide NCT03929653 483 490 O
blood NCT03929653 491 496 B-Observation
samples NCT03929653 497 504 I-Observation
or NCT03929653 505 507 B-Or
tissue NCT03929653 508 514 B-Observation
samples NCT03929653 515 522 I-Observation
for NCT03929653 523 526 O
NGS NCT03929653 527 530 B-Procedure
( NCT03929653 531 532 O
Next NCT03929653 533 537 B-Procedure
Generation NCT03929653 538 548 I-Procedure
Sequencing NCT03929653 549 559 I-Procedure
) NCT03929653 560 561 O
testing NCT03929653 562 569 O
. NCT03929653 569 570 O
The NCT03929653 572 575 O
amount NCT03929653 576 582 O
of NCT03929653 583 585 O
blood NCT03929653 586 591 B-Observation
and NCT03929653 592 595 B-Or
tissue NCT03929653 596 602 B-Observation
samples NCT03929653 603 610 I-Observation
should NCT03929653 611 617 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03929653 618 620 I-Assertion___Assertion-Type-Value:hypothetical
able NCT03929653 621 625 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03929653 626 628 O
meet NCT03929653 629 633 O
the NCT03929653 634 637 O
requirements NCT03929653 638 650 O
of NCT03929653 651 653 O
DNA NCT03929653 654 657 O
extraction NCT03929653 658 668 O
and NCT03929653 669 672 O
quality NCT03929653 673 680 O
control NCT03929653 681 688 O
. NCT03929653 689 690 O

5 NCT03929653 694 695 O
. NCT03929653 695 696 O
Adequate NCT03929653 698 706 O
baseline NCT03929653 707 715 O
organ NCT03929653 716 721 B-Condition
system NCT03929653 722 728 I-Condition
function NCT03929653 729 737 I-Condition
. NCT03929653 738 739 O

6 NCT03929653 743 744 O
. NCT03929653 744 745 O
Patients NCT03929653 747 755 O
could NCT03929653 756 761 B-Assertion___Assertion-Type-Value:hypothetical
receive NCT03929653 762 769 O
treatment NCT03929653 770 779 B-Procedure
program NCT03929653 780 787 O
from NCT03929653 788 792 O
MTB NCT03929653 793 796 B-Procedure
( NCT03929653 797 798 O
Molecular NCT03929653 799 808 B-Procedure
Tumor NCT03929653 809 814 I-Procedure
Board NCT03929653 815 820 I-Procedure
) NCT03929653 821 822 O
. NCT03929653 824 825 O

7 NCT03929653 829 830 O
. NCT03929653 830 831 O
Ability NCT03929653 833 840 O
to NCT03929653 841 843 O
understand NCT03929653 844 854 O
and NCT03929653 855 858 O
the NCT03929653 859 862 O
willingness NCT03929653 863 874 O
to NCT03929653 875 877 O
provide NCT03929653 878 885 O
a NCT03929653 886 887 O
written NCT03929653 888 895 O
informed NCT03929653 896 904 O
consent NCT03929653 905 912 O
document NCT03929653 913 921 O
. NCT03929653 922 923 O

Exclusion NCT03929653 925 934 O
Criteria NCT03929653 935 943 O
: NCT03929653 944 945 O

1 NCT03929653 947 948 O
. NCT03929653 948 949 O
According NCT03929653 950 959 O
to NCT03929653 960 962 O
the NCT03929653 963 966 O
investigator NCT03929653 967 979 O
' NCT03929653 979 980 O
judgment NCT03929653 981 989 O
, NCT03929653 990 991 O
there NCT03929653 992 997 O
are NCT03929653 998 1001 O
serious NCT03929653 1002 1009 O
, NCT03929653 1010 1011 O
uncontrollable NCT03929653 1012 1026 B-Modifier
risks NCT03929653 1027 1032 B-Risk
to NCT03929653 1033 1035 O
patients NCT03929653 1036 1044 O
' NCT03929653 1044 1045 O
safety NCT03929653 1046 1052 O
, NCT03929653 1053 1054 O
or NCT03929653 1055 1057 B-Or
associated NCT03929653 1058 1068 O
diseases NCT03929653 1069 1077 B-Condition
( NCT03929653 1078 1079 O
such NCT03929653 1080 1084 O
as NCT03929653 1085 1087 O
severe NCT03929653 1088 1094 O
diabetes NCT03929653 1095 1103 B-Condition
, NCT03929653 1104 1105 O
thyroid NCT03929653 1106 1113 B-Condition
disease NCT03929653 1114 1121 I-Condition
, NCT03929653 1122 1123 O
infection NCT03929653 1124 1133 B-Condition
, NCT03929653 1134 1135 O
spinal NCT03929653 1136 1142 B-Condition
cord NCT03929653 1143 1147 I-Condition
compression NCT03929653 1148 1159 I-Condition
, NCT03929653 1160 1161 O
superior NCT03929653 1162 1170 B-Condition
vena NCT03929653 1171 1175 I-Condition
cava NCT03929653 1176 1180 I-Condition
syndrome NCT03929653 1181 1189 I-Condition
, NCT03929653 1190 1191 O
neurological NCT03929653 1192 1204 B-Modifier
or NCT03929653 1205 1207 B-Or
psychiatric NCT03929653 1208 1219 B-Modifier
disorders NCT03929653 1220 1229 B-Condition
and NCT03929653 1230 1233 O
so NCT03929653 1234 1236 O
on NCT03929653 1237 1239 O
) NCT03929653 1240 1241 O
that NCT03929653 1242 1246 O
affect NCT03929653 1247 1253 O
the NCT03929653 1254 1257 O
patients NCT03929653 1258 1266 O
completion NCT03929653 1267 1277 O
of NCT03929653 1278 1280 O
the NCT03929653 1281 1284 O
study NCT03929653 1285 1290 B-Study
. NCT03929653 1291 1292 O


Inclusion NCT03927118 0 9 O
Criteria NCT03927118 10 18 O

Patients NCT03927118 19 27 O
who NCT03927118 28 31 O
underwent NCT03927118 32 41 B-Eq-Comparison
first NCT03927118 42 47 I-Eq-Comparison
time NCT03927118 48 52 I-Eq-Comparison
intravitreal NCT03927118 53 65 B-Procedure
injection NCT03927118 66 75 I-Procedure

Exclusion NCT03927118 76 85 O
Criteria NCT03927118 86 94 O

Previously NCT03927118 95 105 B-Eq-Comparison
received NCT03927118 106 114 I-Eq-Comparison
any NCT03927118 115 118 O
surgery NCT03927118 119 126 B-Procedure

Proliferative NCT03927118 127 140 B-Condition
diabetic NCT03927118 141 149 I-Condition
retinopathy NCT03927118 150 161 I-Condition

Glaucoma NCT03927118 162 170 B-Condition
or NCT03927118 171 173 B-Or
glaucoma NCT03927118 174 182 B-Condition
suspicion NCT03927118 183 192 B-Assertion___Assertion-Type-Value:possible

Optic NCT03927118 193 198 B-Condition
disc NCT03927118 199 203 I-Condition
fatigue NCT03927118 204 211 I-Condition

Optic NCT03927118 212 217 B-Condition
disc NCT03927118 218 222 I-Condition
edema NCT03927118 223 228 I-Condition

Uveitis NCT03927118 229 236 B-Condition
and NCT03927118 237 240 B-Or
media NCT03927118 241 246 B-Condition
opacity NCT03927118 247 254 I-Condition

Blurred NCT03927118 255 262 B-Condition
of NCT03927118 263 265 I-Condition
image NCT03927118 266 271 I-Condition
clarity NCT03927118 272 279 I-Condition

Inclusion NCT03922074 0 9 O
Criteria NCT03922074 10 18 O
: NCT03922074 19 20 O

Healthy NCT03922074 22 29 B-Condition
patients NCT03922074 30 38 O
- NCT03922074 39 40 O

Exclusion NCT03922074 42 51 O
Criteria NCT03922074 52 60 O
: NCT03922074 61 62 O

Patients NCT03922074 64 72 O
with NCT03922074 73 77 O
familial NCT03922074 78 86 B-Family-Member
colorectal NCT03922074 87 97 B-Modifier
cancer NCT03922074 98 104 B-Condition
history NCT03922074 105 112 B-Eq-Comparison

- NCT03922074 114 115 O

Inclusion NCT03925727 0 9 O
Criteria NCT03925727 10 18 O
: NCT03925727 19 20 O

- NCT03925727 24 25 O
Subject NCT03925727 27 34 O
- NCT03925727 35 36 O
reported NCT03925727 37 45 O
history NCT03925727 46 53 B-Eq-Comparison
of NCT03925727 54 56 O
dry NCT03925727 57 60 B-Condition
eye NCT03925727 61 64 I-Condition
disease NCT03925727 65 72 I-Condition
in NCT03925727 73 75 O
both NCT03925727 76 80 B-Modifier
eyes NCT03925727 81 85 I-Modifier
for NCT03925727 86 89 O
at NCT03925727 90 92 B-Eq-Comparison
least NCT03925727 93 98 I-Eq-Comparison
6 NCT03925727 99 100 I-Eq-Comparison
months NCT03925727 101 107 I-Eq-Comparison
; NCT03925727 107 108 O

- NCT03925727 111 112 O
History NCT03925727 114 121 B-Eq-Comparison
of NCT03925727 122 124 O
use NCT03925727 125 128 O
of NCT03925727 129 131 O
artificial NCT03925727 132 142 B-Procedure
tear NCT03925727 143 147 I-Procedure
eye NCT03925727 148 151 I-Procedure
drops NCT03925727 152 157 I-Procedure
for NCT03925727 158 161 O
dry NCT03925727 162 165 B-Condition
eye NCT03925727 166 169 I-Condition
symptoms NCT03925727 170 178 B-Assertion___Assertion-Type-Value:possible
; NCT03925727 178 179 O

- NCT03925727 182 183 O
Total NCT03925727 185 190 O
score NCT03925727 191 196 O
of NCT03925727 197 199 O
≥ NCT03925727 200 201 B-Eq-Comparison
40 NCT03925727 202 204 I-Eq-Comparison
on NCT03925727 205 207 O
SANDE NCT03925727 208 213 B-Observation
; NCT03925727 213 214 O

- NCT03925727 217 218 O
TFBUT NCT03925727 220 225 B-Observation
; NCT03925727 225 226 O

- NCT03925727 229 230 O
Corneal NCT03925727 232 239 B-Condition
fluorescein NCT03925727 240 251 I-Condition
staining NCT03925727 252 260 I-Condition
; NCT03925727 260 261 O

- NCT03925727 264 265 O
Lissamine NCT03925727 267 276 B-Modifier
green NCT03925727 277 282 I-Modifier
conjunctival NCT03925727 283 295 B-Condition
staining NCT03925727 296 304 I-Condition
; NCT03925727 304 305 O

- NCT03925727 308 309 O
Schirmer NCT03925727 311 319 B-Observation
's NCT03925727 319 321 I-Observation
test NCT03925727 322 326 I-Observation
score NCT03925727 327 332 O
. NCT03925727 333 334 O

Exclusion NCT03925727 336 345 O
Criteria NCT03925727 346 354 O
: NCT03925727 355 356 O

- NCT03925727 360 361 O
Have NCT03925727 363 367 O
participated NCT03925727 368 380 O
in NCT03925727 381 383 O
a NCT03925727 384 385 O
previous NCT03925727 386 394 B-Eq-Comparison
tavilermide NCT03925727 395 406 B-Drug
( NCT03925727 407 408 O
MIM NCT03925727 409 412 B-Drug
- NCT03925727 413 414 I-Drug
D3 NCT03925727 415 417 I-Drug
) NCT03925727 418 419 O
study NCT03925727 420 425 B-Study
; NCT03925727 425 426 O

- NCT03925727 429 430 O
Have NCT03925727 432 436 O
clinically NCT03925727 437 447 O
significant NCT03925727 448 459 O
slit NCT03925727 460 464 B-Condition
lamp NCT03925727 465 469 I-Condition
findings NCT03925727 470 478 I-Condition
at NCT03925727 479 481 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Visit NCT03925727 482 487 B-Study
1 NCT03925727 488 489 O
; NCT03925727 490 491 O

- NCT03925727 494 495 O
Have NCT03925727 497 501 O
a NCT03925727 502 503 O
history NCT03925727 504 511 B-Eq-Comparison
of NCT03925727 512 514 O
lacrimal NCT03925727 515 523 B-Condition
duct NCT03925727 524 528 I-Condition
obstruction NCT03925727 529 540 I-Condition
within NCT03925727 541 547 B-Eq-Comparison
12 NCT03925727 548 550 I-Eq-Comparison
months NCT03925727 551 557 I-Eq-Comparison
of NCT03925727 558 560 B-Temporal-Connection___Temporal-Connection-Type-Value:before
Visit NCT03925727 561 566 B-Study
1 NCT03925727 567 568 O
; NCT03925727 569 570 O

- NCT03925727 573 574 O
Have NCT03925727 576 580 O
an NCT03925727 581 583 O
uncontrolled NCT03925727 584 596 B-Modifier
systemic NCT03925727 597 605 B-Condition
disease NCT03925727 606 613 I-Condition
; NCT03925727 613 614 O

- NCT03925727 617 618 O
Be NCT03925727 620 622 O
a NCT03925727 623 624 O
woman NCT03925727 625 630 O
who NCT03925727 631 634 B-And
is NCT03925727 635 637 O
pregnant NCT03925727 638 646 B-Condition
, NCT03925727 647 648 O
nursing NCT03925727 649 656 B-Condition
or NCT03925727 657 659 B-Or
planning NCT03925727 660 668 B-Assertion___Assertion-Type-Value:intention
a NCT03925727 669 670 O
pregnancy NCT03925727 671 680 B-Condition
; NCT03925727 680 681 O

- NCT03925727 684 685 O
Be NCT03925727 687 689 O
a NCT03925727 690 691 O
woman NCT03925727 692 697 O
of NCT03925727 698 700 B-And
childbearing NCT03925727 701 713 B-Condition
potential NCT03925727 714 723 I-Condition
who NCT03925727 724 727 B-And
is NCT03925727 728 730 O
not NCT03925727 731 734 B-Negation
using NCT03925727 735 740 B-Eq-Comparison
an NCT03925727 741 743 O
acceptable NCT03925727 744 754 O
means NCT03925727 755 760 O
of NCT03925727 761 763 O
birth NCT03925727 764 769 B-Procedure
control NCT03925727 770 777 I-Procedure
; NCT03925727 777 778 O

- NCT03925727 781 782 O
Have NCT03925727 784 788 O
a NCT03925727 789 790 O
condition NCT03925727 791 800 B-Condition
or NCT03925727 801 803 O
be NCT03925727 804 806 O
in NCT03925727 807 809 O
a NCT03925727 810 811 O
situation NCT03925727 812 821 O
which NCT03925727 822 827 O
the NCT03925727 828 831 O
investigator NCT03925727 832 844 O
feels NCT03925727 845 850 O
may NCT03925727 851 854 O
put NCT03925727 855 858 O
the NCT03925727 859 862 O
subject NCT03925727 863 870 O
at NCT03925727 871 873 O
significant NCT03925727 874 885 O
risk NCT03925727 886 890 B-Risk
, NCT03925727 891 892 O
may NCT03925727 893 896 B-Assertion___Assertion-Type-Value:hypothetical
confound NCT03925727 897 905 O
the NCT03925727 906 909 O
study NCT03925727 910 915 B-Study
results NCT03925727 916 923 O
, NCT03925727 924 925 O
or NCT03925727 926 928 B-Or
may NCT03925727 929 932 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03925727 933 942 O
significantly NCT03925727 943 956 O
with NCT03925727 957 961 O
the NCT03925727 962 965 O
subject NCT03925727 966 973 O
's NCT03925727 973 975 O
participation NCT03925727 976 989 O
in NCT03925727 990 992 O
the NCT03925727 993 996 O
study NCT03925727 997 1002 B-Study
; NCT03925727 1002 1003 O

- NCT03925727 1006 1007 O
Be NCT03925727 1009 1011 O
currently NCT03925727 1012 1021 B-Eq-Comparison
enrolled NCT03925727 1022 1030 O
in NCT03925727 1031 1033 O
an NCT03925727 1034 1036 O
investigational NCT03925727 1037 1052 O
drug NCT03925727 1053 1057 B-Drug
or NCT03925727 1058 1060 B-Or
device NCT03925727 1061 1067 B-Procedure
study NCT03925727 1068 1073 B-Study
or NCT03925727 1074 1076 B-Or
have NCT03925727 1077 1081 O
used NCT03925727 1082 1086 B-Eq-Comparison
an NCT03925727 1087 1089 O
investigational NCT03925727 1090 1105 B-Study
drug NCT03925727 1106 1110 B-Drug
or NCT03925727 1111 1113 B-Or
device NCT03925727 1114 1120 B-Procedure
within NCT03925727 1121 1127 B-Eq-Comparison
45 NCT03925727 1128 1130 I-Eq-Comparison
days NCT03925727 1131 1135 I-Eq-Comparison
prior NCT03925727 1136 1141 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03925727 1142 1144 O
Visit NCT03925727 1145 1150 B-Study
1 NCT03925727 1151 1152 O
. NCT03925727 1152 1153 O

Inclusion NCT03929939 0 9 O
Criteria NCT03929939 10 18 O
: NCT03929939 19 20 O

1 NCT03929939 24 25 O
. NCT03929939 25 26 O
Be NCT03929939 28 30 O
either NCT03929939 31 37 O
a NCT03929939 38 39 O
female NCT03929939 40 46 O
veteran NCT03929939 47 54 B-Observation
with NCT03929939 55 59 B-And
a NCT03929939 60 61 O
current NCT03929939 62 69 B-Eq-Comparison
diagnosis NCT03929939 70 79 O
of NCT03929939 80 82 O
PTSD NCT03929939 83 87 B-Condition
( NCT03929939 88 89 O
for NCT03929939 90 93 O
the NCT03929939 94 97 O
PTSD NCT03929939 98 102 B-Condition
group NCT03929939 103 108 O
) NCT03929939 109 110 O
or NCT03929939 111 113 B-Or
a NCT03929939 114 115 O
female NCT03929939 116 122 O
non NCT03929939 123 126 B-Negation
- NCT03929939 127 128 O
veteran NCT03929939 129 136 B-Observation
without NCT03929939 137 144 B-Negation
a NCT03929939 145 146 O
current NCT03929939 147 154 B-Eq-Comparison
diagnosis NCT03929939 155 164 O
of NCT03929939 165 167 O
PTSD NCT03929939 168 172 B-Condition
( NCT03929939 173 174 O
for NCT03929939 175 178 O
the NCT03929939 179 182 O
non NCT03929939 183 186 B-Negation
- NCT03929939 187 188 O
PTSD NCT03929939 189 193 B-Condition
control NCT03929939 194 201 O
group NCT03929939 202 207 O
) NCT03929939 208 209 O
. NCT03929939 211 212 O

2 NCT03929939 216 217 O
. NCT03929939 217 218 O
Be NCT03929939 220 222 O
between NCT03929939 223 230 O
the NCT03929939 231 234 O
ages NCT03929939 235 239 B-Age
of NCT03929939 240 242 O
18 NCT03929939 243 245 B-Eq-Comparison
- NCT03929939 246 247 I-Eq-Comparison
65 NCT03929939 248 250 I-Eq-Comparison
. NCT03929939 250 251 O

3 NCT03929939 255 256 O
. NCT03929939 256 257 O
Sedentary NCT03929939 259 268 B-Condition
( NCT03929939 269 270 O
exercises NCT03929939 271 280 B-Observation
less NCT03929939 281 285 B-Eq-Comparison
than NCT03929939 286 290 I-Eq-Comparison
three NCT03929939 291 296 I-Eq-Comparison
times NCT03929939 297 302 I-Eq-Comparison
a NCT03929939 303 304 I-Eq-Comparison
week NCT03929939 305 309 I-Eq-Comparison
for NCT03929939 310 313 O
thirty NCT03929939 314 320 B-Eq-Comparison
minutes NCT03929939 321 328 I-Eq-Comparison
or NCT03929939 329 331 I-Eq-Comparison
less NCT03929939 332 336 I-Eq-Comparison
) NCT03929939 337 338 O
. NCT03929939 340 341 O

Exclusion NCT03929939 343 352 O
Criteria NCT03929939 353 361 O
: NCT03929939 362 363 O

1 NCT03929939 367 368 O
. NCT03929939 368 369 O
Any NCT03929939 371 374 O
evidence NCT03929939 375 383 O
of NCT03929939 384 386 O
cardiopulmonary NCT03929939 387 402 B-Modifier
and NCT03929939 403 406 B-Or
neurological NCT03929939 407 419 B-Modifier
diseases NCT03929939 420 428 B-Condition
by NCT03929939 429 431 O
history NCT03929939 432 439 O
or NCT03929939 440 442 O
by NCT03929939 443 445 O
physical NCT03929939 446 454 B-Procedure
examination NCT03929939 455 466 I-Procedure
. NCT03929939 467 468 O

2 NCT03929939 472 473 O
. NCT03929939 473 474 O
Chronic NCT03929939 476 483 B-Modifier
kidney NCT03929939 484 490 B-Condition
disease NCT03929939 491 498 I-Condition
( NCT03929939 499 500 O
serum NCT03929939 501 506 B-Observation
creatinine NCT03929939 507 517 I-Observation
> NCT03929939 518 519 B-Eq-Comparison
1.5 NCT03929939 520 523 I-Eq-Comparison
mg NCT03929939 524 526 I-Eq-Comparison
/ NCT03929939 527 528 I-Eq-Comparison
dL NCT03929939 529 531 I-Eq-Comparison
) NCT03929939 532 533 O
. NCT03929939 535 536 O

3 NCT03929939 540 541 O
. NCT03929939 541 542 O
Peripheral NCT03929939 544 554 B-Condition
vascular NCT03929939 555 563 I-Condition
disease NCT03929939 564 571 I-Condition
. NCT03929939 572 573 O

4 NCT03929939 577 578 O
. NCT03929939 578 579 O
Peripheral NCT03929939 581 591 B-Condition
neuropathy NCT03929939 592 602 I-Condition
. NCT03929939 603 604 O

5 NCT03929939 608 609 O
. NCT03929939 609 610 O
Current NCT03929939 612 619 B-Eq-Comparison
substance NCT03929939 620 629 B-Condition
use NCT03929939 630 633 I-Condition
disorder NCT03929939 634 642 I-Condition
other NCT03929939 643 648 B-Exception
than NCT03929939 649 653 I-Exception
tobacco NCT03929939 654 661 B-Drug
related NCT03929939 662 669 O
. NCT03929939 670 671 O

6 NCT03929939 675 676 O
. NCT03929939 676 677 O
Endurance NCT03929939 679 688 B-Condition
- NCT03929939 689 690 I-Condition
trained NCT03929939 691 698 I-Condition
athletes NCT03929939 699 707 I-Condition
due NCT03929939 708 711 O
to NCT03929939 712 714 O
the NCT03929939 715 718 O
effects NCT03929939 719 726 O
of NCT03929939 727 729 O
exercise NCT03929939 730 738 B-Procedure
training NCT03929939 739 747 I-Procedure
on NCT03929939 748 750 O
sympathetic NCT03929939 751 762 B-Condition
neural NCT03929939 763 769 I-Condition
control NCT03929939 770 777 I-Condition
and NCT03929939 778 781 B-Or
cardiac NCT03929939 782 789 B-Condition
- NCT03929939 790 791 I-Condition
vascular NCT03929939 792 800 I-Condition
function NCT03929939 801 809 I-Condition
. NCT03929939 810 811 O

7 NCT03929939 815 816 O
. NCT03929939 816 817 O
Current NCT03929939 819 826 B-Eq-Comparison
pregnancy NCT03929939 827 836 B-Condition
. NCT03929939 836 837 O

Inclusion NCT03928366 0 9 O
Criteria NCT03928366 10 18 O
: NCT03928366 19 20 O

- NCT03928366 24 25 O
Healthy NCT03928366 27 34 B-Condition
adult NCT03928366 35 40 O
volunteers NCT03928366 41 51 O
( NCT03928366 52 53 O
ASA NCT03928366 54 57 B-Condition
1 NCT03928366 58 59 B-Eq-Comparison
physical NCT03928366 60 68 O
state NCT03928366 69 74 O
) NCT03928366 75 76 O
who NCT03928366 77 80 O
agree NCT03928366 81 86 O
to NCT03928366 87 89 O
participate NCT03928366 90 101 O
voluntarily NCT03928366 102 113 O
in NCT03928366 114 116 O
the NCT03928366 117 120 O
study NCT03928366 121 126 B-Study
, NCT03928366 127 128 O
previous NCT03928366 129 137 B-Eq-Comparison
information NCT03928366 138 149 O
about NCT03928366 150 155 O
it NCT03928366 156 158 O
by NCT03928366 159 161 O
the NCT03928366 162 165 O
Principal NCT03928366 166 175 O
Investigators NCT03928366 176 189 O
( NCT03928366 190 191 O
IP NCT03928366 192 194 O
) NCT03928366 195 196 O
. NCT03928366 198 199 O

Exclusion NCT03928366 201 210 O
Criteria NCT03928366 211 219 O
: NCT03928366 220 221 O

- NCT03928366 225 226 O
Psychological NCT03928366 228 241 B-Modifier
, NCT03928366 242 243 O
psychiatric NCT03928366 244 255 B-Modifier
or NCT03928366 256 258 B-Or
neurological NCT03928366 259 271 B-Modifier
disorders NCT03928366 272 281 B-Condition
. NCT03928366 281 282 O
Consumption NCT03928366 284 295 O
of NCT03928366 296 298 O
drugs NCT03928366 299 304 B-Drug
. NCT03928366 304 305 O
Alterations NCT03928366 307 318 B-Condition
cutaneous NCT03928366 319 328 B-Modifier
or NCT03928366 329 331 B-Or
anatomical NCT03928366 332 342 B-Modifier
cranial NCT03928366 343 350 I-Modifier
. NCT03928366 350 351 O
Idiomatic NCT03928366 353 362 B-Modifier
or NCT03928366 363 365 B-Or
communication NCT03928366 366 379 B-Modifier
barrier NCT03928366 380 387 B-Condition
. NCT03928366 387 388 O
Allergy NCT03928366 390 397 B-Allergy
to NCT03928366 398 400 O
propofol NCT03928366 401 409 B-Drug
, NCT03928366 410 411 O
remifentanil NCT03928366 412 424 B-Drug
or NCT03928366 425 427 O
to NCT03928366 428 430 O
some NCT03928366 431 435 O
of NCT03928366 436 438 O
its NCT03928366 439 442 O
excipients NCT03928366 443 453 O
. NCT03928366 453 454 O
Body NCT03928366 456 460 B-Observation
mass NCT03928366 461 465 I-Observation
index NCT03928366 466 471 I-Observation
( NCT03928366 472 473 O
BMI NCT03928366 474 477 B-Observation
) NCT03928366 478 479 O
< NCT03928366 480 481 B-Eq-Comparison
18 NCT03928366 482 484 I-Eq-Comparison
or NCT03928366 485 487 B-Or
> NCT03928366 488 489 B-Eq-Comparison
30 NCT03928366 490 492 I-Eq-Comparison
kg NCT03928366 493 495 I-Eq-Comparison
/ NCT03928366 496 497 I-Eq-Comparison
m2 NCT03928366 498 500 I-Eq-Comparison
. NCT03928366 500 501 O
Pregnancy NCT03928366 503 512 B-Condition
. NCT03928366 512 513 O
Airway NCT03928366 515 521 B-Modifier
or NCT03928366 522 524 B-Or
ventilation NCT03928366 525 536 B-Modifier
criteria NCT03928366 537 545 O
hard NCT03928366 546 550 B-Condition
. NCT03928366 550 551 O
Absence NCT03928366 553 560 B-Negation
of NCT03928366 561 563 O
accompanying NCT03928366 564 576 O
adult NCT03928366 577 582 B-Family-Member___Family-Member-Type:parent
at NCT03928366 583 585 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928366 586 589 O
end NCT03928366 590 593 O
of NCT03928366 594 596 O
the NCT03928366 597 600 O
study NCT03928366 601 606 B-Study
. NCT03928366 606 607 O

Inclusion NCT03922893 0 9 O
Criteria NCT03922893 10 18 O
: NCT03922893 19 20 O

- NCT03922893 24 25 O
Individuals NCT03922893 27 38 O
who NCT03922893 39 42 O
have NCT03922893 43 47 O
undergone NCT03922893 48 57 O
clinical NCT03922893 58 66 B-Modifier
and NCT03922893 67 70 B-Or
/ NCT03922893 71 72 I-Or
or NCT03922893 73 75 I-Or
research NCT03922893 76 84 B-Modifier
genetic NCT03922893 85 92 B-Procedure
evaluation NCT03922893 93 103 I-Procedure
, NCT03922893 104 105 O
found NCT03922893 106 111 O
to NCT03922893 112 114 O
have NCT03922893 115 119 O
or NCT03922893 120 122 O
not NCT03922893 123 126 O
have NCT03922893 127 131 O
a NCT03922893 132 133 O
germline NCT03922893 134 142 B-Condition
genetic NCT03922893 143 150 I-Condition
variant NCT03922893 151 158 I-Condition
( NCT03922893 159 160 O
pathogenic NCT03922893 161 171 B-Modifier
, NCT03922893 172 173 O
likely NCT03922893 174 180 B-Assertion___Assertion-Type-Value:possible
pathogenic NCT03922893 181 191 B-Modifier
, NCT03922893 192 193 O
variant NCT03922893 194 201 O
of NCT03922893 202 204 O
uncertain NCT03922893 205 214 O
/ NCT03922893 215 216 O
unknown NCT03922893 217 224 O
significance NCT03922893 225 237 O
, NCT03922893 238 239 O
likely NCT03922893 240 246 B-Assertion___Assertion-Type-Value:possible
benign NCT03922893 247 253 B-Modifier
) NCT03922893 254 255 O
. NCT03922893 257 258 O

- NCT03922893 262 263 O
Individuals NCT03922893 265 276 O
with NCT03922893 277 281 O
or NCT03922893 282 284 O
without NCT03922893 285 292 O
a NCT03922893 293 294 O
personal NCT03922893 295 303 O
history NCT03922893 304 311 B-Eq-Comparison
of NCT03922893 312 314 O
malignant NCT03922893 315 324 B-Modifier
or NCT03922893 325 327 B-Or
pre NCT03922893 328 331 B-Modifier
- NCT03922893 332 333 I-Modifier
malignant NCT03922893 334 343 I-Modifier
lesions NCT03922893 344 351 B-Condition
who NCT03922893 352 355 O
demonstrate NCT03922893 356 367 O
: NCT03922893 368 369 O
a NCT03922893 370 371 O
) NCT03922893 372 373 O
clinical NCT03922893 374 382 O
findings NCT03922893 383 391 O
suggestive NCT03922893 392 402 B-Assertion___Assertion-Type-Value:possible
of NCT03922893 403 405 O
a NCT03922893 406 407 O
genetic NCT03922893 408 415 B-Condition
cancer NCT03922893 416 422 I-Condition
susceptibility NCT03922893 423 437 I-Condition
syndrome NCT03922893 438 446 I-Condition
including NCT03922893 447 456 B-And
very NCT03922893 457 461 O
early NCT03922893 462 467 B-Modifier
age NCT03922893 468 471 B-Age
at NCT03922893 472 474 O
onset NCT03922893 475 480 B-Eq-Comparison
, NCT03922893 481 482 O
multiple NCT03922893 483 491 B-Modifier
primary NCT03922893 492 499 I-Modifier
malignancies NCT03922893 500 512 B-Condition
, NCT03922893 513 514 O
or NCT03922893 515 517 B-Or
other NCT03922893 518 523 B-Other
features NCT03922893 524 532 B-Condition
; NCT03922893 532 533 O
and NCT03922893 534 537 B-Or
/ NCT03922893 538 539 I-Or
or NCT03922893 540 542 I-Or
b NCT03922893 543 544 O
) NCT03922893 545 546 O
family NCT03922893 547 553 B-Family-Member
histories NCT03922893 554 563 I-Family-Member
suggestive NCT03922893 564 574 B-Assertion___Assertion-Type-Value:possible
of NCT03922893 575 577 O
a NCT03922893 578 579 O
genetic NCT03922893 580 587 B-Condition
cancer NCT03922893 588 594 I-Condition
susceptibility NCT03922893 595 609 I-Condition
syndrome NCT03922893 610 618 I-Condition
, NCT03922893 619 620 O
or NCT03922893 621 623 O
c NCT03922893 624 625 O
) NCT03922893 626 627 O
other NCT03922893 628 633 B-Other
features NCT03922893 634 642 B-Condition
suggesting NCT03922893 643 653 B-Assertion___Assertion-Type-Value:possible
inherited NCT03922893 654 663 O
etiology NCT03922893 664 672 O
of NCT03922893 673 675 O
malignancy NCT03922893 676 686 B-Condition
as NCT03922893 687 689 O
determined NCT03922893 690 700 O
by NCT03922893 701 703 O
the NCT03922893 704 707 O
PI NCT03922893 708 710 O
. NCT03922893 711 712 O

- NCT03922893 716 717 O
Family NCT03922893 719 725 B-Family-Member
members NCT03922893 726 733 I-Family-Member
of NCT03922893 734 736 O
the NCT03922893 737 740 O
above NCT03922893 741 746 O
participants NCT03922893 747 759 O
. NCT03922893 759 760 O
Both NCT03922893 762 766 O
children NCT03922893 767 775 O
( NCT03922893 776 777 O
with NCT03922893 778 782 O
parental NCT03922893 783 791 O
consent NCT03922893 792 799 O
as NCT03922893 800 802 O
age NCT03922893 803 806 O
appropriate NCT03922893 807 818 O
) NCT03922893 819 820 O
and NCT03922893 821 824 B-Or
adults NCT03922893 825 831 O
are NCT03922893 832 835 O
eligible NCT03922893 836 844 O
to NCT03922893 845 847 O
participation NCT03922893 848 861 O
. NCT03922893 862 863 O

- NCT03922893 867 868 O
Individuals NCT03922893 870 881 O
may NCT03922893 882 885 O
or NCT03922893 886 888 O
may NCT03922893 889 892 O
not NCT03922893 893 896 O
be NCT03922893 897 899 O
enrolled NCT03922893 900 908 O
MSK NCT03922893 909 912 O
patients NCT03922893 913 921 O
; NCT03922893 921 922 O
probands NCT03922893 923 931 O
may NCT03922893 932 935 O
be NCT03922893 936 938 O
referred NCT03922893 939 947 O
to NCT03922893 948 950 O
( NCT03922893 951 952 O
or NCT03922893 953 955 O
self NCT03922893 956 960 O
- NCT03922893 961 962 O
referred NCT03922893 963 971 O
to NCT03922893 972 974 O
) NCT03922893 975 976 O
the NCT03922893 977 980 O
study NCT03922893 981 986 O
and NCT03922893 987 990 O
may NCT03922893 991 994 O
be NCT03922893 995 997 O
enrolled NCT03922893 998 1006 O
at NCT03922893 1007 1009 O
discretion NCT03922893 1010 1020 O
of NCT03922893 1021 1023 O
the NCT03922893 1024 1027 O
PI NCT03922893 1028 1030 O
and NCT03922893 1031 1034 O
if NCT03922893 1035 1037 O
able NCT03922893 1038 1042 O
to NCT03922893 1043 1045 O
provide NCT03922893 1046 1053 O
informed NCT03922893 1054 1062 O
consent NCT03922893 1063 1070 O
. NCT03922893 1071 1072 O

- NCT03922893 1076 1077 O
Biospecimens NCT03922893 1079 1091 O
derived NCT03922893 1092 1099 O
from NCT03922893 1100 1104 O
deceased NCT03922893 1105 1113 B-Death
family NCT03922893 1114 1120 B-Family-Member
members NCT03922893 1121 1128 I-Family-Member
may NCT03922893 1129 1132 O
be NCT03922893 1133 1135 O
used NCT03922893 1136 1140 O
for NCT03922893 1141 1144 O
research NCT03922893 1145 1153 O
in NCT03922893 1154 1156 O
this NCT03922893 1157 1161 O
study NCT03922893 1162 1167 O
if NCT03922893 1168 1170 O
consent NCT03922893 1171 1178 O
if NCT03922893 1179 1181 O
provided NCT03922893 1182 1190 O
by NCT03922893 1191 1193 O
the NCT03922893 1194 1197 O
executor NCT03922893 1198 1206 O
of NCT03922893 1207 1209 O
the NCT03922893 1210 1213 O
estate NCT03922893 1214 1220 O
of NCT03922893 1221 1223 O
that NCT03922893 1224 1228 O
individual NCT03922893 1229 1239 O
. NCT03922893 1240 1241 O

Exclusion NCT03922893 1243 1252 O
Criteria NCT03922893 1253 1261 O
: NCT03922893 1262 1263 O

- NCT03922893 1267 1268 O
Patients NCT03922893 1270 1278 O
will NCT03922893 1279 1283 O
be NCT03922893 1284 1286 O
excluded NCT03922893 1287 1295 B-Negation
from NCT03922893 1296 1300 O
this NCT03922893 1301 1305 O
study NCT03922893 1306 1311 B-Study
if NCT03922893 1312 1314 O
he NCT03922893 1315 1317 O
/ NCT03922893 1318 1319 O
she NCT03922893 1320 1323 O
has NCT03922893 1324 1327 O
physical NCT03922893 1328 1336 B-Modifier
, NCT03922893 1337 1338 O
cognitive NCT03922893 1339 1348 B-Modifier
or NCT03922893 1349 1351 B-Or
psychiatric NCT03922893 1352 1363 B-Modifier
conditions NCT03922893 1364 1374 B-Condition
that NCT03922893 1375 1379 O
interfere NCT03922893 1380 1389 O
with NCT03922893 1390 1394 O
ability NCT03922893 1395 1402 O
to NCT03922893 1403 1405 O
give NCT03922893 1406 1410 O
meaningful NCT03922893 1411 1421 O
informed NCT03922893 1422 1430 O
consent NCT03922893 1431 1438 O
. NCT03922893 1438 1439 O

Inclusion NCT03926377 0 9 O
Criteria NCT03926377 10 18 O
: NCT03926377 19 20 O

- NCT03926377 24 25 O
patients NCT03926377 27 35 O
presenting NCT03926377 36 46 O
a NCT03926377 47 48 O
multi NCT03926377 49 54 B-Modifier
- NCT03926377 55 56 I-Modifier
bullous NCT03926377 57 64 I-Modifier
pemphigoid NCT03926377 65 75 B-Condition
newly NCT03926377 76 81 O
diagnosed NCT03926377 82 91 O
or NCT03926377 92 94 O
relapsed NCT03926377 95 103 O
more NCT03926377 104 108 B-Eq-Comparison
than NCT03926377 109 113 I-Eq-Comparison
3 NCT03926377 114 115 I-Eq-Comparison
months NCT03926377 116 122 I-Eq-Comparison
after NCT03926377 123 128 B-Temporal-Connection___Temporal-Connection-Type-Value:after
stopping NCT03926377 129 137 O
corticosteroids NCT03926377 138 153 B-Drug
and NCT03926377 154 157 B-And
treated NCT03926377 158 165 B-Procedure
according NCT03926377 166 175 O
to NCT03926377 176 178 O
the NCT03926377 179 182 O
national NCT03926377 183 191 O
protocol NCT03926377 192 200 O
for NCT03926377 201 204 O
diagnosis NCT03926377 205 214 O
and NCT03926377 215 218 O
care NCT03926377 219 223 O
issued NCT03926377 224 230 O
by NCT03926377 231 233 O
the NCT03926377 234 237 O
reference NCT03926377 238 247 O
center NCT03926377 248 254 O
for NCT03926377 255 258 O
autoimmune NCT03926377 259 269 O
bullous NCT03926377 270 277 O
diseases NCT03926377 278 286 O
of NCT03926377 287 289 O
April NCT03926377 290 295 O
2016 NCT03926377 296 300 O

- NCT03926377 304 305 O
patients NCT03926377 307 315 O
having NCT03926377 316 322 O
received NCT03926377 323 331 B-Eq-Comparison
written NCT03926377 332 339 O
and NCT03926377 340 343 O
oral NCT03926377 344 348 O
information NCT03926377 349 360 O
and NCT03926377 361 364 O
signed NCT03926377 365 371 O
informed NCT03926377 372 380 O
consent NCT03926377 381 388 O

- NCT03926377 391 392 O
patients NCT03926377 394 402 O
covered NCT03926377 403 410 O
by NCT03926377 411 413 O
national NCT03926377 414 422 O
health NCT03926377 423 429 O
insurance NCT03926377 430 439 O

Exclusion NCT03926377 440 449 O
Criteria NCT03926377 450 458 O
: NCT03926377 459 460 O

- NCT03926377 464 465 O
Patients NCT03926377 467 475 O
under NCT03926377 476 481 O
tutorship NCT03926377 482 491 O
or NCT03926377 492 494 O
curatorship NCT03926377 495 506 O
or NCT03926377 507 509 O
inability NCT03926377 510 519 O
to NCT03926377 520 522 O
give NCT03926377 523 527 O
informed NCT03926377 528 536 O
consent NCT03926377 537 544 O

- NCT03926377 547 548 O
Patients NCT03926377 550 558 O
receiving NCT03926377 559 568 B-Eq-Comparison
an NCT03926377 569 571 O
anti NCT03926377 572 576 B-Drug
- NCT03926377 577 578 I-Drug
osteoporotic NCT03926377 579 591 I-Drug
treatment NCT03926377 592 601 B-Procedure

- NCT03926377 604 605 O
Patients NCT03926377 607 615 O
requiring NCT03926377 616 625 B-Assertion___Assertion-Type-Value:hypothetical
an NCT03926377 626 628 O
anti NCT03926377 629 633 B-Drug
- NCT03926377 634 635 I-Drug
osteoporotic NCT03926377 636 648 I-Drug
baseline NCT03926377 649 657 O
treatment NCT03926377 658 667 B-Procedure
( NCT03926377 668 669 O
T NCT03926377 670 671 B-Observation
- NCT03926377 672 673 I-Observation
score NCT03926377 674 679 I-Observation
⩽ NCT03926377 680 681 B-Eq-Comparison
- NCT03926377 682 683 I-Eq-Comparison
3 NCT03926377 684 685 I-Eq-Comparison
DS NCT03926377 686 688 I-Eq-Comparison
on NCT03926377 689 691 O
at NCT03926377 692 694 B-Eq-Comparison
least NCT03926377 695 700 I-Eq-Comparison
1 NCT03926377 701 702 I-Eq-Comparison
site NCT03926377 703 707 I-Eq-Comparison
or NCT03926377 708 710 B-Or
FRAX NCT03926377 711 715 B-Observation
score NCT03926377 716 721 I-Observation
above NCT03926377 722 727 B-Eq-Comparison
the NCT03926377 728 731 I-Eq-Comparison
therapeutic NCT03926377 732 743 I-Eq-Comparison
intervention NCT03926377 744 756 I-Eq-Comparison
threshold NCT03926377 757 766 I-Eq-Comparison
) NCT03926377 767 768 O

- NCT03926377 776 777 O
Patients NCT03926377 779 787 O
with NCT03926377 788 792 O
one NCT03926377 793 796 B-Eq-Comparison
or NCT03926377 797 799 I-Eq-Comparison
more NCT03926377 800 804 I-Eq-Comparison
major NCT03926377 805 810 O
risk NCT03926377 811 815 B-Risk
factors NCT03926377 816 823 O
for NCT03926377 824 827 O
osteoporosis NCT03926377 828 840 B-Condition

- NCT03926377 843 844 O
Patients NCT03926377 846 854 O
who NCT03926377 855 858 O
have NCT03926377 859 863 O
received NCT03926377 864 872 B-Eq-Comparison
topical NCT03926377 873 880 B-Drug
corticosteroids NCT03926377 881 896 I-Drug
in NCT03926377 897 899 O
less NCT03926377 900 904 B-Eq-Comparison
than NCT03926377 905 909 I-Eq-Comparison
3 NCT03926377 910 911 I-Eq-Comparison
months NCT03926377 912 918 I-Eq-Comparison


Inclusion NCT03923569 0 9 O
Criteria NCT03923569 10 18 O
: NCT03923569 19 20 O

For NCT03923569 22 25 O
all NCT03923569 26 29 O
participants NCT03923569 30 42 O
: NCT03923569 43 44 O

- NCT03923569 48 49 O
age NCT03923569 51 54 B-Age
from NCT03923569 55 59 O
50 NCT03923569 60 62 B-Eq-Comparison
to NCT03923569 63 65 I-Eq-Comparison
75 NCT03923569 66 68 I-Eq-Comparison
years NCT03923569 69 74 I-Eq-Comparison
old NCT03923569 75 78 O

- NCT03923569 81 82 O
affiliated NCT03923569 84 94 O
to NCT03923569 95 97 O
the NCT03923569 98 101 O
French NCT03923569 102 108 O
health NCT03923569 109 115 O
care NCT03923569 116 120 O
system NCT03923569 121 127 O

For NCT03923569 128 131 O
AD NCT03923569 132 134 B-Condition
patients NCT03923569 135 143 O
: NCT03923569 144 145 O

- NCT03923569 149 150 O
meeting NCT03923569 152 159 O
International NCT03923569 160 173 O
Working NCT03923569 174 181 O
Group NCT03923569 182 187 O
( NCT03923569 188 189 O
IWG NCT03923569 190 193 O
) NCT03923569 194 195 O
- NCT03923569 197 198 O
2 NCT03923569 199 200 O
criteria NCT03923569 201 209 O
for NCT03923569 210 213 O
diagnosis NCT03923569 214 223 O

- NCT03923569 226 227 O
Mini NCT03923569 229 233 B-Observation
- NCT03923569 234 235 I-Observation
Mental NCT03923569 236 242 I-Observation
State NCT03923569 243 248 I-Observation
Examination NCT03923569 249 260 I-Observation
( NCT03923569 261 262 O
MMSE NCT03923569 263 267 B-Observation
) NCT03923569 268 269 O
≥ NCT03923569 270 271 B-Eq-Comparison
20 NCT03923569 272 274 I-Eq-Comparison
( NCT03923569 275 276 O
Greco NCT03923569 277 282 O
version NCT03923569 283 290 O
) NCT03923569 291 292 O

For NCT03923569 294 297 O
healthy NCT03923569 298 305 B-Condition
volunteers NCT03923569 306 316 O
: NCT03923569 317 318 O

- NCT03923569 322 323 O
MMSE NCT03923569 325 329 B-Observation
> NCT03923569 330 331 B-Eq-Comparison
25 NCT03923569 332 334 I-Eq-Comparison

- NCT03923569 338 339 O
Dubois NCT03923569 341 347 B-Observation
5 NCT03923569 348 349 I-Observation
words NCT03923569 350 355 I-Observation
test NCT03923569 356 360 I-Observation
≥ NCT03923569 361 362 B-Eq-Comparison
9 NCT03923569 363 364 I-Eq-Comparison

Exclusion NCT03923569 366 375 O
Criteria NCT03923569 376 384 O
: NCT03923569 385 386 O

For NCT03923569 388 391 O
all NCT03923569 392 395 O
participants NCT03923569 396 408 O
: NCT03923569 409 410 O

- NCT03923569 414 415 O
Pregnancy NCT03923569 417 426 B-Condition

- NCT03923569 429 430 O
people NCT03923569 432 438 O
not NCT03923569 439 442 O
able NCT03923569 443 447 O
to NCT03923569 448 450 O
give NCT03923569 451 455 O
consent NCT03923569 456 463 O

- NCT03923569 466 467 O
contraindication NCT03923569 469 485 B-Contraindication
for NCT03923569 486 489 O
MRI NCT03923569 490 493 B-Procedure
( NCT03923569 494 495 O
metallic NCT03923569 496 504 B-Condition
body NCT03923569 505 509 I-Condition
parts NCT03923569 510 515 I-Condition
, NCT03923569 516 517 O
claustrophobia NCT03923569 518 532 B-Condition
) NCT03923569 533 534 O
, NCT03923569 536 537 O

- NCT03923569 541 542 O
aphasia NCT03923569 544 551 B-Condition
, NCT03923569 552 553 O
apraxia NCT03923569 554 561 B-Condition
or NCT03923569 562 564 B-Or
agnosia NCT03923569 565 572 B-Condition

- NCT03923569 575 576 O
neurological NCT03923569 578 590 B-Modifier
( NCT03923569 591 592 O
other NCT03923569 593 598 B-Exception
than NCT03923569 599 603 I-Exception
AD NCT03923569 604 606 B-Condition
) NCT03923569 607 608 O
or NCT03923569 609 611 B-Or
any NCT03923569 612 615 O
other NCT03923569 616 621 B-Other
serious NCT03923569 622 629 O
disease NCT03923569 630 637 B-Condition
( NCT03923569 638 639 O
cancer NCT03923569 640 646 O
, NCT03923569 647 648 O
addiction NCT03923569 649 658 B-Condition
, NCT03923569 659 660 O
systemic NCT03923569 661 669 B-Condition
disease NCT03923569 670 677 I-Condition
) NCT03923569 678 679 O

- NCT03923569 683 684 O
sleep NCT03923569 686 691 O
apnea NCT03923569 692 697 O

- NCT03923569 700 701 O
major NCT03923569 703 708 O
depression NCT03923569 709 719 B-Condition
or NCT03923569 720 722 B-Or
anxiety NCT03923569 723 730 B-Condition
for NCT03923569 731 734 O
more NCT03923569 735 739 B-Eq-Comparison
than NCT03923569 740 744 I-Eq-Comparison
3 NCT03923569 745 746 I-Eq-Comparison
months NCT03923569 747 753 I-Eq-Comparison
( NCT03923569 754 755 O
Beck NCT03923569 756 760 B-Observation
> NCT03923569 761 762 B-Eq-Comparison
10 NCT03923569 763 765 I-Eq-Comparison
) NCT03923569 766 767 O
or NCT03923569 768 770 B-Or
psychiatric NCT03923569 771 782 B-Condition
disease NCT03923569 783 790 I-Condition

- NCT03923569 793 794 O
documented NCT03923569 796 806 O
epilepsy NCT03923569 807 815 B-Condition

- NCT03923569 818 819 O
use NCT03923569 821 824 B-Eq-Comparison
of NCT03923569 825 827 O
neuroleptics NCT03923569 828 840 B-Drug
( NCT03923569 841 842 O
more NCT03923569 843 847 B-Eq-Comparison
than NCT03923569 848 852 I-Eq-Comparison
one NCT03923569 853 856 I-Eq-Comparison
dose NCT03923569 857 861 I-Eq-Comparison
per NCT03923569 862 865 I-Eq-Comparison
day NCT03923569 866 869 I-Eq-Comparison
) NCT03923569 870 871 O

- NCT03923569 875 876 O
use NCT03923569 878 881 B-Eq-Comparison
of NCT03923569 882 884 O
antiepileptics NCT03923569 885 899 B-Drug

- NCT03923569 902 903 O
use NCT03923569 905 908 B-Eq-Comparison
of NCT03923569 909 911 O
benzodiazepines NCT03923569 912 927 B-Drug
at NCT03923569 928 930 O
a NCT03923569 931 932 O
dose NCT03923569 933 937 O
superior NCT03923569 938 946 B-Eq-Comparison
or NCT03923569 947 949 I-Eq-Comparison
equal NCT03923569 950 955 I-Eq-Comparison
to NCT03923569 956 958 I-Eq-Comparison
two NCT03923569 959 962 I-Eq-Comparison
intakes NCT03923569 963 970 I-Eq-Comparison
per NCT03923569 971 974 I-Eq-Comparison
day NCT03923569 975 978 I-Eq-Comparison

- NCT03923569 981 982 O
use NCT03923569 984 987 B-Eq-Comparison
of NCT03923569 988 990 O
antidepressants NCT03923569 991 1006 B-Drug

- NCT03923569 1009 1010 O
restless NCT03923569 1012 1020 B-Condition
leg NCT03923569 1021 1024 I-Condition
syndrome NCT03923569 1025 1033 I-Condition
treated NCT03923569 1034 1041 O
by NCT03923569 1042 1044 O
dopaminergic NCT03923569 1045 1057 B-Drug
agonists NCT03923569 1058 1066 I-Drug
. NCT03923569 1067 1068 O

For NCT03923569 1070 1073 O
AD NCT03923569 1074 1076 B-Condition
patients NCT03923569 1077 1085 O
: NCT03923569 1086 1087 O

- NCT03923569 1091 1092 O
other NCT03923569 1094 1099 B-Other
causes NCT03923569 1100 1106 B-Condition
of NCT03923569 1107 1109 O
dementia NCT03923569 1110 1118 B-Condition

- NCT03923569 1121 1122 O
non NCT03923569 1124 1127 B-Modifier
- NCT03923569 1128 1129 I-Modifier
degenerative NCT03923569 1130 1142 I-Modifier
neurological NCT03923569 1143 1155 I-Modifier
lesions NCT03923569 1156 1163 B-Condition

- NCT03923569 1166 1167 O
white NCT03923569 1169 1174 B-Condition
matter NCT03923569 1175 1181 I-Condition
hypersignals NCT03923569 1182 1194 I-Condition

- NCT03923569 1197 1198 O
acute NCT03923569 1200 1205 O
cognitive NCT03923569 1206 1215 B-Condition
deficits NCT03923569 1216 1224 I-Condition

Inclusion NCT03924206 0 9 O
Criteria NCT03924206 10 18 O
: NCT03924206 19 20 O

- NCT03924206 23 24 O
All NCT03924206 25 28 O
surgical NCT03924206 29 37 B-Procedure
procedures NCT03924206 38 48 I-Procedure
with NCT03924206 49 53 O
a NCT03924206 54 55 O
planned NCT03924206 56 63 B-Eq-Comparison
duration NCT03924206 64 72 O
of NCT03924206 73 75 O
more NCT03924206 76 80 B-Eq-Comparison
than NCT03924206 81 85 I-Eq-Comparison
1 NCT03924206 86 87 I-Eq-Comparison
hour NCT03924206 88 92 I-Eq-Comparison

Exclusion NCT03924206 93 102 O
Criteria NCT03924206 103 111 O
: NCT03924206 112 113 O

- NCT03924206 117 118 O
Patients NCT03924206 120 128 O
with NCT03924206 129 133 O
a NCT03924206 134 135 O
contraindication NCT03924206 136 152 B-Contraindication
for NCT03924206 153 156 O
electrocautery NCT03924206 157 171 B-Procedure
use NCT03924206 172 175 O

- NCT03924206 178 179 O
Patients NCT03924206 181 189 O
with NCT03924206 190 194 O
Pacemaker NCT03924206 195 204 B-Procedure
or NCT03924206 205 207 B-Or
implantable NCT03924206 208 219 B-Procedure
cardioverter NCT03924206 220 232 I-Procedure
- NCT03924206 233 234 I-Procedure
defibrillator NCT03924206 235 248 I-Procedure
( NCT03924206 249 250 O
ICD NCT03924206 251 254 B-Procedure
) NCT03924206 255 256 O

- NCT03924206 260 261 O
Patients NCT03924206 263 271 O
with NCT03924206 272 276 O
an NCT03924206 277 279 O
implanted NCT03924206 280 289 B-Procedure
neurostimulator NCT03924206 290 305 I-Procedure
device NCT03924206 306 312 I-Procedure

Inclusion NCT03925454 0 9 O
Criteria NCT03925454 10 18 O
: NCT03925454 19 20 O

- NCT03925454 24 25 O
Receiving NCT03925454 27 36 B-Eq-Comparison
HHD NCT03925454 37 40 B-Procedure
or NCT03925454 41 43 B-Or
ICHDF NCT03925454 44 49 B-Procedure
for NCT03925454 50 53 O
more NCT03925454 54 58 B-Eq-Comparison
than NCT03925454 59 63 I-Eq-Comparison
3 NCT03925454 64 65 I-Eq-Comparison
months NCT03925454 66 72 I-Eq-Comparison
and NCT03925454 73 76 B-And
less NCT03925454 77 81 B-Eq-Comparison
than NCT03925454 82 86 I-Eq-Comparison
36 NCT03925454 87 89 I-Eq-Comparison
months NCT03925454 90 96 I-Eq-Comparison
. NCT03925454 97 98 O

- NCT03925454 102 103 O
Haemoglobin NCT03925454 105 116 B-Observation
equal NCT03925454 117 122 B-Eq-Comparison
to NCT03925454 123 125 I-Eq-Comparison
or NCT03925454 126 128 I-Eq-Comparison
greater NCT03925454 129 136 I-Eq-Comparison
than100 NCT03925454 137 144 I-Eq-Comparison
g NCT03925454 145 146 I-Eq-Comparison
/ NCT03925454 147 148 I-Eq-Comparison
L NCT03925454 149 150 I-Eq-Comparison
at NCT03925454 151 153 B-Temporal-Connection___Temporal-Connection-Type-Value:during
enrolment NCT03925454 154 163 B-Study
. NCT03925454 164 165 O

- NCT03925454 169 170 O
Willing NCT03925454 172 179 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03925454 180 183 B-And
physically NCT03925454 184 194 O
able NCT03925454 195 199 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03925454 200 202 O
undertake NCT03925454 203 212 O
the NCT03925454 213 216 O
study NCT03925454 217 222 B-Study
assessments NCT03925454 223 234 B-Procedure
/ NCT03925454 235 236 B-Or
tests NCT03925454 237 242 B-Procedure

- NCT03925454 245 246 O
Willing NCT03925454 248 255 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03925454 256 258 O
provide NCT03925454 259 266 O
blood NCT03925454 267 272 B-Observation
for NCT03925454 273 276 O
storage NCT03925454 277 284 O
and NCT03925454 285 288 O
future NCT03925454 289 295 O
analysis NCT03925454 296 304 O

- NCT03925454 307 308 O
Able NCT03925454 310 314 O
to NCT03925454 315 317 O
give NCT03925454 318 322 O
informed NCT03925454 323 331 O
consent NCT03925454 332 339 O

Exclusion NCT03925454 340 349 O
Criteria NCT03925454 350 358 O
: NCT03925454 359 360 O

- NCT03925454 364 365 O
Living NCT03925454 367 373 B-Procedure
donor NCT03925454 374 379 I-Procedure
transplant NCT03925454 380 390 I-Procedure
or NCT03925454 391 393 B-Or
change NCT03925454 394 400 O
to NCT03925454 401 403 O
peritoneal NCT03925454 404 414 B-Procedure
dialysis NCT03925454 415 423 I-Procedure
planned NCT03925454 424 431 B-Eq-Comparison

- NCT03925454 434 435 O
Physical NCT03925454 437 445 B-Procedure
assessments NCT03925454 446 457 I-Procedure
contraindicated NCT03925454 458 473 B-Contraindication
for NCT03925454 474 477 O
the NCT03925454 478 481 O
following NCT03925454 482 491 O
clinical NCT03925454 492 500 O
reasons NCT03925454 501 508 O

- NCT03925454 516 517 O
Acute NCT03925454 519 524 B-Condition
Coronary NCT03925454 525 533 I-Condition
Syndrome NCT03925454 534 542 I-Condition
( NCT03925454 543 544 O
ACS NCT03925454 545 548 B-Condition
) NCT03925454 549 550 O
within NCT03925454 551 557 B-Eq-Comparison
the NCT03925454 558 561 I-Eq-Comparison
last NCT03925454 562 566 I-Eq-Comparison
3 NCT03925454 567 568 I-Eq-Comparison
months NCT03925454 569 575 I-Eq-Comparison
( NCT03925454 576 577 O
chest NCT03925454 578 583 B-Modifier
pain NCT03925454 584 588 B-Condition
, NCT03925454 589 590 O
ECG NCT03925454 591 594 B-Procedure
changes NCT03925454 595 602 O
or NCT03925454 603 605 B-Or
typical NCT03925454 606 613 O
biomarker NCT03925454 614 623 B-Observation
elevation NCT03925454 624 633 O
) NCT03925454 634 635 O
. NCT03925454 637 638 O

- NCT03925454 647 648 O
Any NCT03925454 650 653 O
current NCT03925454 654 661 B-Eq-Comparison
uncontrolled NCT03925454 662 674 B-Modifier
cardiac NCT03925454 675 682 B-Condition
dysrhythmias NCT03925454 683 695 I-Condition
causing NCT03925454 696 703 O
symptoms NCT03925454 704 712 B-Assertion___Assertion-Type-Value:possible
( NCT03925454 713 714 O
chest NCT03925454 715 720 B-Modifier
pain NCT03925454 721 725 B-Condition
, NCT03925454 726 727 O
palpitations NCT03925454 728 740 B-Condition
, NCT03925454 741 742 O
syncope NCT03925454 743 750 B-Condition
or NCT03925454 751 753 B-Or
dizziness NCT03925454 754 763 B-Condition
) NCT03925454 764 765 O

- NCT03925454 774 775 O
Symptomatic NCT03925454 777 788 B-Condition
aortic NCT03925454 789 795 I-Condition
stenosis NCT03925454 796 804 I-Condition

- NCT03925454 812 813 O
New NCT03925454 815 818 B-Condition
York NCT03925454 819 823 I-Condition
Heart NCT03925454 824 829 I-Condition
Association NCT03925454 830 841 I-Condition
grade NCT03925454 842 847 B-Eq-Comparison
IV NCT03925454 848 850 I-Eq-Comparison
Heart NCT03925454 851 856 B-Condition
failure NCT03925454 857 864 I-Condition

- NCT03925454 872 873 O
Severe NCT03925454 875 881 O
chronic NCT03925454 882 889 B-Modifier
obstructive NCT03925454 890 901 B-Condition
pulmonary NCT03925454 902 911 I-Condition
disease NCT03925454 912 919 I-Condition

- NCT03925454 927 928 O
Acute NCT03925454 930 935 O
pulmonary NCT03925454 936 945 B-Condition
embolus NCT03925454 946 953 I-Condition
or NCT03925454 954 956 B-Or
pulmonary NCT03925454 957 966 B-Condition
infarction NCT03925454 967 977 I-Condition
in NCT03925454 978 980 O
the NCT03925454 981 984 O
last NCT03925454 985 989 B-Eq-Comparison
3 NCT03925454 990 991 I-Eq-Comparison
months NCT03925454 992 998 I-Eq-Comparison

- NCT03925454 1006 1007 O
Current NCT03925454 1009 1016 B-Eq-Comparison
acute NCT03925454 1017 1022 B-Condition
myocarditis NCT03925454 1023 1034 I-Condition
or NCT03925454 1035 1037 B-Or
pericarditis NCT03925454 1038 1050 B-Condition

- NCT03925454 1058 1059 O
Suspected NCT03925454 1061 1070 B-Assertion___Assertion-Type-Value:possible
or NCT03925454 1071 1073 B-Or
known NCT03925454 1074 1079 B-Modifier
dissecting NCT03925454 1080 1090 B-Condition
aneurysm NCT03925454 1091 1099 I-Condition

- NCT03925454 1107 1108 O
Acute NCT03925454 1110 1115 O
systemic NCT03925454 1116 1124 B-Modifier
infection NCT03925454 1125 1134 B-Condition
, NCT03925454 1135 1136 O
accompanied NCT03925454 1137 1148 B-And
by NCT03925454 1149 1151 I-And
fever NCT03925454 1152 1157 B-Condition
, NCT03925454 1158 1159 O
body NCT03925454 1160 1164 B-Condition
aches NCT03925454 1165 1170 I-Condition
or NCT03925454 1171 1173 B-Or
swollen NCT03925454 1174 1181 B-Condition
lymph NCT03925454 1182 1187 I-Condition
glands NCT03925454 1188 1194 I-Condition

- NCT03925454 1197 1198 O
Pregnancy NCT03925454 1200 1209 B-Condition

- NCT03925454 1212 1213 O
Life NCT03925454 1215 1219 B-Observation
expectancy NCT03925454 1220 1230 I-Observation
of NCT03925454 1231 1233 O
less NCT03925454 1234 1238 B-Eq-Comparison
than NCT03925454 1239 1243 I-Eq-Comparison
twelve NCT03925454 1244 1250 I-Eq-Comparison
months NCT03925454 1251 1257 I-Eq-Comparison

Inclusion NCT03921632 0 9 O
Criteria NCT03921632 10 18 O
: NCT03921632 19 20 O

- NCT03921632 24 25 O
Patient NCT03921632 27 34 O
of NCT03921632 35 37 O
the NCT03921632 38 41 O
UNC NCT03921632 42 45 O
Center NCT03921632 46 52 O
for NCT03921632 53 56 O
Excellence NCT03921632 57 67 O
for NCT03921632 68 71 O
Eating NCT03921632 72 78 O
Disorders NCT03921632 79 88 O
inpatient NCT03921632 89 98 O
unit NCT03921632 99 103 O
or NCT03921632 104 106 B-Or
outpatient NCT03921632 107 117 O
clinic NCT03921632 118 124 O
. NCT03921632 125 126 O

- NCT03921632 130 131 O
Diagnosis NCT03921632 133 142 O
of NCT03921632 143 145 O
anorexia NCT03921632 146 154 B-Condition
nervosa NCT03921632 155 162 I-Condition
or NCT03921632 163 165 B-Or
bulimia NCT03921632 166 173 B-Condition
nervosa NCT03921632 174 181 I-Condition

- NCT03921632 184 185 O
Aged NCT03921632 187 191 B-Age
13 NCT03921632 192 194 B-Eq-Comparison
- NCT03921632 195 196 I-Eq-Comparison
50 NCT03921632 197 199 I-Eq-Comparison
years NCT03921632 200 205 I-Eq-Comparison

- NCT03921632 208 209 O
English NCT03921632 211 218 O
- NCT03921632 219 220 O
speaking NCT03921632 221 229 O

Exclusion NCT03921632 230 239 O
Criteria NCT03921632 240 248 O
: NCT03921632 249 250 O

- NCT03921632 254 255 O
Decisionally NCT03921632 257 269 B-Condition
impaired NCT03921632 270 278 I-Condition
( NCT03921632 279 280 O
i. NCT03921632 281 283 O
e. NCT03921632 284 286 O
, NCT03921632 287 288 O
Incapable NCT03921632 289 298 O
of NCT03921632 299 301 O
providing NCT03921632 302 311 O
informed NCT03921632 312 320 O
consent NCT03921632 321 328 O
in NCT03921632 329 331 O
the NCT03921632 332 335 O
opinion NCT03921632 336 343 O
of NCT03921632 344 346 O
the NCT03921632 347 350 O
primary NCT03921632 351 358 O
care NCT03921632 359 363 O
provider NCT03921632 364 372 O
in NCT03921632 373 375 O
UNC NCT03921632 376 379 O
Center NCT03921632 380 386 O
for NCT03921632 387 390 O
Excellence NCT03921632 391 401 O
for NCT03921632 402 405 O
Eating NCT03921632 406 412 O
Disorders NCT03921632 413 422 O
) NCT03921632 423 424 O

- NCT03921632 428 429 O
Involuntarily NCT03921632 431 444 B-Observation
committed NCT03921632 445 454 I-Observation
to NCT03921632 455 457 O
the NCT03921632 458 461 O
inpatient NCT03921632 462 471 O
service NCT03921632 472 479 O
of NCT03921632 480 482 O
the NCT03921632 483 486 O
UNC NCT03921632 487 490 B-Provider
Department NCT03921632 491 501 I-Provider
of NCT03921632 502 504 I-Provider
Psychiatry NCT03921632 505 515 I-Provider

Inclusion NCT03928158 0 9 O
Criteria NCT03928158 10 18 O
: NCT03928158 19 20 O

1 NCT03928158 24 25 O
. NCT03928158 25 26 O
Moderate NCT03928158 28 36 O
/ NCT03928158 37 38 B-Or
severe NCT03928158 39 45 O
hypertensive NCT03928158 46 58 B-Modifier
left NCT03928158 59 63 I-Modifier
ventricular NCT03928158 64 75 I-Modifier
( NCT03928158 76 77 O
LV NCT03928158 78 80 B-Modifier
) NCT03928158 81 82 O
hypertrophy NCT03928158 83 94 B-Condition
( NCT03928158 95 96 O
LVMi NCT03928158 97 101 B-Observation
≥ NCT03928158 102 103 B-Eq-Comparison
109 NCT03928158 104 107 I-Eq-Comparison
g NCT03928158 108 109 I-Eq-Comparison
/ NCT03928158 110 111 I-Eq-Comparison
m² NCT03928158 112 114 I-Eq-Comparison
in NCT03928158 115 117 O
women NCT03928158 118 123 O
and NCT03928158 124 127 B-Or
≥ NCT03928158 128 129 B-Eq-Comparison
132 NCT03928158 130 133 I-Eq-Comparison
g NCT03928158 134 135 I-Eq-Comparison
/ NCT03928158 136 137 I-Eq-Comparison
m² NCT03928158 138 140 I-Eq-Comparison
in NCT03928158 141 143 O
men NCT03928158 144 147 O
) NCT03928158 148 149 O
; NCT03928158 150 151 O

2 NCT03928158 154 155 O
. NCT03928158 155 156 O
New NCT03928158 158 161 B-Condition
York NCT03928158 162 166 I-Condition
Heart NCT03928158 167 172 I-Condition
Association NCT03928158 173 184 I-Condition
( NCT03928158 185 186 O
NYHA NCT03928158 187 191 B-Condition
) NCT03928158 192 193 O
class NCT03928158 194 199 B-Eq-Comparison
II NCT03928158 200 202 I-Eq-Comparison
- NCT03928158 203 204 I-Eq-Comparison
III NCT03928158 205 208 I-Eq-Comparison
heart NCT03928158 209 214 B-Condition
failure NCT03928158 215 222 I-Condition
; NCT03928158 222 223 O

3 NCT03928158 226 227 O
. NCT03928158 227 228 O
Left NCT03928158 230 234 B-Observation
ventricular NCT03928158 235 246 I-Observation
ejection NCT03928158 247 255 I-Observation
fraction NCT03928158 256 264 I-Observation
> NCT03928158 265 266 B-Eq-Comparison
50 NCT03928158 267 269 I-Eq-Comparison
% NCT03928158 270 271 I-Eq-Comparison
; NCT03928158 272 273 O

4 NCT03928158 276 277 O
. NCT03928158 277 278 O
Increased NCT03928158 280 289 O
LV NCT03928158 290 292 B-Observation
filling NCT03928158 293 300 I-Observation
pressures NCT03928158 301 310 I-Observation
assessed NCT03928158 311 319 O
at NCT03928158 320 322 O
rest NCT03928158 323 327 B-Modifier
or NCT03928158 328 330 B-Or
at NCT03928158 331 333 O
peak NCT03928158 334 338 B-Modifier
exercise NCT03928158 339 347 I-Modifier
by NCT03928158 348 350 O
echocardiography NCT03928158 351 367 B-Procedure

5 NCT03928158 370 371 O
. NCT03928158 371 372 O
Body NCT03928158 374 378 B-Observation
mass NCT03928158 379 383 I-Observation
index NCT03928158 384 389 I-Observation
( NCT03928158 390 391 O
BMI NCT03928158 392 395 B-Observation
) NCT03928158 396 397 O
> NCT03928158 398 399 B-Eq-Comparison
30 NCT03928158 400 402 I-Eq-Comparison
kg NCT03928158 403 405 I-Eq-Comparison
/ NCT03928158 406 407 I-Eq-Comparison
m² NCT03928158 408 410 I-Eq-Comparison

6 NCT03928158 413 414 O
. NCT03928158 414 415 O
Signed NCT03928158 417 423 O
and NCT03928158 424 427 O
data NCT03928158 428 432 O
informed NCT03928158 433 441 O
consent NCT03928158 442 449 O

Exclusion NCT03928158 450 459 O
Criteria NCT03928158 460 468 O
: NCT03928158 469 470 O

1 NCT03928158 474 475 O
. NCT03928158 475 476 O
Age NCT03928158 478 481 B-Age
≤ NCT03928158 482 483 B-Eq-Comparison
18 NCT03928158 484 486 I-Eq-Comparison
years NCT03928158 487 492 I-Eq-Comparison
; NCT03928158 492 493 O

2 NCT03928158 496 497 O
. NCT03928158 497 498 O
Evidence NCT03928158 500 508 O
of NCT03928158 509 511 O
myocardial NCT03928158 512 522 B-Condition
ischemia NCT03928158 523 531 I-Condition
during NCT03928158 532 538 O
stress NCT03928158 539 545 B-Procedure
echocardiography NCT03928158 546 562 I-Procedure
; NCT03928158 562 563 O

3 NCT03928158 566 567 O
. NCT03928158 567 568 O
Chronic NCT03928158 570 577 B-Modifier
atrial NCT03928158 578 584 B-Condition
flutter NCT03928158 585 592 I-Condition
or NCT03928158 593 595 B-Or
atrial NCT03928158 596 602 B-Condition
fibrillation NCT03928158 603 615 I-Condition
; NCT03928158 615 616 O

4 NCT03928158 619 620 O
. NCT03928158 620 621 O
Alternative NCT03928158 623 634 B-Other
cause NCT03928158 635 640 B-Condition
of NCT03928158 641 643 O
left NCT03928158 644 648 B-Condition
ventricular NCT03928158 649 660 I-Condition
hypertrophy NCT03928158 661 672 I-Condition
and NCT03928158 673 676 B-Or
impaired NCT03928158 677 685 B-Condition
diastolic NCT03928158 686 695 I-Condition
function NCT03928158 696 704 I-Condition
( NCT03928158 705 706 O
hypertrophic NCT03928158 707 719 B-Modifier
/ NCT03928158 720 721 B-Or
restictive NCT03928158 722 732 B-Modifier
cardiomyopathy NCT03928158 733 747 B-Condition
, NCT03928158 748 749 O
aortic NCT03928158 750 756 B-Condition
stenosis NCT03928158 757 765 I-Condition
, NCT03928158 766 767 O
constrictive NCT03928158 768 780 B-Condition
pericarditis NCT03928158 781 793 I-Condition
and NCT03928158 794 797 O
etc NCT03928158 798 801 O
. NCT03928158 801 802 O
) NCT03928158 803 804 O
; NCT03928158 805 806 O

5 NCT03928158 809 810 O
. NCT03928158 810 811 O
NYHA NCT03928158 813 817 B-Condition
classification NCT03928158 818 832 B-Eq-Comparison
I NCT03928158 833 834 I-Eq-Comparison
or NCT03928158 835 837 B-Or
decompensated NCT03928158 838 851 B-Modifier
heart NCT03928158 852 857 B-Condition
failure NCT03928158 858 865 I-Condition
at NCT03928158 866 868 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03928158 869 878 B-Study
; NCT03928158 878 879 O

6 NCT03928158 882 883 O
. NCT03928158 883 884 O
Systolic NCT03928158 886 894 B-Observation
blood NCT03928158 895 900 I-Observation
pressure NCT03928158 901 909 I-Observation
< NCT03928158 910 911 B-Eq-Comparison
110 NCT03928158 912 915 I-Eq-Comparison
mmHg NCT03928158 916 920 I-Eq-Comparison
or NCT03928158 921 923 B-Or
> NCT03928158 924 925 B-Eq-Comparison
180 NCT03928158 926 929 I-Eq-Comparison
mmHg NCT03928158 930 934 I-Eq-Comparison
; NCT03928158 934 935 O

7 NCT03928158 938 939 O
. NCT03928158 939 940 O
Diastolic NCT03928158 942 951 B-Observation
blood NCT03928158 952 957 I-Observation
pressure NCT03928158 958 966 I-Observation
< NCT03928158 967 968 B-Eq-Comparison
40 NCT03928158 969 971 I-Eq-Comparison
mmHg NCT03928158 972 976 I-Eq-Comparison
or NCT03928158 977 979 B-Or
> NCT03928158 980 981 B-Eq-Comparison
100 NCT03928158 982 985 I-Eq-Comparison
mmHg NCT03928158 986 990 I-Eq-Comparison
; NCT03928158 990 991 O

8 NCT03928158 994 995 O
. NCT03928158 995 996 O
Anemia NCT03928158 998 1004 B-Condition
( NCT03928158 1005 1006 O
Hb NCT03928158 1007 1009 B-Observation
< NCT03928158 1010 1011 B-Eq-Comparison
100 NCT03928158 1012 1015 I-Eq-Comparison
g NCT03928158 1016 1017 I-Eq-Comparison
/ NCT03928158 1018 1019 I-Eq-Comparison
l NCT03928158 1020 1021 I-Eq-Comparison
) NCT03928158 1022 1023 O
; NCT03928158 1024 1025 O

9 NCT03928158 1028 1029 O
. NCT03928158 1029 1030 O
Significant NCT03928158 1032 1043 O
left NCT03928158 1044 1048 B-Modifier
sided NCT03928158 1049 1054 I-Modifier
structural NCT03928158 1055 1065 B-Condition
valve NCT03928158 1066 1071 I-Condition
disease NCT03928158 1072 1079 I-Condition
; NCT03928158 1079 1080 O

10 NCT03928158 1082 1084 O
. NCT03928158 1084 1085 O
Secondary NCT03928158 1087 1096 B-Modifier
hypertension NCT03928158 1097 1109 B-Condition
; NCT03928158 1109 1110 O

11 NCT03928158 1112 1114 O
. NCT03928158 1114 1115 O
Dyspnea NCT03928158 1117 1124 B-Condition
due NCT03928158 1125 1128 O
to NCT03928158 1129 1131 O
non NCT03928158 1132 1135 B-Modifier
- NCT03928158 1136 1137 I-Modifier
cardiac NCT03928158 1138 1145 I-Modifier
causes NCT03928158 1146 1152 B-Condition
such NCT03928158 1153 1157 O
as NCT03928158 1158 1160 O
pulmonary NCT03928158 1161 1170 B-Condition
disease NCT03928158 1171 1178 I-Condition
, NCT03928158 1179 1180 O
anemia NCT03928158 1181 1187 B-Condition
, NCT03928158 1188 1189 O
severe NCT03928158 1190 1196 O
obesity NCT03928158 1197 1204 B-Condition
, NCT03928158 1205 1206 O
primary NCT03928158 1207 1214 B-Condition
valvular NCT03928158 1215 1223 I-Condition
, NCT03928158 1224 1225 O
or NCT03928158 1226 1228 B-Or
myocardial NCT03928158 1229 1239 B-Condition
diseases NCT03928158 1240 1248 I-Condition
; NCT03928158 1248 1249 O

12 NCT03928158 1251 1253 O
. NCT03928158 1253 1254 O
Myocardial NCT03928158 1256 1266 B-Condition
infarction NCT03928158 1267 1277 I-Condition
or NCT03928158 1278 1280 B-Or
myocardial NCT03928158 1281 1291 B-Procedure
revascularization NCT03928158 1292 1309 I-Procedure
within NCT03928158 1310 1316 B-Eq-Comparison
the NCT03928158 1317 1320 I-Eq-Comparison
last NCT03928158 1321 1325 I-Eq-Comparison
3 NCT03928158 1326 1327 I-Eq-Comparison
months NCT03928158 1328 1334 I-Eq-Comparison
of NCT03928158 1335 1337 B-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03928158 1338 1347 B-Study
; NCT03928158 1347 1348 O

13 NCT03928158 1350 1352 O
. NCT03928158 1352 1353 O
Stroke NCT03928158 1355 1361 B-Condition
or NCT03928158 1362 1364 B-Or
TIA NCT03928158 1365 1368 B-Condition
within NCT03928158 1369 1375 B-Eq-Comparison
the NCT03928158 1376 1379 I-Eq-Comparison
last NCT03928158 1380 1384 I-Eq-Comparison
3 NCT03928158 1385 1386 I-Eq-Comparison
months NCT03928158 1387 1393 I-Eq-Comparison
of NCT03928158 1394 1396 B-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03928158 1397 1406 B-Study
; NCT03928158 1406 1407 O

14 NCT03928158 1409 1411 O
. NCT03928158 1411 1412 O
Autoimmunic NCT03928158 1414 1425 B-Modifier
and NCT03928158 1426 1429 B-Or
oncological NCT03928158 1430 1441 B-Modifier
diseases NCT03928158 1442 1450 B-Condition
; NCT03928158 1450 1451 O

15 NCT03928158 1453 1455 O
. NCT03928158 1455 1456 O
Impaired NCT03928158 1458 1466 B-Condition
renal NCT03928158 1467 1472 I-Condition
function NCT03928158 1473 1481 I-Condition
, NCT03928158 1482 1483 O
defined NCT03928158 1484 1491 O
as NCT03928158 1492 1494 O
eGFR NCT03928158 1495 1499 B-Observation
< NCT03928158 1500 1501 B-Eq-Comparison
30 NCT03928158 1502 1504 I-Eq-Comparison
ml NCT03928158 1505 1507 I-Eq-Comparison
/ NCT03928158 1508 1509 I-Eq-Comparison
min NCT03928158 1510 1513 I-Eq-Comparison
/ NCT03928158 1514 1515 I-Eq-Comparison
1.73 NCT03928158 1516 1520 I-Eq-Comparison
m² NCT03928158 1521 1523 I-Eq-Comparison
; NCT03928158 1523 1524 O

16 NCT03928158 1526 1528 O
. NCT03928158 1528 1529 O
Impaired NCT03928158 1531 1539 B-Condition
liver NCT03928158 1540 1545 I-Condition
function NCT03928158 1546 1554 I-Condition
; NCT03928158 1554 1555 O

17 NCT03928158 1557 1559 O
. NCT03928158 1559 1560 O
Potassium NCT03928158 1562 1571 B-Observation
concentration NCT03928158 1572 1585 I-Observation
> NCT03928158 1586 1587 O
5.2 NCT03928158 1588 1591 O
mmol NCT03928158 1592 1596 O
/ NCT03928158 1597 1598 O
L. NCT03928158 1599 1601 O

Inclusion NCT03929497 0 9 O
Criteria NCT03929497 10 18 O
: NCT03929497 19 20 O

- NCT03929497 24 25 O
The NCT03929497 27 30 O
patient NCT03929497 31 38 O
completed NCT03929497 39 48 O
Study NCT03929497 49 54 B-Study
17972 NCT03929497 55 60 O
A NCT03929497 61 62 O
. NCT03929497 63 64 O

- NCT03929497 68 69 O
The NCT03929497 71 74 O
patient NCT03929497 75 82 O
and NCT03929497 83 86 O
the NCT03929497 87 90 O
patient NCT03929497 91 98 O
's NCT03929497 98 100 O
caregiver NCT03929497 101 110 O
or NCT03929497 111 113 O
identified NCT03929497 114 124 O
responsible NCT03929497 125 136 O
person NCT03929497 137 143 O
is NCT03929497 144 146 O
able NCT03929497 147 151 O
to NCT03929497 152 154 O
read NCT03929497 155 159 O
and NCT03929497 160 163 O
understand NCT03929497 164 174 O
the NCT03929497 175 178 O
Informed NCT03929497 179 187 O
Consent NCT03929497 188 195 O
Form NCT03929497 196 200 O
. NCT03929497 201 202 O

- NCT03929497 206 207 O
The NCT03929497 209 212 O
patient NCT03929497 213 220 O
has NCT03929497 221 224 O
signed NCT03929497 225 231 O
the NCT03929497 232 235 O
Informed NCT03929497 236 244 O
Consent NCT03929497 245 252 O
Form NCT03929497 253 257 O
specific NCT03929497 258 266 O
for NCT03929497 267 270 O
Study NCT03929497 271 276 B-Study
17972 NCT03929497 277 282 O
B NCT03929497 283 284 O
. NCT03929497 285 286 O

- NCT03929497 290 291 O
The NCT03929497 293 296 O
patient NCT03929497 297 304 O
can NCT03929497 305 308 B-Assertion___Assertion-Type-Value:hypothetical
potentially NCT03929497 309 320 I-Assertion___Assertion-Type-Value:hypothetical
benefit NCT03929497 321 328 O
from NCT03929497 329 333 O
24 NCT03929497 334 336 B-Eq-Comparison
weeks NCT03929497 337 342 I-Eq-Comparison
of NCT03929497 343 345 O
treatment NCT03929497 346 355 B-Procedure
with NCT03929497 356 360 O
Lu NCT03929497 361 363 B-Drug
AF11167 NCT03929497 364 371 I-Drug
according NCT03929497 372 381 O
to NCT03929497 382 384 O
the NCT03929497 385 388 O
investigator NCT03929497 389 401 O
's NCT03929497 401 403 O
clinical NCT03929497 404 412 O
judgment NCT03929497 413 421 O
. NCT03929497 422 423 O

Exclusion NCT03929497 425 434 O
Criteria NCT03929497 435 443 O
: NCT03929497 444 445 O

- NCT03929497 449 450 O
The NCT03929497 452 455 O
patient NCT03929497 456 463 O
has NCT03929497 464 467 O
any NCT03929497 468 471 O
current NCT03929497 472 479 B-Eq-Comparison
primary NCT03929497 480 487 B-Modifier
psychiatric NCT03929497 488 499 B-Condition
disorder NCT03929497 500 508 I-Condition
other NCT03929497 509 514 B-Exception
than NCT03929497 515 519 I-Exception
schizophrenia NCT03929497 520 533 B-Condition
diagnosed NCT03929497 534 543 O
during NCT03929497 544 550 B-Temporal-Connection___Temporal-Connection-Type-Value:during
study NCT03929497 551 556 B-Study
17972 NCT03929497 557 562 O
A NCT03929497 563 564 O

- NCT03929497 567 568 O
The NCT03929497 570 573 O
patient NCT03929497 574 581 O
, NCT03929497 582 583 O
in NCT03929497 584 586 O
the NCT03929497 587 590 O
opinion NCT03929497 591 598 O
of NCT03929497 599 601 O
the NCT03929497 602 605 O
investigator NCT03929497 606 618 O
, NCT03929497 619 620 O
is NCT03929497 621 623 O
at NCT03929497 624 626 O
significant NCT03929497 627 638 O
risk NCT03929497 639 643 B-Risk
of NCT03929497 644 646 O
suicide NCT03929497 647 654 B-Condition

Other NCT03929497 655 660 O
in NCT03929497 661 663 O
- NCT03929497 664 665 O
and NCT03929497 666 669 O
exclusion NCT03929497 670 679 O
criteria NCT03929497 680 688 O
may NCT03929497 689 692 O
apply NCT03929497 693 698 O

Inclusion NCT03921593 0 9 O
Criteria NCT03921593 10 18 O
: NCT03921593 19 20 O

- NCT03921593 24 25 O
Willing NCT03921593 27 34 O
and NCT03921593 35 38 O
able NCT03921593 39 43 O
to NCT03921593 44 46 O
give NCT03921593 47 51 O
informed NCT03921593 52 60 O
consent NCT03921593 61 68 O
for NCT03921593 69 72 O
participation NCT03921593 73 86 O
in NCT03921593 87 89 O
the NCT03921593 90 93 O
study NCT03921593 94 99 O

- NCT03921593 102 103 O
Insulin NCT03921593 105 112 B-Modifier
Dependent NCT03921593 113 122 I-Modifier
Diabetic NCT03921593 123 131 B-Condition
Patients NCT03921593 132 140 O

- NCT03921593 143 144 O
Active NCT03921593 146 152 B-Eq-Comparison
on NCT03921593 153 155 O
Pancreas NCT03921593 156 164 B-Observation
Transplant NCT03921593 165 175 I-Observation
Wait NCT03921593 176 180 I-Observation
List NCT03921593 181 185 I-Observation

Exclusion NCT03921593 186 195 O
Criteria NCT03921593 196 204 O
: NCT03921593 205 206 O

- NCT03921593 210 211 O
Not NCT03921593 213 216 B-Negation
fluent NCT03921593 217 223 O
in NCT03921593 224 226 O
English NCT03921593 227 234 O

Inclusion NCT03927690 0 9 O
Criteria NCT03927690 10 18 O

1 NCT03927690 21 22 O
. NCT03927690 22 23 O
Written NCT03927690 25 32 O
informed NCT03927690 33 41 O
consent NCT03927690 42 49 O
must NCT03927690 50 54 O
be NCT03927690 55 57 O
obtained NCT03927690 58 66 O
before NCT03927690 67 73 O
any NCT03927690 74 77 O
assessment NCT03927690 78 88 O
is NCT03927690 89 91 O
performed NCT03927690 92 101 O
. NCT03927690 102 103 O

2 NCT03927690 107 108 O
. NCT03927690 108 109 O
Male NCT03927690 111 115 O
and NCT03927690 116 119 B-Or
female NCT03927690 120 126 O
patients NCT03927690 127 135 O
age NCT03927690 136 139 B-Age
18 NCT03927690 140 142 B-Eq-Comparison
to NCT03927690 143 145 I-Eq-Comparison
85 NCT03927690 146 148 I-Eq-Comparison
years NCT03927690 149 154 I-Eq-Comparison
of NCT03927690 155 157 O
age NCT03927690 158 161 O
inclusive NCT03927690 162 171 O
at NCT03927690 172 174 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03927690 175 184 B-Study

3 NCT03927690 187 188 O
. NCT03927690 188 189 O
Presence NCT03927690 191 199 O
of NCT03927690 200 202 O
type NCT03927690 203 207 B-Modifier
I NCT03927690 208 209 I-Modifier
or NCT03927690 210 212 B-Or
type NCT03927690 213 217 B-Modifier
II NCT03927690 218 220 I-Modifier
diabetes NCT03927690 221 229 B-Condition
mellitus NCT03927690 230 238 I-Condition

4 NCT03927690 241 242 O
. NCT03927690 242 243 O
The NCT03927690 245 248 O
ETDRS NCT03927690 249 254 B-Observation
letter NCT03927690 255 261 I-Observation
score NCT03927690 262 267 I-Observation
in NCT03927690 268 270 O
the NCT03927690 271 274 O
study NCT03927690 275 280 O
eye NCT03927690 281 284 B-Modifier
must NCT03927690 285 289 O
be NCT03927690 290 292 O
between NCT03927690 293 300 B-Eq-Comparison
24 NCT03927690 301 303 I-Eq-Comparison
and NCT03927690 304 307 I-Eq-Comparison
70 NCT03927690 308 310 I-Eq-Comparison
letters NCT03927690 311 318 I-Eq-Comparison
( NCT03927690 319 320 O
approximate NCT03927690 321 332 O
Snellen NCT03927690 333 340 B-Observation
equivalent NCT03927690 341 351 O
of NCT03927690 352 354 O
20 NCT03927690 355 357 O
/ NCT03927690 358 359 O
40 NCT03927690 360 362 O
- NCT03927690 363 364 B-Eq-Comparison
20 NCT03927690 365 367 I-Eq-Comparison
/ NCT03927690 368 369 O
320 NCT03927690 370 373 O
) NCT03927690 374 375 O
. NCT03927690 376 377 O
The NCT03927690 379 382 O
non NCT03927690 383 386 O
- NCT03927690 387 388 O
study NCT03927690 389 394 O
eye NCT03927690 395 398 O
( NCT03927690 399 400 O
fellow NCT03927690 401 407 O
eye NCT03927690 408 411 O
) NCT03927690 412 413 O
should NCT03927690 414 420 O
be NCT03927690 421 423 O
≥ NCT03927690 424 425 B-Eq-Comparison
34 NCT03927690 426 428 I-Eq-Comparison
letters NCT03927690 429 436 I-Eq-Comparison
or NCT03927690 437 439 I-Eq-Comparison
better NCT03927690 440 446 I-Eq-Comparison
( NCT03927690 447 448 O
approximate NCT03927690 449 460 O
Snellen NCT03927690 461 468 B-Observation
equivalent NCT03927690 469 479 O
of NCT03927690 480 482 O
20 NCT03927690 483 485 B-Eq-Comparison
/ NCT03927690 486 487 I-Eq-Comparison
200 NCT03927690 488 491 I-Eq-Comparison
) NCT03927690 492 493 O
at NCT03927690 494 496 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03927690 497 506 B-Study

5 NCT03927690 509 510 O
. NCT03927690 510 511 O
Presence NCT03927690 513 521 O
of NCT03927690 522 524 O
DME NCT03927690 525 528 B-Condition
in NCT03927690 529 531 O
the NCT03927690 532 535 O
study NCT03927690 536 541 O
eye NCT03927690 542 545 B-Modifier
, NCT03927690 546 547 O
with NCT03927690 548 552 B-And
decrease NCT03927690 553 561 O
in NCT03927690 562 564 O
vision NCT03927690 565 571 B-Condition
due NCT03927690 572 575 O
to NCT03927690 576 578 O
foveal NCT03927690 579 585 B-Condition
thickening NCT03927690 586 596 I-Condition
of NCT03927690 597 599 O
central NCT03927690 600 607 B-Observation
macular NCT03927690 608 615 I-Observation
thickness NCT03927690 616 625 I-Observation
≥ NCT03927690 626 627 B-Eq-Comparison
320 NCT03927690 628 631 I-Eq-Comparison
µm NCT03927690 632 634 I-Eq-Comparison
in NCT03927690 635 637 O
the NCT03927690 638 641 O
central NCT03927690 642 649 B-Modifier
subfield NCT03927690 650 658 I-Modifier
, NCT03927690 659 660 O
as NCT03927690 661 663 O
assessed NCT03927690 664 672 O
on NCT03927690 673 675 O
SD NCT03927690 676 678 B-Procedure
- NCT03927690 679 680 I-Procedure
OCT NCT03927690 681 684 I-Procedure
and NCT03927690 685 688 O
confirmed NCT03927690 689 698 O
by NCT03927690 699 701 O
the NCT03927690 702 705 O
central NCT03927690 706 713 O
reading NCT03927690 714 721 O
center NCT03927690 722 728 O
at NCT03927690 729 731 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03927690 732 741 B-Study

Other NCT03927690 742 747 O
protocol NCT03927690 748 756 O
specified NCT03927690 757 766 O
inclusion NCT03927690 767 776 O
/ NCT03927690 777 778 O
exclusion NCT03927690 779 788 O
criteria NCT03927690 789 797 O
apply NCT03927690 798 803 O
. NCT03927690 803 804 O

Inclusion NCT03926559 0 9 O
Criteria NCT03926559 10 18 O
: NCT03926559 19 20 O

- NCT03926559 24 25 O
Patients NCT03926559 27 35 O
with NCT03926559 36 40 O
a NCT03926559 41 42 O
second NCT03926559 43 49 B-Modifier
degree NCT03926559 50 56 I-Modifier
, NCT03926559 57 58 O
third NCT03926559 59 64 B-Modifier
degree NCT03926559 65 71 I-Modifier
, NCT03926559 72 73 O
or NCT03926559 74 76 B-Or
fourth NCT03926559 77 83 B-Modifier
degree NCT03926559 84 90 I-Modifier
perineal NCT03926559 91 99 B-Condition
tear NCT03926559 100 104 I-Condition
identified NCT03926559 105 115 O
in NCT03926559 116 118 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03926559 119 122 O
immediate NCT03926559 123 132 O
postpartum NCT03926559 133 143 B-Condition
period NCT03926559 144 150 O
. NCT03926559 151 152 O

- NCT03926559 156 157 O
Pregnant NCT03926559 159 167 B-Condition
patients NCT03926559 168 176 O
who NCT03926559 177 180 B-And
received NCT03926559 181 189 B-Eq-Comparison
neuraxial NCT03926559 190 199 B-Procedure
anesthesia NCT03926559 200 210 I-Procedure
during NCT03926559 211 217 B-Temporal-Connection___Temporal-Connection-Type-Value:during
their NCT03926559 218 223 O
labor NCT03926559 224 229 B-Condition
course NCT03926559 230 236 O

- NCT03926559 239 240 O
Women NCT03926559 242 247 O
> NCT03926559 248 249 B-Eq-Comparison
18 NCT03926559 250 252 I-Eq-Comparison
yo NCT03926559 253 255 B-Age

Exclusion NCT03926559 256 265 O
Criteria NCT03926559 266 274 O
: NCT03926559 275 276 O

- NCT03926559 280 281 O
Unwillingness NCT03926559 283 296 O
to NCT03926559 297 299 O
participate NCT03926559 300 311 O
in NCT03926559 312 314 O
the NCT03926559 315 318 O
study NCT03926559 319 324 B-Study

- NCT03926559 327 328 O
Allergy NCT03926559 330 337 B-Allergy
to NCT03926559 338 340 O
morphine NCT03926559 341 349 B-Drug

- NCT03926559 352 353 O
Women NCT03926559 355 360 O
with NCT03926559 361 365 B-And
history NCT03926559 366 373 B-Eq-Comparison
of NCT03926559 374 376 O
polysubstance NCT03926559 377 390 B-Condition
abuse NCT03926559 391 396 I-Condition
/ NCT03926559 397 398 B-Or
narcotic NCT03926559 399 407 B-Condition
abuse NCT03926559 408 413 I-Condition

- NCT03926559 416 417 O
Women NCT03926559 419 424 O
< NCT03926559 425 426 B-Eq-Comparison
18 NCT03926559 427 429 I-Eq-Comparison
yo NCT03926559 430 432 B-Age

Inclusion NCT03924414 0 9 O
Criteria NCT03924414 10 18 O
: NCT03924414 19 20 O

- NCT03924414 24 25 O
Men NCT03924414 27 30 O
and NCT03924414 31 34 B-Or
women NCT03924414 35 40 O
age NCT03924414 41 44 B-Age
65 NCT03924414 45 47 B-Eq-Comparison
years NCT03924414 48 53 I-Eq-Comparison
or NCT03924414 54 56 I-Eq-Comparison
older NCT03924414 57 62 I-Eq-Comparison

- NCT03924414 65 66 O
Current NCT03924414 68 75 B-Eq-Comparison
PD NCT03924414 76 78 B-Condition
diagnosis NCT03924414 79 88 O
with NCT03924414 89 93 B-And
symptoms NCT03924414 94 102 O
severity NCT03924414 103 111 O
at NCT03924414 112 114 O
Hoehn NCT03924414 115 120 B-Condition
& NCT03924414 121 122 I-Condition
Yahr NCT03924414 123 127 I-Condition
( NCT03924414 128 129 O
H&Y NCT03924414 130 133 B-Condition
) NCT03924414 134 135 O
stage NCT03924414 136 141 B-Eq-Comparison
1 NCT03924414 142 143 I-Eq-Comparison
- NCT03924414 144 145 I-Eq-Comparison
4 NCT03924414 146 147 I-Eq-Comparison
based NCT03924414 148 153 O
on NCT03924414 154 156 O
an NCT03924414 157 159 O
expert NCT03924414 160 166 O
assessment NCT03924414 167 177 O
( NCT03924414 178 179 O
movement NCT03924414 180 188 B-Condition
disorders NCT03924414 189 198 I-Condition
neurologist NCT03924414 199 210 B-Provider
report NCT03924414 211 217 O
or NCT03924414 218 220 B-Or
telemedicine NCT03924414 221 233 B-Procedure
evaluation NCT03924414 234 244 I-Procedure
) NCT03924414 245 246 O

- NCT03924414 250 251 O
Willing NCT03924414 253 260 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03924414 261 264 B-And
able NCT03924414 265 269 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924414 270 272 O
continue NCT03924414 273 281 O
in NCT03924414 282 284 O
follow NCT03924414 285 291 B-Encounter
- NCT03924414 292 293 I-Encounter
up NCT03924414 294 296 I-Encounter
for NCT03924414 297 300 O
at NCT03924414 301 303 B-Eq-Comparison
least NCT03924414 304 309 I-Eq-Comparison
2 NCT03924414 310 311 I-Eq-Comparison
years NCT03924414 312 317 I-Eq-Comparison

- NCT03924414 320 321 O
Willing NCT03924414 323 330 O
and NCT03924414 331 334 O
able NCT03924414 335 339 O
to NCT03924414 340 342 O
provide NCT03924414 343 350 O
informed NCT03924414 351 359 O
consent NCT03924414 360 367 O

Exclusion NCT03924414 368 377 O
Criteria NCT03924414 378 386 O
: NCT03924414 387 388 O

- NCT03924414 392 393 O
History NCT03924414 395 402 B-Eq-Comparison
of NCT03924414 403 405 O
hip NCT03924414 406 409 B-Modifier
fracture NCT03924414 410 418 B-Condition

- NCT03924414 421 422 O
Any NCT03924414 424 427 O
use NCT03924414 428 431 O
of NCT03924414 432 434 O
a NCT03924414 435 436 O
bisphosphonate NCT03924414 437 451 B-Drug
drug NCT03924414 452 456 I-Drug
within NCT03924414 457 463 B-Eq-Comparison
the NCT03924414 464 467 I-Eq-Comparison
last NCT03924414 468 472 I-Eq-Comparison
12 NCT03924414 473 475 I-Eq-Comparison
months NCT03924414 476 482 I-Eq-Comparison

- NCT03924414 485 486 O
Use NCT03924414 488 491 O
of NCT03924414 492 494 O
any NCT03924414 495 498 O
other NCT03924414 499 504 B-Other
osteoporosis NCT03924414 505 517 B-Procedure
treatment NCT03924414 518 527 I-Procedure
( NCT03924414 528 529 O
such NCT03924414 530 534 O
as NCT03924414 535 537 O
SERMs NCT03924414 538 543 B-Drug
and NCT03924414 544 547 B-Or
denosumab NCT03924414 548 557 B-Drug
) NCT03924414 558 559 O
within NCT03924414 560 566 B-Eq-Comparison
the NCT03924414 567 570 I-Eq-Comparison
last NCT03924414 571 575 I-Eq-Comparison
6 NCT03924414 576 577 I-Eq-Comparison
months NCT03924414 578 584 I-Eq-Comparison

- NCT03924414 592 593 O
Tooth NCT03924414 595 600 B-Procedure
extraction NCT03924414 601 611 I-Procedure
or NCT03924414 612 614 B-Or
invasive NCT03924414 615 623 B-Modifier
dental NCT03924414 624 630 B-Procedure
procedures NCT03924414 631 641 I-Procedure
within NCT03924414 642 648 B-Eq-Comparison
the NCT03924414 649 652 I-Eq-Comparison
past NCT03924414 653 657 I-Eq-Comparison
30 NCT03924414 658 660 I-Eq-Comparison
days NCT03924414 661 665 I-Eq-Comparison
or NCT03924414 666 668 O
planned NCT03924414 669 676 B-Eq-Comparison
/ NCT03924414 677 678 B-Or
scheduled NCT03924414 679 688 B-Eq-Comparison
extraction NCT03924414 689 699 B-Procedure
/ NCT03924414 700 701 B-Or
procedure NCT03924414 702 711 B-Procedure
in NCT03924414 712 714 O
the NCT03924414 715 718 O
next NCT03924414 719 723 B-Eq-Comparison
12 NCT03924414 724 726 I-Eq-Comparison
months NCT03924414 727 733 I-Eq-Comparison

- NCT03924414 736 737 O
Non NCT03924414 739 742 B-Condition
- NCT03924414 743 744 I-Condition
ambulatory NCT03924414 745 755 I-Condition
, NCT03924414 756 757 O
i. NCT03924414 758 760 O
e. NCT03924414 761 763 O
, NCT03924414 764 765 O
unable NCT03924414 766 772 B-Condition
to NCT03924414 773 775 I-Condition
walk NCT03924414 776 780 I-Condition
without NCT03924414 781 788 O
assistance NCT03924414 789 799 O
of NCT03924414 800 802 O
another NCT03924414 803 810 O
person NCT03924414 811 817 O
. NCT03924414 818 819 O

- NCT03924414 823 824 O
Undergoing NCT03924414 826 836 B-Eq-Comparison
kidney NCT03924414 837 843 B-Procedure
dialysis NCT03924414 844 852 I-Procedure

- NCT03924414 855 856 O
A NCT03924414 858 859 O
diagnosis NCT03924414 860 869 O
of NCT03924414 870 872 O
multiple NCT03924414 873 881 B-Condition
myeloma NCT03924414 882 889 I-Condition
or NCT03924414 890 892 B-Or
Paget NCT03924414 893 898 B-Condition
's NCT03924414 898 900 I-Condition
disease NCT03924414 901 908 I-Condition

- NCT03924414 911 912 O
Unable NCT03924414 914 920 B-Negation
to NCT03924414 921 923 O
speak NCT03924414 924 929 O
or NCT03924414 930 932 O
read NCT03924414 933 937 O
English NCT03924414 938 945 O
sufficiently NCT03924414 946 958 O
to NCT03924414 959 961 O
complete NCT03924414 962 970 O
informed NCT03924414 971 979 O
consent NCT03924414 980 987 O

- NCT03924414 990 991 O
Any NCT03924414 993 996 O
other NCT03924414 997 1002 B-Other
criteria NCT03924414 1003 1011 B-Condition
, NCT03924414 1012 1013 O
which NCT03924414 1014 1019 O
would NCT03924414 1020 1025 O
make NCT03924414 1026 1030 O
the NCT03924414 1031 1034 O
patient NCT03924414 1035 1042 O
unsuitable NCT03924414 1043 1053 O
to NCT03924414 1054 1056 O
participate NCT03924414 1057 1068 O
in NCT03924414 1069 1071 O
this NCT03924414 1072 1076 O
study NCT03924414 1077 1082 O
as NCT03924414 1083 1085 O
determined NCT03924414 1086 1096 O
by NCT03924414 1097 1099 O
the NCT03924414 1100 1103 O
study NCT03924414 1104 1109 O
staff NCT03924414 1110 1115 O
( NCT03924414 1116 1117 O
e. NCT03924414 1118 1120 O
g. NCT03924414 1121 1123 O
, NCT03924414 1124 1125 O
an NCT03924414 1126 1128 O
uncontrolled NCT03924414 1129 1141 O
drug NCT03924414 1142 1146 B-Modifier
and NCT03924414 1147 1150 B-Or
/ NCT03924414 1151 1152 I-Or
or NCT03924414 1153 1155 I-Or
alcohol NCT03924414 1156 1163 B-Modifier
addiction NCT03924414 1164 1173 B-Condition
) NCT03924414 1174 1175 O


Inclusion NCT03928548 0 9 O
Criteria NCT03928548 10 18 O
: NCT03928548 19 20 O

- NCT03928548 24 25 O
Adult NCT03928548 27 32 O
and NCT03928548 33 36 B-Or
pediatric NCT03928548 37 46 O
acute NCT03928548 47 52 B-Encounter
care NCT03928548 53 57 I-Encounter
patients NCT03928548 58 66 O
at NCT03928548 67 69 O
participating NCT03928548 70 83 O
facility NCT03928548 84 92 O

- NCT03928548 95 96 O
Newly NCT03928548 98 103 B-Eq-Comparison
identified NCT03928548 104 114 I-Eq-Comparison
as NCT03928548 115 117 O
needing NCT03928548 118 125 B-Assertion___Assertion-Type-Value:hypothetical
in NCT03928548 126 128 B-Encounter
- NCT03928548 129 130 I-Encounter
patient NCT03928548 131 138 I-Encounter
nutrition NCT03928548 139 148 B-Procedure
care NCT03928548 149 153 I-Procedure
through NCT03928548 154 161 O
current NCT03928548 162 169 O
facility NCT03928548 170 178 O
policy NCT03928548 179 185 O

- NCT03928548 188 189 O
Receive NCT03928548 191 198 O
initial NCT03928548 199 206 B-Eq-Comparison
nutrition NCT03928548 207 216 B-Procedure
care NCT03928548 217 221 I-Procedure
one NCT03928548 222 225 B-Eq-Comparison
day NCT03928548 226 229 I-Eq-Comparison
before NCT03928548 230 236 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03928548 237 242 B-Study
enrollment NCT03928548 243 253 O
day NCT03928548 254 257 O

- NCT03928548 260 261 O
Patient NCT03928548 263 270 O
is NCT03928548 271 273 O
over NCT03928548 274 278 B-Eq-Comparison
one NCT03928548 279 282 I-Eq-Comparison
month NCT03928548 283 288 I-Eq-Comparison
of NCT03928548 289 291 O
age NCT03928548 292 295 B-Age
, NCT03928548 296 297 O
including NCT03928548 298 307 O
infants NCT03928548 308 315 O
, NCT03928548 316 317 O
children NCT03928548 318 326 O
, NCT03928548 327 328 O
teenagers NCT03928548 329 338 O
and NCT03928548 339 342 B-Or
adult NCT03928548 343 348 O
patients NCT03928548 349 357 O
who NCT03928548 358 361 B-And
are NCT03928548 362 365 B-Eq-Comparison
intubated NCT03928548 366 375 B-Procedure
and NCT03928548 376 379 B-Or
/ NCT03928548 380 381 I-Or
or NCT03928548 382 384 I-Or
sedated NCT03928548 385 392 B-Procedure

- NCT03928548 395 396 O
Patient NCT03928548 398 405 O
, NCT03928548 406 407 O
parent NCT03928548 408 414 B-Family-Member___Family-Member-Type:parent
, NCT03928548 415 416 O
legal NCT03928548 417 422 O
guardian NCT03928548 423 431 O
or NCT03928548 432 434 O
legally NCT03928548 435 442 O
authorized NCT03928548 443 453 O
representative NCT03928548 454 468 O
provide NCT03928548 469 476 O
informed NCT03928548 477 485 O
consent NCT03928548 486 493 O
; NCT03928548 493 494 O
children NCT03928548 495 503 O
7 NCT03928548 504 505 B-Eq-Comparison
and NCT03928548 506 509 I-Eq-Comparison
older NCT03928548 510 515 I-Age|Eq-Comparison
provide NCT03928548 516 523 O
assent NCT03928548 524 530 O

- NCT03928548 533 534 O
Patient NCT03928548 536 543 O
and NCT03928548 544 547 O
/ NCT03928548 548 549 O
or NCT03928548 550 552 O
parent NCT03928548 553 559 O
, NCT03928548 560 561 O
legal NCT03928548 562 567 O
guardian NCT03928548 568 576 O
or NCT03928548 577 579 O
legally NCT03928548 580 587 O
authorized NCT03928548 588 598 O
representative NCT03928548 599 613 O
are NCT03928548 614 617 O
fluent NCT03928548 618 624 O
in NCT03928548 625 627 O
English NCT03928548 628 635 O
or NCT03928548 636 638 B-Or
Spanish NCT03928548 639 646 O

Exclusion NCT03928548 647 656 O
Criteria NCT03928548 657 665 O
: NCT03928548 666 667 O

- NCT03928548 671 672 O
Received NCT03928548 674 682 B-Eq-Comparison
nutrition NCT03928548 683 692 B-Procedure
care NCT03928548 693 697 I-Procedure
previously NCT03928548 698 708 B-Eq-Comparison
during NCT03928548 709 715 B-Temporal-Connection___Temporal-Connection-Type-Value:during
current NCT03928548 716 723 B-Eq-Comparison
admission NCT03928548 724 733 B-Encounter

- NCT03928548 736 737 O
Pregnant NCT03928548 739 747 B-Condition
women NCT03928548 748 753 O

- NCT03928548 756 757 O
Prisoners NCT03928548 759 768 B-Observation

- NCT03928548 771 772 O
Infants NCT03928548 774 781 O
currently NCT03928548 782 791 B-Eq-Comparison
in NCT03928548 792 794 B-Encounter
the NCT03928548 795 798 O
neonatal NCT03928548 799 807 O
intensive NCT03928548 808 817 O
care NCT03928548 818 822 O
unit NCT03928548 823 827 O
( NCT03928548 828 829 O
NICU NCT03928548 830 834 O
) NCT03928548 835 836 O
with NCT03928548 837 841 B-And
a NCT03928548 842 843 O
diagnosis NCT03928548 844 853 O
of NCT03928548 854 856 O
prematurity NCT03928548 857 868 B-Condition

- NCT03928548 871 872 O
Neonates NCT03928548 874 882 O
of NCT03928548 883 885 O
uncertain NCT03928548 886 895 B-Condition
viability NCT03928548 896 905 I-Condition
or NCT03928548 906 908 B-Or
non NCT03928548 909 912 B-Condition
- NCT03928548 913 914 I-Condition
viable NCT03928548 915 921 I-Condition
neonates NCT03928548 922 930 O

- NCT03928548 933 934 O
Patients NCT03928548 936 944 O
receiving NCT03928548 945 954 B-Eq-Comparison
palliative NCT03928548 955 965 O
/ NCT03928548 966 967 B-Or
hospice NCT03928548 968 975 O
care NCT03928548 976 980 B-Encounter

- NCT03928548 983 984 O
Patient NCT03928548 986 993 O
admitted NCT03928548 994 1002 B-Encounter
for NCT03928548 1003 1006 O
long NCT03928548 1007 1011 B-Procedure
- NCT03928548 1012 1013 I-Procedure
term NCT03928548 1014 1018 I-Procedure
acute NCT03928548 1019 1024 I-Procedure
care NCT03928548 1025 1029 I-Procedure
( NCT03928548 1030 1031 O
LTAC NCT03928548 1032 1036 B-Procedure
) NCT03928548 1037 1038 O

Subject NCT03927781 0 7 O
Population NCT03927781 8 18 O
Undergoing NCT03927781 19 29 B-Eq-Comparison
elective NCT03927781 30 38 B-Modifier
ureteroscopy NCT03927781 39 51 B-Procedure
with NCT03927781 52 56 O
stent NCT03927781 57 62 B-Procedure
placement NCT03927781 63 72 I-Procedure
by NCT03927781 73 75 O
Dr. NCT03927781 76 79 B-Provider
Murray NCT03927781 81 87 I-Provider
at NCT03927781 88 90 O
University NCT03927781 91 101 O
of NCT03927781 102 104 O
Missouri NCT03927781 105 113 O
Hospital NCT03927781 114 122 O
and NCT03927781 123 126 O
affiliated NCT03927781 127 137 O
facilities NCT03927781 138 148 O

Subject NCT03927781 149 156 O
Inclusion NCT03927781 157 166 O

Age NCT03927781 167 170 B-Age
> NCT03927781 171 172 B-Eq-Comparison
= NCT03927781 174 175 I-Eq-Comparison
18 NCT03927781 176 178 I-Eq-Comparison
years NCT03927781 179 184 I-Eq-Comparison

Subject NCT03927781 185 192 O
Exclusion NCT03927781 193 202 O

- NCT03927781 205 206 O
Renal NCT03927781 208 213 B-Condition
insufficiency NCT03927781 214 227 I-Condition
( NCT03927781 228 229 O
eGFR NCT03927781 230 234 B-Observation
< NCT03927781 235 236 B-Eq-Comparison
30 NCT03927781 237 239 I-Eq-Comparison
mL NCT03927781 240 242 I-Eq-Comparison
/ NCT03927781 243 244 I-Eq-Comparison
minute NCT03927781 245 251 I-Eq-Comparison
/ NCT03927781 252 253 I-Eq-Comparison
1.73 NCT03927781 254 258 I-Eq-Comparison
m2 NCT03927781 259 261 I-Eq-Comparison
) NCT03927781 262 263 O

- NCT03927781 267 268 O
Chronic NCT03927781 270 277 B-Modifier
indwelling NCT03927781 278 288 I-Modifier
ureteral NCT03927781 289 297 B-Procedure
stent NCT03927781 298 303 I-Procedure

- NCT03927781 306 307 O
Chronic NCT03927781 309 316 B-Modifier
opioid NCT03927781 317 323 B-Condition
use NCT03927781 324 327 I-Condition

- NCT03927781 330 331 O
History NCT03927781 333 340 B-Eq-Comparison
of NCT03927781 341 343 O
opioid NCT03927781 344 350 B-Condition
abuse NCT03927781 351 356 I-Condition

- NCT03927781 359 360 O
Chronic NCT03927781 362 369 B-Modifier
gabapentinoid NCT03927781 370 383 B-Drug
use NCT03927781 384 387 O

- NCT03927781 390 391 O
Plan NCT03927781 393 397 B-Eq-Comparison
for NCT03927781 398 401 O
inpatient NCT03927781 402 411 B-Encounter
hospitalization NCT03927781 412 427 I-Encounter

- NCT03927781 430 431 O
Pregnancy NCT03927781 433 442 B-Condition

- NCT03927781 445 446 O
Inability NCT03927781 448 457 B-Negation
of NCT03927781 458 460 O
the NCT03927781 461 464 O
patient NCT03927781 465 472 O
to NCT03927781 473 475 O
consent NCT03927781 476 483 O
for NCT03927781 484 487 O
themselves NCT03927781 488 498 O
in NCT03927781 499 501 O
English NCT03927781 502 509 O

- NCT03927781 512 513 O
Allergy NCT03927781 515 522 B-Allergy
to NCT03927781 523 525 O
gabapentinoid NCT03927781 526 539 B-Drug

- NCT03927781 542 543 O
Liver NCT03927781 545 550 B-Condition
failure NCT03927781 551 558 I-Condition
or NCT03927781 559 561 B-Or
hepatic NCT03927781 562 569 B-Condition
dysfunction NCT03927781 570 581 I-Condition


Inclusion NCT03924908 0 9 O
Criteria NCT03924908 10 18 O
: NCT03924908 19 20 O

- NCT03924908 24 25 O
Burn NCT03924908 27 31 B-Condition
patient NCT03924908 32 39 O
treated NCT03924908 40 47 B-Procedure
as NCT03924908 48 50 B-Temporal-Connection___Temporal-Connection-Type-Value:during
outpatient NCT03924908 51 61 B-Encounter

- NCT03924908 64 65 O
Burn NCT03924908 67 71 B-Observation
surface NCT03924908 72 79 I-Observation
area NCT03924908 80 84 I-Observation
> NCT03924908 85 86 B-Eq-Comparison
or NCT03924908 87 89 I-Eq-Comparison
= NCT03924908 90 91 I-Eq-Comparison
5 NCT03924908 92 93 I-Eq-Comparison
% NCT03924908 94 95 I-Eq-Comparison
of NCT03924908 96 98 O
the NCT03924908 99 102 O
total NCT03924908 103 108 O
body NCT03924908 109 113 O
surface NCT03924908 114 121 O
area NCT03924908 122 126 O

- NCT03924908 129 130 O
mainly NCT03924908 132 138 O
2 NCT03924908 139 140 B-Condition
nd NCT03924908 141 143 I-Condition
degree NCT03924908 144 150 I-Condition
burn NCT03924908 151 155 I-Condition

Exclusion NCT03924908 156 165 O
Criteria NCT03924908 166 174 O
: NCT03924908 175 176 O

- NCT03924908 180 181 O
Psychiatric NCT03924908 183 194 B-Condition
antecedents NCT03924908 195 206 I-Condition

- NCT03924908 209 210 O
Claustrophobia NCT03924908 212 226 B-Condition

- NCT03924908 229 230 O
Heavy NCT03924908 232 237 B-Condition
hearing NCT03924908 238 245 I-Condition

- NCT03924908 248 249 O
Visual NCT03924908 251 257 B-Condition
impairment NCT03924908 258 268 I-Condition

- NCT03924908 271 272 O
Face NCT03924908 274 278 B-Modifier
burn NCT03924908 279 283 B-Condition

- NCT03924908 286 287 O
Conjunctivitis NCT03924908 289 303 B-Condition

- NCT03924908 306 307 O
Consent NCT03924908 309 316 O
not NCT03924908 317 320 O
obtained NCT03924908 321 329 O

Inclusion NCT03924934 0 9 O
Criteria NCT03924934 10 18 O
: NCT03924934 19 20 O

Category NCT03924934 22 30 O
1 NCT03924934 31 32 O
: NCT03924934 33 34 O
Patients NCT03924934 35 43 O
who NCT03924934 44 47 O
live NCT03924934 48 52 O
at NCT03924934 53 55 O
home NCT03924934 56 60 O
and NCT03924934 61 64 O
meet NCT03924934 65 69 O
the NCT03924934 70 73 O
following NCT03924934 74 83 O
criteria NCT03924934 84 92 O
: NCT03924934 93 94 O

- NCT03924934 98 99 O
CDC NCT03924934 101 104 O
- NCT03924934 105 106 O
defined NCT03924934 107 114 O
CRE NCT03924934 115 118 B-Organism
isolated NCT03924934 119 127 I-Organism
during NCT03924934 128 134 B-Temporal-Connection___Temporal-Connection-Type-Value:during
hospitalization NCT03924934 135 150 B-Encounter
or NCT03924934 151 153 B-Or
outpatient NCT03924934 154 164 B-Encounter
visit NCT03924934 165 170 I-Encounter

- NCT03924934 173 174 O
Home NCT03924934 176 180 O
origin NCT03924934 181 187 O

- NCT03924934 190 191 O
First NCT03924934 193 198 B-Eq-Comparison
positive NCT03924934 199 207 O
CRE NCT03924934 208 211 B-Organism
culture NCT03924934 212 219 I-Organism
within NCT03924934 220 226 B-Eq-Comparison
48 NCT03924934 227 229 I-Eq-Comparison
hours NCT03924934 230 235 I-Eq-Comparison
of NCT03924934 236 238 B-Temporal-Connection___Temporal-Connection-Type-Value:after
admission NCT03924934 239 248 B-Encounter
( NCT03924934 249 250 O
in NCT03924934 251 253 O
case NCT03924934 254 258 O
of NCT03924934 259 261 O
hospitalization NCT03924934 262 277 B-Encounter
) NCT03924934 278 279 O

Category NCT03924934 281 289 O
2 NCT03924934 290 291 O
: NCT03924934 292 293 O
Hospitalized NCT03924934 294 306 B-Encounter
patients NCT03924934 307 315 O
with NCT03924934 316 320 B-And
CDC NCT03924934 321 324 O
- NCT03924934 325 326 O
defined NCT03924934 327 334 O
CRE NCT03924934 335 338 B-Organism
isolated NCT03924934 339 347 I-Organism
during NCT03924934 348 354 B-Temporal-Connection___Temporal-Connection-Type-Value:during
hospitalization NCT03924934 355 370 B-Encounter
who NCT03924934 371 374 B-And
are NCT03924934 375 378 O
not NCT03924934 379 382 B-Negation
discharged NCT03924934 383 393 B-Encounter
home NCT03924934 394 398 O
and NCT03924934 399 402 O
who NCT03924934 403 406 O
meet NCT03924934 407 411 O
any NCT03924934 412 415 O
of NCT03924934 416 418 O
the NCT03924934 419 422 B-Criteria-Count
following NCT03924934 423 432 I-Criteria-Count
criteria NCT03924934 433 441 I-Criteria-Count
: NCT03924934 442 443 O

- NCT03924934 447 448 O
Admitted NCT03924934 450 458 B-Encounter
from NCT03924934 459 463 O
other NCT03924934 464 469 B-Other
care NCT03924934 470 474 O
facility NCT03924934 475 483 O
( NCT03924934 484 485 O
not NCT03924934 486 489 O
home NCT03924934 490 494 O
origin NCT03924934 495 501 O
) NCT03924934 502 503 O

- NCT03924934 507 508 O
Do NCT03924934 510 512 O
not NCT03924934 513 516 B-Negation
have NCT03924934 517 521 O
first NCT03924934 522 527 B-Eq-Comparison
positive NCT03924934 528 536 O
CRE NCT03924934 537 540 B-Organism
culture NCT03924934 541 548 I-Organism
within NCT03924934 549 555 B-Eq-Comparison
48 NCT03924934 556 558 I-Eq-Comparison
hours NCT03924934 559 564 I-Eq-Comparison
of NCT03924934 565 567 B-Temporal-Connection___Temporal-Connection-Type-Value:after
admission NCT03924934 568 577 B-Encounter

Category NCT03924934 578 586 O
3 NCT03924934 587 588 O
: NCT03924934 589 590 O
Patients NCT03924934 591 599 O
with NCT03924934 600 604 O
CDC NCT03924934 605 608 O
- NCT03924934 609 610 O
defined NCT03924934 611 618 O
CRE NCT03924934 619 622 B-Organism
isolated NCT03924934 623 631 I-Organism
during NCT03924934 632 638 B-Temporal-Connection___Temporal-Connection-Type-Value:during
hospitalization NCT03924934 639 654 B-Encounter
or NCT03924934 655 657 B-Or
outpatient NCT03924934 658 668 B-Encounter
visit NCT03924934 669 674 I-Encounter
who NCT03924934 675 678 B-And
are NCT03924934 679 682 O
discharged NCT03924934 683 693 B-Encounter
home NCT03924934 694 698 O
and NCT03924934 699 702 O
who NCT03924934 703 706 O
meet NCT03924934 707 711 O
any NCT03924934 712 715 O
of NCT03924934 716 718 O
the NCT03924934 719 722 O
following NCT03924934 723 732 O
criteria NCT03924934 733 741 O
: NCT03924934 742 743 O

- NCT03924934 747 748 O
Admitted NCT03924934 750 758 B-Encounter
from NCT03924934 759 763 O
other NCT03924934 764 769 B-Other
care NCT03924934 770 774 O
facility NCT03924934 775 783 O
( NCT03924934 784 785 O
not NCT03924934 786 789 O
home NCT03924934 790 794 O
origin NCT03924934 795 801 O
) NCT03924934 802 803 O

- NCT03924934 807 808 O
Do NCT03924934 810 812 O
not NCT03924934 813 816 B-Negation
have NCT03924934 817 821 O
first NCT03924934 822 827 B-Eq-Comparison
positive NCT03924934 828 836 O
CRE NCT03924934 837 840 B-Organism
culture NCT03924934 841 848 I-Organism
within NCT03924934 849 855 B-Eq-Comparison
48 NCT03924934 856 858 I-Eq-Comparison
hours NCT03924934 859 864 I-Eq-Comparison
of NCT03924934 865 867 B-Temporal-Connection___Temporal-Connection-Type-Value:after
admission NCT03924934 868 877 B-Encounter
( NCT03924934 878 879 O
in NCT03924934 880 882 O
case NCT03924934 883 887 O
of NCT03924934 888 890 O
hospitalization NCT03924934 891 906 B-Encounter
) NCT03924934 907 908 O

Category NCT03924934 910 918 O
4 NCT03924934 919 920 O
: NCT03924934 921 922 O
Participants NCT03924934 923 935 O
who NCT03924934 936 939 O
meet NCT03924934 940 944 O
the NCT03924934 945 948 O
following NCT03924934 949 958 O
criteria NCT03924934 959 967 O
: NCT03924934 968 969 O

• NCT03924934 971 972 O
Community NCT03924934 973 982 O
contact NCT03924934 983 990 O
of NCT03924934 991 993 O
a NCT03924934 994 995 O
participant NCT03924934 996 1007 O
in NCT03924934 1008 1010 O
Category NCT03924934 1011 1019 O
1 NCT03924934 1020 1021 O
and NCT03924934 1022 1025 O
/ NCT03924934 1026 1027 O
or NCT03924934 1028 1030 O
3 NCT03924934 1031 1032 O
. NCT03924934 1032 1033 O

Exclusion NCT03924934 1035 1044 O
Criteria NCT03924934 1045 1053 O
: NCT03924934 1054 1055 O

In NCT03924934 1057 1059 O
all NCT03924934 1060 1063 O
categories NCT03924934 1064 1074 O
, NCT03924934 1075 1076 O
participants NCT03924934 1077 1089 O
who NCT03924934 1090 1093 O
meet NCT03924934 1094 1098 O
the NCT03924934 1099 1102 O
following NCT03924934 1103 1112 O
criteria NCT03924934 1113 1121 O
will NCT03924934 1122 1126 O
be NCT03924934 1127 1129 O
excluded NCT03924934 1130 1138 O
: NCT03924934 1139 1140 O

• NCT03924934 1142 1143 O
Age NCT03924934 1144 1147 B-Age
< NCT03924934 1148 1149 B-Eq-Comparison
18 NCT03924934 1150 1152 I-Eq-Comparison
years NCT03924934 1153 1158 I-Eq-Comparison

In NCT03924934 1159 1161 O
category NCT03924934 1162 1170 O
1 NCT03924934 1171 1172 O
, NCT03924934 1173 1174 O
the NCT03924934 1175 1178 O
following NCT03924934 1179 1188 O
are NCT03924934 1189 1192 O
exclusionary NCT03924934 1193 1205 O
: NCT03924934 1206 1207 O

- NCT03924934 1211 1212 O
pre NCT03924934 1214 1217 B-Eq-Comparison
- NCT03924934 1218 1219 I-Eq-Comparison
existing NCT03924934 1220 1228 I-Eq-Comparison
renal NCT03924934 1229 1234 B-Condition
failure NCT03924934 1235 1242 I-Condition

- NCT03924934 1245 1246 O
pre NCT03924934 1248 1251 B-Eq-Comparison
- NCT03924934 1252 1253 I-Eq-Comparison
existing NCT03924934 1254 1262 I-Eq-Comparison
liver NCT03924934 1263 1268 B-Condition
disease NCT03924934 1269 1276 I-Condition

- NCT03924934 1279 1280 O
immunocompromised NCT03924934 1282 1299 B-Condition

- NCT03924934 1302 1303 O
history NCT03924934 1305 1312 B-Eq-Comparison
of NCT03924934 1313 1315 O
malignancy NCT03924934 1316 1326 B-Condition

- NCT03924934 1329 1330 O
pregnancy NCT03924934 1332 1341 B-Condition

In NCT03924934 1342 1344 O
addition NCT03924934 1345 1353 O
, NCT03924934 1354 1355 O
in NCT03924934 1356 1358 O
category NCT03924934 1359 1367 O
1 NCT03924934 1368 1369 O
, NCT03924934 1370 1371 O
3 NCT03924934 1372 1373 O
and NCT03924934 1374 1377 O
4 NCT03924934 1378 1379 O
, NCT03924934 1380 1381 O
who NCT03924934 1382 1385 O
meet NCT03924934 1386 1390 O
the NCT03924934 1391 1394 O
following NCT03924934 1395 1404 O
criteria NCT03924934 1405 1413 O
will NCT03924934 1414 1418 O
be NCT03924934 1419 1421 O
excluded NCT03924934 1422 1430 O
: NCT03924934 1431 1432 O

• NCT03924934 1434 1435 O
Unable NCT03924934 1436 1442 O
to NCT03924934 1443 1445 O
provide NCT03924934 1446 1453 O
informed NCT03924934 1454 1462 O
consent NCT03924934 1463 1470 O


Inclusion NCT03924713 0 9 O
Criteria NCT03924713 10 18 O
: NCT03924713 19 20 O

- NCT03924713 24 25 O
Either NCT03924713 27 33 O
have NCT03924713 34 38 O
had NCT03924713 39 42 O
more NCT03924713 43 47 B-Eq-Comparison
than NCT03924713 48 52 I-Eq-Comparison
3 NCT03924713 53 54 I-Eq-Comparison
ED NCT03924713 55 57 B-Encounter
visits NCT03924713 58 64 I-Encounter
in NCT03924713 65 67 O
the NCT03924713 68 71 O
prior NCT03924713 72 77 B-Eq-Comparison
12 NCT03924713 78 80 I-Eq-Comparison
months NCT03924713 81 87 I-Eq-Comparison
, NCT03924713 88 89 O
or NCT03924713 90 92 B-Or
at NCT03924713 93 95 B-Eq-Comparison
least NCT03924713 96 101 I-Eq-Comparison
1 NCT03924713 102 103 I-Eq-Comparison
ambulatory NCT03924713 104 114 B-Modifier
care NCT03924713 115 119 I-Modifier
- NCT03924713 120 121 I-Modifier
sensitive NCT03924713 122 131 I-Modifier
hospitalization NCT03924713 132 147 B-Encounter
in NCT03924713 148 150 O
the NCT03924713 151 154 O
prior NCT03924713 155 160 B-Eq-Comparison
12 NCT03924713 161 163 I-Eq-Comparison
months NCT03924713 164 170 I-Eq-Comparison

Exclusion NCT03924713 171 180 O
Criteria NCT03924713 181 189 O
: NCT03924713 190 191 O

- NCT03924713 195 196 O
None NCT03924713 198 202 O
if NCT03924713 203 205 O
they NCT03924713 206 210 O
meet NCT03924713 211 215 O
above NCT03924713 216 221 O
criteria NCT03924713 222 230 O
. NCT03924713 230 231 O

Inclusion NCT03929237 0 9 O
Criteria NCT03929237 10 18 O
: NCT03929237 19 20 O

- NCT03929237 24 25 O
ACL NCT03929237 27 30 B-Procedure
reconstruction NCT03929237 31 45 I-Procedure
surgery NCT03929237 46 53 I-Procedure

- NCT03929237 56 57 O
currently NCT03929237 59 68 B-Eq-Comparison
enrolled NCT03929237 69 77 O
in NCT03929237 78 80 O
middle NCT03929237 81 87 O
or NCT03929237 88 90 O
high NCT03929237 91 95 O
school NCT03929237 96 102 O
( NCT03929237 103 104 O
grades NCT03929237 105 111 O
6 NCT03929237 112 113 O
- NCT03929237 114 115 O
12 NCT03929237 116 118 O
) NCT03929237 119 120 O

- NCT03929237 124 125 O
Surgery NCT03929237 127 134 B-Procedure
occurs NCT03929237 135 141 O
during NCT03929237 142 148 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03929237 149 152 O
school NCT03929237 153 159 B-Observation
year NCT03929237 160 164 I-Observation

- NCT03929237 167 168 O
No NCT03929237 170 172 B-Negation
concomitant NCT03929237 173 184 B-Modifier
additional NCT03929237 185 195 I-Modifier
ligament NCT03929237 196 204 B-Procedure
surgery NCT03929237 205 212 I-Procedure
( NCT03929237 213 214 O
ie NCT03929237 215 217 O
. NCT03929237 217 218 O
PCL NCT03929237 220 223 B-Procedure
, NCT03929237 224 225 O
MCL NCT03929237 226 229 B-Procedure
, NCT03929237 230 231 O
LCL NCT03929237 232 235 B-Procedure
or NCT03929237 236 238 B-Or
MPFL NCT03929237 239 243 B-Procedure
) NCT03929237 244 245 O

Exclusion NCT03929237 247 256 O
Criteria NCT03929237 257 265 O
: NCT03929237 266 267 O

- NCT03929237 271 272 O
patient NCT03929237 274 281 O
is NCT03929237 282 284 O
home NCT03929237 285 289 B-Observation
schooled NCT03929237 290 298 I-Observation
or NCT03929237 299 301 B-Or
in NCT03929237 302 304 O
non NCT03929237 305 308 B-Observation
- NCT03929237 309 310 I-Observation
traditional NCT03929237 311 322 I-Observation
school NCT03929237 323 329 I-Observation
setting NCT03929237 330 337 I-Observation
( NCT03929237 338 339 O
ie NCT03929237 340 342 O
. NCT03929237 342 343 O
school NCT03929237 345 351 B-Observation
for NCT03929237 352 355 I-Observation
special NCT03929237 356 363 I-Observation
needs NCT03929237 364 369 I-Observation
) NCT03929237 370 371 O

- NCT03929237 375 376 O
concomitant NCT03929237 378 389 B-Modifier
additional NCT03929237 390 400 I-Modifier
ligament NCT03929237 401 409 B-Procedure
surgery NCT03929237 410 417 I-Procedure

- NCT03929237 420 421 O
surgery NCT03929237 423 430 B-Procedure
occurs NCT03929237 431 437 B-Temporal-Connection___Temporal-Connection-Type-Value:during
outside NCT03929237 438 445 B-Negation
of NCT03929237 446 448 O
the NCT03929237 449 452 O
school NCT03929237 453 459 B-Observation
year NCT03929237 460 464 I-Observation
or NCT03929237 465 467 O
on NCT03929237 468 470 O
a NCT03929237 471 472 O
scheduled NCT03929237 473 482 O
break NCT03929237 483 488 O
from NCT03929237 489 493 O
school NCT03929237 494 500 O

Inclusion NCT03926104 0 9 O
Criteria NCT03926104 10 18 O
: NCT03926104 19 20 O

- NCT03926104 24 25 O
Ability NCT03926104 27 34 O
to NCT03926104 35 37 O
provide NCT03926104 38 45 O
an NCT03926104 46 48 O
informed NCT03926104 49 57 O
consent NCT03926104 58 65 O

- NCT03926104 68 69 O
Age NCT03926104 71 74 B-Age
> NCT03926104 75 76 B-Eq-Comparison
18 NCT03926104 77 79 I-Eq-Comparison
years NCT03926104 80 85 I-Eq-Comparison
old NCT03926104 86 89 O

- NCT03926104 92 93 O
Elective NCT03926104 95 103 O
abdominal NCT03926104 104 113 B-Condition
aortic NCT03926104 114 120 I-Condition
aneurysm NCT03926104 121 129 I-Condition
surgery NCT03926104 130 137 B-Procedure

Exclusion NCT03926104 138 147 O
Criteria NCT03926104 148 156 O
: NCT03926104 157 158 O

- NCT03926104 162 163 O
Emergency NCT03926104 165 174 B-Modifier
surgery NCT03926104 175 182 B-Procedure

- NCT03926104 185 186 O
Age NCT03926104 188 191 B-Age
˂ NCT03926104 192 193 B-Eq-Comparison
18 NCT03926104 194 196 I-Eq-Comparison
years NCT03926104 197 202 I-Eq-Comparison
old NCT03926104 203 206 O

- NCT03926104 209 210 O
Creatinine NCT03926104 212 222 B-Observation
> NCT03926104 223 224 B-Eq-Comparison
2 NCT03926104 225 226 I-Eq-Comparison
mg NCT03926104 227 229 I-Eq-Comparison
/ NCT03926104 230 231 I-Eq-Comparison
dl NCT03926104 232 234 I-Eq-Comparison

- NCT03926104 237 238 O
Diseases NCT03926104 240 248 B-Condition
of NCT03926104 249 251 O
ascending NCT03926104 252 261 B-Modifier
aorta NCT03926104 262 267 I-Modifier
, NCT03926104 268 269 O
aortic NCT03926104 270 276 B-Modifier
arch NCT03926104 277 281 I-Modifier
or NCT03926104 282 284 B-Or
thoracic NCT03926104 285 293 B-Modifier
aorta NCT03926104 294 299 I-Modifier

- NCT03926104 302 303 O
Chronic NCT03926104 305 312 B-Modifier
atrial NCT03926104 313 319 B-Condition
fibrillation NCT03926104 320 332 I-Condition

- NCT03926104 335 336 O
Patient NCT03926104 338 345 O
refusal NCT03926104 346 353 O
to NCT03926104 354 356 O
provide NCT03926104 357 364 O
informed NCT03926104 365 373 O
consent NCT03926104 374 381 O

Inclusion NCT03926676 0 9 O
Criteria NCT03926676 10 18 O
: NCT03926676 19 20 O

- NCT03926676 24 25 O
patients NCT03926676 27 35 O
with NCT03926676 36 40 O
badly NCT03926676 41 46 B-Modifier
broken NCT03926676 47 53 B-Condition
vital NCT03926676 54 59 I-Condition
teeth NCT03926676 60 65 I-Condition

good NCT03926676 66 70 B-Modifier
oral NCT03926676 71 75 B-Condition
hygiene NCT03926676 76 83 I-Condition
measures NCT03926676 84 92 O

young NCT03926676 93 98 O
adults NCT03926676 99 105 O
males NCT03926676 106 111 O
or NCT03926676 112 114 B-Or
females NCT03926676 115 122 O

cooperative NCT03926676 123 134 O
patients NCT03926676 135 143 O
approving NCT03926676 144 153 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926676 154 156 O
participate NCT03926676 157 168 O
in NCT03926676 169 171 O
the NCT03926676 172 175 O
study NCT03926676 176 181 B-Study

Exclusion NCT03926676 182 191 O
Criteria NCT03926676 192 200 O
: NCT03926676 201 202 O

- NCT03926676 206 207 O
patients NCT03926676 209 217 O
with NCT03926676 218 222 O
compromised NCT03926676 223 234 B-Modifier
medical NCT03926676 235 242 B-Condition
history NCT03926676 243 250 I-Condition

lack NCT03926676 251 255 O
of NCT03926676 256 258 O
compliance NCT03926676 259 269 O

severe NCT03926676 270 276 O
medical NCT03926676 277 284 B-Condition
condition NCT03926676 285 294 I-Condition

severe NCT03926676 295 301 O
or NCT03926676 302 304 B-Or
active NCT03926676 305 311 B-Eq-Comparison
periodontal NCT03926676 312 323 B-Condition
disease NCT03926676 324 331 I-Condition

Inclusion NCT03922438 0 9 O
Criteria NCT03922438 10 18 O
: NCT03922438 19 20 O

- NCT03922438 24 25 O
Non NCT03922438 27 30 B-Negation
syndromic NCT03922438 31 40 B-Condition
patients NCT03922438 41 49 O

- NCT03922438 52 53 O
Medically NCT03922438 55 64 O
fit NCT03922438 65 68 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03922438 69 72 I-Assertion___Assertion-Type-Value:hypothetical
Surgery NCT03922438 73 80 B-Procedure

- NCT03922438 83 84 O
Patient NCT03922438 86 93 O
with NCT03922438 94 98 O
Primary NCT03922438 99 106 B-Modifier
, NCT03922438 107 108 O
complete NCT03922438 109 117 B-Modifier
cleft NCT03922438 118 123 B-Condition
lip NCT03922438 124 127 I-Condition

- NCT03922438 130 131 O
Patient NCT03922438 133 140 O
's NCT03922438 140 142 O
age NCT03922438 143 146 B-Age
younger NCT03922438 147 154 B-Eq-Comparison
than NCT03922438 155 159 I-Eq-Comparison
six NCT03922438 160 163 I-Eq-Comparison
months NCT03922438 164 170 I-Eq-Comparison

Exclusion NCT03922438 171 180 O
Criteria NCT03922438 181 189 O
: NCT03922438 190 191 O

- NCT03922438 195 196 O
Patient NCT03922438 198 205 O
with NCT03922438 206 210 O
syndromic NCT03922438 211 220 B-Modifier
cleft NCT03922438 221 226 B-Condition
lip NCT03922438 227 230 I-Condition

- NCT03922438 233 234 O
Previous NCT03922438 236 244 B-Eq-Comparison
operated NCT03922438 245 253 B-Procedure
cases NCT03922438 254 259 O

- NCT03922438 262 263 O
Incomplete NCT03922438 265 275 B-Modifier
cleft NCT03922438 276 281 B-Condition
lip NCT03922438 282 285 I-Condition

- NCT03922438 288 289 O
Patient NCT03922438 291 298 O
older NCT03922438 299 304 I-Eq-Comparison
than NCT03922438 305 309 I-Eq-Comparison
six NCT03922438 310 313 I-Eq-Comparison
months NCT03922438 314 320 I-Eq-Comparison

- NCT03922438 323 324 O
Patients NCT03922438 326 334 O
with NCT03922438 335 339 O
any NCT03922438 340 343 O
systemic NCT03922438 344 352 B-Modifier
condition NCT03922438 353 362 B-Condition

Inclusion NCT03921125 0 9 O
Criteria NCT03921125 10 18 O
: NCT03921125 19 20 O

- NCT03921125 24 25 O
Sample NCT03921125 27 33 O
of NCT03921125 34 36 O
40 NCT03921125 37 39 O
healthy NCT03921125 40 47 O
ASA NCT03921125 48 51 B-Condition
I NCT03921125 52 53 B-Eq-Comparison
or NCT03921125 54 56 I-Eq-Comparison
II NCT03921125 57 59 I-Eq-Comparison
donors NCT03921125 60 66 O
' NCT03921125 66 67 O
candidate NCT03921125 68 77 O
for NCT03921125 78 81 O
right NCT03921125 82 87 B-Modifier
lobe NCT03921125 88 92 I-Modifier
hepatectomy NCT03921125 93 104 B-Procedure
for NCT03921125 105 108 O
living NCT03921125 109 115 B-Modifier
donor NCT03921125 116 121 I-Modifier
liver NCT03921125 122 127 B-Procedure
transplantation NCT03921125 128 143 I-Procedure

Exclusion NCT03921125 144 153 O
Criteria NCT03921125 154 162 O
: NCT03921125 163 164 O

- NCT03921125 168 169 O
Lack NCT03921125 171 175 O
of NCT03921125 176 178 O
consent NCT03921125 179 186 O

Inclusion NCT03928561 0 9 O
Criteria NCT03928561 10 18 O
: NCT03928561 19 20 O

- NCT03928561 24 25 O
Controlled NCT03928561 27 37 B-Modifier
intermittent NCT03928561 38 50 I-Modifier
asthma NCT03928561 51 57 B-Condition
( NCT03928561 58 59 O
step NCT03928561 60 64 O
1 NCT03928561 65 66 O
treatment NCT03928561 67 76 O
, NCT03928561 77 78 O
according NCT03928561 79 88 O
to NCT03928561 89 91 O
GINA NCT03928561 92 96 O
Guideline NCT03928561 97 106 O
2016 NCT03928561 107 111 O
) NCT03928561 112 113 O
with NCT03928561 114 118 B-And
or NCT03928561 119 121 O
without NCT03928561 122 129 O
association NCT03928561 130 141 O
with NCT03928561 142 146 O
cat NCT03928561 147 150 O
allergy NCT03928561 151 158 B-Allergy
related NCT03928561 159 166 O
rhino NCT03928561 167 172 B-Modifier
- NCT03928561 173 174 O
conjunctivitis NCT03928561 175 189 B-Condition
; NCT03928561 189 190 O

- NCT03928561 193 194 O
Sensitization NCT03928561 196 209 B-Allergy
to NCT03928561 210 212 O
cat NCT03928561 213 216 O
allergen NCT03928561 217 225 O
extract NCT03928561 226 233 O
as NCT03928561 234 236 O
defined NCT03928561 237 244 O
by NCT03928561 245 247 O
skin NCT03928561 248 252 B-Observation
prick NCT03928561 253 258 I-Observation
test NCT03928561 259 263 I-Observation
for NCT03928561 264 267 O
cat NCT03928561 268 271 B-Modifier
extract NCT03928561 272 279 I-Modifier
with NCT03928561 280 284 O
a NCT03928561 285 286 O
wheal NCT03928561 287 292 O
diameter NCT03928561 293 301 O
of NCT03928561 302 304 O
≥ NCT03928561 305 306 B-Eq-Comparison
3 NCT03928561 307 308 I-Eq-Comparison
mm NCT03928561 309 311 I-Eq-Comparison
greater NCT03928561 312 319 I-Eq-Comparison
than NCT03928561 320 324 I-Eq-Comparison
negative NCT03928561 325 333 I-Eq-Comparison
control NCT03928561 334 341 I-Eq-Comparison
( NCT03928561 342 343 O
ALK NCT03928561 344 347 O
, NCT03928561 348 349 O
HØrsholm NCT03928561 350 358 O
, NCT03928561 359 360 O
Denmark NCT03928561 361 368 O
) NCT03928561 369 370 O
and NCT03928561 371 374 O
specific NCT03928561 375 383 O
IgE NCT03928561 384 387 B-Observation
anti NCT03928561 388 392 I-Observation
Fel NCT03928561 393 396 I-Observation
d NCT03928561 397 398 I-Observation
1 NCT03928561 399 400 B-Eq-Comparison
≥ NCT03928561 401 402 I-Eq-Comparison
0.7 NCT03928561 403 406 I-Eq-Comparison
kU NCT03928561 407 409 I-Eq-Comparison
/ NCT03928561 410 411 I-Eq-Comparison
L NCT03928561 412 413 I-Eq-Comparison
( NCT03928561 414 415 O
ImmunoCAP NCT03928561 416 425 O
, NCT03928561 426 427 O
Thermofisher NCT03928561 428 440 O
, NCT03928561 441 442 O
Uppsala NCT03928561 443 450 O
, NCT03928561 451 452 O
Sweden NCT03928561 453 459 O
) NCT03928561 460 461 O
; NCT03928561 462 463 O

- NCT03928561 466 467 O
FEV1 NCT03928561 469 473 B-Observation
≥ NCT03928561 474 475 B-Eq-Comparison
70 NCT03928561 476 478 I-Eq-Comparison
% NCT03928561 479 480 I-Eq-Comparison
of NCT03928561 481 483 O
the NCT03928561 484 487 O
predicted NCT03928561 488 497 O
value NCT03928561 498 503 O
; NCT03928561 503 504 O

- NCT03928561 507 508 O
No NCT03928561 510 512 B-Negation
cat NCT03928561 513 516 B-Condition
exposure NCT03928561 517 525 I-Condition
at NCT03928561 526 528 O
home NCT03928561 529 533 O
or NCT03928561 534 536 B-Or
outside NCT03928561 537 544 B-Negation
of NCT03928561 545 547 O
the NCT03928561 548 551 O
home NCT03928561 552 556 O
during NCT03928561 557 563 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928561 564 567 O
study NCT03928561 568 573 B-Study
; NCT03928561 573 574 O

- NCT03928561 577 578 O
Positive NCT03928561 580 588 O
methacholine NCT03928561 589 601 B-Observation
challenge NCT03928561 602 611 I-Observation
test NCT03928561 612 616 I-Observation
performed NCT03928561 617 626 B-Eq-Comparison
using NCT03928561 627 632 O
an NCT03928561 633 635 O
AeroDoseur NCT03928561 636 646 B-Modifier
DTF NCT03928561 647 650 I-Modifier
- NCT03928561 651 652 I-Modifier
Atomisor NCT03928561 653 661 I-Modifier
ATO NCT03928561 662 665 I-Modifier
- NCT03928561 666 667 I-Modifier
AD NCT03928561 668 670 I-Modifier
12 NCT03928561 671 673 O
( NCT03928561 674 675 O
Saint NCT03928561 676 681 O
- NCT03928561 682 683 O
Etienne NCT03928561 684 691 O
, NCT03928561 692 693 O
France NCT03928561 694 700 O
) NCT03928561 701 702 O
; NCT03928561 703 704 O

- NCT03928561 712 713 O
Early NCT03928561 715 720 B-Modifier
asthmatic NCT03928561 721 730 B-Condition
response NCT03928561 731 739 O
during NCT03928561 740 746 O
baseline NCT03928561 747 755 O
cat NCT03928561 756 759 B-Condition
allergen NCT03928561 760 768 I-Condition
exposure NCT03928561 769 777 I-Condition
. NCT03928561 778 779 O

Exclusion NCT03928561 781 790 O
Criteria NCT03928561 791 799 O
: NCT03928561 800 801 O

- NCT03928561 805 806 O
Uncontrolled NCT03928561 808 820 B-Modifier
asthma NCT03928561 821 827 B-Condition
, NCT03928561 828 829 O
asthma NCT03928561 830 836 B-Observation
control NCT03928561 837 844 I-Observation
test NCT03928561 845 849 I-Observation
inferior NCT03928561 850 858 B-Eq-Comparison
to NCT03928561 859 861 I-Eq-Comparison
20 NCT03928561 862 864 I-Eq-Comparison
within NCT03928561 865 871 B-Eq-Comparison
the NCT03928561 872 875 I-Eq-Comparison
4 NCT03928561 876 877 I-Eq-Comparison
weeks NCT03928561 878 883 I-Eq-Comparison
preceding NCT03928561 884 893 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03928561 894 897 O
study NCT03928561 898 903 B-Study
. NCT03928561 904 905 O

- NCT03928561 909 910 O
Uncontrolled NCT03928561 912 924 B-Modifier
asthma NCT03928561 925 931 B-Condition
2 NCT03928561 932 933 B-Eq-Comparison
weeks NCT03928561 934 939 I-Eq-Comparison
after NCT03928561 940 945 B-Temporal-Connection___Temporal-Connection-Type-Value:after
stopping NCT03928561 946 954 O
LABA NCT03928561 955 959 B-Drug
treatment NCT03928561 960 969 B-Procedure
. NCT03928561 970 971 O

- NCT03928561 975 976 O
LABA NCT03928561 978 982 B-Drug
treatment NCT03928561 983 992 B-Procedure
within NCT03928561 993 999 B-Eq-Comparison
the NCT03928561 1000 1003 I-Eq-Comparison
2 NCT03928561 1004 1005 I-Eq-Comparison
weeks NCT03928561 1006 1011 I-Eq-Comparison
preceding NCT03928561 1012 1021 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03928561 1022 1025 O
study NCT03928561 1026 1031 B-Study
. NCT03928561 1032 1033 O

- NCT03928561 1037 1038 O
Severe NCT03928561 1040 1046 O
asthma NCT03928561 1047 1053 B-Condition
( NCT03928561 1054 1055 O
> NCT03928561 1057 1058 B-Eq-Comparison
GINA NCT03928561 1059 1063 B-Observation
2 NCT03928561 1064 1065 O
) NCT03928561 1066 1067 O

- NCT03928561 1071 1072 O
Subject NCT03928561 1074 1081 O
lives NCT03928561 1082 1087 O
with NCT03928561 1088 1092 O
a NCT03928561 1093 1094 O
cat NCT03928561 1095 1098 O

- NCT03928561 1101 1102 O
Cat NCT03928561 1104 1107 B-Condition
desensibilisation NCT03928561 1108 1125 I-Condition
within NCT03928561 1126 1132 B-Eq-Comparison
the NCT03928561 1133 1136 I-Eq-Comparison
6 NCT03928561 1137 1138 I-Eq-Comparison
previous NCT03928561 1139 1147 I-Eq-Comparison
months NCT03928561 1148 1154 I-Eq-Comparison
. NCT03928561 1155 1156 O

- NCT03928561 1160 1161 O
Active NCT03928561 1163 1169 B-Eq-Comparison
smoker NCT03928561 1170 1176 B-Condition


Inclusion NCT03922919 0 9 O
Criteria NCT03922919 10 18 O
: NCT03922919 19 20 O

- NCT03922919 24 25 O
Age NCT03922919 27 30 B-Age
≥ NCT03922919 31 32 B-Eq-Comparison
18 NCT03922919 33 35 I-Eq-Comparison
years NCT03922919 36 41 I-Eq-Comparison
old NCT03922919 42 45 O

- NCT03922919 48 49 O
Indication NCT03922919 51 61 B-Indication
for NCT03922919 62 65 O
antibiotic NCT03922919 66 76 B-Drug
treatment NCT03922919 77 86 B-Procedure
with NCT03922919 87 91 O
a NCT03922919 92 93 O
3 NCT03922919 94 95 B-Modifier
rd NCT03922919 96 98 I-Modifier
generation NCT03922919 99 109 I-Modifier
injectable NCT03922919 110 120 I-Modifier
cephalosporin NCT03922919 121 134 B-Drug
( NCT03922919 135 136 O
cefotaxime NCT03922919 137 147 B-Drug
or NCT03922919 148 150 B-Or
ceftriaxone NCT03922919 151 162 B-Drug
) NCT03922919 163 164 O

- NCT03922919 168 169 O
Signed NCT03922919 171 177 O
Informed NCT03922919 178 186 O
Consent NCT03922919 187 194 O

Exclusion NCT03922919 195 204 O
Criteria NCT03922919 205 213 O
: NCT03922919 214 215 O

- NCT03922919 219 220 O
Hypersensitivity NCT03922919 222 238 B-Condition
to NCT03922919 239 241 O
ceftriaxone NCT03922919 242 253 B-Drug
or NCT03922919 254 256 B-Or
cefotaxime NCT03922919 257 267 B-Drug
, NCT03922919 268 269 O
to NCT03922919 270 272 O
another NCT03922919 273 280 B-Other
cephalosporin NCT03922919 281 294 B-Drug
or NCT03922919 295 297 O
to NCT03922919 298 300 O
any NCT03922919 301 304 O
of NCT03922919 305 307 O
the NCT03922919 308 311 O
excipients NCT03922919 312 322 O
of NCT03922919 323 325 O
the NCT03922919 326 329 O
specialities NCT03922919 330 342 O
concerned NCT03922919 343 352 O
. NCT03922919 353 354 O

- NCT03922919 358 359 O
History NCT03922919 361 368 B-Eq-Comparison
of NCT03922919 369 371 O
severe NCT03922919 372 378 O
hypersensitivity NCT03922919 379 395 B-Condition
( NCT03922919 396 397 O
e. NCT03922919 398 400 O
g. NCT03922919 401 403 O
, NCT03922919 404 405 O
anaphylactic NCT03922919 406 418 B-Condition
reaction NCT03922919 419 427 I-Condition
) NCT03922919 428 429 O
to NCT03922919 430 432 O
another NCT03922919 433 440 B-Other
class NCT03922919 441 446 O
of NCT03922919 447 449 O
antibacterial NCT03922919 450 463 B-Drug
agent NCT03922919 464 469 I-Drug
of NCT03922919 470 472 O
the NCT03922919 473 476 O
beta NCT03922919 477 481 B-Modifier
- NCT03922919 482 483 I-Modifier
lactam NCT03922919 484 490 I-Modifier
family NCT03922919 491 497 O
( NCT03922919 498 499 O
penicillins NCT03922919 500 511 B-Drug
, NCT03922919 512 513 O
monobactams NCT03922919 514 525 B-Drug
and NCT03922919 526 529 B-Or
carbapenes NCT03922919 530 540 B-Drug
) NCT03922919 541 542 O

- NCT03922919 546 547 O
Subcutaneous NCT03922919 549 561 B-Modifier
administration NCT03922919 562 576 O
of NCT03922919 577 579 O
ceftriaxone NCT03922919 580 591 B-Drug

- NCT03922919 594 595 O
Pregnant NCT03922919 597 605 B-Condition
and NCT03922919 606 609 B-Or
breastfeeding NCT03922919 610 623 B-Condition
woman NCT03922919 624 629 O

- NCT03922919 632 633 O
Suspicion NCT03922919 635 644 B-Assertion___Assertion-Type-Value:possible
of NCT03922919 645 647 O
Pseudomonas NCT03922919 648 659 B-Condition
infection NCT03922919 660 669 I-Condition
or NCT03922919 670 672 B-Or
documented NCT03922919 673 683 O
Pseudomonas NCT03922919 684 695 B-Condition
infection NCT03922919 696 705 I-Condition
requiring NCT03922919 706 715 B-Assertion___Assertion-Type-Value:hypothetical
ceftazidime NCT03922919 716 727 B-Drug
treatment NCT03922919 728 737 B-Procedure

- NCT03922919 740 741 O
Suspicion NCT03922919 743 752 B-Assertion___Assertion-Type-Value:possible
of NCT03922919 753 755 O
group NCT03922919 756 761 B-Eq-Comparison
III NCT03922919 762 765 I-Eq-Comparison
enterobacteriaceae NCT03922919 766 784 B-Condition
infection NCT03922919 785 794 I-Condition
or NCT03922919 795 797 B-Or
group NCT03922919 798 803 B-Eq-Comparison
III NCT03922919 804 807 I-Eq-Comparison
enterobacteriaceae NCT03922919 808 826 B-Condition
infection NCT03922919 827 836 I-Condition
requiring NCT03922919 837 846 O
cefepime NCT03922919 847 855 B-Drug
treatment NCT03922919 856 865 B-Procedure

Inclusion NCT03926000 0 9 O
Criteria NCT03926000 10 18 O
: NCT03926000 19 20 O

- NCT03926000 24 25 O
Patients NCT03926000 27 35 O
scheduled NCT03926000 36 45 B-Eq-Comparison
for NCT03926000 46 49 O
elective NCT03926000 50 58 B-Modifier
knee NCT03926000 59 63 I-Modifier
arthroscopy NCT03926000 64 75 B-Procedure
. NCT03926000 76 77 O

- NCT03926000 81 82 O
Patients NCT03926000 84 92 O
aged NCT03926000 93 97 B-Age
between NCT03926000 98 105 B-Eq-Comparison
21 NCT03926000 106 108 I-Eq-Comparison
and NCT03926000 109 112 I-Eq-Comparison
50 NCT03926000 113 115 I-Eq-Comparison
years NCT03926000 116 121 I-Eq-Comparison
old NCT03926000 122 125 O
. NCT03926000 126 127 O

- NCT03926000 131 132 O
Patients NCT03926000 134 142 O
with NCT03926000 143 147 O
American NCT03926000 148 156 B-Condition
Society NCT03926000 157 164 I-Condition
of NCT03926000 165 167 I-Condition
Anaesthesiologists NCT03926000 168 186 I-Condition
physical NCT03926000 187 195 O
status NCT03926000 196 202 O
I NCT03926000 203 204 B-Eq-Comparison
or NCT03926000 205 207 I-Eq-Comparison
II NCT03926000 208 210 I-Eq-Comparison
. NCT03926000 211 212 O

Exclusion NCT03926000 214 223 O
Criteria NCT03926000 224 232 O
: NCT03926000 233 234 O

- NCT03926000 238 239 O
Patients NCT03926000 241 249 O
with NCT03926000 250 254 O
known NCT03926000 255 260 O
allergy NCT03926000 261 268 B-Allergy
to NCT03926000 269 271 O
any NCT03926000 272 275 O
drug NCT03926000 276 280 B-Drug
used NCT03926000 281 285 O
in NCT03926000 286 288 O
the NCT03926000 289 292 O
study NCT03926000 293 298 B-Study
. NCT03926000 299 300 O

- NCT03926000 304 305 O
Patients NCT03926000 307 315 O
with NCT03926000 316 320 O
chronic NCT03926000 321 328 B-Modifier
use NCT03926000 329 332 O
of NCT03926000 333 335 O
analgesics NCT03926000 336 346 B-Drug
and NCT03926000 347 350 B-Or
/ NCT03926000 351 352 I-Or
or NCT03926000 353 355 I-Or
sedatives NCT03926000 356 365 B-Drug
. NCT03926000 366 367 O

- NCT03926000 371 372 O
Patients NCT03926000 374 382 O
with NCT03926000 383 387 O
sleep NCT03926000 388 393 B-Condition
apnea NCT03926000 394 399 I-Condition
syndrome NCT03926000 400 408 I-Condition
. NCT03926000 409 410 O

- NCT03926000 414 415 O
Patients NCT03926000 417 425 O
with NCT03926000 426 430 O
renal NCT03926000 431 436 B-Modifier
or NCT03926000 437 439 B-Or
hepatic NCT03926000 440 447 B-Modifier
dysfunction NCT03926000 448 459 B-Condition
. NCT03926000 460 461 O

- NCT03926000 465 466 O
Patients NCT03926000 468 476 O
with NCT03926000 477 481 O
psychiatric NCT03926000 482 493 B-Condition
disorders NCT03926000 494 503 I-Condition
. NCT03926000 503 504 O

Inclusion NCT03924830 0 9 O
Criteria NCT03924830 10 18 O
: NCT03924830 19 20 O

- NCT03924830 24 25 O
All NCT03924830 27 30 O
patients NCT03924830 31 39 O
must NCT03924830 40 44 O
have NCT03924830 45 49 O
at NCT03924830 50 52 O
only NCT03924830 53 57 B-Eq-Comparison
20 NCT03924830 58 60 I-Eq-Comparison
teeth NCT03924830 61 66 B-Condition
in NCT03924830 67 69 I-Condition
function NCT03924830 70 78 I-Condition
, NCT03924830 79 80 O
must NCT03924830 81 85 O
have NCT03924830 86 90 O
at NCT03924830 91 93 O
only NCT03924830 94 98 B-Eq-Comparison
3 NCT03924830 99 100 I-Eq-Comparison
carious NCT03924830 101 108 B-Modifier
occlusal NCT03924830 109 117 I-Modifier
or NCT03924830 118 120 B-Or
proximo NCT03924830 121 128 B-Modifier
- NCT03924830 129 130 I-Modifier
occlusal NCT03924830 131 139 I-Modifier
lesions NCT03924830 140 147 B-Condition
, NCT03924830 148 149 O
or NCT03924830 150 152 B-Or
old NCT03924830 153 156 B-Modifier
restorations NCT03924830 157 169 B-Condition
that NCT03924830 170 174 O
need NCT03924830 175 179 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924830 180 182 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03924830 183 185 I-Assertion___Assertion-Type-Value:hypothetical
changed NCT03924830 186 193 O
, NCT03924830 194 195 O
in NCT03924830 196 198 O
different NCT03924830 199 208 B-Modifier
teeth NCT03924830 209 214 I-Modifier
. NCT03924830 214 215 O
Those NCT03924830 217 222 B-Coreference
lesions NCT03924830 223 230 B-Condition
must NCT03924830 231 235 O
be NCT03924830 236 238 O
more NCT03924830 239 243 B-Eq-Comparison
than NCT03924830 244 248 I-Eq-Comparison
2 NCT03924830 249 250 I-Eq-Comparison
mm NCT03924830 251 253 I-Eq-Comparison
deep NCT03924830 254 258 B-Observation
, NCT03924830 259 260 O
should NCT03924830 261 267 O
have NCT03924830 268 272 O
exposed NCT03924830 273 280 B-Condition
dentin NCT03924830 281 287 I-Condition
, NCT03924830 288 289 O
and NCT03924830 290 293 B-And
must NCT03924830 294 298 O
have NCT03924830 299 303 O
at NCT03924830 304 306 O
only NCT03924830 307 311 B-Eq-Comparison
50 NCT03924830 312 314 I-Eq-Comparison
% NCT03924830 315 316 I-Eq-Comparison
of NCT03924830 317 319 O
margins NCT03924830 320 327 B-Observation
in NCT03924830 328 330 I-Observation
enamel NCT03924830 331 337 I-Observation
. NCT03924830 337 338 O
Teeth NCT03924830 340 345 B-Modifier
should NCT03924830 346 352 O
not NCT03924830 353 356 B-Negation
present NCT03924830 357 364 O
periodontal NCT03924830 365 376 B-Condition
mobility NCT03924830 377 385 I-Condition
. NCT03924830 386 387 O

Exclusion NCT03924830 389 398 O
Criteria NCT03924830 399 407 O
: NCT03924830 408 409 O

- NCT03924830 413 414 O
Volunteers NCT03924830 416 426 O
with NCT03924830 427 431 O
periodontal NCT03924830 432 443 B-Condition
disease NCT03924830 444 451 I-Condition
; NCT03924830 451 452 O
with NCT03924830 453 457 B-Or
gingival NCT03924830 458 466 B-Condition
bleeding NCT03924830 467 475 I-Condition
; NCT03924830 475 476 O
use NCT03924830 477 480 O
of NCT03924830 481 483 O
anti NCT03924830 484 488 B-Drug
- NCT03924830 489 490 I-Drug
inflammatory NCT03924830 491 503 I-Drug
drugs NCT03924830 504 509 I-Drug
in NCT03924830 510 512 O
the NCT03924830 513 516 O
last NCT03924830 517 521 B-Eq-Comparison
30 NCT03924830 522 524 I-Eq-Comparison
days NCT03924830 525 529 I-Eq-Comparison
. NCT03924830 529 530 O

Inclusion NCT03924011 0 9 O
Criteria NCT03924011 10 18 O
: NCT03924011 19 20 O

- NCT03924011 24 25 O
Informed NCT03924011 27 35 O
Consent NCT03924011 36 43 O
as NCT03924011 44 46 O
documented NCT03924011 47 57 O
by NCT03924011 58 60 O
signature NCT03924011 61 70 O

- NCT03924011 73 74 O
Diagnosis NCT03924011 76 85 O
of NCT03924011 86 88 O
non NCT03924011 89 92 B-Modifier
- NCT03924011 93 94 I-Modifier
invasive NCT03924011 95 103 I-Modifier
( NCT03924011 104 105 O
stage NCT03924011 106 111 B-Eq-Comparison
0 NCT03924011 112 113 I-Eq-Comparison
) NCT03924011 114 115 O
or NCT03924011 116 118 B-Or
invasive NCT03924011 119 127 B-Modifier
( NCT03924011 128 129 O
stage NCT03924011 130 135 B-Eq-Comparison
1 NCT03924011 136 137 I-Eq-Comparison
, NCT03924011 138 139 I-Eq-Comparison
2 NCT03924011 140 141 I-Eq-Comparison
and NCT03924011 142 145 I-Eq-Comparison
3 NCT03924011 146 147 I-Eq-Comparison
A NCT03924011 148 149 I-Eq-Comparison
) NCT03924011 150 151 O
breast NCT03924011 152 158 B-Condition
adenocarcinoma NCT03924011 159 173 I-Condition

- NCT03924011 176 177 O
Treatment NCT03924011 179 188 B-Procedure
with NCT03924011 189 193 O
primary NCT03924011 194 201 B-Modifier
breast NCT03924011 202 208 B-Procedure
- NCT03924011 209 210 I-Procedure
sparing NCT03924011 211 218 I-Procedure
surgery NCT03924011 219 226 I-Procedure
( NCT03924011 227 228 O
lumpectomy NCT03924011 229 239 B-Procedure
) NCT03924011 240 241 O
and NCT03924011 242 245 B-Or
/ NCT03924011 246 247 I-Or
or NCT03924011 248 250 I-Or
neoadjuvant NCT03924011 251 262 B-Modifier
( NCT03924011 263 264 O
pre NCT03924011 265 268 B-Modifier
operative NCT03924011 269 278 I-Modifier
) NCT03924011 279 280 O
or NCT03924011 281 283 O
adjuvant NCT03924011 284 292 B-Modifier
( NCT03924011 293 294 O
post NCT03924011 295 299 B-Modifier
operative NCT03924011 300 309 I-Modifier
) NCT03924011 310 311 O
chemotherapy NCT03924011 312 324 B-Procedure
or NCT03924011 325 327 B-Or
hormonal NCT03924011 328 336 B-Procedure
therapy NCT03924011 337 344 I-Procedure

- NCT03924011 347 348 O
Scheduled NCT03924011 350 359 B-Eq-Comparison
for NCT03924011 360 363 O
post NCT03924011 364 368 B-Temporal-Connection___Temporal-Connection-Type-Value:after
operative NCT03924011 369 378 B-Procedure
radiotherapy NCT03924011 379 391 B-Procedure
at NCT03924011 392 394 O
Ziekenhuis NCT03924011 395 405 O
Oost NCT03924011 406 410 O
- NCT03924011 411 412 O
Limburg NCT03924011 413 420 O
, NCT03924011 421 422 O
Genk NCT03924011 423 427 O
: NCT03924011 428 429 O

- NCT03924011 433 434 O
Hypofractionated NCT03924011 436 452 B-Procedure
radiotherapy NCT03924011 453 465 I-Procedure
regimen NCT03924011 466 473 O
( NCT03924011 474 475 O
i. NCT03924011 476 478 O
e. NCT03924011 479 481 O
16 NCT03924011 483 485 B-Eq-Comparison
daily NCT03924011 486 491 I-Eq-Comparison
fractions NCT03924011 492 501 O
of NCT03924011 502 504 O
2.66 NCT03924011 505 509 B-Procedure
Gray NCT03924011 510 514 I-Procedure
to NCT03924011 515 517 O
the NCT03924011 518 521 O
whole NCT03924011 522 527 B-Modifier
breast NCT03924011 528 534 I-Modifier
followed NCT03924011 535 543 B-Temporal-Connection___Temporal-Connection-Type-Value:before
by NCT03924011 544 546 I-Temporal-Connection___Temporal-Connection-Type-Value:before
a NCT03924011 547 548 O
boost NCT03924011 549 554 O
of NCT03924011 555 557 O
5 NCT03924011 558 559 B-Eq-Comparison
fractions NCT03924011 560 569 O
of NCT03924011 570 572 O
2.66 NCT03924011 573 577 B-Procedure
Gray NCT03924011 578 582 I-Procedure
to NCT03924011 583 585 O
the NCT03924011 586 589 O
tumor NCT03924011 590 595 B-Modifier
bed NCT03924011 596 599 I-Modifier
, NCT03924011 600 601 O
5 NCT03924011 602 603 B-Eq-Comparison
x NCT03924011 604 605 I-Eq-Comparison
/ NCT03924011 606 607 I-Eq-Comparison
week NCT03924011 608 612 I-Eq-Comparison
) NCT03924011 613 614 O

Exclusion NCT03924011 620 629 O
Criteria NCT03924011 630 638 O
: NCT03924011 639 640 O

- NCT03924011 644 645 O
Scheduled NCT03924011 647 656 B-Eq-Comparison
for NCT03924011 657 660 O
post NCT03924011 661 665 B-Temporal-Connection___Temporal-Connection-Type-Value:after
operative NCT03924011 666 675 B-Procedure
radiotherapy NCT03924011 676 688 B-Procedure
at NCT03924011 689 691 O
Jessa NCT03924011 692 697 O
Hospital NCT03924011 698 706 O
, NCT03924011 707 708 O
Hasselt NCT03924011 709 716 O
, NCT03924011 717 718 O
Belgium NCT03924011 719 726 O

- NCT03924011 729 730 O
Previous NCT03924011 732 740 B-Eq-Comparison
irradiation NCT03924011 741 752 B-Procedure
to NCT03924011 753 755 O
the NCT03924011 756 759 O
same NCT03924011 760 764 B-Modifier
breast NCT03924011 765 771 I-Modifier

- NCT03924011 774 775 O
Metastatic NCT03924011 777 787 O
disease NCT03924011 788 795 O

- NCT03924011 798 799 O
Concurrent NCT03924011 801 811 O
chemotherapy NCT03924011 812 824 B-Procedure

- NCT03924011 827 828 O
Required NCT03924011 830 838 B-Assertion___Assertion-Type-Value:hypothetical
use NCT03924011 839 842 O
of NCT03924011 843 845 O
bolus NCT03924011 846 851 B-Procedure
material NCT03924011 852 860 O
to NCT03924011 861 863 O
deliver NCT03924011 864 871 O
radiotherapy NCT03924011 872 884 B-Procedure
( NCT03924011 885 886 O
i. NCT03924011 887 889 O
e NCT03924011 890 891 O
material NCT03924011 892 900 O
placed NCT03924011 901 907 O
on NCT03924011 908 910 O
the NCT03924011 911 914 O
to NCT03924011 915 917 O
- NCT03924011 918 919 O
be NCT03924011 920 922 O
- NCT03924011 923 924 O
irradiated NCT03924011 925 935 O
zone NCT03924011 936 940 O
to NCT03924011 941 943 O
modulate NCT03924011 944 952 O
the NCT03924011 953 956 O
delivered NCT03924011 957 966 O
dose NCT03924011 967 971 O
in NCT03924011 972 974 O
order NCT03924011 975 980 O
to NCT03924011 981 983 O
ensure NCT03924011 984 990 O
an NCT03924011 991 993 O
optimal NCT03924011 994 1001 O
distribution NCT03924011 1002 1014 O
of NCT03924011 1015 1017 O
the NCT03924011 1018 1021 O
radiation NCT03924011 1022 1031 O
dose NCT03924011 1032 1036 O
; NCT03924011 1036 1037 O
mostly NCT03924011 1038 1044 O
used NCT03924011 1045 1049 O
for NCT03924011 1050 1053 O
treatment NCT03924011 1054 1063 O
of NCT03924011 1064 1066 O
superficial NCT03924011 1067 1078 O
tumors NCT03924011 1079 1085 O
) NCT03924011 1086 1087 O

- NCT03924011 1091 1092 O
Known NCT03924011 1094 1099 O
or NCT03924011 1100 1102 O
suspected NCT03924011 1103 1112 B-Assertion___Assertion-Type-Value:possible
non NCT03924011 1113 1116 B-Condition
- NCT03924011 1117 1118 I-Condition
compliance NCT03924011 1119 1129 I-Condition
, NCT03924011 1130 1131 O
drug NCT03924011 1132 1136 B-Modifier
or NCT03924011 1137 1139 B-Or
alcohol NCT03924011 1140 1147 B-Modifier
abuse NCT03924011 1148 1153 B-Condition

- NCT03924011 1156 1157 O
Inability NCT03924011 1159 1168 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03924011 1169 1171 O
follow NCT03924011 1172 1178 O
the NCT03924011 1179 1182 O
procedures NCT03924011 1183 1193 B-Procedure
of NCT03924011 1194 1196 O
the NCT03924011 1197 1200 O
study NCT03924011 1201 1206 B-Study
, NCT03924011 1207 1208 O
e. NCT03924011 1209 1211 O
g. NCT03924011 1212 1214 O
due NCT03924011 1216 1219 O
to NCT03924011 1220 1222 O
language NCT03924011 1223 1231 B-Condition
problems NCT03924011 1232 1240 I-Condition
, NCT03924011 1241 1242 O
psyschological NCT03924011 1243 1257 B-Condition
disorders NCT03924011 1258 1267 I-Condition
, NCT03924011 1268 1269 O
dementia NCT03924011 1270 1278 B-Condition
, NCT03924011 1279 1280 O
etc NCT03924011 1281 1284 O
. NCT03924011 1284 1285 O
of NCT03924011 1287 1289 O
the NCT03924011 1290 1293 O
participant NCT03924011 1294 1305 O

- NCT03924011 1308 1309 O
Seizure NCT03924011 1311 1318 B-Condition

- NCT03924011 1321 1322 O
Disorders NCT03924011 1324 1333 B-Condition
triggered NCT03924011 1334 1343 O
by NCT03924011 1344 1346 O
lighttake NCT03924011 1347 1356 O
anticoagulants NCT03924011 1357 1371 B-Drug

- NCT03924011 1374 1375 O
Hemorrhagic NCT03924011 1377 1388 B-Condition
diatheses NCT03924011 1389 1398 I-Condition

- NCT03924011 1401 1402 O
Pregnancy NCT03924011 1404 1413 B-Condition

- NCT03924011 1416 1417 O
Suspected NCT03924011 1419 1428 B-Assertion___Assertion-Type-Value:possible
of NCT03924011 1429 1431 O
carrying NCT03924011 1432 1440 O
serious NCT03924011 1441 1448 O
infectious NCT03924011 1449 1459 B-Condition
disease NCT03924011 1460 1467 I-Condition

- NCT03924011 1470 1471 O
HIV NCT03924011 1473 1476 B-Condition
positive NCT03924011 1477 1485 O
history NCT03924011 1486 1493 B-Eq-Comparison


Inclusion NCT03928171 0 9 O
Criteria NCT03928171 10 18 O
: NCT03928171 19 20 O

- NCT03928171 24 25 O
Adults NCT03928171 27 33 O
( NCT03928171 34 35 O
≥ NCT03928171 37 38 B-Eq-Comparison
18 NCT03928171 39 41 I-Eq-Comparison
years NCT03928171 42 47 I-Eq-Comparison
old NCT03928171 48 51 B-Age
) NCT03928171 52 53 O

- NCT03928171 57 58 O
Scheduled NCT03928171 60 69 B-Eq-Comparison
for NCT03928171 70 73 O
robot NCT03928171 74 79 B-Modifier
- NCT03928171 80 81 I-Modifier
assisted NCT03928171 82 90 I-Modifier
colorectal NCT03928171 91 101 I-Modifier
laparoscopic NCT03928171 102 114 B-Procedure
surgery NCT03928171 115 122 I-Procedure

Exclusion NCT03928171 123 132 O
Criteria NCT03928171 133 141 O
: NCT03928171 142 143 O

- NCT03928171 147 148 O
Severe NCT03928171 150 156 O
liver NCT03928171 157 162 B-Modifier
- NCT03928171 163 164 O
or NCT03928171 165 167 B-Or
renal NCT03928171 168 173 B-Modifier
disease NCT03928171 174 181 B-Condition

- NCT03928171 184 185 O
Pregnancy NCT03928171 187 196 B-Condition
or NCT03928171 197 199 B-Or
lactation NCT03928171 200 209 B-Condition

- NCT03928171 212 213 O
Planned NCT03928171 215 222 B-Eq-Comparison
diagnostics NCT03928171 223 234 B-Procedure
or NCT03928171 235 237 B-Or
treatment NCT03928171 238 247 B-Procedure
with NCT03928171 248 252 O
radioactive NCT03928171 253 264 B-Procedure
iodine NCT03928171 265 271 I-Procedure
< NCT03928171 272 273 B-Eq-Comparison
1 NCT03928171 274 275 I-Eq-Comparison
week NCT03928171 276 280 I-Eq-Comparison
after NCT03928171 281 286 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgery NCT03928171 287 294 B-Procedure

- NCT03928171 297 298 O
BMI NCT03928171 300 303 B-Observation
> NCT03928171 304 305 B-Eq-Comparison
35 NCT03928171 306 308 I-Eq-Comparison
kg NCT03928171 309 311 I-Eq-Comparison
/ NCT03928171 312 313 I-Eq-Comparison
m2 NCT03928171 314 316 I-Eq-Comparison

- NCT03928171 319 320 O
Known NCT03928171 322 327 O
or NCT03928171 328 330 O
suspected NCT03928171 331 340 B-Assertion___Assertion-Type-Value:possible
hypersensitivity NCT03928171 341 357 B-Condition
to NCT03928171 358 360 O
indocyanine NCT03928171 361 372 B-Modifier
green NCT03928171 373 378 I-Modifier
, NCT03928171 379 380 O
sodium NCT03928171 381 387 B-Modifier
iodide NCT03928171 388 394 I-Modifier
or NCT03928171 395 397 O
iodine NCT03928171 398 404 B-Modifier

- NCT03928171 407 408 O
Hyperthyroidism NCT03928171 410 425 B-Condition
or NCT03928171 426 428 B-Or
thyroid NCT03928171 429 436 B-Condition
adenomas NCT03928171 437 445 I-Condition

- NCT03928171 448 449 O
Use NCT03928171 451 454 B-Eq-Comparison
of NCT03928171 455 457 O
medication NCT03928171 458 468 B-Drug
interfering NCT03928171 469 480 O
with NCT03928171 481 485 O
ICG NCT03928171 486 489 B-Condition
absorption NCT03928171 490 500 I-Condition
as NCT03928171 501 503 O
listed NCT03928171 504 510 O
in NCT03928171 511 513 O
the NCT03928171 514 517 O
summary NCT03928171 518 525 O
of NCT03928171 526 528 O
product NCT03928171 529 536 O
characteristics NCT03928171 537 552 O
. NCT03928171 552 553 O

Inclusion NCT03925441 0 9 O
Criteria NCT03925441 10 18 O
: NCT03925441 19 20 O

- NCT03925441 24 25 O
Children NCT03925441 27 35 O
and NCT03925441 36 39 B-Or
adolescents NCT03925441 40 51 O
who NCT03925441 52 55 B-And
are NCT03925441 56 59 O
diagnosed NCT03925441 60 69 O
with NCT03925441 70 74 O
pediatric NCT03925441 75 84 B-Modifier
chronic NCT03925441 85 92 I-Modifier
severe NCT03925441 93 99 O
plaque NCT03925441 100 106 B-Condition
psoriasis NCT03925441 107 116 I-Condition
. NCT03925441 117 118 O

- NCT03925441 122 123 O
Prior NCT03925441 125 130 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03925441 131 133 O
participating NCT03925441 134 147 O
in NCT03925441 148 150 O
the NCT03925441 151 154 O
study NCT03925441 155 160 B-Study
, NCT03925441 161 162 O
adalimumab NCT03925441 163 173 B-Drug
treatment NCT03925441 174 183 B-Procedure
was NCT03925441 184 187 O
determined NCT03925441 188 198 O
according NCT03925441 199 208 O
to NCT03925441 209 211 O
clinical NCT03925441 212 220 O
judgement NCT03925441 221 230 O
of NCT03925441 231 233 O
the NCT03925441 234 237 O
physician NCT03925441 238 247 O
. NCT03925441 248 249 O

- NCT03925441 253 254 O
Participants NCT03925441 256 268 O
( NCT03925441 269 270 O
or NCT03925441 271 273 O
legal NCT03925441 274 279 O
representative NCT03925441 280 294 O
) NCT03925441 295 296 O
who NCT03925441 297 300 O
voluntarily NCT03925441 301 312 O
agreed NCT03925441 313 319 O
to NCT03925441 320 322 O
participate NCT03925441 323 334 O
in NCT03925441 335 337 O
this NCT03925441 338 342 O
study NCT03925441 343 348 O
and NCT03925441 349 352 O
signed NCT03925441 353 359 O
informed NCT03925441 360 368 O
consent NCT03925441 369 376 O
. NCT03925441 377 378 O

Exclusion NCT03925441 380 389 O
Criteria NCT03925441 390 398 O
: NCT03925441 399 400 O

- NCT03925441 404 405 O
Participants NCT03925441 407 419 O
with NCT03925441 420 424 O
contraindication NCT03925441 425 441 B-Contraindication
to NCT03925441 442 444 O
adalimumab NCT03925441 445 455 B-Drug
as NCT03925441 456 458 O
listed NCT03925441 459 465 O
in NCT03925441 466 468 O
the NCT03925441 469 472 O
approved NCT03925441 473 481 O
Korean NCT03925441 482 488 O
label NCT03925441 489 494 O
. NCT03925441 495 496 O

- NCT03925441 500 501 O
Participants NCT03925441 503 515 O
with NCT03925441 516 520 O
prior NCT03925441 521 526 B-Eq-Comparison
treatment NCT03925441 527 536 B-Procedure
with NCT03925441 537 541 O
adalimumab NCT03925441 542 552 B-Drug
. NCT03925441 552 553 O

Inclusion NCT03923959 0 9 O
Criteria NCT03923959 10 18 O
: NCT03923959 19 20 O

1 NCT03923959 24 25 O
. NCT03923959 25 26 O
Provision NCT03923959 28 37 O
of NCT03923959 38 40 O
written NCT03923959 41 48 O
informed NCT03923959 49 57 O
consent NCT03923959 58 65 O

2 NCT03923959 68 69 O
. NCT03923959 69 70 O
Age NCT03923959 72 75 B-Age
> NCT03923959 76 77 B-Eq-Comparison
or NCT03923959 78 80 I-Eq-Comparison
= NCT03923959 81 82 I-Eq-Comparison
to NCT03923959 83 85 I-Eq-Comparison
65 NCT03923959 86 88 I-Eq-Comparison
years NCT03923959 89 94 I-Eq-Comparison

3 NCT03923959 97 98 O
. NCT03923959 98 99 O
Hip NCT03923959 101 104 B-Modifier
fracture NCT03923959 105 113 B-Condition
location NCT03923959 114 122 O
within NCT03923959 123 129 O
the NCT03923959 130 133 O
femoral NCT03923959 134 141 B-Modifier
neck NCT03923959 142 146 I-Modifier
, NCT03923959 147 148 O
intertrochanteric NCT03923959 149 166 B-Modifier
, NCT03923959 167 168 O
and NCT03923959 169 172 O
subtrochanteric NCT03923959 173 188 B-Modifier
regions NCT03923959 189 196 O

4 NCT03923959 199 200 O
. NCT03923959 200 201 O
Indication NCT03923959 203 213 B-Indication
for NCT03923959 214 217 O
one NCT03923959 218 221 B-Eq-Comparison
of NCT03923959 222 224 O
the NCT03923959 225 228 B-Criteria-Count
following NCT03923959 229 238 I-Criteria-Count
surgical NCT03923959 239 247 B-Procedure
interventions NCT03923959 248 261 I-Procedure
: NCT03923959 262 263 O
hemiarthroplasty NCT03923959 264 280 B-Procedure
, NCT03923959 281 282 O
total NCT03923959 283 288 B-Procedure
hip NCT03923959 289 292 I-Procedure
replacement NCT03923959 293 304 I-Procedure
, NCT03923959 305 306 O
sliding NCT03923959 307 314 B-Modifier
plate NCT03923959 315 320 I-Modifier
and NCT03923959 321 324 B-Or
screw NCT03923959 325 330 B-Modifier
fixation NCT03923959 331 339 B-Procedure
, NCT03923959 340 341 O
or NCT03923959 342 344 B-Or
intramedullary NCT03923959 345 359 B-Modifier
fixation NCT03923959 360 368 B-Procedure

Exclusion NCT03923959 369 378 O
Criteria NCT03923959 379 387 O
: NCT03923959 388 389 O

1 NCT03923959 393 394 O
. NCT03923959 394 395 O
Indication NCT03923959 397 407 B-Indication
for NCT03923959 408 411 O
closed NCT03923959 412 418 B-Procedure
reduction NCT03923959 419 428 I-Procedure
or NCT03923959 429 431 B-Or
percutaneous NCT03923959 432 444 B-Procedure
screw NCT03923959 445 450 I-Procedure

2 NCT03923959 453 454 O
. NCT03923959 454 455 O
Allergy NCT03923959 457 464 B-Allergy
to NCT03923959 465 467 O
TXA NCT03923959 468 471 B-Drug

3 NCT03923959 474 475 O
. NCT03923959 475 476 O
Cerebrovascular NCT03923959 478 493 B-Condition
accident NCT03923959 494 502 I-Condition
/ NCT03923959 503 504 B-Or
stroke NCT03923959 505 511 B-Condition
, NCT03923959 512 513 O
active NCT03923959 514 520 B-Eq-Comparison
coronary NCT03923959 521 529 B-Condition
disease NCT03923959 530 537 I-Condition
/ NCT03923959 538 539 B-Or
myocardial NCT03923959 540 550 B-Condition
infarction NCT03923959 551 561 I-Condition
, NCT03923959 562 563 O
or NCT03923959 564 566 B-Or
deep NCT03923959 567 571 B-Condition
vein NCT03923959 572 576 I-Condition
thrombosis NCT03923959 577 587 I-Condition
/ NCT03923959 588 589 B-Or
pulmonary NCT03923959 590 599 B-Condition
emboli NCT03923959 600 606 I-Condition
within NCT03923959 607 613 B-Eq-Comparison
one NCT03923959 614 617 I-Eq-Comparison
( NCT03923959 618 619 I-Eq-Comparison
1 NCT03923959 620 621 I-Eq-Comparison
) NCT03923959 622 623 I-Eq-Comparison
month NCT03923959 624 629 I-Eq-Comparison
of NCT03923959 630 632 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03923959 633 636 O
fracture NCT03923959 637 645 B-Condition

4 NCT03923959 648 649 O
. NCT03923959 649 650 O
Presence NCT03923959 652 660 O
of NCT03923959 661 663 O
hypercoaguable NCT03923959 664 678 B-Condition
disorder NCT03923959 679 687 I-Condition

Inclusion NCT03923192 0 9 O
Criteria NCT03923192 10 18 O
: NCT03923192 19 20 O

- NCT03923192 24 25 O
Patients NCT03923192 27 35 O
aged NCT03923192 36 40 B-Age
from NCT03923192 41 45 O
15 NCT03923192 46 48 B-Eq-Comparison
to NCT03923192 49 51 I-Eq-Comparison
50 NCT03923192 52 54 I-Eq-Comparison
years NCT03923192 55 60 I-Eq-Comparison
. NCT03923192 61 62 O

- NCT03923192 66 67 O
No NCT03923192 69 71 O
gender NCT03923192 72 78 O
restriction NCT03923192 79 90 O
. NCT03923192 91 92 O

- NCT03923192 96 97 O
Patients NCT03923192 99 107 O
should NCT03923192 108 114 O
have NCT03923192 115 119 O
an NCT03923192 120 122 O
acceptable NCT03923192 123 133 O
oral NCT03923192 134 138 O
hygiene NCT03923192 139 146 O
level NCT03923192 147 152 O
. NCT03923192 153 154 O

- NCT03923192 158 159 O
Patients NCT03923192 161 169 O
must NCT03923192 170 174 O
have NCT03923192 175 179 O
at NCT03923192 180 182 B-Eq-Comparison
least NCT03923192 183 188 I-Eq-Comparison
one NCT03923192 189 192 I-Eq-Comparison
posterior NCT03923192 193 202 B-Modifier
proximal NCT03923192 203 211 I-Modifier
caries NCT03923192 212 218 B-Condition

Exclusion NCT03923192 219 228 O
Criteria NCT03923192 229 237 O
: NCT03923192 238 239 O

- NCT03923192 243 244 O
Patients NCT03923192 246 254 O
with NCT03923192 255 259 O
a NCT03923192 260 261 O
compromised NCT03923192 262 273 B-Condition
medical NCT03923192 274 281 O
history NCT03923192 282 289 B-Eq-Comparison
. NCT03923192 290 291 O

- NCT03923192 295 296 O
Severe NCT03923192 298 304 O
or NCT03923192 305 307 B-Or
active NCT03923192 308 314 B-Eq-Comparison
periodontal NCT03923192 315 326 B-Condition
disease NCT03923192 327 334 I-Condition
. NCT03923192 335 336 O

- NCT03923192 340 341 O
Heavy NCT03923192 343 348 B-Modifier
bruxism NCT03923192 349 356 B-Condition
or NCT03923192 357 359 B-Or
a NCT03923192 360 361 O
traumatic NCT03923192 362 371 B-Modifier
occlusion NCT03923192 372 381 B-Condition
. NCT03923192 382 383 O

- NCT03923192 387 388 O
Acute NCT03923192 390 395 O
or NCT03923192 396 398 B-Or
chronic NCT03923192 399 406 B-Modifier
dental NCT03923192 407 413 I-Modifier
infection NCT03923192 414 423 B-Condition
. NCT03923192 424 425 O

- NCT03923192 429 430 O
Pregnant NCT03923192 432 440 B-Condition
or NCT03923192 441 443 B-Or
breastfeeding NCT03923192 444 457 B-Condition
women NCT03923192 458 463 O
. NCT03923192 464 465 O

- NCT03923192 469 470 O
Patients NCT03923192 472 480 O
with NCT03923192 481 485 O
posterior NCT03923192 486 495 B-Modifier
restorations NCT03923192 496 508 B-Procedure
on NCT03923192 509 511 O
molars NCT03923192 512 518 B-Modifier
or NCT03923192 519 521 B-Or
premolars NCT03923192 522 531 B-Modifier

Inclusion NCT03925285 0 9 O
Criteria NCT03925285 10 18 O
: NCT03925285 19 20 O

- NCT03925285 24 25 O
Biopsy NCT03925285 27 33 B-Procedure
confirmed NCT03925285 34 43 O
diagnosis NCT03925285 44 53 O
of NCT03925285 54 56 O
SNIP NCT03925285 57 61 B-Condition
and NCT03925285 62 65 B-And
scheduled NCT03925285 66 75 B-Eq-Comparison
to NCT03925285 76 78 O
undergo NCT03925285 79 86 O
surgical NCT03925285 87 95 B-Procedure
resection NCT03925285 96 105 I-Procedure
; NCT03925285 105 106 O

- NCT03925285 109 110 O
Age NCT03925285 112 115 B-Age
≥ NCT03925285 116 117 B-Eq-Comparison
18 NCT03925285 118 120 I-Eq-Comparison
years NCT03925285 121 126 I-Eq-Comparison
; NCT03925285 126 127 O

- NCT03925285 130 131 O
Written NCT03925285 133 140 O
informed NCT03925285 141 149 O
consent NCT03925285 150 157 O
; NCT03925285 157 158 O

- NCT03925285 161 162 O
Mentally NCT03925285 164 172 B-Condition
competent NCT03925285 173 182 I-Condition
person NCT03925285 183 189 O
that NCT03925285 190 194 O
is NCT03925285 195 197 O
able NCT03925285 198 202 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03925285 203 206 I-Assertion___Assertion-Type-Value:hypothetical
willing NCT03925285 207 214 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03925285 215 217 O
comply NCT03925285 218 224 O
with NCT03925285 225 229 O
study NCT03925285 230 235 B-Study
procedures NCT03925285 236 246 B-Procedure
. NCT03925285 247 248 O

Exclusion NCT03925285 250 259 O
Criteria NCT03925285 260 268 O
: NCT03925285 269 270 O

- NCT03925285 274 275 O
Medical NCT03925285 277 284 B-Modifier
or NCT03925285 285 287 B-Or
psychiatric NCT03925285 288 299 B-Modifier
conditions NCT03925285 300 310 B-Condition
that NCT03925285 311 315 O
compromise NCT03925285 316 326 O
the NCT03925285 327 330 O
patient NCT03925285 331 338 O
's NCT03925285 338 340 O
ability NCT03925285 341 348 O
to NCT03925285 349 351 O
give NCT03925285 352 356 O
informed NCT03925285 357 365 O
consent NCT03925285 366 373 O
; NCT03925285 373 374 O

- NCT03925285 377 378 O
Concurrent NCT03925285 380 390 B-Modifier
uncontrolled NCT03925285 391 403 I-Modifier
medical NCT03925285 404 411 B-Condition
conditions NCT03925285 412 422 I-Condition
; NCT03925285 422 423 O

- NCT03925285 426 427 O
Received NCT03925285 429 437 B-Eq-Comparison
an NCT03925285 438 440 O
investigational NCT03925285 441 456 B-Study
drug NCT03925285 457 461 B-Drug
within NCT03925285 462 468 B-Eq-Comparison
30 NCT03925285 469 471 I-Eq-Comparison
days NCT03925285 472 476 I-Eq-Comparison
prior NCT03925285 477 482 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03925285 483 485 O
the NCT03925285 486 489 O
dose NCT03925285 490 494 O
of NCT03925285 495 497 O
bevacizumab NCT03925285 498 509 B-Drug
- NCT03925285 510 511 I-Drug
IRDye800 NCT03925285 512 520 I-Drug
CW NCT03925285 521 523 I-Drug
; NCT03925285 523 524 O

- NCT03925285 527 528 O
Tumors NCT03925285 530 536 B-Condition
at NCT03925285 537 539 O
sites NCT03925285 540 545 B-Modifier
of NCT03925285 546 548 O
which NCT03925285 549 554 O
the NCT03925285 555 558 O
surgeon NCT03925285 559 566 O
would NCT03925285 567 572 O
assess NCT03925285 573 579 O
that NCT03925285 580 584 O
in NCT03925285 585 587 B-Procedure
vivo NCT03925285 588 592 I-Procedure
imaging NCT03925285 593 600 I-Procedure
would NCT03925285 601 606 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03925285 607 610 B-Negation
be NCT03925285 611 613 O
feasible NCT03925285 614 622 O
; NCT03925285 622 623 O

- NCT03925285 626 627 O
History NCT03925285 629 636 B-Eq-Comparison
of NCT03925285 637 639 O
myocardial NCT03925285 640 650 B-Condition
infarction NCT03925285 651 661 I-Condition
, NCT03925285 662 663 O
cerebrovascular NCT03925285 664 679 B-Condition
accident NCT03925285 680 688 I-Condition
, NCT03925285 689 690 O
uncontrolled NCT03925285 691 703 B-Modifier
cardiac NCT03925285 704 711 I-Modifier
heart NCT03925285 712 717 B-Condition
failure NCT03925285 718 725 I-Condition
, NCT03925285 726 727 O
significant NCT03925285 728 739 O
liver NCT03925285 740 745 B-Condition
disease NCT03925285 746 753 I-Condition
or NCT03925285 754 756 B-Or
unstable NCT03925285 757 765 B-Condition
angina NCT03925285 766 772 I-Condition
within NCT03925285 773 779 B-Eq-Comparison
6 NCT03925285 780 781 I-Eq-Comparison
months NCT03925285 782 788 I-Eq-Comparison
prior NCT03925285 789 794 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03925285 795 797 O
enrollment NCT03925285 798 808 B-Study
; NCT03925285 808 809 O

- NCT03925285 812 813 O
Inadequately NCT03925285 815 827 B-Modifier
controlled NCT03925285 828 838 I-Modifier
hypertension NCT03925285 839 851 B-Condition
with NCT03925285 852 856 O
or NCT03925285 857 859 O
without NCT03925285 860 867 O
current NCT03925285 868 875 B-Eq-Comparison
antihypertensive NCT03925285 876 892 B-Drug
medications NCT03925285 893 904 I-Drug
; NCT03925285 904 905 O

- NCT03925285 908 909 O
History NCT03925285 911 918 B-Eq-Comparison
of NCT03925285 919 921 O
infusion NCT03925285 922 930 B-Modifier
reactions NCT03925285 931 940 B-Condition
to NCT03925285 941 943 O
bevacizumab NCT03925285 944 955 B-Drug
or NCT03925285 956 958 B-Or
other NCT03925285 959 964 B-Other
monoclonal NCT03925285 965 975 B-Procedure
antibody NCT03925285 976 984 I-Procedure
therapies NCT03925285 985 994 I-Procedure
; NCT03925285 994 995 O

- NCT03925285 998 999 O
Pregnant NCT03925285 1001 1009 B-Condition
or NCT03925285 1010 1012 B-Or
lactating NCT03925285 1013 1022 B-Condition
women NCT03925285 1023 1028 O
. NCT03925285 1028 1029 O
Documentation NCT03925285 1031 1044 O
of NCT03925285 1045 1047 O
a NCT03925285 1048 1049 O
negative NCT03925285 1050 1058 O
pregnancy NCT03925285 1059 1068 B-Observation
test NCT03925285 1069 1073 I-Observation
must NCT03925285 1074 1078 O
be NCT03925285 1079 1081 O
available NCT03925285 1082 1091 O
for NCT03925285 1092 1095 O
women NCT03925285 1096 1101 O
of NCT03925285 1102 1104 O
childbearing NCT03925285 1105 1117 B-Condition
potential NCT03925285 1118 1127 I-Condition
. NCT03925285 1127 1128 O
Woman NCT03925285 1130 1135 O
of NCT03925285 1136 1138 O
childbearing NCT03925285 1139 1151 B-Condition
potential NCT03925285 1152 1161 I-Condition
are NCT03925285 1162 1165 B-And
premenopausal NCT03925285 1166 1179 B-Condition
women NCT03925285 1180 1185 O
with NCT03925285 1186 1190 B-And
intact NCT03925285 1191 1197 B-Condition
reproductive NCT03925285 1198 1210 I-Condition
organs NCT03925285 1211 1217 I-Condition
and NCT03925285 1218 1221 B-And
women NCT03925285 1222 1227 O
less NCT03925285 1228 1232 B-Eq-Comparison
than NCT03925285 1233 1237 I-Eq-Comparison
two NCT03925285 1238 1241 I-Eq-Comparison
years NCT03925285 1242 1247 I-Eq-Comparison
after NCT03925285 1248 1253 B-Temporal-Connection___Temporal-Connection-Type-Value:after
menopause NCT03925285 1254 1263 B-Condition
; NCT03925285 1263 1264 O

- NCT03925285 1267 1268 O
Lab NCT03925285 1270 1273 B-Observation
values NCT03925285 1274 1280 I-Observation
that NCT03925285 1281 1285 O
in NCT03925285 1286 1288 O
the NCT03925285 1289 1292 O
opinion NCT03925285 1293 1300 O
of NCT03925285 1301 1303 O
the NCT03925285 1304 1307 O
primary NCT03925285 1308 1315 O
surgeon NCT03925285 1316 1323 O
would NCT03925285 1324 1329 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03925285 1330 1337 B-Negation
surgical NCT03925285 1338 1346 B-Procedure
resection NCT03925285 1347 1356 I-Procedure
; NCT03925285 1356 1357 O

- NCT03925285 1360 1361 O
Life NCT03925285 1363 1367 B-Observation
expectancy NCT03925285 1368 1378 I-Observation
< NCT03925285 1379 1380 B-Eq-Comparison
12 NCT03925285 1381 1383 I-Eq-Comparison
weeks NCT03925285 1384 1389 I-Eq-Comparison
; NCT03925285 1389 1390 O

Inclusion NCT03928951 0 9 O
Criteria NCT03928951 10 18 O
: NCT03928951 19 20 O

- NCT03928951 24 25 O
Every NCT03928951 27 32 O
patient NCT03928951 33 40 O
more NCT03928951 41 45 B-Eq-Comparison
than NCT03928951 46 50 I-Eq-Comparison
18 NCT03928951 51 53 I-Eq-Comparison
years NCT03928951 54 59 I-Age|Eq-Comparison
who NCT03928951 60 63 B-And
was NCT03928951 64 67 O
administered NCT03928951 68 80 B-Eq-Comparison
antibiotherapy NCT03928951 81 95 B-Procedure
for NCT03928951 96 99 O
urinary NCT03928951 100 107 B-Modifier
infection NCT03928951 108 117 B-Condition
in NCT03928951 118 120 O
emergency NCT03928951 121 130 O
department NCT03928951 131 141 O
or NCT03928951 142 144 B-Or
for NCT03928951 145 148 O
whom NCT03928951 149 153 O
urinary NCT03928951 154 161 B-Modifier
infection NCT03928951 162 171 B-Condition
was NCT03928951 172 175 O
diagnosed NCT03928951 176 185 O
in NCT03928951 186 188 O
emergency NCT03928951 189 198 O
department NCT03928951 199 209 O
( NCT03928951 210 211 O
cystitis NCT03928951 212 220 B-Condition
, NCT03928951 221 222 O
acute NCT03928951 223 228 O
pyelonephritis NCT03928951 229 243 B-Condition
, NCT03928951 244 245 O
prostatitis NCT03928951 246 257 B-Condition
) NCT03928951 258 259 O

Exclusion NCT03928951 261 270 O
Criteria NCT03928951 271 279 O
: NCT03928951 280 281 O

- NCT03928951 285 286 O
Patients NCT03928951 288 296 O
less NCT03928951 297 301 B-Eq-Comparison
than NCT03928951 302 306 I-Eq-Comparison
18 NCT03928951 307 309 I-Eq-Comparison
years NCT03928951 310 315 I-Eq-Comparison
old NCT03928951 316 319 B-Age

- NCT03928951 322 323 O
Patients NCT03928951 325 333 O
opposed NCT03928951 334 341 O
to NCT03928951 342 344 O
their NCT03928951 345 350 O
data NCT03928951 351 355 O
use NCT03928951 356 359 O

- NCT03928951 362 363 O
Patients NCT03928951 365 373 O
hospitalized NCT03928951 374 386 B-Encounter
more NCT03928951 387 391 B-Eq-Comparison
than NCT03928951 392 396 I-Eq-Comparison
24 NCT03928951 397 399 I-Eq-Comparison
hours NCT03928951 400 405 I-Eq-Comparison

- NCT03928951 408 409 O
Patients NCT03928951 411 419 O
taking NCT03928951 420 426 B-Eq-Comparison
antibiotherapy NCT03928951 427 441 B-Procedure
already NCT03928951 442 449 O
before NCT03928951 450 456 B-Temporal-Connection___Temporal-Connection-Type-Value:before
their NCT03928951 457 462 O
arrival NCT03928951 463 470 B-Encounter
in NCT03928951 471 473 O
emergency NCT03928951 474 483 O
department NCT03928951 484 494 O

- NCT03928951 497 498 O
Patients NCT03928951 500 508 O
without NCT03928951 509 516 B-Negation
sufficient NCT03928951 517 527 O
reading NCT03928951 528 535 O
capacities NCT03928951 536 546 O
or NCT03928951 547 549 O
understanding NCT03928951 550 563 O
of NCT03928951 564 566 O
french NCT03928951 567 573 O
language NCT03928951 574 582 O
to NCT03928951 583 585 O
express NCT03928951 586 593 O
opposition NCT03928951 594 604 O
to NCT03928951 605 607 O
their NCT03928951 608 613 O
research NCT03928951 614 622 O
participation NCT03928951 623 636 O

- NCT03928951 639 640 O
Any NCT03928951 642 645 O
other NCT03928951 646 651 O
reason NCT03928951 652 658 O
which NCT03928951 659 664 O
, NCT03928951 665 666 O
according NCT03928951 667 676 O
to NCT03928951 677 679 O
investigator NCT03928951 680 692 O
, NCT03928951 693 694 O
might NCT03928951 695 700 O
interfere NCT03928951 701 710 O
with NCT03928951 711 715 O
research NCT03928951 716 724 O
objective NCT03928951 725 734 O
evaluation NCT03928951 735 745 O

Inclusion NCT03921034 0 9 O
Criteria NCT03921034 10 18 O
: NCT03921034 19 20 O

- NCT03921034 24 25 O
Unilateral NCT03921034 27 37 B-Modifier
, NCT03921034 38 39 O
primary NCT03921034 40 47 B-Modifier
tricompartment NCT03921034 48 62 I-Modifier
total NCT03921034 63 68 I-Modifier
knee NCT03921034 69 73 I-Modifier
arthroplasty NCT03921034 74 86 B-Procedure

- NCT03921034 89 90 O
Age NCT03921034 92 95 B-Age
18 NCT03921034 96 98 B-Eq-Comparison
years NCT03921034 99 104 I-Eq-Comparison
or NCT03921034 105 107 I-Eq-Comparison
older NCT03921034 108 113 I-Eq-Comparison

- NCT03921034 116 117 O
ASA NCT03921034 119 122 B-Condition
I NCT03921034 123 124 B-Eq-Comparison
- NCT03921034 125 126 I-Eq-Comparison
III NCT03921034 127 130 I-Eq-Comparison

- NCT03921034 133 134 O
Eligible NCT03921034 136 144 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03921034 145 148 I-Assertion___Assertion-Type-Value:hypothetical
spinal NCT03921034 149 155 B-Modifier
or NCT03921034 156 158 B-Or
combined NCT03921034 159 167 B-Modifier
spinal NCT03921034 168 174 I-Modifier
epidural NCT03921034 175 183 B-Procedure
anesthetic NCT03921034 184 194 I-Procedure

- NCT03921034 197 198 O
Able NCT03921034 200 204 O
to NCT03921034 205 207 O
speak NCT03921034 208 213 O
, NCT03921034 214 215 O
read NCT03921034 216 220 O
, NCT03921034 221 222 O
and NCT03921034 223 226 O
understand NCT03921034 227 237 O
English NCT03921034 238 245 O

- NCT03921034 248 249 O
Willing NCT03921034 251 258 O
to NCT03921034 259 261 O
participate NCT03921034 262 273 O
in NCT03921034 274 276 O
the NCT03921034 277 280 O
trial NCT03921034 281 286 B-Study

Exclusion NCT03921034 287 296 O
Criteria NCT03921034 297 305 O
: NCT03921034 306 307 O

- NCT03921034 311 312 O
Contraindication NCT03921034 314 330 B-Contraindication
to NCT03921034 331 333 O
regional NCT03921034 334 342 B-Procedure
anesthesia NCT03921034 343 353 I-Procedure
or NCT03921034 354 356 B-Or
peripheral NCT03921034 357 367 B-Modifier
nerve NCT03921034 368 373 B-Procedure
blocks NCT03921034 374 380 I-Procedure

- NCT03921034 383 384 O
Allergy NCT03921034 386 393 B-Allergy
to NCT03921034 394 396 O
local NCT03921034 397 402 B-Procedure
anesthetics NCT03921034 403 414 I-Procedure

- NCT03921034 417 418 O
Allergy NCT03921034 420 427 B-Allergy
to NCT03921034 428 430 O
NSAIDs NCT03921034 431 437 B-Drug

- NCT03921034 440 441 O
Chronic NCT03921034 443 450 B-Modifier
renal NCT03921034 451 456 B-Condition
insufficiency NCT03921034 457 470 I-Condition
with NCT03921034 471 475 B-And
Cr NCT03921034 476 478 B-Observation
> NCT03921034 479 480 B-Eq-Comparison
1.4 NCT03921034 481 484 I-Eq-Comparison
or NCT03921034 485 487 B-Or
GFR NCT03921034 488 491 B-Observation
< NCT03921034 492 493 B-Eq-Comparison
60 NCT03921034 494 496 I-Eq-Comparison

- NCT03921034 500 501 O
Have NCT03921034 503 507 O
chronic NCT03921034 508 515 B-Modifier
pain NCT03921034 516 520 B-Condition
that NCT03921034 521 525 O
is NCT03921034 526 528 O
not NCT03921034 529 532 B-Negation
related NCT03921034 533 540 O
to NCT03921034 541 543 O
their NCT03921034 544 549 O
knee NCT03921034 550 554 B-Modifier
joint NCT03921034 555 560 I-Modifier

- NCT03921034 563 564 O
Have NCT03921034 566 570 O
been NCT03921034 571 575 O
using NCT03921034 576 581 B-Eq-Comparison
opioids NCT03921034 582 589 B-Drug
on NCT03921034 590 592 O
a NCT03921034 593 594 O
chronic NCT03921034 595 602 B-Modifier
basis NCT03921034 603 608 O
( NCT03921034 609 610 O
daily NCT03921034 611 616 B-Eq-Comparison
or NCT03921034 617 619 B-Or
almost NCT03921034 620 626 O
daily NCT03921034 627 632 B-Eq-Comparison
opioid NCT03921034 633 639 B-Drug
use NCT03921034 640 643 O
for NCT03921034 644 647 O
3 NCT03921034 648 649 B-Eq-Comparison
months NCT03921034 650 656 I-Eq-Comparison
or NCT03921034 657 659 I-Eq-Comparison
longer NCT03921034 660 666 I-Eq-Comparison
) NCT03921034 667 668 O

- NCT03921034 672 673 O
Have NCT03921034 675 679 O
a NCT03921034 680 681 O
pre NCT03921034 682 685 B-Eq-Comparison
- NCT03921034 686 687 I-Eq-Comparison
existing NCT03921034 688 696 I-Eq-Comparison
peripheral NCT03921034 697 707 B-Condition
neuropathy NCT03921034 708 718 I-Condition
involving NCT03921034 719 728 O
the NCT03921034 729 732 O
operative NCT03921034 733 742 B-Modifier
site NCT03921034 743 747 I-Modifier

- NCT03921034 750 751 O
Body NCT03921034 753 757 B-Observation
mass NCT03921034 758 762 I-Observation
index NCT03921034 763 768 I-Observation
greater NCT03921034 769 776 B-Eq-Comparison
than NCT03921034 777 781 I-Eq-Comparison
or NCT03921034 782 784 I-Eq-Comparison
equal NCT03921034 785 790 I-Eq-Comparison
to NCT03921034 791 793 I-Eq-Comparison
40 NCT03921034 794 796 I-Eq-Comparison

Inclusion NCT03922529 0 9 O
Criteria NCT03922529 10 18 O
: NCT03922529 19 20 O

- NCT03922529 24 25 O
Age NCT03922529 27 30 B-Age
≥ NCT03922529 31 32 B-Eq-Comparison
70 NCT03922529 33 35 I-Eq-Comparison
year NCT03922529 36 40 I-Eq-Comparison

- NCT03922529 43 44 O
Eligible NCT03922529 46 54 O
cardiovascular NCT03922529 55 69 B-Condition
disease NCT03922529 70 77 I-Condition
( NCT03922529 78 79 O
CVD NCT03922529 80 83 B-Condition
) NCT03922529 84 85 O
diagnosis NCT03922529 86 95 O
( NCT03922529 96 97 O
hospitalization NCT03922529 98 113 B-Encounter
for NCT03922529 114 117 O
Acute NCT03922529 118 123 B-Condition
myocardial NCT03922529 124 134 I-Condition
infarction NCT03922529 135 145 I-Condition
( NCT03922529 146 147 O
AMI NCT03922529 148 151 B-Condition
) NCT03922529 152 153 O
/ NCT03922529 155 156 B-Or
Acute NCT03922529 157 162 B-Condition
coronary NCT03922529 163 171 I-Condition
syndrome NCT03922529 172 180 I-Condition
( NCT03922529 181 182 O
ACS NCT03922529 183 186 B-Condition
) NCT03922529 187 188 O
, NCT03922529 190 191 O
stable NCT03922529 192 198 O
Ischemic NCT03922529 199 207 B-Condition
Heart NCT03922529 208 213 I-Condition
Disease NCT03922529 214 221 I-Condition
, NCT03922529 222 223 O
revascularization NCT03922529 224 241 B-Modifier
Coronary NCT03922529 242 250 B-Procedure
artery NCT03922529 251 257 I-Procedure
bypass NCT03922529 258 264 I-Procedure
graft NCT03922529 265 270 I-Procedure
surgery NCT03922529 271 278 I-Procedure
and NCT03922529 279 282 B-Or
Percutaneous NCT03922529 283 295 B-Procedure
Coronary NCT03922529 296 304 I-Procedure
Intervention NCT03922529 305 317 I-Procedure
[ NCT03922529 318 319 O
CABG NCT03922529 320 324 B-Procedure
, NCT03922529 325 326 O
PCI NCT03922529 327 330 B-Procedure
] NCT03922529 331 332 O
, NCT03922529 334 335 O
valvular NCT03922529 336 344 B-Condition
heart NCT03922529 345 350 I-Condition
disease NCT03922529 351 358 I-Condition
[ NCT03922529 359 360 O
specifically NCT03922529 361 373 O
, NCT03922529 374 375 O
surgical NCT03922529 376 384 B-Modifier
or NCT03922529 385 387 B-Or
percutaneous NCT03922529 388 400 B-Modifier
intervention NCT03922529 401 413 B-Procedure
for NCT03922529 414 417 O
mitral NCT03922529 418 424 B-Condition
regurgitation NCT03922529 425 438 I-Condition
or NCT03922529 439 441 B-Or
aortic NCT03922529 442 448 B-Condition
stenosis NCT03922529 449 457 I-Condition
] NCT03922529 458 459 O
, NCT03922529 461 462 O
or NCT03922529 463 465 B-Or
heart NCT03922529 466 471 B-Condition
failure NCT03922529 472 479 I-Condition
( NCT03922529 480 481 O
HF NCT03922529 482 484 B-Condition
) NCT03922529 485 486 O
) NCT03922529 488 489 O

- NCT03922529 493 494 O
English NCT03922529 496 503 O
speaking NCT03922529 504 512 O

- NCT03922529 515 516 O
able NCT03922529 518 522 O
to NCT03922529 523 525 O
provide NCT03922529 526 533 O
written NCT03922529 534 541 O
informed NCT03922529 542 550 O
consent NCT03922529 551 558 O

- NCT03922529 561 562 O
able NCT03922529 564 568 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03922529 569 571 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03922529 572 574 O
assessed NCT03922529 575 583 O
and NCT03922529 584 587 O
undergo NCT03922529 588 595 O
study NCT03922529 596 601 B-Study
interventions NCT03922529 602 615 O
. NCT03922529 616 617 O

Exclusion NCT03922529 619 628 O
Criteria NCT03922529 629 637 O
: NCT03922529 638 639 O

- NCT03922529 643 644 O
Unstable NCT03922529 646 654 O
medical NCT03922529 655 662 B-Condition
condition NCT03922529 663 672 I-Condition
as NCT03922529 673 675 O
indicated NCT03922529 676 685 O
by NCT03922529 686 688 O
history NCT03922529 689 696 O
, NCT03922529 697 698 O
physical NCT03922529 699 707 B-Procedure
exam NCT03922529 708 712 I-Procedure
, NCT03922529 713 714 O
and NCT03922529 715 718 B-Or
/ NCT03922529 719 720 I-Or
or NCT03922529 721 723 I-Or
laboratory NCT03922529 724 734 B-Observation
findings NCT03922529 735 743 I-Observation

- NCT03922529 746 747 O
Presence NCT03922529 749 757 O
of NCT03922529 758 760 O
non NCT03922529 761 764 B-Exception
- NCT03922529 765 766 O
CVD NCT03922529 767 770 B-Condition
conditions NCT03922529 771 781 B-Condition
likely NCT03922529 782 788 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03922529 789 791 B-Eq-Comparison
be NCT03922529 792 794 I-Eq-Comparison
fatal NCT03922529 795 800 B-Death
within NCT03922529 801 807 B-Eq-Comparison
12 NCT03922529 808 810 I-Eq-Comparison
months NCT03922529 811 817 I-Eq-Comparison
( NCT03922529 818 819 O
e. NCT03922529 820 822 O
g. NCT03922529 823 825 O
, NCT03922529 826 827 O
metastatic NCT03922529 828 838 B-Modifier
cancer NCT03922529 839 845 B-Condition
) NCT03922529 846 847 O

- NCT03922529 851 852 O
Severe NCT03922529 854 860 O
cognitive NCT03922529 861 870 B-Condition
impairment NCT03922529 871 881 I-Condition
: NCT03922529 882 883 O
Short NCT03922529 884 889 B-Observation
Blessed NCT03922529 890 897 I-Observation
screening NCT03922529 898 907 I-Observation
with NCT03922529 908 912 O
a NCT03922529 913 914 O
score NCT03922529 915 920 O
of NCT03922529 921 923 O
13 NCT03922529 924 926 B-Eq-Comparison
or NCT03922529 927 929 I-Eq-Comparison
greater NCT03922529 930 937 I-Eq-Comparison
or NCT03922529 938 940 B-Or
can NCT03922529 941 944 O
not NCT03922529 944 947 O
consent NCT03922529 948 955 O
( NCT03922529 956 957 O
as NCT03922529 958 960 O
indicated NCT03922529 961 970 O
by NCT03922529 971 973 O
medical NCT03922529 974 981 O
record NCT03922529 982 988 O
) NCT03922529 989 990 O

- NCT03922529 994 995 O
Long NCT03922529 997 1001 B-Procedure
- NCT03922529 1002 1003 I-Procedure
term NCT03922529 1004 1008 I-Procedure
care NCT03922529 1009 1013 I-Procedure
resident NCT03922529 1014 1022 O
at NCT03922529 1023 1025 B-Temporal-Connection___Temporal-Connection-Type-Value:during
admission NCT03922529 1026 1035 B-Encounter
with NCT03922529 1036 1040 B-And
no NCT03922529 1041 1043 B-Negation
plans NCT03922529 1044 1049 B-Assertion___Assertion-Type-Value:intention
to NCT03922529 1050 1052 O
return NCT03922529 1053 1059 O
to NCT03922529 1060 1062 O
independent NCT03922529 1063 1074 B-Observation
living NCT03922529 1075 1081 I-Observation

- NCT03922529 1084 1085 O
anticipates NCT03922529 1087 1098 B-Assertion___Assertion-Type-Value:hypothetical
inability NCT03922529 1099 1108 B-Negation
to NCT03922529 1109 1111 O
return NCT03922529 1112 1118 O
for NCT03922529 1119 1122 O
required NCT03922529 1123 1131 O
reassessments NCT03922529 1132 1145 B-Procedure
at NCT03922529 1146 1148 O
3 NCT03922529 1149 1150 B-Eq-Comparison
, NCT03922529 1151 1152 I-Eq-Comparison
6 NCT03922529 1153 1154 I-Eq-Comparison
and NCT03922529 1155 1158 I-Eq-Comparison
12 NCT03922529 1159 1161 I-Eq-Comparison
months NCT03922529 1162 1168 I-Eq-Comparison

- NCT03922529 1171 1172 O
long NCT03922529 1174 1178 B-Procedure
- NCT03922529 1179 1180 I-Procedure
term NCT03922529 1181 1185 I-Procedure
care NCT03922529 1186 1190 I-Procedure
residents NCT03922529 1191 1200 O
at NCT03922529 1201 1203 B-Temporal-Connection___Temporal-Connection-Type-Value:during
admission NCT03922529 1204 1213 B-Encounter
with NCT03922529 1214 1218 B-And
no NCT03922529 1219 1221 B-Negation
plans NCT03922529 1222 1227 B-Assertion___Assertion-Type-Value:intention
to NCT03922529 1228 1230 O
return NCT03922529 1231 1237 O
to NCT03922529 1238 1240 O
independent NCT03922529 1241 1252 B-Observation
living NCT03922529 1253 1259 I-Observation
. NCT03922529 1259 1260 O

Inclusion NCT03926767 0 9 O
Criteria NCT03926767 10 18 O
: NCT03926767 19 20 O

- NCT03926767 24 25 O
A NCT03926767 27 28 O
diagnosis NCT03926767 29 38 O
of NCT03926767 39 41 O
painful NCT03926767 42 49 B-Modifier
TMD NCT03926767 50 53 B-Condition
Research NCT03926767 54 62 O
Diagnostic NCT03926767 63 73 O
Criteria NCT03926767 74 82 O
for NCT03926767 83 86 O
TMD NCT03926767 87 90 O
( NCT03926767 91 92 O
RDC NCT03926767 93 96 O
/ NCT03926767 97 98 O
TMD NCT03926767 99 102 O
) NCT03926767 103 104 O

- NCT03926767 108 109 O
A NCT03926767 111 112 O
history NCT03926767 113 120 B-Eq-Comparison
of NCT03926767 121 123 O
orofacial NCT03926767 124 133 B-Modifier
pain NCT03926767 134 138 B-Condition
at NCT03926767 139 141 B-Eq-Comparison
least NCT03926767 142 147 I-Eq-Comparison
three NCT03926767 148 153 I-Eq-Comparison
months NCT03926767 154 160 I-Eq-Comparison
prior NCT03926767 161 166 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926767 167 169 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03926767 170 173 O
study NCT03926767 174 179 B-Study
( NCT03926767 180 181 O
TREEDE NCT03926767 182 188 O
et NCT03926767 189 191 O
al NCT03926767 192 194 O
, NCT03926767 195 196 O
2015 NCT03926767 197 201 O
) NCT03926767 202 203 O

- NCT03926767 211 212 O
age NCT03926767 214 217 B-Age
ranging NCT03926767 218 225 O
between NCT03926767 226 233 O
18 NCT03926767 234 236 B-Eq-Comparison
to NCT03926767 237 239 I-Eq-Comparison
55 NCT03926767 240 242 I-Eq-Comparison
years NCT03926767 243 248 I-Eq-Comparison
, NCT03926767 249 250 O
considering NCT03926767 251 262 O
the NCT03926767 263 266 O
greater NCT03926767 267 274 O
prevalence NCT03926767 275 285 O
of NCT03926767 286 288 O
TMD NCT03926767 289 292 O
associated NCT03926767 293 303 O
with NCT03926767 304 308 O
this NCT03926767 309 313 O
age NCT03926767 314 317 O
period NCT03926767 318 324 O
. NCT03926767 325 326 O

Exclusion NCT03926767 328 337 O
Criteria NCT03926767 338 346 O
: NCT03926767 347 348 O

- NCT03926767 352 353 O
Patients NCT03926767 355 363 O
with NCT03926767 364 368 O
illiteracy NCT03926767 369 379 B-Condition
, NCT03926767 380 381 O
severe NCT03926767 382 388 O
depression NCT03926767 389 399 B-Condition
( NCT03926767 400 401 O
medical NCT03926767 402 409 O
diagnoses NCT03926767 410 419 O
) NCT03926767 420 421 O
, NCT03926767 423 424 O
clinical NCT03926767 425 433 O
history NCT03926767 434 441 B-Eq-Comparison
of NCT03926767 442 444 O
tumors NCT03926767 445 451 B-Condition
in NCT03926767 452 454 O
the NCT03926767 455 458 O
craniofacial NCT03926767 459 471 B-Modifier
region NCT03926767 472 478 I-Modifier
, NCT03926767 479 480 O
patients NCT03926767 481 489 O
in NCT03926767 490 492 O
the NCT03926767 493 496 O
post NCT03926767 497 501 B-Temporal-Connection___Temporal-Connection-Type-Value:after
dental NCT03926767 502 508 B-Procedure
surgery NCT03926767 509 516 I-Procedure
period NCT03926767 517 523 O
or NCT03926767 524 526 B-Or
submitted NCT03926767 527 536 O
to NCT03926767 537 539 O
previous NCT03926767 540 548 B-Eq-Comparison
physical NCT03926767 549 557 B-Procedure
therapy NCT03926767 558 565 I-Procedure
in NCT03926767 566 568 O
the NCT03926767 569 572 O
past NCT03926767 573 577 B-Eq-Comparison
year NCT03926767 578 582 I-Eq-Comparison
or NCT03926767 583 585 B-Or
to NCT03926767 586 588 O
any NCT03926767 589 592 O
health NCT03926767 593 599 B-Modifier
/ NCT03926767 600 601 B-Or
pain NCT03926767 602 606 B-Modifier
education NCT03926767 607 616 B-Procedure
strategy NCT03926767 617 625 I-Procedure
, NCT03926767 626 627 O
pregnant NCT03926767 628 636 B-Condition
women NCT03926767 637 642 O
, NCT03926767 643 644 O
infections NCT03926767 645 655 B-Condition
, NCT03926767 656 657 O
whiplash NCT03926767 658 666 B-Condition
- NCT03926767 667 668 O
associated NCT03926767 669 679 O
disorders NCT03926767 680 689 B-Condition
and NCT03926767 690 693 B-Or
with NCT03926767 694 698 O
chronic NCT03926767 699 706 B-Modifier
degenerative NCT03926767 707 719 I-Modifier
inflammatory NCT03926767 720 732 I-Modifier
or NCT03926767 733 735 B-Or
neurologic NCT03926767 736 746 B-Modifier
disorders NCT03926767 747 756 B-Condition
were NCT03926767 757 761 O
excluded NCT03926767 762 770 B-Negation
from NCT03926767 771 775 O
this NCT03926767 776 780 O
study NCT03926767 781 786 B-Study
. NCT03926767 786 787 O
Patients NCT03926767 789 797 O
will NCT03926767 798 802 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03926767 803 805 I-Assertion___Assertion-Type-Value:hypothetical
instructed NCT03926767 806 816 O
to NCT03926767 817 819 O
not NCT03926767 820 823 B-Negation
use NCT03926767 824 827 O
pain NCT03926767 828 832 B-Condition
relief NCT03926767 833 839 O
medications NCT03926767 840 851 B-Drug
during NCT03926767 852 858 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03926767 859 862 O
intervention NCT03926767 863 875 B-Study
period NCT03926767 876 882 O
of NCT03926767 883 885 O
this NCT03926767 886 890 O
trial NCT03926767 891 896 O
and NCT03926767 897 900 O
if NCT03926767 901 903 O
any NCT03926767 904 907 O
medication NCT03926767 908 918 O
be NCT03926767 919 921 O
used NCT03926767 922 926 O
, NCT03926767 927 928 O
participants NCT03926767 929 941 O
will NCT03926767 942 946 O
be NCT03926767 947 949 O
encouraged NCT03926767 950 960 O
to NCT03926767 961 963 O
report NCT03926767 964 970 O
. NCT03926767 971 972 O


Inclusion NCT03920670 0 9 O
Criteria NCT03920670 10 18 O

- NCT03920670 21 22 O
Age NCT03920670 24 27 B-Age
> NCT03920670 28 29 B-Eq-Comparison
or NCT03920670 30 32 I-Eq-Comparison
= NCT03920670 33 34 I-Eq-Comparison
18 NCT03920670 35 37 I-Eq-Comparison
years NCT03920670 38 43 I-Eq-Comparison
old NCT03920670 44 47 O

- NCT03920670 50 51 O
Patients NCT03920670 53 61 O
willing NCT03920670 62 69 O
to NCT03920670 70 72 O
participate NCT03920670 73 84 O
and NCT03920670 85 88 O
provide NCT03920670 89 96 O
an NCT03920670 97 99 O
informed NCT03920670 100 108 O
consent NCT03920670 109 116 O

- NCT03920670 119 120 O
Patients NCT03920670 122 130 O
undergoing NCT03920670 131 141 B-Eq-Comparison
an NCT03920670 142 144 O
elective NCT03920670 145 153 B-Modifier
surgical NCT03920670 154 162 B-Procedure
procedure NCT03920670 163 172 I-Procedure
that NCT03920670 173 177 O
requires NCT03920670 178 186 B-Assertion___Assertion-Type-Value:hypothetical
use NCT03920670 187 190 O
of NCT03920670 191 193 O
non NCT03920670 194 197 B-Drug
- NCT03920670 198 199 I-Drug
depolarizing NCT03920670 200 212 I-Drug
NMBA NCT03920670 213 217 I-Drug
agents NCT03920670 218 224 I-Drug
administered NCT03920670 225 237 O
intraoperatively NCT03920670 238 254 B-Modifier
. NCT03920670 255 256 O

Exclusion NCT03920670 258 267 O
Criteria NCT03920670 268 276 O

- NCT03920670 279 280 O
Patients NCT03920670 282 290 O
with NCT03920670 291 295 O
unilateral NCT03920670 296 306 B-Condition
disorders NCT03920670 307 316 I-Condition
, NCT03920670 317 318 O
such NCT03920670 319 323 O
as NCT03920670 324 326 O
stroke NCT03920670 327 333 B-Condition
, NCT03920670 334 335 O
carpal NCT03920670 336 342 B-Condition
tunnel NCT03920670 343 349 I-Condition
syndrome NCT03920670 350 358 I-Condition
, NCT03920670 359 360 O
broken NCT03920670 361 367 B-Condition
wrist NCT03920670 368 373 B-Modifier
with NCT03920670 374 378 B-And
nerve NCT03920670 379 384 B-Modifier
damage NCT03920670 385 391 I-Modifier
, NCT03920670 392 393 O
Dupuytren NCT03920670 394 403 B-Condition
contracture NCT03920670 404 415 I-Condition
, NCT03920670 416 417 O
or NCT03920670 418 420 B-Or
any NCT03920670 421 424 O
similar NCT03920670 425 432 O
wrist NCT03920670 433 438 B-Modifier
injury NCT03920670 439 445 B-Condition
. NCT03920670 446 447 O

- NCT03920670 451 452 O
Patients NCT03920670 454 462 O
with NCT03920670 463 467 O
systemic NCT03920670 468 476 B-Modifier
neuromuscular NCT03920670 477 490 B-Condition
diseases NCT03920670 491 499 I-Condition
such NCT03920670 500 504 O
as NCT03920670 505 507 O
myasthenia NCT03920670 508 518 B-Condition
gravis NCT03920670 519 525 I-Condition

- NCT03920670 528 529 O
Patients NCT03920670 531 539 O
with NCT03920670 540 544 O
significant NCT03920670 545 556 O
organ NCT03920670 557 562 B-Condition
dysfunction NCT03920670 563 574 I-Condition
that NCT03920670 575 579 O
can NCT03920670 580 583 B-Assertion___Assertion-Type-Value:hypothetical
significantly NCT03920670 584 597 O
affect NCT03920670 598 604 O
pharmacokinetics NCT03920670 605 621 O
of NCT03920670 622 624 O
neuromuscular NCT03920670 625 638 B-Modifier
blocking NCT03920670 639 647 I-Modifier
and NCT03920670 648 651 B-Or
reversal NCT03920670 652 660 B-Modifier
agents NCT03920670 661 667 B-Drug
, NCT03920670 668 669 O
i. NCT03920670 670 672 O
e. NCT03920670 673 675 O
, NCT03920670 676 677 O
severe NCT03920670 678 684 O
renal NCT03920670 685 690 B-Condition
impairment NCT03920670 691 701 I-Condition
or NCT03920670 702 704 B-Or
end NCT03920670 705 708 B-Modifier
- NCT03920670 709 710 I-Modifier
stage NCT03920670 711 716 I-Modifier
liver NCT03920670 717 722 B-Condition
disease NCT03920670 723 730 I-Condition
. NCT03920670 730 731 O

Inclusion NCT03929640 0 9 O
Criteria NCT03929640 10 18 O
: NCT03929640 19 20 O

- NCT03929640 24 25 O
Pregnant NCT03929640 27 35 B-Condition
women NCT03929640 36 41 O
at NCT03929640 42 44 B-Eq-Comparison
least NCT03929640 45 50 I-Eq-Comparison
18 NCT03929640 51 53 I-Eq-Comparison
years NCT03929640 54 59 I-Eq-Comparison
of NCT03929640 60 62 O
age NCT03929640 63 66 B-Age

- NCT03929640 69 70 O
Planned NCT03929640 72 79 B-Eq-Comparison
delivery NCT03929640 80 88 B-Procedure
via NCT03929640 89 92 O
C NCT03929640 93 94 B-Procedure
- NCT03929640 95 96 I-Procedure
section NCT03929640 97 104 I-Procedure

- NCT03929640 107 108 O
Pfannenstiel NCT03929640 110 122 B-Modifier
skin NCT03929640 123 127 B-Procedure
incision NCT03929640 128 136 I-Procedure

- NCT03929640 139 140 O
Lower NCT03929640 142 147 B-Modifier
uterine NCT03929640 148 155 I-Modifier
segment NCT03929640 156 163 I-Modifier
transverse NCT03929640 164 174 I-Modifier
hysterotomy NCT03929640 175 186 B-Procedure

- NCT03929640 189 190 O
English NCT03929640 192 199 O
speaking NCT03929640 200 208 O

Exclusion NCT03929640 209 218 O
Criteria NCT03929640 219 227 O
: NCT03929640 228 229 O

- NCT03929640 233 234 O
Major NCT03929640 236 241 O
intra NCT03929640 242 247 B-Temporal-Connection___Temporal-Connection-Type-Value:during
- NCT03929640 248 249 O
operative NCT03929640 250 259 B-Procedure
or NCT03929640 260 262 B-Or
post NCT03929640 263 267 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03929640 268 269 O
operative NCT03929640 270 279 B-Procedure
complication NCT03929640 280 292 B-Condition
such NCT03929640 293 297 O
that NCT03929640 298 302 O
clinician NCT03929640 303 312 O
recommends NCT03929640 313 323 B-Assertion___Assertion-Type-Value:hypothetical
patient NCT03929640 324 331 O
should NCT03929640 332 338 O
not NCT03929640 339 342 B-Negation
receive NCT03929640 343 350 O
non NCT03929640 351 354 B-Drug
- NCT03929640 355 356 I-Drug
steroidal NCT03929640 357 366 I-Drug
anti NCT03929640 367 371 I-Drug
- NCT03929640 372 373 I-Drug
inflammatory NCT03929640 374 386 I-Drug
drugs NCT03929640 387 392 I-Drug
or NCT03929640 393 395 B-Or
that NCT03929640 396 400 O
patient NCT03929640 401 408 O
requires NCT03929640 409 417 B-Assertion___Assertion-Type-Value:hypothetical
acetaminophen NCT03929640 418 431 B-Drug
to NCT03929640 432 434 O
treat NCT03929640 435 440 O
fever NCT03929640 441 446 B-Condition
( NCT03929640 447 448 O
ie NCT03929640 449 451 O
suspected NCT03929640 452 461 B-Assertion___Assertion-Type-Value:possible
endometritis NCT03929640 462 474 B-Condition
) NCT03929640 475 476 O

- NCT03929640 480 481 O
Unplanned NCT03929640 483 492 B-Modifier
surgery NCT03929640 493 500 B-Procedure
( NCT03929640 501 502 O
hysterectomy NCT03929640 503 515 B-Procedure
, NCT03929640 516 517 O
bowel NCT03929640 518 523 B-Modifier
/ NCT03929640 524 525 B-Or
bladder NCT03929640 526 533 B-Modifier
repair NCT03929640 534 540 B-Procedure
) NCT03929640 541 542 O

- NCT03929640 546 547 O
Allergy NCT03929640 549 556 B-Allergy
or NCT03929640 557 559 B-Or
contraindication NCT03929640 560 576 B-Contraindication
to NCT03929640 577 579 O
study NCT03929640 580 585 B-Study
medication NCT03929640 586 596 B-Drug

- NCT03929640 599 600 O
Non NCT03929640 602 605 B-Negation
- NCT03929640 606 607 O
English NCT03929640 608 615 O
speaking NCT03929640 616 624 O

- NCT03929640 627 628 O
Inability NCT03929640 630 639 O
to NCT03929640 640 642 O
provide NCT03929640 643 650 O
informed NCT03929640 651 659 O
consent NCT03929640 660 667 O

- NCT03929640 670 671 O
History NCT03929640 673 680 B-Eq-Comparison
of NCT03929640 681 683 O
opioid NCT03929640 684 690 B-Modifier
, NCT03929640 691 692 O
other NCT03929640 693 698 B-Other
illicit NCT03929640 699 706 B-Modifier
substance NCT03929640 707 716 B-Condition
, NCT03929640 717 718 O
or NCT03929640 719 721 B-Or
alcohol NCT03929640 722 729 B-Condition
use NCT03929640 730 733 I-Condition
disorder NCT03929640 734 742 I-Condition
either NCT03929640 743 749 O
before NCT03929640 750 756 B-Temporal-Connection___Temporal-Connection-Type-Value:before
or NCT03929640 757 759 B-Or
during NCT03929640 760 766 B-Temporal-Connection___Temporal-Connection-Type-Value:during
pregnancy NCT03929640 767 776 B-Condition

- NCT03929640 779 780 O
Severe NCT03929640 782 788 O
renal NCT03929640 789 794 B-Modifier
or NCT03929640 795 797 B-Or
hepatic NCT03929640 798 805 B-Modifier
impairment NCT03929640 806 816 B-Condition

Inclusion NCT03927651 0 9 O
Criteria NCT03927651 10 18 O
: NCT03927651 19 20 O

- NCT03927651 24 25 O
Patients NCT03927651 27 35 O
attending NCT03927651 36 45 O
a NCT03927651 46 47 O
pre NCT03927651 48 51 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03927651 52 61 B-Procedure
visit NCT03927651 62 67 B-Encounter
at NCT03927651 68 70 O
the NCT03927651 71 74 O
Center NCT03927651 75 81 O
for NCT03927651 82 85 O
Comprehensive NCT03927651 86 99 O
Gynecology NCT03927651 100 110 O
who NCT03927651 111 114 B-And
will NCT03927651 115 119 B-Eq-Comparison
undergo NCT03927651 120 127 O
surgery NCT03927651 128 135 B-Procedure
. NCT03927651 136 137 O

Exclusion NCT03927651 139 148 O
Criteria NCT03927651 149 157 O
: NCT03927651 158 159 O

- NCT03927651 163 164 O
Not NCT03927651 166 169 O
able NCT03927651 170 174 O
to NCT03927651 175 177 O
comprehend NCT03927651 178 188 O
and NCT03927651 189 192 O
sign NCT03927651 193 197 O
a NCT03927651 198 199 O
written NCT03927651 200 207 O
consent NCT03927651 208 215 O

- NCT03927651 218 219 O
Patients NCT03927651 221 229 O
with NCT03927651 230 234 O
a NCT03927651 235 236 O
history NCT03927651 237 244 B-Eq-Comparison
of NCT03927651 245 247 O
allergy NCT03927651 248 255 B-Allergy
to NCT03927651 256 258 O
iodides NCT03927651 259 266 O

- NCT03927651 269 270 O
Patients NCT03927651 272 280 O
history NCT03927651 281 288 B-Eq-Comparison
of NCT03927651 289 291 O
renal NCT03927651 292 297 B-Condition
failure NCT03927651 298 305 I-Condition
or NCT03927651 306 308 B-Or
uremia NCT03927651 309 315 B-Condition
, NCT03927651 316 317 O
and NCT03927651 318 321 B-And
those NCT03927651 322 327 O
on NCT03927651 328 330 B-Eq-Comparison
dialysis NCT03927651 331 339 B-Procedure

Inclusion NCT03926598 0 9 O
Criteria NCT03926598 10 18 O
: NCT03926598 19 20 O

- NCT03926598 24 25 O
Existing NCT03926598 27 35 O
patients NCT03926598 36 44 O
of NCT03926598 45 47 O
Children NCT03926598 48 56 O
's NCT03926598 56 58 O
Healthcare NCT03926598 59 69 O
of NCT03926598 70 72 O
Atlanta NCT03926598 73 80 O
( NCT03926598 81 82 O
CHOA NCT03926598 83 87 O
) NCT03926598 88 89 O
with NCT03926598 90 94 B-And
Type NCT03926598 95 99 B-Condition
2 NCT03926598 100 101 I-Condition
Diabetes NCT03926598 102 110 I-Condition
that NCT03926598 111 115 O
are NCT03926598 116 119 B-And
12 NCT03926598 120 122 B-Eq-Comparison
or NCT03926598 123 125 I-Eq-Comparison
older NCT03926598 126 131 I-Age|Eq-Comparison
at NCT03926598 132 134 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03926598 135 138 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03926598 139 143 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03926598 144 146 O
participation NCT03926598 147 160 B-Study
or NCT03926598 161 163 O
caretakers NCT03926598 164 174 O
of NCT03926598 175 177 O
existing NCT03926598 178 186 O
patients NCT03926598 187 195 O
of NCT03926598 196 198 O
CHOA NCT03926598 199 203 O
with NCT03926598 204 208 O
Type NCT03926598 209 213 B-Condition
2 NCT03926598 214 215 I-Condition
Diabetes NCT03926598 216 224 I-Condition

- NCT03926598 227 228 O
Front NCT03926598 230 235 O
desk NCT03926598 236 240 O
staff NCT03926598 241 246 O

- NCT03926598 249 250 O
Nurses NCT03926598 252 258 B-Provider
at NCT03926598 259 261 O
CHOA NCT03926598 262 266 O

- NCT03926598 269 270 O
Certified NCT03926598 272 281 O
Diabetes NCT03926598 282 290 O
Educators NCT03926598 291 300 O
at NCT03926598 301 303 O
CHOA NCT03926598 304 308 O

- NCT03926598 311 312 O
Physicians NCT03926598 314 324 B-Provider
working NCT03926598 325 332 O
at NCT03926598 333 335 O
CHOA NCT03926598 336 340 O

- NCT03926598 343 344 O
Participants NCT03926598 346 358 O
must NCT03926598 359 363 O
also NCT03926598 364 368 O
be NCT03926598 369 371 O
fluent NCT03926598 372 378 O
in NCT03926598 379 381 O
English NCT03926598 382 389 O
, NCT03926598 390 391 O
either NCT03926598 392 398 O
as NCT03926598 399 401 O
a NCT03926598 402 403 O
first NCT03926598 404 409 O
or NCT03926598 410 412 O
secondary NCT03926598 413 422 O
language NCT03926598 423 431 O
, NCT03926598 432 433 O
as NCT03926598 434 436 O
the NCT03926598 437 440 O
Guide NCT03926598 441 446 O
- NCT03926598 447 448 O
To NCT03926598 449 451 O
- NCT03926598 452 453 O
Goals NCT03926598 454 459 O
app NCT03926598 460 463 O
is NCT03926598 464 466 O
in NCT03926598 467 469 O
English NCT03926598 470 477 O
. NCT03926598 478 479 O

Exclusion NCT03926598 481 490 O
Criteria NCT03926598 491 499 O
: NCT03926598 500 501 O

- NCT03926598 505 506 O
Individuals NCT03926598 508 519 O
that NCT03926598 520 524 O
are NCT03926598 525 528 O
using NCT03926598 529 534 B-Eq-Comparison
a NCT03926598 535 536 O
care NCT03926598 537 541 B-Procedure
coordination NCT03926598 542 554 I-Procedure
tool NCT03926598 555 559 I-Procedure
other NCT03926598 560 565 B-Exception
than NCT03926598 566 570 I-Exception
GTG NCT03926598 571 574 B-Procedure
to NCT03926598 575 577 O
translate NCT03926598 578 587 O
ADA NCT03926598 588 591 O
clinical NCT03926598 592 600 O
standards NCT03926598 601 610 O
of NCT03926598 611 613 O
care NCT03926598 614 618 O
for NCT03926598 619 622 O
children NCT03926598 623 631 O
with NCT03926598 632 636 O
T2D NCT03926598 637 640 B-Condition
during NCT03926598 641 647 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03926598 648 651 O
study NCT03926598 652 657 B-Study
period NCT03926598 658 664 O
will NCT03926598 665 669 O
be NCT03926598 670 672 O
excluded NCT03926598 673 681 B-Negation
from NCT03926598 682 686 O
this NCT03926598 687 691 O
study NCT03926598 692 697 O
in NCT03926598 698 700 B-Assertion___Assertion-Type-Value:hypothetical
order NCT03926598 701 706 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03926598 707 709 I-Assertion___Assertion-Type-Value:hypothetical
avoid NCT03926598 710 715 O
confounding NCT03926598 716 727 O
factors NCT03926598 728 735 O
. NCT03926598 735 736 O
Examples NCT03926598 738 746 O
of NCT03926598 747 749 O
care NCT03926598 750 754 O
coordination NCT03926598 755 767 O
tools NCT03926598 768 773 O
include NCT03926598 774 781 O
products NCT03926598 782 790 O
that NCT03926598 791 795 O
have NCT03926598 796 800 O
the NCT03926598 801 804 O
capabilities NCT03926598 805 817 O
to NCT03926598 818 820 O
send NCT03926598 821 825 O
and NCT03926598 826 829 O
receive NCT03926598 830 837 O
electronic NCT03926598 838 848 O
messages NCT03926598 849 857 O
to NCT03926598 858 860 O
the NCT03926598 861 864 O
care NCT03926598 865 869 O
team NCT03926598 870 874 O
, NCT03926598 875 876 O
receive NCT03926598 877 884 O
and NCT03926598 885 888 O
discuss NCT03926598 889 896 O
care NCT03926598 897 901 O
plans NCT03926598 902 907 O
, NCT03926598 908 909 O
and NCT03926598 910 913 O
create NCT03926598 914 920 O
and NCT03926598 921 924 O
share NCT03926598 925 930 O
health NCT03926598 931 937 O
logs NCT03926598 938 942 O
. NCT03926598 942 943 O

Participant NCT03922932 0 11 O
- NCT03922932 12 13 O
Related NCT03922932 14 21 O
Inclusion NCT03922932 22 31 O
Criteria NCT03922932 32 40 O
: NCT03922932 41 42 O

I. NCT03922932 44 46 O
All NCT03922932 48 51 O
Diabetics NCT03922932 52 61 B-Condition
( NCT03922932 62 63 O
Groups NCT03922932 64 70 O
A NCT03922932 71 72 O
, NCT03922932 73 74 O
B NCT03922932 75 76 O
, NCT03922932 77 78 O
C NCT03922932 79 80 O
) NCT03922932 81 82 O

- NCT03922932 86 87 O
Type NCT03922932 89 93 B-Condition
1 NCT03922932 94 95 I-Condition
diabetes NCT03922932 96 104 I-Condition
of NCT03922932 105 107 O
at NCT03922932 108 110 B-Eq-Comparison
least NCT03922932 111 116 I-Eq-Comparison
5 NCT03922932 117 118 I-Eq-Comparison
years NCT03922932 119 124 I-Eq-Comparison
duration NCT03922932 125 133 O
or NCT03922932 134 136 B-Or

- NCT03922932 139 140 O
Type NCT03922932 142 146 B-Condition
2 NCT03922932 147 148 I-Condition
diabetes NCT03922932 149 157 I-Condition
of NCT03922932 158 160 O
any NCT03922932 161 164 O
duration NCT03922932 165 173 O
II NCT03922932 174 176 O
. NCT03922932 176 177 O
Group NCT03922932 179 184 O
B NCT03922932 185 186 O

- NCT03922932 189 190 O
Able NCT03922932 192 196 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03922932 197 199 I-Assertion___Assertion-Type-Value:hypothetical
return NCT03922932 200 206 O
for NCT03922932 207 210 O
follow NCT03922932 211 217 B-Encounter
- NCT03922932 218 219 I-Encounter
up NCT03922932 220 222 I-Encounter
over NCT03922932 223 227 B-Eq-Comparison
3 NCT03922932 228 229 I-Eq-Comparison
years NCT03922932 230 235 I-Eq-Comparison

Participant NCT03922932 236 247 O
- NCT03922932 248 249 O
Related NCT03922932 250 257 O
Exclusion NCT03922932 258 267 O
Criteria NCT03922932 268 276 O
: NCT03922932 277 278 O

I. NCT03922932 280 282 O
Group NCT03922932 284 289 O
B NCT03922932 290 291 O

- NCT03922932 294 295 O
Significant NCT03922932 297 308 O
medical NCT03922932 309 316 B-Condition
condition NCT03922932 317 326 I-Condition
that NCT03922932 327 331 O
would NCT03922932 332 337 B-Assertion___Assertion-Type-Value:hypothetical
make NCT03922932 338 342 O
long NCT03922932 343 347 O
- NCT03922932 348 349 O
term NCT03922932 350 354 O
follow NCT03922932 355 361 B-Encounter
- NCT03922932 362 363 I-Encounter
up NCT03922932 364 366 I-Encounter
difficult NCT03922932 367 376 B-Negation
II NCT03922932 377 379 O
. NCT03922932 379 380 O
Controls NCT03922932 382 390 O
( NCT03922932 391 392 O
Group NCT03922932 393 398 O
D NCT03922932 399 400 O
) NCT03922932 401 402 O

- NCT03922932 406 407 O
Any NCT03922932 409 412 O
medical NCT03922932 413 420 B-Condition
problems NCT03922932 421 429 I-Condition
associated NCT03922932 430 440 O
with NCT03922932 441 445 O
retinal NCT03922932 446 453 B-Condition
vascular NCT03922932 454 462 I-Condition
abnormalities NCT03922932 463 476 I-Condition
( NCT03922932 477 478 O
i. NCT03922932 479 481 O
e. NCT03922932 482 484 O
, NCT03922932 485 486 O
hypertension NCT03922932 487 499 B-Condition
, NCT03922932 500 501 O
systemic NCT03922932 502 510 B-Condition
vasculitis NCT03922932 511 521 I-Condition
, NCT03922932 522 523 O
carotid NCT03922932 524 531 B-Condition
insufficiency NCT03922932 532 545 I-Condition
, NCT03922932 546 547 O
etc NCT03922932 548 551 O
. NCT03922932 551 552 O
) NCT03922932 553 554 O

Eye NCT03922932 556 559 O
- NCT03922932 560 561 O
Related NCT03922932 562 569 O
Inclusion NCT03922932 570 579 O
Criteria NCT03922932 580 588 O
: NCT03922932 589 590 O

I. NCT03922932 592 594 O
Group NCT03922932 596 601 O
A NCT03922932 602 603 O
: NCT03922932 604 605 O

- NCT03922932 609 610 O
Presence NCT03922932 612 620 O
of NCT03922932 621 623 O
active NCT03922932 624 630 B-Eq-Comparison
neovascularization NCT03922932 631 649 B-Condition
, NCT03922932 650 651 O
with NCT03922932 652 656 B-Assertion___Assertion-Type-Value:hypothetical
or NCT03922932 657 659 I-Assertion___Assertion-Type-Value:hypothetical
without NCT03922932 660 667 I-Assertion___Assertion-Type-Value:hypothetical
prior NCT03922932 668 673 B-Eq-Comparison
treatment NCT03922932 674 683 B-Procedure

- NCT03922932 686 687 O
Presence NCT03922932 689 697 O
of NCT03922932 698 700 O
involuted NCT03922932 701 710 B-Modifier
fibrovascular NCT03922932 711 724 B-Condition
proliferans NCT03922932 725 736 I-Condition

II NCT03922932 737 739 O
. NCT03922932 739 740 O
Group NCT03922932 742 747 O
B NCT03922932 748 749 O
: NCT03922932 750 751 O

- NCT03922932 755 756 O
NPDR NCT03922932 758 762 B-Condition
of NCT03922932 763 765 O
any NCT03922932 766 769 O
severity NCT03922932 770 778 O
as NCT03922932 779 781 O
defined NCT03922932 782 789 O
by NCT03922932 790 792 O
the NCT03922932 793 796 O
International NCT03922932 797 810 B-Observation
Clinical NCT03922932 811 819 I-Observation
Diabetic NCT03922932 820 828 I-Observation
Retinopathy NCT03922932 829 840 I-Observation
Severity NCT03922932 841 849 I-Observation
Scale NCT03922932 850 855 I-Observation

III NCT03922932 856 859 O
. NCT03922932 859 860 O
Groups NCT03922932 862 868 O
C NCT03922932 869 870 O
& NCT03922932 871 872 O
D NCT03922932 873 874 O
: NCT03922932 875 876 O

- NCT03922932 880 881 O
No NCT03922932 883 885 B-Negation
evidence NCT03922932 886 894 O
of NCT03922932 895 897 O
diabetic NCT03922932 898 906 B-Condition
retinopathy NCT03922932 907 918 I-Condition

IV NCT03922932 919 921 O
. NCT03922932 921 922 O
Group NCT03922932 924 929 O
ME NCT03922932 930 932 O
: NCT03922932 933 934 O

- NCT03922932 938 939 O
Presence NCT03922932 941 949 O
of NCT03922932 950 952 O
center NCT03922932 953 959 B-Modifier
- NCT03922932 960 961 I-Modifier
involving NCT03922932 962 971 I-Modifier
macular NCT03922932 972 979 B-Condition
edema NCT03922932 980 985 I-Condition
requiring NCT03922932 986 995 B-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03922932 996 1005 B-Procedure

Eye NCT03922932 1006 1009 O
- NCT03922932 1010 1011 O
Related NCT03922932 1012 1019 O
Exclusion NCT03922932 1020 1029 O
Criteria NCT03922932 1030 1038 O
: NCT03922932 1039 1040 O
( NCT03922932 1041 1042 O
Applies NCT03922932 1043 1050 O
to NCT03922932 1051 1053 O
study NCT03922932 1054 1059 O
eye NCT03922932 1060 1063 O
only NCT03922932 1064 1068 O
. NCT03922932 1068 1069 O
May NCT03922932 1071 1074 O
be NCT03922932 1075 1077 O
present NCT03922932 1078 1085 O
in NCT03922932 1086 1088 O
non NCT03922932 1089 1092 O
- NCT03922932 1093 1094 O
study NCT03922932 1095 1100 O
eye NCT03922932 1101 1104 O
. NCT03922932 1104 1105 O
) NCT03922932 1106 1107 O

- NCT03922932 1111 1112 O
Visual NCT03922932 1114 1120 B-Observation
acuity NCT03922932 1121 1127 I-Observation
worse NCT03922932 1128 1133 B-Eq-Comparison
than NCT03922932 1134 1138 I-Eq-Comparison
20 NCT03922932 1139 1141 I-Eq-Comparison
/ NCT03922932 1142 1143 I-Eq-Comparison
200 NCT03922932 1144 1147 I-Eq-Comparison

- NCT03922932 1151 1152 O
Inability NCT03922932 1154 1163 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03922932 1164 1166 O
maintain NCT03922932 1167 1175 O
stable NCT03922932 1176 1182 O
fixation NCT03922932 1183 1191 O
for NCT03922932 1192 1195 O
OCT NCT03922932 1196 1199 B-Procedure
imaging NCT03922932 1200 1207 I-Procedure

- NCT03922932 1210 1211 O
History NCT03922932 1213 1220 B-Eq-Comparison
of NCT03922932 1221 1223 O
major NCT03922932 1224 1229 O
eye NCT03922932 1230 1233 B-Procedure
surgery NCT03922932 1234 1241 I-Procedure
( NCT03922932 1242 1243 O
vitrectomy NCT03922932 1244 1254 B-Procedure
, NCT03922932 1255 1256 O
cataract NCT03922932 1257 1265 B-Procedure
surgery NCT03922932 1266 1273 I-Procedure
, NCT03922932 1274 1275 O
scleral NCT03922932 1276 1283 B-Procedure
buckle NCT03922932 1284 1290 I-Procedure
, NCT03922932 1291 1292 O
other NCT03922932 1293 1298 B-Other
intraocular NCT03922932 1299 1310 B-Procedure
surgery NCT03922932 1311 1318 I-Procedure
, NCT03922932 1319 1320 O
etc NCT03922932 1321 1324 O
. NCT03922932 1324 1325 O
) NCT03922932 1326 1327 O
within NCT03922932 1328 1334 B-Eq-Comparison
90 NCT03922932 1335 1337 I-Eq-Comparison
days NCT03922932 1338 1342 I-Eq-Comparison
of NCT03922932 1343 1345 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03922932 1346 1356 B-Study

- NCT03922932 1359 1360 O
History NCT03922932 1362 1369 B-Eq-Comparison
of NCT03922932 1370 1372 O
another NCT03922932 1373 1380 B-Other
eye NCT03922932 1381 1384 B-Condition
disease NCT03922932 1385 1392 I-Condition
or NCT03922932 1393 1395 B-Or
condition NCT03922932 1396 1405 B-Condition
that NCT03922932 1406 1410 O
may NCT03922932 1411 1414 B-Assertion___Assertion-Type-Value:hypothetical
alter NCT03922932 1415 1420 O
retinal NCT03922932 1421 1428 B-Condition
perfusion NCT03922932 1429 1438 B-Modifier
, NCT03922932 1439 1440 O
permeability NCT03922932 1441 1453 B-Modifier
, NCT03922932 1454 1455 O
or NCT03922932 1456 1458 B-Or
retinal NCT03922932 1459 1466 B-Modifier
anatomy NCT03922932 1467 1474 I-Modifier

- NCT03922932 1477 1478 O
Substantial NCT03922932 1480 1491 O
media NCT03922932 1492 1497 B-Condition
opacity NCT03922932 1498 1505 I-Condition
( NCT03922932 1506 1507 O
cataract NCT03922932 1508 1516 B-Condition
, NCT03922932 1517 1518 O
corneal NCT03922932 1519 1526 B-Condition
scar NCT03922932 1527 1531 I-Condition
, NCT03922932 1532 1533 O
vitreous NCT03922932 1534 1542 B-Condition
hemorrhage NCT03922932 1543 1553 I-Condition
) NCT03922932 1554 1555 O
that NCT03922932 1556 1560 O
may NCT03922932 1561 1564 O
interfere NCT03922932 1565 1574 O
with NCT03922932 1575 1579 O
study NCT03922932 1580 1585 B-Study
imaging NCT03922932 1586 1593 B-Procedure


Inclusion NCT03922503 0 9 O
Criteria NCT03922503 10 18 O
: NCT03922503 19 20 O

- NCT03922503 24 25 O
Stage NCT03922503 27 32 B-Eq-Comparison
III NCT03922503 33 36 I-Eq-Comparison
periodontitis NCT03922503 37 50 B-Condition
patient NCT03922503 51 58 O
having NCT03922503 59 65 B-And
at NCT03922503 66 68 B-Eq-Comparison
least NCT03922503 69 74 I-Eq-Comparison
one NCT03922503 75 78 I-Eq-Comparison
tooth NCT03922503 79 84 B-Observation
with NCT03922503 85 89 B-And
one NCT03922503 90 93 B-Modifier
wall NCT03922503 94 98 I-Modifier
or NCT03922503 99 101 B-Or
combined1 NCT03922503 102 111 B-Modifier
- NCT03922503 112 113 I-Modifier
to NCT03922503 114 116 I-Modifier
2 NCT03922503 117 118 I-Modifier
- NCT03922503 119 120 I-Modifier
wall NCT03922503 121 125 I-Modifier
intraosseous NCT03922503 126 138 B-Observation
defect NCT03922503 139 145 I-Observation
≥ NCT03922503 146 147 B-Eq-Comparison
3 NCT03922503 148 149 I-Eq-Comparison
mm NCT03922503 150 152 I-Eq-Comparison
deep NCT03922503 153 157 O
( NCT03922503 158 159 O
assessed NCT03922503 160 168 O
by NCT03922503 169 171 O
trans NCT03922503 172 177 B-Procedure
- NCT03922503 178 179 I-Procedure
gingival NCT03922503 180 188 I-Procedure
probing NCT03922503 189 196 I-Procedure
, NCT03922503 197 198 O
radiographic NCT03922503 199 211 B-Procedure
examination NCT03922503 212 223 I-Procedure
) NCT03922503 224 225 O
with NCT03922503 226 230 O
clinical NCT03922503 231 239 B-Observation
attachment NCT03922503 240 250 I-Observation
level NCT03922503 251 256 I-Observation
( NCT03922503 257 258 O
CAL NCT03922503 259 262 B-Observation
) NCT03922503 263 264 O
≥ NCT03922503 265 266 B-Eq-Comparison
5 NCT03922503 267 268 I-Eq-Comparison
mm NCT03922503 269 271 I-Eq-Comparison
and NCT03922503 272 275 O
pocket NCT03922503 276 282 B-Observation
depth NCT03922503 283 288 I-Observation
( NCT03922503 289 290 O
PD NCT03922503 291 293 B-Observation
) NCT03922503 294 295 O
≥ NCT03922503 296 297 B-Eq-Comparison
6 NCT03922503 298 299 I-Eq-Comparison
mm NCT03922503 300 302 I-Eq-Comparison
. NCT03922503 303 304 O

- NCT03922503 308 309 O
Defect NCT03922503 311 317 B-Condition
not NCT03922503 318 321 B-Negation
extending NCT03922503 322 331 O
to NCT03922503 332 334 O
a NCT03922503 335 336 O
root NCT03922503 337 341 B-Modifier
furcation NCT03922503 342 351 I-Modifier
area NCT03922503 352 356 I-Modifier

- NCT03922503 359 360 O
Vital NCT03922503 362 367 B-Condition
teeth NCT03922503 368 373 I-Condition

- NCT03922503 376 377 O
Non NCT03922503 379 382 B-Negation
- NCT03922503 383 384 O
smokers NCT03922503 385 392 B-Condition
. NCT03922503 393 394 O

- NCT03922503 398 399 O
No NCT03922503 401 403 B-Negation
history NCT03922503 404 411 B-Eq-Comparison
of NCT03922503 412 414 O
intake NCT03922503 415 421 O
of NCT03922503 422 424 O
antibiotics NCT03922503 425 436 B-Drug
or NCT03922503 437 439 B-Or
other NCT03922503 440 445 B-Other
medications NCT03922503 446 457 B-Drug
affecting NCT03922503 458 467 O
the NCT03922503 468 471 O
periodontium NCT03922503 472 484 B-Condition
in NCT03922503 485 487 O
the NCT03922503 488 491 O
previous NCT03922503 492 500 B-Eq-Comparison
6 NCT03922503 501 502 I-Eq-Comparison
months NCT03922503 503 509 I-Eq-Comparison
. NCT03922503 510 511 O

- NCT03922503 515 516 O
No NCT03922503 518 520 B-Negation
periodontal NCT03922503 521 532 B-Procedure
therapy NCT03922503 533 540 I-Procedure
carried NCT03922503 541 548 O
out NCT03922503 549 552 O
in NCT03922503 553 555 O
the NCT03922503 556 559 O
past NCT03922503 560 564 B-Eq-Comparison
6 NCT03922503 565 566 I-Eq-Comparison
months NCT03922503 567 573 I-Eq-Comparison
. NCT03922503 574 575 O

- NCT03922503 579 580 O
Able NCT03922503 582 586 O
to NCT03922503 587 589 O
sign NCT03922503 590 594 O
an NCT03922503 595 597 O
informed NCT03922503 598 606 O
consent NCT03922503 607 614 O
form NCT03922503 615 619 O
. NCT03922503 620 621 O

- NCT03922503 625 626 O
Patients NCT03922503 628 636 O
age NCT03922503 637 640 B-Age
between NCT03922503 641 648 B-Eq-Comparison
25 NCT03922503 649 651 I-Eq-Comparison
and NCT03922503 652 655 I-Eq-Comparison
50 NCT03922503 656 658 I-Eq-Comparison
years NCT03922503 659 664 I-Eq-Comparison
old NCT03922503 665 668 O
. NCT03922503 669 670 O

- NCT03922503 674 675 O
Patients NCT03922503 677 685 O
who NCT03922503 686 689 O
are NCT03922503 690 693 O
cooperative NCT03922503 694 705 O
, NCT03922503 706 707 O
motivated NCT03922503 708 717 O
, NCT03922503 718 719 O
and NCT03922503 720 723 O
hygiene NCT03922503 724 731 O
conscious NCT03922503 732 741 O
. NCT03922503 742 743 O

- NCT03922503 747 748 O
Systemically NCT03922503 750 762 B-Condition
free NCT03922503 763 767 I-Condition
according NCT03922503 768 777 O
to NCT03922503 778 780 O
Cornell NCT03922503 781 788 O
Medical NCT03922503 789 796 O
Index NCT03922503 797 802 O

Exclusion NCT03922503 803 812 O
Criteria NCT03922503 813 821 O
: NCT03922503 822 823 O

- NCT03922503 827 828 O
Pregnancy NCT03922503 830 839 B-Condition
or NCT03922503 840 842 B-Or
breast NCT03922503 843 849 B-Condition
feeding NCT03922503 850 857 I-Condition

- NCT03922503 860 861 O
The NCT03922503 863 866 O
presence NCT03922503 867 875 O
of NCT03922503 876 878 O
an NCT03922503 879 881 O
orthodontic NCT03922503 882 893 B-Procedure
appliance NCT03922503 894 903 I-Procedure

- NCT03922503 906 907 O
Teeth NCT03922503 909 914 B-Observation
mobility NCT03922503 915 923 I-Observation
greater NCT03922503 924 931 B-Eq-Comparison
than NCT03922503 932 936 I-Eq-Comparison
grade NCT03922503 937 942 I-Eq-Comparison
I NCT03922503 943 944 I-Eq-Comparison

Inclusion NCT03928990 0 9 O
Criteria NCT03928990 10 18 O
: NCT03928990 19 20 O

- NCT03928990 24 25 O
Patients NCT03928990 27 35 O
aged NCT03928990 36 40 B-Age
18 NCT03928990 41 43 B-Eq-Comparison
to NCT03928990 44 46 I-Eq-Comparison
80 NCT03928990 47 49 I-Eq-Comparison
years NCT03928990 50 55 I-Eq-Comparison
old NCT03928990 56 59 O

- NCT03928990 62 63 O
Multiple NCT03928990 65 73 B-Condition
sclerosis NCT03928990 74 83 I-Condition
according NCT03928990 84 93 O
to NCT03928990 94 96 O
McDonald NCT03928990 97 105 O
criteria NCT03928990 106 114 O
; NCT03928990 115 116 O

- NCT03928990 119 120 O
Expanded NCT03928990 122 130 B-Observation
Disability NCT03928990 131 141 I-Observation
Status NCT03928990 142 148 I-Observation
Scale NCT03928990 149 154 I-Observation
( NCT03928990 155 156 O
EDSS NCT03928990 157 161 B-Observation
) NCT03928990 162 163 O
between NCT03928990 164 171 B-Eq-Comparison
0 NCT03928990 172 173 I-Eq-Comparison
and NCT03928990 174 177 I-Eq-Comparison
6.5 NCT03928990 178 181 I-Eq-Comparison
; NCT03928990 182 183 O

- NCT03928990 186 187 O
Patient NCT03928990 189 196 O
able NCT03928990 197 201 B-Condition
to NCT03928990 202 204 I-Condition
move NCT03928990 205 209 I-Condition
with NCT03928990 210 214 O
or NCT03928990 215 217 O
without NCT03928990 218 225 O
mechanical NCT03928990 226 236 B-Procedure
assistance NCT03928990 237 247 I-Procedure
. NCT03928990 248 249 O

Exclusion NCT03928990 251 260 O
Criteria NCT03928990 261 269 O
: NCT03928990 270 271 O

- NCT03928990 275 276 O
Deterioration NCT03928990 278 291 O
of NCT03928990 292 294 O
neurological NCT03928990 295 307 B-Condition
symptomatology NCT03928990 308 322 I-Condition
within NCT03928990 323 329 B-Eq-Comparison
60 NCT03928990 330 332 I-Eq-Comparison
day NCT03928990 333 336 I-Eq-Comparison
before NCT03928990 337 343 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03928990 344 354 B-Study
; NCT03928990 355 356 O

- NCT03928990 359 360 O
Changes NCT03928990 362 369 O
brought NCT03928990 370 377 O
to NCT03928990 378 380 O
the NCT03928990 381 384 O
multiple NCT03928990 385 393 B-Condition
sclerosis NCT03928990 394 403 I-Condition
treatment NCT03928990 404 413 B-Procedure
within NCT03928990 414 420 B-Eq-Comparison
6 NCT03928990 421 422 I-Eq-Comparison
months NCT03928990 423 429 I-Eq-Comparison
before NCT03928990 430 436 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03928990 437 447 B-Study
; NCT03928990 448 449 O

- NCT03928990 452 453 O
Introduction NCT03928990 455 467 B-Eq-Comparison
of NCT03928990 468 470 O
a NCT03928990 471 472 O
treatment NCT03928990 473 482 B-Procedure
acting NCT03928990 483 489 O
on NCT03928990 490 492 O
spasticity NCT03928990 493 503 B-Condition
or NCT03928990 504 506 B-Or
fatigue NCT03928990 507 514 B-Condition
within NCT03928990 515 521 B-Eq-Comparison
30 NCT03928990 522 524 I-Eq-Comparison
day NCT03928990 525 528 I-Eq-Comparison
before NCT03928990 529 535 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03928990 536 546 B-Study

- NCT03928990 549 550 O
Changes NCT03928990 552 559 O
brought NCT03928990 560 567 O
to NCT03928990 568 570 O
reeducation NCT03928990 571 582 B-Procedure
protocol NCT03928990 583 591 I-Procedure
throughout NCT03928990 592 602 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928990 603 606 I-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03928990 607 615 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03928990 616 618 O
the NCT03928990 619 622 O
study NCT03928990 623 628 B-Study

- NCT03928990 631 632 O
Patient NCT03928990 634 641 O
unable NCT03928990 642 648 B-Negation
to NCT03928990 649 651 O
provide NCT03928990 652 659 O
an NCT03928990 660 662 O
effort NCT03928990 663 669 O
equivalent NCT03928990 670 680 O
to NCT03928990 681 683 O
3 NCT03928990 684 685 B-Eq-Comparison
times NCT03928990 686 691 I-Eq-Comparison
the NCT03928990 692 695 O
resting NCT03928990 696 703 B-Observation
metabolic NCT03928990 704 713 I-Observation
value NCT03928990 714 719 I-Observation
= NCT03928990 720 721 O
3 NCT03928990 722 723 B-Eq-Comparison
Metabolic NCT03928990 724 733 B-Observation
Equivalent NCT03928990 734 744 I-Observation
of NCT03928990 745 747 I-Observation
Task NCT03928990 748 752 I-Observation
( NCT03928990 753 754 O
METs NCT03928990 755 759 B-Observation
) NCT03928990 760 761 O
. NCT03928990 762 763 O

Inclusion NCT03923621 0 9 O
Criteria NCT03923621 10 18 O
: NCT03923621 19 20 O

- NCT03923621 24 25 O
ASA NCT03923621 27 30 B-Condition
I NCT03923621 31 32 B-Eq-Comparison
or NCT03923621 33 35 I-Eq-Comparison
II NCT03923621 36 38 I-Eq-Comparison

- NCT03923621 41 42 O
Pilonidal NCT03923621 44 53 B-Condition
disease NCT03923621 54 61 I-Condition
< NCT03923621 62 63 B-Eq-Comparison
3 NCT03923621 64 65 I-Eq-Comparison
previous NCT03923621 66 74 B-Eq-Comparison
treatments NCT03923621 75 85 B-Procedure

- NCT03923621 88 89 O
Previous NCT03923621 91 99 B-Eq-Comparison
incision NCT03923621 100 108 B-Procedure
and NCT03923621 109 112 B-Or
drainage NCT03923621 113 121 B-Procedure
allowed NCT03923621 122 129 O

- NCT03923621 132 133 O
Over NCT03923621 135 139 B-Eq-Comparison
16 NCT03923621 140 142 I-Eq-Comparison
years NCT03923621 143 148 I-Age|Eq-Comparison

Exclusion NCT03923621 149 158 O
Criteria NCT03923621 159 167 O
: NCT03923621 168 169 O

- NCT03923621 173 174 O
Co NCT03923621 176 178 B-Condition
- NCT03923621 179 180 I-Condition
morbidity NCT03923621 181 190 I-Condition
> NCT03923621 191 192 O
ASA NCT03923621 193 196 B-Condition
II NCT03923621 197 199 B-Eq-Comparison

- NCT03923621 202 203 O
Unable NCT03923621 205 211 O
to NCT03923621 212 214 O
consent NCT03923621 215 222 O
themselves NCT03923621 223 233 O

- NCT03923621 236 237 O
Under NCT03923621 239 244 B-Eq-Comparison
16 NCT03923621 245 247 I-Eq-Comparison
years NCT03923621 248 253 I-Age|Eq-Comparison

- NCT03923621 256 257 O
Vulnerable NCT03923621 259 269 B-Condition
adults NCT03923621 270 276 O

Inclusion NCT03923153 0 9 O
Criteria NCT03923153 10 18 O
: NCT03923153 19 20 O

- NCT03923153 24 25 O
No NCT03923153 27 29 B-Negation
contraindication NCT03923153 30 46 B-Contraindication
for NCT03923153 47 50 O
pulmonary NCT03923153 51 60 B-Procedure
physiotherapy NCT03923153 61 74 I-Procedure

- NCT03923153 77 78 O
Anjina NCT03923153 80 86 B-Condition
patients NCT03923153 87 95 O
who NCT03923153 96 99 O
are NCT03923153 100 103 O
clinically NCT03923153 104 114 O
stable NCT03923153 115 121 O

- NCT03923153 124 125 O
have NCT03923153 127 131 O
no NCT03923153 132 134 B-Negation
other NCT03923153 135 140 B-Other
disease NCT03923153 141 148 B-Condition
that NCT03923153 149 153 O
may NCT03923153 154 157 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03923153 158 164 O
respiratory NCT03923153 165 176 B-Condition
function NCT03923153 177 185 I-Condition

- NCT03923153 188 189 O
Individuals NCT03923153 191 202 O
who NCT03923153 203 206 O
have NCT03923153 207 211 O
the NCT03923153 212 215 O
good NCT03923153 216 220 O
cooperation NCT03923153 221 232 O

Exclusion NCT03923153 233 242 O
Criteria NCT03923153 243 251 O
: NCT03923153 252 253 O

- NCT03923153 257 258 O
Patients NCT03923153 260 268 O
under NCT03923153 269 274 B-Eq-Comparison
the NCT03923153 275 278 I-Eq-Comparison
age NCT03923153 279 282 I-Eq-Comparison
of NCT03923153 283 285 I-Eq-Comparison
18 NCT03923153 286 288 I-Eq-Comparison

- NCT03923153 292 293 O
Pregnancy NCT03923153 295 304 B-Condition

- NCT03923153 307 308 O
Active NCT03923153 310 316 B-Eq-Comparison
infection NCT03923153 317 326 B-Condition

- NCT03923153 329 330 O
Patients NCT03923153 332 340 O
with NCT03923153 341 345 O
known NCT03923153 346 351 O
malignancies NCT03923153 352 364 B-Condition

- NCT03923153 367 368 O
patients NCT03923153 370 378 O
without NCT03923153 379 386 O
consent NCT03923153 387 394 O

- NCT03923153 397 398 O
known NCT03923153 400 405 O
arrhythmia NCT03923153 406 416 B-Condition
, NCT03923153 417 418 O
dilated NCT03923153 419 426 B-Modifier
or NCT03923153 427 429 B-Or
hypertrophic NCT03923153 430 442 B-Modifier
cardiomyopathy NCT03923153 443 457 B-Condition
, NCT03923153 458 459 O
heart NCT03923153 460 465 B-Condition
failure NCT03923153 466 473 I-Condition
( NCT03923153 474 475 O
EF NCT03923153 476 478 B-Observation
< NCT03923153 479 480 B-Eq-Comparison
40 NCT03923153 481 483 I-Eq-Comparison
% NCT03923153 484 485 I-Eq-Comparison
) NCT03923153 487 488 O

Inclusion NCT03926611 0 9 O
Criteria NCT03926611 10 18 O
: NCT03926611 19 20 O

- NCT03926611 24 25 O
Male NCT03926611 27 31 O
and NCT03926611 32 35 B-Or
female NCT03926611 36 42 O
subjects NCT03926611 43 51 O
aged NCT03926611 52 56 B-Age
≥ NCT03926611 57 58 B-Eq-Comparison
18 NCT03926611 59 61 I-Eq-Comparison
years NCT03926611 62 67 I-Eq-Comparison
of NCT03926611 68 70 O
age NCT03926611 71 74 O

- NCT03926611 77 78 O
CSU NCT03926611 80 83 B-Condition
diagnosis NCT03926611 84 93 O
for NCT03926611 94 97 O
≥ NCT03926611 98 99 B-Eq-Comparison
6 NCT03926611 100 101 I-Eq-Comparison
months NCT03926611 102 108 I-Eq-Comparison
prior NCT03926611 109 114 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926611 115 117 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03926611 118 127 B-Study

- NCT03926611 130 131 O
Presence NCT03926611 133 141 O
of NCT03926611 142 144 O
itch NCT03926611 145 149 B-Condition
and NCT03926611 150 153 B-And
hives NCT03926611 154 159 B-Condition
for NCT03926611 160 163 O
≥ NCT03926611 164 165 B-Eq-Comparison
6 NCT03926611 166 167 I-Eq-Comparison
consecutive NCT03926611 168 179 I-Eq-Comparison
weeks NCT03926611 180 185 I-Eq-Comparison
prior NCT03926611 186 191 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926611 192 194 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03926611 195 204 B-Study
in NCT03926611 205 207 B-And
spite NCT03926611 208 213 I-And
of NCT03926611 214 216 I-And
use NCT03926611 217 220 O
of NCT03926611 221 223 O
non NCT03926611 224 227 B-Negation
- NCT03926611 228 229 O
sedating NCT03926611 230 238 B-Modifier
H1 NCT03926611 239 241 B-Drug
- NCT03926611 242 243 I-Drug
antihistamines NCT03926611 244 258 I-Drug
according NCT03926611 259 268 O
to NCT03926611 269 271 O
local NCT03926611 272 277 O
Treatment NCT03926611 278 287 O
guidelines NCT03926611 288 298 O
during NCT03926611 299 305 O
this NCT03926611 306 310 O
time NCT03926611 311 315 O
period NCT03926611 316 322 O

- NCT03926611 325 326 O
UAS7 NCT03926611 328 332 B-Observation
score NCT03926611 333 338 I-Observation
( NCT03926611 339 340 O
range NCT03926611 341 346 O
0 NCT03926611 347 348 B-Eq-Comparison
- NCT03926611 349 350 I-Eq-Comparison
42 NCT03926611 351 353 O
) NCT03926611 354 355 O
≥ NCT03926611 356 357 B-Eq-Comparison
16 NCT03926611 358 360 I-Eq-Comparison
and NCT03926611 361 364 B-And
HSS7 NCT03926611 365 369 B-Observation
score NCT03926611 370 375 I-Observation
( NCT03926611 376 377 O
range NCT03926611 378 383 O
0 NCT03926611 384 385 B-Eq-Comparison
- NCT03926611 386 387 I-Eq-Comparison
21 NCT03926611 388 390 O
) NCT03926611 391 392 O
≥ NCT03926611 393 394 B-Eq-Comparison
8 NCT03926611 395 396 I-Eq-Comparison
during NCT03926611 397 403 B-Temporal-Connection___Temporal-Connection-Type-Value:during
7 NCT03926611 404 405 B-Eq-Comparison
days NCT03926611 406 410 I-Eq-Comparison
prior NCT03926611 411 416 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926611 417 419 I-Temporal-Connection___Temporal-Connection-Type-Value:before
randomization NCT03926611 420 433 B-Study
( NCT03926611 434 435 O
Day NCT03926611 436 439 O
1 NCT03926611 440 441 O
) NCT03926611 442 443 O

- NCT03926611 447 448 O
Willing NCT03926611 450 457 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03926611 458 461 I-Assertion___Assertion-Type-Value:hypothetical
able NCT03926611 462 466 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03926611 467 469 O
complete NCT03926611 470 478 O
an NCT03926611 479 481 O
Urticaria NCT03926611 482 491 B-Procedure
Participant NCT03926611 492 503 I-Procedure
Daily NCT03926611 504 509 I-Procedure
eDiary NCT03926611 510 516 I-Procedure
( NCT03926611 517 518 O
UPDD NCT03926611 519 523 B-Procedure
) NCT03926611 524 525 O
for NCT03926611 526 529 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03926611 530 533 I-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03926611 534 542 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03926611 543 545 O
the NCT03926611 546 549 O
study NCT03926611 550 555 B-Study

Exclusion NCT03926611 556 565 O
Criteria NCT03926611 566 574 O
: NCT03926611 575 576 O

- NCT03926611 580 581 O
Hypersensitivity NCT03926611 583 599 B-Condition
to NCT03926611 600 602 O
any NCT03926611 603 606 O
of NCT03926611 607 609 O
the NCT03926611 610 613 O
study NCT03926611 614 619 B-Study
treatments NCT03926611 620 630 B-Procedure

- NCT03926611 633 634 O
Clearly NCT03926611 636 643 O
defined NCT03926611 644 651 O
predominant NCT03926611 652 663 B-Modifier
or NCT03926611 664 666 B-Or
sole NCT03926611 667 671 B-Modifier
trigger NCT03926611 672 679 I-Modifier
of NCT03926611 680 682 O
their NCT03926611 683 688 O
chronic NCT03926611 689 696 B-Condition
urticaria NCT03926611 697 706 I-Condition
( NCT03926611 707 708 O
chronic NCT03926611 709 716 B-Modifier
inducible NCT03926611 717 726 B-Condition
urticaria NCT03926611 727 736 I-Condition
) NCT03926611 737 738 O

- NCT03926611 742 743 O
Other NCT03926611 745 750 B-Other
diseases NCT03926611 751 759 B-Condition
with NCT03926611 760 764 O
symptoms NCT03926611 765 773 B-Assertion___Assertion-Type-Value:possible
of NCT03926611 774 776 O
urticaria NCT03926611 777 786 B-Condition
or NCT03926611 787 789 B-Or
angioedema NCT03926611 790 800 B-Condition

- NCT03926611 803 804 O
Other NCT03926611 806 811 B-Other
skin NCT03926611 812 816 B-Condition
disease NCT03926611 817 824 I-Condition
associated NCT03926611 825 835 O
with NCT03926611 836 840 O
chronic NCT03926611 841 848 B-Modifier
itching NCT03926611 849 856 B-Condition
that NCT03926611 857 861 O
might NCT03926611 862 867 B-Assertion___Assertion-Type-Value:hypothetical
influence NCT03926611 868 877 O
in NCT03926611 878 880 O
the NCT03926611 881 884 O
investigators NCT03926611 885 898 O
opinion NCT03926611 899 906 O
the NCT03926611 907 910 O
study NCT03926611 911 916 B-Study
evaluations NCT03926611 917 928 O
and NCT03926611 929 932 O
results NCT03926611 933 940 O
, NCT03926611 941 942 O

- NCT03926611 946 947 O
Known NCT03926611 949 954 O
or NCT03926611 955 957 O
suspected NCT03926611 958 967 B-Assertion___Assertion-Type-Value:possible
history NCT03926611 968 975 B-Eq-Comparison
of NCT03926611 976 978 O
an NCT03926611 979 981 O
ongoing NCT03926611 982 989 B-Eq-Comparison
, NCT03926611 990 991 O
chronic NCT03926611 992 999 B-Modifier
or NCT03926611 1000 1002 B-Or
recurrent NCT03926611 1003 1012 B-Modifier
infectious NCT03926611 1013 1023 B-Condition
disease NCT03926611 1024 1031 I-Condition
including NCT03926611 1032 1041 O
but NCT03926611 1042 1045 O
not NCT03926611 1046 1049 O
limited NCT03926611 1050 1057 O
to NCT03926611 1058 1060 O
opportunistic NCT03926611 1061 1074 B-Condition
infections NCT03926611 1075 1085 I-Condition
( NCT03926611 1086 1087 O
eg NCT03926611 1088 1090 O
tuberculosis NCT03926611 1091 1103 B-Condition
, NCT03926611 1104 1105 O
atypical NCT03926611 1106 1114 B-Modifier
mycobacterioses NCT03926611 1115 1130 B-Condition
, NCT03926611 1131 1132 O
listeriosis NCT03926611 1133 1144 B-Condition
or NCT03926611 1145 1147 B-Or
aspergillosis NCT03926611 1148 1161 B-Condition
) NCT03926611 1162 1163 O
, NCT03926611 1165 1166 O
HIV NCT03926611 1167 1170 B-Condition
, NCT03926611 1171 1172 O
Hepatitis NCT03926611 1173 1182 B-Condition
B NCT03926611 1183 1184 B-Modifier
/ NCT03926611 1185 1186 B-Or
C NCT03926611 1187 1188 B-Modifier
. NCT03926611 1189 1190 O

- NCT03926611 1194 1195 O
Pregnant NCT03926611 1197 1205 B-Condition
or NCT03926611 1206 1208 B-Or
nursing NCT03926611 1209 1216 B-Condition
( NCT03926611 1217 1218 O
lactating NCT03926611 1219 1228 B-Condition
) NCT03926611 1229 1230 O
women NCT03926611 1231 1236 O

- NCT03926611 1239 1240 O
Women NCT03926611 1242 1247 O
of NCT03926611 1248 1250 B-And
child NCT03926611 1251 1256 B-Condition
- NCT03926611 1257 1258 I-Condition
bearing NCT03926611 1259 1266 I-Condition
potential NCT03926611 1267 1276 I-Condition
not NCT03926611 1277 1280 B-Negation
using NCT03926611 1281 1286 B-Eq-Comparison
highly NCT03926611 1287 1293 B-Modifier
effective NCT03926611 1294 1303 I-Modifier
methods NCT03926611 1304 1311 I-Modifier
of NCT03926611 1312 1314 O
contraception NCT03926611 1315 1328 B-Procedure

Other NCT03926611 1329 1334 O
protocol NCT03926611 1335 1343 O
- NCT03926611 1344 1345 O
defined NCT03926611 1346 1353 O
inclusion NCT03926611 1354 1363 O
/ NCT03926611 1364 1365 O
exclusion NCT03926611 1366 1375 O
criteria NCT03926611 1376 1384 O
may NCT03926611 1385 1388 O
apply NCT03926611 1389 1394 O
. NCT03926611 1394 1395 O

Inclusion NCT03929536 0 9 O
Criteria NCT03929536 10 18 O
: NCT03929536 19 20 O

- NCT03929536 24 25 O
surgical NCT03929536 27 35 B-Procedure
treatment NCT03929536 36 45 I-Procedure
of NCT03929536 46 48 O
acetabular NCT03929536 49 59 B-Modifier
fracture NCT03929536 60 68 B-Condition
between NCT03929536 69 76 B-Eq-Comparison
2009 NCT03929536 77 81 I-Eq-Comparison
and NCT03929536 82 85 I-Eq-Comparison
2018 NCT03929536 86 90 I-Eq-Comparison

Exclusion NCT03929536 92 101 O
Criteria NCT03929536 102 110 O
: NCT03929536 111 112 O

- NCT03929536 116 117 O
pathological NCT03929536 119 131 B-Modifier
fractures NCT03929536 132 141 B-Condition
due NCT03929536 142 145 O
to NCT03929536 146 148 O
neoplasm NCT03929536 149 157 B-Condition
or NCT03929536 158 160 B-Or
metastasis NCT03929536 161 171 B-Condition

- NCT03929536 174 175 O
status NCT03929536 177 183 O
after NCT03929536 184 189 B-Temporal-Connection___Temporal-Connection-Type-Value:after
implantation NCT03929536 190 202 B-Procedure
of NCT03929536 203 205 I-Procedure
an NCT03929536 206 208 I-Procedure
endoprosthesis NCT03929536 209 223 I-Procedure

Inclusion NCT03928600 0 9 O
Criteria NCT03928600 10 18 O
: NCT03928600 19 20 O

- NCT03928600 24 25 O
full NCT03928600 27 31 B-Condition
- NCT03928600 32 33 I-Condition
term NCT03928600 34 38 I-Condition
( NCT03928600 39 40 O
≥ NCT03928600 42 43 B-Eq-Comparison
37 NCT03928600 44 46 I-Eq-Comparison
weeks NCT03928600 47 52 I-Eq-Comparison
of NCT03928600 53 55 O
gestation NCT03928600 56 65 B-Observation
) NCT03928600 66 67 O

- NCT03928600 71 72 O
singleton NCT03928600 74 83 B-Condition

- NCT03928600 86 87 O
vertex NCT03928600 89 95 B-Condition
- NCT03928600 96 97 I-Condition
presenting NCT03928600 98 108 I-Condition
gestations NCT03928600 109 119 I-Condition

- NCT03928600 122 123 O
with NCT03928600 125 129 O
no NCT03928600 130 132 B-Negation
contraindication NCT03928600 133 149 B-Contraindication
to NCT03928600 150 152 O
vaginal NCT03928600 153 160 B-Procedure
delivery NCT03928600 161 169 I-Procedure

- NCT03928600 172 173 O
intact NCT03928600 175 181 B-Condition
membranes NCT03928600 182 191 I-Condition

- NCT03928600 194 195 O
Bishop NCT03928600 197 203 B-Observation
score NCT03928600 204 209 I-Observation
< NCT03928600 210 211 B-Eq-Comparison
7 NCT03928600 212 213 I-Eq-Comparison
and NCT03928600 214 217 B-And
cervical NCT03928600 218 226 B-Observation
dilation NCT03928600 227 235 I-Observation
≤ NCT03928600 236 237 B-Eq-Comparison
2 NCT03928600 238 239 I-Eq-Comparison
cm NCT03928600 240 242 I-Eq-Comparison

Exclusion NCT03928600 243 252 O
Criteria NCT03928600 253 261 O
: NCT03928600 262 263 O

- NCT03928600 267 268 O
contraindication NCT03928600 270 286 B-Contraindication
for NCT03928600 287 290 O
misoprostol NCT03928600 291 302 B-Drug

- NCT03928600 305 306 O
history NCT03928600 308 315 B-Eq-Comparison
of NCT03928600 316 318 I-Eq-Comparison
previous NCT03928600 319 327 I-Eq-Comparison
caesarean NCT03928600 328 337 B-Procedure

- NCT03928600 340 341 O
rupture NCT03928600 343 350 B-Condition
of NCT03928600 351 353 I-Condition
membranes NCT03928600 354 363 I-Condition
, NCT03928600 364 365 O

- NCT03928600 369 370 O
fetal NCT03928600 372 377 B-Modifier
or NCT03928600 378 380 B-Or
maternal NCT03928600 381 389 B-Modifier
morbidities NCT03928600 390 401 B-Condition
( NCT03928600 402 403 O
fetal NCT03928600 404 409 B-Condition
major NCT03928600 410 415 I-Condition
abnormalities NCT03928600 416 429 I-Condition
, NCT03928600 430 431 O
FIGO NCT03928600 432 436 O
definition NCT03928600 437 447 O
of NCT03928600 448 450 O
pathological NCT03928600 451 463 B-Modifier
CTG NCT03928600 464 467 B-Condition
, NCT03928600 468 469 O
HELLP NCT03928600 470 475 B-Condition
syndrome NCT03928600 476 484 I-Condition
, NCT03928600 485 486 O
preeclampsia NCT03928600 487 499 B-Condition
or NCT03928600 500 502 B-Or
hypertension NCT03928600 503 515 B-Condition
with NCT03928600 516 520 O
severe NCT03928600 521 527 O
features NCT03928600 528 536 O
, NCT03928600 537 538 O
fetal NCT03928600 539 544 B-Condition
growth NCT03928600 545 551 I-Condition
restriction NCT03928600 552 563 I-Condition
) NCT03928600 564 565 O

Inclusion NCT03923972 0 9 O
Criteria NCT03923972 10 18 O
: NCT03923972 19 20 O

- NCT03923972 24 25 O
all NCT03923972 27 30 O
adult NCT03923972 31 36 O
patients NCT03923972 37 45 O
with NCT03923972 46 50 O
non NCT03923972 51 54 B-Modifier
- NCT03923972 55 56 I-Modifier
dialysis NCT03923972 57 65 I-Modifier
dependent NCT03923972 66 75 I-Modifier
chronic NCT03923972 76 83 B-Condition
kidney NCT03923972 84 90 I-Condition
disease NCT03923972 91 98 I-Condition
, NCT03923972 99 100 O
peritoneal NCT03923972 101 111 B-Procedure
dialysis NCT03923972 112 120 I-Procedure
, NCT03923972 121 122 O
hemodialysis NCT03923972 123 135 B-Procedure
, NCT03923972 136 137 O
renal NCT03923972 138 143 B-Procedure
transplantation NCT03923972 144 159 I-Procedure

- NCT03923972 162 163 O
all NCT03923972 165 168 O
active NCT03923972 169 175 B-Eq-Comparison
physicians NCT03923972 176 186 O
in NCT03923972 187 189 O
the NCT03923972 190 193 O
department NCT03923972 194 204 O
of NCT03923972 205 207 O
nephrology NCT03923972 208 218 B-Provider
involved NCT03923972 219 227 O
in NCT03923972 228 230 O
patient NCT03923972 231 238 O
care NCT03923972 239 243 O

- NCT03923972 246 247 O
all NCT03923972 249 252 O
active NCT03923972 253 259 B-Eq-Comparison
nurses NCT03923972 260 266 O
in NCT03923972 267 269 O
the NCT03923972 270 273 O
department NCT03923972 274 284 O
of NCT03923972 285 287 O
nephrology NCT03923972 288 298 B-Provider
involved NCT03923972 299 307 O
in NCT03923972 308 310 O
patient NCT03923972 311 318 O
care NCT03923972 319 323 O

- NCT03923972 326 327 O
all NCT03923972 329 332 O
heads NCT03923972 333 338 O
of NCT03923972 339 341 O
nephrology NCT03923972 342 352 B-Provider
departments NCT03923972 353 364 O

Exclusion NCT03923972 365 374 O
Criteria NCT03923972 375 383 O
: NCT03923972 384 385 O

- NCT03923972 389 390 O
children NCT03923972 392 400 O

- NCT03923972 403 404 O
no NCT03923972 406 408 B-Negation
physical NCT03923972 409 417 B-Condition
disability NCT03923972 418 428 I-Condition
making NCT03923972 429 435 O
it NCT03923972 436 438 O
impossible NCT03923972 439 449 B-Negation
to NCT03923972 450 452 B-Assertion___Assertion-Type-Value:hypothetical
conduct NCT03923972 453 460 I-Assertion___Assertion-Type-Value:hypothetical
exercise NCT03923972 461 469 B-Procedure
training NCT03923972 470 478 I-Procedure

- NCT03923972 481 482 O
no NCT03923972 484 486 B-Negation
mental NCT03923972 487 493 B-Condition
disability NCT03923972 494 504 I-Condition
or NCT03923972 505 507 B-Or
language NCT03923972 508 516 B-Condition
problem NCT03923972 517 524 I-Condition
making NCT03923972 525 531 O
it NCT03923972 532 534 O
impossible NCT03923972 535 545 B-Negation
to NCT03923972 546 548 O
understand NCT03923972 549 559 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03923972 560 563 I-Assertion___Assertion-Type-Value:hypothetical
fill NCT03923972 564 568 I-Assertion___Assertion-Type-Value:hypothetical
in NCT03923972 569 571 I-Assertion___Assertion-Type-Value:hypothetical
a NCT03923972 572 573 O
questionnaire NCT03923972 574 587 B-Observation

Inclusion NCT03922113 0 9 O
Criteria NCT03922113 10 18 O
: NCT03922113 19 20 O

- NCT03922113 24 25 O
Collaborative NCT03922113 27 40 O
ICU NCT03922113 41 44 B-Encounter
patients NCT03922113 45 53 O
with NCT03922113 54 58 O
length NCT03922113 59 65 O
of NCT03922113 66 68 O
stay NCT03922113 69 73 O
> NCT03922113 74 75 B-Eq-Comparison
48 NCT03922113 76 78 I-Eq-Comparison
h NCT03922113 79 80 I-Eq-Comparison

- NCT03922113 83 84 O
Surgical NCT03922113 86 94 O
patients NCT03922113 95 103 O
scheduled NCT03922113 104 113 B-Eq-Comparison
for NCT03922113 114 117 O
colorectal NCT03922113 118 128 B-Procedure
surgery NCT03922113 129 136 I-Procedure

- NCT03922113 139 140 O
Healthy NCT03922113 142 149 B-Condition
subjects NCT03922113 150 158 O

Exclusion NCT03922113 159 168 O
Criteria NCT03922113 169 177 O
: NCT03922113 178 179 O

- NCT03922113 183 184 O
a NCT03922113 186 187 O
score NCT03922113 188 193 O
> NCT03922113 194 195 B-Eq-Comparison
1 NCT03922113 196 197 I-Eq-Comparison
or NCT03922113 198 200 B-Or
< NCT03922113 201 202 B-Eq-Comparison
- NCT03922113 203 204 I-Eq-Comparison
1 NCT03922113 205 206 I-Eq-Comparison
on NCT03922113 207 209 O
the NCT03922113 210 213 O
Richmond NCT03922113 214 222 B-Observation
Agitation NCT03922113 223 232 I-Observation
and NCT03922113 233 236 I-Observation
Sedation NCT03922113 237 245 I-Observation
Scale NCT03922113 246 251 I-Observation
( NCT03922113 252 253 O
RASS NCT03922113 254 258 B-Observation
) NCT03922113 259 260 O

- NCT03922113 264 265 O
coma NCT03922113 267 271 B-Condition

- NCT03922113 274 275 O
total NCT03922113 277 282 B-Modifier
hip NCT03922113 283 286 I-Modifier
or NCT03922113 287 289 B-Or
knee NCT03922113 290 294 B-Modifier
arthroplasty NCT03922113 295 307 B-Procedure
in NCT03922113 308 310 O
the NCT03922113 311 314 O
dominant NCT03922113 315 323 B-Modifier
limb NCT03922113 324 328 I-Modifier

- NCT03922113 331 332 O
unauthorized NCT03922113 334 346 B-Condition
support NCT03922113 347 354 I-Condition
on NCT03922113 355 357 O
the NCT03922113 358 361 O
dominant NCT03922113 362 370 B-Modifier
leg NCT03922113 371 374 I-Modifier

- NCT03922113 377 378 O
open NCT03922113 380 384 B-Condition
wound NCT03922113 385 390 I-Condition
located NCT03922113 391 398 O
at NCT03922113 399 401 O
the NCT03922113 402 405 O
ankle NCT03922113 406 411 B-Modifier
's NCT03922113 411 413 I-Modifier
anterior NCT03922113 414 422 I-Modifier
face NCT03922113 423 427 I-Modifier
of NCT03922113 428 430 I-Modifier
the NCT03922113 431 434 I-Modifier
dominant NCT03922113 435 443 I-Modifier
leg NCT03922113 444 447 I-Modifier

- NCT03922113 450 451 O
pre NCT03922113 453 456 B-Eq-Comparison
- NCT03922113 457 458 I-Eq-Comparison
existing NCT03922113 459 467 I-Eq-Comparison
myopathy NCT03922113 468 476 B-Condition
or NCT03922113 477 479 B-Or
polyneuropathy NCT03922113 480 494 B-Condition

- NCT03922113 497 498 O
para NCT03922113 500 504 B-Modifier
- NCT03922113 505 506 O
or NCT03922113 507 509 B-Or
tetraparesis NCT03922113 510 522 B-Condition
, NCT03922113 523 524 O
para NCT03922113 525 529 B-Modifier
- NCT03922113 530 531 O
or NCT03922113 532 534 B-Or
tetraplegia NCT03922113 535 546 B-Condition

- NCT03922113 549 550 O
refusal NCT03922113 552 559 O
. NCT03922113 559 560 O

Inclusion NCT03923231 0 9 O
Criteria NCT03923231 10 18 O
: NCT03923231 19 20 O

1 NCT03923231 24 25 O
. NCT03923231 25 26 O
Evidence NCT03923231 28 36 O
of NCT03923231 37 39 O
a NCT03923231 40 41 O
personally NCT03923231 42 52 O
signed NCT03923231 53 59 O
and NCT03923231 60 63 O
dated NCT03923231 64 69 O
informed NCT03923231 70 78 O
consent NCT03923231 79 86 O
document NCT03923231 87 95 O
indicating NCT03923231 96 106 O
that NCT03923231 107 111 O
the NCT03923231 112 115 O
participant NCT03923231 116 127 O
( NCT03923231 128 129 O
or NCT03923231 130 132 O
a NCT03923231 133 134 O
legal NCT03923231 135 140 O
representative NCT03923231 141 155 O
) NCT03923231 156 157 O
has NCT03923231 158 161 O
been NCT03923231 162 166 O
informed NCT03923231 167 175 O
of NCT03923231 176 178 O
all NCT03923231 179 182 O
pertinent NCT03923231 183 192 O
aspects NCT03923231 193 200 O
of NCT03923231 201 203 O
the NCT03923231 204 207 O
study NCT03923231 208 213 O
. NCT03923231 214 215 O

2 NCT03923231 219 220 O
. NCT03923231 220 221 O
In NCT03923231 223 225 O
a NCT03923231 226 227 O
child NCT03923231 228 233 O
aged NCT03923231 234 238 B-Age
≥ NCT03923231 239 240 B-Eq-Comparison
7 NCT03923231 241 242 I-Eq-Comparison
years NCT03923231 243 248 I-Eq-Comparison
( NCT03923231 249 250 O
South NCT03923231 251 256 O
Africa NCT03923231 257 263 O
) NCT03923231 264 265 O
or NCT03923231 266 268 B-Or
aged NCT03923231 269 273 B-Age
≥ NCT03923231 274 275 B-Eq-Comparison
8 NCT03923231 276 277 I-Eq-Comparison
years NCT03923231 278 283 I-Eq-Comparison
( NCT03923231 284 285 O
Uganda NCT03923231 286 292 O
) NCT03923231 293 294 O
, NCT03923231 296 297 O
evidence NCT03923231 298 306 O
of NCT03923231 307 309 O
assent NCT03923231 310 316 O
to NCT03923231 317 319 O
participate NCT03923231 320 331 O

3 NCT03923231 334 335 O
. NCT03923231 335 336 O
Participants NCT03923231 338 350 O
who NCT03923231 351 354 O
are NCT03923231 355 358 O
willing NCT03923231 359 366 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03923231 367 370 B-And
able NCT03923231 371 375 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03923231 376 378 O
comply NCT03923231 379 385 O
with NCT03923231 386 390 O
scheduled NCT03923231 391 400 B-Eq-Comparison
visits NCT03923231 401 407 B-Encounter
, NCT03923231 408 409 O
laboratory NCT03923231 410 420 B-Observation
tests NCT03923231 421 426 I-Observation
, NCT03923231 427 428 O
and NCT03923231 429 432 B-And
other NCT03923231 433 438 O
study NCT03923231 439 444 B-Study
procedures NCT03923231 445 455 O
. NCT03923231 456 457 O

4 NCT03923231 461 462 O
. NCT03923231 462 463 O
HIV NCT03923231 465 468 B-Condition
- NCT03923231 469 470 I-Condition
infected NCT03923231 471 479 I-Condition
, NCT03923231 480 481 O
receiving NCT03923231 482 491 B-Eq-Comparison
ATV NCT03923231 492 495 B-Drug
- NCT03923231 496 497 O
based NCT03923231 498 503 O
ART NCT03923231 504 507 B-Procedure
treatment NCT03923231 508 517 I-Procedure
OR NCT03923231 518 520 B-Or
HIV NCT03923231 521 524 B-Condition
- NCT03923231 525 526 I-Condition
infected NCT03923231 527 535 I-Condition
receiving NCT03923231 536 545 B-Eq-Comparison
second NCT03923231 546 552 B-Modifier
- NCT03923231 553 554 I-Modifier
line NCT03923231 555 559 I-Modifier
ART NCT03923231 560 563 B-Procedure
with NCT03923231 564 568 B-And
concurrent NCT03923231 569 579 B-Eq-Comparison
rifamycin NCT03923231 580 589 B-Drug
- NCT03923231 590 591 O
based NCT03923231 592 597 O
TB NCT03923231 598 600 B-Procedure
treatment NCT03923231 601 610 I-Procedure

5 NCT03923231 613 614 O
. NCT03923231 614 615 O
Participant NCT03923231 617 628 O
is NCT03923231 629 631 O
within NCT03923231 632 638 O
one NCT03923231 639 642 O
of NCT03923231 643 645 O
the NCT03923231 646 649 O
target NCT03923231 650 656 O
populations NCT03923231 657 668 O
: NCT03923231 669 670 O

1 NCT03923231 679 680 O
. NCT03923231 680 681 O
Pregnant NCT03923231 683 691 B-Condition
( NCT03923231 692 693 O
> NCT03923231 695 696 B-Eq-Comparison
20 NCT03923231 697 699 I-Eq-Comparison
weeks NCT03923231 700 705 I-Eq-Comparison
) NCT03923231 706 707 O

2 NCT03923231 716 717 O
. NCT03923231 717 718 O
Body NCT03923231 720 724 B-Observation
mass NCT03923231 725 729 I-Observation
index NCT03923231 730 735 I-Observation
> NCT03923231 736 737 B-Eq-Comparison
30 NCT03923231 738 740 I-Eq-Comparison
or NCT03923231 741 743 B-Or
< NCT03923231 744 745 B-Eq-Comparison
18.5 NCT03923231 746 750 I-Eq-Comparison
Kg NCT03923231 751 753 I-Eq-Comparison
/ NCT03923231 754 755 I-Eq-Comparison
m2 NCT03923231 756 758 I-Eq-Comparison

3 NCT03923231 766 767 O
. NCT03923231 767 768 O
Child NCT03923231 770 775 O
or NCT03923231 776 778 B-Or
adolescent NCT03923231 779 789 O
aged NCT03923231 790 794 B-Age
< NCT03923231 795 796 B-Eq-Comparison
18 NCT03923231 797 799 I-Eq-Comparison
years NCT03923231 800 805 I-Eq-Comparison

Exclusion NCT03923231 806 815 O
Criteria NCT03923231 816 824 O
: NCT03923231 825 826 O

1 NCT03923231 830 831 O
. NCT03923231 831 832 O
Medical NCT03923231 834 841 B-Modifier
, NCT03923231 842 843 O
psychiatric NCT03923231 844 855 B-Modifier
or NCT03923231 856 858 B-Or
obstetric NCT03923231 859 868 B-Modifier
condition NCT03923231 869 878 B-Condition
that NCT03923231 879 883 O
might NCT03923231 884 889 O
affect NCT03923231 890 896 O
participation NCT03923231 897 910 O
in NCT03923231 911 913 O
the NCT03923231 914 917 O
stuy NCT03923231 918 922 B-Study
based NCT03923231 923 928 O
on NCT03923231 929 931 O
investigator NCT03923231 932 944 O
judgement NCT03923231 945 954 O

2 NCT03923231 957 958 O
. NCT03923231 958 959 O
Dissent NCT03923231 961 968 O
from NCT03923231 969 973 O
a NCT03923231 974 975 O
minor NCT03923231 976 981 O

3 NCT03923231 984 985 O
. NCT03923231 985 986 O
For NCT03923231 988 991 O
pregnant NCT03923231 992 1000 B-Condition
women NCT03923231 1001 1006 O
in NCT03923231 1007 1009 B-And
Uganda NCT03923231 1010 1016 O
, NCT03923231 1017 1018 O
where NCT03923231 1019 1024 B-And
the NCT03923231 1025 1028 O
husband NCT03923231 1029 1036 B-Family-Member___Family-Member-Type:spouse
is NCT03923231 1037 1039 O
reasonably NCT03923231 1040 1050 O
involved NCT03923231 1051 1059 O
, NCT03923231 1060 1061 O
paternal NCT03923231 1062 1070 O
objection NCT03923231 1071 1080 O

Inclusion NCT03923543 0 9 O
Criteria NCT03923543 10 18 O
: NCT03923543 19 20 O

- NCT03923543 24 25 O
newborn NCT03923543 27 34 O
to NCT03923543 35 37 B-Eq-Comparison
be NCT03923543 38 40 I-Eq-Comparison
operated NCT03923543 41 49 B-Procedure
with NCT03923543 50 54 B-And
the NCT03923543 55 58 O
diagnosis NCT03923543 59 68 O
of NCT03923543 69 71 O
congenital NCT03923543 72 82 B-Condition
heart NCT03923543 83 88 I-Condition
disease NCT03923543 89 96 I-Condition

Exclusion NCT03923543 97 106 O
Criteria NCT03923543 107 115 O
: NCT03923543 116 117 O

- NCT03923543 121 122 O
age NCT03923543 124 127 B-Age
older NCT03923543 128 133 B-Eq-Comparison
than NCT03923543 134 138 I-Eq-Comparison
1 NCT03923543 139 140 I-Eq-Comparison
month NCT03923543 141 146 I-Eq-Comparison
not NCT03923543 147 150 B-Negation
to NCT03923543 151 153 B-Eq-Comparison
be NCT03923543 154 156 I-Eq-Comparison
operated NCT03923543 157 165 B-Procedure

Inclusion NCT03923595 0 9 O
Criteria NCT03923595 10 18 O
: NCT03923595 19 20 O

- NCT03923595 24 25 O
all NCT03923595 27 30 O
consecutive NCT03923595 31 42 O
patients NCT03923595 43 51 O
from NCT03923595 52 56 O
SERD NCT03923595 57 61 O
of NCT03923595 62 64 O
18 NCT03923595 65 67 B-Eq-Comparison
yrs NCT03923595 68 71 I-Eq-Comparison
or NCT03923595 72 74 I-Eq-Comparison
older NCT03923595 75 80 I-Age|Eq-Comparison
either NCT03923595 81 87 O
naive NCT03923595 88 93 B-Condition
or NCT03923595 94 96 B-Or
previously NCT03923595 97 107 B-Eq-Comparison
treated NCT03923595 108 115 B-Procedure
including NCT03923595 116 125 O
HBsAg NCT03923595 126 131 B-Condition
positive NCT03923595 132 140 O
and NCT03923595 141 144 B-Or
HIV NCT03923595 145 148 B-Condition
positive NCT03923595 149 157 O
. NCT03923595 158 159 O

Exclusion NCT03923595 161 170 O
Criteria NCT03923595 171 179 O
: NCT03923595 180 181 O

- NCT03923595 185 186 O
GFR NCT03923595 188 191 B-Observation
< NCT03923595 192 193 B-Eq-Comparison
50 NCT03923595 194 196 I-Eq-Comparison
ml NCT03923595 197 199 I-Eq-Comparison
/ NCT03923595 200 201 I-Eq-Comparison
min NCT03923595 202 205 I-Eq-Comparison
, NCT03923595 206 207 O
pregnancy NCT03923595 208 217 B-Condition
, NCT03923595 218 219 O
breast NCT03923595 220 226 B-Condition
- NCT03923595 227 228 I-Condition
feeding NCT03923595 229 236 I-Condition
, NCT03923595 237 238 O
cirrhosis NCT03923595 239 248 B-Condition
of NCT03923595 249 251 B-And
CHILD NCT03923595 252 257 B-Condition
- NCT03923595 258 259 I-Condition
PUGH NCT03923595 260 264 I-Condition
- NCT03923595 265 266 I-Condition
TURCOTTE NCT03923595 267 275 I-Condition
B7 NCT03923595 276 278 B-Eq-Comparison
o NCT03923595 279 280 I-Eq-Comparison
> NCT03923595 281 282 I-Eq-Comparison
. NCT03923595 283 284 O

Inclusion NCT03923556 0 9 O
Criteria NCT03923556 10 18 O
: NCT03923556 19 20 O

- NCT03923556 24 25 O
At NCT03923556 27 29 B-Eq-Comparison
least NCT03923556 30 35 I-Eq-Comparison
18 NCT03923556 36 38 I-Eq-Comparison
years NCT03923556 39 44 I-Eq-Comparison
or NCT03923556 45 47 I-Eq-Comparison
older NCT03923556 48 53 I-Age|Eq-Comparison

- NCT03923556 56 57 O
Diagnosed NCT03923556 59 68 O
with NCT03923556 69 73 O
severe NCT03923556 74 80 O
kidney NCT03923556 81 87 B-Condition
dysfunction NCT03923556 88 99 I-Condition
( NCT03923556 100 101 O
defined NCT03923556 102 109 O
by NCT03923556 110 112 O
plasma NCT03923556 113 119 B-Observation
creatinine NCT03923556 120 130 I-Observation
clearance NCT03923556 131 140 I-Observation
< NCT03923556 141 142 B-Eq-Comparison
30 NCT03923556 143 145 I-Eq-Comparison
mL NCT03923556 146 148 I-Eq-Comparison
/ NCT03923556 149 150 I-Eq-Comparison
min NCT03923556 151 154 I-Eq-Comparison
) NCT03923556 155 156 O

- NCT03923556 160 161 O
Planning NCT03923556 163 171 B-Assertion___Assertion-Type-Value:intention
on NCT03923556 172 174 O
kidney NCT03923556 175 181 B-Procedure
transplantation NCT03923556 182 197 I-Procedure
surgery NCT03923556 198 205 I-Procedure
at NCT03923556 206 208 O
the NCT03923556 209 212 O
University NCT03923556 213 223 O
of NCT03923556 224 226 O
Colorado NCT03923556 227 235 O
Hospital NCT03923556 236 244 O
. NCT03923556 245 246 O

Exclusion NCT03923556 248 257 O
Criteria NCT03923556 258 266 O
: NCT03923556 267 268 O

- NCT03923556 272 273 O
Patients NCT03923556 275 283 O
unable NCT03923556 284 290 O
to NCT03923556 291 293 O
sign NCT03923556 294 298 O
the NCT03923556 299 302 O
informed NCT03923556 303 311 O
consent NCT03923556 312 319 O

- NCT03923556 322 323 O
Pregnant NCT03923556 325 333 B-Condition
women NCT03923556 334 339 O

- NCT03923556 342 343 O
Body NCT03923556 345 349 B-Observation
Mass NCT03923556 350 354 I-Observation
Index NCT03923556 355 360 I-Observation
( NCT03923556 361 362 O
BMI NCT03923556 363 366 B-Observation
) NCT03923556 367 368 O
> NCT03923556 369 370 B-Eq-Comparison
40 NCT03923556 371 373 I-Eq-Comparison
kg NCT03923556 374 376 I-Eq-Comparison
/ NCT03923556 377 378 I-Eq-Comparison
m2 NCT03923556 379 381 I-Eq-Comparison

- NCT03923556 384 385 O
Pre NCT03923556 387 390 B-Eq-Comparison
- NCT03923556 391 392 I-Eq-Comparison
existing NCT03923556 393 401 I-Eq-Comparison
oxygen NCT03923556 402 408 B-Modifier
or NCT03923556 409 411 B-Or
ventilatory NCT03923556 412 423 B-Modifier
dependency NCT03923556 424 434 B-Condition
( NCT03923556 435 436 O
24 NCT03923556 437 439 B-Eq-Comparison
h NCT03923556 440 441 I-Eq-Comparison
use NCT03923556 442 445 O
of NCT03923556 446 448 O
oxygen NCT03923556 449 455 B-Procedure
or NCT03923556 456 458 B-Or
other NCT03923556 459 464 B-Other
noninvasive NCT03923556 465 476 B-Modifier
or NCT03923556 477 479 B-Or
invasive NCT03923556 480 488 B-Modifier
ventilatory NCT03923556 489 500 B-Procedure
support NCT03923556 501 508 I-Procedure
) NCT03923556 509 510 O

- NCT03923556 514 515 O
Patients NCT03923556 517 525 O
with NCT03923556 526 530 O
any NCT03923556 531 534 O
pulmonary NCT03923556 535 544 B-Modifier
, NCT03923556 545 546 O
neuromuscular NCT03923556 547 560 B-Modifier
or NCT03923556 561 563 B-Or
other NCT03923556 564 569 B-Other
disease NCT03923556 570 577 B-Condition
that NCT03923556 578 582 O
severely NCT03923556 583 591 O
limits NCT03923556 592 598 O
their NCT03923556 599 604 O
respiratory NCT03923556 605 616 B-Condition
functional NCT03923556 617 627 I-Condition
status NCT03923556 628 634 O
( NCT03923556 635 636 O
e. NCT03923556 637 639 O
g. NCT03923556 640 642 O
unable NCT03923556 644 650 B-Negation
to NCT03923556 651 653 O
achieve NCT03923556 654 661 O
4 NCT03923556 662 663 B-Eq-Comparison
Metabolic NCT03923556 664 673 B-Observation
Equivalent NCT03923556 674 684 I-Observation
of NCT03923556 685 687 I-Observation
Tasks NCT03923556 688 693 I-Observation
, NCT03923556 694 695 O
METs NCT03923556 696 700 B-Observation
, NCT03923556 701 702 O
such NCT03923556 703 707 O
as NCT03923556 708 710 O
climbing NCT03923556 711 719 B-Observation
up NCT03923556 720 722 I-Observation
1 NCT03923556 723 724 I-Observation
flight NCT03923556 725 731 I-Observation
of NCT03923556 732 734 I-Observation
stairs NCT03923556 735 741 I-Observation
) NCT03923556 742 743 O

- NCT03923556 747 748 O
Presence NCT03923556 750 758 O
of NCT03923556 759 761 O
any NCT03923556 762 765 O
contraindication NCT03923556 766 782 B-Contraindication
for NCT03923556 783 786 O
any NCT03923556 787 790 O
of NCT03923556 791 793 O
the NCT03923556 794 797 O
study NCT03923556 798 803 B-Study
- NCT03923556 804 805 O
related NCT03923556 806 813 O
medications NCT03923556 814 825 B-Drug
or NCT03923556 826 828 B-Or
interventions NCT03923556 829 842 B-Procedure
. NCT03923556 842 843 O

Inclusion NCT03923218 0 9 O
Criteria NCT03923218 10 18 O
for NCT03923218 19 22 O
chronic NCT03923218 23 30 B-Condition
periodontitis NCT03923218 31 44 I-Condition
groups NCT03923218 45 51 O
: NCT03923218 52 53 O

- NCT03923218 57 58 O
Clinical NCT03923218 60 68 B-Observation
attachment NCT03923218 69 79 I-Observation
loss NCT03923218 80 84 I-Observation
≥ NCT03923218 85 86 B-Eq-Comparison
5 NCT03923218 87 88 I-Eq-Comparison
mm NCT03923218 89 91 I-Eq-Comparison

- NCT03923218 94 95 O
Probing NCT03923218 97 104 B-Observation
depth NCT03923218 105 110 I-Observation
≥ NCT03923218 111 112 B-Eq-Comparison
5 NCT03923218 113 114 I-Eq-Comparison
mm NCT03923218 115 117 I-Eq-Comparison

- NCT03923218 120 121 O
Bone NCT03923218 123 127 B-Observation
loss NCT03923218 128 132 I-Observation
affecting NCT03923218 133 142 O
> NCT03923218 143 144 B-Eq-Comparison
30 NCT03923218 145 147 I-Eq-Comparison
% NCT03923218 148 149 I-Eq-Comparison
of NCT03923218 150 152 O
the NCT03923218 153 156 O
existing NCT03923218 157 165 O
teeth NCT03923218 166 171 B-Modifier
on NCT03923218 172 174 O
clinical NCT03923218 175 183 B-Modifier
and NCT03923218 184 187 B-Or
radiographic NCT03923218 188 200 B-Modifier
examination NCT03923218 201 212 B-Procedure

- NCT03923218 215 216 O
gingival NCT03923218 218 226 B-Observation
index NCT03923218 227 232 I-Observation
( NCT03923218 233 234 O
GI NCT03923218 235 237 B-Observation
) NCT03923218 238 239 O
score NCT03923218 240 245 O
> NCT03923218 246 247 B-Eq-Comparison
1 NCT03923218 248 249 I-Eq-Comparison

Inclusion NCT03923218 251 260 O
criteria NCT03923218 261 269 O
for NCT03923218 270 273 O
control NCT03923218 274 281 O
group NCT03923218 282 287 O
: NCT03923218 288 289 O

- NCT03923218 293 294 O
full NCT03923218 296 300 B-Modifier
- NCT03923218 301 302 I-Modifier
mouth NCT03923218 303 308 I-Modifier
PD NCT03923218 309 311 B-Observation
was NCT03923218 312 315 O
≤ NCT03923218 316 317 B-Eq-Comparison
3 NCT03923218 318 319 I-Eq-Comparison
mm NCT03923218 320 322 O
, NCT03923218 323 324 O

- NCT03923218 328 329 O
Gingival NCT03923218 331 339 B-Observation
index NCT03923218 340 345 I-Observation
< NCT03923218 346 347 B-Eq-Comparison
1 NCT03923218 348 349 I-Eq-Comparison

- NCT03923218 353 354 O
there NCT03923218 356 361 O
was NCT03923218 362 365 O
no NCT03923218 366 368 B-Negation
indication NCT03923218 369 379 O
of NCT03923218 380 382 O
Attachment NCT03923218 383 393 B-Condition
Loss NCT03923218 394 398 I-Condition
or NCT03923218 399 401 B-Or
no NCT03923218 402 404 B-Negation
radiographic NCT03923218 405 417 B-Procedure
evidence NCT03923218 418 426 I-Procedure
of NCT03923218 427 429 O
alveolar NCT03923218 430 438 B-Condition
bone NCT03923218 439 443 I-Condition
loss NCT03923218 444 448 I-Condition
in NCT03923218 449 451 O
control NCT03923218 452 459 O
group NCT03923218 460 465 O
. NCT03923218 466 467 O

- NCT03923218 471 472 O
Non NCT03923218 474 477 B-Negation
- NCT03923218 478 479 O
smokers NCT03923218 480 487 B-Condition
. NCT03923218 488 489 O

Smoking NCT03923218 491 498 B-Condition
criteria NCT03923218 499 507 O
for NCT03923218 508 511 O
groups NCT03923218 512 518 O
: NCT03923218 519 520 O

- NCT03923218 524 525 O
patients NCT03923218 527 535 O
smoked NCT03923218 536 542 B-Observation
more NCT03923218 543 547 B-Eq-Comparison
than NCT03923218 548 552 I-Eq-Comparison
10 NCT03923218 553 555 I-Eq-Comparison
cigarettes NCT03923218 556 566 I-Eq-Comparison
in NCT03923218 567 569 I-Eq-Comparison
a NCT03923218 570 571 I-Eq-Comparison
day NCT03923218 572 575 I-Eq-Comparison

- NCT03923218 578 579 O
smoking NCT03923218 581 588 B-Condition
for NCT03923218 589 592 O
3 NCT03923218 593 594 B-Eq-Comparison
or NCT03923218 595 597 I-Eq-Comparison
more NCT03923218 598 602 I-Eq-Comparison
years NCT03923218 603 608 I-Eq-Comparison
, NCT03923218 609 610 O

Exclusion NCT03923218 612 621 O
Criteria NCT03923218 622 630 O
: NCT03923218 631 632 O

- NCT03923218 636 637 O
systemic NCT03923218 639 647 B-Modifier
condition NCT03923218 648 657 B-Condition
( NCT03923218 658 659 O
diabetes NCT03923218 660 668 B-Condition
, NCT03923218 669 670 O
cardiovascular NCT03923218 671 685 B-Condition
disease NCT03923218 686 693 I-Condition
, NCT03923218 694 695 O
immunologic NCT03923218 696 707 B-Condition
disorders NCT03923218 708 717 I-Condition
, NCT03923218 718 719 O
hepatitis NCT03923218 720 729 B-Condition
, NCT03923218 730 731 O
e. NCT03923218 732 734 O
g. NCT03923218 735 737 O
) NCT03923218 738 739 O

- NCT03923218 743 744 O
pregnancy NCT03923218 746 755 B-Condition
, NCT03923218 756 757 O
lactation NCT03923218 758 767 B-Condition
or NCT03923218 768 770 B-Or
menopause NCT03923218 771 780 B-Condition
term NCT03923218 781 785 O
, NCT03923218 786 787 O

- NCT03923218 791 792 O
antibiotic NCT03923218 794 804 B-Drug
treatment NCT03923218 805 814 B-Procedure
or NCT03923218 815 817 B-Or
non NCT03923218 818 821 B-Drug
- NCT03923218 822 823 I-Drug
steroidal NCT03923218 824 833 I-Drug
anti NCT03923218 834 838 I-Drug
- NCT03923218 839 840 I-Drug
inflammatory NCT03923218 841 853 I-Drug
medications NCT03923218 854 865 I-Drug
within NCT03923218 866 872 B-Eq-Comparison
the NCT03923218 873 876 I-Eq-Comparison
last NCT03923218 877 881 I-Eq-Comparison
3 NCT03923218 882 883 I-Eq-Comparison
months NCT03923218 884 890 I-Eq-Comparison
before NCT03923218 891 897 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03923218 898 901 O
study NCT03923218 902 907 B-Study
, NCT03923218 908 909 O

- NCT03923218 913 914 O
non NCT03923218 916 919 B-Modifier
- NCT03923218 920 921 I-Modifier
surgical NCT03923218 922 930 I-Modifier
periodontal NCT03923218 931 942 B-Procedure
treatment NCT03923218 943 952 I-Procedure
during NCT03923218 953 959 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03923218 960 963 O
last NCT03923218 964 968 B-Eq-Comparison
6 NCT03923218 969 970 I-Eq-Comparison
months NCT03923218 971 977 I-Eq-Comparison
before NCT03923218 978 984 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03923218 985 988 O
study NCT03923218 989 994 B-Study
, NCT03923218 995 996 O

- NCT03923218 1000 1001 O
treatment NCT03923218 1003 1012 B-Procedure
with NCT03923218 1013 1017 O
Vitamin NCT03923218 1018 1025 B-Drug
D NCT03923218 1026 1027 I-Drug
supplementation NCT03923218 1028 1043 I-Drug
before NCT03923218 1044 1050 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03923218 1051 1054 O
study NCT03923218 1055 1060 B-Study

Inclusion NCT03923998 0 9 O
Criteria NCT03923998 10 18 O
: NCT03923998 19 20 O

1 NCT03923998 24 25 O
. NCT03923998 25 26 O
Histologically NCT03923998 28 42 B-Procedure
confirmed NCT03923998 43 52 O
stage NCT03923998 53 58 B-Eq-Comparison
IVa NCT03923998 59 62 I-Eq-Comparison
squamous NCT03923998 63 71 B-Condition
cell NCT03923998 72 76 I-Condition
carcinoma NCT03923998 77 86 I-Condition
of NCT03923998 87 89 O
the NCT03923998 90 93 O
oral NCT03923998 94 98 B-Modifier
cavity NCT03923998 99 105 I-Modifier
. NCT03923998 106 107 O

2 NCT03923998 111 112 O
. NCT03923998 112 113 O
Surgically NCT03923998 115 125 B-Modifier
resectable NCT03923998 126 136 I-Modifier
oral NCT03923998 137 141 I-Modifier
squamous NCT03923998 142 150 B-Condition
carcinoma NCT03923998 151 160 I-Condition
with NCT03923998 161 165 O
invasion NCT03923998 166 174 B-Modifier
of NCT03923998 175 177 I-Modifier
mandible NCT03923998 178 186 I-Modifier
or NCT03923998 187 189 B-Or
maxilla NCT03923998 190 197 B-Modifier
. NCT03923998 198 199 O

3 NCT03923998 203 204 O
. NCT03923998 204 205 O
Newly NCT03923998 207 212 B-Eq-Comparison
diagnosed NCT03923998 213 222 O
or NCT03923998 223 225 B-Or
previously NCT03923998 226 236 B-Eq-Comparison
untreated NCT03923998 237 246 B-Modifier
squamous NCT03923998 247 255 B-Condition
cell NCT03923998 256 260 I-Condition
carcinoma NCT03923998 261 270 I-Condition
of NCT03923998 271 273 O
the NCT03923998 274 277 O
oral NCT03923998 278 282 B-Modifier
cavity NCT03923998 283 289 I-Modifier
. NCT03923998 290 291 O

Exclusion NCT03923998 293 302 O
Criteria NCT03923998 303 311 O
: NCT03923998 312 313 O

1 NCT03923998 317 318 O
. NCT03923998 318 319 O
Patients NCT03923998 321 329 O
with NCT03923998 330 334 O
distant NCT03923998 335 342 B-Condition
metastases NCT03923998 343 353 I-Condition
. NCT03923998 354 355 O

2 NCT03923998 359 360 O
. NCT03923998 360 361 O
Patients NCT03923998 363 371 O
with NCT03923998 372 376 O
contraindication NCT03923998 377 393 B-Contraindication
to NCT03923998 394 396 O
radiotherapy NCT03923998 397 409 B-Procedure
. NCT03923998 410 411 O

3 NCT03923998 415 416 O
. NCT03923998 416 417 O
Patients NCT03923998 419 427 O
with NCT03923998 428 432 O
vascular NCT03923998 433 441 B-Condition
disorders NCT03923998 442 451 I-Condition
or NCT03923998 452 454 B-Or
ischemic NCT03923998 455 463 B-Condition
heart NCT03923998 464 469 I-Condition
disease NCT03923998 470 477 I-Condition
. NCT03923998 477 478 O
- NCT03923998 480 481 O

Inclusion NCT03921619 0 9 O
Criteria NCT03921619 10 18 O
: NCT03921619 19 20 O

- NCT03921619 24 25 O
Greater NCT03921619 27 34 B-Eq-Comparison
than NCT03921619 35 39 I-Eq-Comparison
or NCT03921619 40 42 I-Eq-Comparison
equal NCT03921619 43 48 I-Eq-Comparison
to NCT03921619 49 51 I-Eq-Comparison
65 NCT03921619 52 54 I-Eq-Comparison
years NCT03921619 55 60 I-Eq-Comparison
of NCT03921619 61 63 O
age NCT03921619 64 67 B-Age

Exclusion NCT03921619 68 77 O
Criteria NCT03921619 78 86 O
: NCT03921619 87 88 O

- NCT03921619 92 93 O
Younger NCT03921619 95 102 B-Eq-Comparison
than NCT03921619 103 107 I-Eq-Comparison
65 NCT03921619 108 110 I-Eq-Comparison
years NCT03921619 111 116 I-Eq-Comparison
of NCT03921619 117 119 O
age NCT03921619 120 123 B-Age

- NCT03921619 126 127 O
Pre NCT03921619 129 132 B-Eq-Comparison
- NCT03921619 133 134 I-Eq-Comparison
existing NCT03921619 135 143 I-Eq-Comparison
cognitive NCT03921619 144 153 B-Condition
impairment NCT03921619 154 164 I-Condition

- NCT03921619 167 168 O
Pre NCT03921619 170 173 B-Eq-Comparison
- NCT03921619 174 175 I-Eq-Comparison
existing NCT03921619 176 184 I-Eq-Comparison
mobility NCT03921619 185 193 B-Condition
impairment NCT03921619 194 204 I-Condition

- NCT03921619 207 208 O
Pre NCT03921619 210 213 B-Eq-Comparison
- NCT03921619 214 215 I-Eq-Comparison
existing NCT03921619 216 224 I-Eq-Comparison
symptomatic NCT03921619 225 236 B-Assertion___Assertion-Type-Value:possible
upper NCT03921619 237 242 B-Modifier
or NCT03921619 243 245 B-Or
lower NCT03921619 246 251 B-Modifier
extremity NCT03921619 252 261 I-Modifier
disease NCT03921619 262 269 B-Condition

Inclusion NCT03929523 0 9 O
Criteria NCT03929523 10 18 O
: NCT03929523 19 20 O

- NCT03929523 24 25 O
Provide NCT03929523 27 34 O
written NCT03929523 35 42 O
informed NCT03929523 43 51 O
consent NCT03929523 52 59 O
prior NCT03929523 60 65 O
to NCT03929523 66 68 O
the NCT03929523 69 72 O
performance NCT03929523 73 84 O
of NCT03929523 85 87 O
any NCT03929523 88 91 O
study NCT03929523 92 97 B-Study
specific NCT03929523 98 106 O
procedure NCT03929523 107 116 B-Procedure

- NCT03929523 119 120 O
Affiliated NCT03929523 122 132 O
to NCT03929523 133 135 O
the NCT03929523 136 139 O
French NCT03929523 140 146 O
social NCT03929523 147 153 O
security NCT03929523 154 162 O
system NCT03929523 163 169 O

- NCT03929523 172 173 O
Recipient NCT03929523 175 184 O
age NCT03929523 185 188 B-Age
≥ NCT03929523 189 190 B-Eq-Comparison
18 NCT03929523 191 193 I-Eq-Comparison
years NCT03929523 194 199 I-Eq-Comparison

- NCT03929523 202 203 O
Patients NCT03929523 205 213 O
undergoing NCT03929523 214 224 B-Eq-Comparison
primary NCT03929523 225 232 B-Modifier
liver NCT03929523 233 238 B-Procedure
transplantation NCT03929523 239 254 I-Procedure
. NCT03929523 255 256 O

- NCT03929523 260 261 O
Candidate NCT03929523 263 272 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03929523 273 276 O
a NCT03929523 277 278 O
first NCT03929523 279 284 B-Eq-Comparison
elective NCT03929523 285 293 B-Modifier
liver NCT03929523 294 299 B-Procedure
transplantation NCT03929523 300 315 I-Procedure
, NCT03929523 316 317 O
whatever NCT03929523 318 326 O
the NCT03929523 327 330 O
indication NCT03929523 331 341 O
, NCT03929523 342 343 O
with NCT03929523 344 348 B-And
a NCT03929523 349 350 O
liver NCT03929523 351 356 B-Procedure
graft NCT03929523 357 362 I-Procedure
harvested NCT03929523 363 372 O
from NCT03929523 373 377 O
a NCT03929523 378 379 O
brain NCT03929523 380 385 B-Procedure
- NCT03929523 386 387 I-Procedure
dead NCT03929523 388 392 I-Procedure
ECD NCT03929523 393 396 I-Procedure
defined NCT03929523 397 404 O
by NCT03929523 405 407 O
the NCT03929523 408 411 O
presence NCT03929523 412 420 O
of NCT03929523 421 423 O
at NCT03929523 424 426 B-Eq-Comparison
least NCT03929523 427 432 I-Eq-Comparison
one NCT03929523 433 436 I-Eq-Comparison
of NCT03929523 437 439 O
the NCT03929523 440 443 B-Criteria-Count
following NCT03929523 444 453 I-Criteria-Count
criteria NCT03929523 454 462 I-Criteria-Count
: NCT03929523 463 464 O

- NCT03929523 473 474 O
Donor NCT03929523 476 481 B-Modifier
age NCT03929523 482 485 B-Age
> NCT03929523 486 487 B-Eq-Comparison
65 NCT03929523 488 490 I-Eq-Comparison
years NCT03929523 491 496 I-Eq-Comparison

- NCT03929523 504 505 O
Intensive NCT03929523 507 516 B-Encounter
care NCT03929523 517 521 I-Encounter
unit NCT03929523 522 526 I-Encounter
stay NCT03929523 527 531 O
> NCT03929523 532 533 B-Eq-Comparison
7 NCT03929523 534 535 I-Eq-Comparison
days NCT03929523 536 540 I-Eq-Comparison

- NCT03929523 548 549 O
BMI NCT03929523 551 554 B-Observation
> NCT03929523 555 556 B-Eq-Comparison
30 NCT03929523 557 559 I-Eq-Comparison

- NCT03929523 568 569 O
Proven NCT03929523 571 577 O
macro NCT03929523 578 583 B-Observation
- NCT03929523 584 585 I-Observation
steatosis NCT03929523 586 595 I-Observation
biopsy NCT03929523 596 602 B-Procedure
≥ NCT03929523 603 604 B-Eq-Comparison
30 NCT03929523 605 607 I-Eq-Comparison
% NCT03929523 608 609 I-Eq-Comparison

- NCT03929523 618 619 O
Natremia NCT03929523 621 629 B-Observation
> NCT03929523 630 631 B-Eq-Comparison
155 NCT03929523 632 635 I-Eq-Comparison
mmol NCT03929523 636 640 I-Eq-Comparison
/ NCT03929523 641 642 I-Eq-Comparison
L NCT03929523 643 644 I-Eq-Comparison
at NCT03929523 645 647 B-Eq-Comparison
any NCT03929523 648 651 I-Eq-Comparison
time NCT03929523 652 656 I-Eq-Comparison

- NCT03929523 664 665 O
AST NCT03929523 667 670 B-Observation
> NCT03929523 671 672 B-Eq-Comparison
150 NCT03929523 673 676 I-Eq-Comparison
IU NCT03929523 677 679 I-Eq-Comparison
/ NCT03929523 680 681 I-Eq-Comparison
mL NCT03929523 682 684 I-Eq-Comparison
at NCT03929523 685 687 B-Eq-Comparison
any NCT03929523 688 691 I-Eq-Comparison
time NCT03929523 692 696 I-Eq-Comparison

- NCT03929523 704 705 O
ALT NCT03929523 707 710 B-Observation
> NCT03929523 711 712 B-Eq-Comparison
170 NCT03929523 713 716 I-Eq-Comparison
IU NCT03929523 717 719 I-Eq-Comparison
/ NCT03929523 720 721 I-Eq-Comparison
mL NCT03929523 722 724 I-Eq-Comparison
at NCT03929523 725 727 B-Eq-Comparison
any NCT03929523 728 731 I-Eq-Comparison
time NCT03929523 732 736 I-Eq-Comparison
. NCT03929523 737 738 O

Exclusion NCT03929523 740 749 O
Criteria NCT03929523 750 758 O
: NCT03929523 759 760 O

- NCT03929523 764 765 O
Fulminant NCT03929523 767 776 B-Condition
hepatic NCT03929523 777 784 I-Condition
failure NCT03929523 785 792 I-Condition

- NCT03929523 795 796 O
Retransplantation NCT03929523 798 815 B-Procedure

- NCT03929523 818 819 O
Split NCT03929523 821 826 B-Modifier
liver NCT03929523 827 832 B-Procedure
transplantation NCT03929523 833 848 I-Procedure

- NCT03929523 851 852 O
Living NCT03929523 854 860 B-Modifier
donor NCT03929523 861 866 I-Modifier
liver NCT03929523 867 872 B-Procedure
transplantation NCT03929523 873 888 I-Procedure

- NCT03929523 891 892 O
Grafts NCT03929523 894 900 B-Observation
donated NCT03929523 901 908 I-Observation
after NCT03929523 909 914 B-Temporal-Connection___Temporal-Connection-Type-Value:after
cardiac NCT03929523 915 922 B-Condition
arrest NCT03929523 923 929 I-Condition
( NCT03929523 930 931 O
DCD NCT03929523 932 935 B-Observation
grafts NCT03929523 936 942 I-Observation
) NCT03929523 943 944 O

- NCT03929523 948 949 O
Domino NCT03929523 951 957 B-Modifier
transplantation NCT03929523 958 973 B-Procedure

- NCT03929523 976 977 O
Combined NCT03929523 979 987 B-Modifier
liver NCT03929523 988 993 B-Procedure
transplant NCT03929523 994 1004 I-Procedure

- NCT03929523 1007 1008 O
Unexpected NCT03929523 1010 1020 O
medical NCT03929523 1021 1028 O
contraindication NCT03929523 1029 1045 B-Contraindication
to NCT03929523 1046 1048 O
liver NCT03929523 1049 1054 B-Procedure
transplantation NCT03929523 1055 1070 I-Procedure

- NCT03929523 1073 1074 O
Patient NCT03929523 1076 1083 O
participating NCT03929523 1084 1097 B-Eq-Comparison
in NCT03929523 1098 1100 O
other NCT03929523 1101 1106 B-Other
interventional NCT03929523 1107 1121 B-Study
research NCT03929523 1122 1130 I-Study
, NCT03929523 1131 1132 O
excluding NCT03929523 1133 1142 B-Exception
routine NCT03929523 1143 1150 B-Modifier
care NCT03929523 1151 1155 I-Modifier
research NCT03929523 1156 1164 B-Study
( NCT03929523 1165 1166 O
old NCT03929523 1167 1170 B-Modifier
regulation NCT03929523 1171 1181 I-Modifier
) NCT03929523 1182 1183 O
and NCT03929523 1184 1187 B-Or
category NCT03929523 1188 1196 B-Modifier
2 NCT03929523 1197 1198 I-Modifier
research NCT03929523 1199 1207 B-Study
not NCT03929523 1208 1211 B-Negation
interfering NCT03929523 1212 1223 O
with NCT03929523 1224 1228 O
primary NCT03929523 1229 1236 O
endpoint NCT03929523 1237 1245 O
analysis NCT03929523 1246 1254 B-Study

- NCT03929523 1257 1258 O
Patient NCT03929523 1260 1267 O
under NCT03929523 1268 1273 O
legal NCT03929523 1274 1279 B-Observation
protection NCT03929523 1280 1290 I-Observation

- NCT03929523 1293 1294 O
Patient NCT03929523 1296 1303 O
deprived NCT03929523 1304 1312 B-Observation
of NCT03929523 1313 1315 I-Observation
liberty NCT03929523 1316 1323 I-Observation
by NCT03929523 1324 1326 O
a NCT03929523 1327 1328 O
judicial NCT03929523 1329 1337 O
or NCT03929523 1338 1340 O
administrative NCT03929523 1341 1355 O
decision NCT03929523 1356 1364 O

- NCT03929523 1367 1368 O
Patient NCT03929523 1370 1377 O
refusing NCT03929523 1378 1386 O
to NCT03929523 1387 1389 O
participate NCT03929523 1390 1401 O
in NCT03929523 1402 1404 O
the NCT03929523 1405 1408 O
study NCT03929523 1409 1414 O

- NCT03929523 1417 1418 O
Pregnant NCT03929523 1420 1428 B-Condition
or NCT03929523 1429 1431 B-Or
lactating NCT03929523 1432 1441 B-Condition
women NCT03929523 1442 1447 O

- NCT03929523 1450 1451 O
Inability NCT03929523 1453 1462 B-Condition
to NCT03929523 1463 1465 I-Condition
understand NCT03929523 1466 1476 I-Condition
information NCT03929523 1477 1488 O
concerning NCT03929523 1489 1499 O
the NCT03929523 1500 1503 O
protocol NCT03929523 1504 1512 O

Inclusion NCT03922516 0 9 O
Criteria NCT03922516 10 18 O
: NCT03922516 19 20 O

- NCT03922516 24 25 O
all NCT03922516 27 30 O
patients NCT03922516 31 39 O
who NCT03922516 40 43 O
are NCT03922516 44 47 O
assigned NCT03922516 48 56 O
to NCT03922516 57 59 O
a NCT03922516 60 61 O
clinically NCT03922516 62 72 O
indicated NCT03922516 73 82 B-Indication
chest NCT03922516 83 88 B-Modifier
X NCT03922516 89 90 B-Procedure
- NCT03922516 91 92 I-Procedure
ray NCT03922516 93 96 I-Procedure
by NCT03922516 97 99 O
the NCT03922516 100 103 O
emergency NCT03922516 104 113 O
department NCT03922516 114 124 O
of NCT03922516 125 127 O
Vienna NCT03922516 128 134 O
General NCT03922516 135 142 O
Hospital NCT03922516 143 151 O

- NCT03922516 154 155 O
ability NCT03922516 157 164 O
to NCT03922516 165 167 O
provide NCT03922516 168 175 O
informed NCT03922516 176 184 O
consent NCT03922516 185 192 O

- NCT03922516 195 196 O
informed NCT03922516 198 206 O
consent NCT03922516 207 214 O
after NCT03922516 215 220 O
detailed NCT03922516 221 229 O
patient NCT03922516 230 237 O
briefing NCT03922516 238 246 O

Exclusion NCT03922516 247 256 O
Criteria NCT03922516 257 265 O
: NCT03922516 266 267 O

- NCT03922516 271 272 O
the NCT03922516 274 277 O
emergency NCT03922516 278 287 O
departments NCT03922516 288 299 O
assessment NCT03922516 300 310 B-Procedure
of NCT03922516 311 313 O
a NCT03922516 314 315 O
critical NCT03922516 316 324 O
clinical NCT03922516 325 333 B-Condition
condition NCT03922516 334 343 I-Condition
oppose NCT03922516 344 350 B-Assertion___Assertion-Type-Value:hypothetical
an NCT03922516 351 353 O
examination NCT03922516 354 365 B-Procedure
with NCT03922516 366 370 O
both NCT03922516 371 375 B-Modifier
modalities NCT03922516 376 386 I-Modifier
( NCT03922516 387 388 O
ULDCT NCT03922516 389 394 B-Procedure
of NCT03922516 395 397 O
the NCT03922516 398 401 O
chest NCT03922516 402 407 B-Modifier
, NCT03922516 408 409 O
chest NCT03922516 410 415 B-Modifier
X NCT03922516 416 417 B-Procedure
- NCT03922516 418 419 I-Procedure
ray NCT03922516 420 423 I-Procedure
) NCT03922516 424 425 O

- NCT03922516 429 430 O
assigned NCT03922516 432 440 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03922516 441 443 O
chest NCT03922516 444 449 B-Modifier
X NCT03922516 450 451 B-Procedure
- NCT03922516 452 453 I-Procedure
ray NCT03922516 454 457 I-Procedure
as NCT03922516 458 460 O
follow NCT03922516 461 467 O
- NCT03922516 468 469 O
up NCT03922516 470 472 O

- NCT03922516 475 476 O
women NCT03922516 478 483 O
with NCT03922516 484 488 B-And
positive NCT03922516 489 497 O
ß NCT03922516 498 499 B-Observation
- NCT03922516 500 501 I-Observation
HCG NCT03922516 502 505 I-Observation
- NCT03922516 506 507 I-Observation
test NCT03922516 508 512 I-Observation

Inclusion NCT03923608 0 9 O
Criteria NCT03923608 10 18 O
: NCT03923608 19 20 O
should NCT03923608 21 27 O
report NCT03923608 28 34 O
the NCT03923608 35 38 O
absence NCT03923608 39 46 B-Negation
of NCT03923608 47 49 O
: NCT03923608 50 51 O

- NCT03923608 55 56 O
anemia NCT03923608 58 64 B-Condition
, NCT03923608 65 66 O

- NCT03923608 70 71 O
diabetes NCT03923608 73 81 B-Condition
, NCT03923608 82 83 O

- NCT03923608 87 88 O
cardiovascular NCT03923608 90 104 B-Condition
disease NCT03923608 105 112 I-Condition
, NCT03923608 113 114 O

- NCT03923608 118 119 O
and NCT03923608 121 124 O
upper NCT03923608 125 130 B-Modifier
limb NCT03923608 131 135 I-Modifier
and NCT03923608 136 139 B-Or
spinal NCT03923608 140 146 B-Modifier
muscular NCT03923608 147 155 I-Modifier
injuries NCT03923608 156 164 B-Condition
in NCT03923608 165 167 O
the NCT03923608 168 171 O
last NCT03923608 172 176 B-Eq-Comparison
six NCT03923608 177 180 I-Eq-Comparison
months NCT03923608 181 187 I-Eq-Comparison

Exclusion NCT03923608 188 197 O
Criteria NCT03923608 198 206 O
: NCT03923608 207 208 O

- NCT03923608 212 213 O
absence NCT03923608 215 222 B-Negation
at NCT03923608 223 225 O
any NCT03923608 226 229 O
study NCT03923608 230 235 B-Study
session NCT03923608 236 243 O
and NCT03923608 244 247 O

- NCT03923608 250 251 O
episode NCT03923608 253 260 O
of NCT03923608 261 263 O
muscle NCT03923608 264 270 B-Modifier
- NCT03923608 271 272 I-Modifier
tendon NCT03923608 273 279 I-Modifier
or NCT03923608 280 282 B-Or
osteoarticular NCT03923608 283 297 B-Modifier
injury NCT03923608 298 304 B-Condition
in NCT03923608 305 307 O
the NCT03923608 308 311 O
upper NCT03923608 312 317 B-Modifier
limbs NCT03923608 318 323 I-Modifier
during NCT03923608 324 330 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03923608 331 334 O
study NCT03923608 335 340 B-Study
. NCT03923608 340 341 O

Inclusion NCT03924167 0 9 O
Criteria NCT03924167 10 18 O
: NCT03924167 19 20 O

Inclusion NCT03924167 22 31 O
Criteria NCT03924167 32 40 O
for NCT03924167 41 44 O
community NCT03924167 45 54 O
health NCT03924167 55 61 O
representatives NCT03924167 62 77 O
( NCT03924167 78 79 O
CHR NCT03924167 80 83 B-Condition
) NCT03924167 84 85 O
s. NCT03924167 86 88 O
> NCT03924167 90 91 B-Eq-Comparison
> NCT03924167 93 94 O
18 NCT03924167 95 97 I-Eq-Comparison
years NCT03924167 98 103 I-Eq-Comparison
of NCT03924167 104 106 O
age NCT03924167 107 110 B-Age
or NCT03924167 111 113 O
older NCT03924167 114 119 O

- NCT03924167 122 123 O
have NCT03924167 125 129 O
at NCT03924167 130 132 B-Eq-Comparison
least NCT03924167 133 138 I-Eq-Comparison
a NCT03924167 139 140 O
high NCT03924167 141 145 B-Observation
school NCT03924167 146 152 I-Observation
degree NCT03924167 153 159 I-Observation

- NCT03924167 162 163 O
have NCT03924167 165 169 O
experience NCT03924167 170 180 O
and NCT03924167 181 184 O
/ NCT03924167 185 186 O
or NCT03924167 187 189 O
interest NCT03924167 190 198 O
in NCT03924167 199 201 O
working NCT03924167 202 209 O
with NCT03924167 210 214 O
tribal NCT03924167 215 221 O
children NCT03924167 222 230 O
and NCT03924167 231 234 O
families NCT03924167 235 243 O
. NCT03924167 244 245 O

Exclusion NCT03924167 247 256 O
criteria NCT03924167 257 265 O
: NCT03924167 266 267 O

- NCT03924167 271 272 O
having NCT03924167 274 280 O
less NCT03924167 281 285 B-Eq-Comparison
than NCT03924167 286 290 I-Eq-Comparison
a NCT03924167 291 292 O
high NCT03924167 293 297 B-Observation
school NCT03924167 298 304 I-Observation
degree NCT03924167 305 311 I-Observation

- NCT03924167 314 315 O
not NCT03924167 317 320 O
having NCT03924167 321 327 O
experience NCT03924167 328 338 O
with NCT03924167 339 343 O
tribal NCT03924167 344 350 O
families NCT03924167 351 359 O

Inclusion NCT03924167 360 369 O
criteria NCT03924167 370 378 O
for NCT03924167 379 382 O
families NCT03924167 383 391 O

- NCT03924167 394 395 O
includes NCT03924167 397 405 O
written NCT03924167 406 413 O
consent NCT03924167 414 421 O
for NCT03924167 422 425 O
adults NCT03924167 426 432 O
and NCT03924167 433 436 O
assent NCT03924167 437 443 O
for NCT03924167 444 447 O
children NCT03924167 448 456 O
ages NCT03924167 457 461 B-Age
12 NCT03924167 462 464 B-Eq-Comparison
- NCT03924167 465 466 I-Eq-Comparison
17 NCT03924167 467 469 O
. NCT03924167 469 470 O

- NCT03924167 474 475 O
at NCT03924167 477 479 O
least NCT03924167 480 485 O
one NCT03924167 486 489 O
parent NCT03924167 490 496 O
/ NCT03924167 497 498 O
caregiver NCT03924167 499 508 O
who NCT03924167 509 512 O
is NCT03924167 513 515 O
a NCT03924167 516 517 O
member NCT03924167 518 524 O
of NCT03924167 525 527 O
the NCT03924167 528 531 O
focal NCT03924167 532 537 O
tribe NCT03924167 538 543 O
and NCT03924167 544 547 O
at NCT03924167 548 550 O
least NCT03924167 551 556 O
one NCT03924167 557 560 O
child NCT03924167 561 566 O
, NCT03924167 567 568 O
aged NCT03924167 569 573 B-Age
12 NCT03924167 574 576 B-Eq-Comparison
- NCT03924167 577 578 I-Eq-Comparison
18 NCT03924167 579 581 O
living NCT03924167 582 588 O
in NCT03924167 589 591 O
the NCT03924167 592 595 O
household NCT03924167 596 605 O

Exclusion NCT03924167 606 615 O
Criteria NCT03924167 616 624 O
: NCT03924167 625 626 O

- NCT03924167 630 631 O
current NCT03924167 633 640 B-Eq-Comparison
protective NCT03924167 641 651 B-Observation
order NCT03924167 652 657 I-Observation

- NCT03924167 660 661 O
current NCT03924167 663 670 B-Eq-Comparison
intimate NCT03924167 671 679 B-Condition
partner NCT03924167 680 687 I-Condition
violence NCT03924167 688 696 I-Condition
( NCT03924167 697 698 O
IPV NCT03924167 699 702 B-Condition
) NCT03924167 703 704 O
record NCT03924167 705 711 O
will NCT03924167 712 716 O
be NCT03924167 717 719 O
excluded NCT03924167 720 728 B-Negation
. NCT03924167 728 729 O

Inclusion NCT03926572 0 9 O
Criteria NCT03926572 10 18 O
: NCT03926572 19 20 O

- NCT03926572 24 25 O
Adult NCT03926572 27 32 O
patients NCT03926572 33 41 O
over NCT03926572 42 46 B-Eq-Comparison
18 NCT03926572 47 49 I-Eq-Comparison
years NCT03926572 50 55 I-Age|Eq-Comparison

- NCT03926572 58 59 O
Diagnosis NCT03926572 61 70 O
of NCT03926572 71 73 O
Pulmonary NCT03926572 74 83 B-Condition
arterial NCT03926572 84 92 I-Condition
hypertension NCT03926572 93 105 I-Condition
or NCT03926572 106 108 B-Or
non NCT03926572 109 112 B-Modifier
- NCT03926572 113 114 I-Modifier
operable NCT03926572 115 123 I-Modifier
chronic NCT03926572 124 131 I-Modifier
thromboembolic NCT03926572 132 146 B-Condition
pulmonary NCT03926572 147 156 I-Condition
hypertension NCT03926572 157 169 I-Condition
established NCT03926572 170 181 O
by NCT03926572 182 184 O
right NCT03926572 185 190 B-Procedure
cardiac NCT03926572 191 198 I-Procedure
catheterization NCT03926572 199 214 I-Procedure
prior NCT03926572 215 220 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926572 221 223 O
inclusion NCT03926572 224 233 O
in NCT03926572 234 236 O
the NCT03926572 237 240 O
study NCT03926572 241 246 B-Study

- NCT03926572 249 250 O
Patients NCT03926572 252 260 O
admitted NCT03926572 261 269 B-Encounter
in NCT03926572 270 272 I-Encounter
intensive NCT03926572 273 282 I-Encounter
care NCT03926572 283 287 I-Encounter
unit NCT03926572 288 292 I-Encounter
for NCT03926572 293 296 O
acute NCT03926572 297 302 O
decompensation NCT03926572 303 317 B-Modifier
of NCT03926572 318 320 O
pulmonary NCT03926572 321 330 B-Condition
hypertension NCT03926572 331 343 I-Condition
requiring NCT03926572 344 353 O
intravenous NCT03926572 354 365 B-Modifier
diuretic NCT03926572 366 374 B-Procedure
therapy NCT03926572 375 382 I-Procedure
± NCT03926572 383 384 B-Or
use NCT03926572 385 388 O
of NCT03926572 389 391 O
inotropes NCT03926572 392 401 B-Drug
or NCT03926572 402 404 B-Or
vasopressors NCT03926572 405 417 B-Drug
. NCT03926572 418 419 O

- NCT03926572 423 424 O
Patients NCT03926572 426 434 O
must NCT03926572 435 439 O
have NCT03926572 440 444 O
given NCT03926572 445 450 O
their NCT03926572 451 456 O
written NCT03926572 457 464 O
informed NCT03926572 465 473 O
consent NCT03926572 474 481 O
to NCT03926572 482 484 O
participate NCT03926572 485 496 O
in NCT03926572 497 499 O
the NCT03926572 500 503 O
study NCT03926572 504 509 B-Study
after NCT03926572 510 515 O
having NCT03926572 516 522 O
received NCT03926572 523 531 O
adequate NCT03926572 532 540 O
previous NCT03926572 541 549 O
information NCT03926572 550 561 O
and NCT03926572 562 565 O
prior NCT03926572 566 571 O
to NCT03926572 572 574 O
any NCT03926572 575 578 O
study NCT03926572 579 584 B-Study
- NCT03926572 585 586 O
specific NCT03926572 587 595 O
procedures NCT03926572 596 606 B-Procedure

Exclusion NCT03926572 607 616 O
Criteria NCT03926572 617 625 O
: NCT03926572 626 627 O

- NCT03926572 631 632 O
Patients NCT03926572 634 642 O
with NCT03926572 643 647 O
post NCT03926572 648 652 B-Modifier
- NCT03926572 653 654 I-Modifier
capillary NCT03926572 655 664 I-Modifier
pulmonary NCT03926572 665 674 B-Condition
hypertension NCT03926572 675 687 I-Condition

- NCT03926572 690 691 O
Patients NCT03926572 693 701 O
with NCT03926572 702 706 O
pulmonary NCT03926572 707 716 B-Condition
hypertension NCT03926572 717 729 I-Condition
associated NCT03926572 730 740 O
with NCT03926572 741 745 O
chronic NCT03926572 746 753 B-Modifier
respiratory NCT03926572 754 765 B-Condition
disease NCT03926572 766 773 I-Condition

- NCT03926572 776 777 O
Patients NCT03926572 779 787 O
with NCT03926572 788 792 O
pulmonary NCT03926572 793 802 B-Condition
hypertension NCT03926572 803 815 I-Condition
with NCT03926572 816 820 O
unclear NCT03926572 821 828 B-Modifier
/ NCT03926572 829 830 O
or NCT03926572 831 833 B-Or
multifactorial NCT03926572 834 848 B-Modifier
mechanisms NCT03926572 849 859 I-Modifier

- NCT03926572 862 863 O
Patients NCT03926572 865 873 O
with NCT03926572 874 878 O
operable NCT03926572 879 887 B-Modifier
chronic NCT03926572 888 895 I-Modifier
thromboembolic NCT03926572 896 910 I-Modifier
pulmonary NCT03926572 911 920 B-Condition
hypertension NCT03926572 921 933 I-Condition

- NCT03926572 936 937 O
Shock NCT03926572 939 944 B-Condition
due NCT03926572 945 948 O
to NCT03926572 949 951 O
another NCT03926572 952 959 B-Other
cause NCT03926572 960 965 B-Condition
than NCT03926572 966 970 B-Exception
acute NCT03926572 971 976 O
decompensation NCT03926572 977 991 B-Modifier
of NCT03926572 992 994 O
pulmonary NCT03926572 995 1004 B-Condition
hypertension NCT03926572 1005 1017 I-Condition

- NCT03926572 1020 1021 O
Pregnant NCT03926572 1023 1031 B-Condition
women NCT03926572 1032 1037 O
, NCT03926572 1038 1039 O
or NCT03926572 1040 1042 B-Or
breast NCT03926572 1043 1049 B-Condition
feeding NCT03926572 1050 1057 I-Condition
women NCT03926572 1058 1063 O

- NCT03926572 1066 1067 O
Adult NCT03926572 1069 1074 O
protected NCT03926572 1075 1084 B-Observation
person NCT03926572 1085 1091 I-Observation

- NCT03926572 1094 1095 O
Person NCT03926572 1097 1103 O
deprived NCT03926572 1104 1112 B-Observation
of NCT03926572 1113 1115 I-Observation
liberty NCT03926572 1116 1123 I-Observation

- NCT03926572 1126 1127 O
Person NCT03926572 1129 1135 O
admitted NCT03926572 1136 1144 O
without NCT03926572 1145 1152 O
consent NCT03926572 1153 1160 O

- NCT03926572 1163 1164 O
Pregnant NCT03926572 1166 1174 B-Condition
or NCT03926572 1175 1177 B-Or
breastfeeding NCT03926572 1178 1191 B-Condition
women NCT03926572 1192 1197 O

Inclusion NCT03926273 0 9 O
Criteria NCT03926273 10 18 O
: NCT03926273 19 20 O

- NCT03926273 24 25 O
All NCT03926273 27 30 O
participants NCT03926273 31 43 O
were NCT03926273 44 48 O
included NCT03926273 49 57 O
if NCT03926273 58 60 O
their NCT03926273 61 66 O
age NCT03926273 67 70 B-Age
more NCT03926273 71 75 B-Eq-Comparison
than NCT03926273 76 80 I-Eq-Comparison
or NCT03926273 81 83 I-Eq-Comparison
equal NCT03926273 84 89 I-Eq-Comparison
to NCT03926273 90 92 I-Eq-Comparison
18 NCT03926273 93 95 I-Eq-Comparison
years NCT03926273 96 101 I-Eq-Comparison
. NCT03926273 101 102 O
Body NCT03926273 104 108 B-Observation
mass NCT03926273 109 113 I-Observation
index NCT03926273 114 119 I-Observation
< NCT03926273 120 121 B-Eq-Comparison
30 NCT03926273 122 124 I-Eq-Comparison
kg NCT03926273 125 127 I-Eq-Comparison
/ NCT03926273 128 129 I-Eq-Comparison
m2 NCT03926273 130 132 I-Eq-Comparison
, NCT03926273 133 134 O
total NCT03926273 135 140 B-Observation
cholesterol NCT03926273 141 152 I-Observation
< NCT03926273 153 154 B-Eq-Comparison
200 NCT03926273 155 158 I-Eq-Comparison
mg NCT03926273 159 161 I-Eq-Comparison
/ NCT03926273 162 163 I-Eq-Comparison
dl NCT03926273 164 166 I-Eq-Comparison
, NCT03926273 167 168 O
serum NCT03926273 169 174 B-Observation
triglycerides NCT03926273 175 188 I-Observation
< NCT03926273 189 190 B-Eq-Comparison
200 NCT03926273 191 194 I-Eq-Comparison
mg NCT03926273 195 197 I-Eq-Comparison
/ NCT03926273 198 199 I-Eq-Comparison
dl NCT03926273 200 202 I-Eq-Comparison
and NCT03926273 203 206 B-And
random NCT03926273 207 213 B-Modifier
blood NCT03926273 214 219 B-Observation
glucose NCT03926273 220 227 I-Observation
level NCT03926273 228 233 I-Observation
< NCT03926273 234 235 B-Eq-Comparison
126 NCT03926273 236 239 I-Eq-Comparison
mg NCT03926273 240 242 I-Eq-Comparison
/ NCT03926273 243 244 I-Eq-Comparison
dl NCT03926273 245 247 I-Eq-Comparison
. NCT03926273 248 249 O

Exclusion NCT03926273 251 260 O
Criteria NCT03926273 261 269 O
: NCT03926273 270 271 O

- NCT03926273 275 276 O
Participants NCT03926273 278 290 O
had NCT03926273 291 294 O
acute NCT03926273 295 300 O
or NCT03926273 301 303 B-Or
chronic NCT03926273 304 311 B-Modifier
metabolic NCT03926273 312 321 B-Condition
disorders NCT03926273 322 331 I-Condition
( NCT03926273 332 333 O
liver NCT03926273 334 339 B-Modifier
, NCT03926273 340 341 O
kidney NCT03926273 342 348 B-Modifier
, NCT03926273 349 350 O
thyroid NCT03926273 351 358 B-Modifier
, NCT03926273 359 360 O
endocrine NCT03926273 361 370 B-Modifier
or NCT03926273 371 373 B-Or
gastrointestinal NCT03926273 374 390 B-Modifier
disorders NCT03926273 391 400 B-Condition
) NCT03926273 401 402 O
. NCT03926273 404 405 O

- NCT03926273 409 410 O
Females NCT03926273 412 419 O
with NCT03926273 420 424 B-And
irregular NCT03926273 425 434 B-Condition
menstrual NCT03926273 435 444 I-Condition
cycle NCT03926273 445 450 I-Condition
or NCT03926273 451 453 B-Or
on NCT03926273 454 456 B-Eq-Comparison
estrogen NCT03926273 457 465 B-Procedure
therapy NCT03926273 466 473 I-Procedure
( NCT03926273 474 475 O
7 NCT03926273 476 477 O
) NCT03926273 478 479 O
. NCT03926273 481 482 O

- NCT03926273 486 487 O
Participants NCT03926273 489 501 O
with NCT03926273 502 506 O
organic NCT03926273 507 514 B-Modifier
cerebral NCT03926273 515 523 B-Condition
lesion NCT03926273 524 530 I-Condition
that NCT03926273 531 535 O
was NCT03926273 536 539 O
detected NCT03926273 540 548 O
on NCT03926273 549 551 O
cranial NCT03926273 552 559 B-Modifier
computed NCT03926273 560 568 B-Procedure
tomography NCT03926273 569 579 I-Procedure
( NCT03926273 580 581 O
CT NCT03926273 582 584 B-Procedure
) NCT03926273 585 586 O
or NCT03926273 587 589 B-Or
cranial NCT03926273 590 597 B-Modifier
magnetic NCT03926273 598 606 B-Procedure
resonance NCT03926273 607 616 I-Procedure
imaging NCT03926273 617 624 I-Procedure
( NCT03926273 625 626 O
MRI NCT03926273 627 630 B-Procedure
) NCT03926273 631 632 O
. NCT03926273 633 634 O

Inclusion NCT03925961 0 9 O
Criteria NCT03925961 10 18 O
: NCT03925961 19 20 O

- NCT03925961 24 25 O
General NCT03925961 27 34 O
surgical NCT03925961 35 43 O
patients NCT03925961 44 52 O
who NCT03925961 53 56 O
will NCT03925961 57 61 B-Eq-Comparison
undergo NCT03925961 62 69 I-Eq-Comparison
same NCT03925961 70 74 B-Modifier
- NCT03925961 75 76 I-Modifier
day NCT03925961 77 80 I-Modifier
laparoscopic NCT03925961 81 93 B-Procedure
ventral NCT03925961 94 101 I-Procedure
hernia NCT03925961 102 108 I-Procedure
, NCT03925961 109 110 O
inguinal NCT03925961 111 119 B-Procedure
hernia NCT03925961 120 126 I-Procedure
, NCT03925961 127 128 O
and NCT03925961 129 132 B-Or
gallbladder NCT03925961 133 144 B-Procedure
surgery NCT03925961 145 152 I-Procedure
at NCT03925961 153 155 O
Howard NCT03925961 156 162 O
County NCT03925961 163 169 O
General NCT03925961 170 177 O
Hospital NCT03925961 178 186 O
with NCT03925961 187 191 O
the NCT03925961 192 195 O
general NCT03925961 196 203 B-Provider
surgery NCT03925961 204 211 I-Provider
practice NCT03925961 212 220 I-Provider
at NCT03925961 221 223 O
Johns NCT03925961 224 229 O
Hopkins NCT03925961 230 237 O
Community NCT03925961 238 247 O
Physicians NCT03925961 248 258 O
. NCT03925961 259 260 O

Exclusion NCT03925961 262 271 O
Criteria NCT03925961 272 280 O
: NCT03925961 281 282 O

- NCT03925961 286 287 O
Patients NCT03925961 289 297 O
less NCT03925961 298 302 B-Eq-Comparison
than NCT03925961 303 307 I-Eq-Comparison
18 NCT03925961 308 310 I-Eq-Comparison
years NCT03925961 311 316 I-Eq-Comparison
of NCT03925961 317 319 O
age NCT03925961 320 323 B-Age

- NCT03925961 326 327 O
Adults NCT03925961 329 335 O
who NCT03925961 336 339 O
lack NCT03925961 340 344 O
the NCT03925961 345 348 O
capacity NCT03925961 349 357 O
to NCT03925961 358 360 O
consent NCT03925961 361 368 O

- NCT03925961 371 372 O
Pregnant NCT03925961 374 382 B-Condition
women NCT03925961 383 388 O

- NCT03925961 391 392 O
Prisoners NCT03925961 394 403 B-Observation

- NCT03925961 406 407 O
Non NCT03925961 409 412 B-Negation
- NCT03925961 413 414 O
English NCT03925961 415 422 O
speakers NCT03925961 423 431 O
. NCT03925961 431 432 O

Inclusion NCT03921736 0 9 O
Criteria NCT03921736 10 18 O
: NCT03921736 19 20 O

- NCT03921736 24 25 O
Treatment NCT03921736 27 36 B-Procedure
- NCT03921736 37 38 O
naive NCT03921736 39 44 B-Negation
postmenopausal NCT03921736 45 59 B-Condition
women NCT03921736 60 65 O

- NCT03921736 68 69 O
Diagnosed NCT03921736 71 80 O
hypertension NCT03921736 81 93 B-Condition
( NCT03921736 94 95 O
grade NCT03921736 96 101 B-Eq-Comparison
1 NCT03921736 102 103 I-Eq-Comparison
or NCT03921736 104 106 I-Eq-Comparison
2 NCT03921736 107 108 I-Eq-Comparison
according NCT03921736 109 118 O
to NCT03921736 119 121 O
ESH NCT03921736 122 125 O
/ NCT03921736 126 127 O
ESC NCT03921736 128 131 O
2013 NCT03921736 132 136 O
guidelines NCT03921736 137 147 O
) NCT03921736 148 149 O

Exclusion NCT03921736 151 160 O
Criteria NCT03921736 161 169 O
: NCT03921736 170 171 O

- NCT03921736 175 176 O
breast NCT03921736 178 184 B-Modifier
cancer NCT03921736 185 191 B-Condition
in NCT03921736 192 194 O
a NCT03921736 195 196 O
first NCT03921736 197 202 B-Family-Member
- NCT03921736 203 204 I-Family-Member
degree NCT03921736 205 211 I-Family-Member
relative NCT03921736 212 220 I-Family-Member

- NCT03921736 223 224 O
hyperplasia NCT03921736 226 237 B-Condition
diagnosed NCT03921736 238 247 O
by NCT03921736 248 250 O
endometrial NCT03921736 251 262 B-Procedure
biopsy NCT03921736 263 269 I-Procedure
, NCT03921736 270 271 O

- NCT03921736 275 276 O
history NCT03921736 278 285 B-Eq-Comparison
of NCT03921736 286 288 O
thromboembolic NCT03921736 289 303 B-Condition
diseases NCT03921736 304 312 I-Condition
, NCT03921736 313 314 O

- NCT03921736 318 319 O
current NCT03921736 321 328 B-Eq-Comparison
or NCT03921736 329 331 B-Or
history NCT03921736 332 339 B-Eq-Comparison
of NCT03921736 340 342 O
use NCT03921736 343 346 O
of NCT03921736 347 349 O
estrogen NCT03921736 350 358 B-Procedure
- NCT03921736 359 360 I-Procedure
progestin NCT03921736 361 370 I-Procedure
therapy NCT03921736 371 378 I-Procedure
or NCT03921736 379 381 B-Or
contraceptives NCT03921736 382 396 B-Procedure

- NCT03921736 399 400 O
diabetes NCT03921736 402 410 B-Condition
, NCT03921736 411 412 O

- NCT03921736 416 417 O
kidney NCT03921736 419 425 B-Condition
failure NCT03921736 426 433 I-Condition
, NCT03921736 434 435 O

- NCT03921736 439 440 O
thyroid NCT03921736 442 449 B-Condition
disease NCT03921736 450 457 I-Condition
, NCT03921736 458 459 O

- NCT03921736 463 464 O
heart NCT03921736 466 471 B-Modifier
and NCT03921736 472 475 B-Or
other NCT03921736 476 481 B-Other
chronic NCT03921736 482 489 B-Modifier
diseases NCT03921736 490 498 B-Condition
( NCT03921736 499 500 O
secondary NCT03921736 501 510 B-Condition
hypertension NCT03921736 511 523 I-Condition
, NCT03921736 524 525 O
atrial NCT03921736 526 532 B-Condition
fibrillation NCT03921736 533 545 I-Condition
) NCT03921736 546 547 O

Inclusion NCT03923647 0 9 O
Criteria NCT03923647 10 18 O
: NCT03923647 19 20 O

- NCT03923647 24 25 O
stable NCT03923647 27 33 O
patients NCT03923647 34 42 O
with NCT03923647 43 47 O
definite NCT03923647 48 56 O
occurrence NCT03923647 57 67 O
of NCT03923647 68 70 O
intra NCT03923647 71 76 B-Modifier
- NCT03923647 77 78 I-Modifier
abdominal NCT03923647 79 88 I-Modifier
injury NCT03923647 89 95 B-Condition

- NCT03923647 98 99 O
patients NCT03923647 101 109 O
with NCT03923647 110 114 O
equivocal NCT03923647 115 124 O
result NCT03923647 125 131 O
by NCT03923647 132 134 O
clinical NCT03923647 135 143 O
and NCT03923647 144 147 O
radiological NCT03923647 148 160 B-Procedure
evaluation NCT03923647 161 171 I-Procedure

Exclusion NCT03923647 172 181 O
Criteria NCT03923647 182 190 O
: NCT03923647 191 192 O

- NCT03923647 196 197 O
patients NCT03923647 199 207 O
with NCT03923647 208 212 O
penetrating NCT03923647 213 224 B-Modifier
abdominal NCT03923647 225 234 I-Modifier
trauma NCT03923647 235 241 B-Condition

- NCT03923647 244 245 O
stable NCT03923647 247 253 O
patients NCT03923647 254 262 O
not NCT03923647 263 266 B-Negation
in NCT03923647 267 269 O
need NCT03923647 270 274 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03923647 275 278 I-Assertion___Assertion-Type-Value:hypothetical
any NCT03923647 279 282 O
intervention NCT03923647 283 295 B-Procedure
for NCT03923647 296 299 O
conservative NCT03923647 300 312 B-Procedure
management NCT03923647 313 323 I-Procedure

- NCT03923647 326 327 O
patients NCT03923647 329 337 O
with NCT03923647 338 342 O
marked NCT03923647 343 349 O
haemodynamic NCT03923647 350 362 B-Condition
instability NCT03923647 363 374 I-Condition

- NCT03923647 377 378 O
polyt NCT03923647 380 385 B-Condition
- NCT03923647 386 387 I-Condition
traumatized NCT03923647 388 399 I-Condition
Patients NCT03923647 400 408 O

Inclusion NCT03924128 0 9 O
Criteria NCT03924128 10 18 O
: NCT03924128 19 20 O

- NCT03924128 24 25 O
Selected NCT03924128 27 35 O
will NCT03924128 36 40 O
be NCT03924128 41 43 O
subjects NCT03924128 44 52 O
to NCT03924128 53 55 O
meeting NCT03924128 56 63 O
the NCT03924128 64 67 O
following NCT03924128 68 77 O
criteria NCT03924128 78 86 O
: NCT03924128 87 88 O
male NCT03924128 89 93 O
and NCT03924128 94 97 B-Or
female NCT03924128 98 104 O
subjects NCT03924128 105 113 O
age NCT03924128 114 117 B-Age
≥ NCT03924128 118 119 B-Eq-Comparison
20 NCT03924128 120 122 I-Eq-Comparison
years NCT03924128 123 128 I-Eq-Comparison
old NCT03924128 129 132 O
, NCT03924128 133 134 O
diagnosed NCT03924128 135 144 O
with NCT03924128 145 149 O
Osteoarthritis NCT03924128 150 164 B-Condition
stages NCT03924128 165 171 B-Eq-Comparison
III NCT03924128 172 175 I-Eq-Comparison
and NCT03924128 176 179 I-Eq-Comparison
IV NCT03924128 180 182 I-Eq-Comparison
according NCT03924128 183 192 O
to NCT03924128 193 195 O
the NCT03924128 196 199 O
American NCT03924128 200 208 O
College NCT03924128 209 216 O
of NCT03924128 217 219 O
Rheumatology NCT03924128 220 232 O
, NCT03924128 233 234 O
manifesting NCT03924128 235 246 O
pain NCT03924128 247 251 B-Condition
, NCT03924128 252 253 O
functional NCT03924128 254 264 B-Condition
impairment NCT03924128 265 275 I-Condition
for NCT03924128 276 279 O
more NCT03924128 280 284 B-Eq-Comparison
than NCT03924128 285 289 I-Eq-Comparison
3 NCT03924128 290 291 I-Eq-Comparison
months NCT03924128 292 298 I-Eq-Comparison
, NCT03924128 299 300 O
able NCT03924128 301 305 B-Condition
to NCT03924128 306 308 I-Condition
wander NCT03924128 309 315 I-Condition
with NCT03924128 316 320 B-Modifier
or NCT03924128 321 323 I-Modifier
without NCT03924128 324 331 I-Modifier
canes NCT03924128 332 337 I-Modifier
. NCT03924128 338 339 O

Exclusion NCT03924128 341 350 O
Criteria NCT03924128 351 359 O
: NCT03924128 360 361 O

- NCT03924128 365 366 O
Will NCT03924128 368 372 O
be NCT03924128 373 375 O
excluded NCT03924128 376 384 B-Negation
from NCT03924128 385 389 O
study NCT03924128 390 395 B-Study
subjects NCT03924128 396 404 O
with NCT03924128 405 409 O
history NCT03924128 410 417 B-Eq-Comparison
of NCT03924128 418 420 O
cancer NCT03924128 421 427 B-Condition
, NCT03924128 428 429 O
unstable NCT03924128 430 438 O
cardiovascular NCT03924128 439 453 B-Condition
disease NCT03924128 454 461 I-Condition
, NCT03924128 462 463 O
uncontrolled NCT03924128 464 476 B-Modifier
hypertension NCT03924128 477 489 B-Condition
, NCT03924128 490 491 O
morbid NCT03924128 492 498 B-Condition
obesity NCT03924128 499 506 I-Condition
, NCT03924128 507 508 O
that NCT03924128 509 513 O
is NCT03924128 514 516 O
, NCT03924128 517 518 O
BMI NCT03924128 519 522 B-Observation
≥ NCT03924128 523 524 B-Eq-Comparison
40 NCT03924128 525 527 I-Eq-Comparison
, NCT03924128 528 529 O
terminal NCT03924128 530 538 B-Condition
illness NCT03924128 539 546 I-Condition
, NCT03924128 547 548 O
cerebrovascular NCT03924128 549 564 B-Condition
disease NCT03924128 565 572 I-Condition
, NCT03924128 573 574 O
dementia NCT03924128 575 583 B-Condition
, NCT03924128 584 585 O
heart NCT03924128 586 591 B-Procedure
pacemaker NCT03924128 592 601 I-Procedure
, NCT03924128 602 603 O
superior NCT03924128 604 612 B-Modifier
or NCT03924128 613 615 B-Or
inferior NCT03924128 616 624 B-Modifier
limb NCT03924128 625 629 I-Modifier
fractures NCT03924128 630 639 B-Condition
. NCT03924128 639 640 O

Inclusion NCT03924882 0 9 O
Criteria NCT03924882 10 18 O
: NCT03924882 19 20 O

1 NCT03924882 24 25 O
. NCT03924882 25 26 O
Female NCT03924882 28 34 O
, NCT03924882 35 36 O
age NCT03924882 37 40 B-Age
≥ NCT03924882 41 42 B-Eq-Comparison
18 NCT03924882 43 45 I-Eq-Comparison
years NCT03924882 46 51 I-Eq-Comparison
and NCT03924882 52 55 B-And
≤ NCT03924882 56 57 B-Eq-Comparison
70 NCT03924882 58 60 I-Eq-Comparison
years NCT03924882 61 66 I-Eq-Comparison
, NCT03924882 67 68 O
signed NCT03924882 69 75 O
informed NCT03924882 76 84 O
consent NCT03924882 85 92 O
. NCT03924882 93 94 O

2 NCT03924882 98 99 O
. NCT03924882 99 100 O
Histologically NCT03924882 102 116 B-Procedure
or NCT03924882 117 119 B-Or
pathologically NCT03924882 120 134 B-Procedure
confirmed NCT03924882 135 144 O
diagnosis NCT03924882 145 154 O
of NCT03924882 155 157 O
epithelial NCT03924882 158 168 B-Condition
carcinoma NCT03924882 169 178 I-Condition
of NCT03924882 179 181 O
the NCT03924882 182 185 O
ovary NCT03924882 186 191 B-Modifier
. NCT03924882 192 193 O

3 NCT03924882 197 198 O
. NCT03924882 198 199 O
Platinum NCT03924882 201 209 B-Modifier
resistant NCT03924882 210 219 I-Modifier
ovarian NCT03924882 220 227 I-Modifier
cancer NCT03924882 228 234 B-Condition
( NCT03924882 235 236 O
defined NCT03924882 237 244 O
as NCT03924882 245 247 O
relapsing NCT03924882 248 257 B-Coreference
within NCT03924882 258 264 B-Eq-Comparison
6 NCT03924882 265 266 I-Eq-Comparison
months NCT03924882 267 273 I-Eq-Comparison
after NCT03924882 274 279 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03924882 280 283 O
last NCT03924882 284 288 B-Eq-Comparison
administration NCT03924882 289 303 O
of NCT03924882 304 306 O
platinum NCT03924882 307 315 B-Modifier
- NCT03924882 316 317 I-Modifier
based NCT03924882 318 323 I-Modifier
chemotherapy NCT03924882 324 336 B-Procedure
) NCT03924882 337 338 O
OR NCT03924882 339 341 B-Or
platinum NCT03924882 342 350 B-Modifier
refractory NCT03924882 351 361 I-Modifier
ovarian NCT03924882 362 369 I-Modifier
cancer NCT03924882 370 376 B-Condition
( NCT03924882 377 378 O
defined NCT03924882 379 386 O
as NCT03924882 387 389 O
progressing NCT03924882 390 401 B-Coreference
while NCT03924882 402 407 B-Temporal-Connection___Temporal-Connection-Type-Value:during
on NCT03924882 408 410 I-Temporal-Connection___Temporal-Connection-Type-Value:during
a NCT03924882 411 412 O
platinum NCT03924882 413 421 B-Modifier
- NCT03924882 422 423 I-Modifier
based NCT03924882 424 429 I-Modifier
chemotherapy NCT03924882 430 442 B-Procedure
) NCT03924882 443 444 O

4 NCT03924882 448 449 O
. NCT03924882 449 450 O
At NCT03924882 452 454 B-Eq-Comparison
least NCT03924882 455 460 I-Eq-Comparison
treated NCT03924882 461 468 I-Eq-Comparison
with NCT03924882 469 473 I-Eq-Comparison
one NCT03924882 474 477 I-Eq-Comparison
line NCT03924882 478 482 O
of NCT03924882 483 485 O
platinum NCT03924882 486 494 B-Modifier
- NCT03924882 495 496 I-Modifier
based NCT03924882 497 502 I-Modifier
chemotherapy NCT03924882 503 515 B-Procedure

5 NCT03924882 518 519 O
. NCT03924882 519 520 O
Eastern NCT03924882 522 529 B-Observation
Cooperative NCT03924882 530 541 I-Observation
Oncology NCT03924882 542 550 I-Observation
Group NCT03924882 551 556 I-Observation
( NCT03924882 557 558 O
ECOG NCT03924882 559 563 B-Observation
) NCT03924882 564 565 O
performance NCT03924882 566 577 O
status NCT03924882 578 584 O
0 NCT03924882 585 586 B-Eq-Comparison
- NCT03924882 587 588 I-Eq-Comparison
2 NCT03924882 589 590 O

6 NCT03924882 594 595 O
. NCT03924882 595 596 O
Measurable NCT03924882 598 608 B-Observation
disease NCT03924882 609 616 I-Observation
according NCT03924882 617 626 O
to NCT03924882 627 629 O
Response NCT03924882 630 638 O
Evaluation NCT03924882 639 649 O
Criteria NCT03924882 650 658 O
in NCT03924882 659 661 O
Solid NCT03924882 662 667 O
Tumors NCT03924882 668 674 O
( NCT03924882 675 676 O
RECIST NCT03924882 677 683 O
) NCT03924882 684 685 O
1.1 NCT03924882 686 689 O
version NCT03924882 690 697 O
or NCT03924882 698 700 O
CA125 NCT03924882 701 706 B-Observation

7 NCT03924882 714 715 O
. NCT03924882 715 716 O
Patients NCT03924882 718 726 O
must NCT03924882 727 731 O
have NCT03924882 732 736 O
a NCT03924882 737 738 O
life NCT03924882 739 743 B-Observation
expectancy NCT03924882 744 754 I-Observation
of NCT03924882 755 757 O
at NCT03924882 758 760 B-Eq-Comparison
least NCT03924882 761 766 I-Eq-Comparison
3 NCT03924882 767 768 I-Eq-Comparison
months NCT03924882 769 775 I-Eq-Comparison
. NCT03924882 776 777 O

8 NCT03924882 781 782 O
. NCT03924882 782 783 O
Patients NCT03924882 785 793 O
must NCT03924882 794 798 O
have NCT03924882 799 803 O
adequate NCT03924882 804 812 O
organ NCT03924882 813 818 B-Condition
function NCT03924882 819 827 I-Condition
. NCT03924882 828 829 O

Exclusion NCT03924882 831 840 O
Criteria NCT03924882 841 849 O
: NCT03924882 850 851 O

1 NCT03924882 855 856 O
. NCT03924882 856 857 O
Had NCT03924882 859 862 O
prior NCT03924882 863 868 B-Eq-Comparison
exposure NCT03924882 869 877 O
to NCT03924882 878 880 O
anlotinib NCT03924882 881 890 B-Drug
or NCT03924882 891 893 B-Or
has NCT03924882 894 897 O
known NCT03924882 898 903 O
allegies NCT03924882 904 912 B-Allergy
to NCT03924882 913 915 O
any NCT03924882 916 919 O
of NCT03924882 920 922 O
the NCT03924882 923 926 O
excipients NCT03924882 927 937 O
, NCT03924882 938 939 O
Inadequately NCT03924882 940 952 B-Modifier
controlled NCT03924882 953 963 I-Modifier
hypertension NCT03924882 964 976 B-Condition

2 NCT03924882 979 980 O
. NCT03924882 980 981 O
History NCT03924882 983 990 B-Eq-Comparison
of NCT03924882 991 993 O
myocardial NCT03924882 994 1004 B-Condition
infarction NCT03924882 1005 1015 I-Condition
, NCT03924882 1016 1017 O
or NCT03924882 1018 1020 B-Or
unstable NCT03924882 1021 1029 B-Condition
angina NCT03924882 1030 1036 I-Condition
, NCT03924882 1037 1038 O
or NCT03924882 1039 1041 B-Or
New NCT03924882 1042 1045 B-Condition
York NCT03924882 1046 1050 I-Condition
Heart NCT03924882 1051 1056 I-Condition
Association NCT03924882 1057 1068 I-Condition
( NCT03924882 1069 1070 O
NYHA NCT03924882 1071 1075 B-Condition
) NCT03924882 1076 1077 O
Grade NCT03924882 1078 1083 B-Eq-Comparison
III NCT03924882 1084 1087 I-Eq-Comparison
- NCT03924882 1088 1089 I-Eq-Comparison
IV NCT03924882 1090 1092 I-Eq-Comparison
within NCT03924882 1093 1099 B-Eq-Comparison
6 NCT03924882 1100 1101 I-Eq-Comparison
months NCT03924882 1102 1108 I-Eq-Comparison
prior NCT03924882 1109 1114 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03924882 1115 1117 I-Temporal-Connection___Temporal-Connection-Type-Value:before
Day NCT03924882 1118 1121 B-Study
1 NCT03924882 1122 1123 O
. NCT03924882 1123 1124 O

3 NCT03924882 1128 1129 O
. NCT03924882 1129 1130 O
History NCT03924882 1132 1139 B-Eq-Comparison
of NCT03924882 1140 1142 O
abdominal NCT03924882 1143 1152 B-Condition
fistula NCT03924882 1153 1160 I-Condition
or NCT03924882 1161 1163 B-Or
gastrointestinal NCT03924882 1164 1180 B-Condition
perforation NCT03924882 1181 1192 I-Condition
within NCT03924882 1193 1199 B-Eq-Comparison
28 NCT03924882 1200 1202 I-Eq-Comparison
days NCT03924882 1203 1207 I-Eq-Comparison
prior NCT03924882 1208 1213 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03924882 1214 1216 I-Temporal-Connection___Temporal-Connection-Type-Value:before
Day NCT03924882 1217 1220 B-Study
1 NCT03924882 1221 1222 O

4 NCT03924882 1226 1227 O
. NCT03924882 1227 1228 O
Major NCT03924882 1230 1235 O
surgical NCT03924882 1236 1244 B-Procedure
procedure NCT03924882 1245 1254 I-Procedure
within NCT03924882 1255 1261 B-Eq-Comparison
28 NCT03924882 1262 1264 I-Eq-Comparison
days NCT03924882 1265 1269 I-Eq-Comparison
prior NCT03924882 1270 1275 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03924882 1276 1278 I-Temporal-Connection___Temporal-Connection-Type-Value:before
Day NCT03924882 1279 1282 B-Study
1 NCT03924882 1283 1284 O
, NCT03924882 1285 1286 O
Serious NCT03924882 1287 1294 O
, NCT03924882 1295 1296 O
non NCT03924882 1297 1300 B-Modifier
- NCT03924882 1301 1302 I-Modifier
healing NCT03924882 1303 1310 I-Modifier
wound NCT03924882 1311 1316 B-Condition
, NCT03924882 1317 1318 O
active NCT03924882 1319 1325 B-Eq-Comparison
ulcer NCT03924882 1326 1331 B-Condition
, NCT03924882 1332 1333 O
bowel NCT03924882 1334 1339 B-Condition
obstruction NCT03924882 1340 1351 I-Condition
within NCT03924882 1352 1358 B-Eq-Comparison
28 NCT03924882 1359 1361 I-Eq-Comparison
days NCT03924882 1362 1366 I-Eq-Comparison
prior NCT03924882 1367 1372 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03924882 1373 1375 I-Temporal-Connection___Temporal-Connection-Type-Value:before
Day NCT03924882 1376 1379 B-Study
1 NCT03924882 1380 1381 O

5 NCT03924882 1385 1386 O
. NCT03924882 1386 1387 O
Symptomatic NCT03924882 1389 1400 B-Assertion___Assertion-Type-Value:possible
central NCT03924882 1401 1408 B-Modifier
nervous NCT03924882 1409 1416 I-Modifier
system NCT03924882 1417 1423 I-Modifier
( NCT03924882 1424 1425 O
CNS NCT03924882 1426 1429 B-Modifier
) NCT03924882 1430 1431 O
metastasis NCT03924882 1432 1442 B-Condition


Inclusion NCT03921905 0 9 O
Criteria NCT03921905 10 18 O
: NCT03921905 19 20 O

- NCT03921905 24 25 O
Patients NCT03921905 27 35 O
of NCT03921905 36 38 O
both NCT03921905 39 43 O
sexes NCT03921905 44 49 O
with NCT03921905 50 54 O
a NCT03921905 55 56 O
diagnosis NCT03921905 57 66 O
of NCT03921905 67 69 O
stable NCT03921905 70 76 O
CAD NCT03921905 77 80 B-Condition
as NCT03921905 81 83 O
follows NCT03921905 84 91 O
: NCT03921905 92 93 O
acute NCT03921905 94 99 B-Condition
myocardial NCT03921905 100 110 I-Condition
infarction NCT03921905 111 121 I-Condition
or NCT03921905 122 124 B-Or
percutaneous NCT03921905 125 137 B-Procedure
coronary NCT03921905 138 146 I-Procedure
revascularization NCT03921905 147 164 I-Procedure
or NCT03921905 165 167 B-Or
coronary NCT03921905 168 176 B-Procedure
artery NCT03921905 177 183 I-Procedure
bypass NCT03921905 184 190 I-Procedure
graft NCT03921905 191 196 I-Procedure
surgery NCT03921905 197 204 I-Procedure
occured NCT03921905 205 212 O
at NCT03921905 213 215 B-Eq-Comparison
least NCT03921905 216 221 I-Eq-Comparison
12 NCT03921905 222 224 I-Eq-Comparison
months NCT03921905 225 231 I-Eq-Comparison
before NCT03921905 232 238 B-Temporal-Connection___Temporal-Connection-Type-Value:before
entering NCT03921905 239 247 O
the NCT03921905 248 251 O
study NCT03921905 252 257 B-Study
or NCT03921905 258 260 B-Or
chronic NCT03921905 261 268 B-Modifier
stable NCT03921905 269 275 O
angina NCT03921905 276 282 B-Condition
. NCT03921905 283 284 O

Exclusion NCT03921905 286 295 O
Criteria NCT03921905 296 304 O
: NCT03921905 305 306 O

- NCT03921905 310 311 O
Mental NCT03921905 313 319 B-Condition
illness NCT03921905 320 327 I-Condition
limiting NCT03921905 328 336 O
the NCT03921905 337 340 O
capacity NCT03921905 341 349 O
of NCT03921905 350 352 O
self NCT03921905 353 357 B-Procedure
- NCT03921905 358 359 I-Procedure
care NCT03921905 360 364 I-Procedure
or NCT03921905 365 367 B-Or
any NCT03921905 368 371 O
condition NCT03921905 372 381 B-Condition
limiting NCT03921905 382 390 O
seriously NCT03921905 391 400 O
the NCT03921905 401 404 O
life NCT03921905 405 409 B-Observation
expectancy NCT03921905 410 420 I-Observation
less NCT03921905 421 425 B-Eq-Comparison
than NCT03921905 426 430 I-Eq-Comparison
12 NCT03921905 431 433 I-Eq-Comparison
months NCT03921905 434 440 I-Eq-Comparison
. NCT03921905 440 441 O

Inclusion NCT03926663 0 9 O
Criteria NCT03926663 10 18 O
: NCT03926663 19 20 O

- NCT03926663 24 25 O
Patients NCT03926663 27 35 O
aged NCT03926663 36 40 B-Age
from NCT03926663 41 45 O
18 NCT03926663 46 48 B-Eq-Comparison
- NCT03926663 49 50 I-Eq-Comparison
60 NCT03926663 51 53 I-Eq-Comparison
years NCT03926663 54 59 I-Eq-Comparison

- NCT03926663 62 63 O
ASA NCT03926663 65 68 B-Condition
physical NCT03926663 69 77 O
status NCT03926663 78 84 O
I NCT03926663 85 86 B-Eq-Comparison

- NCT03926663 89 90 O
Undergoing NCT03926663 92 102 B-Eq-Comparison
septoplasty NCT03926663 103 114 B-Procedure

Exclusion NCT03926663 115 124 O
Criteria NCT03926663 125 133 O
: NCT03926663 134 135 O

- NCT03926663 139 140 O
Patients NCT03926663 142 150 O
with NCT03926663 151 155 O
cardiovascular NCT03926663 156 170 B-Condition
disease NCT03926663 171 178 I-Condition
( NCT03926663 179 180 O
congestive NCT03926663 181 191 B-Condition
heart NCT03926663 192 197 I-Condition
failure NCT03926663 198 205 I-Condition
, NCT03926663 206 207 O
coronary NCT03926663 208 216 B-Condition
artery NCT03926663 217 223 I-Condition
disease NCT03926663 224 231 I-Condition
, NCT03926663 232 233 O
hypertension NCT03926663 234 246 B-Condition
. NCT03926663 247 248 O

- NCT03926663 252 253 O
History NCT03926663 255 262 B-Eq-Comparison
of NCT03926663 263 265 O
renal NCT03926663 266 271 B-Modifier
or NCT03926663 272 274 B-Or
hepatic NCT03926663 275 282 B-Modifier
insufficiency NCT03926663 283 296 B-Condition

- NCT03926663 299 300 O
Endocrinal NCT03926663 302 312 B-Condition
Diseases NCT03926663 313 321 I-Condition

Inclusion NCT03924921 0 9 O
Criteria NCT03924921 10 18 O
: NCT03924921 19 20 O

- NCT03924921 24 25 O
Being NCT03924921 27 32 O
older NCT03924921 33 38 I-Eq-Comparison
than NCT03924921 39 43 I-Eq-Comparison
18 NCT03924921 44 46 I-Eq-Comparison
; NCT03924921 47 48 O

- NCT03924921 51 52 O
have NCT03924921 54 58 O
a NCT03924921 59 60 O
diagnosis NCT03924921 61 70 O
of NCT03924921 71 73 O
HIV NCT03924921 74 77 B-Condition
; NCT03924921 77 78 O

- NCT03924921 81 82 O
present NCT03924921 84 91 O
at NCT03924921 92 94 B-Eq-Comparison
least NCT03924921 95 100 I-Eq-Comparison
one NCT03924921 101 104 I-Eq-Comparison
of NCT03924921 105 107 O
the NCT03924921 108 111 B-Criteria-Count
following NCT03924921 112 121 I-Criteria-Count
symptoms NCT03924921 122 130 I-Criteria-Count
during NCT03924921 131 137 O
the NCT03924921 138 141 O
preceding NCT03924921 142 151 B-Eq-Comparison
two NCT03924921 152 155 I-Eq-Comparison
weeks NCT03924921 156 161 I-Eq-Comparison
: NCT03924921 162 163 O
sleep NCT03924921 164 169 B-Condition
problems NCT03924921 170 178 I-Condition
, NCT03924921 179 180 O
fatigue NCT03924921 181 188 B-Condition
, NCT03924921 189 190 O
pain NCT03924921 191 195 B-Condition
, NCT03924921 196 197 O
anxiety NCT03924921 198 205 B-Condition
or NCT03924921 206 208 B-Or
symptoms NCT03924921 209 217 B-Assertion___Assertion-Type-Value:possible
of NCT03924921 218 220 O
depression NCT03924921 221 231 B-Condition
; NCT03924921 231 232 O

- NCT03924921 235 236 O
understand NCT03924921 238 248 O
and NCT03924921 249 252 O
speak NCT03924921 253 258 O
French NCT03924921 259 265 O
and NCT03924921 266 269 O
; NCT03924921 269 270 O

- NCT03924921 273 274 O
be NCT03924921 276 278 O
able NCT03924921 279 283 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924921 284 286 I-Assertion___Assertion-Type-Value:hypothetical
follow NCT03924921 287 293 O
the NCT03924921 294 297 O
instructions NCT03924921 298 310 O
to NCT03924921 311 313 O
learn NCT03924921 314 319 O
the NCT03924921 320 323 O
relaxation NCT03924921 324 334 B-Procedure
technique NCT03924921 335 344 I-Procedure
. NCT03924921 345 346 O

Exclusion NCT03924921 348 357 O
Criteria NCT03924921 358 366 O
: NCT03924921 367 368 O

- NCT03924921 371 372 O

Inclusion NCT03928470 0 9 O
Criteria NCT03928470 10 18 O
: NCT03928470 19 20 O

1 NCT03928470 24 25 O
. NCT03928470 25 26 O
Male NCT03928470 28 32 O
or NCT03928470 33 35 B-Or
Female NCT03928470 36 42 O
aged NCT03928470 43 47 B-Age
≥ NCT03928470 48 49 B-Eq-Comparison
19 NCT03928470 50 52 I-Eq-Comparison
years NCT03928470 53 58 I-Eq-Comparison

2 NCT03928470 61 62 O
. NCT03928470 62 63 O
Episode NCT03928470 65 72 O
of NCT03928470 73 75 O
heartburn NCT03928470 76 85 B-Condition
for NCT03928470 86 89 O
3 NCT03928470 90 91 B-Eq-Comparison
months NCT03928470 92 98 I-Eq-Comparison
or NCT03928470 99 101 I-Eq-Comparison
more NCT03928470 102 106 I-Eq-Comparison
during NCT03928470 107 113 B-Temporal-Connection___Temporal-Connection-Type-Value:during
prior NCT03928470 114 119 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03928470 120 122 I-Temporal-Connection___Temporal-Connection-Type-Value:before
randomization NCT03928470 123 136 B-Study
visit NCT03928470 137 142 O
. NCT03928470 143 144 O

3 NCT03928470 148 149 O
. NCT03928470 149 150 O
Episode NCT03928470 152 159 O
of NCT03928470 160 162 O
heartburn NCT03928470 163 172 B-Condition
for NCT03928470 173 176 O
2 NCT03928470 177 178 B-Eq-Comparison
days NCT03928470 179 183 I-Eq-Comparison
or NCT03928470 184 186 I-Eq-Comparison
more NCT03928470 187 191 I-Eq-Comparison
during NCT03928470 192 198 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928470 199 202 O
last NCT03928470 203 207 B-Eq-Comparison
7 NCT03928470 208 209 I-Eq-Comparison
days NCT03928470 210 214 I-Eq-Comparison
prior NCT03928470 215 220 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03928470 221 223 I-Temporal-Connection___Temporal-Connection-Type-Value:before
randomization NCT03928470 224 237 B-Study
visit NCT03928470 238 243 O
. NCT03928470 244 245 O

4 NCT03928470 249 250 O
. NCT03928470 250 251 O
Grade NCT03928470 253 258 B-Eq-Comparison
N NCT03928470 259 260 I-Eq-Comparison
, NCT03928470 261 262 I-Eq-Comparison
M NCT03928470 263 264 I-Eq-Comparison
by NCT03928470 265 267 O
EGD NCT03928470 268 271 B-Procedure
test NCT03928470 272 276 I-Procedure
. NCT03928470 277 278 O

Exclusion NCT03928470 280 289 O
Criteria NCT03928470 290 298 O
: NCT03928470 299 300 O

1 NCT03928470 304 305 O
. NCT03928470 305 306 O
Surgery NCT03928470 308 315 B-Procedure
history NCT03928470 316 323 B-Eq-Comparison
on NCT03928470 324 326 O
stomach NCT03928470 327 334 B-Modifier
or NCT03928470 335 337 B-Or
esophagus NCT03928470 338 347 B-Modifier

2 NCT03928470 350 351 O
. NCT03928470 351 352 O
Active NCT03928470 354 360 B-Eq-Comparison
medical NCT03928470 361 368 O
history NCT03928470 369 376 O
of NCT03928470 377 379 O
stomach NCT03928470 380 387 B-Modifier
, NCT03928470 388 389 O
esophagus NCT03928470 390 399 B-Modifier
area NCT03928470 400 404 O

3 NCT03928470 407 408 O
. NCT03928470 408 409 O
Other NCT03928470 411 416 B-Other
system NCT03928470 417 423 B-Modifier
disorder NCT03928470 424 432 B-Condition
which NCT03928470 433 438 O
can NCT03928470 439 442 B-Assertion___Assertion-Type-Value:hypothetical
disturb NCT03928470 443 450 O
this NCT03928470 451 455 O
trial NCT03928470 456 461 B-Study

4 NCT03928470 464 465 O
. NCT03928470 465 466 O
Patients NCT03928470 468 476 O
taking NCT03928470 477 483 B-Eq-Comparison
the NCT03928470 484 487 O
contraindication NCT03928470 488 504 B-Contraindication
of NCT03928470 505 507 O
concomitant NCT03928470 508 519 B-Modifier
medications NCT03928470 520 531 B-Drug

5 NCT03928470 534 535 O
. NCT03928470 535 536 O
Clinically NCT03928470 538 548 O
significant NCT03928470 549 560 O
Abnormal NCT03928470 561 569 O
Lab NCT03928470 570 573 B-Observation
test NCT03928470 574 578 I-Observation

6 NCT03928470 581 582 O
. NCT03928470 582 583 O
Pregnant NCT03928470 585 593 B-Condition
woman NCT03928470 594 599 O
, NCT03928470 600 601 O
Breastfeeding NCT03928470 602 615 B-Condition
woman NCT03928470 616 621 O
. NCT03928470 621 622 O

Inclusion NCT03925168 0 9 O
Criteria NCT03925168 10 18 O
: NCT03925168 19 20 O

- NCT03925168 24 25 O
English NCT03925168 27 34 O
- NCT03925168 35 36 O
speaking NCT03925168 37 45 O
, NCT03925168 46 47 O
adult NCT03925168 48 53 O
( NCT03925168 54 55 O
21 NCT03925168 56 58 B-Eq-Comparison
+ NCT03925168 59 60 I-Eq-Comparison
) NCT03925168 62 63 O
hemodialysis NCT03925168 64 76 B-Procedure
patients NCT03925168 77 85 O
who NCT03925168 86 89 B-And
receive NCT03925168 90 97 B-Eq-Comparison
dialysis NCT03925168 98 106 B-Procedure
at NCT03925168 107 109 O
the NCT03925168 110 113 O
one NCT03925168 114 117 O
of NCT03925168 118 120 O
the NCT03925168 121 124 O
two NCT03925168 125 128 O
outpatient NCT03925168 129 139 O
dialysis NCT03925168 140 148 O
centers NCT03925168 149 156 O

Exclusion NCT03925168 157 166 O
Criteria NCT03925168 167 175 O
: NCT03925168 176 177 O

- NCT03925168 181 182 O
do NCT03925168 184 186 O
not NCT03925168 187 190 B-Negation
speak NCT03925168 191 196 O
English NCT03925168 197 204 O
, NCT03925168 205 206 O
deafness NCT03925168 207 215 B-Condition

Inclusion NCT03922607 0 9 O
Criteria NCT03922607 10 18 O
: NCT03922607 19 20 O

- NCT03922607 24 25 O
Volunteer NCT03922607 27 36 O
should NCT03922607 37 43 O
be NCT03922607 44 46 O
between NCT03922607 47 54 B-Eq-Comparison
18 NCT03922607 55 57 I-Eq-Comparison
and NCT03922607 58 61 I-Eq-Comparison
55 NCT03922607 62 64 I-Eq-Comparison
years NCT03922607 65 70 I-Eq-Comparison
of NCT03922607 71 73 O
age NCT03922607 74 77 B-Age
and NCT03922607 78 81 B-And
in NCT03922607 82 84 O
general NCT03922607 85 92 B-Condition
good NCT03922607 93 97 I-Condition
health NCT03922607 98 104 I-Condition
for NCT03922607 105 108 O
Substudy NCT03922607 109 117 O
1 NCT03922607 118 119 O
and NCT03922607 120 123 B-And
participant NCT03922607 124 135 O
with NCT03922607 136 140 O
moderate NCT03922607 141 149 B-Eq-Comparison
to NCT03922607 150 152 I-Eq-Comparison
severe NCT03922607 153 159 I-Eq-Comparison
chronic NCT03922607 160 167 B-Modifier
plaque NCT03922607 168 174 B-Condition
psoriasis NCT03922607 175 184 I-Condition
between NCT03922607 185 192 B-Eq-Comparison
18 NCT03922607 193 195 I-Eq-Comparison
and NCT03922607 196 199 I-Eq-Comparison
75 NCT03922607 200 202 I-Eq-Comparison
years NCT03922607 203 208 I-Eq-Comparison
of NCT03922607 209 211 O
age NCT03922607 212 215 B-Age
for NCT03922607 216 219 O
Substudy NCT03922607 220 228 O
2 NCT03922607 229 230 O
at NCT03922607 231 233 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03922607 234 237 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03922607 238 242 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03922607 243 245 O
enrollment NCT03922607 246 256 B-Study
. NCT03922607 257 258 O

- NCT03922607 262 263 O
Participant NCT03922607 265 276 O
should NCT03922607 277 283 O
meet NCT03922607 284 288 O
the NCT03922607 289 292 O
laboratory NCT03922607 293 303 O
assessments NCT03922607 304 315 O
as NCT03922607 316 318 O
mentioned NCT03922607 319 328 O
in NCT03922607 329 331 O
the NCT03922607 332 335 O
protocol NCT03922607 336 344 O
. NCT03922607 345 346 O

Exclusion NCT03922607 348 357 O
Criteria NCT03922607 358 366 O
: NCT03922607 367 368 O

- NCT03922607 372 373 O
Participant NCT03922607 375 386 O
has NCT03922607 387 390 O
a NCT03922607 391 392 O
history NCT03922607 393 400 B-Eq-Comparison
of NCT03922607 401 403 O
epilepsy NCT03922607 404 412 B-Condition
, NCT03922607 413 414 O
any NCT03922607 415 418 O
significant NCT03922607 419 430 O
cardiac NCT03922607 431 438 B-Modifier
, NCT03922607 439 440 O
respiratory NCT03922607 441 452 B-Modifier
, NCT03922607 453 454 O
renal NCT03922607 455 460 B-Modifier
, NCT03922607 461 462 O
hepatic NCT03922607 463 470 B-Modifier
, NCT03922607 471 472 O
gastrointestinal NCT03922607 473 489 B-Modifier
, NCT03922607 490 491 O
opthalmologic NCT03922607 492 505 B-Modifier
, NCT03922607 506 507 O
hematologic NCT03922607 508 519 B-Modifier
, NCT03922607 520 521 O
or NCT03922607 522 524 B-Or
psychiatric NCT03922607 525 536 B-Modifier
disease NCT03922607 537 544 B-Condition
or NCT03922607 545 547 B-Or
disorder NCT03922607 548 556 B-Condition
, NCT03922607 557 558 O
or NCT03922607 559 561 B-Or
any NCT03922607 562 565 O
uncontrolled NCT03922607 566 578 B-Modifier
medical NCT03922607 579 586 B-Condition
illness NCT03922607 587 594 I-Condition
. NCT03922607 594 595 O

Inclusion NCT03927794 0 9 O
Criteria NCT03927794 10 18 O
: NCT03927794 19 20 O

- NCT03927794 24 25 O
≥ NCT03927794 27 28 B-Eq-Comparison
1 NCT03927794 29 30 I-Eq-Comparison
Primary NCT03927794 31 38 B-Modifier
Anterior NCT03927794 39 47 I-Modifier
Teeth NCT03927794 48 53 I-Modifier
with NCT03927794 54 58 O
early NCT03927794 59 64 B-Modifier
carious NCT03927794 65 72 B-Condition
lesion NCT03927794 73 79 I-Condition
( NCT03927794 80 81 O
Class NCT03927794 82 87 B-Eq-Comparison
V NCT03927794 88 89 I-Eq-Comparison
) NCT03927794 90 91 O
of NCT03927794 92 94 B-And
ICDAS NCT03927794 95 100 B-Observation
scores NCT03927794 101 107 I-Observation
1 NCT03927794 108 109 B-Eq-Comparison
- NCT03927794 110 111 I-Eq-Comparison
2 NCT03927794 112 113 O
. NCT03927794 113 114 O

- NCT03927794 118 119 O
Subjects NCT03927794 121 129 O
whose NCT03927794 130 135 O
parents NCT03927794 136 143 O
are NCT03927794 144 147 O
willing NCT03927794 148 155 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03927794 156 159 I-Assertion___Assertion-Type-Value:hypothetical
able NCT03927794 160 164 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03927794 165 167 O
maintain NCT03927794 168 176 O
good NCT03927794 177 181 O
oral NCT03927794 182 186 B-Condition
hygiene NCT03927794 187 194 I-Condition
for NCT03927794 195 198 O
their NCT03927794 199 204 O
children NCT03927794 205 213 B-Family-Member___Family-Member-Type:child
and NCT03927794 214 217 B-And
attend NCT03927794 218 224 O
study NCT03927794 225 230 B-Study
visits NCT03927794 231 237 O
. NCT03927794 238 239 O

- NCT03927794 243 244 O
Subjects NCT03927794 246 254 O
with NCT03927794 255 259 O
Saliva NCT03927794 260 266 B-Observation
of NCT03927794 267 269 O
normal NCT03927794 270 276 O
flow NCT03927794 277 281 B-Modifier
rates NCT03927794 282 287 I-Modifier
( NCT03927794 288 289 O
30 NCT03927794 290 292 B-Eq-Comparison
- NCT03927794 293 294 I-Eq-Comparison
60 NCT03927794 295 297 I-Eq-Comparison
sec NCT03927794 298 301 I-Eq-Comparison
) NCT03927794 302 303 O
and NCT03927794 304 307 B-And
with NCT03927794 308 312 O
healthy NCT03927794 313 320 O
saliva NCT03927794 321 327 B-Observation
pH NCT03927794 328 330 I-Observation
6.75 NCT03927794 331 335 B-Eq-Comparison
- NCT03927794 336 337 I-Eq-Comparison
7.25 NCT03927794 338 342 I-Eq-Comparison
. NCT03927794 342 343 O

- NCT03927794 352 353 O
Patients NCT03927794 355 363 O
aged NCT03927794 364 368 B-Age
between NCT03927794 369 376 B-Eq-Comparison
3 NCT03927794 377 378 I-Eq-Comparison
- NCT03927794 379 380 I-Eq-Comparison
5 NCT03927794 381 382 I-Eq-Comparison
years NCT03927794 383 388 I-Eq-Comparison
. NCT03927794 389 390 O

- NCT03927794 394 395 O
Subjects NCT03927794 397 405 O
with NCT03927794 406 410 O
a NCT03927794 411 412 O
minimum NCT03927794 413 420 B-Eq-Comparison
of NCT03927794 421 423 I-Eq-Comparison
1 NCT03927794 424 425 I-Eq-Comparison
and NCT03927794 426 429 O
a NCT03927794 430 431 O
maximum NCT03927794 432 439 B-Eq-Comparison
of NCT03927794 440 442 I-Eq-Comparison
12 NCT03927794 443 445 I-Eq-Comparison
primary NCT03927794 446 453 B-Modifier
anterior NCT03927794 454 462 I-Modifier
teeth NCT03927794 463 468 I-Modifier
with NCT03927794 469 473 O
early NCT03927794 474 479 B-Modifier
carious NCT03927794 480 487 B-Condition
lesions NCT03927794 488 495 I-Condition
Class NCT03927794 496 501 B-Eq-Comparison
V NCT03927794 502 503 I-Eq-Comparison
of NCT03927794 504 506 B-And
ICDAS NCT03927794 507 512 B-Observation
score NCT03927794 513 518 I-Observation
1 NCT03927794 519 520 B-Eq-Comparison
- NCT03927794 521 522 I-Eq-Comparison
2 NCT03927794 523 524 O
. NCT03927794 524 525 O

Exclusion NCT03927794 527 536 O
Criteria NCT03927794 537 545 O
: NCT03927794 546 547 O

- NCT03927794 551 552 O
Primary NCT03927794 554 561 B-Modifier
anterior NCT03927794 562 570 I-Modifier
teeth NCT03927794 571 576 I-Modifier
in NCT03927794 577 579 O
which NCT03927794 580 585 O
carious NCT03927794 586 593 B-Condition
lesions NCT03927794 594 601 I-Condition
are NCT03927794 602 605 O
scored NCT03927794 606 612 O
with NCT03927794 613 617 B-And
ICDAS NCT03927794 618 623 B-Observation
≥ NCT03927794 624 625 B-Eq-Comparison
3 NCT03927794 626 627 I-Eq-Comparison
. NCT03927794 627 628 O

- NCT03927794 632 633 O
Subjects NCT03927794 635 643 O
on NCT03927794 644 646 B-Eq-Comparison
medication NCT03927794 647 657 B-Drug
that NCT03927794 658 662 O
affects NCT03927794 663 670 O
the NCT03927794 671 674 O
salivary NCT03927794 675 683 B-Observation
flow NCT03927794 684 688 I-Observation
rate NCT03927794 689 693 I-Observation
. NCT03927794 694 695 O

- NCT03927794 699 700 O
Subjects NCT03927794 702 710 O
with NCT03927794 711 715 O
evidence NCT03927794 716 724 O
of NCT03927794 725 727 O
reduced NCT03927794 728 735 O
salivary NCT03927794 736 744 B-Observation
flow NCT03927794 745 749 I-Observation
( NCT03927794 750 751 O
> NCT03927794 753 754 B-Eq-Comparison
60 NCT03927794 755 757 I-Eq-Comparison
sec NCT03927794 758 761 I-Eq-Comparison
) NCT03927794 762 763 O
or NCT03927794 764 766 B-Or
with NCT03927794 767 771 O
acidic NCT03927794 772 778 B-Modifier
saliva NCT03927794 779 785 B-Observation
pH NCT03927794 786 788 I-Observation
˂ NCT03927794 789 790 B-Eq-Comparison
5.8 NCT03927794 791 794 I-Eq-Comparison
. NCT03927794 794 795 O


Inclusion NCT03924505 0 9 O
Criteria NCT03924505 10 18 O
: NCT03924505 19 20 O

- NCT03924505 24 25 O
SSPs NCT03924505 27 31 B-Condition
that NCT03924505 32 36 O
participate NCT03924505 37 48 O
in NCT03924505 49 51 O
the NCT03924505 52 55 O
on NCT03924505 56 58 O
- NCT03924505 59 60 O
line NCT03924505 61 65 O
screening NCT03924505 66 75 B-Study
survey NCT03924505 76 82 O
and NCT03924505 83 86 B-And
fall NCT03924505 87 91 O
into NCT03924505 92 96 O
the NCT03924505 97 100 O
implementation NCT03924505 101 115 B-Modifier
phase NCT03924505 116 121 I-Modifier
of NCT03924505 122 124 O
the NCT03924505 125 128 O
EPIS NCT03924505 129 133 B-Condition
continuum NCT03924505 134 143 I-Condition
will NCT03924505 144 148 O
be NCT03924505 149 151 O
recruited NCT03924505 152 161 O
into NCT03924505 162 166 O
the NCT03924505 167 170 O
study NCT03924505 171 176 O
. NCT03924505 177 178 O

Exclusion NCT03924505 180 189 O
Criteria NCT03924505 190 198 O
: NCT03924505 199 200 O

- NCT03924505 203 204 O

Inclusion NCT03926312 0 9 O
Criteria NCT03926312 10 18 O
: NCT03926312 19 20 O

1 NCT03926312 24 25 O
. NCT03926312 25 26 O
Signed NCT03926312 28 34 O
informed NCT03926312 35 43 O
consent NCT03926312 44 51 O
with NCT03926312 52 56 O
the NCT03926312 57 60 O
study NCT03926312 61 66 O

2 NCT03926312 69 70 O
. NCT03926312 70 71 O
Men NCT03926312 73 76 O
and NCT03926312 77 80 B-Or
women NCT03926312 81 86 O
> NCT03926312 87 88 B-Eq-Comparison
18 NCT03926312 89 91 I-Eq-Comparison
years NCT03926312 92 97 I-Eq-Comparison
of NCT03926312 98 100 O
age NCT03926312 101 104 B-Age

3 NCT03926312 107 108 O
. NCT03926312 108 109 O
Patients NCT03926312 111 119 O
≥ NCT03926312 120 121 B-Eq-Comparison
1 NCT03926312 122 123 I-Eq-Comparison
and NCT03926312 124 127 B-And
≤ NCT03926312 128 129 B-Eq-Comparison
6 NCT03926312 130 131 I-Eq-Comparison
months NCT03926312 132 138 I-Eq-Comparison
after NCT03926312 139 144 B-Temporal-Connection___Temporal-Connection-Type-Value:after
type NCT03926312 145 149 B-Eq-Comparison
I NCT03926312 150 151 I-Eq-Comparison
myocardial NCT03926312 152 162 B-Condition
infarction NCT03926312 163 173 I-Condition

4 NCT03926312 176 177 O
. NCT03926312 177 178 O
Physical NCT03926312 180 188 B-Condition
inactivity NCT03926312 189 199 I-Condition
before NCT03926312 200 206 B-Temporal-Connection___Temporal-Connection-Type-Value:before
MI NCT03926312 207 209 B-Condition
defined NCT03926312 210 217 O
as NCT03926312 218 220 O
the NCT03926312 221 224 O
absence NCT03926312 225 232 B-Negation
of NCT03926312 233 235 O
moderate NCT03926312 236 244 B-Eq-Comparison
to NCT03926312 245 247 I-Eq-Comparison
vigorous NCT03926312 248 256 I-Eq-Comparison
exercise NCT03926312 257 265 B-Observation
for NCT03926312 266 269 O
at NCT03926312 270 272 B-Eq-Comparison
least NCT03926312 273 278 I-Eq-Comparison
30 NCT03926312 279 281 I-Eq-Comparison
minutes NCT03926312 282 289 I-Eq-Comparison
5 NCT03926312 290 291 B-Eq-Comparison
or NCT03926312 292 294 I-Eq-Comparison
more NCT03926312 295 299 I-Eq-Comparison
days NCT03926312 300 304 I-Eq-Comparison
a NCT03926312 305 306 I-Eq-Comparison
week NCT03926312 307 311 I-Eq-Comparison

Exclusion NCT03926312 312 321 O
Criteria NCT03926312 322 330 O
: NCT03926312 331 332 O

1 NCT03926312 336 337 O
. NCT03926312 337 338 O
Heart NCT03926312 340 345 B-Condition
failure NCT03926312 346 353 I-Condition
NYHA NCT03926312 354 358 B-Condition
IIIB NCT03926312 359 363 B-Eq-Comparison
- NCT03926312 364 365 I-Eq-Comparison
IV NCT03926312 366 368 I-Eq-Comparison

2 NCT03926312 371 372 O
. NCT03926312 372 373 O
Planned NCT03926312 375 382 B-Eq-Comparison
coronary NCT03926312 383 391 B-Procedure
revascularization NCT03926312 392 409 I-Procedure

3 NCT03926312 412 413 O
. NCT03926312 413 414 O
Planned NCT03926312 416 423 B-Eq-Comparison
major NCT03926312 424 429 O
surgery NCT03926312 430 437 B-Procedure
within NCT03926312 438 444 B-Eq-Comparison
the NCT03926312 445 448 I-Eq-Comparison
next NCT03926312 449 453 I-Eq-Comparison
12 NCT03926312 454 456 I-Eq-Comparison
months NCT03926312 457 463 I-Eq-Comparison

4 NCT03926312 466 467 O
. NCT03926312 467 468 O
Inability NCT03926312 470 479 B-Condition
to NCT03926312 480 482 I-Condition
walk NCT03926312 483 487 I-Condition
for NCT03926312 488 491 O
any NCT03926312 492 495 O
reason NCT03926312 496 502 O

5 NCT03926312 505 506 O
. NCT03926312 506 507 O
Comorbidities NCT03926312 509 522 B-Condition
that NCT03926312 523 527 O
would NCT03926312 528 533 B-Assertion___Assertion-Type-Value:hypothetical
preclude NCT03926312 534 542 O
adherence NCT03926312 543 552 O
to NCT03926312 553 555 O
the NCT03926312 556 559 O
rehabilitation NCT03926312 560 574 B-Procedure
program NCT03926312 575 582 I-Procedure
( NCT03926312 583 584 O
e. NCT03926312 585 587 O
g. NCT03926312 588 590 O
arthrosis NCT03926312 592 601 B-Condition
, NCT03926312 602 603 O
active NCT03926312 604 610 B-Eq-Comparison
malignancy NCT03926312 611 621 B-Condition
, NCT03926312 622 623 O
major NCT03926312 624 629 B-Condition
depression NCT03926312 630 640 I-Condition
or NCT03926312 641 643 O
other NCT03926312 644 649 B-Other
significant NCT03926312 650 661 O
psychiatric NCT03926312 662 673 B-Condition
disorder NCT03926312 674 682 I-Condition
, NCT03926312 683 684 O
cognitive NCT03926312 685 694 B-Condition
impairment NCT03926312 695 705 I-Condition
) NCT03926312 706 707 O
- NCT03926312 708 709 O
at NCT03926312 710 712 O
the NCT03926312 713 716 O
discretion NCT03926312 717 727 O
of NCT03926312 728 730 O
the NCT03926312 731 734 O
physician NCT03926312 735 744 O

6 NCT03926312 747 748 O
. NCT03926312 748 749 O
Life NCT03926312 751 755 B-Observation
expectancy NCT03926312 756 766 I-Observation
less NCT03926312 767 771 B-Eq-Comparison
than NCT03926312 772 776 I-Eq-Comparison
12 NCT03926312 777 779 I-Eq-Comparison
months NCT03926312 780 786 I-Eq-Comparison

7 NCT03926312 789 790 O
. NCT03926312 790 791 O
Pregnancy NCT03926312 793 802 B-Condition

8 NCT03926312 805 806 O
. NCT03926312 806 807 O
Inability NCT03926312 809 818 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03926312 819 821 O
operate NCT03926312 822 829 B-Observation
the NCT03926312 830 833 I-Observation
smart NCT03926312 834 839 I-Observation
- NCT03926312 840 841 I-Observation
watch NCT03926312 842 847 I-Observation

Inclusion NCT03927742 0 9 O
Criteria NCT03927742 10 18 O
: NCT03927742 19 20 O

- NCT03927742 24 25 O
18 NCT03927742 27 29 B-Eq-Comparison
- NCT03927742 30 31 I-Eq-Comparison
75 NCT03927742 32 34 I-Eq-Comparison
years NCT03927742 35 40 I-Eq-Comparison
old NCT03927742 41 44 B-Age

- NCT03927742 47 48 O
Diagnosed NCT03927742 50 59 O
with NCT03927742 60 64 O
cutaneous NCT03927742 65 74 B-Condition
invasive NCT03927742 75 83 I-Condition
melanoma NCT03927742 84 92 I-Condition
within NCT03927742 93 99 O
HealthPartners NCT03927742 100 114 O
system NCT03927742 115 121 O
since NCT03927742 122 127 B-Eq-Comparison
2010 NCT03927742 128 132 I-Eq-Comparison

- NCT03927742 136 137 O
Able NCT03927742 139 143 O
to NCT03927742 144 146 O
read NCT03927742 147 151 O
/ NCT03927742 152 153 O
write NCT03927742 154 159 O
in NCT03927742 160 162 O
English NCT03927742 163 170 O

- NCT03927742 173 174 O
Own NCT03927742 176 179 O
a NCT03927742 180 181 O
smartphone NCT03927742 182 192 O

- NCT03927742 195 196 O
Able NCT03927742 198 202 O
to NCT03927742 203 205 O
provide NCT03927742 206 213 O
voluntary NCT03927742 214 223 O
informed NCT03927742 224 232 O
consent NCT03927742 233 240 O

Exclusion NCT03927742 241 250 O
Criteria NCT03927742 251 259 O
: NCT03927742 260 261 O

- NCT03927742 265 266 O
Inability NCT03927742 268 277 O
to NCT03927742 278 280 O
provide NCT03927742 281 288 O
informed NCT03927742 289 297 O
written NCT03927742 298 305 O
consent NCT03927742 306 313 O

- NCT03927742 316 317 O
Pregnancy NCT03927742 319 328 B-Condition

Inclusion NCT03925155 0 9 O
Criteria NCT03925155 10 18 O
: NCT03925155 19 20 O

- NCT03925155 24 25 O
Females NCT03925155 27 34 O
aged NCT03925155 35 39 B-Age
18 NCT03925155 40 42 B-Eq-Comparison
- NCT03925155 43 44 I-Eq-Comparison
50 NCT03925155 45 47 I-Eq-Comparison
years NCT03925155 48 53 I-Eq-Comparison

- NCT03925155 56 57 O
The NCT03925155 59 62 O
study NCT03925155 63 68 O
will NCT03925155 69 73 O
be NCT03925155 74 76 O
offered NCT03925155 77 84 O
to NCT03925155 85 87 O
women NCT03925155 88 93 O
at NCT03925155 94 96 B-And
> NCT03925155 97 98 B-Eq-Comparison
24 NCT03925155 99 101 I-Eq-Comparison
weeks NCT03925155 102 107 I-Eq-Comparison
gestation NCT03925155 108 117 B-Observation
who NCT03925155 118 121 B-And
are NCT03925155 122 125 O
undergoing NCT03925155 126 136 B-Eq-Comparison
nonemergent NCT03925155 137 148 B-Modifier
cesarean NCT03925155 149 157 B-Procedure
delivery NCT03925155 158 166 I-Procedure
with NCT03925155 167 171 B-And
ruptured NCT03925155 172 180 B-Condition
amniotic NCT03925155 181 189 I-Condition
membranes NCT03925155 190 199 I-Condition
. NCT03925155 200 201 O

- NCT03925155 205 206 O
All NCT03925155 208 211 O
patients NCT03925155 212 220 O
undergoing NCT03925155 221 231 B-Eq-Comparison
cesarean NCT03925155 232 240 B-Procedure
delivery NCT03925155 241 249 I-Procedure
with NCT03925155 250 254 B-And
ruptured NCT03925155 255 263 B-Condition
amniotic NCT03925155 264 272 I-Condition
membranes NCT03925155 273 282 I-Condition
. NCT03925155 283 284 O

Exclusion NCT03925155 286 295 O
Criteria NCT03925155 296 304 O
: NCT03925155 305 306 O

- NCT03925155 310 311 O
Minors NCT03925155 313 319 O

- NCT03925155 322 323 O
Emergent NCT03925155 325 333 B-Modifier
cesarean NCT03925155 334 342 B-Procedure
delivery NCT03925155 343 351 I-Procedure
. NCT03925155 352 353 O

- NCT03925155 357 358 O
No NCT03925155 360 362 B-Negation
ruptured NCT03925155 363 371 B-Condition
membranes NCT03925155 372 381 I-Condition
. NCT03925155 382 383 O

- NCT03925155 387 388 O
Allergy NCT03925155 390 397 B-Allergy
to NCT03925155 398 400 O
chlorhexidine NCT03925155 401 414 B-Drug
or NCT03925155 415 417 B-Or
povidone NCT03925155 418 426 B-Drug
- NCT03925155 427 428 I-Drug
iodine NCT03925155 429 435 I-Drug
. NCT03925155 435 436 O

Inclusion NCT03929380 0 9 O
Criteria NCT03929380 10 18 O
: NCT03929380 19 20 O

- NCT03929380 24 25 O
Males NCT03929380 27 32 O
, NCT03929380 33 34 O
with NCT03929380 35 39 B-And
at NCT03929380 40 42 B-Eq-Comparison
least NCT03929380 43 48 I-Eq-Comparison
a NCT03929380 49 50 I-Eq-Comparison
year NCT03929380 51 55 I-Eq-Comparison
of NCT03929380 56 58 O
experience NCT03929380 59 69 O
in NCT03929380 70 72 O
heavylift NCT03929380 73 82 B-Modifier
exercises NCT03929380 83 92 B-Observation
, NCT03929380 93 94 O
age NCT03929380 95 98 B-Age
between NCT03929380 99 106 B-Eq-Comparison
20 NCT03929380 107 109 I-Eq-Comparison
and NCT03929380 110 113 I-Eq-Comparison
35 NCT03929380 114 116 I-Eq-Comparison
years NCT03929380 117 122 I-Eq-Comparison
. NCT03929380 123 124 O

Exclusion NCT03929380 126 135 O
Criteria NCT03929380 136 144 O
: NCT03929380 145 146 O

- NCT03929380 150 151 O


Inclusion NCT03921086 0 9 O
Criteria NCT03921086 10 18 O
: NCT03921086 19 20 O

- NCT03921086 24 25 O
Adult NCT03921086 27 32 O
( NCT03921086 33 34 O
older NCT03921086 35 40 I-Eq-Comparison
than NCT03921086 41 45 I-Eq-Comparison
18 NCT03921086 46 48 I-Eq-Comparison
years NCT03921086 49 54 I-Eq-Comparison
) NCT03921086 55 56 O

- NCT03921086 60 61 O
Elective NCT03921086 63 71 B-Modifier
surgery NCT03921086 72 79 B-Procedure
at NCT03921086 80 82 B-Temporal-Connection___Temporal-Connection-Type-Value:during
pre NCT03921086 83 86 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03921086 87 96 B-Procedure
in NCT03921086 97 99 B-Encounter
- NCT03921086 100 101 I-Encounter
hospital NCT03921086 102 110 I-Encounter
visit NCT03921086 111 116 I-Encounter

- NCT03921086 119 120 O
All NCT03921086 122 125 O
stage NCT03921086 126 131 O
1 NCT03921086 132 133 B-Eq-Comparison
and NCT03921086 134 137 I-Eq-Comparison
stage NCT03921086 138 143 I-Eq-Comparison
2 NCT03921086 144 145 I-Eq-Comparison
hypertensive NCT03921086 146 158 B-Condition
patients NCT03921086 159 167 O
as NCT03921086 168 170 O
defined NCT03921086 171 178 O
by NCT03921086 179 181 O
the NCT03921086 182 185 O
South NCT03921086 186 191 O
African NCT03921086 192 199 O
Hypertension NCT03921086 200 212 O
Practice NCT03921086 213 221 O
Guideline NCT03921086 222 231 O
2014 NCT03921086 232 236 O

Exclusion NCT03921086 238 247 O
Criteria NCT03921086 248 256 O
: NCT03921086 257 258 O

- NCT03921086 262 263 O
Patient NCT03921086 265 272 O
refusal NCT03921086 273 280 O

- NCT03921086 283 284 O
Day NCT03921086 286 289 B-Modifier
case NCT03921086 290 294 I-Modifier
surgery NCT03921086 295 302 B-Procedure

- NCT03921086 305 306 O
Obstetric NCT03921086 308 317 B-Modifier
and NCT03921086 318 321 B-Or
cardiac NCT03921086 322 329 B-Modifier
surgery NCT03921086 330 337 B-Procedure

- NCT03921086 340 341 O
Patients NCT03921086 343 351 O
with NCT03921086 352 356 O
severe NCT03921086 357 363 O
hypertension NCT03921086 364 376 B-Condition|Observation
( NCT03921086 377 378 O
> NCT03921086 380 381 B-Eq-Comparison
180 NCT03921086 382 385 I-Eq-Comparison
/ NCT03921086 386 387 I-Eq-Comparison
110 NCT03921086 388 391 I-Eq-Comparison
mmHg NCT03921086 392 396 I-Eq-Comparison
) NCT03921086 397 398 O
as NCT03921086 399 401 O
defined NCT03921086 402 409 O
by NCT03921086 410 412 O
the NCT03921086 413 416 O
South NCT03921086 417 422 O
African NCT03921086 423 430 O
Hypertension NCT03921086 431 443 O
Practice NCT03921086 444 452 O
Guideline NCT03921086 453 462 O
2014 NCT03921086 463 467 O

Inclusion NCT03927391 0 9 O
Criteria NCT03927391 10 18 O
: NCT03927391 19 20 O

- NCT03927391 24 25 O
Frailᵃ NCT03927391 27 33 O
male NCT03927391 34 38 O
patients NCT03927391 39 47 O
with NCT03927391 48 52 B-And
prostate NCT03927391 53 61 B-Modifier
cancer NCT03927391 62 68 B-Condition
who NCT03927391 69 72 B-And
will NCT03927391 73 77 B-Eq-Comparison
start NCT03927391 78 83 B-Eq-Comparison
treatment NCT03927391 84 93 B-Procedure
with NCT03927391 94 98 O
enzalutamide NCT03927391 99 111 B-Drug
within NCT03927391 112 118 B-Modifier
label NCT03927391 119 124 I-Modifier

- NCT03927391 127 128 O
Age NCT03927391 130 133 B-Age
at NCT03927391 134 136 B-Eq-Comparison
least NCT03927391 137 142 I-Eq-Comparison
18 NCT03927391 143 145 I-Eq-Comparison
years NCT03927391 146 151 I-Eq-Comparison

- NCT03927391 154 155 O
Patient NCT03927391 157 164 O
who NCT03927391 165 168 O
are NCT03927391 169 172 O
able NCT03927391 173 177 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03927391 178 181 I-Assertion___Assertion-Type-Value:hypothetical
willing NCT03927391 182 189 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03927391 190 192 O
give NCT03927391 193 197 O
written NCT03927391 198 205 O
informed NCT03927391 206 214 O
consent NCT03927391 215 222 O
prior NCT03927391 223 228 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03927391 229 231 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03927391 232 241 B-Study

- NCT03927391 244 245 O
Patients NCT03927391 247 255 O
from NCT03927391 256 260 O
whom NCT03927391 261 265 O
it NCT03927391 266 268 O
is NCT03927391 269 271 O
possible NCT03927391 272 280 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03927391 281 283 I-Assertion___Assertion-Type-Value:hypothetical
collect NCT03927391 284 291 I-Assertion___Assertion-Type-Value:hypothetical
blood NCT03927391 292 297 B-Observation
samples NCT03927391 298 305 I-Observation

- NCT03927391 308 309 O
Patients NCT03927391 311 319 O
who NCT03927391 320 323 O
are NCT03927391 324 327 O
willing NCT03927391 328 335 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03927391 336 338 I-Assertion___Assertion-Type-Value:hypothetical
answer NCT03927391 339 345 O
the NCT03927391 346 349 O
questionnaires NCT03927391 350 364 B-Observation
and NCT03927391 365 368 B-And
test NCT03927391 369 373 B-Observation

- NCT03927391 376 377 O
Life NCT03927391 379 383 B-Observation
expectancy NCT03927391 384 394 I-Observation
of NCT03927391 395 397 O
> NCT03927391 398 399 B-Eq-Comparison
6 NCT03927391 400 401 I-Eq-Comparison
months NCT03927391 402 408 I-Eq-Comparison

- NCT03927391 411 412 O
Capable NCT03927391 414 421 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03927391 422 424 I-Assertion___Assertion-Type-Value:hypothetical
understanding NCT03927391 425 438 O
and NCT03927391 439 442 O
answering NCT03927391 443 452 O
Dutch NCT03927391 453 458 O
tests NCT03927391 459 464 B-Observation
and NCT03927391 465 468 B-And
questionnaires NCT03927391 469 483 B-Observation
, NCT03927391 484 485 O
as NCT03927391 486 488 O
determined NCT03927391 489 499 O
by NCT03927391 500 502 O
the NCT03927391 503 506 O
investigator NCT03927391 507 519 O

ᵃ NCT03927391 520 521 O
Frail NCT03927391 522 527 B-Condition
is NCT03927391 528 530 O
defined NCT03927391 531 538 O
as NCT03927391 539 541 O
: NCT03927391 542 543 O

- NCT03927391 547 548 O
a NCT03927391 550 551 O
score NCT03927391 552 557 O
on NCT03927391 558 560 O
the NCT03927391 561 564 O
comprehensive NCT03927391 565 578 O
G8 NCT03927391 579 581 B-Observation
assessment NCT03927391 582 592 I-Observation
with NCT03927391 593 597 O
cut NCT03927391 598 601 O
- NCT03927391 602 603 O
off NCT03927391 604 607 O
≤ NCT03927391 608 609 B-Eq-Comparison
14 NCT03927391 610 612 I-Eq-Comparison
points NCT03927391 613 619 O
and NCT03927391 620 623 O

- NCT03927391 626 627 O
score NCT03927391 629 634 O
≥ NCT03927391 635 636 B-Eq-Comparison
grade NCT03927391 637 642 I-Eq-Comparison
1 NCT03927391 643 644 I-Eq-Comparison
for NCT03927391 645 648 O
Central NCT03927391 649 656 B-Condition
Nervous NCT03927391 657 664 I-Condition
Disorders NCT03927391 665 674 I-Condition
according NCT03927391 675 684 O
to NCT03927391 685 687 O
the NCT03927391 688 691 O
Common NCT03927391 692 698 O
Toxicity NCT03927391 699 707 O
Criteria NCT03927391 708 716 O
Adverse NCT03927391 717 724 O
Event NCT03927391 725 730 O
( NCT03927391 731 732 O
CTCAE NCT03927391 733 738 O
) NCT03927391 739 740 O
criteria NCT03927391 741 749 O
, NCT03927391 750 751 O
of NCT03927391 752 754 O
one NCT03927391 755 758 B-Eq-Comparison
of NCT03927391 759 761 O
the NCT03927391 762 765 B-Criteria-Count
following NCT03927391 766 775 I-Criteria-Count
: NCT03927391 776 777 O
Fatigue NCT03927391 778 785 B-Condition
, NCT03927391 786 787 O
Concentration NCT03927391 788 801 B-Condition
impairment NCT03927391 802 812 I-Condition
, NCT03927391 813 814 O
cognitive NCT03927391 815 824 B-Condition
disturbance NCT03927391 825 836 I-Condition
, NCT03927391 837 838 O
amnesia NCT03927391 839 846 B-Condition
, NCT03927391 847 848 O
depressed NCT03927391 849 858 B-Condition
level NCT03927391 859 864 I-Condition
of NCT03927391 865 867 I-Condition
consciousness NCT03927391 868 881 I-Condition
, NCT03927391 882 883 O
memory NCT03927391 884 890 B-Condition
impairment NCT03927391 891 901 I-Condition
, NCT03927391 902 903 O
hypersomnia NCT03927391 904 915 B-Condition
. NCT03927391 916 917 O

Exclusion NCT03927391 919 928 O
Criteria NCT03927391 929 937 O
: NCT03927391 938 939 O

- NCT03927391 943 944 O
change NCT03927391 946 952 O
in NCT03927391 953 955 O
dose NCT03927391 956 960 O
of NCT03927391 961 963 O
opioids NCT03927391 964 971 B-Drug
/ NCT03927391 972 973 B-Or
sedatives NCT03927391 974 983 B-Drug
/ NCT03927391 984 985 B-Or
benzodiazepines NCT03927391 986 1001 B-Drug
during NCT03927391 1002 1008 B-Temporal-Connection___Temporal-Connection-Type-Value:during
last NCT03927391 1009 1013 B-Eq-Comparison
2 NCT03927391 1014 1015 I-Eq-Comparison
weeks NCT03927391 1016 1021 I-Eq-Comparison
before NCT03927391 1022 1028 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03927391 1029 1034 B-Study
) NCT03927391 1035 1036 O

- NCT03927391 1040 1041 O
Use NCT03927391 1043 1046 O
of NCT03927391 1047 1049 O
psychostimulants NCT03927391 1050 1066 B-Drug
such NCT03927391 1067 1071 O
as NCT03927391 1072 1074 O
methylphenidate NCT03927391 1075 1090 B-Drug
within NCT03927391 1091 1097 B-Eq-Comparison
1 NCT03927391 1098 1099 I-Eq-Comparison
week NCT03927391 1100 1104 I-Eq-Comparison
of NCT03927391 1105 1107 B-Temporal-Connection___Temporal-Connection-Type-Value:before
start NCT03927391 1108 1113 B-Eq-Comparison
of NCT03927391 1114 1116 O
study NCT03927391 1117 1122 B-Study

- NCT03927391 1125 1126 O
Diagnosed NCT03927391 1128 1137 O
with NCT03927391 1138 1142 O
medical NCT03927391 1143 1150 B-Condition
conditions NCT03927391 1151 1161 I-Condition
that NCT03927391 1162 1166 O
affect NCT03927391 1167 1173 O
cognition NCT03927391 1174 1183 B-Condition
: NCT03927391 1184 1185 O
Dementia NCT03927391 1186 1194 B-Condition
, NCT03927391 1195 1196 O
Alzheimer NCT03927391 1197 1206 B-Condition
disease NCT03927391 1207 1214 I-Condition
, NCT03927391 1215 1216 O
Parkinson NCT03927391 1217 1226 B-Condition
's NCT03927391 1226 1228 I-Condition
disease NCT03927391 1229 1236 I-Condition
, NCT03927391 1237 1238 O
psychiatric NCT03927391 1239 1250 B-Condition
disorders NCT03927391 1251 1260 I-Condition
that NCT03927391 1261 1265 O
affect NCT03927391 1266 1272 O
cognition NCT03927391 1273 1282 B-Condition
other NCT03927391 1283 1288 B-Exception
than NCT03927391 1289 1293 I-Exception
depression NCT03927391 1294 1304 B-Condition
or NCT03927391 1305 1307 B-Or
anxiety NCT03927391 1308 1315 B-Condition
complaints NCT03927391 1316 1326 O
related NCT03927391 1327 1334 O
to NCT03927391 1335 1337 O
the NCT03927391 1338 1341 B-Coreference
disease NCT03927391 1342 1349 I-Coreference

- NCT03927391 1352 1353 O
Active NCT03927391 1355 1361 B-Eq-Comparison
infection NCT03927391 1362 1371 B-Condition
or NCT03927391 1372 1374 B-Or
other NCT03927391 1375 1380 B-Other
comorbidities NCT03927391 1381 1394 B-Condition
that NCT03927391 1395 1399 O
may NCT03927391 1400 1403 O
contribute NCT03927391 1404 1414 O
to NCT03927391 1415 1417 O
REDOSE NCT03927391 1418 1424 O
, NCT03927391 1425 1426 O
February NCT03927391 1427 1435 O
2019 NCT03927391 1436 1440 O
Page NCT03927391 1441 1445 O
7 NCT03927391 1446 1447 O
of NCT03927391 1448 1450 O
53 NCT03927391 1451 1453 O
fatigue NCT03927391 1454 1461 B-Condition
or NCT03927391 1462 1464 B-Or
cognition NCT03927391 1465 1474 B-Condition
change NCT03927391 1475 1481 O
within NCT03927391 1482 1488 B-Eq-Comparison
4 NCT03927391 1489 1490 I-Eq-Comparison
weeks NCT03927391 1491 1496 I-Eq-Comparison
of NCT03927391 1497 1499 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03927391 1500 1505 B-Study
entry NCT03927391 1506 1511 O

- NCT03927391 1514 1515 O
Clinical NCT03927391 1517 1525 O
relevant NCT03927391 1526 1534 O
anaemia NCT03927391 1535 1542 B-Condition

- NCT03927391 1545 1546 O
MoCa NCT03927391 1548 1552 B-Observation
score NCT03927391 1553 1558 I-Observation
< NCT03927391 1559 1560 B-Eq-Comparison
20 NCT03927391 1561 1563 I-Eq-Comparison

- NCT03927391 1567 1568 O
Hypersensitivity NCT03927391 1570 1586 B-Condition
to NCT03927391 1587 1589 O
the NCT03927391 1590 1593 O
active NCT03927391 1594 1600 B-Drug
substance NCT03927391 1601 1610 I-Drug
or NCT03927391 1611 1613 B-Or
to NCT03927391 1614 1616 O
any NCT03927391 1617 1620 B-Modifier
of NCT03927391 1621 1623 I-Modifier
the NCT03927391 1624 1627 I-Modifier
excipients NCT03927391 1628 1638 I-Modifier
. NCT03927391 1638 1639 O

Inclusion NCT03924115 0 9 O
Criteria NCT03924115 10 18 O
: NCT03924115 19 20 O

- NCT03924115 24 25 O
People NCT03924115 27 33 O
under NCT03924115 34 39 B-Eq-Comparison
treatment NCT03924115 40 49 B-Procedure
for NCT03924115 50 53 O
hypertension NCT03924115 54 66 B-Condition

- NCT03924115 69 70 O
Both NCT03924115 72 76 O
sexes NCT03924115 77 82 O

- NCT03924115 85 86 O
Older NCT03924115 88 93 I-Eq-Comparison
than NCT03924115 94 98 I-Eq-Comparison
60 NCT03924115 99 101 I-Eq-Comparison
years NCT03924115 102 107 I-Eq-Comparison

- NCT03924115 110 111 O
Autovalent NCT03924115 113 123 B-Condition

- NCT03924115 126 127 O
read NCT03924115 129 133 O
and NCT03924115 134 137 O
write NCT03924115 138 143 O

Exclusion NCT03924115 144 153 O
Criteria NCT03924115 154 162 O
: NCT03924115 163 164 O

- NCT03924115 168 169 O
Under NCT03924115 171 176 B-Eq-Comparison
treatment NCT03924115 177 186 B-Procedure
for NCT03924115 187 190 O
severe NCT03924115 191 197 O
psychiatric NCT03924115 198 209 B-Condition
pathology NCT03924115 210 219 I-Condition

- NCT03924115 222 223 O
Mental NCT03924115 225 231 B-Condition
retardation NCT03924115 232 243 I-Condition
. NCT03924115 243 244 O

Inclusion NCT03926702 0 9 O
Criteria NCT03926702 10 18 O
: NCT03926702 19 20 O

- NCT03926702 24 25 O
Healthy NCT03926702 27 34 O
Volunteers NCT03926702 35 45 O
: NCT03926702 46 47 O
Subjects NCT03926702 48 56 O
must NCT03926702 57 61 O
be NCT03926702 62 64 O
aged NCT03926702 65 69 B-Age
50 NCT03926702 70 72 B-Eq-Comparison
and NCT03926702 73 76 I-Eq-Comparison
over NCT03926702 77 81 I-Eq-Comparison
. NCT03926702 81 82 O
These NCT03926702 84 89 O
individuals NCT03926702 90 101 O
will NCT03926702 102 106 O
all NCT03926702 107 110 O
be NCT03926702 111 113 O
of NCT03926702 114 116 O
good NCT03926702 117 121 O
general NCT03926702 122 129 B-Condition
medical NCT03926702 130 137 I-Condition
health NCT03926702 138 144 I-Condition
with NCT03926702 145 149 B-And
no NCT03926702 150 152 B-Negation
neurological NCT03926702 153 165 B-Condition
diseases NCT03926702 166 174 I-Condition
and NCT03926702 175 178 O
capable NCT03926702 179 186 O
of NCT03926702 187 189 O
providing NCT03926702 190 199 O
informed NCT03926702 200 208 O
consent NCT03926702 209 216 O
. NCT03926702 217 218 O

- NCT03926702 222 223 O
Patients NCT03926702 225 233 O
: NCT03926702 234 235 O
Subjects NCT03926702 236 244 O
must NCT03926702 245 249 O
be NCT03926702 250 252 O
aged NCT03926702 253 257 B-Age
50 NCT03926702 258 260 B-Eq-Comparison
and NCT03926702 261 264 I-Eq-Comparison
over NCT03926702 265 269 I-Eq-Comparison
. NCT03926702 269 270 O
Patients NCT03926702 272 280 O
will NCT03926702 281 285 O
meet NCT03926702 286 290 O
diagnostic NCT03926702 291 301 O
criteria NCT03926702 302 310 O
at NCT03926702 311 313 O
UCSF NCT03926702 314 318 O
for NCT03926702 319 322 O
Alzheimer NCT03926702 323 332 B-Condition
's NCT03926702 332 334 I-Condition
disease NCT03926702 335 342 I-Condition
( NCT03926702 343 344 O
AD NCT03926702 345 347 B-Condition
) NCT03926702 348 349 O
, NCT03926702 351 352 O
mild NCT03926702 353 357 O
cognitive NCT03926702 358 367 B-Condition
impairment NCT03926702 368 378 I-Condition
( NCT03926702 379 380 O
MCI NCT03926702 381 384 B-Condition
) NCT03926702 385 386 O
, NCT03926702 388 389 O
or NCT03926702 390 392 B-Or
progressive NCT03926702 393 404 B-Condition
supranuclear NCT03926702 405 417 I-Condition
palsy NCT03926702 418 423 I-Condition
( NCT03926702 424 425 O
PSP NCT03926702 426 429 B-Condition
) NCT03926702 430 431 O
. NCT03926702 433 434 O

Exclusion NCT03926702 436 445 O
Criteria NCT03926702 446 454 O
: NCT03926702 455 456 O

- NCT03926702 460 461 O
Any NCT03926702 463 466 O
medical NCT03926702 467 474 O
contraindications NCT03926702 475 492 B-Contraindication
to NCT03926702 493 495 O
an NCT03926702 496 498 O
MRI NCT03926702 499 502 B-Procedure
scan NCT03926702 503 507 I-Procedure

- NCT03926702 510 511 O
A NCT03926702 513 514 O
pacemaker NCT03926702 515 524 B-Procedure

- NCT03926702 527 528 O
Metal NCT03926702 530 535 B-Condition
clips NCT03926702 536 541 I-Condition
in NCT03926702 542 544 O
brain NCT03926702 545 550 B-Modifier
or NCT03926702 551 553 B-Or
tattoos NCT03926702 554 561 B-Observation
above NCT03926702 562 567 B-Modifier
neck NCT03926702 568 572 I-Modifier

- NCT03926702 575 576 O
Metallic NCT03926702 578 586 B-Condition
implants NCT03926702 587 595 I-Condition
or NCT03926702 596 598 B-Or
shrapnel NCT03926702 599 607 B-Condition
in NCT03926702 608 610 O
body NCT03926702 611 615 B-Modifier

- NCT03926702 618 619 O
Any NCT03926702 621 624 O
body NCT03926702 625 629 B-Modifier
jewelry NCT03926702 630 637 B-Observation
or NCT03926702 638 640 B-Or
piercings NCT03926702 641 650 B-Observation
that NCT03926702 651 655 O
are NCT03926702 656 659 O
not NCT03926702 660 663 B-Modifier
removable NCT03926702 664 673 I-Modifier

- NCT03926702 676 677 O
A NCT03926702 679 680 O
history NCT03926702 681 688 B-Eq-Comparison
of NCT03926702 689 691 O
claustrophobia NCT03926702 692 706 B-Condition

- NCT03926702 709 710 O
A NCT03926702 712 713 O
known NCT03926702 714 719 O
major NCT03926702 720 725 O
systemic NCT03926702 726 734 B-Condition
disease NCT03926702 735 742 I-Condition

- NCT03926702 745 746 O
A NCT03926702 748 749 O
history NCT03926702 750 757 B-Eq-Comparison
of NCT03926702 758 760 O
a NCT03926702 761 762 O
psychiatric NCT03926702 763 774 B-Condition
disorder NCT03926702 775 783 I-Condition

- NCT03926702 786 787 O
A NCT03926702 789 790 O
history NCT03926702 791 798 B-Eq-Comparison
of NCT03926702 799 801 O
substance NCT03926702 802 811 B-Condition
abuse NCT03926702 812 817 I-Condition
( NCT03926702 818 819 O
prescription NCT03926702 820 832 B-Modifier
or NCT03926702 833 835 B-Or
non NCT03926702 836 839 B-Modifier
- NCT03926702 840 841 I-Modifier
prescription NCT03926702 842 854 I-Modifier
) NCT03926702 855 856 O
within NCT03926702 857 863 B-Eq-Comparison
the NCT03926702 864 867 I-Eq-Comparison
past NCT03926702 868 872 I-Eq-Comparison
5 NCT03926702 873 874 I-Eq-Comparison
years NCT03926702 875 880 I-Eq-Comparison

- NCT03926702 883 884 O
A NCT03926702 886 887 O
current NCT03926702 888 895 B-Eq-Comparison
weight NCT03926702 896 902 B-Observation
of NCT03926702 903 905 O
less NCT03926702 906 910 B-Eq-Comparison
than NCT03926702 911 915 I-Eq-Comparison
45 NCT03926702 916 918 I-Eq-Comparison
kilograms NCT03926702 919 928 I-Eq-Comparison
( NCT03926702 929 930 O
100 NCT03926702 931 934 B-Eq-Comparison
pounds NCT03926702 935 941 I-Eq-Comparison
) NCT03926702 942 943 O

- NCT03926702 947 948 O
Difficulty NCT03926702 950 960 B-Condition
in NCT03926702 961 963 I-Condition
urinating NCT03926702 964 973 I-Condition
or NCT03926702 974 976 B-Or
emptying NCT03926702 977 985 B-Condition
the NCT03926702 986 989 I-Condition
bladder NCT03926702 990 997 I-Condition

- NCT03926702 1000 1001 O
Under NCT03926702 1003 1008 B-Eq-Comparison
age NCT03926702 1009 1012 I-Eq-Comparison
50 NCT03926702 1013 1015 I-Eq-Comparison

- NCT03926702 1019 1020 O
Participating NCT03926702 1022 1035 B-Eq-Comparison
in NCT03926702 1036 1038 O
an NCT03926702 1039 1041 O
experimental NCT03926702 1042 1054 B-Modifier
radiotracer NCT03926702 1055 1066 B-Procedure
study NCT03926702 1067 1072 B-Study

- NCT03926702 1075 1076 O
Subjects NCT03926702 1078 1086 O
must NCT03926702 1087 1091 O
be NCT03926702 1092 1094 O
fluent NCT03926702 1095 1101 O
English NCT03926702 1102 1109 O
speakers NCT03926702 1110 1118 O

Inclusion NCT03929419 0 9 O
Criteria NCT03929419 10 18 O
: NCT03929419 19 20 O

- NCT03929419 24 25 O
female NCT03929419 27 33 O
volunteer NCT03929419 34 43 O
adults NCT03929419 44 50 O

- NCT03929419 53 54 O
HbA1c NCT03929419 56 61 B-Observation
< NCT03929419 62 63 B-Eq-Comparison
6.0 NCT03929419 64 67 I-Eq-Comparison
% NCT03929419 68 69 I-Eq-Comparison

- NCT03929419 73 74 O
Age NCT03929419 76 79 B-Age
between NCT03929419 80 87 B-Eq-Comparison
18 NCT03929419 88 90 I-Eq-Comparison
and NCT03929419 91 94 I-Eq-Comparison
30 NCT03929419 95 97 I-Eq-Comparison
years NCT03929419 98 103 I-Eq-Comparison

- NCT03929419 106 107 O
Standard NCT03929419 109 117 O
routine NCT03929419 118 125 B-Modifier
laboratory NCT03929419 126 136 B-Observation

- NCT03929419 139 140 O
No NCT03929419 142 144 B-Negation
underlying NCT03929419 145 155 O
diseases NCT03929419 156 164 B-Condition

- NCT03929419 167 168 O
No NCT03929419 170 172 B-Negation
medication NCT03929419 173 183 B-Drug

- NCT03929419 186 187 O
No NCT03929419 189 191 B-Negation
hormonal NCT03929419 192 200 B-Procedure
contraception NCT03929419 201 214 I-Procedure

- NCT03929419 217 218 O
Understanding NCT03929419 220 233 O
of NCT03929419 234 236 O
the NCT03929419 237 240 O
explanations NCT03929419 241 253 O
of NCT03929419 254 256 O
the NCT03929419 257 260 O
study NCT03929419 261 266 O
and NCT03929419 267 270 O
the NCT03929419 271 274 O
instructions NCT03929419 275 287 O

Exclusion NCT03929419 288 297 O
Criteria NCT03929419 298 306 O
: NCT03929419 307 308 O

- NCT03929419 312 313 O
Persons NCT03929419 315 322 O
with NCT03929419 323 327 O
limited NCT03929419 328 335 O
temperature NCT03929419 336 347 B-Condition
perception NCT03929419 348 358 I-Condition
and NCT03929419 359 362 B-Or
/ NCT03929419 363 364 I-Or
or NCT03929419 365 367 I-Or
increased NCT03929419 368 377 O
temperature NCT03929419 378 389 B-Condition
Sensitivity NCT03929419 390 401 I-Condition
to NCT03929419 402 404 O
warming NCT03929419 405 412 B-Modifier
of NCT03929419 413 415 I-Modifier
the NCT03929419 416 419 I-Modifier
body NCT03929419 420 424 I-Modifier

- NCT03929419 427 428 O
Cardiovascular NCT03929419 430 444 B-Condition
disease NCT03929419 445 452 I-Condition
, NCT03929419 453 454 O
such NCT03929419 455 459 O
as NCT03929419 460 462 O
manifest NCT03929419 463 471 O
coronary NCT03929419 472 480 B-Condition
Heart NCT03929419 481 486 I-Condition
disease NCT03929419 487 494 I-Condition
, NCT03929419 495 496 O
heart NCT03929419 497 502 B-Condition
failure NCT03929419 503 510 I-Condition
greater NCT03929419 511 518 B-Eq-Comparison
than NCT03929419 519 523 I-Eq-Comparison
NYHA NCT03929419 524 528 I-Condition|Eq-Comparison
2 NCT03929419 529 530 I-Eq-Comparison
, NCT03929419 531 532 O
recent NCT03929419 533 539 B-Eq-Comparison
myocardial NCT03929419 540 550 B-Condition
infarction NCT03929419 551 561 I-Condition

- NCT03929419 564 565 O
People NCT03929419 567 573 O
with NCT03929419 574 578 O
a NCT03929419 579 580 O
hearing NCT03929419 581 588 B-Condition
disorder NCT03929419 589 597 I-Condition
or NCT03929419 598 600 B-Or
increased NCT03929419 601 610 O
sensitivity NCT03929419 611 622 B-Condition
to NCT03929419 623 625 I-Condition
loud NCT03929419 626 630 I-Condition
Sounds NCT03929419 631 637 I-Condition

- NCT03929419 640 641 O
persons NCT03929419 643 650 O
with NCT03929419 651 655 O
claustrophobia NCT03929419 656 670 B-Condition

- NCT03929419 673 674 O
Minors NCT03929419 676 682 O
or NCT03929419 683 685 O
non NCT03929419 686 689 O
- NCT03929419 690 691 O
consenting NCT03929419 692 702 O
subjects NCT03929419 703 711 O
are NCT03929419 712 715 O
also NCT03929419 716 720 O
excluded NCT03929419 721 729 B-Negation

- NCT03929419 732 733 O
Pregnancy NCT03929419 735 744 B-Condition
or NCT03929419 745 747 B-Or
breastfeeding NCT03929419 748 761 B-Condition
women NCT03929419 762 767 O

- NCT03929419 770 771 O
Surgery NCT03929419 773 780 B-Procedure
less NCT03929419 781 785 B-Eq-Comparison
than NCT03929419 786 790 I-Eq-Comparison
3 NCT03929419 791 792 I-Eq-Comparison
months NCT03929419 793 799 I-Eq-Comparison
ago NCT03929419 800 803 I-Eq-Comparison

- NCT03929419 806 807 O
Simultaneous NCT03929419 809 821 O
participation NCT03929419 822 835 O
in NCT03929419 836 838 O
other NCT03929419 839 844 B-Other
interventional NCT03929419 845 859 O
studies NCT03929419 860 867 B-Study

- NCT03929419 870 871 O
Acute NCT03929419 873 878 O
illness NCT03929419 879 886 B-Condition
or NCT03929419 887 889 B-Or
infection NCT03929419 890 899 B-Condition
within NCT03929419 900 906 B-Eq-Comparison
the NCT03929419 907 910 I-Eq-Comparison
last NCT03929419 911 915 I-Eq-Comparison
4 NCT03929419 916 917 I-Eq-Comparison
weeks NCT03929419 918 923 I-Eq-Comparison

- NCT03929419 926 927 O
Neurological NCT03929419 929 941 B-Modifier
and NCT03929419 942 945 B-Or
psychiatric NCT03929419 946 957 B-Modifier
disorders NCT03929419 958 967 B-Condition

- NCT03929419 970 971 O
Subjects NCT03929419 973 981 O
with NCT03929419 982 986 O
hemoglobin NCT03929419 987 997 B-Observation
Hb NCT03929419 998 1000 I-Observation
< NCT03929419 1001 1002 B-Eq-Comparison
12 NCT03929419 1003 1005 I-Eq-Comparison
g NCT03929419 1006 1007 I-Eq-Comparison
/ NCT03929419 1008 1009 I-Eq-Comparison
dl NCT03929419 1010 1012 I-Eq-Comparison
( NCT03929419 1013 1014 O
at NCT03929419 1015 1017 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03929419 1018 1027 B-Study
) NCT03929419 1028 1029 O

- NCT03929419 1033 1034 O
Allergic NCT03929419 1036 1044 B-Allergy
diseases NCT03929419 1045 1053 B-Condition

- NCT03929419 1056 1057 O
Individuals NCT03929419 1059 1070 O
with NCT03929419 1071 1075 O
a NCT03929419 1076 1077 O
history NCT03929419 1078 1085 B-Eq-Comparison
of NCT03929419 1086 1088 O
heparin NCT03929419 1089 1096 B-Drug
- NCT03929419 1097 1098 O
induced NCT03929419 1099 1106 B-Modifier
thrombocytopenia NCT03929419 1107 1123 B-Condition
( NCT03929419 1124 1125 O
HIT NCT03929419 1126 1129 B-Condition
) NCT03929419 1130 1131 O

Inclusion NCT03928288 0 9 O
Criteria NCT03928288 10 18 O
: NCT03928288 19 20 O

- NCT03928288 24 25 O
Female NCT03928288 27 33 O
with NCT03928288 34 38 O
surgically NCT03928288 39 49 B-Procedure
- NCT03928288 50 51 O
confirmed NCT03928288 52 61 O
endometriosis NCT03928288 62 75 B-Condition
, NCT03928288 76 77 O
determined NCT03928288 78 88 O
at NCT03928288 89 91 O
laparoscopy NCT03928288 92 103 B-Procedure
performed NCT03928288 104 113 O
within NCT03928288 114 120 B-Eq-Comparison
3 NCT03928288 121 122 I-Eq-Comparison
y NCT03928288 123 124 I-Eq-Comparison
prior NCT03928288 125 130 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03928288 131 133 I-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03928288 134 139 B-Study
baseline NCT03928288 140 148 O

- NCT03928288 151 152 O
Age NCT03928288 154 157 B-Age
15 NCT03928288 158 160 B-Eq-Comparison
years NCT03928288 161 166 I-Eq-Comparison
to NCT03928288 167 169 I-Eq-Comparison
40 NCT03928288 170 172 I-Eq-Comparison
years NCT03928288 173 178 I-Eq-Comparison

- NCT03928288 181 182 O
Current NCT03928288 184 191 B-Eq-Comparison
use NCT03928288 192 195 O
≥ NCT03928288 196 197 B-Eq-Comparison
2 NCT03928288 198 199 I-Eq-Comparison
months NCT03928288 200 206 I-Eq-Comparison
duration NCT03928288 207 215 O
of NCT03928288 216 218 O
hormonal NCT03928288 219 227 B-Procedure
therapy NCT03928288 228 235 I-Procedure
such NCT03928288 236 240 O
as NCT03928288 241 243 O
combined NCT03928288 244 252 B-Modifier
oral NCT03928288 253 257 B-Procedure
contraceptives NCT03928288 258 272 I-Procedure
, NCT03928288 273 274 O
norethindrone NCT03928288 275 288 B-Drug
acetate NCT03928288 289 296 I-Drug
, NCT03928288 297 298 O
or NCT03928288 299 301 B-Or
levonorgestrel NCT03928288 302 316 B-Procedure
intrauterine NCT03928288 317 329 I-Procedure
device NCT03928288 330 336 I-Procedure

- NCT03928288 339 340 O
Current NCT03928288 342 349 B-Eq-Comparison
pelvic NCT03928288 350 356 B-Modifier
pain NCT03928288 357 361 B-Condition|Observation
( NCT03928288 362 363 O
score NCT03928288 364 369 O
≥ NCT03928288 370 371 B-Eq-Comparison
3 NCT03928288 372 373 I-Eq-Comparison
on NCT03928288 374 376 O
Visual NCT03928288 377 383 O
Analog NCT03928288 384 390 O
Scale NCT03928288 391 396 O
, NCT03928288 397 398 O
where NCT03928288 399 404 O
0 NCT03928288 405 406 O
represents NCT03928288 407 417 O
absence NCT03928288 418 425 O
of NCT03928288 426 428 O
pain NCT03928288 429 433 O
and NCT03928288 434 437 O
10 NCT03928288 438 440 O
indicates NCT03928288 441 450 O
unbearable NCT03928288 451 461 O
pain NCT03928288 462 466 O
) NCT03928288 467 468 O
present NCT03928288 469 476 O
for NCT03928288 477 480 O
≥ NCT03928288 481 482 B-Eq-Comparison
14 NCT03928288 483 485 I-Eq-Comparison
days NCT03928288 486 490 I-Eq-Comparison
/ NCT03928288 491 492 I-Eq-Comparison
month NCT03928288 493 498 I-Eq-Comparison
over NCT03928288 499 503 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928288 504 507 O
2 NCT03928288 508 509 B-Eq-Comparison
months NCT03928288 510 516 I-Eq-Comparison
prior NCT03928288 517 522 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03928288 523 525 I-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03928288 526 531 B-Study
enrollment NCT03928288 532 542 O

- NCT03928288 545 546 O
Willingness NCT03928288 548 559 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03928288 560 562 O
comply NCT03928288 563 569 O
with NCT03928288 570 574 O
visit NCT03928288 575 580 B-Encounter
schedule NCT03928288 581 589 O
and NCT03928288 590 593 O
protocol NCT03928288 594 602 O

Exclusion NCT03928288 603 612 O
Criteria NCT03928288 613 621 O
: NCT03928288 622 623 O

- NCT03928288 627 628 O
Pre NCT03928288 630 633 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03928288 634 635 O
menarche NCT03928288 636 644 B-Condition
or NCT03928288 645 647 B-Or
post NCT03928288 648 652 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03928288 653 654 O
menopause NCT03928288 655 664 B-Condition

- NCT03928288 667 668 O
Contraindications NCT03928288 670 687 B-Contraindication
to NCT03928288 688 690 O
cabergoline NCT03928288 691 702 B-Drug
( NCT03928288 703 704 O
e. NCT03928288 705 707 O
g. NCT03928288 708 710 O
, NCT03928288 711 712 O
cardiac NCT03928288 713 720 B-Condition
valve NCT03928288 721 726 I-Condition
disorder NCT03928288 727 735 I-Condition
; NCT03928288 735 736 O
pulmonary NCT03928288 737 746 B-Modifier
, NCT03928288 747 748 O
pericardial NCT03928288 749 760 B-Modifier
, NCT03928288 761 762 O
retroperitoneal NCT03928288 763 778 B-Modifier
fibrotic NCT03928288 779 787 I-Modifier
disorder NCT03928288 788 796 B-Condition
; NCT03928288 796 797 O
hypersensitivity NCT03928288 798 814 B-Condition
to NCT03928288 815 817 O
ergot NCT03928288 818 823 B-Modifier
derivatives NCT03928288 824 835 I-Modifier
; NCT03928288 835 836 O
uncontrolled NCT03928288 837 849 B-Modifier
hypertension NCT03928288 850 862 B-Condition
) NCT03928288 863 864 O

- NCT03928288 868 869 O
Significant NCT03928288 871 882 O
mental NCT03928288 883 889 B-Modifier
or NCT03928288 890 892 B-Or
chronic NCT03928288 893 900 B-Modifier
systemic NCT03928288 901 909 I-Modifier
illness NCT03928288 910 917 B-Condition
that NCT03928288 918 922 O
might NCT03928288 923 928 B-Assertion___Assertion-Type-Value:hypothetical
confound NCT03928288 929 937 O
pain NCT03928288 938 942 B-Procedure
assessment NCT03928288 943 953 I-Procedure
or NCT03928288 954 956 B-Or
the NCT03928288 957 960 O
ability NCT03928288 961 968 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03928288 969 971 I-Assertion___Assertion-Type-Value:hypothetical
complete NCT03928288 972 980 O
the NCT03928288 981 984 O
study NCT03928288 985 990 B-Study

- NCT03928288 993 994 O
Pregnant NCT03928288 996 1004 B-Condition
, NCT03928288 1005 1006 O
breastfeeding NCT03928288 1007 1020 B-Condition
, NCT03928288 1021 1022 O
or NCT03928288 1023 1025 B-Or
planning NCT03928288 1026 1034 B-Assertion___Assertion-Type-Value:intention
to NCT03928288 1035 1037 I-Assertion___Assertion-Type-Value:intention
become NCT03928288 1038 1044 I-Assertion___Assertion-Type-Value:intention
pregnant NCT03928288 1045 1053 B-Condition
in NCT03928288 1054 1056 O
the NCT03928288 1057 1060 O
next NCT03928288 1061 1065 B-Eq-Comparison
6 NCT03928288 1066 1067 I-Eq-Comparison
months NCT03928288 1068 1074 I-Eq-Comparison

- NCT03928288 1077 1078 O
Impaired NCT03928288 1080 1088 O
liver NCT03928288 1089 1094 O
function NCT03928288 1095 1103 O
( NCT03928288 1104 1105 O
ALT NCT03928288 1106 1109 O
> NCT03928288 1110 1111 O
2 NCT03928288 1112 1113 O
x NCT03928288 1114 1115 O
normal NCT03928288 1116 1122 O
) NCT03928288 1123 1124 O
or NCT03928288 1125 1127 O
liver NCT03928288 1128 1133 O
disease NCT03928288 1134 1141 O

- NCT03928288 1144 1145 O
Breast NCT03928288 1147 1153 B-Modifier
cancer NCT03928288 1154 1160 B-Condition
, NCT03928288 1161 1162 O
current NCT03928288 1163 1170 B-Eq-Comparison
or NCT03928288 1171 1173 B-Or
previous NCT03928288 1174 1182 B-Eq-Comparison

- NCT03928288 1185 1186 O
Thromboembolic NCT03928288 1188 1202 B-Condition
disease NCT03928288 1203 1210 I-Condition
, NCT03928288 1211 1212 O
current NCT03928288 1213 1220 B-Eq-Comparison
or NCT03928288 1221 1223 B-Or
previous NCT03928288 1224 1232 B-Eq-Comparison

- NCT03928288 1235 1236 O
Use NCT03928288 1238 1241 O
of NCT03928288 1242 1244 O
other NCT03928288 1245 1250 B-Other
drugs NCT03928288 1251 1256 B-Drug
that NCT03928288 1257 1261 O
affect NCT03928288 1262 1268 O
dopamine NCT03928288 1269 1277 B-Drug
( NCT03928288 1278 1279 O
e. NCT03928288 1280 1282 O
g. NCT03928288 1283 1285 O
, NCT03928288 1286 1287 O
phenothiazines NCT03928288 1288 1302 B-Drug
, NCT03928288 1303 1304 O
metoclopramide NCT03928288 1305 1319 B-Drug
, NCT03928288 1320 1321 O
butyrophenones NCT03928288 1322 1336 B-Drug
) NCT03928288 1337 1338 O

Inclusion NCT03925948 0 9 O
Criteria NCT03925948 10 18 O
: NCT03925948 19 20 O

- NCT03925948 24 25 O
African NCT03925948 27 34 O
Americans NCT03925948 35 44 O
residing NCT03925948 45 53 O
in NCT03925948 54 56 O
Baltimore NCT03925948 57 66 O
, NCT03925948 67 68 O
Maryland NCT03925948 69 77 O

- NCT03925948 80 81 O
had NCT03925948 83 86 O
uncontrolled NCT03925948 87 99 B-Modifier
diabetes NCT03925948 100 108 B-Condition
( NCT03925948 109 110 O
defined NCT03925948 111 118 O
as NCT03925948 119 121 O
HbA1C NCT03925948 122 127 B-Observation
> NCT03925948 128 129 B-Eq-Comparison
7 NCT03925948 130 131 I-Eq-Comparison
% NCT03925948 132 133 I-Eq-Comparison
) NCT03925948 135 136 O

Exclusion NCT03925948 138 147 O
Criteria NCT03925948 148 156 O
: NCT03925948 157 158 O

- NCT03925948 162 163 O
Unable NCT03925948 165 171 O
to NCT03925948 172 174 O
give NCT03925948 175 179 O
informed NCT03925948 180 188 O
consent NCT03925948 189 196 O

- NCT03925948 199 200 O
Physical NCT03925948 202 210 B-Modifier
or NCT03925948 211 213 B-Or
mental NCT03925948 214 220 B-Modifier
health NCT03925948 221 227 B-Condition
conditions NCT03925948 228 238 I-Condition
that NCT03925948 239 243 O
could NCT03925948 244 249 B-Assertion___Assertion-Type-Value:hypothetical
limit NCT03925948 250 255 O
active NCT03925948 256 262 O
participation NCT03925948 263 276 O
in NCT03925948 277 279 O
the NCT03925948 280 283 O
study NCT03925948 284 289 B-Study
( NCT03925948 290 291 O
e. NCT03925948 292 294 O
g. NCT03925948 295 297 O
, NCT03925948 298 299 O
blindness NCT03925948 300 309 B-Condition
in NCT03925948 310 312 O
both NCT03925948 313 317 B-Modifier
eyes NCT03925948 318 322 I-Modifier
, NCT03925948 323 324 O
severe NCT03925948 325 331 O
immobility NCT03925948 332 342 B-Condition
, NCT03925948 343 344 O
psychiatric NCT03925948 345 356 B-Condition
diseases NCT03925948 357 365 I-Condition
) NCT03925948 366 367 O

- NCT03925948 371 372 O
Hematological NCT03925948 374 387 B-Condition
condition NCT03925948 388 397 I-Condition
that NCT03925948 398 402 O
would NCT03925948 403 408 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03925948 409 415 O
HbA1C NCT03925948 416 421 B-Observation
assay NCT03925948 422 427 I-Observation
, NCT03925948 428 429 O
e. NCT03925948 430 432 O
g. NCT03925948 433 435 O
, NCT03925948 436 437 O
hemolytic NCT03925948 438 447 B-Condition
anemia NCT03925948 448 454 I-Condition
, NCT03925948 455 456 O
sickle NCT03925948 457 463 B-Condition
cell NCT03925948 464 468 I-Condition
anemia NCT03925948 469 475 I-Condition

Inclusion NCT03926299 0 9 O
criteria NCT03926299 10 18 O
: NCT03926299 19 20 O

- NCT03926299 24 25 O
Diagnosis NCT03926299 27 36 O
of NCT03926299 37 39 O
vulvar NCT03926299 40 46 B-Condition
lichen NCT03926299 47 53 I-Condition
sclerosus NCT03926299 54 63 I-Condition

- NCT03926299 66 67 O
Clinical NCT03926299 69 77 O
LS NCT03926299 78 80 B-Observation
score NCT03926299 81 86 I-Observation
≥ NCT03926299 87 88 B-Eq-Comparison
4 NCT03926299 89 90 I-Eq-Comparison

Exclusion NCT03926299 92 101 O
criteria NCT03926299 102 110 O
: NCT03926299 111 112 O

- NCT03926299 116 117 O
Concomitant NCT03926299 119 130 B-Modifier
steroid NCT03926299 131 138 B-Drug
, NCT03926299 139 140 O
calcineurin NCT03926299 141 152 B-Drug
inhibitor NCT03926299 153 162 I-Drug
or NCT03926299 163 165 B-Or
any NCT03926299 166 169 O
other NCT03926299 170 175 B-Other
topical NCT03926299 176 183 B-Modifier
or NCT03926299 184 186 B-Or
systemic NCT03926299 187 195 B-Modifier
treatment NCT03926299 196 205 B-Procedure
for NCT03926299 206 209 O
LS NCT03926299 210 212 B-Condition

- NCT03926299 215 216 O
< NCT03926299 218 219 B-Eq-Comparison
3 NCT03926299 220 221 I-Eq-Comparison
months NCT03926299 222 228 I-Eq-Comparison
since NCT03926299 229 234 B-Temporal-Connection___Temporal-Connection-Type-Value:after
start NCT03926299 235 240 B-Eq-Comparison
of NCT03926299 241 243 O
vaginal NCT03926299 244 251 B-Modifier
estrogen NCT03926299 252 260 B-Procedure
treatment NCT03926299 261 270 I-Procedure

- NCT03926299 273 274 O
Malignant NCT03926299 276 285 B-Condition
disease NCT03926299 286 293 I-Condition
as NCT03926299 294 296 O
the NCT03926299 297 300 O
cause NCT03926299 301 306 O
of NCT03926299 307 309 O
the NCT03926299 310 313 O
vulval NCT03926299 314 320 B-Condition
symptoms NCT03926299 321 329 B-Assertion___Assertion-Type-Value:possible

- NCT03926299 332 333 O
BMI NCT03926299 335 338 B-Observation
> NCT03926299 339 340 B-Eq-Comparison
35 NCT03926299 341 343 I-Eq-Comparison
kg NCT03926299 344 346 I-Eq-Comparison
/ NCT03926299 347 348 I-Eq-Comparison
m² NCT03926299 349 351 I-Eq-Comparison

- NCT03926299 354 355 O
Acute NCT03926299 357 362 O
infection NCT03926299 363 372 B-Condition
( NCT03926299 373 374 O
fungal NCT03926299 375 381 B-Modifier
, NCT03926299 382 383 O
bacterial NCT03926299 384 393 B-Modifier
, NCT03926299 394 395 O
viral NCT03926299 396 401 B-Modifier
) NCT03926299 402 403 O
of NCT03926299 404 406 O
the NCT03926299 407 410 O
vulva NCT03926299 411 416 B-Modifier
, NCT03926299 417 418 O
vagina NCT03926299 419 425 B-Modifier
or NCT03926299 426 428 B-Or
bladder NCT03926299 429 436 B-Modifier

- NCT03926299 439 440 O
Presence NCT03926299 442 450 O
of NCT03926299 451 453 O
contraindications NCT03926299 454 471 B-Contraindication
for NCT03926299 472 475 O
the NCT03926299 476 479 O
laser NCT03926299 480 485 B-Procedure
treatment NCT03926299 486 495 I-Procedure
or NCT03926299 496 498 B-Or
topical NCT03926299 499 506 B-Drug
steroid NCT03926299 507 514 I-Drug
treatment NCT03926299 515 524 B-Procedure

Inclusion NCT03923478 0 9 O
Criteria NCT03923478 10 18 O
: NCT03923478 19 20 O

- NCT03923478 24 25 O
Established NCT03923478 27 38 O
diagnosis NCT03923478 39 48 O
of NCT03923478 49 51 O
UC NCT03923478 52 54 B-Condition
for NCT03923478 55 58 O
at NCT03923478 59 61 B-Eq-Comparison
least NCT03923478 62 67 I-Eq-Comparison
3 NCT03923478 68 69 I-Eq-Comparison
months NCT03923478 70 76 I-Eq-Comparison
prior NCT03923478 77 82 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03923478 83 85 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03923478 86 95 B-Study
, NCT03923478 96 97 O
with NCT03923478 98 102 B-And
minimum NCT03923478 103 110 B-Observation
disease NCT03923478 111 118 I-Observation
extent NCT03923478 119 125 I-Observation
of NCT03923478 126 128 O
15 NCT03923478 129 131 B-Eq-Comparison
cm NCT03923478 132 134 I-Eq-Comparison
from NCT03923478 135 139 O
the NCT03923478 140 143 O
anal NCT03923478 144 148 B-Modifier
verge NCT03923478 149 154 I-Modifier

- NCT03923478 157 158 O
Mildly NCT03923478 160 166 B-Eq-Comparison
to NCT03923478 167 169 I-Eq-Comparison
moderately NCT03923478 170 180 I-Eq-Comparison
active NCT03923478 181 187 B-Eq-Comparison
UC NCT03923478 188 190 B-Condition

- NCT03923478 193 194 O
Inadequate NCT03923478 196 206 B-Modifier
response NCT03923478 207 215 I-Modifier
to NCT03923478 216 218 O
ongoing NCT03923478 219 226 B-Eq-Comparison
treatment NCT03923478 227 236 B-Procedure
with NCT03923478 237 241 O
oral NCT03923478 242 246 B-Drug
mesalamine NCT03923478 247 257 I-Drug
≥ NCT03923478 258 259 B-Eq-Comparison
2.4 NCT03923478 260 263 I-Eq-Comparison
g NCT03923478 264 265 I-Eq-Comparison
/ NCT03923478 266 267 I-Eq-Comparison
day NCT03923478 268 271 I-Eq-Comparison
for NCT03923478 272 275 O
≥ NCT03923478 276 277 B-Eq-Comparison
4 NCT03923478 278 279 I-Eq-Comparison
weeks NCT03923478 280 285 I-Eq-Comparison
from NCT03923478 286 290 B-Temporal-Connection___Temporal-Connection-Type-Value:after
screening NCT03923478 291 300 B-Study
visit NCT03923478 301 306 O

Exclusion NCT03923478 307 316 O
Criteria NCT03923478 317 325 O
: NCT03923478 326 327 O

- NCT03923478 331 332 O
Possible NCT03923478 334 342 B-Assertion___Assertion-Type-Value:possible
or NCT03923478 343 345 O
confirmed NCT03923478 346 355 O
diagnosis NCT03923478 356 365 O
of NCT03923478 366 368 O
Crohn NCT03923478 369 374 B-Condition
's NCT03923478 374 376 I-Condition
Disease NCT03923478 377 384 I-Condition
or NCT03923478 385 387 B-Or
other NCT03923478 388 393 B-Other
forms NCT03923478 394 399 O
of NCT03923478 400 402 O
inflammatory NCT03923478 403 415 B-Modifier
bowel NCT03923478 416 421 B-Condition
disorders NCT03923478 422 431 I-Condition

- NCT03923478 434 435 O
Ongoing NCT03923478 437 444 B-Eq-Comparison
or NCT03923478 445 447 B-Or
failed NCT03923478 448 454 B-Modifier
prior NCT03923478 455 460 B-Eq-Comparison
treatment NCT03923478 461 470 B-Procedure
for NCT03923478 471 474 O
UC NCT03923478 475 477 B-Condition
with NCT03923478 478 482 O
methotrexate NCT03923478 483 495 B-Drug
, NCT03923478 496 497 O
azathioprine NCT03923478 498 510 B-Drug
, NCT03923478 511 512 O

6 NCT03923478 519 520 B-Drug
- NCT03923478 521 522 I-Drug
mercaptopurine NCT03923478 523 537 I-Drug
, NCT03923478 538 539 O
cyclosporine NCT03923478 540 552 B-Drug
, NCT03923478 553 554 O
tofacitinib NCT03923478 555 566 B-Drug
, NCT03923478 567 568 O
mycophenolate NCT03923478 569 582 B-Drug
mofetil NCT03923478 583 590 I-Drug
, NCT03923478 591 592 O
sirolimus NCT03923478 593 602 B-Drug
( NCT03923478 603 604 O
rapamycin NCT03923478 605 614 B-Drug
) NCT03923478 615 616 O
, NCT03923478 618 619 O
thalidomide NCT03923478 620 631 B-Drug
, NCT03923478 632 633 O
tacrolimus NCT03923478 634 644 B-Drug
( NCT03923478 645 646 O
FK NCT03923478 647 649 B-Drug
- NCT03923478 650 651 I-Drug
506 NCT03923478 652 655 I-Drug
) NCT03923478 656 657 O
, NCT03923478 659 660 O
or NCT03923478 661 663 B-Or
biologics NCT03923478 664 673 B-Drug
( NCT03923478 674 675 O
e. NCT03923478 676 678 O
g. NCT03923478 679 681 O
, NCT03923478 682 683 O
TNF NCT03923478 684 687 B-Drug
- NCT03923478 688 689 I-Drug
alpha NCT03923478 690 695 I-Drug
- NCT03923478 696 697 I-Drug
antagonists NCT03923478 698 709 I-Drug
, NCT03923478 710 711 O
anti NCT03923478 712 716 B-Drug
- NCT03923478 717 718 I-Drug
integrin NCT03923478 719 727 I-Drug
therapies NCT03923478 728 737 I-Drug
, NCT03923478 738 739 O
or NCT03923478 740 742 B-Or
agents NCT03923478 743 749 B-Drug
targeting NCT03923478 750 759 I-Drug
IL NCT03923478 760 762 B-Modifier
- NCT03923478 763 764 I-Modifier
12 NCT03923478 765 767 I-Modifier
or NCT03923478 768 770 B-Or
IL NCT03923478 771 773 B-Modifier
- NCT03923478 774 775 I-Modifier
23 NCT03923478 776 778 I-Modifier
, NCT03923478 779 780 O
etc NCT03923478 781 784 O
. NCT03923478 784 785 O
) NCT03923478 786 787 O

- NCT03923478 791 792 O
Any NCT03923478 794 797 O
immunosuppressive NCT03923478 798 815 B-Condition
condition NCT03923478 816 825 I-Condition
or NCT03923478 826 828 B-Or
treatment NCT03923478 829 838 B-Procedure
with NCT03923478 839 843 O
immunosuppressive NCT03923478 844 861 B-Drug
medications NCT03923478 862 873 I-Drug

- NCT03923478 876 877 O
History NCT03923478 879 886 B-Eq-Comparison
of NCT03923478 887 889 I-Eq-Comparison
prior NCT03923478 890 895 I-Eq-Comparison
surgical NCT03923478 896 904 B-Procedure
intervention NCT03923478 905 917 I-Procedure
in NCT03923478 918 920 O
any NCT03923478 921 924 O
region NCT03923478 925 931 O
of NCT03923478 932 934 O
the NCT03923478 935 938 O
gastrointestinal NCT03923478 939 955 B-Modifier
tract NCT03923478 956 961 I-Modifier
( NCT03923478 962 963 O
excluding NCT03923478 964 973 B-Exception
minor NCT03923478 974 979 B-Procedure
surgery NCT03923478 980 987 I-Procedure
) NCT03923478 988 989 O

- NCT03923478 993 994 O
Prior NCT03923478 996 1001 B-Eq-Comparison
diagnosis NCT03923478 1002 1011 O
of NCT03923478 1012 1014 O
any NCT03923478 1015 1018 O
cardiovascular NCT03923478 1019 1033 B-Modifier
, NCT03923478 1034 1035 O
renal NCT03923478 1036 1041 B-Modifier
, NCT03923478 1042 1043 O
hepatic NCT03923478 1044 1051 B-Modifier
, NCT03923478 1052 1053 O
endocrine NCT03923478 1054 1063 B-Modifier
, NCT03923478 1064 1065 O
infectious NCT03923478 1066 1076 B-Modifier
, NCT03923478 1077 1078 O
hematological NCT03923478 1079 1092 B-Modifier
, NCT03923478 1093 1094 O
oncologic NCT03923478 1095 1104 B-Modifier
, NCT03923478 1105 1106 O
neuro NCT03923478 1107 1112 B-Modifier
- NCT03923478 1113 1114 I-Modifier
psychiatric NCT03923478 1115 1126 I-Modifier
or NCT03923478 1127 1129 B-Or
immune NCT03923478 1130 1136 B-Modifier
- NCT03923478 1137 1138 I-Modifier
mediated NCT03923478 1139 1147 I-Modifier
disorder NCT03923478 1148 1156 B-Condition
, NCT03923478 1157 1158 O
which NCT03923478 1159 1164 O
in NCT03923478 1165 1167 O
the NCT03923478 1168 1171 O
opinion NCT03923478 1172 1179 O
of NCT03923478 1180 1182 O
the NCT03923478 1183 1186 O
Principal NCT03923478 1187 1196 O
Investigator NCT03923478 1197 1209 O
might NCT03923478 1210 1215 B-Assertion___Assertion-Type-Value:hypothetical
impact NCT03923478 1216 1222 O
the NCT03923478 1223 1226 O
subject NCT03923478 1227 1234 O
's NCT03923478 1234 1236 O
safety NCT03923478 1237 1243 O
or NCT03923478 1244 1246 O
compliance NCT03923478 1247 1257 O
, NCT03923478 1258 1259 O
or NCT03923478 1260 1262 O
the NCT03923478 1263 1266 O
interpretation NCT03923478 1267 1281 O
of NCT03923478 1282 1284 O
results NCT03923478 1285 1292 B-Study

- NCT03923478 1295 1296 O
Treatment NCT03923478 1298 1307 B-Procedure
with NCT03923478 1308 1312 O
any NCT03923478 1313 1316 O
other NCT03923478 1317 1322 B-Other
investigational NCT03923478 1323 1338 B-Study
drugs NCT03923478 1339 1344 B-Drug
≤ NCT03923478 1345 1346 B-Eq-Comparison
12 NCT03923478 1347 1349 I-Eq-Comparison
weeks NCT03923478 1350 1355 I-Eq-Comparison
prior NCT03923478 1356 1361 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03923478 1362 1364 I-Temporal-Connection___Temporal-Connection-Type-Value:before
baseline NCT03923478 1365 1373 B-Study
visit NCT03923478 1374 1379 O

- NCT03923478 1382 1383 O
The NCT03923478 1385 1388 O
participant NCT03923478 1389 1400 O
has NCT03923478 1401 1404 O
a NCT03923478 1405 1406 O
condition NCT03923478 1407 1416 B-Condition
or NCT03923478 1417 1419 O
is NCT03923478 1420 1422 O
in NCT03923478 1423 1425 O
a NCT03923478 1426 1427 O
situation NCT03923478 1428 1437 O
which NCT03923478 1438 1443 O
, NCT03923478 1444 1445 O
in NCT03923478 1446 1448 O
the NCT03923478 1449 1452 O
Principal NCT03923478 1453 1462 O
Investigator NCT03923478 1463 1475 O
's NCT03923478 1475 1477 O
opinion NCT03923478 1478 1485 O
, NCT03923478 1486 1487 O
may NCT03923478 1488 1491 O
put NCT03923478 1492 1495 O
the NCT03923478 1496 1499 O
participant NCT03923478 1500 1511 O
at NCT03923478 1512 1514 O
significant NCT03923478 1515 1526 O
risk NCT03923478 1527 1531 B-Risk
, NCT03923478 1532 1533 O
may NCT03923478 1534 1537 B-Assertion___Assertion-Type-Value:hypothetical
confound NCT03923478 1538 1546 O
the NCT03923478 1547 1550 O
study NCT03923478 1551 1556 B-Study
results NCT03923478 1557 1564 O
, NCT03923478 1565 1566 O
or NCT03923478 1567 1569 B-Or
may NCT03923478 1570 1573 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03923478 1574 1583 O
significantly NCT03923478 1584 1597 O
with NCT03923478 1598 1602 O
the NCT03923478 1603 1606 O
participant NCT03923478 1607 1618 O
's NCT03923478 1618 1620 O
participation NCT03923478 1621 1634 O
in NCT03923478 1635 1637 O
the NCT03923478 1638 1641 O
study NCT03923478 1642 1647 B-Study

Inclusion NCT03925753 0 9 O
Criteria NCT03925753 10 18 O
: NCT03925753 19 20 O

- NCT03925753 24 25 O
Both NCT03925753 27 31 O
sexes NCT03925753 32 37 O
aged NCT03925753 38 42 B-Age
between NCT03925753 43 50 O
20 NCT03925753 51 53 B-Eq-Comparison
- NCT03925753 54 55 I-Eq-Comparison
90 NCT03925753 56 58 I-Eq-Comparison
years NCT03925753 59 64 I-Eq-Comparison
. NCT03925753 65 66 O

- NCT03925753 70 71 O
Received NCT03925753 73 81 B-Eq-Comparison
stable NCT03925753 82 88 O
hemodialysis NCT03925753 89 101 B-Procedure
at NCT03925753 102 104 B-Eq-Comparison
least NCT03925753 105 110 I-Eq-Comparison
3 NCT03925753 111 112 I-Eq-Comparison
months NCT03925753 113 119 I-Eq-Comparison
. NCT03925753 120 121 O

- NCT03925753 125 126 O
Written NCT03925753 128 135 O
informed NCT03925753 136 144 O
consent NCT03925753 145 152 O
. NCT03925753 153 154 O

Exclusion NCT03925753 156 165 O
Criteria NCT03925753 166 174 O
: NCT03925753 175 176 O

- NCT03925753 180 181 O
patients NCT03925753 183 191 O
with NCT03925753 192 196 O
severe NCT03925753 197 203 O
infections NCT03925753 204 214 B-Condition
, NCT03925753 215 216 O
severe NCT03925753 217 223 O
heart NCT03925753 224 229 B-Condition
disease NCT03925753 230 237 I-Condition
and NCT03925753 238 241 B-Or
liver NCT03925753 242 247 B-Condition
disease NCT03925753 248 255 I-Condition
, NCT03925753 256 257 O
malignancy NCT03925753 258 268 B-Condition
, NCT03925753 269 270 O
autoimmune NCT03925753 271 281 B-Condition
disorders NCT03925753 282 291 I-Condition
, NCT03925753 292 293 O
severe NCT03925753 294 300 O
malnutrition NCT03925753 301 313 B-Condition
, NCT03925753 314 315 O
or NCT03925753 316 318 B-Or
clinical NCT03925753 319 327 O
conditions NCT03925753 328 338 B-Condition
requiring NCT03925753 339 348 O
oral NCT03925753 349 353 B-Procedure
nutrition NCT03925753 354 363 I-Procedure
supplements NCT03925753 364 375 I-Procedure
; NCT03925753 375 376 O

- NCT03925753 379 380 O
Inability NCT03925753 382 391 O
to NCT03925753 392 394 O
follow NCT03925753 395 401 O
protocol NCT03925753 402 410 O
. NCT03925753 411 412 O

- NCT03925753 416 417 O
Pregnancy NCT03925753 419 428 B-Condition
or NCT03925753 429 431 B-Or
wishing NCT03925753 432 439 B-Assertion___Assertion-Type-Value:intention
/ NCT03925753 440 441 B-Or
trying NCT03925753 442 448 B-Assertion___Assertion-Type-Value:intention
to NCT03925753 449 451 O
get NCT03925753 452 455 O
pregnant NCT03925753 456 464 B-Condition

Inclusion NCT03925779 0 9 O
Criteria NCT03925779 10 18 O
: NCT03925779 19 20 O

- NCT03925779 24 25 O
ASA NCT03925779 27 30 B-Condition
I NCT03925779 31 32 B-Eq-Comparison
or NCT03925779 33 35 I-Eq-Comparison
II NCT03925779 36 38 I-Eq-Comparison
physical NCT03925779 39 47 O
status NCT03925779 48 54 O

- NCT03925779 57 58 O
18 NCT03925779 60 62 B-Eq-Comparison
- NCT03925779 63 64 I-Eq-Comparison
65 NCT03925779 65 67 I-Eq-Comparison
years NCT03925779 68 73 I-Age|Eq-Comparison

- NCT03925779 76 77 O
Scheduled NCT03925779 79 88 B-Eq-Comparison
for NCT03925779 89 92 O
elective NCT03925779 93 101 B-Modifier
colonoscopy NCT03925779 102 113 B-Procedure

Exclusion NCT03925779 114 123 O
Criteria NCT03925779 124 132 O
: NCT03925779 133 134 O

- NCT03925779 138 139 O
History NCT03925779 141 148 B-Eq-Comparison
of NCT03925779 149 151 O
allergy NCT03925779 152 159 B-Allergy
to NCT03925779 160 162 O
any NCT03925779 163 166 O
of NCT03925779 167 169 O
the NCT03925779 170 173 O
study NCT03925779 174 179 B-Study
drugs NCT03925779 180 185 B-Drug

- NCT03925779 188 189 O
Alcohol NCT03925779 191 198 B-Modifier
or NCT03925779 199 201 B-Or
drug NCT03925779 202 206 B-Modifier
abuse NCT03925779 207 212 B-Condition
. NCT03925779 213 214 O

- NCT03925779 218 219 O
Second NCT03925779 221 227 B-Eq-Comparison
and NCT03925779 228 231 I-Eq-Comparison
third NCT03925779 232 237 I-Eq-Comparison
- NCT03925779 238 239 I-Eq-Comparison
degree NCT03925779 240 246 I-Eq-Comparison
heart NCT03925779 247 252 B-Condition
block NCT03925779 253 258 I-Condition
. NCT03925779 259 260 O

- NCT03925779 264 265 O
Morbid NCT03925779 267 273 B-Condition
obesity NCT03925779 274 281 I-Condition
. NCT03925779 282 283 O

- NCT03925779 287 288 O
Pregnant NCT03925779 290 298 B-Condition
and NCT03925779 299 302 B-Or
lactating NCT03925779 303 312 B-Condition
women NCT03925779 313 318 O
. NCT03925779 319 320 O

- NCT03925779 324 325 O
Psychiatric NCT03925779 327 338 B-Condition
disorders NCT03925779 339 348 I-Condition
. NCT03925779 349 350 O

- NCT03925779 354 355 O
Severe NCT03925779 357 363 O
cardiac NCT03925779 364 371 B-Modifier
, NCT03925779 372 373 O
respiratory NCT03925779 374 385 B-Modifier
, NCT03925779 386 387 O
renal NCT03925779 388 393 B-Modifier
, NCT03925779 394 395 O
and NCT03925779 396 399 B-Or
liver NCT03925779 400 405 B-Modifier
diseases NCT03925779 406 414 B-Condition

Inclusion NCT03921047 0 9 O
Criteria NCT03921047 10 18 O
: NCT03921047 19 20 O

- NCT03921047 24 25 O
Diagnosis NCT03921047 27 36 O
of NCT03921047 37 39 O
AML NCT03921047 40 43 B-Condition
scheduled NCT03921047 44 53 B-Eq-Comparison
to NCT03921047 54 56 O
undergo NCT03921047 57 64 O
HSCT NCT03921047 65 69 B-Procedure
at NCT03921047 70 72 O
University NCT03921047 73 83 O
of NCT03921047 84 86 O
Southern NCT03921047 87 95 O
California NCT03921047 96 106 O
( NCT03921047 107 108 O
USC NCT03921047 109 112 O
) NCT03921047 113 114 O

Exclusion NCT03921047 116 125 O
Criteria NCT03921047 126 134 O
: NCT03921047 135 136 O

- NCT03921047 140 141 O
Inability NCT03921047 143 152 O
to NCT03921047 153 155 O
provide NCT03921047 156 163 O
consent NCT03921047 164 171 O
because NCT03921047 172 179 O
of NCT03921047 180 182 O
severe NCT03921047 183 189 B-Condition
mental NCT03921047 190 196 I-Condition
disorders NCT03921047 197 206 I-Condition

- NCT03921047 209 210 O
Donor NCT03921047 212 217 O
unwilling NCT03921047 218 227 O
to NCT03921047 228 230 O
provide NCT03921047 231 238 O
consent NCT03921047 239 246 O

Inclusion NCT03929341 0 9 O
Criteria NCT03929341 10 18 O
: NCT03929341 19 20 O

- NCT03929341 24 25 O
Men NCT03929341 27 30 O
and NCT03929341 31 34 B-Or
women NCT03929341 35 40 O
age NCT03929341 41 44 B-Age
≥ NCT03929341 45 46 B-Eq-Comparison
40 NCT03929341 47 49 I-Eq-Comparison
years NCT03929341 50 55 I-Eq-Comparison
of NCT03929341 56 58 O
age NCT03929341 59 62 O

- NCT03929341 65 66 O
Stable NCT03929341 68 74 O
chest NCT03929341 75 80 B-Modifier
pain NCT03929341 81 85 B-Condition
or NCT03929341 86 88 B-Or
equivalent NCT03929341 89 99 B-Modifier
symptoms NCT03929341 100 108 B-Assertion___Assertion-Type-Value:possible

- NCT03929341 111 112 O
Planned NCT03929341 114 121 B-Eq-Comparison
non NCT03929341 122 125 B-Negation
- NCT03929341 126 127 O
urgent NCT03929341 128 134 B-Modifier
, NCT03929341 135 136 O
non NCT03929341 137 140 B-Negation
- NCT03929341 141 142 O
invasive NCT03929341 143 151 B-Modifier
testing NCT03929341 152 159 B-Procedure
for NCT03929341 160 163 O
diagnosis NCT03929341 164 173 O
of NCT03929341 174 176 O
chest NCT03929341 177 182 B-Modifier
pain NCT03929341 183 187 B-Condition
or NCT03929341 188 190 B-Or
equivalent NCT03929341 191 201 B-Modifier
symptoms NCT03929341 202 210 B-Assertion___Assertion-Type-Value:possible

Exclusion NCT03929341 211 220 O
Criteria NCT03929341 221 229 O
: NCT03929341 230 231 O

- NCT03929341 235 236 O
Acute NCT03929341 238 243 O
coronary NCT03929341 244 252 B-Condition
syndrome NCT03929341 253 261 I-Condition
, NCT03929341 262 263 O
including NCT03929341 264 273 O
acute NCT03929341 274 279 O
myocardial NCT03929341 280 290 B-Condition
infarction NCT03929341 291 301 I-Condition
or NCT03929341 302 304 B-Or
unstable NCT03929341 305 313 O
angina NCT03929341 314 320 B-Condition
, NCT03929341 321 322 O
known NCT03929341 323 328 O
non NCT03929341 329 332 B-Negation
- NCT03929341 333 334 O
ischemic NCT03929341 335 343 B-Modifier
cardiomyopathy NCT03929341 344 358 B-Condition
or NCT03929341 359 361 B-Or
other NCT03929341 362 367 B-Other
cardiac NCT03929341 368 375 B-Condition
disease NCT03929341 376 383 I-Condition
( NCT03929341 384 385 O
e. NCT03929341 386 388 O
g. NCT03929341 389 391 O
mitral NCT03929341 393 399 B-Condition
valve NCT03929341 400 405 I-Condition
prolapse NCT03929341 406 414 I-Condition
, NCT03929341 415 416 O
etc NCT03929341 417 420 O
. NCT03929341 420 421 O
) NCT03929341 422 423 O
which NCT03929341 424 429 O
would NCT03929341 430 435 B-Assertion___Assertion-Type-Value:hypothetical
require NCT03929341 436 443 O
urgent NCT03929341 444 450 B-Modifier
cardiac NCT03929341 451 458 B-Procedure
evaluation NCT03929341 459 469 I-Procedure

- NCT03929341 472 473 O
Known NCT03929341 475 480 O
CAD NCT03929341 481 484 B-Condition

- NCT03929341 487 488 O
Prior NCT03929341 490 495 B-Eq-Comparison
cardiac NCT03929341 496 503 B-Procedure
evaluation NCT03929341 504 514 I-Procedure
for NCT03929341 515 518 O
current NCT03929341 519 526 B-Eq-Comparison
episode NCT03929341 527 534 O
of NCT03929341 535 537 O
symptoms NCT03929341 538 546 B-Condition

- NCT03929341 549 550 O
Previously NCT03929341 552 562 B-Eq-Comparison
investigated NCT03929341 563 575 B-Procedure
for NCT03929341 576 579 O
CAD NCT03929341 580 583 B-Condition
in NCT03929341 584 586 O
the NCT03929341 587 590 O
last NCT03929341 591 595 B-Eq-Comparison
12 NCT03929341 596 598 I-Eq-Comparison
months NCT03929341 599 605 I-Eq-Comparison

- NCT03929341 608 609 O
Severe NCT03929341 611 617 O
allergic NCT03929341 618 626 B-Allergy
reaction NCT03929341 627 635 O
to NCT03929341 636 638 O
iodinated NCT03929341 639 648 O
contrast NCT03929341 649 657 O
( NCT03929341 658 659 O
mild NCT03929341 660 664 O
reactions NCT03929341 665 674 O
such NCT03929341 675 679 O
as NCT03929341 680 682 O
urticaria NCT03929341 683 692 B-Condition
that NCT03929341 693 697 O
can NCT03929341 698 701 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03929341 702 704 O
controlled NCT03929341 705 715 O
by NCT03929341 716 718 O
premedication NCT03929341 719 732 B-Procedure
with NCT03929341 733 737 O
Benadryl NCT03929341 738 746 B-Drug
& NCT03929341 747 748 B-Or
Prednisone NCT03929341 749 759 B-Drug
may NCT03929341 760 763 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03929341 764 766 O
included NCT03929341 767 775 O
in NCT03929341 776 778 O
the NCT03929341 779 782 O
study NCT03929341 783 788 B-Study
) NCT03929341 789 790 O

- NCT03929341 794 795 O
Renal NCT03929341 797 802 B-Condition
failure NCT03929341 803 810 I-Condition
or NCT03929341 811 813 B-Or
dysfunction NCT03929341 814 825 B-Condition
( NCT03929341 826 827 O
estimated NCT03929341 828 837 B-Observation
Glomerular NCT03929341 838 848 I-Observation
Filtration NCT03929341 849 859 I-Observation
Rate NCT03929341 860 864 I-Observation
< NCT03929341 865 866 B-Eq-Comparison
30 NCT03929341 867 869 I-Eq-Comparison
ml NCT03929341 870 872 I-Eq-Comparison
/ NCT03929341 873 874 I-Eq-Comparison
min NCT03929341 875 878 I-Eq-Comparison
/ NCT03929341 879 880 I-Eq-Comparison
m2 NCT03929341 881 883 I-Eq-Comparison
within NCT03929341 884 890 B-Eq-Comparison
the NCT03929341 891 894 I-Eq-Comparison
past NCT03929341 895 899 I-Eq-Comparison
3 NCT03929341 900 901 I-Eq-Comparison
months NCT03929341 902 908 I-Eq-Comparison
) NCT03929341 909 910 O

- NCT03929341 914 915 O
Pregnancy NCT03929341 917 926 B-Condition
( NCT03929341 927 928 O
status NCT03929341 929 935 O
will NCT03929341 936 940 O
be NCT03929341 941 943 O
confirmed NCT03929341 944 953 O
verbally NCT03929341 954 962 O
. NCT03929341 962 963 O
For NCT03929341 965 968 O
premenopausal NCT03929341 969 982 B-Condition
patients NCT03929341 983 991 O
who NCT03929341 992 995 O
are NCT03929341 996 999 O
unsure NCT03929341 1000 1006 O
, NCT03929341 1007 1008 O
status NCT03929341 1009 1015 O
will NCT03929341 1016 1020 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03929341 1021 1023 I-Assertion___Assertion-Type-Value:hypothetical
confirmed NCT03929341 1024 1033 O
by NCT03929341 1034 1036 O
completing NCT03929341 1037 1047 O
a NCT03929341 1048 1049 O
pregnancy NCT03929341 1050 1059 B-Observation
strip NCT03929341 1060 1065 I-Observation
test NCT03929341 1066 1070 I-Observation
) NCT03929341 1071 1072 O
. NCT03929341 1073 1074 O

Inclusion NCT03927378 0 9 O
Criteria NCT03927378 10 18 O
: NCT03927378 19 20 O

- NCT03927378 24 25 O
Parturients NCT03927378 27 38 O
with NCT03927378 39 43 O
age NCT03927378 44 47 B-Age
≥ NCT03927378 48 49 B-Eq-Comparison
18 NCT03927378 50 52 I-Eq-Comparison
years NCT03927378 53 58 I-Eq-Comparison
; NCT03927378 58 59 O

- NCT03927378 62 63 O
Presence NCT03927378 65 73 O
of NCT03927378 74 76 O
prenatal NCT03927378 77 85 B-Modifier
depression NCT03927378 86 96 B-Condition
( NCT03927378 97 98 O
EPDS NCT03927378 99 103 B-Observation
score NCT03927378 104 109 I-Observation
≥ NCT03927378 110 111 B-Eq-Comparison
10 NCT03927378 112 114 I-Eq-Comparison
) NCT03927378 115 116 O
; NCT03927378 117 118 O

- NCT03927378 121 122 O
Provide NCT03927378 124 131 O
written NCT03927378 132 139 O
informed NCT03927378 140 148 O
consents NCT03927378 149 157 O
. NCT03927378 158 159 O

Exclusion NCT03927378 161 170 O
Criteria NCT03927378 171 179 O
: NCT03927378 180 181 O

- NCT03927378 185 186 O
History NCT03927378 188 195 B-Eq-Comparison
of NCT03927378 196 198 O
psychiatric NCT03927378 199 210 B-Condition
disease NCT03927378 211 218 I-Condition
( NCT03927378 219 220 O
schizophrenia NCT03927378 221 234 B-Condition
) NCT03927378 235 236 O
or NCT03927378 237 239 B-Or
communication NCT03927378 240 253 B-Condition
barriers NCT03927378 254 262 I-Condition
that NCT03927378 263 267 O
prevent NCT03927378 268 275 B-Negation
normal NCT03927378 276 282 O
communication NCT03927378 283 296 B-Observation
before NCT03927378 297 303 B-Temporal-Connection___Temporal-Connection-Type-Value:before
childbirth NCT03927378 304 314 B-Procedure
; NCT03927378 314 315 O

- NCT03927378 318 319 O
Severe NCT03927378 321 327 O
complications NCT03927378 328 341 B-Condition
during NCT03927378 342 348 B-Temporal-Connection___Temporal-Connection-Type-Value:during
pregnancy NCT03927378 349 358 B-Condition
( NCT03927378 359 360 O
such NCT03927378 361 365 O
as NCT03927378 366 368 O
severe NCT03927378 369 375 O
preeclampsia NCT03927378 376 388 B-Condition
, NCT03927378 389 390 O
placenta NCT03927378 391 399 B-Condition
accreta NCT03927378 400 407 I-Condition
, NCT03927378 408 409 O
or NCT03927378 410 412 B-Or
HELLP NCT03927378 413 418 B-Condition
[ NCT03927378 419 420 O
Hemolysis NCT03927378 421 430 B-Condition
, NCT03927378 431 432 I-Condition
Elevated NCT03927378 433 441 I-Condition
Liver NCT03927378 442 447 I-Condition
enzymes NCT03927378 448 455 I-Condition
and NCT03927378 456 459 I-Condition
Low NCT03927378 460 463 I-Condition
Platelets NCT03927378 464 473 I-Condition
] NCT03927378 474 475 O
syndrome NCT03927378 476 484 B-Modifier
) NCT03927378 485 486 O
; NCT03927378 487 488 O

- NCT03927378 491 492 O
ASA NCT03927378 494 497 B-Condition
physical NCT03927378 498 506 O
status NCT03927378 507 513 O
classification NCT03927378 514 528 B-Eq-Comparison
≥ NCT03927378 529 530 I-Eq-Comparison
III NCT03927378 531 534 I-Eq-Comparison
; NCT03927378 534 535 O

- NCT03927378 538 539 O
Presence NCT03927378 541 549 O
of NCT03927378 550 552 O
contraindications NCT03927378 553 570 B-Contraindication
to NCT03927378 571 573 O
ketamine NCT03927378 574 582 B-Drug
, NCT03927378 583 584 O
including NCT03927378 585 594 O
refractory NCT03927378 595 605 B-Modifier
hypertension NCT03927378 606 618 B-Condition
, NCT03927378 619 620 O
severe NCT03927378 621 627 O
cardiovascular NCT03927378 628 642 B-Condition
disease NCT03927378 643 650 I-Condition
( NCT03927378 651 652 O
heart NCT03927378 653 658 B-Condition
function NCT03927378 659 667 I-Condition
classification NCT03927378 668 682 B-Eq-Comparison
≥ NCT03927378 683 684 I-Eq-Comparison
III NCT03927378 685 688 I-Eq-Comparison
) NCT03927378 689 690 O
, NCT03927378 692 693 O
or NCT03927378 694 696 B-Or
hyperthyroidism NCT03927378 697 712 B-Condition
; NCT03927378 712 713 O

- NCT03927378 716 717 O
Refuse NCT03927378 719 725 O
to NCT03927378 726 728 O
participate NCT03927378 729 740 O
. NCT03927378 740 741 O

Inclusion NCT03925584 0 9 O
Criteria NCT03925584 10 18 O
: NCT03925584 19 20 O

- NCT03925584 24 25 O
Greater NCT03925584 27 34 B-Eq-Comparison
than NCT03925584 35 39 I-Eq-Comparison
37 NCT03925584 40 42 I-Eq-Comparison
weeks NCT03925584 43 48 I-Eq-Comparison
gestation NCT03925584 49 58 B-Observation
, NCT03925584 59 60 O

- NCT03925584 64 65 O
Between NCT03925584 67 74 B-Eq-Comparison
0 NCT03925584 75 76 I-Eq-Comparison
to NCT03925584 77 79 I-Eq-Comparison
30 NCT03925584 80 82 I-Eq-Comparison
days NCT03925584 83 87 I-Eq-Comparison
of NCT03925584 88 90 O
age NCT03925584 91 94 B-Age

- NCT03925584 97 98 O
24 NCT03925584 100 102 B-Eq-Comparison
hours NCT03925584 103 108 I-Eq-Comparison
post NCT03925584 109 113 B-Temporal-Connection___Temporal-Connection-Type-Value:after
congenital NCT03925584 114 124 B-Modifier
heart NCT03925584 125 130 B-Procedure
surgery NCT03925584 131 138 I-Procedure

- NCT03925584 141 142 O
Receiving NCT03925584 144 153 B-Eq-Comparison
mechanical NCT03925584 154 164 B-Procedure
ventilation NCT03925584 165 176 I-Procedure

- NCT03925584 179 180 O
Background NCT03925584 182 192 B-Observation
noise NCT03925584 193 198 I-Observation
level NCT03925584 199 204 I-Observation
( NCT03925584 205 206 O
at NCT03925584 207 209 O
bedside NCT03925584 210 217 B-Modifier
) NCT03925584 218 219 O
at NCT03925584 220 222 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03925584 223 226 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03925584 227 231 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03925584 232 234 O
music NCT03925584 235 240 B-Procedure
therapy NCT03925584 241 248 I-Procedure
must NCT03925584 249 253 O
be NCT03925584 254 256 O
55 NCT03925584 257 259 B-Eq-Comparison
dB NCT03925584 260 262 I-Eq-Comparison
or NCT03925584 263 265 I-Eq-Comparison
less NCT03925584 266 270 I-Eq-Comparison
. NCT03925584 271 272 O

Exclusion NCT03925584 274 283 O
Criteria NCT03925584 284 292 O
: NCT03925584 293 294 O

- NCT03925584 298 299 O
Hemodynamically NCT03925584 301 316 B-Condition
unstable NCT03925584 317 325 O
or NCT03925584 326 328 B-Or
end NCT03925584 329 332 B-Death|Risk
of NCT03925584 333 335 I-Death|Risk
life NCT03925584 336 340 I-Death|Risk

- NCT03925584 343 344 O
If NCT03925584 346 348 O
patient NCT03925584 349 356 O
is NCT03925584 357 359 O
in NCT03925584 360 362 O
a NCT03925584 363 364 O
closed NCT03925584 365 371 O
Giraffe NCT03925584 372 379 O
bed NCT03925584 380 383 O

- NCT03925584 386 387 O
Evidence NCT03925584 389 397 O
of NCT03925584 398 400 O
hearing NCT03925584 401 408 B-Condition
impairment NCT03925584 409 419 I-Condition

- NCT03925584 422 423 O
Patient NCT03925584 425 432 O
has NCT03925584 433 436 O
known NCT03925584 437 442 O
or NCT03925584 443 445 O
suspected NCT03925584 446 455 B-Assertion___Assertion-Type-Value:possible
active NCT03925584 456 462 B-Eq-Comparison
seizure NCT03925584 463 470 B-Condition
disorder NCT03925584 471 479 I-Condition

Inclusion NCT03925181 0 9 O
Criteria NCT03925181 10 18 O
for NCT03925181 19 22 O
Patients NCT03925181 23 31 O
: NCT03925181 32 33 O

- NCT03925181 37 38 O
Spent NCT03925181 40 45 O
more NCT03925181 46 50 B-Eq-Comparison
than NCT03925181 51 55 I-Eq-Comparison
4 NCT03925181 56 57 I-Eq-Comparison
days NCT03925181 58 62 I-Eq-Comparison
in NCT03925181 63 65 O
the NCT03925181 66 69 O
ICU NCT03925181 70 73 B-Encounter
, NCT03925181 74 75 O

- NCT03925181 79 80 O
Were NCT03925181 82 86 O
discharged NCT03925181 87 97 B-Encounter
into NCT03925181 98 102 O
the NCT03925181 103 106 O
community NCT03925181 107 116 O
within NCT03925181 117 123 B-Eq-Comparison
4 NCT03925181 124 125 I-Eq-Comparison
months NCT03925181 126 132 I-Eq-Comparison
of NCT03925181 133 135 B-Temporal-Connection___Temporal-Connection-Type-Value:after
transfer NCT03925181 136 144 B-Encounter
out NCT03925181 145 148 I-Encounter
of NCT03925181 149 151 I-Encounter
the NCT03925181 152 155 I-Encounter
ICU NCT03925181 156 159 I-Encounter
( NCT03925181 160 161 O
excluding NCT03925181 162 171 B-Exception
patients NCT03925181 172 180 O
who NCT03925181 181 184 O
were NCT03925181 185 189 O
in NCT03925181 190 192 O
hospital NCT03925181 193 201 B-Encounter
long NCT03925181 202 206 B-Eq-Comparison
- NCT03925181 207 208 I-Eq-Comparison
term NCT03925181 209 213 I-Eq-Comparison
) NCT03925181 214 215 O

- NCT03925181 219 220 O
Speaks NCT03925181 222 228 O
English NCT03925181 229 236 O

- NCT03925181 239 240 O
Has NCT03925181 242 245 O
a NCT03925181 246 247 O
fixed NCT03925181 248 253 O
address NCT03925181 254 261 O

- NCT03925181 264 265 O
Does NCT03925181 267 271 O
not NCT03925181 272 275 B-Negation
have NCT03925181 276 280 O
pre NCT03925181 281 284 B-Eq-Comparison
- NCT03925181 285 286 I-Eq-Comparison
existing NCT03925181 287 295 I-Eq-Comparison
psychiatric NCT03925181 296 307 B-Condition
diagnoses NCT03925181 308 317 O
documented NCT03925181 318 328 O
in NCT03925181 329 331 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03925181 332 335 O
ICU NCT03925181 336 339 B-Encounter
transfer NCT03925181 340 348 I-Encounter
summary NCT03925181 349 356 O

- NCT03925181 359 360 O
Lives NCT03925181 362 367 B-Observation
within NCT03925181 368 374 O
or NCT03925181 375 377 O
surrounding NCT03925181 378 389 O
Calgary NCT03925181 390 397 O
. NCT03925181 398 399 O

Inclusion NCT03925181 401 410 O
Criteria NCT03925181 411 419 O
for NCT03925181 420 423 O
Caregivers NCT03925181 424 434 O
: NCT03925181 435 436 O

- NCT03925181 440 441 O
Caregiver NCT03925181 443 452 O
of NCT03925181 453 455 O
an NCT03925181 456 458 O
ICU NCT03925181 459 462 O
survivor NCT03925181 463 471 O
participant NCT03925181 472 483 O
meeting NCT03925181 484 491 O
criteria NCT03925181 492 500 O
above NCT03925181 501 506 O

- NCT03925181 509 510 O
Speaks NCT03925181 512 518 O
English NCT03925181 519 526 O

- NCT03925181 529 530 O
Has NCT03925181 532 535 O
a NCT03925181 536 537 O
fixed NCT03925181 538 543 O
address NCT03925181 544 551 O

- NCT03925181 554 555 O
Lives NCT03925181 557 562 B-Observation
within NCT03925181 563 569 O
or NCT03925181 570 572 O
surrounding NCT03925181 573 584 O
Calgary NCT03925181 585 592 O
. NCT03925181 593 594 O

Exclusion NCT03925181 596 605 O
Criteria NCT03925181 606 614 O
for NCT03925181 615 618 O
Patients NCT03925181 619 627 O
: NCT03925181 628 629 O

- NCT03925181 632 633 O
Long NCT03925181 634 638 B-Eq-Comparison
- NCT03925181 639 640 I-Eq-Comparison
term NCT03925181 641 645 I-Eq-Comparison
hospital NCT03925181 646 654 B-Encounter
stay NCT03925181 655 659 O

Excluding NCT03925181 660 669 O
Criteria NCT03925181 670 678 O
for NCT03925181 679 682 O
Caregivers NCT03925181 683 693 O
: NCT03925181 694 695 O

- NCT03925181 698 699 O
None NCT03925181 700 704 O

Inclusion NCT03929744 0 9 O
Criteria NCT03929744 10 18 O
: NCT03929744 19 20 O

- NCT03929744 24 25 O
Healthy NCT03929744 27 34 B-Condition
male NCT03929744 35 39 O
or NCT03929744 40 42 B-Or
females NCT03929744 43 50 O
, NCT03929744 51 52 O
as NCT03929744 53 55 O
determined NCT03929744 56 66 O
by NCT03929744 67 69 O
medical NCT03929744 70 77 O
history NCT03929744 78 85 O

- NCT03929744 88 89 O
Have NCT03929744 91 95 O
safety NCT03929744 96 102 B-Modifier
laboratory NCT03929744 103 113 B-Observation
results NCT03929744 114 121 I-Observation
within NCT03929744 122 128 B-Eq-Comparison
normal NCT03929744 129 135 I-Eq-Comparison
reference NCT03929744 136 145 I-Eq-Comparison
ranges NCT03929744 146 152 I-Eq-Comparison

Exclusion NCT03929744 153 162 O
Criteria NCT03929744 163 171 O
: NCT03929744 172 173 O

- NCT03929744 177 178 O
Have NCT03929744 180 184 O
known NCT03929744 185 190 O
allergies NCT03929744 191 200 B-Allergy
to NCT03929744 201 203 O
LY3502970 NCT03929744 204 213 B-Drug
, NCT03929744 214 215 O
glucagon NCT03929744 216 224 B-Drug
- NCT03929744 225 226 I-Drug
like NCT03929744 227 231 I-Drug
peptide NCT03929744 232 239 I-Drug
- NCT03929744 240 241 I-Drug
1 NCT03929744 242 243 I-Drug
( NCT03929744 244 245 O
GLP NCT03929744 246 249 B-Drug
- NCT03929744 250 251 I-Drug
1 NCT03929744 252 253 I-Drug
) NCT03929744 254 255 O
analogs NCT03929744 256 263 B-Modifier
, NCT03929744 264 265 O
related NCT03929744 266 273 O
compounds NCT03929744 274 283 O

- NCT03929744 286 287 O
Abnormal NCT03929744 289 297 O
electrocardiogram NCT03929744 298 315 B-Procedure
( NCT03929744 316 317 O
ECG NCT03929744 318 321 B-Procedure
) NCT03929744 322 323 O
at NCT03929744 324 326 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03929744 327 336 B-Study

- NCT03929744 339 340 O
Significant NCT03929744 342 353 O
history NCT03929744 354 361 B-Eq-Comparison
of NCT03929744 362 364 O
or NCT03929744 365 367 B-Or
current NCT03929744 368 375 B-Eq-Comparison
cardiovascular NCT03929744 376 390 B-Modifier
, NCT03929744 391 392 O
respiratory NCT03929744 393 404 B-Modifier
, NCT03929744 405 406 O
hepatic NCT03929744 407 414 B-Modifier
, NCT03929744 415 416 O
renal NCT03929744 417 422 B-Modifier
, NCT03929744 423 424 O
gastrointestinal NCT03929744 425 441 B-Modifier
, NCT03929744 442 443 O
endocrine NCT03929744 444 453 B-Modifier
, NCT03929744 454 455 O
hematological NCT03929744 456 469 B-Modifier
or NCT03929744 470 472 B-Or
neurological NCT03929744 473 485 B-Modifier
disorders NCT03929744 486 495 B-Condition
. NCT03929744 495 496 O

Inclusion NCT03920774 0 9 O
Criteria NCT03920774 10 18 O
: NCT03920774 19 20 O

- NCT03920774 24 25 O
Patients NCT03920774 27 35 O
of NCT03920774 36 38 O
any NCT03920774 39 42 O
age NCT03920774 43 46 O
with NCT03920774 47 51 O
a NCT03920774 52 53 O
diagnosis NCT03920774 54 63 O
of NCT03920774 64 66 O
familial NCT03920774 67 75 B-Condition
dysautonomia NCT03920774 76 88 I-Condition
( NCT03920774 89 90 O
FD NCT03920774 91 93 B-Condition
) NCT03920774 94 95 O
with NCT03920774 96 100 B-And
molecular NCT03920774 101 110 O
confirmation NCT03920774 111 123 O
of NCT03920774 124 126 O
the NCT03920774 127 130 O
IKBKAP NCT03920774 131 137 B-Condition
mutation NCT03920774 138 146 I-Condition
. NCT03920774 147 148 O

- NCT03920774 152 153 O
Ability NCT03920774 155 162 O
to NCT03920774 163 165 O
provide NCT03920774 166 173 O
informed NCT03920774 174 182 O
consent NCT03920774 183 190 O
( NCT03920774 191 192 O
or NCT03920774 193 195 O
assent NCT03920774 196 202 O
) NCT03920774 203 204 O
and NCT03920774 205 208 O
comply NCT03920774 209 215 O
with NCT03920774 216 220 O
the NCT03920774 221 224 O
study NCT03920774 225 230 O
protocol NCT03920774 231 239 O

Exclusion NCT03920774 240 249 O
Criteria NCT03920774 250 258 O
: NCT03920774 259 260 O

- NCT03920774 264 265 O
Subjects NCT03920774 267 275 O
that NCT03920774 276 280 O
do NCT03920774 281 283 O
not NCT03920774 284 287 O
wish NCT03920774 288 292 O
to NCT03920774 293 295 O
be NCT03920774 296 298 O
a NCT03920774 299 300 O
part NCT03920774 301 305 O
of NCT03920774 306 308 O
the NCT03920774 309 312 O
study NCT03920774 313 318 O
. NCT03920774 318 319 O

Inclusion NCT03925142 0 9 O
Criteria NCT03925142 10 18 O
: NCT03925142 19 20 O

- NCT03925142 24 25 O
Male NCT03925142 27 31 O
or NCT03925142 32 34 B-Or
female NCT03925142 35 41 O

- NCT03925142 44 45 O
30 NCT03925142 47 49 B-Eq-Comparison
- NCT03925142 50 51 I-Eq-Comparison
69 NCT03925142 52 54 I-Eq-Comparison
years NCT03925142 55 60 I-Eq-Comparison
old NCT03925142 61 64 B-Age

- NCT03925142 67 68 O
BMI NCT03925142 70 73 B-Observation
25 NCT03925142 74 76 I-Eq-Comparison
- NCT03925142 77 78 I-Eq-Comparison
37 NCT03925142 79 81 I-Eq-Comparison
kg NCT03925142 82 84 I-Eq-Comparison
/ NCT03925142 85 86 I-Eq-Comparison
m2 NCT03925142 87 89 I-Eq-Comparison

- NCT03925142 92 93 O
Total NCT03925142 95 100 B-Observation
cholesterol NCT03925142 101 112 I-Observation
< NCT03925142 113 114 B-Eq-Comparison
260 NCT03925142 115 118 I-Eq-Comparison
mg NCT03925142 119 121 I-Eq-Comparison
/ NCT03925142 122 123 I-Eq-Comparison
dL NCT03925142 124 126 I-Eq-Comparison

- NCT03925142 129 130 O
Low NCT03925142 132 135 B-Observation
- NCT03925142 136 137 I-Observation
density NCT03925142 138 145 I-Observation
lipoprotein NCT03925142 146 157 I-Observation
cholesterol NCT03925142 158 169 I-Observation
< NCT03925142 170 171 B-Eq-Comparison
190 NCT03925142 172 175 I-Eq-Comparison
mg NCT03925142 176 178 I-Eq-Comparison
/ NCT03925142 179 180 I-Eq-Comparison
dL NCT03925142 181 183 I-Eq-Comparison

- NCT03925142 186 187 O
Glucose NCT03925142 189 196 B-Observation
< NCT03925142 197 198 B-Eq-Comparison
110 NCT03925142 199 202 I-Eq-Comparison
mg NCT03925142 203 205 I-Eq-Comparison
/ NCT03925142 206 207 I-Eq-Comparison
dL NCT03925142 208 210 I-Eq-Comparison

- NCT03925142 213 214 O
Systolic NCT03925142 216 224 B-Modifier
/ NCT03925142 225 226 B-Or
diastolic NCT03925142 227 236 B-Modifier
blood NCT03925142 237 242 B-Observation
pressure NCT03925142 243 251 I-Observation
< NCT03925142 252 253 B-Eq-Comparison
140 NCT03925142 254 257 I-Eq-Comparison
/ NCT03925142 258 259 I-Eq-Comparison
90 NCT03925142 260 262 I-Eq-Comparison

- NCT03925142 266 267 O
Body NCT03925142 269 273 B-Observation
weight NCT03925142 274 280 I-Observation
stable NCT03925142 281 287 O
for NCT03925142 288 291 O
3 NCT03925142 292 293 B-Eq-Comparison
months NCT03925142 294 300 I-Eq-Comparison
prior NCT03925142 301 306 I-Eq-Comparison
( NCT03925142 307 308 O
± NCT03925142 310 311 B-Eq-Comparison
3 NCT03925142 312 313 I-Eq-Comparison
kg NCT03925142 314 316 I-Eq-Comparison
) NCT03925142 317 318 O

- NCT03925142 322 323 O
Stable NCT03925142 325 331 O
physical NCT03925142 332 340 B-Observation
activity NCT03925142 341 349 I-Observation
regimen NCT03925142 350 357 O
3 NCT03925142 358 359 B-Eq-Comparison
months NCT03925142 360 366 I-Eq-Comparison
prior NCT03925142 367 372 I-Eq-Comparison

- NCT03925142 375 376 O
Medication NCT03925142 378 388 B-Drug
use NCT03925142 389 392 O
stable NCT03925142 393 399 O
for NCT03925142 400 403 O
6 NCT03925142 404 405 B-Eq-Comparison
months NCT03925142 406 412 I-Eq-Comparison
prior NCT03925142 413 418 I-Eq-Comparison

- NCT03925142 421 422 O
Non NCT03925142 424 427 B-Negation
- NCT03925142 428 429 O
smoking NCT03925142 430 437 B-Condition

- NCT03925142 440 441 O
Not NCT03925142 443 446 B-Negation
drinking NCT03925142 447 455 B-Condition|Observation
more NCT03925142 456 460 B-Eq-Comparison
than NCT03925142 461 465 I-Eq-Comparison
2 NCT03925142 466 467 I-Eq-Comparison
alcoholic NCT03925142 468 477 I-Eq-Comparison
drinks NCT03925142 478 484 I-Eq-Comparison
per NCT03925142 485 488 I-Eq-Comparison
day NCT03925142 489 492 I-Eq-Comparison

- NCT03925142 495 496 O
Non NCT03925142 498 501 B-Negation
- NCT03925142 502 503 O
diabetic NCT03925142 504 512 B-Condition

- NCT03925142 515 516 O
Not NCT03925142 518 521 B-Negation
lactose NCT03925142 522 529 B-Condition
- NCT03925142 530 531 I-Condition
intolerant NCT03925142 532 542 I-Condition

- NCT03925142 545 546 O
Not NCT03925142 548 551 B-Negation
acutely NCT03925142 552 559 O
ill NCT03925142 560 563 B-Condition

- NCT03925142 566 567 O
Non NCT03925142 569 572 B-Negation
- NCT03925142 573 574 O
pregnant NCT03925142 575 583 B-Condition
and NCT03925142 584 587 B-And
not NCT03925142 588 591 B-Negation
lactating NCT03925142 592 601 B-Condition
. NCT03925142 602 603 O

- NCT03925142 607 608 O
Participants NCT03925142 610 622 O
must NCT03925142 623 627 O
be NCT03925142 628 630 O
willing NCT03925142 631 638 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03925142 639 642 I-Assertion___Assertion-Type-Value:hypothetical
able NCT03925142 643 647 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03925142 648 650 O
consume NCT03925142 651 658 O
the NCT03925142 659 662 O
prescribed NCT03925142 663 673 O
diets NCT03925142 674 679 B-Procedure
( NCT03925142 680 681 O
lacto NCT03925142 682 687 B-Modifier
- NCT03925142 688 689 I-Modifier
ovo NCT03925142 690 693 I-Modifier
vegetarian NCT03925142 694 704 I-Modifier
and NCT03925142 705 708 B-Or
omnivorous NCT03925142 709 719 B-Modifier
) NCT03925142 720 721 O
. NCT03925142 723 724 O

Exclusion NCT03925142 726 735 O
Criteria NCT03925142 736 744 O
: NCT03925142 745 746 O

- NCT03925142 750 751 O
< NCT03925142 753 754 B-Eq-Comparison
30 NCT03925142 755 757 I-Eq-Comparison
or NCT03925142 758 760 B-Or
> NCT03925142 761 762 B-Eq-Comparison
69 NCT03925142 763 765 I-Eq-Comparison
years NCT03925142 766 771 I-Eq-Comparison
old NCT03925142 772 775 B-Age

- NCT03925142 778 779 O
BMI NCT03925142 781 784 B-Observation
< NCT03925142 785 786 O
25.0 NCT03925142 787 791 O
or NCT03925142 792 794 B-Or
> NCT03925142 795 796 B-Eq-Comparison
37 NCT03925142 797 799 I-Eq-Comparison
kg NCT03925142 800 802 I-Eq-Comparison
/ NCT03925142 803 804 I-Eq-Comparison
m2 NCT03925142 805 807 I-Eq-Comparison

- NCT03925142 810 811 O
Fasting NCT03925142 813 820 B-Modifier
serum NCT03925142 821 826 B-Observation
total NCT03925142 827 832 I-Observation
cholesterol NCT03925142 833 844 I-Observation
> NCT03925142 845 846 B-Eq-Comparison
260 NCT03925142 847 850 I-Eq-Comparison
mg NCT03925142 851 853 I-Eq-Comparison
/ NCT03925142 854 855 I-Eq-Comparison
dL NCT03925142 856 858 I-Eq-Comparison

- NCT03925142 861 862 O
Low NCT03925142 864 867 B-Observation
- NCT03925142 868 869 I-Observation
density NCT03925142 870 877 I-Observation
lipoprotein NCT03925142 878 889 I-Observation
cholesterol NCT03925142 890 901 I-Observation
> NCT03925142 902 903 B-Eq-Comparison
189 NCT03925142 904 907 I-Eq-Comparison
mg NCT03925142 908 910 I-Eq-Comparison
/ NCT03925142 911 912 I-Eq-Comparison
dL NCT03925142 913 915 I-Eq-Comparison

- NCT03925142 918 919 O
Glucose NCT03925142 921 928 B-Observation
> NCT03925142 929 930 B-Eq-Comparison
110 NCT03925142 931 934 I-Eq-Comparison
mg NCT03925142 935 937 I-Eq-Comparison
/ NCT03925142 938 939 I-Eq-Comparison
dL NCT03925142 940 942 I-Eq-Comparison

- NCT03925142 945 946 O
Systolic NCT03925142 948 956 B-Modifier
/ NCT03925142 957 958 B-Or
diastolic NCT03925142 959 968 B-Modifier
blood NCT03925142 969 974 B-Observation
pressure NCT03925142 975 983 I-Observation
> NCT03925142 984 985 B-Eq-Comparison
140 NCT03925142 986 989 I-Eq-Comparison
/ NCT03925142 990 991 I-Eq-Comparison
90 NCT03925142 992 994 I-Eq-Comparison

- NCT03925142 998 999 O
Body NCT03925142 1001 1005 B-Observation
weight NCT03925142 1006 1012 I-Observation
stable NCT03925142 1013 1019 O
for NCT03925142 1020 1023 O
< NCT03925142 1024 1025 B-Eq-Comparison
3 NCT03925142 1026 1027 I-Eq-Comparison
months NCT03925142 1028 1034 I-Eq-Comparison
prior NCT03925142 1035 1040 I-Eq-Comparison
( NCT03925142 1041 1042 O
± NCT03925142 1044 1045 B-Eq-Comparison
3 NCT03925142 1046 1047 I-Eq-Comparison
kg NCT03925142 1048 1050 I-Eq-Comparison
) NCT03925142 1051 1052 O

- NCT03925142 1056 1057 O
Stable NCT03925142 1059 1065 O
physical NCT03925142 1066 1074 B-Observation
activity NCT03925142 1075 1083 I-Observation
regimen NCT03925142 1084 1091 O
< NCT03925142 1092 1093 B-Eq-Comparison
3 NCT03925142 1094 1095 I-Eq-Comparison
months NCT03925142 1096 1102 I-Eq-Comparison
prior NCT03925142 1103 1108 I-Eq-Comparison

- NCT03925142 1111 1112 O
Medication NCT03925142 1114 1124 B-Drug
use NCT03925142 1125 1128 O
unstable NCT03925142 1129 1137 O
for NCT03925142 1138 1141 O
6 NCT03925142 1142 1143 B-Eq-Comparison
months NCT03925142 1144 1150 I-Eq-Comparison
prior NCT03925142 1151 1156 I-Eq-Comparison
and NCT03925142 1157 1160 B-And
using NCT03925142 1161 1166 B-Eq-Comparison
medications NCT03925142 1167 1178 B-Drug

- NCT03925142 1181 1182 O
Smoking NCT03925142 1184 1191 O

- NCT03925142 1194 1195 O
Drinking NCT03925142 1197 1205 B-Condition|Observation
more NCT03925142 1206 1210 B-Eq-Comparison
than NCT03925142 1211 1215 I-Eq-Comparison
2 NCT03925142 1216 1217 I-Eq-Comparison
alcoholic NCT03925142 1218 1227 I-Eq-Comparison
drinks NCT03925142 1228 1234 I-Eq-Comparison
per NCT03925142 1235 1238 I-Eq-Comparison
day NCT03925142 1239 1242 I-Eq-Comparison

- NCT03925142 1245 1246 O
Diabetic NCT03925142 1248 1256 B-Condition

- NCT03925142 1259 1260 O
Have NCT03925142 1262 1266 O
renal NCT03925142 1267 1272 B-Condition
failure NCT03925142 1273 1280 I-Condition

- NCT03925142 1283 1284 O
Have NCT03925142 1286 1290 O
liver NCT03925142 1291 1296 B-Condition
failure NCT03925142 1297 1304 I-Condition

- NCT03925142 1307 1308 O
Have NCT03925142 1310 1314 O
cardiovascular NCT03925142 1315 1329 B-Condition
events NCT03925142 1330 1336 I-Condition
( NCT03925142 1337 1338 O
myocardial NCT03925142 1339 1349 B-Condition
infarction NCT03925142 1350 1360 I-Condition
or NCT03925142 1361 1363 B-Or
stroke NCT03925142 1364 1370 B-Condition
) NCT03925142 1371 1372 O
during NCT03925142 1373 1379 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03925142 1380 1383 O
6 NCT03925142 1384 1385 B-Eq-Comparison
months NCT03925142 1386 1392 I-Eq-Comparison
prior NCT03925142 1393 1398 I-Eq-Comparison
to NCT03925142 1399 1401 O
the NCT03925142 1402 1405 O
study NCT03925142 1406 1411 B-Study

- NCT03925142 1414 1415 O
Pregnant NCT03925142 1417 1425 B-Condition
or NCT03925142 1426 1428 B-Or
lactating NCT03925142 1429 1438 B-Condition

Inclusion NCT03927755 0 9 O
Criteria NCT03927755 10 18 O
: NCT03927755 19 20 O

- NCT03927755 24 25 O
Physicians NCT03927755 27 37 B-Provider
with NCT03927755 38 42 O
experience NCT03927755 43 53 O
in NCT03927755 54 56 O
bedside NCT03927755 57 64 B-Modifier
cardiac NCT03927755 65 72 B-Procedure
ultrasound NCT03927755 73 83 I-Procedure

Exclusion NCT03927755 84 93 O
Criteria NCT03927755 94 102 O
: NCT03927755 103 104 O

- NCT03927755 108 109 O
Unwilling NCT03927755 111 120 O
to NCT03927755 121 123 O
consent NCT03927755 124 131 O
to NCT03927755 132 134 O
study NCT03927755 135 140 B-Study

- NCT03927755 143 144 O
Appropriate NCT03927755 146 157 O
ultrasound NCT03927755 158 168 B-Procedure
equipment NCT03927755 169 178 O
not NCT03927755 179 182 O
available NCT03927755 183 192 O

Inclusion NCT03920748 0 9 O
Criteria NCT03920748 10 18 O
: NCT03920748 19 20 O

- NCT03920748 24 25 O
Newborn NCT03920748 27 34 O
and NCT03920748 35 38 B-Or
infant NCT03920748 39 45 O
age NCT03920748 46 49 O
group NCT03920748 50 55 O

- NCT03920748 58 59 O
Undergoing NCT03920748 61 71 B-Eq-Comparison
elective NCT03920748 72 80 B-Modifier
surgery NCT03920748 81 88 B-Procedure
requiring NCT03920748 89 98 O
intubation NCT03920748 99 109 B-Procedure
under NCT03920748 110 115 O
general NCT03920748 116 123 B-Procedure
anesthesia NCT03920748 124 134 I-Procedure

Exclusion NCT03920748 135 144 O
Criteria NCT03920748 145 153 O
: NCT03920748 154 155 O

- NCT03920748 159 160 O
History NCT03920748 162 169 B-Eq-Comparison
of NCT03920748 170 172 O
congenital NCT03920748 173 183 B-Modifier
maxillofacial NCT03920748 184 197 B-Condition
defect NCT03920748 198 204 I-Condition
, NCT03920748 205 206 O

- NCT03920748 210 211 O
History NCT03920748 213 220 B-Eq-Comparison
of NCT03920748 221 223 O
upper NCT03920748 224 229 B-Condition
airway NCT03920748 230 236 I-Condition
pathology NCT03920748 237 246 I-Condition
( NCT03920748 247 248 O
tumor NCT03920748 249 254 B-Condition
, NCT03920748 255 256 O
cleft NCT03920748 257 262 B-Condition
palate NCT03920748 263 269 I-Condition
- NCT03920748 270 271 I-Condition
lips NCT03920748 272 276 I-Condition
, NCT03920748 277 278 O
etc NCT03920748 279 282 O
. NCT03920748 282 283 O
) NCT03920748 284 285 O

- NCT03920748 289 290 O
History NCT03920748 292 299 B-Eq-Comparison
of NCT03920748 300 302 O
head NCT03920748 303 307 B-Modifier
and NCT03920748 308 311 B-Or
neck NCT03920748 312 316 B-Modifier
trauma NCT03920748 317 323 B-Condition
( NCT03920748 324 325 O
fracture NCT03920748 326 334 B-Condition
, NCT03920748 335 336 O
swelling NCT03920748 337 345 B-Condition
, NCT03920748 346 347 O
scar NCT03920748 348 352 B-Condition
) NCT03920748 353 354 O

Inclusion NCT03921697 0 9 O
Criteria NCT03921697 10 18 O
: NCT03921697 19 20 O

- NCT03921697 24 25 O
Idiopathic NCT03921697 27 37 B-Modifier
Parkinson NCT03921697 38 47 B-Condition
's NCT03921697 47 49 I-Condition
disease NCT03921697 50 57 I-Condition
diagnosed NCT03921697 58 67 O
by NCT03921697 68 70 O
a NCT03921697 71 72 O
neurologist NCT03921697 73 84 B-Provider

- NCT03921697 87 88 O
Ability NCT03921697 90 97 O
to NCT03921697 98 100 O
sign NCT03921697 101 105 O
informed NCT03921697 106 114 O
consent NCT03921697 115 122 O

Exclusion NCT03921697 123 132 O
Criteria NCT03921697 133 141 O
: NCT03921697 142 143 O

- NCT03921697 147 148 O
Inability NCT03921697 150 159 O
to NCT03921697 160 162 O
sign NCT03921697 163 167 O
informed NCT03921697 168 176 O
consent NCT03921697 177 184 O

- NCT03921697 187 188 O
Inability NCT03921697 190 199 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03921697 200 202 O
fill NCT03921697 203 207 O
out NCT03921697 208 211 O
questionnaires NCT03921697 212 226 B-Observation
( NCT03921697 227 228 O
i. NCT03921697 229 231 O
e. NCT03921697 232 234 O
due NCT03921697 236 239 O
to NCT03921697 240 242 O
poor NCT03921697 243 247 B-Condition
vision NCT03921697 248 254 I-Condition
, NCT03921697 255 256 O
inability NCT03921697 257 266 B-Condition
to NCT03921697 267 269 I-Condition
read NCT03921697 270 274 I-Condition
, NCT03921697 275 276 O
etc NCT03921697 277 280 O
) NCT03921697 281 282 O

- NCT03921697 286 287 O
Presence NCT03921697 289 297 O
of NCT03921697 298 300 O
psychiatric NCT03921697 301 312 B-Condition
diseases NCT03921697 313 321 I-Condition
( NCT03921697 322 323 O
episode NCT03921697 324 331 O
or NCT03921697 332 334 O
any NCT03921697 335 338 O
form NCT03921697 339 343 O
of NCT03921697 344 346 O
psychosis NCT03921697 347 356 B-Condition
, NCT03921697 357 358 O
diagnosed NCT03921697 359 368 O
by NCT03921697 369 371 O
a NCT03921697 372 373 O
psychiatrist NCT03921697 374 386 B-Provider
in NCT03921697 387 389 O
the NCT03921697 390 393 O
last NCT03921697 394 398 B-Eq-Comparison
year NCT03921697 399 403 I-Eq-Comparison
) NCT03921697 404 405 O
. NCT03921697 407 408 O

- NCT03921697 412 413 O
Age NCT03921697 415 418 B-Age
under NCT03921697 419 424 B-Eq-Comparison
18 NCT03921697 425 427 I-Eq-Comparison
yrs NCT03921697 428 431 I-Eq-Comparison
old NCT03921697 432 435 I-Eq-Comparison

Inclusion NCT03924076 0 9 O
Criteria NCT03924076 10 18 O
: NCT03924076 19 20 O

- NCT03924076 24 25 O
children NCT03924076 27 35 O
at NCT03924076 36 38 B-And
age NCT03924076 39 42 B-Age
of NCT03924076 43 45 O
7 NCT03924076 46 47 B-Eq-Comparison
- NCT03924076 48 49 I-Eq-Comparison
9 NCT03924076 50 51 I-Eq-Comparison
years NCT03924076 52 57 I-Eq-Comparison

- NCT03924076 60 61 O
have NCT03924076 63 67 O
normal NCT03924076 68 74 O
body NCT03924076 75 79 B-Observation
mass NCT03924076 80 84 I-Observation
index NCT03924076 85 90 I-Observation
( NCT03924076 91 92 O
BMI NCT03924076 93 96 B-Observation
) NCT03924076 97 98 O
i. NCT03924076 99 101 O
e. NCT03924076 102 104 O
- NCT03924076 106 107 B-Eq-Comparison
2 NCT03924076 108 109 I-Eq-Comparison
≤ NCT03924076 110 111 I-Eq-Comparison
z NCT03924076 112 113 I-Eq-Comparison
- NCT03924076 114 115 I-Eq-Comparison
score NCT03924076 116 121 I-Eq-Comparison
< NCT03924076 122 123 I-Eq-Comparison
+ NCT03924076 124 125 I-Eq-Comparison
1 NCT03924076 126 127 I-Eq-Comparison
, NCT03924076 128 129 O
slightly NCT03924076 130 138 O
overweight NCT03924076 139 149 B-Observation
z NCT03924076 150 151 B-Eq-Comparison
- NCT03924076 152 153 I-Eq-Comparison
score NCT03924076 154 159 I-Eq-Comparison
< NCT03924076 160 161 I-Eq-Comparison
+ NCT03924076 162 163 I-Eq-Comparison
1.5 NCT03924076 164 167 I-Eq-Comparison
, NCT03924076 168 169 O
and NCT03924076 170 173 B-Or
slightly NCT03924076 174 182 O
underweight NCT03924076 183 194 B-Observation
z NCT03924076 195 196 B-Eq-Comparison
- NCT03924076 197 198 I-Eq-Comparison
score NCT03924076 199 204 I-Eq-Comparison
> NCT03924076 205 206 I-Eq-Comparison
- NCT03924076 207 208 I-Eq-Comparison
3 NCT03924076 209 210 I-Eq-Comparison
. NCT03924076 210 211 O

Exclusion NCT03924076 213 222 O
Criteria NCT03924076 223 231 O
: NCT03924076 232 233 O

- NCT03924076 237 238 O
allergic NCT03924076 240 248 B-Allergy
to NCT03924076 249 251 O
milk NCT03924076 252 256 O

- NCT03924076 259 260 O
consuming NCT03924076 262 271 B-Eq-Comparison
other NCT03924076 272 277 B-Other
probiotic NCT03924076 278 287 B-Drug
product NCT03924076 288 295 I-Drug

- NCT03924076 298 299 O
he NCT03924076 301 303 O
/ NCT03924076 304 305 O
she NCT03924076 306 309 O
do NCT03924076 310 312 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03924076 313 316 I-Assertion___Assertion-Type-Value:hypothetical
want NCT03924076 317 321 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03924076 322 324 O
stop NCT03924076 325 329 O
consumption NCT03924076 330 341 B-Coreference
& NCT03924076 342 343 B-And
doing NCT03924076 344 349 O
washout NCT03924076 350 357 B-Procedure
for NCT03924076 358 361 O
2 NCT03924076 362 363 B-Eq-Comparison
weeks NCT03924076 364 369 I-Eq-Comparison
. NCT03924076 369 370 O

Inclusion NCT03923686 0 9 O
Criteria NCT03923686 10 18 O
: NCT03923686 19 20 O

- NCT03923686 24 25 O
walled NCT03923686 27 33 B-Condition
- NCT03923686 34 35 I-Condition
off NCT03923686 36 39 I-Condition
pancreatic NCT03923686 40 50 I-Condition
necrosis NCT03923686 51 59 I-Condition
( NCT03923686 60 61 O
WON NCT03923686 62 65 B-Condition
) NCT03923686 66 67 O
indicated NCT03923686 68 77 B-Indication
for NCT03923686 78 81 O
endoscopical NCT03923686 82 94 B-Procedure
drainage NCT03923686 95 103 I-Procedure

- NCT03923686 106 107 O
signed NCT03923686 109 115 O
informed NCT03923686 116 124 O
consent NCT03923686 125 132 O
form NCT03923686 133 137 O

Exclusion NCT03923686 138 147 O
Criteria NCT03923686 148 156 O
: NCT03923686 157 158 O

- NCT03923686 162 163 O
patient NCT03923686 165 172 O
disagreement NCT03923686 173 185 O
with NCT03923686 186 190 O
the NCT03923686 191 194 O
study NCT03923686 195 200 O

- NCT03923686 203 204 O
types NCT03923686 206 211 O
of NCT03923686 212 214 O
collections NCT03923686 215 226 B-Condition
other NCT03923686 227 232 B-Exception
than NCT03923686 233 237 I-Exception
WON NCT03923686 238 241 B-Condition

- NCT03923686 244 245 O
drainage NCT03923686 247 255 B-Procedure
with NCT03923686 256 260 O
stents NCT03923686 261 267 B-Procedure
other NCT03923686 268 273 B-Exception
than NCT03923686 274 278 I-Exception
LAMS NCT03923686 279 283 B-Procedure

- NCT03923686 286 287 O
previous NCT03923686 289 297 B-Eq-Comparison
attempts NCT03923686 298 306 O
at NCT03923686 307 309 O
drainage NCT03923686 310 318 B-Procedure
of NCT03923686 319 321 O
WON NCT03923686 322 325 B-Condition

- NCT03923686 328 329 O
severe NCT03923686 331 337 O
coagulopathy NCT03923686 338 350 B-Condition
or NCT03923686 351 353 B-Or
thrombocytopenia NCT03923686 354 370 B-Condition

Inclusion NCT03924843 0 9 O
Criteria NCT03924843 10 18 O
: NCT03924843 19 20 O

- NCT03924843 24 25 O
Men NCT03924843 27 30 O
/ NCT03924843 31 32 B-Or
Women NCT03924843 33 38 O
age NCT03924843 39 42 B-Age
> NCT03924843 43 44 B-Eq-Comparison
40 NCT03924843 45 47 I-Eq-Comparison
years NCT03924843 48 53 I-Eq-Comparison
. NCT03924843 54 55 O

- NCT03924843 59 60 O
Diagnoses NCT03924843 62 71 O
of NCT03924843 72 74 O
COPD NCT03924843 75 79 B-Condition
according NCT03924843 80 89 O
to NCT03924843 90 92 O
criteria NCT03924843 93 101 O
of NCT03924843 102 104 O
the NCT03924843 105 108 O
American NCT03924843 109 117 O
Thoracic NCT03924843 118 126 O
Society NCT03924843 127 134 O
( NCT03924843 135 136 O
ATS NCT03924843 137 140 O
) NCT03924843 141 142 O
, NCT03924843 144 145 O
a NCT03924843 146 147 O
disease NCT03924843 148 155 O
state NCT03924843 156 161 O
characterized NCT03924843 162 175 O
by NCT03924843 176 178 O
the NCT03924843 179 182 O
presence NCT03924843 183 191 O
of NCT03924843 192 194 O
chronic NCT03924843 195 202 B-Condition
airway NCT03924843 203 209 I-Condition
obstruction NCT03924843 210 221 I-Condition
due NCT03924843 222 225 O
to NCT03924843 226 228 O
chronic NCT03924843 229 236 B-Condition
bronchitis NCT03924843 237 247 I-Condition
( NCT03924843 248 249 O
cough NCT03924843 250 255 B-Condition
/ NCT03924843 256 257 B-Or
sputum NCT03924843 258 264 B-Condition
on NCT03924843 265 267 O
most NCT03924843 268 272 O
days NCT03924843 273 277 B-Eq-Comparison
a NCT03924843 278 279 I-Eq-Comparison
week NCT03924843 280 284 I-Eq-Comparison
for NCT03924843 285 288 O
3 NCT03924843 289 290 B-Eq-Comparison
months NCT03924843 291 297 I-Eq-Comparison
in NCT03924843 298 300 I-Eq-Comparison
a NCT03924843 301 302 I-Eq-Comparison
year NCT03924843 303 307 I-Eq-Comparison
for NCT03924843 308 311 O
at NCT03924843 312 314 B-Eq-Comparison
least NCT03924843 315 320 I-Eq-Comparison
two NCT03924843 321 324 I-Eq-Comparison
successive NCT03924843 325 335 I-Eq-Comparison
years NCT03924843 336 341 I-Eq-Comparison
) NCT03924843 342 343 O
and NCT03924843 344 347 B-Or
/ NCT03924843 348 349 I-Or
or NCT03924843 350 352 I-Or
emphysema NCT03924843 353 362 B-Condition

- NCT03924843 365 366 O
Diagnosis NCT03924843 368 377 O
of NCT03924843 378 380 O
moderate NCT03924843 381 389 B-Eq-Comparison
or NCT03924843 390 392 I-Eq-Comparison
severe NCT03924843 393 399 I-Eq-Comparison
COPD NCT03924843 400 404 B-Condition
exacerbation NCT03924843 405 417 I-Condition
( NCT03924843 418 419 O
see NCT03924843 420 423 O
" NCT03924843 424 425 O
Definitions NCT03924843 425 436 O
" NCT03924843 436 437 O
) NCT03924843 438 439 O

- NCT03924843 443 444 O
FEV1 NCT03924843 446 450 B-Observation
> NCT03924843 451 452 B-Eq-Comparison
0.8 NCT03924843 453 456 I-Eq-Comparison
L NCT03924843 457 458 I-Eq-Comparison
and NCT03924843 459 462 B-And
ability NCT03924843 463 470 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924843 471 473 I-Assertion___Assertion-Type-Value:hypothetical
produce NCT03924843 474 481 B-Condition
sputum NCT03924843 482 488 I-Condition
after NCT03924843 489 494 B-Temporal-Connection___Temporal-Connection-Type-Value:after
hypertonic NCT03924843 495 505 B-Drug
saline NCT03924843 506 512 I-Drug
production NCT03924843 513 523 I-Drug

- NCT03924843 526 527 O
Post NCT03924843 529 533 B-Temporal-Connection___Temporal-Connection-Type-Value:after
bronchodilator NCT03924843 534 548 B-Procedure
FEV1 NCT03924843 549 553 B-Observation
/ NCT03924843 554 555 B-Or
Forced NCT03924843 556 562 B-Observation
Vital NCT03924843 563 568 I-Observation
Capacity NCT03924843 569 577 I-Observation
( NCT03924843 578 579 O
FVC NCT03924843 580 583 B-Observation
) NCT03924843 584 585 O
ratio NCT03924843 586 591 O
< NCT03924843 592 593 B-Eq-Comparison
70 NCT03924843 594 596 I-Eq-Comparison
% NCT03924843 597 598 I-Eq-Comparison
and NCT03924843 599 602 B-And
post NCT03924843 603 607 B-Temporal-Connection___Temporal-Connection-Type-Value:after
bronchodilator NCT03924843 608 622 B-Procedure
FEV1 NCT03924843 623 627 B-Observation
< NCT03924843 628 629 B-Eq-Comparison
80 NCT03924843 630 632 I-Eq-Comparison
% NCT03924843 633 634 I-Eq-Comparison
pred NCT03924843 635 639 O
. NCT03924843 640 641 O

- NCT03924843 645 646 O
A NCT03924843 648 649 O
smoking NCT03924843 650 657 B-Condition|Observation
history NCT03924843 658 665 B-Eq-Comparison
of NCT03924843 666 668 O
> NCT03924843 669 670 B-Eq-Comparison
10 NCT03924843 671 673 I-Eq-Comparison
pack NCT03924843 674 678 I-Eq-Comparison
years NCT03924843 679 684 I-Eq-Comparison

Exclusion NCT03924843 685 694 O
Criteria NCT03924843 695 703 O
: NCT03924843 704 705 O

- NCT03924843 709 710 O
Pneumonia NCT03924843 712 721 B-Condition
as NCT03924843 722 724 O
determined NCT03924843 725 735 O
by NCT03924843 736 738 O
X NCT03924843 739 740 B-Procedure
- NCT03924843 741 742 I-Procedure
ray NCT03924843 743 746 I-Procedure

- NCT03924843 749 750 O
> NCT03924843 752 753 B-Eq-Comparison
48 NCT03924843 754 756 I-Eq-Comparison
h NCT03924843 757 758 I-Eq-Comparison
intake NCT03924843 759 765 O
of NCT03924843 766 768 O
prednisolon NCT03924843 769 780 B-Drug
/ NCT03924843 781 782 B-Or
antibiotics NCT03924843 783 794 B-Drug

- NCT03924843 797 798 O
Need NCT03924843 800 804 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03924843 805 808 I-Assertion___Assertion-Type-Value:hypothetical
mechanical NCT03924843 809 819 B-Procedure
ventilation NCT03924843 820 831 I-Procedure
( NCT03924843 832 833 O
either NCT03924843 834 840 O
invasive NCT03924843 841 849 B-Modifier
or NCT03924843 850 852 B-Or
non NCT03924843 853 856 B-Modifier
- NCT03924843 857 858 I-Modifier
invasive NCT03924843 859 867 I-Modifier
) NCT03924843 868 869 O

- NCT03924843 873 874 O
Treatment NCT03924843 876 885 B-Procedure
with NCT03924843 886 890 O
immune NCT03924843 891 897 B-Drug
- NCT03924843 898 899 I-Drug
modulating NCT03924843 900 910 I-Drug
agents NCT03924843 911 917 I-Drug
for NCT03924843 918 921 O
any NCT03924843 922 925 O
disease NCT03924843 926 933 B-Condition

- NCT03924843 936 937 O
Experimental NCT03924843 939 951 O
interventions NCT03924843 952 965 B-Procedure
for NCT03924843 966 969 O
COPD NCT03924843 970 974 B-Condition
last NCT03924843 975 979 B-Eq-Comparison
half NCT03924843 980 984 I-Eq-Comparison
year NCT03924843 985 989 I-Eq-Comparison

- NCT03924843 992 993 O
Former NCT03924843 995 1001 B-Eq-Comparison
/ NCT03924843 1002 1003 B-Or
concomitant NCT03924843 1004 1015 B-Modifier
diagnosis NCT03924843 1016 1025 O
of NCT03924843 1026 1028 O
asthma NCT03924843 1029 1035 B-Condition

- NCT03924843 1038 1039 O
Any NCT03924843 1041 1044 O
significant NCT03924843 1045 1056 O
other NCT03924843 1057 1062 B-Other
pulmonary NCT03924843 1063 1072 B-Modifier
disease NCT03924843 1073 1080 B-Condition
or NCT03924843 1081 1083 B-Or
disorder NCT03924843 1084 1092 B-Condition

- NCT03924843 1095 1096 O
Other NCT03924843 1098 1103 O
significant NCT03924843 1104 1115 O
disease NCT03924843 1116 1123 B-Condition
or NCT03924843 1124 1126 B-Or
disorder NCT03924843 1127 1135 B-Condition
( NCT03924843 1136 1137 O
like NCT03924843 1138 1142 O
alpha NCT03924843 1143 1148 B-Condition
- NCT03924843 1149 1150 I-Condition
1 NCT03924843 1151 1152 I-Condition
- NCT03924843 1153 1154 I-Condition
antitrypsine NCT03924843 1155 1167 I-Condition
deficiency NCT03924843 1168 1178 I-Condition
, NCT03924843 1179 1180 O
significant NCT03924843 1181 1192 O
bronchiectasis NCT03924843 1193 1207 B-Condition
, NCT03924843 1208 1209 O
cardiovascular NCT03924843 1210 1224 B-Modifier
, NCT03924843 1225 1226 O
gastrointestinal NCT03924843 1227 1243 B-Modifier
, NCT03924843 1244 1245 O
liver NCT03924843 1246 1251 B-Modifier
, NCT03924843 1252 1253 O
renal NCT03924843 1254 1259 B-Modifier
, NCT03924843 1260 1261 O
neurological NCT03924843 1262 1274 B-Modifier
, NCT03924843 1275 1276 O
musculoskeletal NCT03924843 1277 1292 B-Modifier
, NCT03924843 1293 1294 O
endocrine NCT03924843 1295 1304 B-Modifier
, NCT03924843 1305 1306 O
metabolic NCT03924843 1307 1316 B-Modifier
( NCT03924843 1317 1318 O
including NCT03924843 1319 1328 O
diagnosed NCT03924843 1329 1338 O
diabetes NCT03924843 1339 1347 B-Condition
) NCT03924843 1348 1349 O
, NCT03924843 1351 1352 O
malignant NCT03924843 1353 1362 B-Modifier
, NCT03924843 1363 1364 O
psychiatric NCT03924843 1365 1376 B-Modifier
, NCT03924843 1377 1378 O
major NCT03924843 1379 1384 B-Modifier
physical NCT03924843 1385 1393 I-Modifier
impairment NCT03924843 1394 1404 B-Condition
) NCT03924843 1405 1406 O
, NCT03924843 1408 1409 O
which NCT03924843 1410 1415 O
, NCT03924843 1416 1417 O
in NCT03924843 1418 1420 O
the NCT03924843 1421 1424 O
opinion NCT03924843 1425 1432 O
of NCT03924843 1433 1435 O
the NCT03924843 1436 1439 O
investigators NCT03924843 1440 1453 O
may NCT03924843 1454 1457 B-Assertion___Assertion-Type-Value:hypothetical
either NCT03924843 1458 1464 O
put NCT03924843 1465 1468 O
the NCT03924843 1469 1472 O
patient NCT03924843 1473 1480 O
at NCT03924843 1481 1483 O
risk NCT03924843 1484 1488 B-Risk
because NCT03924843 1489 1496 O
of NCT03924843 1497 1499 O
participation NCT03924843 1500 1513 O
in NCT03924843 1514 1516 O
the NCT03924843 1517 1520 O
study NCT03924843 1521 1526 O
, NCT03924843 1527 1528 O
or NCT03924843 1529 1531 O
may NCT03924843 1532 1535 B-Assertion___Assertion-Type-Value:hypothetical
influence NCT03924843 1536 1545 O
the NCT03924843 1546 1549 O
results NCT03924843 1550 1557 O
of NCT03924843 1558 1560 O
the NCT03924843 1561 1564 O
study NCT03924843 1565 1570 B-Study
, NCT03924843 1571 1572 O
or NCT03924843 1573 1575 O
the NCT03924843 1576 1579 O
patient NCT03924843 1580 1587 O
's NCT03924843 1587 1589 O
ability NCT03924843 1590 1597 O
to NCT03924843 1598 1600 O
participate NCT03924843 1601 1612 O
in NCT03924843 1613 1615 O
the NCT03924843 1616 1619 O
study NCT03924843 1620 1625 O
. NCT03924843 1626 1627 O

- NCT03924843 1631 1632 O
Existing NCT03924843 1634 1642 B-Eq-Comparison
pregnancy NCT03924843 1643 1652 B-Condition
/ NCT03924843 1653 1654 B-Or
current NCT03924843 1655 1662 B-Eq-Comparison
willingness NCT03924843 1663 1674 B-Assertion___Assertion-Type-Value:intention
for NCT03924843 1675 1678 I-Assertion___Assertion-Type-Value:intention
becoming NCT03924843 1679 1687 I-Assertion___Assertion-Type-Value:intention
pregnant NCT03924843 1688 1696 B-Condition

Inclusion NCT03929432 0 9 O
Criteria NCT03929432 10 18 O
: NCT03929432 19 20 O

- NCT03929432 24 25 O
Presence NCT03929432 27 35 O
of NCT03929432 36 38 O
post NCT03929432 39 43 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03929432 44 45 O
stroke NCT03929432 46 52 B-Condition
aphasia NCT03929432 53 60 B-Condition

- NCT03929432 63 64 O
Single NCT03929432 66 72 B-Eq-Comparison
left NCT03929432 73 77 B-Modifier
hemisphere NCT03929432 78 88 I-Modifier
stroke NCT03929432 89 95 B-Condition
etiology NCT03929432 96 104 B-Modifier

- NCT03929432 107 108 O
At NCT03929432 110 112 B-Eq-Comparison
least NCT03929432 113 118 I-Eq-Comparison
6 NCT03929432 119 120 I-Eq-Comparison
months NCT03929432 121 127 I-Eq-Comparison
post NCT03929432 128 132 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03929432 133 134 O
stroke NCT03929432 135 141 B-Condition

- NCT03929432 144 145 O
Age NCT03929432 147 150 B-Age
range NCT03929432 151 156 O
between NCT03929432 157 164 B-Eq-Comparison
18 NCT03929432 165 167 I-Eq-Comparison
and NCT03929432 168 171 I-Eq-Comparison
80 NCT03929432 172 174 I-Eq-Comparison
years NCT03929432 175 180 I-Eq-Comparison
old NCT03929432 181 184 O

- NCT03929432 187 188 O
Speak NCT03929432 190 195 O
English NCT03929432 196 203 O
as NCT03929432 204 206 O
a NCT03929432 207 208 O
native NCT03929432 209 215 O
language NCT03929432 216 224 O

- NCT03929432 227 228 O
Adequate NCT03929432 230 238 O
hearing NCT03929432 239 246 B-Condition
and NCT03929432 247 250 B-And
vision NCT03929432 251 257 B-Condition
to NCT03929432 258 260 B-Assertion___Assertion-Type-Value:hypothetical
complete NCT03929432 261 269 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03929432 270 273 O
tasks NCT03929432 274 279 B-Observation

Exclusion NCT03929432 280 289 O
Criteria NCT03929432 290 298 O
: NCT03929432 299 300 O

- NCT03929432 304 305 O
Severe NCT03929432 307 313 O
auditory NCT03929432 314 322 B-Condition
comprehension NCT03929432 323 336 I-Condition
deficits NCT03929432 337 345 I-Condition
( NCT03929432 346 347 O
determined NCT03929432 348 358 O
by NCT03929432 359 361 O
pretest NCT03929432 362 369 B-Procedure
) NCT03929432 370 371 O
( NCT03929432 372 373 O
i. NCT03929432 374 376 O
e. NCT03929432 377 379 O
, NCT03929432 380 381 O
global NCT03929432 382 388 B-Condition
aphasia NCT03929432 389 396 I-Condition
, NCT03929432 397 398 O
Wernicke NCT03929432 399 407 B-Condition
's NCT03929432 407 409 I-Condition
aphasia NCT03929432 410 417 I-Condition
, NCT03929432 418 419 O
transcortical NCT03929432 420 433 B-Condition
sensory NCT03929432 434 441 I-Condition
aphasia NCT03929432 442 449 I-Condition
) NCT03929432 450 451 O

- NCT03929432 455 456 O
Inability NCT03929432 458 467 O
to NCT03929432 468 470 O
provide NCT03929432 471 478 O
informed NCT03929432 479 487 O
consent NCT03929432 488 495 O

- NCT03929432 498 499 O
Co NCT03929432 501 503 O
- NCT03929432 504 505 O
occurring NCT03929432 506 515 O
history NCT03929432 516 523 B-Eq-Comparison
of NCT03929432 524 526 O
neurological NCT03929432 527 539 B-Modifier
disease NCT03929432 540 547 B-Condition
/ NCT03929432 548 549 B-Or
disorder NCT03929432 550 558 B-Condition
/ NCT03929432 559 560 B-Or
injury NCT03929432 561 567 B-Condition
( NCT03929432 568 569 O
e. NCT03929432 570 572 O
g. NCT03929432 573 575 O
, NCT03929432 576 577 O
traumatic NCT03929432 578 587 B-Condition
brain NCT03929432 588 593 I-Condition
injury NCT03929432 594 600 I-Condition
, NCT03929432 601 602 O
right NCT03929432 603 608 B-Modifier
hemisphere NCT03929432 609 619 I-Modifier
stroke NCT03929432 620 626 B-Condition
, NCT03929432 627 628 O
dementia NCT03929432 629 637 B-Condition
) NCT03929432 638 639 O

- NCT03929432 643 644 O
Co NCT03929432 646 648 O
- NCT03929432 649 650 O
occurring NCT03929432 651 660 O
history NCT03929432 661 668 B-Eq-Comparison
of NCT03929432 669 671 O
a NCT03929432 672 673 O
major NCT03929432 674 679 O
mental NCT03929432 680 686 B-Condition
illness NCT03929432 687 694 I-Condition
( NCT03929432 695 696 O
e. NCT03929432 697 699 O
g. NCT03929432 700 702 O
, NCT03929432 703 704 O
schizophrenia NCT03929432 705 718 B-Condition
, NCT03929432 719 720 O
drug NCT03929432 721 725 B-Condition
addiction NCT03929432 726 735 I-Condition
, NCT03929432 736 737 O
bipolar NCT03929432 738 745 B-Condition
) NCT03929432 746 747 O

- NCT03929432 751 752 O
Clinical NCT03929432 754 762 O
conditions NCT03929432 763 773 B-Condition
contraindicated NCT03929432 774 789 B-Contraindication
for NCT03929432 790 793 O
MRI NCT03929432 794 797 B-Procedure
or NCT03929432 798 800 B-Or
tDCS NCT03929432 801 805 B-Procedure
( NCT03929432 806 807 O
e. NCT03929432 808 810 O
g. NCT03929432 811 813 O
, NCT03929432 814 815 O
implanted NCT03929432 816 825 B-Procedure
electrical NCT03929432 826 836 I-Procedure
devices NCT03929432 837 844 I-Procedure
, NCT03929432 845 846 O
claustrophobia NCT03929432 847 861 B-Condition
, NCT03929432 862 863 O
seizure NCT03929432 864 871 B-Condition
disorder NCT03929432 872 880 I-Condition
) NCT03929432 881 882 O

- NCT03929432 886 887 O
Positive NCT03929432 889 897 O
pregnancy NCT03929432 898 907 B-Observation
test NCT03929432 908 912 I-Observation
( NCT03929432 913 914 O
for NCT03929432 915 918 O
females NCT03929432 919 926 O
) NCT03929432 927 928 O

Inclusion NCT03924102 0 9 O
Criteria NCT03924102 10 18 O
: NCT03924102 19 20 O

- NCT03924102 24 25 O
At NCT03924102 27 29 B-Eq-Comparison
least NCT03924102 30 35 I-Eq-Comparison
18 NCT03924102 36 38 I-Eq-Comparison
years NCT03924102 39 44 I-Eq-Comparison
of NCT03924102 45 47 O
age NCT03924102 48 51 B-Age
. NCT03924102 52 53 O

- NCT03924102 57 58 O
Enrollment NCT03924102 60 70 O
in NCT03924102 71 73 O
the NCT03924102 74 77 O
UAB NCT03924102 78 81 O
CMC NCT03924102 82 85 O
- NCT03924102 86 87 O
ADHF NCT03924102 88 92 O
study NCT03924102 93 98 O
under NCT03924102 99 104 O
the NCT03924102 105 108 O
separate NCT03924102 109 117 O
UAB NCT03924102 118 121 O
approved NCT03924102 122 130 O
research NCT03924102 131 139 O
protocol NCT03924102 140 148 O
( NCT03924102 149 150 O
IRB NCT03924102 151 154 O
- NCT03924102 155 156 O
300000114 NCT03924102 157 166 O
, NCT03924102 167 168 O
PI NCT03924102 169 171 O
Rajapreyar NCT03924102 172 182 O
) NCT03924102 183 184 O

- NCT03924102 188 189 O
Negative NCT03924102 191 199 O
urine NCT03924102 200 205 O
or NCT03924102 206 208 B-Or
serum NCT03924102 209 214 O
β NCT03924102 215 216 B-Observation
- NCT03924102 217 218 I-Observation
hCG NCT03924102 219 222 I-Observation
test NCT03924102 223 227 I-Observation
within NCT03924102 228 234 B-Eq-Comparison
48 NCT03924102 235 237 I-Eq-Comparison
hours NCT03924102 238 243 I-Eq-Comparison
of NCT03924102 244 246 B-Temporal-Connection___Temporal-Connection-Type-Value:after
[ NCT03924102 247 248 O
11 NCT03924102 249 251 B-Modifier
C NCT03924102 252 253 I-Modifier
] NCT03924102 254 255 O
acetate NCT03924102 256 263 B-Drug
administration NCT03924102 264 278 I-Drug
in NCT03924102 279 281 B-And
women NCT03924102 282 287 O
of NCT03924102 288 290 B-And
child NCT03924102 291 296 B-Condition
bearing NCT03924102 297 304 I-Condition
potential NCT03924102 305 314 I-Condition
. NCT03924102 314 315 O
Women NCT03924102 317 322 O
who NCT03924102 323 326 B-And
are NCT03924102 327 330 O
post NCT03924102 331 335 B-Condition
- NCT03924102 336 337 I-Condition
menopausal NCT03924102 338 348 I-Condition
with NCT03924102 349 353 B-And
at NCT03924102 354 356 B-Eq-Comparison
least NCT03924102 357 362 I-Eq-Comparison
1 NCT03924102 363 364 I-Eq-Comparison
year NCT03924102 365 369 I-Eq-Comparison
since NCT03924102 370 375 B-Temporal-Connection___Temporal-Connection-Type-Value:after
last NCT03924102 376 380 B-Eq-Comparison
menses NCT03924102 381 387 B-Condition
or NCT03924102 388 390 B-Or
documented NCT03924102 391 401 O
surgical NCT03924102 402 410 B-Procedure
sterilization NCT03924102 411 424 I-Procedure
will NCT03924102 425 429 O
not NCT03924102 430 433 B-Negation
require NCT03924102 434 441 B-Assertion___Assertion-Type-Value:hypothetical
pregnancy NCT03924102 442 451 B-Observation
testing NCT03924102 452 459 I-Observation
. NCT03924102 460 461 O

Exclusion NCT03924102 463 472 O
Criteria NCT03924102 473 481 O
: NCT03924102 482 483 O

- NCT03924102 487 488 O
Inability NCT03924102 490 499 O
to NCT03924102 500 502 O
provide NCT03924102 503 510 O
informed NCT03924102 511 519 O
consent NCT03924102 520 527 O

- NCT03924102 530 531 O
Pregnancy NCT03924102 533 542 B-Condition

- NCT03924102 545 546 O
Inability NCT03924102 548 557 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03924102 558 560 O
lie NCT03924102 561 564 O
still NCT03924102 565 570 O
for NCT03924102 571 574 O
the NCT03924102 575 578 O
imaging NCT03924102 579 586 B-Procedure
study NCT03924102 587 592 I-Procedure

- NCT03924102 595 596 O
Weight NCT03924102 598 604 B-Observation
exceeding NCT03924102 605 614 O
the NCT03924102 615 618 O
weight NCT03924102 619 625 O
limit NCT03924102 626 631 O
of NCT03924102 632 634 O
the NCT03924102 635 638 O
PET NCT03924102 639 642 B-Procedure
imaging NCT03924102 643 650 I-Procedure
table NCT03924102 651 656 I-Procedure
( NCT03924102 657 658 O
500 NCT03924102 659 662 B-Eq-Comparison
pounds NCT03924102 663 669 I-Eq-Comparison
) NCT03924102 670 671 O
. NCT03924102 672 673 O

Inclusion NCT03924466 0 9 O
Criteria NCT03924466 10 18 O
: NCT03924466 19 20 O

Patients NCT03924466 22 30 O
will NCT03924466 31 35 O
only NCT03924466 36 40 O
be NCT03924466 41 43 O
included NCT03924466 44 52 O
in NCT03924466 53 55 O
the NCT03924466 56 59 O
study NCT03924466 60 65 O
if NCT03924466 66 68 O
they NCT03924466 69 73 O
meet NCT03924466 74 78 O
all NCT03924466 79 82 O
of NCT03924466 83 85 O
the NCT03924466 86 89 O
following NCT03924466 90 99 O
criteria NCT03924466 100 108 O
: NCT03924466 109 110 O

- NCT03924466 114 115 O
Patient NCT03924466 117 124 O
who NCT03924466 125 128 O
has NCT03924466 129 132 O
given NCT03924466 133 138 O
informed NCT03924466 139 147 O
consent NCT03924466 148 155 O

- NCT03924466 158 159 O
Patient NCT03924466 161 168 O
with NCT03924466 169 173 O
age NCT03924466 174 177 B-Age
18 NCT03924466 178 180 B-Eq-Comparison
years NCT03924466 181 186 I-Eq-Comparison
or NCT03924466 187 189 I-Eq-Comparison
older NCT03924466 190 195 I-Eq-Comparison

- NCT03924466 198 199 O
Patient NCT03924466 201 208 O
with NCT03924466 209 213 O
locally NCT03924466 214 221 B-Modifier
or NCT03924466 222 224 B-Or
distantly NCT03924466 225 234 B-Modifier
advanced NCT03924466 235 243 I-Modifier
breast NCT03924466 244 250 I-Modifier
carcinoma NCT03924466 251 260 B-Condition
, NCT03924466 261 262 O
with NCT03924466 263 267 B-And
at NCT03924466 268 270 B-Eq-Comparison
least NCT03924466 271 276 I-Eq-Comparison
1 NCT03924466 277 278 I-Eq-Comparison
lesion NCT03924466 279 285 B-Condition|Observation
of NCT03924466 286 288 O
at NCT03924466 289 291 B-Eq-Comparison
least NCT03924466 292 297 I-Eq-Comparison
12 NCT03924466 298 300 I-Eq-Comparison
mm NCT03924466 301 303 I-Eq-Comparison
maximal NCT03924466 304 311 B-Modifier
diameter NCT03924466 312 320 I-Modifier
. NCT03924466 320 321 O
For NCT03924466 323 326 O
lymph NCT03924466 327 332 B-Modifier
node NCT03924466 333 337 I-Modifier
metastases NCT03924466 338 348 B-Condition|Observation
, NCT03924466 349 350 O
the NCT03924466 351 354 O
largest NCT03924466 355 362 B-Modifier
diameter NCT03924466 363 371 I-Modifier
should NCT03924466 372 378 O
be NCT03924466 379 381 O
at NCT03924466 382 384 B-Eq-Comparison
least NCT03924466 385 390 I-Eq-Comparison
15 NCT03924466 391 393 I-Eq-Comparison
mm NCT03924466 394 396 I-Eq-Comparison
and NCT03924466 397 400 B-And
the NCT03924466 401 404 O
short NCT03924466 405 410 B-Observation
axis NCT03924466 411 415 I-Observation
at NCT03924466 416 418 B-Eq-Comparison
least NCT03924466 419 424 I-Eq-Comparison
12 NCT03924466 425 427 I-Eq-Comparison
mm NCT03924466 428 430 I-Eq-Comparison
. NCT03924466 431 432 O

Exclusion NCT03924466 434 443 O
Criteria NCT03924466 444 452 O
: NCT03924466 453 454 O

Patients NCT03924466 456 464 O
will NCT03924466 465 469 O
not NCT03924466 470 473 B-Negation
be NCT03924466 474 476 O
included NCT03924466 477 485 O
in NCT03924466 486 488 O
the NCT03924466 489 492 O
study NCT03924466 493 498 B-Study
if NCT03924466 499 501 O
one NCT03924466 502 505 O
or NCT03924466 506 508 O
more NCT03924466 509 513 O
of NCT03924466 514 516 O
the NCT03924466 517 520 O
following NCT03924466 521 530 O
criteria NCT03924466 531 539 O

applies NCT03924466 540 547 O
: NCT03924466 548 549 O

- NCT03924466 553 554 O
Patient NCT03924466 556 563 O
is NCT03924466 564 566 O
pregnant NCT03924466 567 575 B-Condition

- NCT03924466 578 579 O
Patient NCT03924466 581 588 O
is NCT03924466 589 591 O
breast NCT03924466 592 598 B-Condition
feeding NCT03924466 599 606 I-Condition

- NCT03924466 609 610 O
Patient NCT03924466 612 619 O
with NCT03924466 620 624 O
recent NCT03924466 625 631 B-Eq-Comparison
( NCT03924466 632 633 O
< NCT03924466 635 636 B-Eq-Comparison
1 NCT03924466 637 638 I-Eq-Comparison
week NCT03924466 639 643 I-Eq-Comparison
) NCT03924466 644 645 O
gastrointestinal NCT03924466 646 662 B-Condition
disorders NCT03924466 663 672 I-Condition
with NCT03924466 673 677 O
diarrhea NCT03924466 678 686 B-Condition
as NCT03924466 687 689 O
major NCT03924466 690 695 O
symptom NCT03924466 696 703 O

- NCT03924466 706 707 O
Patient NCT03924466 709 716 O
with NCT03924466 717 721 O
any NCT03924466 722 725 O
serious NCT03924466 726 733 O
active NCT03924466 734 740 B-Eq-Comparison
infection NCT03924466 741 750 B-Condition

- NCT03924466 753 754 O
Patient NCT03924466 756 763 O
who NCT03924466 764 767 O
has NCT03924466 768 771 O
any NCT03924466 772 775 O
other NCT03924466 776 781 B-Other
life NCT03924466 782 786 B-Death|Risk
- NCT03924466 787 788 I-Death|Risk
threatening NCT03924466 789 800 I-Death|Risk
illness NCT03924466 801 808 B-Condition
or NCT03924466 809 811 B-Or
organ NCT03924466 812 817 B-Modifier
system NCT03924466 818 824 I-Modifier
dysfunction NCT03924466 825 836 B-Condition
, NCT03924466 837 838 O
which NCT03924466 839 844 O
in NCT03924466 845 847 O
the NCT03924466 848 851 O
opinion NCT03924466 852 859 O
of NCT03924466 860 862 O
the NCT03924466 863 866 O
investigator NCT03924466 867 879 O
would NCT03924466 880 885 O
either NCT03924466 886 892 O
compromise NCT03924466 893 903 O
patient NCT03924466 904 911 O
safety NCT03924466 912 918 O
or NCT03924466 919 921 O
interfere NCT03924466 922 931 O
with NCT03924466 932 936 O
the NCT03924466 937 940 O
evaluation NCT03924466 941 951 O
of NCT03924466 952 954 O
the NCT03924466 955 958 O
test NCT03924466 959 963 B-Study
radiopharmaceutical NCT03924466 964 983 B-Procedure

- NCT03924466 986 987 O
Patient NCT03924466 989 996 O
who NCT03924466 997 1000 O
can NCT03924466 1001 1004 B-Negation
not NCT03924466 1004 1007 I-Negation
communicate NCT03924466 1008 1019 B-Condition
reliably NCT03924466 1020 1028 O
with NCT03924466 1029 1033 O
the NCT03924466 1034 1037 O
investigator NCT03924466 1038 1050 O

- NCT03924466 1053 1054 O
Patient NCT03924466 1056 1063 O
who NCT03924466 1064 1067 O
is NCT03924466 1068 1070 O
unlikely NCT03924466 1071 1079 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924466 1080 1082 O
cooperate NCT03924466 1083 1092 O
with NCT03924466 1093 1097 O
the NCT03924466 1098 1101 O
requirements NCT03924466 1102 1114 O
of NCT03924466 1115 1117 O
the NCT03924466 1118 1121 O
study NCT03924466 1122 1127 B-Study

- NCT03924466 1130 1131 O
Patient NCT03924466 1133 1140 O
who NCT03924466 1141 1144 O
is NCT03924466 1145 1147 O
unwilling NCT03924466 1148 1157 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03924466 1158 1161 B-Or
/ NCT03924466 1162 1163 I-Or
or NCT03924466 1164 1166 I-Or
unable NCT03924466 1167 1173 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924466 1174 1176 O
give NCT03924466 1177 1181 O
informed NCT03924466 1182 1190 O
consent NCT03924466 1191 1198 O

- NCT03924466 1201 1202 O
Patient NCT03924466 1204 1211 O
at NCT03924466 1212 1214 O
increased NCT03924466 1215 1224 O
risk NCT03924466 1225 1229 B-Risk
of NCT03924466 1230 1232 O
death NCT03924466 1233 1238 B-Death
from NCT03924466 1239 1243 O
a NCT03924466 1244 1245 O
pre NCT03924466 1246 1249 B-Eq-Comparison
- NCT03924466 1250 1251 I-Eq-Comparison
existing NCT03924466 1252 1260 I-Eq-Comparison
concurrent NCT03924466 1261 1271 B-Modifier
illness NCT03924466 1272 1279 B-Condition

- NCT03924466 1282 1283 O
Patient NCT03924466 1285 1292 O
who NCT03924466 1293 1296 O
participated NCT03924466 1297 1309 O
already NCT03924466 1310 1317 O
in NCT03924466 1318 1320 O
this NCT03924466 1321 1325 O
study NCT03924466 1326 1331 O
. NCT03924466 1331 1332 O

Inclusion NCT03923309 0 9 O
Criteria NCT03923309 10 18 O
: NCT03923309 19 20 O

- NCT03923309 24 25 O
biopsy NCT03923309 27 33 B-Procedure
proven NCT03923309 34 40 O
rectal NCT03923309 41 47 B-Modifier
cancer NCT03923309 48 54 B-Condition
( NCT03923309 55 56 O
anal NCT03923309 57 61 B-Observation
verge NCT03923309 62 67 I-Observation
≤ NCT03923309 68 69 B-Eq-Comparison
10 NCT03923309 70 72 I-Eq-Comparison
cm NCT03923309 73 75 O
) NCT03923309 76 77 O

- NCT03923309 81 82 O
neoadjuvant NCT03923309 84 95 B-Modifier
radiotherapy NCT03923309 96 108 B-Procedure
or NCT03923309 109 111 B-Or
chemoradiotherapy NCT03923309 112 129 B-Procedure

- NCT03923309 132 133 O
no NCT03923309 135 137 B-Negation
radical NCT03923309 138 145 B-Modifier
surgery NCT03923309 146 153 B-Procedure
after NCT03923309 154 159 B-Temporal-Connection___Temporal-Connection-Type-Value:after
neoadjuvant NCT03923309 160 171 B-Procedure
therapy NCT03923309 172 179 I-Procedure

Exclusion NCT03923309 180 189 O
Criteria NCT03923309 190 198 O
: NCT03923309 199 200 O

- NCT03923309 204 205 O
other NCT03923309 207 212 B-Other
malignant NCT03923309 213 222 B-Condition
disease NCT03923309 223 230 I-Condition

- NCT03923309 233 234 O
other NCT03923309 236 241 B-Other
fatel NCT03923309 242 247 B-Condition
disease NCT03923309 248 255 I-Condition

- NCT03923309 258 259 O
incompletion NCT03923309 261 273 B-Negation
of NCT03923309 274 276 O
half NCT03923309 277 281 O
of NCT03923309 282 284 O
radiotherapy NCT03923309 285 297 B-Procedure
course NCT03923309 298 304 O

- NCT03923309 307 308 O
metastasis NCT03923309 310 320 B-Condition
on NCT03923309 321 323 B-Temporal-Connection___Temporal-Connection-Type-Value:during
initial NCT03923309 324 331 B-Eq-Comparison
presentation NCT03923309 332 344 B-Condition

Inclusion NCT03923335 0 9 O
Criteria NCT03923335 10 18 O
: NCT03923335 19 20 O

1 NCT03923335 24 25 O
. NCT03923335 25 26 O
TNM NCT03923335 28 31 O
stage NCT03923335 32 37 O
I NCT03923335 38 39 O
- NCT03923335 40 41 O
II NCT03923335 42 44 O
( NCT03923335 45 46 O
T1 NCT03923335 47 49 O
- NCT03923335 50 51 B-Eq-Comparison
4 NCT03923335 52 53 I-Eq-Comparison
N0M0 NCT03923335 54 58 O
) NCT03923335 59 60 O
colorectal NCT03923335 61 71 B-Modifier
cancer NCT03923335 72 78 B-Condition
cases NCT03923335 79 84 O

2 NCT03923335 87 88 O
. NCT03923335 88 89 O
receive NCT03923335 91 98 O
radical NCT03923335 99 106 B-Modifier
surgical NCT03923335 107 115 B-Procedure
resection NCT03923335 116 125 I-Procedure

3 NCT03923335 128 129 O
. NCT03923335 129 130 O
have NCT03923335 132 136 O
completed NCT03923335 137 146 O
data NCT03923335 147 151 O
of NCT03923335 152 154 O
tumor NCT03923335 155 160 B-Condition
location NCT03923335 161 169 B-Modifier
, NCT03923335 170 171 O
histological NCT03923335 172 184 B-Modifier
type NCT03923335 185 189 I-Modifier
, NCT03923335 190 191 O
behavioral NCT03923335 192 202 B-Modifier
characteristics NCT03923335 203 218 I-Modifier
or NCT03923335 219 221 B-Or
TNM NCT03923335 222 225 B-Modifier
staging NCT03923335 226 233 I-Modifier

4 NCT03923335 236 237 O
. NCT03923335 237 238 O
have NCT03923335 240 244 O
tumor NCT03923335 245 250 B-Observation
specimens NCT03923335 251 260 I-Observation
and NCT03923335 261 264 B-And
either NCT03923335 265 271 O
a NCT03923335 272 273 O
valid NCT03923335 274 279 O
microsatellite NCT03923335 280 294 B-Observation
instability NCT03923335 295 306 I-Observation
( NCT03923335 307 308 O
MSI NCT03923335 309 312 B-Observation
) NCT03923335 313 314 O
or NCT03923335 315 317 B-Or
immuno NCT03923335 318 324 B-Observation
- NCT03923335 325 326 I-Observation
histochemistry NCT03923335 327 341 I-Observation
( NCT03923335 342 343 O
IHC NCT03923335 344 347 B-Observation
) NCT03923335 348 349 O
data NCT03923335 350 354 O

5 NCT03923335 357 358 O
. NCT03923335 358 359 O
have NCT03923335 361 365 O
valid NCT03923335 366 371 O
V NCT03923335 372 373 B-Observation
- NCT03923335 374 375 I-Observation
raf NCT03923335 376 379 I-Observation
murine NCT03923335 380 386 I-Observation
sarcoma NCT03923335 387 394 I-Observation
viral NCT03923335 395 400 I-Observation
oncogene NCT03923335 401 409 I-Observation
homolog NCT03923335 410 417 I-Observation
B1 NCT03923335 418 420 I-Observation
( NCT03923335 421 422 O
BRAF NCT03923335 423 427 B-Observation
) NCT03923335 428 429 O
, NCT03923335 431 432 O
kirsten NCT03923335 433 440 B-Observation
rat NCT03923335 441 444 I-Observation
sarcoma NCT03923335 445 452 I-Observation
viral NCT03923335 453 458 I-Observation
oncogene NCT03923335 459 467 I-Observation
( NCT03923335 468 469 O
KRAS NCT03923335 470 474 B-Observation
) NCT03923335 475 476 O
, NCT03923335 478 479 O
CpG NCT03923335 480 483 B-Observation
island NCT03923335 484 490 I-Observation
methylator NCT03923335 491 501 I-Observation
phenotype NCT03923335 502 511 I-Observation
( NCT03923335 512 513 O
CIMP NCT03923335 514 518 B-Observation
) NCT03923335 519 520 O
results NCT03923335 521 528 O

6 NCT03923335 531 532 O
. NCT03923335 532 533 O
have NCT03923335 535 539 O
at NCT03923335 540 542 B-Eq-Comparison
least NCT03923335 543 548 I-Eq-Comparison
4 NCT03923335 549 550 I-Eq-Comparison
years NCT03923335 551 556 I-Eq-Comparison
of NCT03923335 557 559 O
follow NCT03923335 560 566 B-Encounter
- NCT03923335 567 568 I-Encounter
up NCT03923335 569 571 I-Encounter

7 NCT03923335 574 575 O
. NCT03923335 575 576 O
have NCT03923335 578 582 O
valid NCT03923335 583 588 O
time NCT03923335 589 593 B-Modifier
to NCT03923335 594 596 I-Modifier
local NCT03923335 597 602 I-Modifier
recurrence NCT03923335 603 613 B-Condition
/ NCT03923335 614 615 B-Or
metastasis NCT03923335 616 626 B-Condition
in NCT03923335 627 629 B-Temporal-Connection___Temporal-Connection-Type-Value:during
follow NCT03923335 630 636 B-Encounter
- NCT03923335 637 638 I-Encounter
up NCT03923335 639 641 I-Encounter

8 NCT03923335 644 645 O
. NCT03923335 645 646 O
have NCT03923335 648 652 O
clinical NCT03923335 653 661 O
/ NCT03923335 662 663 O
treatment NCT03923335 664 673 B-Procedure
record NCT03923335 674 680 O
data NCT03923335 681 685 O
and NCT03923335 686 689 B-And
valid NCT03923335 690 695 O
pre NCT03923335 696 699 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03923335 700 709 B-Procedure
status NCT03923335 710 716 O
of NCT03923335 717 719 O
intestinal NCT03923335 720 730 B-Condition
obstruction NCT03923335 731 742 I-Condition
or NCT03923335 743 745 I-Condition
perforation NCT03923335 746 757 I-Condition
( NCT03923335 758 759 O
IOP NCT03923335 760 763 B-Condition
) NCT03923335 764 765 O
, NCT03923335 767 768 O
counts NCT03923335 769 775 B-Eq-Comparison
of NCT03923335 776 778 O
lymph NCT03923335 779 784 B-Procedure
node NCT03923335 785 789 I-Procedure
removed NCT03923335 790 797 I-Procedure
in NCT03923335 798 800 B-Temporal-Connection___Temporal-Connection-Type-Value:during
surgical NCT03923335 801 809 B-Procedure
resection NCT03923335 810 819 I-Procedure
. NCT03923335 820 821 O

Exclusion NCT03923335 823 832 O
Criteria NCT03923335 833 841 O
: NCT03923335 842 843 O

1 NCT03923335 847 848 O
. NCT03923335 848 849 O
have NCT03923335 851 855 O
had NCT03923335 856 859 O
a NCT03923335 860 861 O
previous NCT03923335 862 870 B-Eq-Comparison
diagnosis NCT03923335 871 880 O
of NCT03923335 881 883 O
any NCT03923335 884 887 O
cancer NCT03923335 888 894 B-Condition
or NCT03923335 895 897 B-Or
presence NCT03923335 898 906 O
of NCT03923335 907 909 O
any NCT03923335 910 913 O
tumor NCT03923335 914 919 B-Condition
other NCT03923335 920 925 B-Exception
than NCT03923335 926 930 I-Exception
the NCT03923335 931 934 O
CRC NCT03923335 935 938 B-Condition

2 NCT03923335 941 942 O
. NCT03923335 942 943 O
have NCT03923335 945 949 O
had NCT03923335 950 953 O
inflammatory NCT03923335 954 966 B-Condition
bowel NCT03923335 967 972 I-Condition
disease NCT03923335 973 980 I-Condition

3 NCT03923335 983 984 O
. NCT03923335 984 985 O
have NCT03923335 987 991 O
had NCT03923335 992 995 O
hereditary NCT03923335 996 1006 B-Modifier
colorectal NCT03923335 1007 1017 I-Modifier
cancer NCT03923335 1018 1024 B-Condition
syndromes NCT03923335 1025 1034 I-Condition
, NCT03923335 1035 1036 O
including NCT03923335 1037 1046 O
Familial NCT03923335 1047 1055 B-Condition
adenomatous NCT03923335 1056 1067 I-Condition
polyposis NCT03923335 1068 1077 I-Condition
, NCT03923335 1078 1079 O
mutyh NCT03923335 1080 1085 B-Modifier
( NCT03923335 1086 1087 O
MYH NCT03923335 1088 1091 B-Modifier
) NCT03923335 1092 1093 O
- NCT03923335 1095 1096 O
associated NCT03923335 1097 1107 O
polyposis NCT03923335 1108 1117 B-Condition
, NCT03923335 1118 1119 O
Peutz NCT03923335 1120 1125 B-Condition
- NCT03923335 1126 1127 I-Condition
Jeghers NCT03923335 1128 1135 I-Condition
syndrome NCT03923335 1136 1144 I-Condition
, NCT03923335 1145 1146 O
Juvenile NCT03923335 1147 1155 B-Condition
polyposis NCT03923335 1156 1165 I-Condition
coli NCT03923335 1166 1170 I-Condition
, NCT03923335 1171 1172 O
phosphate NCT03923335 1173 1182 B-Condition
and NCT03923335 1183 1186 I-Condition
tension NCT03923335 1187 1194 I-Condition
homology NCT03923335 1195 1203 I-Condition
deleted NCT03923335 1204 1211 I-Condition
on NCT03923335 1212 1214 I-Condition
chromosome NCT03923335 1215 1225 I-Condition
ten NCT03923335 1226 1229 I-Condition
( NCT03923335 1230 1231 O
PTEN NCT03923335 1232 1236 B-Condition
) NCT03923335 1237 1238 O
tumor NCT03923335 1239 1244 B-Condition
- NCT03923335 1245 1246 I-Condition
hamartoma NCT03923335 1247 1256 I-Condition
syndromes NCT03923335 1257 1266 I-Condition
, NCT03923335 1267 1268 O
Lynch NCT03923335 1269 1274 B-Condition
Syndrome NCT03923335 1275 1283 I-Condition
, NCT03923335 1284 1285 O
and NCT03923335 1286 1289 B-Or
Familial NCT03923335 1290 1298 B-Modifier
Colorectal NCT03923335 1299 1309 I-Modifier
Cancer NCT03923335 1310 1316 B-Condition
Type NCT03923335 1317 1321 O
X. NCT03923335 1322 1324 O

